DDI-DrugBank.d97.s0|0-9|Indinavir|drug
DDI-DrugBank.d97.s0|16-25|inhibitor|drug
DDI-DrugBank.d97.s0|57-64|CYP3A4.|brand
DDI-DrugBank.d97.s1|0-16|Coadministration|drug
DDI-DrugBank.d97.s1|20-28|CRIXIVAN|brand
DDI-DrugBank.d97.s1|64-70|CYP3A4|brand
DDI-DrugBank.d97.s1|85-94|increased|drug
DDI-DrugBank.d97.s1|148-156|increase|drug
DDI-DrugBank.d97.s2|0-9|Indinavir|drug
DDI-DrugBank.d97.s2|28-35|CYP3A4.|brand
DDI-DrugBank.d97.s3|11-17|induce|drug
DDI-DrugBank.d97.s3|18-24|CYP3A4|brand
DDI-DrugBank.d97.s3|55-63|increase|drug
DDI-DrugBank.d97.s3|81-91|indinavir,|drug
DDI-DrugBank.d97.s3|92-101|resulting|drug
DDI-DrugBank.d97.s3|138-148|indinavir.|drug
DDI-DrugBank.d97.s4|0-16|Coadministration|drug
DDI-DrugBank.d97.s4|20-28|CRIXIVAN|brand
DDI-DrugBank.d97.s4|50-57|inhibit|drug
DDI-DrugBank.d97.s4|58-64|CYP3A4|brand
DDI-DrugBank.d97.s4|95-104|indinavir|drug
DDI-DrugBank.d97.s4|123-132|increased|drug
DDI-DrugBank.d97.s4|158-168|indinavir.|drug
DDI-DrugBank.d97.s6|25-39|Coadministered|drug
DDI-DrugBank.d97.s6|45-53|CRIXIVAN|brand
DDI-DrugBank.d97.s7|22-30|Clinical|drug
DDI-DrugBank.d97.s9|0-15|CONTRAINDICATED|brand
DDI-DrugBank.d97.s9|52-68|life-threatening|drug
DDI-DrugBank.d97.s10|19-37|dihydroergotamine,|drug
DDI-DrugBank.d97.s10|38-49|ergonovine,|drug
DDI-DrugBank.d97.s10|50-61|ergotamine,|drug
DDI-DrugBank.d97.s10|62-78|methylergonovine|drug
DDI-DrugBank.d97.s11|0-15|CONTRAINDICATED|brand
DDI-DrugBank.d97.s11|52-68|life-threatening|drug
DDI-DrugBank.d97.s12|31-40|triazolam|drug
DDI-DrugBank.d97.s13|0-15|CONTRAINDICATED|brand
DDI-DrugBank.d97.s13|52-68|life-threatening|drug
DDI-DrugBank.d97.s13|100-109|increased|drug
DDI-DrugBank.d97.s14|20-29|cisapride|drug
DDI-DrugBank.d97.s15|0-15|CONTRAINDICATED|brand
DDI-DrugBank.d97.s15|52-68|life-threatening|drug
DDI-DrugBank.d97.s16|0-12|Neuroleptic:|drug
DDI-DrugBank.d97.s16|13-21|pimozide|drug
DDI-DrugBank.d97.s17|0-15|CONTRAINDICATED|brand
DDI-DrugBank.d97.s17|52-68|life-threatening|drug
DDI-DrugBank.d97.s19|66-74|CRIXIVAN|brand
DDI-DrugBank.d97.s19|103-114|inhibitors.|drug
DDI-DrugBank.d97.s20|19-27|rifampin|drug
DDI-DrugBank.d97.s21|66-74|CRIXIVAN|brand
DDI-DrugBank.d97.s21|103-113|inhibitors|drug
DDI-DrugBank.d97.s21|123-137|coadministered|drug
DDI-DrugBank.d97.s21|138-152|antiretroviral|group
DDI-DrugBank.d97.s22|18-29|inhibitors:|drug
DDI-DrugBank.d97.s22|30-41|lovastatin,|drug
DDI-DrugBank.d97.s22|42-53|simvastatin|drug
DDI-DrugBank.d97.s23|57-66|including|drug
DDI-DrugBank.d97.s24|9-19|inhibitor:|drug
DDI-DrugBank.d97.s24|20-30|atazanavir|drug
DDI-DrugBank.d97.s25|5-13|CRIXIVAN|brand
DDI-DrugBank.d97.s25|18-28|atazanavir|drug
DDI-DrugBank.d97.s25|49-57|indirect|drug
DDI-DrugBank.d97.s25|73-92|hyperbilirubinemia.|drug
DDI-DrugBank.d97.s26|0-12|Combinations|drug
DDI-DrugBank.d97.s26|54-70|coadministration|drug
DDI-DrugBank.d97.s26|74-82|CRIXIVAN|brand
DDI-DrugBank.d97.s26|87-97|atazanavir|drug
DDI-DrugBank.d97.s31|0-8|Clinical|drug
DDI-DrugBank.d97.s33|0-11|Delavirdine|drug
DDI-DrugBank.d97.s34|0-9|indinavir|drug
DDI-DrugBank.d97.s35|18-26|CRIXIVAN|brand
DDI-DrugBank.d97.s35|77-83|taking|drug
DDI-DrugBank.d97.s35|84-95|delavirdine|drug
DDI-DrugBank.d97.s36|0-10|Didanosine|drug
DDI-DrugBank.d97.s37|0-9|Indinavir|drug
DDI-DrugBank.d97.s37|14-24|didanosine|drug
DDI-DrugBank.d97.s37|38-48|containing|group
DDI-DrugBank.d97.s37|66-78|administered|drug
DDI-DrugBank.d97.s39|0-9|indinavir|drug
DDI-DrugBank.d97.s40|20-30|indinavir,|drug
DDI-DrugBank.d97.s40|45-56|combination|drug
DDI-DrugBank.d97.s41|0-10|Increasing|drug
DDI-DrugBank.d97.s41|15-24|indinavir|drug
DDI-DrugBank.d97.s41|83-92|increased|drug
DDI-DrugBank.d97.s41|93-102|indinavir|drug
DDI-DrugBank.d97.s42|0-10|Nelfinavir|drug
DDI-DrugBank.d97.s43|0-9|indinavir|drug
DDI-DrugBank.d97.s44|31-43|combination,|drug
DDI-DrugBank.d97.s45|0-10|Nevirapine|drug
DDI-DrugBank.d97.s46|0-9|indinavir|drug
DDI-DrugBank.d97.s47|0-9|Indinavir|drug
DDI-DrugBank.d97.s47|61-72|nevirapine.|drug
DDI-DrugBank.d97.s48|31-43|combination,|drug
DDI-DrugBank.d97.s49|0-9|Ritonavir|drug
DDI-DrugBank.d97.s50|0-9|indinavir|drug
DDI-DrugBank.d97.s50|26-35|ritonavir|drug
DDI-DrugBank.d97.s51|31-43|combination,|drug
DDI-DrugBank.d97.s52|0-11|Preliminary|drug
DDI-DrugBank.d97.s52|12-20|clinical|drug
DDI-DrugBank.d97.s52|43-52|incidence|drug
DDI-DrugBank.d97.s52|94-103|receiving|drug
DDI-DrugBank.d97.s52|104-113|indinavir|drug
DDI-DrugBank.d97.s52|117-128|combination|drug
DDI-DrugBank.d97.s52|134-143|ritonavir|drug
DDI-DrugBank.d97.s52|155-164|receiving|drug
DDI-DrugBank.d97.s52|165-173|CRIXIVAN|brand
DDI-DrugBank.d97.s53|0-10|Saquinavir|drug
DDI-DrugBank.d97.s54|0-10|saquinavir|drug
DDI-DrugBank.d97.s55|31-43|combination,|drug
DDI-DrugBank.d97.s57|27-36|lidocaine|drug
DDI-DrugBank.d97.s57|52-61|quinidine|drug
DDI-DrugBank.d97.s58|0-14|antiarrhythmic|group
DDI-DrugBank.d97.s59|51-61|monitoring|drug
DDI-DrugBank.d97.s59|81-96|antiarrhythmics|group
DDI-DrugBank.d97.s59|102-116|coadministered|drug
DDI-DrugBank.d97.s59|122-131|CRIXIVAN.|brand
DDI-DrugBank.d97.s60|17-31|carbamazepine,|drug
DDI-DrugBank.d97.s60|47-56|phenytoin|drug
DDI-DrugBank.d97.s61|0-9|indinavir|drug
DDI-DrugBank.d97.s63|0-8|CRIXIVAN|brand
DDI-DrugBank.d97.s63|47-56|indinavir|drug
DDI-DrugBank.d97.s63|84-90|taking|drug
DDI-DrugBank.d97.s64|0-7|Calcium|drug
DDI-DrugBank.d97.s64|26-42|Dihydropyridine:|drug
DDI-DrugBank.d97.s64|49-60|felodipine,|drug
DDI-DrugBank.d97.s64|61-72|nifedipine,|drug
DDI-DrugBank.d97.s64|73-84|nicardipine|drug
DDI-DrugBank.d97.s65|0-15|dihydropyridine|drug
DDI-DrugBank.d97.s65|16-23|calcium|drug
DDI-DrugBank.d97.s66|25-33|clinical|drug
DDI-DrugBank.d97.s66|34-44|monitoring|drug
DDI-DrugBank.d97.s67|0-14|Clarithromycin|drug
DDI-DrugBank.d97.s68|0-14|clarithromycin|drug
DDI-DrugBank.d97.s68|31-40|indinavir|drug
DDI-DrugBank.d97.s69|31-43|combination,|drug
DDI-DrugBank.d97.s70|29-41|atorvastatin|drug
DDI-DrugBank.d97.s71|0-12|atorvastatin|drug
DDI-DrugBank.d97.s72|28-40|atorvastatin|drug
DDI-DrugBank.d97.s72|54-65|monitoring,|drug
DDI-DrugBank.d97.s72|96-106|inhibitors|drug
DDI-DrugBank.d97.s72|145-152|CYP3A4,|brand
DDI-DrugBank.d97.s72|161-173|pravastatin,|drug
DDI-DrugBank.d97.s72|174-186|fluvastatin,|drug
DDI-DrugBank.d97.s72|190-202|rosuvastatin|drug
DDI-DrugBank.d97.s72|206-217|combination|drug
DDI-DrugBank.d97.s72|223-232|CRIXIVAN.|brand
DDI-DrugBank.d97.s73|20-33|cyclosporine,|drug
DDI-DrugBank.d97.s75|29-38|increased|drug
DDI-DrugBank.d97.s75|42-51|CRIXIVAN.|brand
DDI-DrugBank.d97.s76|0-12|Itraconazole|drug
DDI-DrugBank.d97.s77|0-9|indinavir|drug
DDI-DrugBank.d97.s78|18-26|CRIXIVAN|brand
DDI-DrugBank.d97.s78|71-84|administering|drug
DDI-DrugBank.d97.s78|85-97|itraconazole|drug
DDI-DrugBank.d97.s79|0-12|Ketoconazole|drug
DDI-DrugBank.d97.s80|0-9|indinavir|drug
DDI-DrugBank.d97.s81|18-26|CRIXIVAN|brand
DDI-DrugBank.d97.s82|0-9|Rifabutin|drug
DDI-DrugBank.d97.s83|0-9|indinavir|drug
DDI-DrugBank.d97.s83|26-35|rifabutin|drug
DDI-DrugBank.d97.s84|18-27|rifabutin|drug
DDI-DrugBank.d97.s84|65-73|increase|drug
DDI-DrugBank.d97.s84|77-85|CRIXIVAN|brand
DDI-DrugBank.d97.s84|104-110|333-mg|drug_n
DDI-DrugBank.d97.s84|156-165|rifabutin|drug
DDI-DrugBank.d97.s84|170-178|CRIXIVAN|brand
DDI-DrugBank.d97.s84|183-198|coadministered.|drug
DDI-DrugBank.d97.s87|86-95|receiving|drug
DDI-DrugBank.d97.s87|108-117|indinavir|drug
DDI-DrugBank.d97.s90|85-94|receiving|drug
DDI-DrugBank.d97.s90|107-116|indinavir|drug
DDI-DrugBank.d97.s93|59-66|24-hour|drug_n
DDI-DrugBank.d97.s93|86-95|receiving|drug
DDI-DrugBank.d97.s93|108-117|indinavir|drug
DDI-DrugBank.d97.s95|2-11|increase;|drug
DDI-DrugBank.d55.s0|14-27|hydrochloride|drug
DDI-DrugBank.d55.s0|28-37|injection|drug
DDI-DrugBank.d55.s0|42-53|epinephrine|drug
DDI-DrugBank.d55.s0|68-80|administered|drug
DDI-DrugBank.d55.s0|155-163|combined|drug
DDI-DrugBank.d55.s0|176-182|induce|drug
DDI-DrugBank.d55.s1|27-39|administered|drug
DDI-DrugBank.d55.s1|70-78|interval|drug
DDI-DrugBank.d55.s2|0-7|ISUPREL|brand
DDI-DrugBank.d55.s2|60-72|inhalational|drug
DDI-DrugBank.d55.s2|154-164|myocardium|drug
DDI-DrugBank.d55.s2|195-202|amines.|drug
DDI-MedLine.d86.s0|0-15|Pharmacokinetic|drug
DDI-MedLine.d86.s0|16-27|interaction|drug
DDI-MedLine.d86.s0|36-42|single|drug
DDI-MedLine.d86.s1|8-19|BACKGROUND:|brand
DDI-MedLine.d86.s1|24-39|pharmacokinetic|drug
DDI-MedLine.d86.s1|40-51|interaction|drug
DDI-MedLine.d86.s1|73-82|macrolide|drug
DDI-MedLine.d86.s1|116-123|CYP3A4,|brand
DDI-MedLine.d86.s1|132-139|calcium|drug
DDI-MedLine.d86.s2|8-18|clinically|drug
DDI-MedLine.d86.s2|29-41|interactions|drug
DDI-MedLine.d86.s2|154-161|calcium|drug
DDI-MedLine.d86.s3|0-8|METHODS:|brand
DDI-MedLine.d86.s3|128-144|pharmacokinetics|drug
DDI-MedLine.d86.s3|150-156|single|drug
DDI-MedLine.d86.s3|157-162|10-mg|drug_n
DDI-MedLine.d86.s3|189-195|single|drug
DDI-MedLine.d86.s3|201-207|120-mg|drug_n
DDI-MedLine.d86.s4|44-50|21-day|drug_n
DDI-MedLine.d86.s5|0-8|RESULTS:|brand
DDI-MedLine.d86.s5|44-53|interval)|drug
DDI-MedLine.d86.s5|54-59|whole|drug
DDI-MedLine.d86.s5|123-132|increased|drug
DDI-MedLine.d86.s5|202-211|increased|drug
DDI-MedLine.d86.s5|263-280|coadministration,|drug
DDI-MedLine.d86.s5|298-309|elimination|drug
DDI-MedLine.d86.s7|162-178|coadministration|drug
DDI-MedLine.d86.s7|272-280|pressure|group
DDI-MedLine.d86.s8|0-12|CONCLUSIONS:|brand
DDI-MedLine.d86.s8|13-24|Single-dose|drug
DDI-MedLine.d86.s8|35-51|coadministration|drug
DDI-MedLine.d86.s8|78-87|exposure,|group
DDI-MedLine.d86.s8|102-112|inhibition|drug
DDI-MedLine.d86.s9|26-38|intersubject|drug
DDI-MedLine.d86.s9|92-104|interaction,|drug
DDI-MedLine.d86.s9|105-110|whole|drug
DDI-DrugBank.d503.s0|20-28|increase|drug
DDI-DrugBank.d503.s0|69-77|lithium.|drug
DDI-DrugBank.d503.s1|18-25|lithium|drug
DDI-DrugBank.d503.s1|26-39|intoxication,|drug
DDI-DrugBank.d503.s1|40-47|lithium|drug
DDI-DrugBank.d503.s2|47-55|opioids,|group
DDI-DrugBank.d503.s2|102-107|50%),|drug_n
DDI-DrugBank.d503.s2|186-193|opioids|group
DDI-DrugBank.d503.s4|8-16|seizures|group
DDI-DrugBank.d503.s4|46-58|combination.|drug
DDI-DrugBank.d503.s5|102-117|benzodiazepines|drug
DDI-DrugBank.d503.s7|28-37|combining|drug
DDI-DrugBank.d503.s7|65-80|anticholinergic|group
DDI-DrugBank.d503.s7|98-113|antidepressants|group
DDI-DrugBank.d503.s7|118-134|antiparkinsonian|group
DDI-DrugBank.d503.s7|181-190|delirium,|drug
DDI-DrugBank.d291.s0|65-74|medicines|drug
DDI-DrugBank.d291.s0|93-102|following|drug
DDI-DrugBank.d291.s0|103-115|interactions|drug
DDI-DrugBank.d291.s0|199-213|anticoagulants|group
DDI-DrugBank.d291.s0|221-229|coumarin|drug
DDI-DrugBank.d291.s1|33-46|anticoagulant|group
DDI-DrugBank.d291.s1|152-161|according|drug
DDI-DrugBank.d291.s1|175-183|clotting|drug
DDI-DrugBank.d291.s3|16-30|sulphonylureas|group
DDI-DrugBank.d291.s3|35-42|insulin|drug
DDI-DrugBank.d291.s4|82-89|insulin|drug
DDI-DrugBank.d291.s6|100-113|corresponding|drug
DDI-DrugBank.d291.s6|114-122|increase|drug
DDI-DrugBank.d291.s6|136-146|creatinine|drug
DDI-DrugBank.d291.s6|201-210|receiving|drug
DDI-DrugBank.d291.s7|0-12|Accordingly,|drug
DDI-DrugBank.d291.s7|187-199|discontinued|group
DDI-DrugBank.d291.s9|74-80|resins|drug
DDI-DrugBank.d291.s9|87-104|cholestryramine),|drug
DDI-DrugBank.d291.s9|108-116|interval|drug
DDI-DrugBank.d291.s9|147-157|maintained|drug
DDI-DrugBank.d291.s9|174-184|medicines,|drug
DDI-DrugBank.d291.s9|185-190|since|drug
DDI-DrugBank.d291.s11|2-13|Perhexiline|drug
DDI-DrugBank.d291.s11|14-22|hydrogen|drug
DDI-DrugBank.d291.s11|34-48|MAO-inhibitors|drug
DDI-DrugBank.d291.s11|90-102|administered|drug
DDI-DrugBank.d385.s0|19-27|REGRANEX|brand
DDI-DrugBank.d385.s0|32-41|interacts|drug
DDI-DrugBank.d385.s1|11-19|REGRANEX|brand
DDI-DrugBank.d513.s0|59-68|receiving|drug
DDI-DrugBank.d513.s0|78-86|blocking|drug
DDI-DrugBank.d513.s0|130-138|pressure|group
DDI-DrugBank.d513.s1|16-25|abdominal|drug
DDI-DrugBank.d513.s1|83-92|pressure.|group
DDI-DrugBank.d439.s0|0-13|Corticotropin|drug
DDI-DrugBank.d439.s0|66-74|diuretic|group
DDI-DrugBank.d540.s0|15-26|interaction|drug
DDI-DrugBank.d540.s0|60-69|Cetrotide|drug
DDI-DrugBank.d475.s0|3-15|interactions|drug
DDI-DrugBank.d475.s0|43-53|nizatidine|drug
DDI-DrugBank.d475.s0|58-71|theophylline,|drug
DDI-DrugBank.d475.s0|101-111|lidocaine,|drug
DDI-DrugBank.d475.s0|112-122|phenytoin,|drug
DDI-DrugBank.d475.s0|127-136|warfarin.|drug
DDI-DrugBank.d475.s1|0-10|Nizatidine|drug
DDI-DrugBank.d475.s1|20-27|inhibit|drug
DDI-DrugBank.d475.s1|43-55|P-450-linked|drug
DDI-DrugBank.d475.s1|56-73|drug-metabolizing|drug
DDI-DrugBank.d475.s2|16-28|interactions|drug
DDI-DrugBank.d475.s2|41-51|inhibition|drug
DDI-DrugBank.d475.s3|47-54|aspirin|brand
DDI-DrugBank.d475.s3|62-71|increases|drug
DDI-DrugBank.d475.s3|114-125|nizatidine,|drug
DDI-DrugBank.d475.s3|145-157|administered|drug
DDI-DrugBank.d507.s0|18-27|increased|drug
DDI-DrugBank.d507.s0|42-52|guanfacine|drug
DDI-DrugBank.d507.s1|4-18|administration|drug
DDI-DrugBank.d507.s1|22-32|guanfacine|drug
DDI-DrugBank.d507.s1|76-83|inducer|drug
DDI-DrugBank.d507.s1|102-112|phenytoin)|drug
DDI-DrugBank.d507.s1|200-211|elimination|drug
DDI-DrugBank.d507.s2|40-46|dosing|drug
DDI-DrugBank.d507.s2|77-85|maintain|drug
DDI-DrugBank.d507.s3|12-22|guanfacine|drug
DDI-DrugBank.d507.s3|32-44|discontinued|group
DDI-DrugBank.d507.s3|71-79|tapering|drug
DDI-DrugBank.d507.s4|40-51|guanfacine.|drug
DDI-DrugBank.d507.s5|33-62|(nadolol,porpranolol,timolol)|drug
DDI-DrugBank.d507.s5|104-114|guanfacine|drug
DDI-DrugBank.d507.s7|26-35|guafacine|drug
DDI-DrugBank.d507.s8|57-71|anticoagulants|group
DDI-DrugBank.d507.s8|83-94|guanfacine,|drug
DDI-DrugBank.d507.s9|42-58|anticoagulation.|group
DDI-DrugBank.d507.s10|11-26|well-controlled|group
DDI-DrugBank.d507.s10|36-46|guanfacine|drug
DDI-DrugBank.d507.s10|51-63|administered|drug
DDI-DrugBank.d507.s10|78-87|diuretics|group
DDI-DrugBank.d507.s10|101-113|interactions|drug
DDI-DrugBank.d507.s11|33-43|guanfacine|drug
DDI-DrugBank.d507.s11|108-121|interactions.|drug
DDI-DrugBank.d507.s12|4-13|principal|drug
DDI-DrugBank.d507.s12|225-244|antihyperlipidemics|group
DDI-DrugBank.d507.s12|251-259|antigout|group
DDI-DrugBank.d507.s12|277-291|contraceptives|group
DDI-DrugBank.d507.s12|320-327|insulin|drug
DDI-DrugBank.d507.s13|19-27|clinical|drug
DDI-DrugBank.d507.s13|39-49|clinically|drug
DDI-DrugBank.d507.s13|133-139|during|drug
DDI-DrugBank.d507.s13|166-177|guanfacine.|drug
DDI-DrugBank.d507.s14|89-99|guanfacine|drug
DDI-DrugBank.d240.s0|0-13|Ethopropazine|drug
DDI-DrugBank.d240.s0|18-26|interact|drug
DDI-DrugBank.d240.s0|66-73|causing|drug
DDI-DrugBank.d240.s0|74-83|increased|drug
DDI-DrugBank.d240.s1|12-20|interact|drug
DDI-DrugBank.d240.s1|26-36|amantadine|drug
DDI-DrugBank.d240.s1|46-61|anticholinergic|group
DDI-DrugBank.d240.s1|88-97|intensify|drug
DDI-DrugBank.d240.s1|102-117|anticholinergic|group
DDI-DrugBank.d240.s2|0-13|Ethopropazine|drug
DDI-DrugBank.d240.s2|18-26|interact|drug
DDI-DrugBank.d240.s2|32-47|chlorpromazine,|drug
DDI-DrugBank.d240.s2|48-58|increasing|drug
DDI-DrugBank.d240.s2|77-92|chlorpromazine.|drug
DDI-DrugBank.d277.s0|3-13|evaluating|drug
DDI-DrugBank.d277.s0|32-44|interactions|drug
DDI-DrugBank.d277.s0|51-66|co-administered|drug
DDI-DrugBank.d277.s0|67-79|antiepilepsy|group
DDI-DrugBank.d277.s0|116-123|induces|drug
DDI-DrugBank.d277.s0|136-142|induce|drug
DDI-DrugBank.d277.s1|0-10|Phenytoin,|drug
DDI-DrugBank.d277.s1|29-42|carbamazepine|drug
DDI-DrugBank.d277.s1|79-88|inducers;|drug
DDI-DrugBank.d277.s2|14-24|gabapentin|drug
DDI-DrugBank.d277.s3|0-8|GABITRIL|brand
DDI-DrugBank.d277.s3|42-50|inducing|drug
DDI-DrugBank.d277.s4|9-20|interaction|drug
DDI-DrugBank.d277.s4|57-65|obtained|drug
DDI-DrugBank.d277.s4|79-88|involving|drug
DDI-DrugBank.d277.s5|11-19|GABITRIL|brand
DDI-DrugBank.d277.s5|57-67|Phenytoin:|drug
DDI-DrugBank.d277.s5|68-77|Tiagabine|drug
DDI-DrugBank.d277.s5|137-146|phenytoin|drug
DDI-DrugBank.d277.s6|0-14|Carbamazepine:|drug
DDI-DrugBank.d277.s6|15-24|Tiagabine|drug
DDI-DrugBank.d277.s6|84-97|carbamazepine|drug
DDI-DrugBank.d277.s6|105-112|epoxide|drug
DDI-DrugBank.d277.s7|11-20|Tiagabine|drug
DDI-DrugBank.d277.s8|39-54|pharmacokinetic|drug
DDI-DrugBank.d277.s8|83-92|examining|drug
DDI-DrugBank.d277.s8|109-118|tiagabine|drug
DDI-DrugBank.d277.s8|131-141|containing|group
DDI-DrugBank.d277.s9|16-25|tiagabine|drug
DDI-DrugBank.d277.s9|67-82|well-controlled|group
DDI-DrugBank.d277.s10|46-54|GABITRIL|brand
DDI-DrugBank.d277.s10|57-71|Carbamazepine:|drug
DDI-DrugBank.d277.s10|83-98|pharmacokinetic|drug
DDI-DrugBank.d277.s10|108-116|indicate|drug
DDI-DrugBank.d277.s10|122-131|tiagabine|drug
DDI-DrugBank.d277.s10|169-175|taking|drug
DDI-DrugBank.d277.s10|176-189|carbamazepine|drug
DDI-DrugBank.d277.s10|220-228|inducing|drug
DDI-DrugBank.d277.s11|0-10|Phenytoin:|drug
DDI-DrugBank.d277.s11|22-37|pharmacokinetic|drug
DDI-DrugBank.d277.s11|47-55|indicate|drug
DDI-DrugBank.d277.s11|61-70|tiagabine|drug
DDI-DrugBank.d277.s11|108-114|taking|drug
DDI-DrugBank.d277.s11|115-124|phenytoin|drug
DDI-DrugBank.d277.s11|155-163|inducing|drug
DDI-DrugBank.d277.s12|38-53|pharmacokinetic|drug
DDI-DrugBank.d277.s12|63-71|indicate|drug
DDI-DrugBank.d277.s12|77-86|tiagabine|drug
DDI-DrugBank.d277.s12|124-130|taking|drug
DDI-DrugBank.d277.s12|179-194|enzyme-inducing|drug
DDI-DrugBank.d277.s13|27-36|tiagabine|drug
DDI-DrugBank.d277.s13|49-55|taking|drug
DDI-DrugBank.d277.s13|95-104|tiagabine|drug
DDI-DrugBank.d277.s13|105-122|pharmacokinetics,|drug
DDI-DrugBank.d277.s13|161-170|tiagabine|drug
DDI-DrugBank.d277.s13|171-178|binding|drug
DDI-DrugBank.d277.s13|201-207|94.8%,|drug_n
DDI-DrugBank.d277.s13|229-237|increase|drug
DDI-DrugBank.d277.s13|271-280|tiagabine|drug
DDI-DrugBank.d277.s14|4-12|clinical|drug
DDI-DrugBank.d277.s14|40-47|finding|drug
DDI-DrugBank.d277.s15|15-23|GABITRIL|brand
DDI-DrugBank.d277.s15|43-53|Cimetidine|drug
DDI-DrugBank.d277.s15|56-73|Co-administration|drug
DDI-DrugBank.d277.s15|77-87|cimetidine|drug
DDI-DrugBank.d277.s15|113-119|taking|drug
DDI-DrugBank.d277.s15|120-129|tiagabine|drug
DDI-DrugBank.d277.s15|159-168|tiagabine|drug
DDI-DrugBank.d277.s15|169-186|pharmacokinetics.|drug
DDI-DrugBank.d277.s16|0-13|Theophylline:|drug
DDI-DrugBank.d277.s16|16-22|single|drug
DDI-DrugBank.d277.s16|37-46|tiagabine|drug
DDI-DrugBank.d277.s16|66-82|pharmacokinetics|drug
DDI-DrugBank.d277.s16|86-98|theophylline|drug
DDI-DrugBank.d277.s17|0-9|Warfarin:|drug
DDI-DrugBank.d277.s17|71-87|pharmacokinetics|drug
DDI-DrugBank.d277.s17|91-101|R-warfarin|drug
DDI-DrugBank.d277.s17|105-115|S-warfarin|drug
DDI-DrugBank.d277.s17|137-146|tiagabine|drug
DDI-DrugBank.d277.s17|158-164|single|drug
DDI-DrugBank.d277.s18|0-11|Prothrombin|drug
DDI-DrugBank.d277.s18|39-49|tiagabine.|drug
DDI-DrugBank.d277.s19|0-8|Digoxin:|drug
DDI-DrugBank.d277.s19|21-35|administration|drug
DDI-DrugBank.d277.s19|39-48|tiagabine|drug
DDI-DrugBank.d277.s19|81-97|pharmacokinetics|drug
DDI-DrugBank.d277.s19|101-108|digoxin|drug
DDI-DrugBank.d277.s19|149-157|digoxin.|drug
DDI-DrugBank.d277.s20|0-7|Ethanol|drug
DDI-DrugBank.d277.s20|70-86|pharmacokinetics|drug
DDI-DrugBank.d277.s20|90-99|triazolam|drug
DDI-DrugBank.d277.s20|115-124|tiagabine|drug
DDI-DrugBank.d277.s20|158-164|single|drug
DDI-DrugBank.d277.s21|4-20|pharmacokinetics|drug
DDI-DrugBank.d277.s21|24-31|ethanol|drug
DDI-DrugBank.d277.s21|67-81|administration|drug
DDI-DrugBank.d277.s21|85-95|tiagabine.|drug
DDI-DrugBank.d277.s22|0-9|Tiagabine|drug
DDI-DrugBank.d277.s22|23-33|clinically|drug
DDI-DrugBank.d277.s23|87-94|ethanol|drug
DDI-DrugBank.d277.s23|98-107|triazolam|drug
DDI-DrugBank.d277.s23|137-148|combination|drug
DDI-DrugBank.d277.s23|154-164|tiagabine.|drug
DDI-DrugBank.d277.s24|35-49|administration|drug
DDI-DrugBank.d277.s24|53-62|tiagabine|drug
DDI-DrugBank.d277.s24|104-120|pharmacokinetics|drug
DDI-DrugBank.d277.s24|129-143|contraceptives|group
DDI-DrugBank.d277.s24|164-176|childbearing|drug
DDI-DrugBank.d277.s25|0-10|Antipyrine|drug
DDI-DrugBank.d277.s25|13-23|Antipyrine|drug
DDI-DrugBank.d277.s25|24-40|pharmacokinetics|drug
DDI-DrugBank.d277.s25|91-100|tiagabine|drug
DDI-DrugBank.d277.s26|5-14|indicates|drug
DDI-DrugBank.d277.s26|20-29|tiagabine|drug
DDI-DrugBank.d277.s26|45-54|induction|drug
DDI-DrugBank.d277.s26|58-68|inhibition|drug
DDI-DrugBank.d277.s26|144-155|antipyrine.|group
DDI-DrugBank.d277.s27|15-23|GABITRIL|brand
DDI-DrugBank.d277.s27|36-43|Protein|drug
DDI-DrugBank.d277.s27|83-92|tiagabine|drug
DDI-DrugBank.d277.s27|122-129|protein|drug
DDI-DrugBank.d277.s27|165-173|interact|drug
DDI-DrugBank.d277.s27|192-199|protein|drug
DDI-DrugBank.d277.s28|8-19|interaction|drug
DDI-DrugBank.d277.s28|76-85|tiagabine|drug
DDI-DrugBank.d277.s28|93-102|competing|drug
DDI-DrugBank.d558.s1|23-34|Cimetidine:|drug
DDI-DrugBank.d558.s1|54-64|cimetidine|drug
DDI-DrugBank.d558.s1|68-84|contraindicated.|group
DDI-DrugBank.d558.s2|0-10|Cimetidine|drug
DDI-DrugBank.d558.s2|55-70|co-administered|drug
DDI-DrugBank.d558.s2|76-83|TIKOSYN|brand
DDI-DrugBank.d558.s2|127-135|increase|drug
DDI-DrugBank.d558.s2|136-146|dofetilide|drug
DDI-DrugBank.d558.s3|0-10|Cimetidine|drug
DDI-DrugBank.d558.s3|63-71|increase|drug
DDI-DrugBank.d558.s3|75-85|dofetilide|drug
DDI-DrugBank.d558.s3|109-115|single|drug
DDI-DrugBank.d558.s4|34-46|intermediate|drug
DDI-DrugBank.d558.s4|56-67|cimetidine.|drug
DDI-DrugBank.d558.s5|22-29|TIKOSYN|brand
DDI-DrugBank.d558.s5|34-44|anti-ulcer|group
DDI-DrugBank.d558.s5|75-86|omeprazole,|drug
DDI-DrugBank.d558.s5|87-98|ranitidine,|drug
DDI-DrugBank.d558.s5|102-110|antacids|group
DDI-DrugBank.d558.s5|111-120|(aluminum|drug
DDI-DrugBank.d558.s5|125-134|magnesium|drug
DDI-DrugBank.d558.s5|135-146|hydroxides)|drug
DDI-DrugBank.d558.s5|174-185|cimetidine,|drug
DDI-DrugBank.d558.s5|224-239|pharmacokinetic|drug
DDI-DrugBank.d558.s5|251-259|TIKOSYN.|brand
DDI-DrugBank.d558.s6|43-59|contraindicated.|group
DDI-DrugBank.d558.s7|0-17|Co-administration|drug
DDI-DrugBank.d558.s7|21-28|TIKOSYN|brand
DDI-DrugBank.d558.s7|56-65|increases|drug
DDI-DrugBank.d558.s7|69-79|dofetilide|drug
DDI-DrugBank.d558.s7|124-132|exposure|group
DDI-DrugBank.d558.s7|136-146|dofetilide|drug
DDI-DrugBank.d558.s7|169-179|increased.|drug
DDI-DrugBank.d558.s8|54-61|DIAMOND|brand
DDI-DrugBank.d558.s8|99-113|administration|drug
DDI-DrugBank.d558.s8|132-142|dofetilide|drug
DDI-DrugBank.d558.s8|197-205|pointes.|drug
DDI-DrugBank.d558.s9|0-13|Ketoconazole:|drug
DDI-DrugBank.d558.s9|33-45|ketoconazole|drug
DDI-DrugBank.d558.s9|49-65|contraindicated.|group
DDI-DrugBank.d558.s10|0-12|Ketoconazole|drug
DDI-DrugBank.d558.s10|70-85|co-administered|drug
DDI-DrugBank.d558.s10|91-98|TIKOSYN|brand
DDI-DrugBank.d558.s10|142-150|increase|drug
DDI-DrugBank.d558.s10|151-161|dofetilide|drug
DDI-DrugBank.d558.s11|25-36|Combination|drug
DDI-DrugBank.d558.s11|42-59|Sulfamethoxazole:|drug
DDI-DrugBank.d558.s11|104-115|combination|drug
DDI-DrugBank.d558.s11|121-137|sulfamethoxazole|drug
DDI-DrugBank.d558.s11|141-157|contraindicated.|group
DDI-DrugBank.d558.s12|0-19|Hydrochlorothiazide|group
DDI-DrugBank.d558.s12|20-26|(HCTZ)|brand
DDI-DrugBank.d558.s12|39-50|Combination|drug
DDI-DrugBank.d558.s12|105-116|combination|drug
DDI-DrugBank.d558.s12|137-153|contraindicated.|group
DDI-DrugBank.d558.s13|34-40|50/100|drug_n
DDI-DrugBank.d558.s13|51-66|co-administered|drug
DDI-DrugBank.d558.s13|72-79|TIKOSYN|brand
DDI-DrugBank.d558.s13|105-115|(following|drug
DDI-DrugBank.d558.s13|126-134|diuretic|group
DDI-DrugBank.d558.s14|12-21|receiving|drug
DDI-DrugBank.d558.s14|34-44|dofetilide|drug
DDI-DrugBank.d558.s14|49-58|increased|drug
DDI-DrugBank.d558.s15|36-45|increased|drug
DDI-DrugBank.d558.s15|59-67|increase|drug
DDI-DrugBank.d558.s15|103-113|increase).|drug
DDI-DrugBank.d558.s16|36-45|increased|drug
DDI-DrugBank.d558.s16|59-67|increase|drug
DDI-DrugBank.d558.s16|103-113|increase).|drug
DDI-DrugBank.d558.s17|35-44|explained|drug
DDI-DrugBank.d558.s17|50-61|combination|drug
DDI-DrugBank.d558.s17|69-77|increase|drug
DDI-DrugBank.d558.s17|81-91|dofetilide|drug
DDI-DrugBank.d558.s17|92-100|exposure|group
DDI-DrugBank.d558.s17|129-139|potassium.|drug
DDI-DrugBank.d558.s18|7-14|DIAMOND|brand
DDI-DrugBank.d558.s18|55-62|TIKOSYN|brand
DDI-DrugBank.d558.s18|67-76|diuretics|group
DDI-DrugBank.d558.s18|155-164|receiving|drug
DDI-DrugBank.d558.s18|177-187|diuretics.|group
DDI-DrugBank.d558.s19|28-37|potassium|drug
DDI-DrugBank.d558.s19|38-47|depleting|drug
DDI-DrugBank.d558.s19|48-57|diuretics|group
DDI-DrugBank.d558.s19|104-111|DIAMOND|brand
DDI-DrugBank.d558.s19|136-143|TIKOSYN|brand
DDI-DrugBank.d558.s19|216-222|0.376,|drug_n
DDI-DrugBank.d558.s19|223-230|1.230).|drug_n
DDI-DrugBank.d558.s20|28-38|Dofetilide|drug
DDI-DrugBank.d558.s20|42-52|eliminated|drug
DDI-DrugBank.d558.s21|43-58|contraindicated|group
DDI-DrugBank.d558.s21|64-72|TIKOSYN.|brand
DDI-DrugBank.d558.s22|81-90|metformin|drug
DDI-DrugBank.d558.s22|116-131|co-administered|drug
DDI-DrugBank.d558.s22|156-164|increase|drug
DDI-DrugBank.d558.s22|165-175|dofetilide|drug
DDI-DrugBank.d558.s23|0-10|Dofetilide|drug
DDI-DrugBank.d558.s23|51-57|CYP3A4|brand
DDI-DrugBank.d558.s24|18-24|CYP3A4|brand
DDI-DrugBank.d558.s24|41-49|increase|drug
DDI-DrugBank.d558.s24|59-69|dofetilide|drug
DDI-DrugBank.d558.s24|70-79|exposure.|group
DDI-DrugBank.d558.s25|36-45|macrolide|drug
DDI-DrugBank.d558.s25|46-58|antibiotics,|group
DDI-DrugBank.d558.s25|59-64|azole|drug
DDI-DrugBank.d558.s25|65-75|antifungal|group
DDI-DrugBank.d558.s25|93-104|inhibitors,|drug
DDI-DrugBank.d558.s25|105-114|serotonin|drug
DDI-DrugBank.d558.s25|124-135|inhibitors,|drug
DDI-DrugBank.d558.s25|148-161|cannabinoids,|group
DDI-DrugBank.d558.s25|203-215|norfloxacin,|drug
DDI-DrugBank.d558.s25|216-224|quinine,|drug
DDI-DrugBank.d558.s25|259-273|coadministered|drug
DDI-DrugBank.d558.s25|279-286|TIKOSYN|brand
DDI-DrugBank.d558.s25|311-319|increase|drug
DDI-DrugBank.d558.s25|320-330|dofetilide|drug
DDI-DrugBank.d558.s26|0-10|Dofetilide|drug
DDI-DrugBank.d558.s26|21-30|inhibitor|drug
DDI-DrugBank.d558.s26|34-40|CYP3A4|brand
DDI-DrugBank.d558.s26|88-95|CYP2C9,|brand
DDI-DrugBank.d558.s26|96-103|CYP2D6)|brand
DDI-DrugBank.d558.s26|127-135|increase|drug
DDI-DrugBank.d558.s26|167-174|CYP3A4.|brand
DDI-DrugBank.d558.s27|35-43|Digoxin:|drug
DDI-DrugBank.d558.s27|90-97|TIKOSYN|brand
DDI-DrugBank.d558.s27|118-134|pharmacokinetics|drug
DDI-DrugBank.d558.s27|138-146|digoxin.|drug
DDI-DrugBank.d558.s28|29-43|administration|drug
DDI-DrugBank.d558.s28|47-54|digoxin|drug
DDI-DrugBank.d558.s28|60-70|dofetilide|drug
DDI-DrugBank.d558.s28|125-133|pointes.|drug
DDI-DrugBank.d558.s29|43-54|interaction|drug
DDI-DrugBank.d558.s29|60-67|TIKOSYN|brand
DDI-DrugBank.d558.s29|139-147|digoxin;|drug
DDI-DrugBank.d558.s31|3-11|increase|drug
DDI-DrugBank.d558.s31|50-56|taking|drug
DDI-DrugBank.d558.s31|57-64|digoxin|drug
DDI-DrugBank.d558.s32|36-47|amlodipine,|drug
DDI-DrugBank.d558.s32|48-58|phenytoin,|drug
DDI-DrugBank.d558.s32|70-81|ranitidine,|drug
DDI-DrugBank.d558.s32|82-93|omeprazole,|drug
DDI-DrugBank.d558.s32|125-136|combination|drug
DDI-DrugBank.d558.s32|195-204|(aluminum|drug
DDI-DrugBank.d558.s32|209-218|magnesium|drug
DDI-DrugBank.d558.s32|219-230|hydroxides)|drug
DDI-DrugBank.d558.s32|235-247|theophylline|drug
DDI-DrugBank.d558.s32|267-283|pharmacokinetics|drug
DDI-DrugBank.d558.s32|287-295|TIKOSYN.|brand
DDI-DrugBank.d558.s33|59-66|TIKOSYN|brand
DDI-DrugBank.d558.s33|87-103|pharmacokinetics|drug
DDI-DrugBank.d558.s33|127-136|warfarin,|drug
DDI-DrugBank.d558.s33|144-160|pharmacokinetics|drug
DDI-DrugBank.d558.s33|164-175|propranolol|drug
DDI-DrugBank.d558.s33|197-207|phenytoin,|drug
DDI-DrugBank.d558.s33|208-221|theophylline,|drug
DDI-DrugBank.d558.s33|230-245|contraceptives.|group
DDI-DrugBank.d558.s34|11-26|pharmacokinetic|drug
DDI-DrugBank.d558.s34|102-110|clinical|drug
DDI-DrugBank.d558.s34|121-128|examine|drug
DDI-DrugBank.d558.s35|44-55|inhibitors,|drug
DDI-DrugBank.d558.s35|61-76|anticoagulants,|group
DDI-DrugBank.d558.s35|77-84|calcium|drug
DDI-DrugBank.d558.s35|138-146|inducers|drug
DDI-DrugBank.d558.s35|150-157|CYP3A4,|brand
DDI-DrugBank.d558.s35|173-183|inhibitors|drug
DDI-DrugBank.d558.s35|187-194|CYP3A4,|brand
DDI-DrugBank.d558.s35|210-220|inhibitors|drug
DDI-DrugBank.d558.s35|224-239|P-glycoprotein,|drug
DDI-DrugBank.d558.s35|250-265|sulphonylureas,|group
DDI-DrugBank.d558.s35|271-281|diuretics,|group
DDI-DrugBank.d558.s35|282-291|potassium|drug
DDI-DrugBank.d558.s35|292-299|sparing|drug
DDI-DrugBank.d558.s35|300-310|diuretics,|group
DDI-DrugBank.d558.s35|311-319|thiazide|group
DDI-DrugBank.d558.s35|320-330|diuretics,|group
DDI-DrugBank.d558.s35|346-356|inhibitors|drug
DDI-DrugBank.d558.s35|398-412|QTc-prolonging|drug
DDI-DrugBank.d558.s37|23-33|dofetilide|drug
DDI-DrugBank.d558.s37|72-80|thiazide|group
DDI-DrugBank.d558.s37|81-90|diuretics|group
DDI-DrugBank.d558.s37|95-105|inhibitors|drug
DDI-MedLine.d103.s0|0-9|Magnesium|drug
DDI-MedLine.d103.s1|36-45|magnesium|drug
DDI-MedLine.d103.s1|75-84|magnesium|drug
DDI-MedLine.d103.s1|125-130|since|drug
DDI-MedLine.d103.s1|144-153|magnesium|drug
DDI-MedLine.d103.s1|177-188|normalizing|drug
DDI-MedLine.d103.s1|193-202|magnesium|drug
DDI-MedLine.d103.s1|203-209|intake|drug
DDI-MedLine.d103.s1|230-239|magnesium|drug
DDI-MedLine.d103.s1|258-264|induce|drug
DDI-MedLine.d103.s1|274-279|since|drug
DDI-MedLine.d103.s1|302-311|magnesium|drug
DDI-MedLine.d103.s2|22-31|magnesium|drug
DDI-MedLine.d103.s2|65-75|indication|drug
DDI-MedLine.d103.s2|98-107|magnesium|drug
DDI-MedLine.d103.s3|37-47|acquainted|drug
DDI-MedLine.d103.s3|57-65|clinical|drug
DDI-MedLine.d103.s3|70-82|paraclinical|drug
DDI-MedLine.d103.s3|94-103|magnesium|drug
DDI-MedLine.d103.s3|119-131|discriminate|drug
DDI-MedLine.d103.s3|140-149|magnesium|drug
DDI-MedLine.d103.s3|171-183|insufficient|drug
DDI-MedLine.d103.s3|184-193|magnesium|drug
DDI-MedLine.d103.s3|194-200|intake|drug
DDI-MedLine.d103.s3|260-269|magnesium|drug
DDI-MedLine.d103.s3|314-321|control|group
DDI-MedLine.d103.s3|336-345|magnesium|drug
DDI-MedLine.d103.s4|19-28|magnesium|drug
DDI-MedLine.d103.s4|77-86|magnesium|drug
DDI-MedLine.d103.s5|19-28|magnesium|drug
DDI-MedLine.d103.s5|110-119|magnesium|drug
DDI-MedLine.d103.s5|153-171|contra-indication:|group
DDI-MedLine.d103.s5|184-192|failure.|group
DDI-MedLine.d103.s6|37-46|magnesium|drug
DDI-MedLine.d103.s6|68-73|using|drug
DDI-MedLine.d103.s6|86-95|magnesium|drug
DDI-MedLine.d103.s6|96-103|sparing|drug
DDI-MedLine.d103.s6|104-114|diuretics,|group
DDI-MedLine.d103.s6|140-147|vitamin|drug
DDI-MedLine.d103.s6|175-182|vitamin|drug
DDI-MedLine.d103.s6|192-201|selenium.|drug
DDI-MedLine.d103.s7|50-57|induced|drug
DDI-MedLine.d103.s7|107-116|magnesium|drug
DDI-MedLine.d103.s7|160-171|indications|drug
DDI-MedLine.d103.s7|219-231|indications.|drug
DDI-MedLine.d103.s8|21-33|indications:|drug
DDI-MedLine.d103.s8|79-88|magnesium|drug
DDI-MedLine.d103.s8|155-164|magnesium|drug
DDI-MedLine.d103.s9|22-31|magnesium|drug
DDI-MedLine.d103.s9|40-46|mainly|drug
DDI-MedLine.d103.s10|9-20|indications|drug
DDI-MedLine.d103.s10|67-73|pointe|drug
DDI-MedLine.d103.s11|74-85|indications|drug
DDI-MedLine.d103.s11|89-99|magnesium.|drug
DDI-MedLine.d103.s12|0-9|Magnesium|drug
DDI-MedLine.d103.s12|10-19|infusions|drug
DDI-MedLine.d103.s12|45-54|intensive|drug
DDI-MedLine.d103.s12|79-89|monitoring|drug
DDI-MedLine.d103.s12|109-118|pressure,|group
DDI-MedLine.d103.s12|148-157|diuresis,|group
DDI-MedLine.d103.s12|192-203|recordings.|drug
DDI-MedLine.d103.s13|10-19|magnesium|drug
DDI-MedLine.d103.s13|60-65|bring|drug
DDI-MedLine.d103.s14|10-16|remain|drug
DDI-MedLine.d103.s14|22-33|indications|drug
DDI-MedLine.d103.s14|88-98|magnesium,|drug
DDI-MedLine.d103.s14|112-118|during|drug
DDI-MedLine.d103.s14|119-131|intermittent|drug
DDI-MedLine.d103.s15|71-80|magnesium|drug
DDI-DrugBank.d217.s0|26-38|theophylline|drug
DDI-DrugBank.d217.s0|75-84|quinolone|drug
DDI-DrugBank.d217.s1|27-47|theophylline-related|drug
DDI-DrugBank.d217.s1|101-112|norfloxacin|drug
DDI-DrugBank.d217.s1|117-130|theophylline.|drug
DDI-DrugBank.d217.s2|11-21|monitoring|drug
DDI-DrugBank.d217.s2|25-37|theophylline|drug
DDI-DrugBank.d217.s2|87-99|theophylline|drug
DDI-DrugBank.d217.s3|25-37|cyclosporine|drug
DDI-DrugBank.d217.s3|81-93|cyclosporine|drug
DDI-DrugBank.d217.s3|99-111|norfloxacin.|drug
DDI-DrugBank.d217.s4|11-23|cyclosporine|drug
DDI-DrugBank.d217.s4|73-85|cyclosporine|drug
DDI-DrugBank.d217.s5|0-11|Quinolones,|drug
DDI-DrugBank.d217.s5|12-21|including|drug
DDI-DrugBank.d217.s5|22-34|norfloxacin,|drug
DDI-DrugBank.d217.s5|67-82|anticoagulants,|group
DDI-DrugBank.d217.s5|83-92|including|drug
DDI-DrugBank.d217.s5|93-101|warfarin|drug
DDI-DrugBank.d217.s6|24-36|administered|drug
DDI-DrugBank.d217.s6|52-63|prothrombin|drug
DDI-DrugBank.d217.s7|16-30|administration|drug
DDI-DrugBank.d217.s7|34-44|quinolones|drug
DDI-DrugBank.d217.s7|45-54|including|drug
DDI-DrugBank.d217.s7|55-66|norfloxacin|drug
DDI-DrugBank.d217.s7|72-81|glyburide|drug
DDI-DrugBank.d217.s7|85-97|sulfonylurea|group
DDI-DrugBank.d217.s8|11-21|monitoring|drug
DDI-DrugBank.d217.s8|76-92|co-administered.|drug
DDI-DrugBank.d217.s9|0-10|Diminished|drug
DDI-DrugBank.d217.s9|11-18|urinary|drug
DDI-DrugBank.d217.s9|32-43|norfloxacin|drug
DDI-DrugBank.d217.s9|62-68|during|drug
DDI-DrugBank.d217.s9|85-99|administration|drug
DDI-DrugBank.d217.s9|118-130|norfloxacin.|drug
DDI-DrugBank.d217.s10|23-37|nitrofurantoin|drug
DDI-DrugBank.d217.s10|57-62|since|drug
DDI-DrugBank.d217.s10|63-77|nitrofurantoin|drug
DDI-DrugBank.d217.s10|97-110|antibacterial|group
DDI-DrugBank.d217.s10|121-132|Norfloxacin|drug
DDI-DrugBank.d217.s10|140-147|urinary|drug
DDI-DrugBank.d217.s11|0-14|Multivitamins,|drug
DDI-DrugBank.d217.s11|33-43|containing|group
DDI-DrugBank.d217.s11|52-57|zinc,|drug
DDI-DrugBank.d217.s11|58-66|antacids|group
DDI-DrugBank.d217.s11|95-107|administered|drug
DDI-DrugBank.d217.s11|131-137|within|drug
DDI-DrugBank.d217.s11|154-168|administration|drug
DDI-DrugBank.d217.s11|172-184|norfloxacin,|drug
DDI-DrugBank.d217.s11|202-211|interfere|drug
DDI-DrugBank.d217.s11|228-237|resulting|drug
DDI-DrugBank.d217.s11|257-262|urine|drug
DDI-DrugBank.d217.s11|273-285|norfloxacin.|drug
DDI-DrugBank.d217.s12|6-18|(Didanosine)|drug
DDI-DrugBank.d217.s12|101-113|administered|drug
DDI-DrugBank.d217.s12|137-143|within|drug
DDI-DrugBank.d217.s12|160-174|administration|drug
DDI-DrugBank.d217.s12|178-190|norfloxacin,|drug
DDI-DrugBank.d217.s12|218-227|interfere|drug
DDI-DrugBank.d217.s12|244-253|resulting|drug
DDI-DrugBank.d217.s12|273-278|urine|drug
DDI-DrugBank.d217.s12|289-301|norfloxacin.|drug
DDI-DrugBank.d217.s13|5-15|quinolones|drug
DDI-DrugBank.d217.s13|40-49|interfere|drug
DDI-DrugBank.d217.s13|73-82|caffeine.|drug
DDI-DrugBank.d217.s14|38-46|caffeine|drug
DDI-DrugBank.d364.s0|61-78|drug-metabolizing|drug
DDI-DrugBank.d364.s0|88-96|inducers|drug
DDI-DrugBank.d364.s0|100-110|inhibitors|drug
DDI-DrugBank.d364.s1|0-11|Fluvoxamine|drug
DDI-DrugBank.d364.s1|30-39|inhibitor|drug
DDI-DrugBank.d364.s1|43-49|CYP1A2|brand
DDI-DrugBank.d364.s1|59-67|inhibits|drug
DDI-DrugBank.d364.s1|68-75|CYP3A4,|brand
DDI-DrugBank.d364.s1|76-83|CYP2C9,|brand
DDI-DrugBank.d364.s1|88-96|CYP2C19.|brand
DDI-DrugBank.d364.s2|5-20|pharmacokinetic|drug
DDI-DrugBank.d364.s2|64-75|fluvoxamine|drug
DDI-DrugBank.d364.s2|79-89|escalating|drug
DDI-DrugBank.d364.s2|140-156|coadministration|drug
DDI-DrugBank.d364.s3|0-11|Fluvoxamine|drug
DDI-DrugBank.d364.s3|12-21|increased|drug
DDI-DrugBank.d364.s3|59-64|(AUC)|brand
DDI-DrugBank.d364.s3|79-85|6-fold|drug_n
DDI-DrugBank.d364.s3|131-138|3-fold.|drug_n
DDI-DrugBank.d364.s4|12-26|administration|drug
DDI-DrugBank.d364.s4|44-55|fluvoxamine|drug
DDI-DrugBank.d364.s4|59-75|contraindicated.|group
DDI-DrugBank.d364.s5|12-26|administration|drug
DDI-DrugBank.d364.s5|53-59|CYP1A2|brand
DDI-DrugBank.d364.s5|60-71|inhibitors,|drug
DDI-DrugBank.d364.s5|72-81|including|drug
DDI-DrugBank.d364.s5|82-91|quinolone|drug
DDI-DrugBank.d364.s5|92-103|antibiotics|group
DDI-DrugBank.d364.s5|108-119|cimetidine,|drug
DDI-DrugBank.d364.s5|173-183|clinically|drug
DDI-DrugBank.d364.s5|228-241|interactions.|drug
DDI-DrugBank.d364.s6|0-12|Ketoconazole|drug
DDI-DrugBank.d364.s6|31-40|inhibitor|drug
DDI-DrugBank.d364.s6|44-51|CYP3A4.|brand
DDI-DrugBank.d364.s7|5-20|pharmacokinetic|drug
DDI-DrugBank.d364.s7|64-76|ketoconazole|drug
DDI-DrugBank.d364.s7|113-129|coadministration|drug
DDI-DrugBank.d364.s8|0-12|Ketoconazole|drug
DDI-DrugBank.d364.s8|13-22|increased|drug
DDI-DrugBank.d364.s8|60-65|(AUC)|brand
DDI-DrugBank.d364.s9|42-54|ketoconazole|drug
DDI-DrugBank.d364.s9|59-71|administered|drug
DDI-DrugBank.d364.s10|0-16|Coadministration|drug
DDI-DrugBank.d364.s10|41-47|CYP3A4|brand
DDI-DrugBank.d364.s10|48-59|inhibitors,|drug
DDI-DrugBank.d364.s10|68-83|clarithromycin,|drug
DDI-DrugBank.d364.s10|84-98|telithromycin,|drug
DDI-DrugBank.d364.s10|108-119|inhibitors,|drug
DDI-DrugBank.d364.s10|120-133|voriconazole,|drug
DDI-DrugBank.d364.s10|138-150|itraconazole|drug
DDI-DrugBank.d364.s10|246-259|interactions.|drug
DDI-DrugBank.d364.s11|14-23|induction|drug
DDI-DrugBank.d364.s11|27-37|inhibition|drug
DDI-DrugBank.d364.s11|59-67|exposure|group
DDI-DrugBank.d364.s12|112-119|inhibit|drug
DDI-DrugBank.d364.s12|150-155|2C19.|brand
DDI-DrugBank.d364.s13|39-46|27-fold|drug_n
DDI-DrugBank.d364.s13|127-136|inhibited|drug
DDI-DrugBank.d364.s14|55-62|inhibit|drug
DDI-DrugBank.d364.s14|63-69|CYP2E1|brand
DDI-DrugBank.d364.s14|90-100|inhibition|drug
DDI-DrugBank.d364.s14|109-115|CYP1A2|brand
DDI-DrugBank.d364.s15|37-47|inhibition|drug
DDI-DrugBank.d364.s15|80-90|clinically|drug
DDI-DrugBank.d364.s15|142-155|procainamide,|drug
DDI-DrugBank.d364.s15|160-172|hydralazine.|drug
DDI-DrugBank.d364.s16|14-20|CYP1A2|brand
DDI-DrugBank.d364.s16|47-55|clinical|drug
DDI-DrugBank.d364.s16|56-67|interaction|drug
DDI-DrugBank.d364.s16|79-91|theophylline|drug
DDI-DrugBank.d364.s17|43-53|clinically|drug
DDI-DrugBank.d364.s17|110-123|contraceptive|group
DDI-DrugBank.d364.s17|131-138|ethinyl|drug
DDI-DrugBank.d364.s17|168-175|(CYP3A4|brand
DDI-DrugBank.d364.s18|2-10|clinical|drug
DDI-DrugBank.d364.s18|11-22|interaction|drug
DDI-DrugBank.d364.s18|71-77|CYP3A4|brand
DDI-DrugBank.d364.s19|26-35|cisapride|drug
DDI-DrugBank.d364.s19|53-61|interval|drug
DDI-DrugBank.d364.s20|27-36|monoamine|drug
DDI-DrugBank.d364.s20|53-63|intestinal|drug
DDI-DrugBank.d364.s20|93-105|intraluminal|drug
DDI-DrugBank.d364.s20|135-144|examined.|drug
DDI-DrugBank.d364.s21|94-101|inhibit|drug
DDI-DrugBank.d364.s21|221-226|2C19,|brand
DDI-DrugBank.d364.s22|29-35|induce|drug
DDI-DrugBank.d364.s22|62-67|(CYP)|brand
DDI-DrugBank.d364.s22|73-85|metabolizing|drug
DDI-DrugBank.d364.s23|34-40|induce|drug
DDI-DrugBank.d364.s23|60-65|2C19.|brand
DDI-DrugBank.d364.s24|40-46|induce|drug
DDI-DrugBank.d202.s0|47-62|antidepressants|group
DDI-DrugBank.d202.s0|108-118|cimetidine|drug
DDI-DrugBank.d202.s1|8-23|anticholinergic|group
DDI-DrugBank.d202.s1|52-59|urinary|drug
DDI-DrugBank.d202.s1|157-172|antidepressants|group
DDI-DrugBank.d202.s1|178-188|cimetidine|drug
DDI-DrugBank.d202.s2|81-96|antidepressants|group
DDI-DrugBank.d202.s2|132-141|initiated|drug
DDI-DrugBank.d202.s2|162-168|taking|drug
DDI-DrugBank.d202.s2|169-180|cimetidine.|drug
DDI-DrugBank.d202.s3|3-18|well-controlled|group
DDI-DrugBank.d202.s3|28-38|undergoing|drug
DDI-DrugBank.d202.s3|63-74|cimetidine,|drug
DDI-DrugBank.d202.s3|140-155|antidepressants|group
DDI-DrugBank.d202.s3|171-182|cime-tidine|drug
DDI-DrugBank.d202.s3|194-207|discontinued.|group
DDI-DrugBank.d202.s4|38-53|antidepressants|group
DDI-DrugBank.d202.s4|96-106|cimetidine|drug
DDI-DrugBank.d202.s4|110-123|discontinued.|group
DDI-DrugBank.d202.s5|25-40|antidepressants|group
DDI-DrugBank.d202.s6|29-35|2-fold|drug_n
DDI-DrugBank.d202.s6|36-45|increases|drug
DDI-DrugBank.d202.s6|90-106|antidepressants,|group
DDI-DrugBank.d202.s6|107-116|including|drug
DDI-DrugBank.d202.s6|117-131|nortriptyline,|drug
DDI-DrugBank.d202.s6|137-147|fluoxetine|drug
DDI-DrugBank.d202.s6|148-161|hydrochloride|drug
DDI-DrugBank.d202.s6|171-183|administered|drug
DDI-DrugBank.d202.s6|187-198|combination|drug
DDI-DrugBank.d202.s7|0-10|Fluoxetine|drug
DDI-DrugBank.d202.s7|38-53|norfluoxe-tine,|drug
DDI-DrugBank.d202.s7|93-108|norfluoxetine),|drug
DDI-DrugBank.d202.s7|136-142|during|drug
DDI-DrugBank.d202.s8|0-14|Administration|drug
DDI-DrugBank.d202.s8|18-27|reserpine|drug
DDI-DrugBank.d202.s8|28-34|during|drug
DDI-DrugBank.d202.s8|60-74|antidepressant|group
DDI-DrugBank.d202.s8|104-115|stimulating|drug
DDI-DrugBank.d202.s9|73-86|nortriptyline|drug
DDI-DrugBank.d202.s9|87-100|hydrochloride|drug
DDI-DrugBank.d202.s9|120-135|anticholinergic|group
DDI-DrugBank.d202.s10|22-30|informed|drug
DDI-DrugBank.d202.s11|21-29|P450IID6|brand
DDI-DrugBank.d202.s11|94-101|certain|drug
DDI-DrugBank.d202.s11|107-119|metabolizing|drug
DDI-DrugBank.d202.s11|166-175|P450IID6.|brand
DDI-DrugBank.d202.s12|5-16|individuals|drug
DDI-DrugBank.d202.s12|73-85|debrisoquin,|drug
DDI-DrugBank.d202.s12|122-138|antidepressants.|group
DDI-DrugBank.d202.s13|6-17|individuals|drug
DDI-DrugBank.d202.s13|83-98|antidepressants|group
DDI-DrugBank.d202.s14|13-20|certain|drug
DDI-DrugBank.d202.s14|67-76|including|drug
DDI-DrugBank.d202.s14|82-97|antidepressants|group
DDI-DrugBank.d202.s14|109-125|antidepressants,|group
DDI-DrugBank.d202.s14|136-145|serotonin|drug
DDI-DrugBank.d202.s14|155-166|inhibitors,|drug
DDI-DrugBank.d202.s14|184-191|inhibit|drug
DDI-DrugBank.d202.s14|377-384|leading|drug
DDI-DrugBank.d202.s14|393-406|interactions.|drug
DDI-DrugBank.d202.s15|29-44|antidepressants|group
DDI-DrugBank.d202.s15|88-96|P450IID6|brand
DDI-DrugBank.d202.s15|170-184|antidepressant|group
DDI-DrugBank.d202.s16|11-28|co-administration|drug
DDI-DrugBank.d202.s16|42-57|antidepressants|group
DDI-DrugBank.d202.s16|115-124|including|drug
DDI-DrugBank.d202.s16|131-147|antidepressants,|group
DDI-DrugBank.d202.s16|148-163|phenothiazines,|drug
DDI-DrugBank.d202.s16|164-178|carbamazepine,|drug
DDI-DrugBank.d202.s16|191-206|antiarrhythmics|group
DDI-DrugBank.d202.s16|225-236|flecainide,|drug
DDI-DrugBank.d202.s16|241-252|encainide),|drug
DDI-DrugBank.d202.s16|261-268|inhibit|drug
DDI-DrugBank.d202.s16|286-297|quinidine),|drug
DDI-MedLine.d104.s0|15-21|DCG-IV|brand
DDI-MedLine.d104.s0|26-33|L-CCG-1|brand
DDI-MedLine.d104.s0|39-52|phencyclidine|drug
DDI-MedLine.d104.s0|53-66|(PCP)-induced|drug
DDI-MedLine.d104.s1|31-38|induced|drug
DDI-MedLine.d104.s2|0-9|injection|drug
DDI-MedLine.d104.s2|13-26|phencyclidine|drug
DDI-MedLine.d104.s2|27-32|(PCP)|brand
DDI-MedLine.d104.s2|50-59|measuring|drug
DDI-MedLine.d104.s3|71-77|DCG-IV|brand
DDI-MedLine.d104.s3|82-90|L-CCG-1,|brand
DDI-MedLine.d104.s3|123-130|induced|drug
DDI-MedLine.d104.s4|15-21|DCG-IV|brand
DDI-MedLine.d104.s4|68-79|PCP-induced|drug
DDI-MedLine.d104.s5|15-22|L-CCG-1|brand
DDI-MedLine.d104.s6|9-18|injection|drug
DDI-MedLine.d104.s6|48-55|induced|drug
DDI-MedLine.d104.s6|102-110|injected|drug
DDI-MedLine.d104.s8|12-19|examine|drug
DDI-MedLine.d104.s8|25-34|molecular|drug
DDI-MedLine.d104.s8|49-60|PCP-induced|drug
DDI-MedLine.d104.s8|176-183|DCG-IV,|brand
DDI-MedLine.d104.s8|188-195|L-CCG-1|brand
DDI-MedLine.d39.s0|23-40|endotoxin-induced|drug
DDI-MedLine.d39.s1|3-11|examined|drug
DDI-MedLine.d39.s1|93-100|induced|drug
DDI-MedLine.d39.s1|141-150|endotoxin|drug
DDI-MedLine.d39.s1|216-226|endotoxin.|drug
DDI-MedLine.d39.s2|56-65|endotoxin|drug
DDI-MedLine.d39.s2|129-139|endotoxin.|drug
DDI-MedLine.d39.s3|49-66|endotoxin-treated|drug
DDI-MedLine.d39.s3|109-126|endotoxin-treated|drug
DDI-MedLine.d39.s3|132-141|increased|drug
DDI-MedLine.d39.s3|149-157|5-fold).|drug_n
DDI-MedLine.d39.s4|49-66|endotoxin-treated|drug
DDI-MedLine.d39.s4|117-134|endotoxin-treated|drug
DDI-MedLine.d39.s4|151-157|30-40%|drug_n
DDI-MedLine.d39.s5|0-6|0.001.|drug_n
DDI-MedLine.d39.s6|37-46|influence|drug
DDI-MedLine.d39.s6|65-82|endotoxin-induced|drug
DDI-MedLine.d39.s7|32-39|induced|drug
DDI-MedLine.d39.s7|71-80|endotoxin|drug
DDI-MedLine.d39.s7|85-94|increased|drug
DDI-MedLine.d39.s7|116-123|induced|drug
DDI-DrugBank.d338.s0|50-56|acting|drug
DDI-DrugBank.d338.s1|18-33|benzodiazepines|drug
DDI-DrugBank.d338.s1|56-72|anticonvulsants,|group
DDI-DrugBank.d338.s1|73-88|antihistamines,|group
DDI-DrugBank.d338.s1|112-121|monoamine|drug
DDI-DrugBank.d338.s1|130-141|inhibitors,|drug
DDI-DrugBank.d338.s1|153-168|phenothiazines,|drug
DDI-DrugBank.d338.s2|16-25|increased|drug
DDI-DrugBank.d338.s2|39-54|benzodiazepines|drug
DDI-DrugBank.d338.s4|27-38|interaction|drug
DDI-DrugBank.d338.s4|70-79|estazolam|drug
DDI-DrugBank.d338.s4|84-92|inducers|drug
DDI-DrugBank.d338.s4|96-102|CYP3A,|brand
DDI-DrugBank.d338.s4|129-134|CYP3A|brand
DDI-DrugBank.d338.s4|135-143|inducers|drug
DDI-DrugBank.d338.s4|153-167|carbamazepine,|drug
DDI-DrugBank.d338.s4|168-178|phenytoin,|drug
DDI-DrugBank.d338.s4|179-188|rifampin,|drug
DDI-DrugBank.d338.s4|237-246|estazolam|drug
DDI-DrugBank.d338.s5|81-89|(CYP3A):|brand
DDI-DrugBank.d338.s5|108-117|estazolam|drug
DDI-DrugBank.d338.s5|131-142|circulating|drug
DDI-DrugBank.d338.s5|154-173|4-hydroxy-estazolam|drug_n
DDI-DrugBank.d338.s5|202-225|triazolobenzodiazepines|drug
DDI-DrugBank.d338.s5|242-248|CYP3A.|brand
DDI-DrugBank.d338.s6|14-23|estazolam|drug
DDI-DrugBank.d338.s6|54-63|receiving|drug
DDI-DrugBank.d338.s6|64-76|ketoconazole|drug
DDI-DrugBank.d338.s6|81-94|itraconazole,|drug
DDI-DrugBank.d338.s6|117-127|inhibitors|drug
DDI-DrugBank.d338.s6|131-137|CYP3A.|brand
DDI-DrugBank.d338.s7|11-21|inhibiting|drug
DDI-DrugBank.d338.s7|22-27|CYP3A|brand
DDI-DrugBank.d338.s7|71-80|estazolam|drug
DDI-DrugBank.d338.s8|4-13|following|drug
DDI-DrugBank.d338.s8|45-52|inhibit|drug
DDI-DrugBank.d338.s8|85-101|benzodiazepines,|drug
DDI-DrugBank.d338.s8|121-131|inhibition|drug
DDI-DrugBank.d338.s8|135-141|CYP3A:|brand
DDI-DrugBank.d338.s8|154-166|fluvoxamine,|drug
DDI-DrugBank.d338.s8|167-178|cimetidine,|drug
DDI-DrugBank.d338.s8|211-220|macrolide|drug
DDI-DrugBank.d338.s8|221-233|antibiotics.|group
DDI-DrugBank.d338.s9|22-33|Fluoxetine:|drug
DDI-DrugBank.d338.s9|94-104|fluoxetine|drug
DDI-DrugBank.d338.s9|122-138|pharmacokinetics|drug
DDI-DrugBank.d338.s9|142-151|estazolam|drug
DDI-DrugBank.d338.s10|4-20|pharmacokinetics|drug
DDI-DrugBank.d338.s10|24-33|estazolam|drug
DDI-DrugBank.d338.s10|67-73|during|drug
DDI-DrugBank.d338.s10|88-99|fluoxetine,|drug
DDI-DrugBank.d338.s10|100-110|suggesting|drug
DDI-DrugBank.d338.s10|114-124|clinically|drug
DDI-DrugBank.d338.s10|137-152|pharmacokinetic|drug
DDI-DrugBank.d338.s10|153-165|interaction.|drug
DDI-DrugBank.d338.s11|80-86|(CYP):|brand
DDI-DrugBank.d338.s11|90-100|clinically|drug
DDI-DrugBank.d338.s11|143-151|indicate|drug
DDI-DrugBank.d338.s11|157-166|estazolam|drug
DDI-DrugBank.d338.s11|183-193|inhibitory|drug
DDI-DrugBank.d338.s11|237-244|CYP1A2,|brand
DDI-DrugBank.d338.s11|245-252|CYP2A6,|brand
DDI-DrugBank.d338.s11|253-260|CYP2C9,|brand
DDI-DrugBank.d338.s11|261-269|CYP2C19,|brand
DDI-DrugBank.d338.s11|270-277|CYP2D6,|brand
DDI-DrugBank.d338.s11|278-285|CYP2E1,|brand
DDI-DrugBank.d338.s11|290-296|CYP3A.|brand
DDI-DrugBank.d338.s12|41-50|estazolam|drug
DDI-DrugBank.d338.s12|71-78|inhibit|drug
DDI-MedLine.d83.s0|0-11|Olanzapine:|drug
DDI-MedLine.d83.s1|0-11|Olanzapine,|drug
DDI-MedLine.d83.s1|14-34|thienobenzodiazepine|drug
DDI-MedLine.d83.s1|81-94|antipsychotic|group
DDI-MedLine.d83.s1|127-134|against|drug_n
DDI-MedLine.d83.s2|27-42|antipsychotics,|group
DDI-MedLine.d83.s2|58-66|affinity|drug
DDI-MedLine.d83.s2|71-80|serotonin|drug
DDI-MedLine.d83.s2|81-87|5-HT2A|brand
DDI-MedLine.d83.s2|97-105|dopamine|drug
DDI-MedLine.d83.s3|15-25|controlled|group
DDI-MedLine.d83.s3|86-96|olanzapine|drug
DDI-MedLine.d83.s3|212-218|rating|drug
DDI-MedLine.d83.s4|4-10|1-year|drug_n
DDI-MedLine.d83.s4|76-86|olanzapine|drug
DDI-MedLine.d83.s5|13-25|double-blind|drug
DDI-MedLine.d83.s5|57-67|olanzapine|drug
DDI-MedLine.d83.s5|85-95|olanzapine|drug
DDI-MedLine.d83.s6|3-12|contrast,|group
DDI-MedLine.d83.s6|13-24|preliminary|drug
DDI-MedLine.d83.s6|41-47|8-week|drug_n
DDI-MedLine.d83.s6|48-58|controlled|group
DDI-MedLine.d83.s6|117-127|olanzapine|drug
DDI-MedLine.d83.s6|143-150|against|drug_n
DDI-MedLine.d83.s6|197-203|0.05),|drug_n
DDI-MedLine.d83.s6|291-299|measures|group
DDI-MedLine.d83.s7|53-63|olanzapine|drug
DDI-MedLine.d83.s7|79-85|1-year|drug_n
DDI-MedLine.d83.s7|86-96|controlled|group
DDI-MedLine.d83.s8|9-20|preliminary|drug
DDI-MedLine.d83.s8|37-43|8-week|drug_n
DDI-MedLine.d83.s8|78-87|enhancing|drug
DDI-MedLine.d83.s8|99-109|olanzapine|drug
DDI-MedLine.d83.s9|16-24|indicate|drug
DDI-MedLine.d83.s9|30-40|olanzapine|drug
DDI-MedLine.d83.s9|54-61|against|drug_n
DDI-MedLine.d83.s9|158-168|olanzapine|drug
DDI-MedLine.d83.s10|0-10|Olanzapine|drug
DDI-MedLine.d83.s11|13-23|olanzapine|drug
DDI-MedLine.d83.s11|86-95|clozapine|drug
DDI-MedLine.d83.s11|99-109|clinically|drug
DDI-MedLine.d83.s11|122-141|hyperprolactinaemia|drug
DDI-MedLine.d83.s11|193-202|interval.|drug
DDI-MedLine.d83.s12|46-56|olanzapine|drug
DDI-MedLine.d83.s12|72-77|gain,|drug_n
DDI-MedLine.d83.s12|78-89|somnolence,|drug
DDI-MedLine.d83.s12|90-100|dizziness,|drug
DDI-MedLine.d83.s12|101-116|anticholinergic|group
DDI-MedLine.d83.s13|95-105|olanzapine|drug
DDI-MedLine.d83.s13|169-178|increased|drug
DDI-MedLine.d83.s13|284-295|olanzapine.|drug
DDI-MedLine.d83.s14|29-39|olanzapine|drug
DDI-MedLine.d83.s14|89-99|(inpatient|drug
DDI-MedLine.d83.s15|26-34|indicate|drug
DDI-MedLine.d83.s15|40-50|olanzapine|drug
DDI-MedLine.d83.s15|74-83|increase,|drug
DDI-MedLine.d83.s16|27-37|olanzapine|drug
DDI-MedLine.d83.s17|0-10|Olanzapine|drug
DDI-MedLine.d83.s18|0-12|CONCLUSIONS:|brand
DDI-MedLine.d83.s18|13-23|Olanzapine|drug
DDI-MedLine.d83.s18|46-59|antipsychotic|group
DDI-MedLine.d83.s19|180-190|olanzapine|drug
DDI-MedLine.d83.s19|196-206|first-line|drug
DDI-MedLine.d83.s19|280-291|maintenance|drug
DDI-MedLine.d111.s0|10-24|coadministered|drug
DDI-MedLine.d111.s0|35-42|ethanol|drug
DDI-MedLine.d111.s0|50-57|binding|drug
DDI-MedLine.d111.s1|15-29|coadministered|drug
DDI-MedLine.d111.s1|40-47|ethanol|drug
DDI-MedLine.d111.s1|55-62|binding|drug
DDI-MedLine.d111.s1|112-125|investigated.|drug
DDI-MedLine.d111.s2|0-14|Acetaminophen,|drug
DDI-MedLine.d111.s2|15-25|lidocaine,|drug
DDI-MedLine.d111.s2|41-51|quinidine,|drug
DDI-MedLine.d111.s2|52-65|theophylline,|drug
DDI-MedLine.d111.s2|98-104|pooled|drug
DDI-MedLine.d111.s3|74-81|ranging|drug
DDI-MedLine.d111.s4|4-13|following|drug
DDI-MedLine.d111.s4|43-55|combinations|drug
DDI-MedLine.d111.s4|70-98|acetaminophen/phenobarbital.|drug
DDI-MedLine.d111.s5|0-27|acetaminophen/theophylline,|drug
DDI-MedLine.d111.s5|28-48|lidocaine/quinidine,|drug
DDI-MedLine.d111.s5|49-77|phenobarbital/acetaminophen,|drug
DDI-MedLine.d111.s5|107-127|quinidine/lidocaine,|drug
DDI-MedLine.d111.s5|128-155|theophylline/acetaminophen,|drug
DDI-MedLine.d111.s6|135-142|against|drug_n
DDI-MedLine.d111.s7|39-49|quinidine,|drug
DDI-MedLine.d111.s7|54-67|theophylline,|drug
DDI-MedLine.d111.s7|127-134|ethanol|drug
DDI-MedLine.d111.s8|23-30|binding|drug
DDI-MedLine.d111.s9|0-13|Acetaminophen|drug
DDI-MedLine.d111.s9|14-24|diminished|drug
DDI-MedLine.d111.s9|29-36|binding|drug
DDI-MedLine.d111.s9|40-52|theophylline|drug
DDI-MedLine.d111.s9|104-112|increase|drug
DDI-MedLine.d111.s9|135-141|[FDF],|brand
DDI-MedLine.d111.s9|142-148|11.0%)|drug_n
DDI-MedLine.d111.s9|207-215|increase|drug
DDI-MedLine.d111.s9|224-230|13.7%)|drug_n
DDI-MedLine.d111.s10|0-12|Theophylline|drug
DDI-MedLine.d111.s10|27-34|binding|drug
DDI-MedLine.d111.s10|38-51|acetaminophen|drug
DDI-MedLine.d111.s10|88-96|increase|drug
DDI-MedLine.d111.s10|105-110|8.8%)|drug_n
DDI-MedLine.d111.s10|114-119|277.5|drug_n
DDI-MedLine.d111.s11|61-69|increase|drug
DDI-MedLine.d111.s11|78-83|8.5%)|drug_n
DDI-MedLine.d111.s12|14-24|diminished|drug
DDI-MedLine.d111.s12|25-32|binding|drug
DDI-MedLine.d111.s12|86-94|increase|drug
DDI-MedLine.d111.s12|103-109|21.2%)|drug_n
DDI-MedLine.d111.s13|50-62|combinations|drug
DDI-MedLine.d111.s13|87-95|ethanol.|drug
DDI-MedLine.d111.s14|0-11|Coingestion|drug
DDI-MedLine.d111.s14|15-28|acetaminophen|drug
DDI-MedLine.d111.s14|34-47|theophylline,|drug
DDI-MedLine.d111.s14|67-81|acetaminophen,|drug
DDI-MedLine.d111.s14|165-172|binding|drug
DDI-MedLine.d111.s15|4-13|resulting|drug
DDI-MedLine.d111.s15|14-22|increase|drug
DDI-DrugBank.d215.s0|32-43|anileridine|drug
DDI-DrugBank.d215.s0|47-61|coadministered|drug
DDI-DrugBank.d215.s0|73-81|opioids,|group
DDI-DrugBank.d215.s0|93-108|phenothiazines,|drug
DDI-DrugBank.d215.s0|145-153|increase|drug
DDI-MedLine.d24.s0|27-32|urine|drug
DDI-MedLine.d24.s0|39-47|exposure|group
DDI-MedLine.d24.s1|48-56|includes|drug
DDI-MedLine.d24.s1|90-101|inactivated|drug
DDI-MedLine.d24.s1|140-150|SH-bearing|drug
DDI-MedLine.d24.s1|151-161|molecules.|drug
DDI-MedLine.d24.s2|45-50|urine|drug
DDI-MedLine.d24.s2|66-71|acids|group
DDI-MedLine.d24.s3|53-60|urinary|drug
DDI-MedLine.d24.s3|110-118|exposure|group
DDI-MedLine.d24.s5|47-57|industrial|drug
DDI-MedLine.d24.s5|66-74|involved|drug
DDI-MedLine.d24.s5|93-106|incineration.|drug
DDI-MedLine.d24.s6|9-18|increased|drug
DDI-MedLine.d24.s6|78-86|exposure|group
DDI-MedLine.d24.s7|49-55|within|drug
DDI-MedLine.d24.s7|143-152|exposure.|group
DDI-MedLine.d24.s8|61-66|urine|drug
DDI-MedLine.d24.s8|140-151|monitoring.|drug
DDI-DrugBank.d333.s0|28-44|Pharmacokinetics|drug
DDI-DrugBank.d333.s0|101-117|pharmacokinetics|drug
DDI-DrugBank.d333.s0|121-131|phenytoin,|drug
DDI-DrugBank.d333.s0|132-146|carbamazepine,|drug
DDI-DrugBank.d333.s1|71-84|investigated.|drug
DDI-DrugBank.d333.s2|29-45|Pharmacokinetics|drug
DDI-DrugBank.d333.s2|61-71|Literature|group
DDI-DrugBank.d333.s2|93-104|ranitidine,|drug
DDI-DrugBank.d333.s2|180-197|pharmacokinetics.|drug
DDI-DrugBank.d333.s3|47-61|disintegrating|drug
DDI-DrugBank.d333.s3|73-85|administered|drug
DDI-DrugBank.d333.s3|103-116|propantheline|drug
DDI-DrugBank.d333.s3|121-136|anticholinergic|group
DDI-DrugBank.d333.s3|298-312|disintegrating|drug
DDI-DrugBank.d333.s3|335-348|propantheline|drug
DDI-DrugBank.d333.s4|0-10|Fluoxetine|drug
DDI-DrugBank.d333.s4|31-47|pharmacokinetics|drug
DDI-DrugBank.d333.s5|11-16|P-450|brand
DDI-DrugBank.d333.s5|17-26|inducers,|drug
DDI-DrugBank.d333.s5|35-45|phenytoin,|drug
DDI-DrugBank.d333.s5|46-59|carbamazepine|drug
DDI-DrugBank.d333.s5|79-85|induce|drug
DDI-DrugBank.d333.s5|109-116|causing|drug
DDI-DrugBank.d333.s6|9-17|clinical|drug
DDI-DrugBank.d333.s6|64-75|involvement|drug
DDI-DrugBank.d333.s6|94-99|P-450|brand
DDI-DrugBank.d333.s6|136-146|inhibitors|drug
DDI-DrugBank.d333.s6|183-193|antifungal|group
DDI-DrugBank.d333.s6|240-249|receiving|drug
DDI-DrugBank.d333.s7|63-77|benzodiazepine|drug
DDI-DrugBank.d333.s7|175-186|antianxiety|group
DDI-DrugBank.d333.s7|199-214|phenothiazines,|drug
DDI-DrugBank.d333.s7|257-270|antipsychotic|group
DDI-DrugBank.d333.s7|279-288|monoamine|drug
DDI-DrugBank.d333.s7|297-307|inhibitors|drug
DDI-DrugBank.d333.s7|326-342|antidepressants,|group
DDI-DrugBank.d333.s7|356-370|anticonvulsant|group
DDI-DrugBank.d384.s0|17-24|vitamin|drug
DDI-DrugBank.d384.s0|37-45|(Vitamin|drug
DDI-DrugBank.d384.s0|50-57|Vitamin|drug
DDI-DrugBank.d384.s0|90-105|Cholestyramine:|drug
DDI-DrugBank.d384.s0|106-120|Cholestyramine|drug
DDI-DrugBank.d384.s0|149-159|intestinal|drug
DDI-DrugBank.d384.s0|186-195|vitamins;|drug
DDI-DrugBank.d384.s1|22-32|intestinal|drug
DDI-DrugBank.d384.s1|54-61|vitamin|drug
DDI-DrugBank.d384.s2|0-24|Phenytoin/Phenobarbital:|drug
DDI-DrugBank.d384.s2|29-45|coadministration|drug
DDI-DrugBank.d384.s2|49-58|phenytoin|drug
DDI-DrugBank.d384.s2|117-124|vitamin|drug
DDI-DrugBank.d384.s2|200-212|accelerating|drug
DDI-DrugBank.d384.s3|0-5|Since|drug
DDI-DrugBank.d384.s3|126-138|administered|drug
DDI-DrugBank.d384.s4|34-40|induce|drug
DDI-DrugBank.d384.s4|75-82|calcium|drug
DDI-DrugBank.d384.s4|96-102|urine.|drug
DDI-DrugBank.d384.s5|45-59|administration|drug
DDI-DrugBank.d384.s5|63-72|thiazides|group
DDI-DrugBank.d384.s5|78-85|vitamin|drug
DDI-DrugBank.d384.s6|43-59|coadministration|drug
DDI-DrugBank.d384.s7|11-18|Vitamin|drug
DDI-DrugBank.d384.s7|36-46|determined|drug
DDI-DrugBank.d384.s7|69-79|undergoing|drug
DDI-DrugBank.d384.s8|0-13|Ketoconazole:|drug
DDI-DrugBank.d384.s8|14-26|Ketoconazole|drug
DDI-DrugBank.d384.s8|31-38|inhibit|drug
DDI-DrugBank.d384.s8|79-86|vitamin|drug
DDI-DrugBank.d384.s9|31-38|vitamin|drug
DDI-DrugBank.d384.s9|75-84|following|drug
DDI-DrugBank.d384.s9|89-103|administration|drug
DDI-DrugBank.d384.s9|133-145|ketoconazole|drug
DDI-DrugBank.d384.s10|22-33|interaction|drug
DDI-DrugBank.d384.s10|45-57|ketoconazole|drug
DDI-DrugBank.d384.s10|63-70|vitamin|drug
DDI-DrugBank.d384.s10|87-100|investigated.|drug
DDI-DrugBank.d384.s11|0-16|Corticosteroids:|group
DDI-DrugBank.d384.s11|72-79|vitamin|drug
DDI-DrugBank.d384.s11|107-114|calcium|drug
DDI-DrugBank.d384.s11|131-147|corticosteroids,|group
DDI-DrugBank.d384.s11|154-161|inhibit|drug
DDI-DrugBank.d384.s11|162-169|calcium|drug
DDI-DrugBank.d384.s12|0-17|Phosphate-Binding|drug
DDI-DrugBank.d384.s12|26-31|Since|drug
DDI-DrugBank.d384.s12|32-39|vitamin|drug
DDI-DrugBank.d384.s12|91-101|intestine,|drug
DDI-DrugBank.d384.s12|135-152|phosphate-binding|drug
DDI-DrugBank.d384.s13|0-7|Vitamin|drug
DDI-DrugBank.d384.s13|15-31|coadministration|drug
DDI-DrugBank.d384.s13|46-53|vitamin|drug
DDI-DrugBank.d384.s14|0-7|Calcium|drug
DDI-DrugBank.d384.s14|21-33|Uncontrolled|group
DDI-DrugBank.d384.s14|34-40|intake|drug
DDI-DrugBank.d384.s14|55-73|calcium-containing|group
DDI-DrugBank.d384.s15|0-10|Magnesium:|drug
DDI-DrugBank.d384.s15|11-31|Magnesium-containing|group
DDI-DrugBank.d384.s15|50-59|antacids)|group
DDI-DrugBank.d384.s15|120-126|during|drug
DDI-DrugBank.d384.s15|140-147|vitamin|drug
DDI-DrugBank.d300.s0|15-26|interaction|drug
DDI-DrugBank.d36.s0|31-40|receiving|drug
DDI-DrugBank.d36.s0|63-70|aspirin|brand
DDI-DrugBank.d36.s0|84-93|anhydrase|drug
DDI-DrugBank.d36.s0|94-105|inhibitors,|drug
DDI-DrugBank.d36.s0|109-118|anorexia,|drug
DDI-DrugBank.d36.s0|197-209|interaction.|drug
DDI-MedLine.d108.s0|0-14|Administration|drug
DDI-MedLine.d108.s0|18-25|lithium|drug
DDI-MedLine.d108.s1|91-98|lithium|drug
DDI-MedLine.d108.s2|4-18|administrative|drug
DDI-MedLine.d108.s2|82-90|increase|drug
DDI-DrugBank.d463.s0|33-46|hydrochloride|drug
DDI-DrugBank.d463.s0|82-92|inhibitors|drug
DDI-DrugBank.d463.s0|128-142|administration|drug
DDI-DrugBank.d463.s1|20-30|suggesting|drug
DDI-DrugBank.d463.s1|69-82|hydrochloride|drug
DDI-DrugBank.d463.s1|133-139|6-fold|drug_n
DDI-DrugBank.d463.s1|159-164|(ALT)|brand
DDI-DrugBank.d463.s2|20-30|attempting|drug
DDI-DrugBank.d463.s2|49-57|finding,|drug
DDI-DrugBank.d463.s2|61-72|interactive|drug
DDI-DrugBank.d463.s2|91-104|transaminases|drug
DDI-DrugBank.d463.s3|45-59|administration|drug
DDI-DrugBank.d463.s3|105-114|increased|drug
DDI-DrugBank.d463.s4|4-12|clinical|drug
DDI-DrugBank.d463.s4|34-41|finding|drug
DDI-DrugBank.d463.s5|63-73|phenytoin,|drug
DDI-DrugBank.d463.s5|74-86|propranolol,|drug
DDI-DrugBank.d463.s5|91-99|warfarin|drug
DDI-DrugBank.d463.s5|111-120|proteins.|drug
DDI-DrugBank.d463.s6|48-59|prothrombin|drug
DDI-DrugBank.d463.s6|131-140|warfarin.|drug
DDI-DrugBank.d463.s7|33-42|receiving|drug
DDI-DrugBank.d463.s7|43-53|phenytoin,|drug
DDI-DrugBank.d463.s7|69-77|digoxin,|drug
DDI-DrugBank.d463.s7|82-95|levothyroxine|drug
DDI-DrugBank.d463.s7|96-103|sodium.|drug
DDI-DrugBank.d463.s8|62-70|digoxin.|drug
DDI-DrugBank.d463.s9|4-12|clinical|drug
DDI-DrugBank.d279.s0|23-33|CAMPTOSAR,|brand
DDI-DrugBank.d279.s0|118-132|antineoplastic|group
DDI-DrugBank.d279.s0|140-146|having|drug
DDI-DrugBank.d279.s1|46-55|abdominal|drug
DDI-DrugBank.d279.s1|75-84|increased|drug
DDI-DrugBank.d279.s1|117-126|following|drug
DDI-DrugBank.d279.s1|131-145|administration|drug
DDI-DrugBank.d279.s1|149-159|CAMPTOSAR.|brand
DDI-DrugBank.d279.s2|15-29|administration|drug
DDI-DrugBank.d279.s2|33-42|CAMPTOSAR|brand
DDI-DrugBank.d279.s3|46-55|receiving|drug
DDI-DrugBank.d279.s3|56-66|CAMPTOSAR,|brand
DDI-DrugBank.d279.s3|95-109|administration|drug
DDI-DrugBank.d279.s3|130-140|antiemetic|group
DDI-DrugBank.d279.s4|31-41|infections|drug
DDI-DrugBank.d279.s5|49-58|receiving|drug
DDI-DrugBank.d279.s5|59-69|CAMPTOSAR.|brand
DDI-DrugBank.d279.s6|103-114|intolerance|drug
DDI-DrugBank.d279.s6|124-138|administration|drug
DDI-DrugBank.d279.s6|142-152|CAMPTOSAR.|brand
DDI-DrugBank.d279.s7|44-54|antiemetic|group
DDI-DrugBank.d279.s7|68-79|contributed|group
DDI-DrugBank.d279.s8|4-13|incidence|drug
DDI-DrugBank.d279.s8|30-38|clinical|drug
DDI-DrugBank.d279.s8|115-131|prochlorperazine|drug
DDI-DrugBank.d279.s8|136-148|administered|drug
DDI-DrugBank.d279.s8|168-177|CAMPTOSAR|brand
DDI-DrugBank.d279.s9|9-18|incidence|drug
DDI-DrugBank.d279.s9|45-51|within|drug
DDI-DrugBank.d279.s9|82-98|prochlorperazine|drug
DDI-DrugBank.d279.s10|39-45|during|drug
DDI-DrugBank.d279.s10|59-68|CAMPTOSAR|brand
DDI-DrugBank.d279.s10|86-95|incidence|drug
DDI-DrugBank.d279.s11|33-44|dehydration|drug
DDI-DrugBank.d279.s11|58-66|vomiting|drug
DDI-DrugBank.d279.s11|83-90|induced|drug
DDI-DrugBank.d279.s11|94-104|CAMPTOSAR,|brand
DDI-DrugBank.d279.s11|140-149|diuretics|group
DDI-DrugBank.d279.s11|150-156|during|drug
DDI-DrugBank.d279.s11|157-163|dosing|drug
DDI-DrugBank.d279.s11|169-178|CAMPTOSAR|brand
DDI-DrugBank.d279.s11|184-194|certainly,|drug
DDI-DrugBank.d279.s11|195-201|during|drug
DDI-DrugBank.d279.s11|220-228|vomiting|drug
DDI-DrugBank.d279.s12|53-65|interactions|drug
DDI-DrugBank.d279.s12|74-83|CAMPTOSAR|brand
DDI-DrugBank.d6.s0|14-29|nondepolarizing|drug
DDI-DrugBank.d6.s1|37-46|medicines|drug
DDI-DrugBank.d6.s2|24-39|nondepolarizing|drug
DDI-DrugBank.d6.s2|186-191|oxide|drug
DDI-DrugBank.d533.s0|45-53|in-vitro|drug
DDI-DrugBank.d533.s1|0-17|Co-administration|drug
DDI-DrugBank.d533.s1|21-32|lovastatin,|drug
DDI-DrugBank.d533.s1|43-52|warfarin,|drug
DDI-DrugBank.d533.s1|65-73|digoxin,|drug
DDI-DrugBank.d533.s1|85-105|hydrochlorothiazide,|group
DDI-DrugBank.d533.s1|127-136|metformin|drug
DDI-DrugBank.d533.s1|141-151|amlodipine|drug
DDI-DrugBank.d533.s1|170-180|clinically|drug
DDI-DrugBank.d533.s1|193-202|increases|drug
DDI-DrugBank.d533.s1|216-225|exposure.|group
DDI-DrugBank.d533.s2|0-17|Co-administration|drug
DDI-DrugBank.d533.s2|80-87|dosing.|drug
DDI-DrugBank.d533.s3|0-17|Co-administration|drug
DDI-DrugBank.d533.s3|21-33|atorvastatin|drug
DDI-DrugBank.d533.s3|58-66|increase|drug
DDI-DrugBank.d533.s3|108-115|dosing.|drug
DDI-DrugBank.d533.s4|0-13|Ketoconazole:|drug
DDI-DrugBank.d533.s4|14-31|Co-administration|drug
DDI-DrugBank.d533.s4|54-66|ketoconazole|drug
DDI-DrugBank.d533.s4|113-121|increase|drug
DDI-DrugBank.d533.s5|66-74|increase|drug
DDI-DrugBank.d533.s6|55-62|inhibit|drug
DDI-DrugBank.d533.s6|67-73|CYP450|brand
DDI-DrugBank.d533.s6|85-93|(CYP1A2,|brand
DDI-DrugBank.d533.s6|104-109|2C19,|brand
DDI-DrugBank.d533.s6|135-141|induce|drug
DDI-DrugBank.d533.s7|0-17|Co-administration|drug
DDI-DrugBank.d533.s7|64-80|pharmacokinetics|drug
DDI-DrugBank.d533.s7|84-95|lovastatin,|drug
DDI-DrugBank.d533.s7|96-104|digoxin,|drug
DDI-DrugBank.d533.s7|116-127|amlodipine,|drug
DDI-DrugBank.d533.s7|128-138|metformin,|drug
DDI-DrugBank.d533.s7|160-173|atorvastatin,|drug
DDI-DrugBank.d533.s7|186-206|hydrochlorothiazide.|group
DDI-DrugBank.d533.s8|0-9|Warfarin:|drug
DDI-DrugBank.d533.s8|38-46|warfarin|drug
DDI-DrugBank.d533.s8|47-63|pharmacokinetics|drug
DDI-DrugBank.d533.s8|93-108|well-controlled|group
DDI-DrugBank.d533.s8|109-117|clinical|drug
DDI-DrugBank.d533.s9|31-46|co-administered|drug
DDI-DrugBank.d533.s9|84-94|furosemide|drug
DDI-DrugBank.d29.s0|0-12|Esomeprazole|drug
DDI-DrugBank.d29.s0|56-63|CYP2C19|brand
DDI-DrugBank.d29.s0|68-75|CYP3A4.|brand
DDI-DrugBank.d29.s1|45-57|esomeprazole|drug
DDI-DrugBank.d29.s1|75-82|inhibit|drug
DDI-DrugBank.d29.s2|3-13|clinically|drug
DDI-DrugBank.d29.s2|23-35|interactions|drug
DDI-DrugBank.d29.s3|5-16|interaction|drug
DDI-DrugBank.d29.s3|41-53|esomeprazole|drug
DDI-DrugBank.d29.s3|72-82|clinically|drug
DDI-DrugBank.d29.s3|95-107|interactions|drug
DDI-DrugBank.d29.s3|113-123|phenytoin,|drug
DDI-DrugBank.d29.s3|124-133|warfarin,|drug
DDI-DrugBank.d29.s3|134-144|quinidine,|drug
DDI-DrugBank.d29.s3|145-159|clarithromycin|drug
DDI-DrugBank.d29.s3|163-175|amoxicillin.|drug
DDI-DrugBank.d29.s4|0-14|Post-marketing|drug
DDI-DrugBank.d29.s4|37-48|prothrombin|drug
DDI-DrugBank.d29.s4|49-57|measures|group
DDI-DrugBank.d29.s4|107-115|warfarin|drug
DDI-DrugBank.d29.s4|120-132|esomeprazole|drug
DDI-DrugBank.d29.s5|21-32|prothrombin|drug
DDI-DrugBank.d29.s5|59-67|bleeding|drug
DDI-DrugBank.d29.s6|34-44|inhibitors|drug
DDI-DrugBank.d29.s6|49-57|warfarin|drug
DDI-DrugBank.d29.s6|101-110|increases|drug
DDI-DrugBank.d29.s6|122-133|prothrombin|drug
DDI-DrugBank.d29.s7|0-12|Esomeprazole|drug
DDI-DrugBank.d29.s7|29-38|interfere|drug
DDI-DrugBank.d29.s7|44-52|CYP2C19,|brand
DDI-DrugBank.d29.s7|63-75|esomeprazole|drug
DDI-DrugBank.d29.s7|76-88|metabolizing|drug
DDI-DrugBank.d29.s8|0-16|Coadministration|drug
DDI-DrugBank.d29.s8|20-32|esomeprazole|drug
DDI-DrugBank.d29.s8|55-62|CYP2C19|brand
DDI-DrugBank.d29.s9|65-71|dosing|drug
DDI-DrugBank.d29.s10|80-89|interval,|drug
DDI-DrugBank.d29.s10|104-115|interaction|drug
DDI-DrugBank.d29.s10|137-145|clinical|drug
DDI-DrugBank.d29.s11|0-12|Esomeprazole|drug
DDI-DrugBank.d29.s11|13-21|inhibits|drug
DDI-DrugBank.d29.s12|11-23|esomeprazole|drug
DDI-DrugBank.d29.s12|28-37|interfere|drug
DDI-DrugBank.d29.s12|100-111|determinant|drug
DDI-DrugBank.d29.s12|136-149|ketoconazole,|drug
DDI-DrugBank.d29.s12|165-174|digoxin).|drug
DDI-DrugBank.d29.s13|0-16|Coadministration|drug
DDI-DrugBank.d29.s13|25-40|contraceptives,|group
DDI-DrugBank.d29.s13|51-61|phenytoin,|drug
DDI-DrugBank.d29.s13|65-74|quinidine|drug
DDI-DrugBank.d29.s13|102-117|pharmacokinetic|drug
DDI-DrugBank.d29.s13|129-142|esomeprazole.|drug
DDI-DrugBank.d29.s14|12-26|administration|drug
DDI-DrugBank.d29.s14|30-44|clarithromycin|drug
DDI-DrugBank.d29.s14|50-58|pimozide|drug
DDI-DrugBank.d29.s14|62-78|contraindicated.|group
DDI-DrugBank.d15.s0|3-11|clinical|drug
DDI-DrugBank.d15.s0|35-48|Fondaparinux,|drug
DDI-DrugBank.d15.s0|77-91|anticoagulants|group
DDI-DrugBank.d15.s0|92-103|(warfarin),|drug
DDI-DrugBank.d15.s0|113-123|inhibitors|drug
DDI-DrugBank.d15.s0|172-179|digoxin|drug
DDI-DrugBank.d15.s0|213-246|pharmacokinetics/pharmacodynamics|drug
DDI-DrugBank.d15.s0|250-262|fondaparinux|drug
DDI-DrugBank.d15.s0|263-270|sodium.|drug
DDI-DrugBank.d15.s1|13-25|Fondaparinux|drug
DDI-DrugBank.d15.s1|34-44|influenced|drug
DDI-DrugBank.d15.s1|69-78|warfarin,|drug
DDI-DrugBank.d15.s1|116-124|digoxin,|drug
DDI-DrugBank.d15.s1|133-149|pharmacokinetics|drug
DDI-DrugBank.d15.s1|153-160|digoxin|drug
DDI-DrugBank.d15.s2|57-69|discontinued|group
DDI-DrugBank.d15.s2|79-89|initiation|drug
DDI-DrugBank.d15.s2|93-105|Fondaparinux|drug
DDI-DrugBank.d15.s3|3-20|co-administration|drug
DDI-DrugBank.d15.s3|41-51|monitoring|drug
DDI-DrugBank.d15.s4|48-58|inhibition|drug
DDI-DrugBank.d15.s4|62-68|CYP2A6|brand
DDI-DrugBank.d15.s4|69-82|hydroxylation|drug
DDI-DrugBank.d15.s4|86-94|coumarin|drug
DDI-DrugBank.d15.s4|98-110|fondaparinux|drug
DDI-DrugBank.d15.s4|142-149|17-28%.|drug_n
DDI-DrugBank.d15.s5|59-64|2C19,|brand
DDI-DrugBank.d15.s5|88-94|0-16%.|drug_n
DDI-DrugBank.d15.s6|0-5|Since|drug
DDI-DrugBank.d15.s6|6-18|fondaparinux|drug
DDI-DrugBank.d15.s6|37-44|inhibit|drug
DDI-DrugBank.d15.s6|53-61|(CYP1A2,|brand
DDI-DrugBank.d15.s6|62-69|CYP2A6,|brand
DDI-DrugBank.d15.s6|70-77|CYP2C9,|brand
DDI-DrugBank.d15.s6|78-86|CYP2C19,|brand
DDI-DrugBank.d15.s6|87-94|CYP2D6,|brand
DDI-DrugBank.d15.s6|95-102|CYP2E1,|brand
DDI-DrugBank.d15.s6|106-113|CYP3A4)|brand
DDI-DrugBank.d15.s6|124-136|fondaparinux|drug
DDI-DrugBank.d15.s6|137-143|sodium|drug
DDI-DrugBank.d15.s6|177-185|interact|drug
DDI-DrugBank.d15.s6|214-224|inhibition|drug
DDI-DrugBank.d15.s7|0-5|Since|drug
DDI-DrugBank.d15.s7|6-18|fondaparinux|drug
DDI-DrugBank.d15.s7|19-25|sodium|drug
DDI-DrugBank.d15.s7|64-72|proteins|drug
DDI-DrugBank.d15.s7|84-90|ATIII,|brand
DDI-DrugBank.d15.s7|99-111|interactions|drug
DDI-DrugBank.d15.s7|115-130|protein-binding|drug
DDI-MedLine.d130.s0|10-19|cisplatin|drug
DDI-MedLine.d130.s0|25-31|sodium|drug
DDI-MedLine.d130.s1|45-54|cisplatin|drug
DDI-MedLine.d130.s1|82-92|injection.|drug
DDI-MedLine.d130.s2|0-6|Sodium|drug
DDI-MedLine.d130.s2|24-36|neutralizing|drug
DDI-MedLine.d130.s2|47-56|cisplatin|drug
DDI-MedLine.d130.s2|71-78|against|drug_n
DDI-MedLine.d130.s3|3-12|determine|drug
DDI-MedLine.d130.s3|21-30|injection|drug
DDI-MedLine.d130.s3|75-84|cisplatin|drug
DDI-MedLine.d130.s3|91-104|administered,|drug
DDI-MedLine.d130.s3|113-121|9.9-g/m2|drug_n
DDI-MedLine.d130.s3|152-165|intravenously|drug
DDI-MedLine.d130.s3|201-211|escalating|drug
DDI-MedLine.d130.s3|221-231|cisplatin.|drug
DDI-MedLine.d130.s4|0-9|Cisplatin|drug
DDI-MedLine.d130.s4|14-26|administered|drug
DDI-MedLine.d130.s4|70-79|infusion.|drug
DDI-MedLine.d130.s5|0-5|Using|drug
DDI-MedLine.d130.s5|54-63|cisplatin|drug
DDI-MedLine.d130.s5|89-102|dose-limiting|drug
DDI-MedLine.d130.s6|14-23|cisplatin|drug
DDI-MedLine.d130.s6|24-40|pharmacokinetics|drug
DDI-MedLine.d130.s6|66-71|202.5|drug_n
DDI-MedLine.d130.s6|159-168|indicated|drug
DDI-MedLine.d130.s6|203-214|elimination|drug
DDI-MedLine.d130.s6|281-291|cisplatin.|drug
DDI-MedLine.d130.s7|15-23|exposure|group
DDI-MedLine.d130.s7|79-88|cisplatin|drug
DDI-MedLine.d130.s8|40-54|administration|drug
DDI-MedLine.d130.s8|97-105|increase|drug
DDI-MedLine.d130.s8|124-132|exposure|group
DDI-MedLine.d130.s8|136-146|cisplatin.|drug
DDI-DrugBank.d508.s0|4-15|interaction|drug
DDI-DrugBank.d508.s1|15-23|bleeding|drug
DDI-DrugBank.d508.s1|40-47|heparin|drug
DDI-DrugBank.d508.s1|52-59|vitamin|drug
DDI-DrugBank.d508.s1|141-153|dipyridamole|drug
DDI-DrugBank.d508.s1|173-181|increase|drug
DDI-DrugBank.d508.s1|194-202|bleeding|drug
DDI-DrugBank.d508.s1|206-218|administered|drug
DDI-DrugBank.d508.s1|229-236|during,|drug
DDI-DrugBank.d508.s2|23-30|Aspirin|brand
DDI-DrugBank.d508.s2|35-42|heparin|drug
DDI-DrugBank.d508.s2|53-65|administered|drug
DDI-DrugBank.d508.s2|89-98|following|drug
DDI-DrugBank.d508.s2|99-108|infusions|drug
DDI-DrugBank.d508.s2|159-169|infarction|drug
DDI-DrugBank.d508.s3|8-16|heparin,|drug
DDI-DrugBank.d508.s3|17-25|aspirin,|brand
DDI-DrugBank.d508.s3|48-56|bleeding|drug
DDI-DrugBank.d508.s3|80-90|monitoring|drug
DDI-DrugBank.d508.s3|95-103|bleeding|drug
DDI-DrugBank.d508.s3|139-147|puncture|group
DDI-DrugBank.d508.s4|23-30|heparin|drug
DDI-DrugBank.d508.s4|34-41|aspirin|brand
DDI-DrugBank.d508.s4|42-48|during|drug
DDI-DrugBank.d508.s4|68-77|following|drug
DDI-DrugBank.d508.s4|115-120|NINDS|brand
DDI-DrugBank.d504.s0|122-130|loxapine|drug
DDI-DrugBank.d504.s1|12-17|using|drug
DDI-DrugBank.d504.s1|18-26|loxapine|drug
DDI-DrugBank.d504.s1|30-41|combination|drug
DDI-DrugBank.d504.s2|49-63|administration|drug
DDI-DrugBank.d504.s2|67-75|loxapine|drug
DDI-DrugBank.d372.s1|52-66|hydrocortisone|drug
DDI-DrugBank.d372.s2|0-17|Aminoglutethimide|drug
DDI-DrugBank.d372.s2|18-28|diminishes|drug
DDI-DrugBank.d372.s2|43-51|coumarin|drug
DDI-DrugBank.d372.s2|56-65|warfarin.|drug
DDI-DrugBank.d561.s0|0-10|Diuretics:|group
DDI-DrugBank.d561.s0|23-33|diuretics,|group
DDI-DrugBank.d561.s0|59-67|diuretic|group
DDI-DrugBank.d561.s0|89-100|instituted,|drug
DDI-DrugBank.d561.s0|161-169|pressure|group
DDI-DrugBank.d561.s0|176-186|initiation|drug
DDI-DrugBank.d561.s0|203-212|Lotensin.|drug
DDI-DrugBank.d561.s1|44-52|Lotensin|drug
DDI-DrugBank.d561.s1|60-69|minimized|drug
DDI-DrugBank.d561.s1|80-93|discontinuing|group
DDI-DrugBank.d561.s1|98-106|diuretic|group
DDI-DrugBank.d561.s1|110-120|increasing|drug
DDI-DrugBank.d561.s1|130-136|intake|drug
DDI-DrugBank.d561.s1|146-156|initiation|drug
DDI-DrugBank.d561.s1|175-184|Lotensin.|drug
DDI-DrugBank.d561.s2|29-37|starting|drug
DDI-DrugBank.d561.s3|0-9|Potassium|drug
DDI-DrugBank.d561.s3|26-43|Potassium-Sparing|drug
DDI-DrugBank.d561.s3|44-53|Diuretics|group
DDI-DrugBank.d561.s3|54-62|Lotensin|drug
DDI-DrugBank.d561.s3|77-86|potassium|drug
DDI-DrugBank.d561.s3|102-110|thiazide|group
DDI-DrugBank.d561.s3|111-121|diuretics.|group
DDI-DrugBank.d561.s4|0-17|Potassium-sparing|drug
DDI-DrugBank.d561.s4|18-27|diuretics|group
DDI-DrugBank.d561.s4|84-93|potassium|drug
DDI-DrugBank.d561.s4|110-118|increase|drug
DDI-DrugBank.d561.s5|48-58|indicated,|drug
DDI-DrugBank.d561.s5|118-127|potassium|drug
DDI-DrugBank.d561.s6|45-53|warfarin|drug
DDI-DrugBank.d561.s6|95-105|clinically|drug
DDI-DrugBank.d561.s6|155-163|clinical|drug
DDI-DrugBank.d561.s6|181-196|anticoagulants.|group
DDI-DrugBank.d561.s7|0-8|Lithium:|drug
DDI-DrugBank.d561.s7|25-32|lithium|drug
DDI-DrugBank.d561.s7|56-63|lithium|drug
DDI-DrugBank.d561.s7|104-113|receiving|drug
DDI-DrugBank.d561.s7|118-128|inhibitors|drug
DDI-DrugBank.d561.s7|129-135|during|drug
DDI-DrugBank.d561.s7|149-157|lithium.|drug
DDI-DrugBank.d561.s8|22-36|coadministered|drug
DDI-DrugBank.d561.s8|64-74|monitoring|drug
DDI-DrugBank.d561.s8|84-91|lithium|drug
DDI-DrugBank.d561.s9|5-13|diuretic|group
DDI-DrugBank.d561.s9|40-47|lithium|drug
DDI-DrugBank.d561.s9|64-74|increased.|drug
DDI-DrugBank.d561.s10|9-19|clinically|drug
DDI-DrugBank.d561.s10|30-45|pharmacokinetic|drug
DDI-DrugBank.d561.s10|46-58|interactions|drug
DDI-DrugBank.d561.s10|73-81|Lotensin|drug
DDI-DrugBank.d561.s10|86-98|administered|drug
DDI-DrugBank.d561.s10|118-138|hydrochlorothiazide,|group
DDI-DrugBank.d561.s10|167-175|digoxin,|drug
DDI-DrugBank.d561.s10|176-188|propranolol,|drug
DDI-DrugBank.d561.s10|212-223|cimetidine.|drug
DDI-DrugBank.d561.s11|0-8|Lotensin|drug
DDI-DrugBank.d561.s11|42-66|beta-adrenergic-blocking|drug
DDI-DrugBank.d561.s11|75-99|calcium-channel-blocking|drug
DDI-DrugBank.d561.s11|108-118|diuretics,|group
DDI-DrugBank.d561.s11|119-127|digoxin,|drug
DDI-DrugBank.d561.s11|132-144|hydralazine,|drug
DDI-DrugBank.d561.s11|165-175|clinically|drug
DDI-DrugBank.d561.s11|194-207|interactions.|drug
DDI-DrugBank.d561.s12|27-38|inhibitors,|drug
DDI-DrugBank.d561.s12|147-155|pressure|group
DDI-DrugBank.d561.s12|159-169|inhibiting|drug
DDI-DrugBank.d561.s12|183-200|renin-angiotensin|drug
DDI-DrugBank.d67.s0|7-17|controlled|group
DDI-DrugBank.d67.s0|28-36|clinical|drug
DDI-DrugBank.d67.s0|140-153|desloratadine|drug
DDI-DrugBank.d67.s0|203-217|coadministered|drug
DDI-DrugBank.d67.s0|223-235|erythromycin|drug
DDI-DrugBank.d67.s0|260-272|ketoconazole|drug
DDI-DrugBank.d67.s1|18-29|controlled,|group
DDI-DrugBank.d67.s1|45-53|clinical|drug
DDI-DrugBank.d67.s1|76-89|desloratadine|drug
DDI-DrugBank.d67.s1|97-105|clinical|drug
DDI-DrugBank.d67.s1|128-142|coadministered|drug
DDI-DrugBank.d67.s1|148-160|azithromycin|drug
DDI-DrugBank.d67.s1|224-234|fluoxetine|drug
DDI-DrugBank.d67.s1|303-313|fluoxetine|drug
DDI-DrugBank.d67.s1|329-339|cimetidine|drug
DDI-DrugBank.d67.s2|9-18|increased|drug
DDI-DrugBank.d67.s2|69-82|desloratadine|drug
DDI-DrugBank.d67.s2|87-109|3-hydroxydesloratadine|drug_n
DDI-DrugBank.d67.s2|140-150|clinically|drug
DDI-DrugBank.d67.s2|193-207|desloratadine,|drug
DDI-DrugBank.d67.s2|255-265|(including|drug
DDI-DrugBank.d67.s2|283-293|interval),|drug
DDI-DrugBank.d67.s2|294-302|clinical|drug
DDI-DrugBank.d67.s3|19-32|Desloratadine|drug
DDI-DrugBank.d67.s3|37-59|3-Hydroxydesloratadine|drug_n
DDI-DrugBank.d67.s3|60-76|Pharmacokinetics|drug
DDI-DrugBank.d67.s5|0-13|Desloratadine|drug
DDI-DrugBank.d67.s5|14-36|3-Hydroxydesloratadine|drug_n
DDI-DrugBank.d67.s8|0-12|Erythromycin|drug
DDI-DrugBank.d67.s11|0-12|Ketoconazole|drug
DDI-DrugBank.d67.s14|0-12|Azithromycin|drug
DDI-DrugBank.d67.s17|0-10|Fluoxetine|drug
DDI-DrugBank.d67.s20|0-10|Cimetidine|drug
DDI-DrugBank.d465.s0|4-16|vasodilating|drug
DDI-DrugBank.d465.s0|28-38|isosorbide|drug
DDI-DrugBank.d465.s0|39-48|dinitrate|drug
DDI-DrugBank.d460.s0|33-41|indicate|drug
DDI-DrugBank.d460.s0|58-71|predominantly|drug
DDI-DrugBank.d460.s0|115-121|CYP2C9|brand
DDI-DrugBank.d460.s0|151-157|CYP3A4|brand
DDI-DrugBank.d460.s1|23-32|inhibitor|drug
DDI-DrugBank.d460.s1|40-46|CYP2C9|brand
DDI-DrugBank.d460.s1|68-77|indicated|drug
DDI-DrugBank.d460.s1|96-103|inhibit|drug
DDI-DrugBank.d460.s2|14-20|CYP3A4|brand
DDI-DrugBank.d460.s3|94-106|administered|drug
DDI-DrugBank.d460.s3|166-177|combination|drug
DDI-DrugBank.d460.s3|183-192|glyburide|drug
DDI-DrugBank.d460.s4|14-24|clinically|drug
DDI-DrugBank.d460.s4|53-69|pharmacokinetics|drug
DDI-DrugBank.d460.s5|0-10|Metformin:|drug
DDI-DrugBank.d460.s5|66-78|administered|drug
DDI-DrugBank.d460.s5|82-93|combination|drug
DDI-DrugBank.d460.s5|99-108|metformin|drug
DDI-DrugBank.d460.s5|182-192|clinically|drug
DDI-DrugBank.d460.s5|217-233|pharmacokinetics|drug
DDI-DrugBank.d460.s6|0-8|Digoxin:|drug
DDI-DrugBank.d460.s6|46-58|administered|drug
DDI-DrugBank.d460.s6|62-73|combination|drug
DDI-DrugBank.d460.s6|81-87|single|drug
DDI-DrugBank.d460.s6|101-108|digoxin|drug
DDI-DrugBank.d460.s6|146-156|clinically|drug
DDI-DrugBank.d460.s6|181-197|pharmacokinetics|drug
DDI-DrugBank.d460.s7|0-9|Warfarin:|drug
DDI-DrugBank.d460.s7|37-49|administered|drug
DDI-DrugBank.d460.s7|113-124|combination|drug
DDI-DrugBank.d460.s7|132-138|single|drug
DDI-DrugBank.d460.s7|147-155|warfarin|drug
DDI-DrugBank.d460.s7|205-221|pharmacokinetics|drug
DDI-DrugBank.d460.s8|0-11|Prothrombin|drug
DDI-DrugBank.d460.s9|12-26|Administration|drug
DDI-DrugBank.d460.s9|30-37|morning|drug
DDI-DrugBank.d460.s9|75-86|combination|drug
DDI-DrugBank.d460.s9|94-100|single|drug
DDI-DrugBank.d460.s9|101-106|75-mg|drug_n
DDI-DrugBank.d460.s9|190-206|pharmacokinetics|drug
DDI-DrugBank.d460.s10|0-11|Nateglinide|drug
DDI-DrugBank.d460.s10|38-46|proteins|drug
DDI-DrugBank.d460.s10|54-60|mainly|drug
DDI-DrugBank.d460.s10|61-69|albumin.|drug
DDI-DrugBank.d460.s11|42-55|protein-bound|drug
DDI-DrugBank.d460.s11|82-94|propranolol,|drug
DDI-DrugBank.d460.s11|106-118|nicardipine,|drug
DDI-DrugBank.d460.s11|119-131|pravastatin,|drug
DDI-DrugBank.d460.s11|143-152|warfarin,|drug
DDI-DrugBank.d460.s11|153-163|phenytoin,|drug
DDI-DrugBank.d460.s11|203-212|metformin|drug
DDI-DrugBank.d460.s11|223-232|influence|drug
DDI-DrugBank.d460.s11|250-261|nateglinide|drug
DDI-DrugBank.d460.s11|262-269|protein|drug
DDI-DrugBank.d460.s11|270-278|binding.|drug
DDI-DrugBank.d460.s12|11-22|nateglinide|drug
DDI-DrugBank.d460.s12|30-39|influence|drug
DDI-DrugBank.d460.s12|53-60|protein|drug
DDI-DrugBank.d460.s12|61-68|binding|drug
DDI-DrugBank.d460.s12|72-84|propranolol,|drug
DDI-DrugBank.d460.s12|96-108|nicardipine,|drug
DDI-DrugBank.d460.s12|109-118|warfarin,|drug
DDI-DrugBank.d460.s12|119-129|phenytoin,|drug
DDI-DrugBank.d460.s12|156-167|tolbutamide|drug
DDI-DrugBank.d460.s13|31-41|individual|drug
DDI-DrugBank.d460.s13|68-76|clinical|drug
DDI-DrugBank.d460.s13|77-85|setting.|drug
DDI-DrugBank.d460.s14|0-7|Certain|drug
DDI-DrugBank.d460.s14|15-24|including|drug
DDI-DrugBank.d460.s14|38-55|anti-inflammatory|group
DDI-DrugBank.d460.s14|86-95|monoamine|drug
DDI-DrugBank.d460.s14|104-115|inhibitors,|drug
DDI-DrugBank.d460.s14|134-158|beta-adrenergic-blocking|drug
DDI-DrugBank.d460.s14|231-243|antidiabetic|group
DDI-DrugBank.d460.s15|0-7|Certain|drug
DDI-DrugBank.d460.s15|14-23|including|drug
DDI-DrugBank.d460.s15|24-34|thiazides,|group
DDI-DrugBank.d460.s15|35-51|corticosteroids,|group
DDI-DrugBank.d460.s15|152-164|antidiabetic|group
DDI-DrugBank.d460.s16|21-33|administered|drug
DDI-DrugBank.d460.s16|64-73|receiving|drug
DDI-DrugBank.d460.s16|146-154|control.|group
DDI-DrugBank.d514.s0|0-7|Opioids|group
DDI-DrugBank.d514.s0|95-104|tolerance|drug
DDI-DrugBank.d514.s0|105-113|allowing|drug
DDI-DrugBank.d514.s0|124-133|increased|drug
DDI-DrugBank.d514.s1|3-14|combination|drug
DDI-DrugBank.d514.s1|62-68|heroin|drug
DDI-DrugBank.d514.s1|130-139|tolerance|drug
DDI-DrugBank.d514.s1|204-214|increased.|drug
DDI-DrugBank.d514.s2|22-36|heroin-related|drug
DDI-DrugBank.d514.s2|60-71|involvement|drug
DDI-DrugBank.d514.s2|117-126|including|drug
DDI-DrugBank.d514.s2|136-151|benzodiazepines|drug
DDI-DrugBank.d514.s2|169-178|(Valium),|drug
DDI-DrugBank.d514.s2|189-195|rising|drug
DDI-DrugBank.d514.s3|12-27|benzodiazepines|drug
DDI-DrugBank.d514.s3|63-69|heroin|drug
DDI-DrugBank.d514.s4|0-7|Cocaine|drug
DDI-DrugBank.d514.s4|50-61|combination|drug
DDI-DrugBank.d514.s4|67-74|heroin.|drug
DDI-DrugBank.d356.s0|5-14|amiloride|drug
DDI-DrugBank.d356.s0|22-34|administered|drug
DDI-DrugBank.d356.s0|57-79|angiotensin-converting|drug
DDI-DrugBank.d356.s0|87-97|inhibitor,|drug
DDI-DrugBank.d356.s0|130-140|increased.|drug
DDI-DrugBank.d356.s1|49-58|indicated|drug
DDI-DrugBank.d356.s1|147-157|monitoring|drug
DDI-DrugBank.d356.s1|167-177|potassium.|drug
DDI-DrugBank.d356.s2|0-7|Lithium|drug
DDI-DrugBank.d356.s2|43-52|diuretics|group
DDI-DrugBank.d356.s2|116-123|lithium|drug
DDI-DrugBank.d356.s3|19-26|lithium|drug
DDI-DrugBank.d356.s4|22-36|administration|drug
DDI-DrugBank.d356.s4|56-73|anti-inflammatory|group
DDI-DrugBank.d356.s4|95-104|diuretic,|group
DDI-DrugBank.d356.s4|105-117|natriuretic,|group
DDI-DrugBank.d356.s4|122-138|antihypertensive|group
DDI-DrugBank.d356.s4|156-173|potassium-sparing|drug
DDI-DrugBank.d356.s4|178-186|thiazide|group
DDI-DrugBank.d356.s4|187-197|diuretics.|group
DDI-DrugBank.d356.s5|16-23|MIDAMOR|brand
DDI-DrugBank.d356.s5|42-59|anti-inflammatory|group
DDI-DrugBank.d356.s5|133-142|determine|drug
DDI-DrugBank.d356.s5|172-180|diuretic|group
DDI-DrugBank.d356.s5|184-193|obtained.|drug
DDI-DrugBank.d356.s6|0-5|Since|drug
DDI-DrugBank.d356.s6|6-18|indomethacin|drug
DDI-DrugBank.d356.s6|23-40|potassium-sparing|drug
DDI-DrugBank.d356.s6|41-51|diuretics,|group
DDI-DrugBank.d356.s6|52-61|including|drug
DDI-DrugBank.d356.s6|62-70|MIDAMOR,|brand
DDI-DrugBank.d356.s6|99-108|increased|drug
DDI-DrugBank.d356.s6|115-124|potassium|drug
DDI-DrugBank.d356.s6|158-167|potassium|drug
DDI-DrugBank.d356.s6|168-176|kinetics|drug
DDI-DrugBank.d356.s6|239-251|administered|drug
DDI-DrugBank.d377.s0|0-11|Phospholine|drug
DDI-DrugBank.d377.s0|12-18|Iodide|drug
DDI-DrugBank.d377.s0|37-51|cholinesterase|drug
DDI-DrugBank.d377.s0|52-62|inhibitors|drug
DDI-DrugBank.d377.s0|71-86|succinylcholine|drug
DDI-DrugBank.d377.s0|90-105|organophosphate|drug
DDI-DrugBank.d377.s0|120-133|insecticides.|drug
DDI-DrugBank.d377.s1|9-19|undergoing|drug
DDI-DrugBank.d377.s1|29-47|anticholinesterase|group
DDI-DrugBank.d377.s1|111-122|Phospholine|drug
DDI-DrugBank.d3.s0|42-49|protein|drug
DDI-DrugBank.d3.s0|56-63|99.2%).|drug_n
DDI-DrugBank.d3.s1|0-9|Warfarin,|drug
DDI-DrugBank.d3.s1|10-18|Digoxin,|drug
DDI-DrugBank.d3.s1|35-42|Heparin|drug
DDI-DrugBank.d3.s1|56-63|binding|drug
DDI-DrugBank.d3.s1|67-75|warfarin|drug
DDI-DrugBank.d3.s1|86-94|proteins|drug
DDI-DrugBank.d3.s1|133-145|tromethamine|drug
DDI-DrugBank.d3.s1|153-160|control|group
DDI-DrugBank.d3.s1|164-170|99.3%)|drug_n
DDI-DrugBank.d3.s2|25-32|digoxin|drug
DDI-DrugBank.d3.s2|33-40|protein|drug
DDI-DrugBank.d3.s2|41-49|binding.|drug
DDI-DrugBank.d3.s3|17-25|indicate|drug
DDI-DrugBank.d3.s3|94-101|binding|drug
DDI-DrugBank.d3.s3|146-151|99.2%|drug_n
DDI-DrugBank.d3.s3|155-161|97.5%,|drug_n
DDI-DrugBank.d3.s3|162-174|representing|drug
DDI-DrugBank.d3.s3|195-203|increase|drug
DDI-DrugBank.d3.s4|30-38|digoxin,|drug
DDI-DrugBank.d3.s4|39-48|warfarin,|drug
DDI-DrugBank.d3.s4|81-95|acetaminophen,|drug
DDI-DrugBank.d3.s4|96-105|phenytoin|drug
DDI-DrugBank.d3.s4|106-120|andtolbutamide|drug
DDI-DrugBank.d3.s4|145-157|tromethamine|drug
DDI-DrugBank.d3.s4|158-165|protein|drug
DDI-DrugBank.d3.s4|166-174|binding.|drug
DDI-DrugBank.d3.s5|11-20|involving|drug
DDI-DrugBank.d3.s5|42-53|TORADOLORAL|brand
DDI-DrugBank.d3.s5|58-72|coadministered|drug
DDI-DrugBank.d3.s5|80-86|single|drug
DDI-DrugBank.d3.s5|101-110|warfarin,|drug
DDI-DrugBank.d3.s5|111-118|causing|drug
DDI-DrugBank.d3.s5|145-161|pharmacokinetics|drug
DDI-DrugBank.d3.s5|185-194|warfarin.|drug
DDI-DrugBank.d3.s6|3-10|another|drug
DDI-DrugBank.d3.s6|18-30|TORADOLIV/IM|brand
DDI-DrugBank.d3.s6|69-76|heparin|drug
DDI-DrugBank.d3.s6|103-112|resulting|drug
DDI-DrugBank.d3.s6|132-140|bleeding|drug
DDI-DrugBank.d3.s6|153-160|minutes|drug
DDI-DrugBank.d3.s6|205-212|minutes|drug
DDI-DrugBank.d3.s6|234-241|heparin|drug
DDI-DrugBank.d3.s6|256-263|minutes|drug
DDI-DrugBank.d3.s7|30-38|indicate|drug
DDI-DrugBank.d3.s7|53-64|interaction|drug
DDI-DrugBank.d3.s7|73-80|TORADOL|brand
DDI-DrugBank.d3.s7|85-93|warfarin|drug
DDI-DrugBank.d3.s7|97-105|heparin,|drug
DDI-DrugBank.d3.s7|110-124|administration|drug
DDI-DrugBank.d3.s7|128-135|TORADOL|brand
DDI-DrugBank.d3.s7|148-154|taking|drug
DDI-DrugBank.d3.s7|155-169|anticoagulants|group
DDI-DrugBank.d3.s8|12-19|TORADOL|brand
DDI-DrugBank.d3.s8|20-25|IV/IM|brand
DDI-DrugBank.d3.s8|38-46|diuretic|group
DDI-DrugBank.d3.s8|59-69|furosemide|drug
DDI-DrugBank.d3.s8|73-85|normovolemic|drug
DDI-DrugBank.d3.s8|130-136|sodium|drug
DDI-DrugBank.d3.s8|141-148|urinary|drug
DDI-DrugBank.d3.s8|166-171|17%).|drug_n
DDI-DrugBank.d3.s9|24-38|administration|drug
DDI-DrugBank.d3.s9|42-49|TORADOL|brand
DDI-DrugBank.d3.s9|131-140|increases|drug
DDI-DrugBank.d3.s9|179-188|increased|drug
DDI-DrugBank.d3.s9|244-252|terminal|drug
DDI-DrugBank.d3.s9|263-272|increased|drug
DDI-DrugBank.d3.s10|30-37|TORADOL|brand
DDI-DrugBank.d3.s10|56-72|contraindicated.|group
DDI-DrugBank.d3.s11|0-8|Lithium:|drug
DDI-DrugBank.d3.s11|29-36|lithium|drug
DDI-DrugBank.d3.s11|48-55|leading|drug
DDI-DrugBank.d3.s11|62-70|increase|drug
DDI-DrugBank.d3.s11|81-88|lithium|drug
DDI-DrugBank.d3.s11|132-145|prostaglandin|drug
DDI-DrugBank.d3.s11|146-166|synthesis-inhibiting|drug
DDI-DrugBank.d3.s12|14-21|TORADOL|brand
DDI-DrugBank.d3.s12|32-39|lithium|drug
DDI-DrugBank.d3.s12|75-84|increased|drug
DDI-DrugBank.d3.s12|85-92|lithium|drug
DDI-DrugBank.d3.s12|107-113|during|drug
DDI-DrugBank.d3.s12|114-121|TORADOL|brand
DDI-DrugBank.d3.s13|26-40|administration|drug
DDI-DrugBank.d3.s13|132-141|enhancing|drug
DDI-DrugBank.d3.s14|14-21|TORADOL|brand
DDI-DrugBank.d3.s15|0-15|Nondepolarizing|drug
DDI-DrugBank.d3.s15|37-50|postmarketing|drug
DDI-DrugBank.d3.s15|100-111|interaction|drug
DDI-DrugBank.d3.s15|120-132|TORADOLIV/IM|brand
DDI-DrugBank.d3.s15|137-152|nondepolarizing|drug
DDI-DrugBank.d3.s16|22-29|TORADOL|brand
DDI-DrugBank.d3.s17|39-49|inhibitors|drug
DDI-DrugBank.d3.s17|54-62|increase|drug
DDI-DrugBank.d3.s18|39-47|seizures|group
DDI-DrugBank.d3.s18|67-73|during|drug
DDI-DrugBank.d3.s18|93-100|TORADOL|brand
DDI-DrugBank.d3.s18|105-118|antiepileptic|group
DDI-DrugBank.d3.s18|125-136|(phenytoin,|drug
DDI-DrugBank.d3.s18|137-152|carbamazepine).|drug
DDI-DrugBank.d3.s19|20-34|Hallucinations|drug
DDI-DrugBank.d3.s19|59-66|TORADOL|brand
DDI-DrugBank.d3.s19|88-94|taking|drug
DDI-DrugBank.d3.s19|114-126|(fluoxetine,|drug
DDI-DrugBank.d3.s20|0-9|Morphine:|drug
DDI-DrugBank.d3.s20|10-22|TORADOLIV/IM|brand
DDI-DrugBank.d3.s20|32-44|administered|drug
DDI-DrugBank.d3.s20|63-71|morphine|drug
DDI-DrugBank.d3.s20|83-91|clinical|drug
DDI-DrugBank.d3.s20|149-162|interactions.|drug
DDI-DrugBank.d3.s21|11-18|TORADOL|brand
DDI-DrugBank.d3.s21|23-31|morphine|drug
DDI-DrugBank.d3.s21|44-52|syringe.|drug
DDI-DrugBank.d3.s22|53-60|TORADOL|brand
DDI-DrugBank.d3.s22|61-68|induces|drug
DDI-DrugBank.d3.s22|72-80|inhibits|drug
DDI-DrugBank.d3.s22|108-120|metabolizing|drug
DDI-DrugBank.d191.s0|23-35|interference|drug
DDI-DrugBank.d191.s0|50-58|clinical|drug
DDI-DrugBank.d191.s1|0-8|Steroids|group
DDI-DrugBank.d191.s1|47-54|calcium|drug
DDI-DrugBank.d191.s1|55-63|disodium|drug
DDI-DrugBank.d191.s1|86-93|calcium|drug
DDI-DrugBank.d191.s1|94-102|disodium|drug
DDI-DrugBank.d191.s1|103-113|interferes|drug
DDI-DrugBank.d191.s1|138-145|insulin|drug
DDI-DrugBank.d191.s1|162-171|chelating|drug
DDI-DrugBank.d191.s1|176-181|zinc.|drug
DDI-DrugBank.d497.s0|0-5|AZOPT|brand
DDI-DrugBank.d497.s0|6-19|(brinzolamide|drug
DDI-DrugBank.d497.s0|46-54|contains|group
DDI-DrugBank.d497.s0|66-75|anhydrase|drug
DDI-DrugBank.d497.s0|76-86|inhibitor.|drug
DDI-DrugBank.d497.s1|63-71|clinical|drug
DDI-DrugBank.d497.s1|84-97|brinzolamide.|drug
DDI-DrugBank.d497.s2|48-57|anhydrase|drug
DDI-DrugBank.d497.s2|58-69|inhibitors,|drug
DDI-DrugBank.d497.s2|75-84|instances|drug
DDI-DrugBank.d497.s2|93-105|interactions|drug
DDI-DrugBank.d497.s3|39-50|interaction|drug
DDI-DrugBank.d497.s3|84-93|receiving|drug
DDI-DrugBank.d497.s3|94-99|AZOPT|brand
DDI-DrugBank.d497.s3|100-113|(brinzolamide|drug
DDI-MedLine.d73.s0|42-51|following|drug
DDI-MedLine.d73.s0|52-96|1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine|drug_n
DDI-MedLine.d73.s0|97-103|(MPTP)|brand
DDI-MedLine.d73.s0|108-124|methamphetamine.|drug
DDI-MedLine.d73.s1|46-55|following|drug
DDI-MedLine.d73.s1|61-75|administration|drug
DDI-MedLine.d73.s1|134-143|following|drug
DDI-MedLine.d73.s1|144-159|methamphetamine|drug
DDI-MedLine.d73.s1|160-175|administration.|drug
DDI-MedLine.d73.s2|26-33|induced|drug
DDI-MedLine.d73.s2|39-46|lasting|drug
DDI-MedLine.d73.s2|70-78|dopamine|drug
DDI-MedLine.d73.s2|143-152|pargyline|drug
DDI-MedLine.d73.s3|4-16|MPTP-induced|drug
DDI-MedLine.d73.s3|44-53|tolerance|drug
DDI-MedLine.d73.s3|83-94|amphetamine|drug
DDI-MedLine.d73.s3|147-158|apomorphine|drug
DDI-MedLine.d73.s3|167-177|responding|drug
DDI-MedLine.d73.s3|192-202|controlled|group
DDI-MedLine.d73.s4|0-16|Methamphetamine,|drug
DDI-MedLine.d73.s4|22-27|MPTP,|brand
DDI-MedLine.d73.s4|60-68|dopamine|drug
DDI-MedLine.d73.s4|107-116|pargyline|drug
DDI-MedLine.d73.s5|78-87|following|drug
DDI-MedLine.d73.s5|92-106|administration|drug
DDI-MedLine.d73.s5|110-119|pargyline|drug
DDI-MedLine.d73.s5|137-148|Parkinson's|drug
DDI-MedLine.d48.s0|24-33|histidine|drug
DDI-MedLine.d48.s0|79-90|Clostridium|drug
DDI-MedLine.d48.s0|101-106|toxin|drug
DDI-MedLine.d48.s1|0-11|Clostridium|drug
DDI-MedLine.d48.s1|22-27|toxin|drug
DDI-MedLine.d48.s2|39-44|toxin|drug
DDI-MedLine.d48.s2|109-120|GTP-binding|drug
DDI-MedLine.d48.s2|121-129|proteins|drug
DDI-MedLine.d48.s3|72-81|histidine|drug
DDI-MedLine.d48.s3|94-99|toxin|drug
DDI-MedLine.d48.s4|16-21|toxin|drug
DDI-MedLine.d48.s4|112-117|toxin|drug
DDI-MedLine.d48.s5|13-18|toxin|drug
DDI-MedLine.d48.s5|89-98|labelling|drug
DDI-MedLine.d48.s5|102-111|histidine|drug
DDI-MedLine.d48.s5|128-133|toxin|drug
DDI-MedLine.d48.s5|134-144|molecules.|drug
DDI-MedLine.d48.s6|58-71|hydroxylamine|drug
DDI-MedLine.d48.s7|32-41|histidine|drug
DDI-MedLine.d48.s7|54-59|toxin|drug
DDI-MedLine.d48.s8|0-9|Histidine|drug
DDI-MedLine.d48.s8|84-89|toxin|drug
DDI-MedLine.d48.s9|43-50|binding|drug
DDI-MedLine.d48.s9|54-59|toxin|drug
DDI-MedLine.d48.s9|63-69|bovine|drug
DDI-MedLine.d48.s9|70-83|thyroglobulin|drug
DDI-MedLine.d48.s9|90-95|ELISA|brand
DDI-MedLine.d48.s9|115-122|binding|drug
DDI-MedLine.d48.s9|156-173|haemagglutination|drug
DDI-MedLine.d48.s10|26-35|histidine|drug
DDI-MedLine.d48.s10|67-83|receptor-binding|drug
DDI-MedLine.d48.s10|96-101|toxin|drug
DDI-MedLine.d48.s11|8-18|histidines|drug
DDI-MedLine.d48.s11|22-27|toxin|drug
DDI-MedLine.d48.s11|150-155|toxin|drug
DDI-MedLine.d48.s11|158-163|using|drug
DDI-MedLine.d48.s11|164-178|zinc-chelating|drug
DDI-DrugBank.d474.s0|80-92|discontinued|group
DDI-DrugBank.d474.s0|102-112|initiation|drug
DDI-DrugBank.d474.s1|13-20|include|drug
DDI-DrugBank.d474.s1|42-57|anticoagulants,|group
DDI-DrugBank.d474.s1|67-77|inhibitors|drug
DDI-DrugBank.d474.s1|78-87|including|drug
DDI-DrugBank.d474.s1|131-141|(including|drug
DDI-DrugBank.d474.s1|152-166|tromethamine),|drug
DDI-DrugBank.d474.s1|167-180|dipyridamole,|drug
DDI-DrugBank.d474.s1|184-199|sulfinpyrazone.|drug
DDI-DrugBank.d474.s2|3-20|co-administration|drug
DDI-DrugBank.d474.s2|49-57|clinical|drug
DDI-DrugBank.d474.s2|73-83|monitoring|drug
DDI-DrugBank.d511.s0|16-27|interaction|drug
DDI-DrugBank.d511.s0|31-39|FOSCAVIR|brand
DDI-DrugBank.d511.s0|44-55|intravenous|drug
DDI-DrugBank.d511.s0|56-67|pentamidine|drug
DDI-DrugBank.d511.s1|53-60|Kingdom|drug
DDI-DrugBank.d511.s1|66-74|FOSCAVIR|brand
DDI-DrugBank.d511.s1|79-90|intravenous|drug
DDI-DrugBank.d511.s1|91-102|pentamidine|drug
DDI-DrugBank.d511.s3|56-67|pentamidine|drug
DDI-DrugBank.d511.s4|69-77|FOSCAVIR|brand
DDI-DrugBank.d511.s4|99-110|combination|drug
DDI-DrugBank.d511.s4|154-170|aminoglycosides,|drug
DDI-DrugBank.d511.s4|171-183|amphotericin|drug
DDI-DrugBank.d511.s4|190-201|intravenous|drug
DDI-DrugBank.d511.s4|202-213|pentamidine|drug
DDI-DrugBank.d511.s5|0-5|Since|drug
DDI-DrugBank.d511.s5|6-14|FOSCAVIR|brand
DDI-DrugBank.d511.s5|57-65|calcium,|drug
DDI-DrugBank.d511.s5|113-122|influence|drug
DDI-DrugBank.d511.s5|129-136|calcium|drug
DDI-DrugBank.d511.s6|17-33|pharmacokinetics|drug
DDI-DrugBank.d511.s6|95-104|receiving|drug
DDI-DrugBank.d511.s6|141-152|alternating|drug
DDI-DrugBank.d511.s6|165-176|maintenance|drug
DDI-DrugBank.d490.s2|0-8|Clinical|drug
DDI-DrugBank.d490.s4|0-9|increased|drug
DDI-DrugBank.d490.s4|10-18|creatine|drug
DDI-DrugBank.d490.s5|9-20|antinuclear|group
DDI-DrugBank.d490.s7|0-13|phosphokinase|drug
DDI-DrugBank.d490.s8|0-8|antibody|group
DDI-DrugBank.d490.s10|0-9|increased|drug
DDI-DrugBank.d490.s10|10-19|bilirubin|drug
DDI-DrugBank.d490.s13|0-9|increased|drug
DDI-DrugBank.d490.s16|0-13|transaminases|drug
DDI-DrugBank.d490.s19|0-7|(SGOT),|brand
DDI-DrugBank.d490.s19|12-18|(SGPT)|brand
DDI-DrugBank.d490.s22|0-9|increased|drug
DDI-DrugBank.d490.s22|10-18|alkaline|drug
DDI-DrugBank.d490.s37|0-12|eosinophilia|drug
DDI-DrugBank.d312.s0|15-26|interaction|drug
DDI-DrugBank.d312.s0|40-55|anti-neoplastic|group
DDI-DrugBank.d312.s1|55-81|irinotecan/5-FU/leucovorin|drug
DDI-DrugBank.d312.s1|110-118|AVASTIN.|brand
DDI-DrugBank.d312.s2|0-10|Irinotecan|drug
DDI-DrugBank.d312.s2|51-60|receiving|drug
DDI-DrugBank.d312.s2|84-95|combination|drug
DDI-DrugBank.d312.s2|101-109|AVASTIN.|brand
DDI-DrugBank.d312.s3|22-27|SN38,|brand
DDI-DrugBank.d312.s3|53-64|irinotecan,|drug
DDI-DrugBank.d312.s3|104-113|receiving|drug
DDI-DrugBank.d312.s3|127-138|combination|drug
DDI-DrugBank.d312.s3|144-151|AVASTIN|brand
DDI-DrugBank.d312.s4|21-30|receiving|drug
DDI-DrugBank.d312.s4|46-53|AVASTIN|brand
DDI-DrugBank.d312.s4|67-76|incidence|drug
DDI-DrugBank.d312.s5|12-25|inter-patient|drug
DDI-DrugBank.d312.s5|50-59|sampling,|drug
DDI-DrugBank.d312.s5|78-86|increase|drug
DDI-DrugBank.d312.s5|114-123|receiving|drug
DDI-DrugBank.d312.s5|135-145|irinotecan|drug
DDI-DrugBank.d312.s5|150-157|AVASTIN|brand
DDI-DrugBank.d312.s5|161-171|uncertain.|drug
DDI-DrugBank.d411.s0|150-162|intercurrent|drug
DDI-DrugBank.d411.s0|236-242|timing|drug
DDI-DrugBank.d411.s0|251-266|administration.|drug
DDI-DrugBank.d411.s1|115-126|elimination|drug
DDI-DrugBank.d411.s1|169-182|levothyroxine|drug
DDI-DrugBank.d411.s1|183-190|sodium.|drug
DDI-DrugBank.d411.s2|0-13|Levothyroxine|drug
DDI-DrugBank.d411.s2|14-20|Sodium|drug
DDI-DrugBank.d411.s2|37-46|following|drug
DDI-DrugBank.d411.s2|90-103|levothyroxine|drug
DDI-DrugBank.d411.s2|104-110|sodium|drug
DDI-DrugBank.d411.s2|120-136|gastrointestinal|drug
DDI-DrugBank.d411.s2|144-152|aluminum|drug
DDI-DrugBank.d411.s2|163-177|cholestyramine|drug
DDI-DrugBank.d411.s2|178-184|resin,|drug
DDI-DrugBank.d411.s2|185-195|colestipol|drug
DDI-DrugBank.d411.s2|196-210|hydrochloride,|drug
DDI-DrugBank.d411.s2|228-234|sodium|drug
DDI-DrugBank.d411.s2|279-285|infant|drug
DDI-DrugBank.d411.s3|0-7|Binding|drug
DDI-DrugBank.d411.s3|17-26|Proteins:|drug
DDI-DrugBank.d411.s3|31-40|following|drug
DDI-DrugBank.d411.s3|59-66|inhibit|drug
DDI-DrugBank.d411.s3|67-80|levothyroxine|drug
DDI-DrugBank.d411.s3|81-87|sodium|drug
DDI-DrugBank.d411.s3|88-95|binding|drug
DDI-DrugBank.d411.s3|105-113|proteins|drug
DDI-DrugBank.d411.s3|151-158|binding|drug
DDI-DrugBank.d411.s3|159-168|proteins:|drug
DDI-DrugBank.d411.s3|210-223|asparaginase,|drug
DDI-DrugBank.d411.s3|250-269|estrogen-containing|group
DDI-DrugBank.d411.s3|281-296|5-fluorouracil,|drug_n
DDI-DrugBank.d411.s3|309-325|glucocorticoids,|group
DDI-DrugBank.d411.s3|372-385|perphenazine,|drug
DDI-DrugBank.d411.s3|402-412|phenytoin,|drug
DDI-DrugBank.d411.s4|24-33|following|drug
DDI-DrugBank.d411.s4|189-201|elimination,|drug
DDI-DrugBank.d411.s4|228-246|aminoglutethimide,|drug
DDI-DrugBank.d411.s4|247-263|p-aminosalicylic|drug
DDI-DrugBank.d411.s4|381-392|antithyroid|group
DDI-DrugBank.d411.s4|413-421|blocking|drug
DDI-DrugBank.d411.s4|430-444|carbamazepine,|drug
DDI-DrugBank.d411.s4|453-461|hydrate,|drug
DDI-DrugBank.d411.s4|472-480|dopamine|drug
DDI-DrugBank.d411.s4|485-493|dopamine|drug
DDI-DrugBank.d411.s4|517-533|glucocorticoids,|group
DDI-DrugBank.d411.s4|534-542|heparin,|drug
DDI-DrugBank.d411.s4|558-567|inducers,|drug
DDI-DrugBank.d411.s4|568-576|insulin,|drug
DDI-DrugBank.d411.s4|577-586|iodinated|drug
DDI-DrugBank.d411.s4|587-602|cholestographic|drug
DDI-DrugBank.d411.s4|611-628|iodine-containing|group
DDI-DrugBank.d411.s4|650-661|lovastatin,|drug
DDI-DrugBank.d411.s4|662-670|lithium,|drug
DDI-DrugBank.d411.s4|671-688|6-mercaptopurine,|drug_n
DDI-DrugBank.d411.s4|745-755|phenytoin,|drug
DDI-DrugBank.d411.s4|756-767|resorcinol,|drug
DDI-DrugBank.d411.s4|768-777|rifampin,|drug
DDI-DrugBank.d411.s4|778-790|somatostatin|drug
DDI-DrugBank.d411.s4|814-828|sulfonylureas,|group
DDI-DrugBank.d411.s4|829-837|thiazide|group
DDI-DrugBank.d411.s4|838-848|diuretics.|group
DDI-DrugBank.d411.s5|0-17|Adrenocorticoids:|group
DDI-DrugBank.d411.s5|41-57|adrenocorticoids|group
DDI-DrugBank.d411.s5|99-108|increased|drug
DDI-DrugBank.d411.s5|165-173|changing|drug
DDI-DrugBank.d411.s7|27-46|hypoprothrombinemic|drug
DDI-DrugBank.d411.s7|57-71|anticoagulants|group
DDI-DrugBank.d411.s7|106-115|increased|drug
DDI-DrugBank.d411.s7|130-137|vitamin|drug
DDI-DrugBank.d411.s7|150-158|clotting|drug
DDI-DrugBank.d411.s8|20-29|(Insulin,|drug
DDI-DrugBank.d411.s8|30-45|Sulfonylureas):|group
DDI-DrugBank.d411.s8|63-70|insulin|drug
DDI-DrugBank.d411.s8|79-91|antidiabetic|group
DDI-DrugBank.d411.s8|182-190|increase|drug
DDI-DrugBank.d411.s8|200-210|initiation|drug
DDI-DrugBank.d411.s9|13-21|Blocking|drug
DDI-DrugBank.d411.s9|49-62|beta-blocking|drug
DDI-DrugBank.d411.s10|0-9|Cytokines|drug
DDI-DrugBank.d411.s10|10-22|(interferon,|drug
DDI-DrugBank.d411.s10|23-36|interleukin):|drug
DDI-DrugBank.d411.s10|37-46|Cytokines|drug
DDI-DrugBank.d411.s10|69-75|induce|drug
DDI-DrugBank.d411.s13|0-9|Ketamine:|drug
DDI-DrugBank.d411.s13|97-111|administration|drug
DDI-DrugBank.d411.s13|115-128|levothyroxine|drug
DDI-DrugBank.d411.s13|129-135|sodium|drug
DDI-DrugBank.d411.s13|140-149|ketamine.|drug
DDI-DrugBank.d411.s14|0-12|Maprotiline:|drug
DDI-DrugBank.d411.s14|45-54|increase.|drug
DDI-DrugBank.d411.s15|0-6|Sodium|drug
DDI-DrugBank.d411.s15|7-13|Iodide|drug
DDI-DrugBank.d411.s15|14-19|(123I|brand
DDI-DrugBank.d411.s15|24-30|131I),|brand
DDI-DrugBank.d411.s15|31-37|Sodium|drug
DDI-DrugBank.d411.s16|0-20|Somatrem/Somatropin:|drug
DDI-DrugBank.d411.s16|91-99|closure.|group
DDI-DrugBank.d411.s17|29-38|interfere|drug
DDI-DrugBank.d411.s17|79-90|somatropin.|drug
DDI-DrugBank.d411.s18|0-13|Theophylline:|drug
DDI-DrugBank.d411.s18|14-26|Theophylline|drug
DDI-DrugBank.d411.s19|46-54|increase|drug
DDI-DrugBank.d411.s19|120-129|increased|drug
DDI-DrugBank.d411.s19|130-143|catecholamine|drug
DDI-DrugBank.d411.s21|33-42|increased|drug
DDI-DrugBank.d411.s21|60-73|insufficiency|drug
DDI-DrugBank.d530.s0|14-23|monoamine|drug
DDI-DrugBank.d530.s0|32-37|(MAO)|brand
DDI-DrugBank.d530.s0|38-48|inhibitors|drug
DDI-DrugBank.d530.s0|51-60|including|drug
DDI-DrugBank.d530.s0|61-71|phenelzine|drug
DDI-DrugBank.d530.s0|81-96|tranylcypromine|drug
DDI-DrugBank.d530.s0|109-118|pargyline|drug
DDI-DrugBank.d530.s1|19-34|L-phenylalanine|drug
DDI-DrugBank.d530.s1|57-67|inhibitors|drug
DDI-DrugBank.d530.s2|0-10|Selegiline|drug
DDI-DrugBank.d530.s2|13-28|L-phenylalanine|drug
DDI-DrugBank.d530.s2|51-60|inhibitor|drug
DDI-DrugBank.d530.s2|61-71|selegiline|drug
DDI-DrugBank.d530.s2|93-107|antidepressant|group
DDI-DrugBank.d530.s3|0-11|Neuroleptic|drug
DDI-DrugBank.d530.s3|20-35|L-phenylalanine|drug
DDI-DrugBank.d530.s3|63-73|dyskinesia|drug
DDI-DrugBank.d530.s3|92-103|neuroleptic|drug
DDI-MedLine.d25.s0|35-46|interaction|drug
DDI-MedLine.d25.s0|55-66|simvastatin|drug
DDI-MedLine.d25.s0|71-86|clarithromycin.|drug
DDI-MedLine.d25.s1|0-10|OBJECTIVE:|brand
DDI-MedLine.d25.s1|46-55|resulting|drug
DDI-MedLine.d25.s1|80-94|clarithromycin|drug
DDI-MedLine.d25.s1|99-111|simvastatin.|drug
DDI-MedLine.d25.s2|5-13|SUMMARY:|brand
DDI-MedLine.d25.s2|16-27|64-year-old|drug_n
DDI-MedLine.d25.s2|82-91|worsening|drug
DDI-MedLine.d25.s2|98-106|failure,|group
DDI-MedLine.d25.s2|116-124|creatine|drug
DDI-MedLine.d25.s2|125-139|phosphokinase,|drug
DDI-MedLine.d25.s2|155-160|pain,|drug
DDI-MedLine.d25.s3|65-79|clarithromycin|drug
DDI-MedLine.d25.s3|84-94|sinusitis.|drug
DDI-MedLine.d25.s4|21-30|receiving|drug
DDI-MedLine.d25.s4|31-42|simvastatin|drug
DDI-MedLine.d25.s5|33-44|intravenous|drug
DDI-MedLine.d25.s5|45-55|hydration,|drug
DDI-MedLine.d25.s5|56-62|sodium|drug
DDI-MedLine.d25.s6|25-36|necrotizing|drug
DDI-MedLine.d25.s6|61-67|toxin.|drug
DDI-MedLine.d25.s7|12-21|continued|group
DDI-MedLine.d25.s7|33-45|intermittent|drug
DDI-MedLine.d25.s7|80-90|infectious|drug
DDI-MedLine.d25.s8|43-52|increased|drug
DDI-MedLine.d25.s8|66-76|developing|drug
DDI-MedLine.d25.s8|93-102|including|drug
DDI-MedLine.d25.s8|117-125|failure.|group
DDI-MedLine.d25.s9|0-11|DISCUSSION:|brand
DDI-MedLine.d25.s9|12-26|Clarithromycin|drug
DDI-MedLine.d25.s9|39-48|inhibitor|drug
DDI-MedLine.d25.s9|52-59|CYP3A4,|brand
DDI-MedLine.d25.s9|93-104|simvastatin|drug
DDI-MedLine.d25.s10|16-30|administration|drug
DDI-MedLine.d25.s10|34-43|macrolide|drug
DDI-MedLine.d25.s10|44-55|antibiotics|group
DDI-MedLine.d25.s10|66-87|hydroxymethylglutaryl|drug
DDI-MedLine.d25.s10|119-129|inhibitors|drug
DDI-MedLine.d25.s11|18-26|increase|drug
DDI-MedLine.d25.s11|49-61|interaction,|drug
DDI-MedLine.d25.s11|62-71|including|drug
DDI-MedLine.d25.s11|76-90|administration|drug
DDI-MedLine.d25.s11|147-157|underlying|drug
DDI-MedLine.d25.s11|164-178|insufficiency,|drug
DDI-MedLine.d25.s11|183-197|administration|drug
DDI-MedLine.d25.s11|233-244|inhibitors.|drug
DDI-MedLine.d25.s12|0-12|CONCLUSIONS:|brand
DDI-MedLine.d25.s12|13-22|Macrolide|drug
DDI-MedLine.d25.s12|23-34|antibiotics|group
DDI-MedLine.d25.s12|35-42|inhibit|drug
DDI-MedLine.d25.s12|79-89|inhibitors|drug
DDI-MedLine.d25.s12|114-120|CYP3A4|brand
DDI-MedLine.d25.s12|128-141|atorvastatin,|drug
DDI-MedLine.d25.s12|142-155|cerivastatin,|drug
DDI-MedLine.d25.s12|156-167|lovastatin,|drug
DDI-MedLine.d25.s12|168-181|simvastatin).|drug
DDI-MedLine.d25.s13|5-16|interaction|drug
DDI-MedLine.d25.s13|96-109|insufficiency|drug
DDI-MedLine.d25.s13|140-146|taking|drug
DDI-MedLine.d123.s0|0-10|Vancomycin|drug
DDI-MedLine.d123.s0|49-60|flavonoids.|group
DDI-MedLine.d123.s1|19-27|clinical|drug
DDI-MedLine.d123.s1|28-48|vancomycin-resistant|drug
DDI-MedLine.d123.s1|49-56|strains|drug
DDI-MedLine.d123.s1|72-77|(VRE)|brand
DDI-MedLine.d123.s2|20-31|combination|drug
DDI-MedLine.d123.s2|35-43|galangin|drug
DDI-MedLine.d123.s2|47-67|3,7-dihydroxyflavone|drug_n
DDI-MedLine.d123.s2|73-83|vancomycin|drug
DDI-MedLine.d123.s2|119-126|strains|drug
DDI-MedLine.d123.s2|169-176|faecium|drug
DDI-MedLine.d123.s2|193-213|vancomycin-sensitive|drug
DDI-MedLine.d123.s2|214-222|strains.|drug
DDI-MedLine.d123.s3|0-7|Minimum|drug
DDI-MedLine.d123.s3|8-18|inhibitory|drug
DDI-MedLine.d123.s3|64-74|determined|drug
DDI-MedLine.d123.s3|98-103|using|drug
DDI-MedLine.d123.s4|8-18|vancomycin|drug
DDI-MedLine.d123.s4|19-26|against|drug_n
DDI-MedLine.d123.s4|44-52|clinical|drug
DDI-MedLine.d123.s4|73-79|strain|drug
DDI-MedLine.d123.s5|35-43|galangin|drug
DDI-MedLine.d123.s5|68-88|3,7-dihydroxyflavone|drug_n
DDI-MedLine.d123.s6|23-30|culture|group
DDI-MedLine.d123.s7|14-19|51299|drug_n
DDI-MedLine.d123.s7|31-41|flavonoids|group
DDI-MedLine.d123.s7|88-95|forming|drug
DDI-MedLine.d123.s8|10-20|maintained|drug
DDI-MedLine.d123.s8|66-84|vancomycin/flavone|drug
DDI-MedLine.d123.s8|85-98|combinations.|drug
DDI-MedLine.d123.s9|5-18|combinational|drug
DDI-MedLine.d123.s9|29-38|reversing|drug
DDI-MedLine.d123.s9|39-49|vancomycin|drug
DDI-MedLine.d123.s9|166-173|against|drug_n
DDI-MedLine.d51.s0|11-19|xanthine|drug
DDI-MedLine.d51.s0|69-81|contribution|group
DDI-MedLine.d51.s0|85-94|adenosine|drug
DDI-MedLine.d51.s1|3-15|investigated|drug
DDI-MedLine.d51.s1|31-40|adenosine|drug
DDI-MedLine.d51.s1|63-72|caffeine,|drug
DDI-MedLine.d51.s1|73-86|theophylline,|drug
DDI-MedLine.d51.s1|87-108|8-phenyltheophylline,|drug_n
DDI-MedLine.d51.s1|113-147|8-cyclopentyl-1,3-dipropylxanthine|drug_n
DDI-MedLine.d51.s1|148-156|(DPCPX),|brand
DDI-MedLine.d51.s3|26-38|theophylline|drug
DDI-MedLine.d51.s3|77-83|21680,|drug_n
DDI-MedLine.d51.s3|120-143|N6-cyclopentyladenosine|drug
DDI-MedLine.d51.s3|144-150|(CPA),|brand
DDI-MedLine.d51.s4|31-51|theophylline-induced|drug
DDI-MedLine.d51.s4|74-82|CGS21680|brand
DDI-MedLine.d51.s4|142-155|DPCPX-induced|drug
DDI-MedLine.d51.s4|204-209|21680|drug_n
DDI-MedLine.d51.s5|0-8|Finally,|drug
DDI-MedLine.d51.s5|28-44|xanthine-derived|drug
DDI-MedLine.d51.s5|45-54|adenosine|drug
DDI-MedLine.d51.s6|32-37|minor|drug
DDI-MedLine.d51.s6|38-50|contribution|group
DDI-MedLine.d51.s6|54-63|adenosine|drug
DDI-MedLine.d51.s6|101-121|theophylline-induced|drug
DDI-DrugBank.d351.s0|35-47|antibiotics,|group
DDI-DrugBank.d351.s0|81-90|inhibited|drug
DDI-DrugBank.d351.s0|140-148|increase|drug
DDI-DrugBank.d24.s0|3-14|information|drug
DDI-DrugBank.d520.s0|65-77|Carboplatin.|drug
DDI-DrugBank.d322.s0|0-11|Amantadine,|drug
DDI-DrugBank.d322.s0|22-38|antidepressants,|group
DDI-DrugBank.d322.s0|53-61|increase|drug
DDI-DrugBank.d322.s0|62-77|anticholinergic|group
DDI-DrugBank.d322.s0|88-98|clidinium.|drug
DDI-DrugBank.d322.s1|0-9|Clidinium|drug
DDI-DrugBank.d322.s1|37-52|phenothiazines,|drug
DDI-DrugBank.d322.s1|67-80|ketoconazole.|drug
DDI-DrugBank.d329.s0|18-33|co-administered|drug
DDI-DrugBank.d329.s1|52-61|increased|drug
DDI-DrugBank.d329.s2|14-23|increased|drug
DDI-DrugBank.d329.s3|46-62|coadministration|drug
DDI-DrugBank.d329.s4|17-25|indicate|drug
DDI-DrugBank.d329.s4|50-57|inhibit|drug
DDI-DrugBank.d329.s4|58-81|P-glycoprotein-mediated|drug
DDI-DrugBank.d329.s4|95-102|digoxin|drug
DDI-DrugBank.d329.s4|106-117|vinblastine|drug
DDI-DrugBank.d329.s4|160-183|P-glycoprotein-mediated|drug
DDI-DrugBank.d329.s5|43-51|indicate|drug
DDI-DrugBank.d329.s5|76-83|inhibit|drug
DDI-DrugBank.d329.s5|118-127|following|drug
DDI-DrugBank.d329.s5|148-153|(CYP)|brand
DDI-DrugBank.d329.s5|174-179|2C19,|brand
DDI-DrugBank.d329.s6|5-17|interactions|drug
DDI-DrugBank.d329.s6|28-38|inhibition|drug
DDI-DrugBank.d329.s6|42-65|P-glycoprotein-mediated|drug
DDI-DrugBank.d329.s7|40-48|clinical|drug
DDI-DrugBank.d329.s7|54-65|interaction|drug
DDI-DrugBank.d324.s0|44-55|interaction|drug
DDI-DrugBank.d324.s1|17-25|Ethanol:|drug
DDI-DrugBank.d324.s1|55-68|CNS-impairing|drug
DDI-DrugBank.d324.s1|80-87|ethanol|drug
DDI-DrugBank.d324.s1|109-116|testing|drug
DDI-DrugBank.d324.s1|152-159|ethanol|drug
DDI-DrugBank.d324.s1|160-174|administration|drug
DDI-DrugBank.d324.s1|217-224|(DSST),|brand
DDI-DrugBank.d324.s1|232-239|copying|drug
DDI-DrugBank.d324.s1|326-333|ethanol|drug
DDI-DrugBank.d324.s1|334-349|administration.|drug
DDI-DrugBank.d324.s2|53-65|interaction;|drug
DDI-DrugBank.d324.s3|28-44|pharmacokinetics|drug
DDI-DrugBank.d324.s3|48-56|ethanol.|drug
DDI-DrugBank.d324.s4|0-11|Imipramine:|drug
DDI-DrugBank.d324.s4|12-28|Coadministration|drug
DDI-DrugBank.d324.s4|32-38|single|drug
DDI-DrugBank.d324.s4|65-75|imipramine|drug
DDI-DrugBank.d324.s4|191-206|administration.|drug
DDI-DrugBank.d324.s5|4-15|interaction|drug
DDI-DrugBank.d324.s5|62-78|pharmacokinetics|drug
DDI-DrugBank.d324.s6|0-11|Paroxetine:|drug
DDI-DrugBank.d324.s6|12-28|Coadministration|drug
DDI-DrugBank.d324.s6|34-40|single|drug
DDI-DrugBank.d324.s6|66-76|paroxetine|drug
DDI-DrugBank.d324.s6|120-131|interaction|drug
DDI-DrugBank.d324.s7|14-24|paroxetine|drug
DDI-DrugBank.d324.s7|43-59|pharmacokinetics|drug
DDI-DrugBank.d324.s7|71-81|reflecting|drug
DDI-DrugBank.d324.s7|107-113|CYP2D6|brand
DDI-DrugBank.d324.s8|0-13|Thioridazine:|drug
DDI-DrugBank.d324.s8|14-30|Coadministration|drug
DDI-DrugBank.d324.s8|34-40|single|drug
DDI-DrugBank.d324.s8|67-79|thioridazine|drug
DDI-DrugBank.d324.s8|195-210|administration.|drug
DDI-DrugBank.d324.s9|4-15|interaction|drug
DDI-DrugBank.d324.s9|62-78|pharmacokinetics|drug
DDI-DrugBank.d324.s10|0-12|Venlafaxine:|drug
DDI-DrugBank.d324.s10|13-29|Coadministration|drug
DDI-DrugBank.d324.s10|35-41|single|drug
DDI-DrugBank.d324.s10|87-98|venlafaxine|drug
DDI-DrugBank.d324.s10|177-193|pharmacokinetics|drug
DDI-DrugBank.d324.s10|216-228|venlafaxine.|drug
DDI-DrugBank.d324.s11|42-53|interaction|drug
DDI-DrugBank.d324.s11|69-85|coadministration|drug
DDI-DrugBank.d324.s11|102-113|venlafaxine|drug
DDI-DrugBank.d324.s12|0-13|Promethazine:|drug
DDI-DrugBank.d324.s12|14-30|Coadministration|drug
DDI-DrugBank.d324.s12|36-42|single|drug
DDI-DrugBank.d324.s12|64-76|promethazine|drug
DDI-DrugBank.d324.s13|33-49|coadministration|drug
DDI-DrugBank.d324.s13|66-78|promethazine|drug
DDI-DrugBank.d324.s14|52-67|coadministered.|drug
DDI-DrugBank.d324.s15|18-24|CYP3A4|brand
DDI-DrugBank.d324.s15|25-34|Rifampin:|drug
DDI-DrugBank.d324.s15|35-41|CYP3A4|brand
DDI-DrugBank.d324.s15|45-55|ordinarily|drug
DDI-DrugBank.d324.s15|58-63|minor|drug
DDI-DrugBank.d324.s15|64-76|metabolizing|drug
DDI-DrugBank.d324.s16|14-28|administration|drug
DDI-DrugBank.d324.s16|43-49|CYP3A4|brand
DDI-DrugBank.d324.s16|50-57|inducer|drug
DDI-DrugBank.d324.s16|58-66|rifampin|drug
DDI-DrugBank.d324.s17|4-20|coadministration|drug
DDI-DrugBank.d324.s17|33-39|CYP3A4|brand
DDI-DrugBank.d324.s17|47-55|inducer,|drug
DDI-DrugBank.d324.s17|69-75|posing|drug
DDI-DrugBank.d324.s17|113-128|ineffectiveness|drug
DDI-DrugBank.d324.s18|81-87|taking|drug
DDI-DrugBank.d324.s18|88-94|CYP3A4|brand
DDI-DrugBank.d324.s18|95-103|inducers|drug
DDI-DrugBank.d324.s18|112-121|rifampin,|drug
DDI-DrugBank.d324.s18|122-132|phenytoin,|drug
DDI-DrugBank.d324.s18|133-147|carbamazepine,|drug
DDI-DrugBank.d324.s19|19-25|CYP3A4|brand
DDI-DrugBank.d324.s19|26-32|CYP3A4|brand
DDI-DrugBank.d324.s19|38-43|minor|drug
DDI-DrugBank.d324.s19|70-81|elimination|drug
DDI-DrugBank.d324.s19|142-148|CYP3A4|brand
DDI-DrugBank.d324.s19|180-202|5-oxo-desethylzaleplon|drug_n
DDI-DrugBank.d324.s19|207-229|5-oxo-desethylzaleplon|drug_n
DDI-DrugBank.d324.s19|270-277|urinary|drug
DDI-DrugBank.d324.s20|0-16|Coadministration|drug
DDI-DrugBank.d324.s20|20-27|single,|drug
DDI-DrugBank.d324.s20|56-68|erythromycin|drug
DDI-DrugBank.d324.s20|123-129|CYP3A4|brand
DDI-DrugBank.d324.s20|130-139|inhibitor|drug
DDI-DrugBank.d324.s20|155-163|increase|drug
DDI-DrugBank.d324.s20|217-225|increase|drug
DDI-DrugBank.d324.s21|17-28|interaction|drug
DDI-DrugBank.d324.s21|52-64|erythromycin|drug
DDI-DrugBank.d324.s22|23-29|CYP3A4|brand
DDI-DrugBank.d324.s22|30-40|inhibitors|drug
DDI-DrugBank.d324.s22|49-61|ketoconazole|drug
DDI-DrugBank.d324.s22|86-94|increase|drug
DDI-DrugBank.d324.s22|99-107|exposure|group
DDI-DrugBank.d324.s23|2-9|routine|drug
DDI-DrugBank.d324.s25|0-16|Diphenhydramine:|drug
DDI-DrugBank.d324.s25|17-32|Diphenhydramine|drug
DDI-DrugBank.d324.s25|58-67|inhibitor|drug
DDI-DrugBank.d324.s25|110-120|inhibitory|drug
DDI-DrugBank.d324.s26|12-27|pharmacokinetic|drug
DDI-DrugBank.d324.s26|28-39|interaction|drug
DDI-DrugBank.d324.s26|61-76|diphenhydramine|drug
DDI-DrugBank.d324.s26|77-86|following|drug
DDI-DrugBank.d324.s26|91-105|administration|drug
DDI-DrugBank.d324.s26|111-117|single|drug
DDI-DrugBank.d324.s28|45-51|CYP3A4|brand
DDI-DrugBank.d324.s28|52-63|Cimetidine:|drug
DDI-DrugBank.d324.s28|64-74|Cimetidine|drug
DDI-DrugBank.d324.s28|75-83|inhibits|drug
DDI-DrugBank.d324.s28|121-127|CYP3A4|brand
DDI-DrugBank.d324.s29|12-26|administration|drug
DDI-DrugBank.d324.s29|49-59|cimetidine|drug
DDI-DrugBank.d324.s29|85-93|increase|drug
DDI-DrugBank.d324.s30|3-10|initial|drug
DDI-DrugBank.d324.s30|74-79|being|drug
DDI-DrugBank.d324.s30|93-104|cimetidine.|drug
DDI-DrugBank.d324.s31|29-36|Protein|drug
DDI-DrugBank.d324.s31|76-84|proteins|drug
DDI-DrugBank.d324.s31|105-110|15%);|drug_n
DDI-DrugBank.d324.s32|89-96|protein|drug
DDI-DrugBank.d324.s32|97-105|binding.|drug
DDI-DrugBank.d324.s33|13-27|administration|drug
DDI-DrugBank.d324.s33|51-57|taking|drug
DDI-DrugBank.d324.s33|58-65|another|drug
DDI-DrugBank.d324.s33|86-93|protein|drug
DDI-DrugBank.d324.s33|127-135|increase|drug
DDI-DrugBank.d324.s34|38-46|Digoxin:|drug
DDI-DrugBank.d324.s34|81-96|pharmacokinetic|drug
DDI-DrugBank.d324.s34|127-134|digoxin|drug
DDI-DrugBank.d324.s35|0-9|Warfarin:|drug
DDI-DrugBank.d324.s35|84-100|pharmacokinetics|drug
DDI-DrugBank.d324.s35|104-112|warfarin|drug
DDI-DrugBank.d324.s35|113-118|(R+)-|brand
DDI-DrugBank.d324.s35|163-175|(prothrombin|drug
DDI-DrugBank.d324.s35|182-191|following|drug
DDI-DrugBank.d324.s35|194-200|single|drug
DDI-DrugBank.d324.s35|201-206|25-mg|drug_n
DDI-DrugBank.d324.s35|220-229|warfarin.|drug
DDI-DrugBank.d324.s37|22-37|pharmacokinetic|drug
DDI-DrugBank.d324.s37|38-49|interaction|drug
DDI-DrugBank.d324.s37|81-90|following|drug
DDI-DrugBank.d324.s37|91-97|single|drug
DDI-DrugBank.d324.s37|103-117|administration|drug
DDI-DrugBank.d324.s38|135-147|administered|drug
DDI-DrugBank.d153.s0|4-18|administration|drug
DDI-DrugBank.d153.s0|49-59|containing|group
DDI-DrugBank.d153.s0|60-71|epinephrine|drug
DDI-DrugBank.d153.s0|75-89|norepinephrine|drug
DDI-DrugBank.d153.s0|102-111|receiving|drug
DDI-DrugBank.d153.s0|112-121|monoamine|drug
DDI-DrugBank.d153.s0|130-140|inhibitors|drug
DDI-DrugBank.d153.s0|154-169|antidepressants|group
DDI-DrugBank.d153.s2|72-82|monitoring|drug
DDI-DrugBank.d153.s3|11-25|administration|drug
DDI-DrugBank.d153.s4|0-14|Phenothiazines|drug
DDI-DrugBank.d153.s4|78-90|epinephrine.|drug
DDI-DrugBank.d548.s0|36-47|Duloxetine:|drug
DDI-DrugBank.d548.s0|53-59|CYP1A2|brand
DDI-DrugBank.d548.s0|64-70|CYP2D6|brand
DDI-DrugBank.d548.s0|91-101|duloxetine|drug
DDI-DrugBank.d548.s1|14-21|CYP1A2:|brand
DDI-DrugBank.d548.s1|41-51|duloxetine|drug
DDI-DrugBank.d548.s1|57-69|fluvoxamine,|drug
DDI-DrugBank.d548.s1|73-82|inhibitor|drug
DDI-DrugBank.d548.s1|86-93|CYP1A2,|brand
DDI-DrugBank.d548.s1|121-127|6-fold|drug_n
DDI-DrugBank.d548.s1|128-136|increase|drug
DDI-DrugBank.d548.s1|156-164|2.5-fold|drug_n
DDI-DrugBank.d548.s1|165-173|increase|drug
DDI-DrugBank.d548.s1|185-196|duloxetine.|drug
DDI-DrugBank.d548.s2|5-14|quinolone|drug
DDI-DrugBank.d548.s2|15-26|antibiotics|group
DDI-DrugBank.d548.s2|79-91|combinations|drug
DDI-DrugBank.d548.s3|14-21|CYP2D6:|brand
DDI-DrugBank.d548.s3|30-36|CYP2D6|brand
DDI-DrugBank.d548.s3|40-48|involved|drug
DDI-DrugBank.d548.s3|52-62|duloxetine|drug
DDI-DrugBank.d548.s3|94-104|duloxetine|drug
DDI-DrugBank.d548.s3|117-127|inhibitors|drug
DDI-DrugBank.d548.s3|131-137|CYP2D6|brand
DDI-DrugBank.d548.s3|177-188|duloxetine.|drug
DDI-DrugBank.d548.s4|0-10|Paroxetine|drug
DDI-DrugBank.d548.s4|22-31|increased|drug
DDI-DrugBank.d548.s4|53-63|duloxetine|drug
DDI-DrugBank.d548.s4|112-122|inhibition|drug
DDI-DrugBank.d548.s4|157-168|paroxetine.|drug
DDI-DrugBank.d548.s5|52-58|CYP2D6|brand
DDI-DrugBank.d548.s5|59-69|inhibitors|drug
DDI-DrugBank.d548.s5|77-88|fluoxetine,|drug
DDI-DrugBank.d548.s5|89-100|quinidine).|drug
DDI-DrugBank.d548.s6|14-24|Duloxetine|drug
DDI-DrugBank.d548.s6|69-76|CYP1A2:|brand
DDI-DrugBank.d548.s6|91-102|interaction|drug
DDI-DrugBank.d548.s6|128-138|duloxetine|drug
DDI-DrugBank.d548.s6|148-154|induce|drug
DDI-DrugBank.d548.s6|155-161|CYP1A2|brand
DDI-DrugBank.d548.s6|201-211|clinically|drug
DDI-DrugBank.d548.s6|252-258|CYP1A2|brand
DDI-DrugBank.d548.s7|21-28|CYP2D6:|brand
DDI-DrugBank.d548.s7|29-39|Duloxetine|drug
DDI-DrugBank.d548.s7|54-63|inhibitor|drug
DDI-DrugBank.d548.s7|67-74|CYP2D6.|brand
DDI-DrugBank.d548.s8|5-15|duloxetine|drug
DDI-DrugBank.d548.s8|20-32|administered|drug
DDI-DrugBank.d548.s8|80-86|single|drug
DDI-DrugBank.d548.s8|87-92|50-mg|drug_n
DDI-DrugBank.d548.s8|101-113|desipramine,|drug
DDI-DrugBank.d548.s8|116-122|CYP2D6|brand
DDI-DrugBank.d548.s8|145-156|desipramine|drug
DDI-DrugBank.d548.s8|157-166|increased|drug
DDI-DrugBank.d548.s8|167-174|3-fold.|drug_n
DDI-DrugBank.d548.s9|11-28|co-administration|drug
DDI-DrugBank.d548.s9|32-42|Duloxetine|drug
DDI-DrugBank.d548.s9|145-151|index,|drug
DDI-DrugBank.d548.s9|152-161|including|drug
DDI-DrugBank.d548.s9|162-169|certain|drug
DDI-DrugBank.d548.s9|170-185|antidepressants|group
DDI-DrugBank.d548.s9|197-212|antidepressants|group
DDI-DrugBank.d548.s9|229-243|nortriptyline,|drug
DDI-DrugBank.d548.s9|244-258|amitriptyline,|drug
DDI-DrugBank.d548.s9|263-275|imipramine),|drug
DDI-DrugBank.d548.s9|276-290|phenothiazines|drug
DDI-DrugBank.d548.s9|303-318|antiarrhythmics|group
DDI-DrugBank.d548.s9|339-351|flecainide),|drug
DDI-DrugBank.d548.s10|110-125|co-administered|drug
DDI-DrugBank.d548.s10|131-142|Duloxetine.|drug
DDI-DrugBank.d548.s11|126-139|thioridazine,|drug
DDI-DrugBank.d548.s11|140-150|Duloxetine|drug
DDI-DrugBank.d548.s11|155-167|thioridazine|drug
DDI-DrugBank.d548.s11|182-198|co-administered.|drug
DDI-DrugBank.d548.s12|21-27|CYP3A:|brand
DDI-DrugBank.d548.s12|73-83|duloxetine|drug
DDI-DrugBank.d548.s12|93-100|inhibit|drug
DDI-DrugBank.d548.s12|104-110|induce|drug
DDI-DrugBank.d548.s12|111-116|CYP3A|brand
DDI-DrugBank.d548.s13|0-10|Duloxetine|drug
DDI-DrugBank.d548.s13|22-32|Clinically|drug
DDI-DrugBank.d548.s13|64-73|Following|drug
DDI-DrugBank.d548.s13|101-111|Duloxetine|drug
DDI-DrugBank.d548.s13|116-123|ethanol|drug
DDI-DrugBank.d548.s13|129-141|administered|drug
DDI-DrugBank.d548.s13|204-213|coincide,|drug
DDI-DrugBank.d548.s13|214-224|Duloxetine|drug
DDI-DrugBank.d548.s13|233-241|increase|drug
DDI-DrugBank.d548.s14|7-17|Duloxetine|drug
DDI-DrugBank.d548.s14|18-26|clinical|drug
DDI-DrugBank.d548.s14|50-68|Duloxetine-treated|drug
DDI-DrugBank.d548.s14|88-94|injury|drug
DDI-DrugBank.d548.s14|126-135|bilirubin|drug
DDI-DrugBank.d548.s15|12-24|intercurrent|drug
DDI-DrugBank.d548.s15|25-32|ethanol|drug
DDI-DrugBank.d548.s15|91-102|contributed|group
DDI-DrugBank.d548.s16|4-10|Acting|drug
DDI-DrugBank.d548.s16|51-62|Duloxetine,|drug
DDI-DrugBank.d548.s16|114-125|combination|drug
DDI-DrugBank.d548.s16|166-172|acting|drug
DDI-DrugBank.d548.s16|180-189|including|drug
DDI-DrugBank.d548.s17|66-76|Duloxetine|drug
DDI-DrugBank.d548.s17|92-99|coating|drug
DDI-DrugBank.d548.s17|131-139|reaching|drug
DDI-DrugBank.d548.s17|157-173|gastrointestinal|drug
DDI-DrugBank.d548.s18|32-43|Duloxetine,|drug
DDI-DrugBank.d548.s18|71-79|coating,|drug
DDI-DrugBank.d548.s18|92-102|hydrolysis|drug
DDI-DrugBank.d548.s19|22-27|using|drug
DDI-DrugBank.d548.s19|28-38|Duloxetine|drug
DDI-DrugBank.d548.s19|89-97|emptying|drug
DDI-DrugBank.d548.s20|21-37|gastrointestinal|drug
DDI-DrugBank.d548.s20|75-86|duloxetine.|drug
DDI-DrugBank.d548.s21|9-26|co-administration|drug
DDI-DrugBank.d548.s21|30-40|Duloxetine|drug
DDI-DrugBank.d548.s21|46-55|aluminum-|drug
DDI-DrugBank.d548.s21|60-80|magnesium-containing|group
DDI-DrugBank.d548.s21|81-89|antacids|group
DDI-DrugBank.d548.s21|102-112|Duloxetine|drug
DDI-DrugBank.d548.s21|118-129|famotidine,|drug
DDI-DrugBank.d548.s21|181-191|duloxetine|drug
DDI-DrugBank.d548.s21|209-223|administration|drug
DDI-DrugBank.d548.s21|229-234|40-mg|drug_n
DDI-DrugBank.d548.s22|38-52|administration|drug
DDI-DrugBank.d548.s22|68-78|inhibitors|drug
DDI-DrugBank.d548.s22|87-97|duloxetine|drug
DDI-MedLine.d64.s0|53-64|paroxetine.|drug
DDI-MedLine.d64.s1|14-22|reaching|drug
DDI-MedLine.d64.s2|48-56|becoming|drug
DDI-DrugBank.d60.s0|0-14|Administration|drug
DDI-DrugBank.d60.s0|18-27|0.1-mg/kg|drug_n
DDI-DrugBank.d60.s0|33-38|ED95)|brand
DDI-DrugBank.d60.s0|39-45|NIMBEX|brand
DDI-DrugBank.d60.s0|69-78|following|drug
DDI-DrugBank.d60.s0|82-92|intubating|drug
DDI-DrugBank.d60.s0|101-116|succinylcholine|drug
DDI-DrugBank.d60.s1|35-44|following|drug
DDI-DrugBank.d60.s1|45-51|NIMBEX|brand
DDI-DrugBank.d60.s1|71-78|minutes|drug
DDI-DrugBank.d60.s1|97-111|administration|drug
DDI-DrugBank.d60.s1|115-131|succinylcholine.|drug
DDI-DrugBank.d60.s2|6-20|administration|drug
DDI-DrugBank.d60.s2|24-39|succinylcholine|drug
DDI-DrugBank.d60.s2|93-102|following|drug
DDI-DrugBank.d60.s2|103-110|initial|drug
DDI-DrugBank.d60.s2|114-125|maintenance|drug
DDI-DrugBank.d60.s2|141-148|NIMBEX.|brand
DDI-DrugBank.d60.s3|25-31|NIMBEX|brand
DDI-DrugBank.d60.s3|44-56|administered|drug
DDI-DrugBank.d60.s3|57-72|succinylcholine|drug
DDI-DrugBank.d60.s3|82-91|infusions|drug
DDI-DrugBank.d60.s3|95-101|NIMBEX|brand
DDI-DrugBank.d60.s3|151-166|succinylcholine|drug
DDI-DrugBank.d60.s3|175-188|administered.|drug
DDI-DrugBank.d60.s4|11-17|NIMBEX|brand
DDI-DrugBank.d60.s4|25-40|succinylcholine|drug
DDI-DrugBank.d60.s4|82-97|succinylcholine|drug
DDI-DrugBank.d60.s5|39-47|clinical|drug
DDI-DrugBank.d60.s5|64-76|interactions|drug
DDI-DrugBank.d60.s5|96-107|vecuronium,|drug
DDI-DrugBank.d60.s5|108-120|pancuronium,|drug
DDI-DrugBank.d60.s5|124-134|atracurium|drug
DDI-DrugBank.d60.s5|140-152|administered|drug
DDI-DrugBank.d60.s5|153-162|following|drug
DDI-DrugBank.d60.s5|163-170|varying|drug
DDI-DrugBank.d60.s5|196-202|single|drug
DDI-DrugBank.d60.s5|212-221|infusions|drug
DDI-DrugBank.d60.s5|225-232|NIMBEX.|brand
DDI-DrugBank.d60.s6|24-36|administered|drug
DDI-DrugBank.d60.s6|83-91|[Minimum|drug
DDI-DrugBank.d60.s6|132-142|clinically|drug
DDI-DrugBank.d60.s6|175-182|initial|drug
DDI-DrugBank.d60.s6|187-198|maintenance|drug
DDI-DrugBank.d60.s6|208-214|NIMBEX|brand
DDI-DrugBank.d60.s6|241-249|infusion|drug
DDI-DrugBank.d60.s6|258-265|NIMBEX.|brand
DDI-DrugBank.d60.s7|61-75|administration|drug
DDI-DrugBank.d60.s8|14-21|minutes|drug
DDI-DrugBank.d60.s8|25-33|exposure|group
DDI-DrugBank.d60.s8|74-81|minimal|drug
DDI-DrugBank.d60.s8|119-126|initial|drug
DDI-DrugBank.d60.s8|136-142|NIMBEX|brand
DDI-DrugBank.d60.s8|179-186|initial|drug
DDI-DrugBank.d60.s8|217-223|NIMBEX|brand
DDI-DrugBank.d60.s8|227-239|administered|drug
DDI-DrugBank.d60.s8|254-264|initiation|drug
DDI-DrugBank.d60.s9|17-27|procedures|group
DDI-DrugBank.d60.s9|28-34|during|drug
DDI-DrugBank.d60.s9|85-96|maintenance|drug
DDI-DrugBank.d60.s9|97-104|dosing,|drug
DDI-DrugBank.d60.s9|111-122|maintenance|drug
DDI-DrugBank.d60.s9|141-149|infusion|drug
DDI-DrugBank.d60.s9|159-165|NIMBEX|brand
DDI-DrugBank.d60.s10|12-20|infusion|drug
DDI-DrugBank.d60.s11|3-11|clinical|drug
DDI-DrugBank.d60.s11|72-78|dosing|drug
DDI-DrugBank.d60.s11|96-103|NIMBEX.|brand
DDI-DrugBank.d60.s12|48-56|blocking|drug
DDI-DrugBank.d60.s12|67-82|nondepolarizing|drug
DDI-DrugBank.d60.s12|98-104|NIMBEX|brand
DDI-DrugBank.d60.s12|105-112|include|drug
DDI-DrugBank.d60.s12|113-120|certain|drug
DDI-DrugBank.d60.s12|121-132|antibiotics|group
DDI-DrugBank.d60.s12|141-157|aminoglycosides,|drug
DDI-DrugBank.d60.s12|158-172|tetracyclines,|drug
DDI-DrugBank.d60.s12|173-184|bacitracin,|drug
DDI-DrugBank.d60.s12|185-196|polymyxins,|drug
DDI-DrugBank.d60.s12|197-208|lincomycin,|drug
DDI-DrugBank.d60.s12|209-221|clindamycin,|drug
DDI-DrugBank.d60.s12|222-231|colistin,|drug
DDI-DrugBank.d60.s12|236-242|sodium|drug
DDI-DrugBank.d60.s12|260-269|magnesium|drug
DDI-DrugBank.d60.s12|277-285|lithium,|drug
DDI-DrugBank.d60.s12|305-318|procainamide,|drug
DDI-DrugBank.d60.s12|323-333|quinidine.|drug
DDI-DrugBank.d60.s13|32-40|blocking|drug
DDI-DrugBank.d60.s13|51-66|nondepolarizing|drug
DDI-DrugBank.d60.s13|81-89|blocking|drug
DDI-DrugBank.d60.s13|143-155|administered|drug
DDI-DrugBank.d60.s13|156-165|phenytoin|drug
DDI-DrugBank.d60.s13|169-183|carbamazepine.|drug
DDI-DrugBank.d60.s14|29-38|phenytoin|drug
DDI-DrugBank.d60.s14|42-55|carbamazepine|drug
DDI-DrugBank.d60.s14|81-87|NIMBEX|brand
DDI-DrugBank.d60.s14|158-169|anticipated|group
DDI-DrugBank.d60.s14|174-182|infusion|drug
DDI-DrugBank.d270.s0|0-10|Nevirapine|drug
DDI-DrugBank.d270.s0|14-25|principally|drug
DDI-DrugBank.d270.s1|0-10|Nevirapine|drug
DDI-DrugBank.d270.s1|29-36|inducer|drug
DDI-DrugBank.d270.s2|112-126|coadministered|drug
DDI-DrugBank.d270.s2|132-143|nevirapine.|drug
DDI-DrugBank.d270.s3|13-28|pharmacokinetic|drug
DDI-DrugBank.d270.s3|53-70|co-administration|drug
DDI-DrugBank.d270.s3|74-84|nevirapine|drug
DDI-DrugBank.d270.s3|115-123|CLINICAL|brand
DDI-DrugBank.d270.s3|124-137|PHARMACOLOGY,|brand
DDI-DrugBank.d270.s4|0-8|Clinical|drug
DDI-DrugBank.d270.s4|69-84|pharmacokinetic|drug
DDI-DrugBank.d270.s5|9-17|inTables|drug
DDI-DrugBank.d270.s5|59-70|interaction|drug
DDI-DrugBank.d270.s5|92-97|HIV-1|brand
DDI-DrugBank.d270.s5|137-147|indicated.|drug
DDI-DrugBank.d270.s6|32-45|interactions,|drug
DDI-DrugBank.d270.s6|69-84|pharmacokinetic|drug
DDI-DrugBank.d270.s6|85-97|interactions|drug
DDI-DrugBank.d270.s6|106-116|nevirapine|drug
DDI-DrugBank.d270.s7|21-33|interactions|drug
DDI-DrugBank.d270.s8|23-34|interaction|drug
DDI-DrugBank.d270.s8|46-51|HIV-1|brand
DDI-DrugBank.d270.s8|153-161|clinical|drug
DDI-DrugBank.d270.s8|162-172|monitoring|drug
DDI-DrugBank.d270.s8|195-211|co-administering|drug
DDI-DrugBank.d270.s9|13-24|interaction|drug
DDI-DrugBank.d270.s9|33-43|nevirapine|drug
DDI-DrugBank.d270.s9|52-66|antithrombotic|group
DDI-DrugBank.d270.s9|73-81|warfarin|drug
DDI-DrugBank.d270.s10|18-24|giving|drug
DDI-DrugBank.d270.s10|59-67|warfarin|drug
DDI-DrugBank.d270.s10|109-118|increases|drug
DDI-DrugBank.d270.s11|5-13|warfarin|drug
DDI-DrugBank.d270.s11|17-32|co-administered|drug
DDI-DrugBank.d270.s11|38-49|nevirapine,|drug
DDI-DrugBank.d270.s11|50-65|anticoagulation|group
DDI-DrugBank.d270.s14|27-37|Nevirapine|drug
DDI-DrugBank.d270.s15|0-8|Clinical|drug
DDI-DrugBank.d270.s16|0-14|Clarithromycin|drug
DDI-DrugBank.d270.s17|0-14|Clarithromycin|drug
DDI-DrugBank.d270.s17|16-21|14OH-|brand
DDI-DrugBank.d270.s17|22-36|clarithromycin|drug
DDI-DrugBank.d270.s18|0-14|Clarithromycin|drug
DDI-DrugBank.d270.s18|15-23|exposure|group
DDI-DrugBank.d270.s18|55-66|nevirapine;|drug
DDI-DrugBank.d270.s19|9-14|14-OH|brand
DDI-DrugBank.d270.s19|46-63|increased.Because|drug
DDI-DrugBank.d270.s19|64-78|clarithromycin|drug
DDI-DrugBank.d270.s19|118-125|against|drug_n
DDI-DrugBank.d270.s19|126-159|Mycobacteriumavium-intracellulare|drug
DDI-DrugBank.d270.s19|185-192|against|drug_n
DDI-DrugBank.d270.s20|16-35|clarithromycin,such|drug
DDI-DrugBank.d270.s20|39-52|azithromycin,|drug
DDI-DrugBank.d270.s23|27-38|combination|drug
DDI-DrugBank.d270.s24|0-7|Ethinyl|drug
DDI-DrugBank.d270.s24|22-35|Norethindrone|drug
DDI-DrugBank.d270.s25|0-7|Ethinyl|drug
DDI-DrugBank.d270.s25|18-31|Norethindrone|drug
DDI-DrugBank.d270.s26|5-19|contraceptives|group
DDI-DrugBank.d270.s26|55-62|control|group
DDI-DrugBank.d270.s26|103-116|contraception|group
DDI-DrugBank.d270.s26|117-124|inwomen|drug
DDI-DrugBank.d270.s26|125-131|taking|drug
DDI-DrugBank.d270.s26|132-143|nevirapine,|drug
DDI-DrugBank.d270.s26|144-149|since|drug
DDI-DrugBank.d270.s26|150-163|nevirapinemay|drug
DDI-DrugBank.d270.s27|39-52|contraception|group
DDI-DrugBank.d270.s28|0-11|Fluconazole|drug
DDI-DrugBank.d270.s29|0-10|Nevirapine|drug
DDI-DrugBank.d270.s30|23-32|increased|drug
DDI-DrugBank.d270.s30|33-41|exposure|group
DDI-DrugBank.d270.s30|42-55|tonevirapine,|drug
DDI-DrugBank.d270.s30|79-92|inconcomitant|drug
DDI-DrugBank.d270.s30|93-108|administration,|drug
DDI-DrugBank.d270.s30|154-175|nevirapine-associated|drug
DDI-DrugBank.d270.s31|0-9|Indinavir|drug
DDI-DrugBank.d270.s32|0-9|Indinavir|drug
DDI-DrugBank.d270.s33|27-38|combination|drug
DDI-DrugBank.d270.s33|66-74|increase|drug
DDI-DrugBank.d270.s33|91-100|indinavir|drug
DDI-DrugBank.d270.s34|0-12|Ketoconazole|drug
DDI-DrugBank.d270.s35|0-12|Ketoconazole|drug
DDI-DrugBank.d270.s36|0-10|Nevirapine|drug
DDI-DrugBank.d270.s36|15-27|ketoconazole|drug
DDI-DrugBank.d270.s36|39-53|beadministered|drug
DDI-DrugBank.d270.s36|88-100|ketoconazole|drug
DDI-DrugBank.d270.s37|0-19|Lopinavir/Ritonavir|drug
DDI-DrugBank.d270.s38|0-9|Lopinavir|drug
DDI-DrugBank.d270.s39|7-15|increase|drug
DDI-DrugBank.d270.s39|19-38|lopinavir/ritonavir|drug
DDI-DrugBank.d270.s39|42-49|533/133|drug_n
DDI-DrugBank.d270.s39|92-103|combination|drug
DDI-DrugBank.d270.s39|109-120|nevirapine.|drug
DDI-DrugBank.d270.s42|35-44|increased|drug
DDI-DrugBank.d270.s42|121-131|maintained|drug
DDI-DrugBank.d270.s42|141-150|beginning|drug
DDI-DrugBank.d270.s42|151-161|nevirapine|drug
DDI-DrugBank.d270.s42|254-266|accordingly.|drug
DDI-DrugBank.d270.s43|0-10|Nelfinavir|drug
DDI-DrugBank.d270.s44|0-10|Nelfinavir|drug
DDI-DrugBank.d270.s45|25-35|nelfinavir|drug
DDI-DrugBank.d270.s45|36-49|incombination|drug
DDI-DrugBank.d270.s45|55-66|nevirapine,|drug
DDI-DrugBank.d270.s46|0-9|Rifabutin|drug
DDI-DrugBank.d270.s47|0-9|Rifabutin|drug
DDI-DrugBank.d270.s48|0-9|Rifabutin|drug
DDI-DrugBank.d270.s48|59-69|increased.|drug
DDI-DrugBank.d270.s49|7-23|highintersubject|drug
DDI-DrugBank.d270.s49|80-89|increases|drug
DDI-DrugBank.d270.s49|90-101|inrifabutin|drug
DDI-DrugBank.d270.s49|102-110|exposure|group
DDI-DrugBank.d270.s49|140-149|rifabutin|drug
DDI-DrugBank.d270.s50|49-64|administration.|drug
DDI-DrugBank.d270.s51|0-8|Rifampin|drug
DDI-DrugBank.d270.s52|0-10|Nevirapine|drug
DDI-DrugBank.d270.s53|0-10|Nevirapine|drug
DDI-DrugBank.d270.s53|15-23|rifampin|drug
DDI-DrugBank.d270.s53|35-49|beadministered|drug
DDI-DrugBank.d270.s53|84-94|nevirapine|drug
DDI-DrugBank.d270.s54|11-18|needing|drug
DDI-DrugBank.d270.s54|36-47|co-infected|drug
DDI-DrugBank.d270.s54|66-74|andusing|drug
DDI-DrugBank.d270.s54|77-87|nevirapine|drug
DDI-DrugBank.d270.s54|88-98|containing|group
DDI-DrugBank.d270.s54|114-123|rifabutin|drug
DDI-DrugBank.d270.s54|124-132|instead.|drug
DDI-DrugBank.d270.s55|0-10|Saquinavir|drug
DDI-DrugBank.d270.s56|0-10|Saquinavir|drug
DDI-DrugBank.d270.s57|27-38|combination|drug
DDI-DrugBank.d270.s57|66-74|increase|drug
DDI-DrugBank.d270.s57|91-101|saquinavir|drug
DDI-DrugBank.d270.s58|75-85|nevirapine|drug
DDI-DrugBank.d270.s59|80-95|Co-administered|drug
DDI-DrugBank.d270.s59|143-151|Clinical|drug
DDI-DrugBank.d270.s60|69-86|Co-administration|drug
DDI-DrugBank.d270.s60|92-102|Nevirapine|drug
DDI-DrugBank.d270.s63|26-35|lidocaine|drug
DDI-DrugBank.d270.s65|0-14|Carbamazepine,|drug
DDI-DrugBank.d270.s65|27-39|ethosuximide|drug
DDI-DrugBank.d270.s67|0-12|Itraconazole|drug
DDI-DrugBank.d270.s68|0-7|Calcium|drug
DDI-DrugBank.d270.s69|11-22|nifedipine,|drug
DDI-DrugBank.d270.s71|0-16|Cyclophosphamide|drug
DDI-DrugBank.d270.s72|6-15|alkaloids|group
DDI-DrugBank.d270.s73|0-10|Ergotamine|drug
DDI-DrugBank.d270.s75|0-12|Cyclosporin,|drug
DDI-DrugBank.d270.s77|0-9|Cisapride|drug
DDI-DrugBank.d270.s80|69-86|Co-administration|drug
DDI-DrugBank.d270.s80|92-102|Nevirapine|drug
DDI-DrugBank.d270.s82|0-8|Warfarin|drug
DDI-DrugBank.d270.s83|20-36|anticoagulation.|group
DDI-DrugBank.d270.s84|0-10|Monitoring|drug
DDI-DrugBank.d270.s84|14-29|anticoagulation|group
DDI-DrugBank.d270.s85|60-69|including|drug
DDI-DrugBank.d270.s85|144-152|wasting,|drug
DDI-DrugBank.d270.s85|160-168|wasting,|drug
DDI-DrugBank.d270.s85|193-203|cushingoid|drug
DDI-DrugBank.d270.s85|246-255|receiving|drug
DDI-DrugBank.d270.s85|256-270|antiretroviral|group
DDI-DrugBank.d70.s1|0-8|Clinical|drug
DDI-DrugBank.d70.s1|49-59|inhibitors|drug
DDI-DrugBank.d70.s1|67-83|pharmacokinetics|drug
DDI-DrugBank.d70.s2|0-15|Carcinogenesis,|drug
DDI-DrugBank.d70.s2|67-81|carcinogenesis|drug
DDI-DrugBank.d70.s2|130-143|intramuscular|drug
DDI-DrugBank.d70.s3|52-58|5-fold|drug_n
DDI-DrugBank.d70.s3|76-81|1.3-,|drug_n
DDI-DrugBank.d70.s3|82-87|1.3-,|drug_n
DDI-DrugBank.d70.s3|92-100|1.6-fold|drug_n
DDI-DrugBank.d70.s3|125-133|exposure|group
DDI-DrugBank.d70.s3|134-142|[AUC0-30|brand
DDI-DrugBank.d70.s3|168-177|receiving|drug
DDI-DrugBank.d70.s4|3-12|increased|drug
DDI-DrugBank.d70.s4|13-22|incidence|drug
DDI-DrugBank.d70.s5|69-78|endocrine|drug
DDI-DrugBank.d70.s5|103-115|gonadotropin|drug
DDI-DrugBank.d70.s5|136-149|antiestrogen.|group
DDI-DrugBank.d70.s6|180-187|strains|drug
DDI-DrugBank.d70.s6|202-213|typhimurium|drug
DDI-DrugBank.d70.s7|28-40|administered|drug
DDI-DrugBank.d70.s7|153-159|[BSA],|brand
DDI-DrugBank.d70.s7|196-205|following|drug
DDI-DrugBank.d70.s7|206-213|mating,|drug
DDI-DrugBank.d70.s8|102-107|0.001|drug_n
DDI-DrugBank.d70.s8|175-180|BSA).|brand
DDI-DrugBank.d70.s9|53-61|controls|group
DDI-DrugBank.d70.s9|74-83|following|drug
DDI-DrugBank.d70.s9|86-92|29-day|drug_n
DDI-DrugBank.d70.s9|117-123|dosing|drug
DDI-DrugBank.d70.s9|170-175|BSA).|brand
DDI-DrugBank.d70.s10|92-107|anti-estrogenic|group
DDI-DrugBank.d70.s11|96-103|6-month|drug_n
DDI-DrugBank.d70.s11|145-158|intramuscular|drug
DDI-DrugBank.d70.s11|276-288|seminiferous|drug
DDI-DrugBank.d70.s11|298-310|seminiferous|drug
DDI-DrugBank.d70.s12|85-92|dosing.|drug
DDI-DrugBank.d70.s13|64-70|3-fold|drug_n
DDI-DrugBank.d70.s13|84-92|exposure|group
DDI-DrugBank.d70.s13|93-101|[AUC0-30|brand
DDI-DrugBank.d70.s16|85-92|[BSA]),|brand
DDI-DrugBank.d70.s16|223-238|anti-estrogenic|group
DDI-DrugBank.d70.s17|22-31|increased|drug
DDI-DrugBank.d70.s17|32-41|incidence|drug
DDI-DrugBank.d70.s17|81-88|flexure|group
DDI-DrugBank.d70.s18|202-214|administered|drug
DDI-DrugBank.d70.s18|215-221|during|drug
DDI-DrugBank.d70.s18|236-250|organogenesis.|drug
DDI-DrugBank.d70.s19|18-26|maintain|drug
DDI-DrugBank.d70.s19|110-116|during|drug
DDI-DrugBank.d70.s19|131-145|organogenesis.|drug
DDI-DrugBank.d70.s20|78-83|BSA),|brand
DDI-DrugBank.d70.s20|84-93|increases|drug
DDI-DrugBank.d70.s21|35-44|increased|drug
DDI-DrugBank.d70.s21|45-54|incidence|drug
DDI-DrugBank.d70.s22|37-49|administered|drug
DDI-DrugBank.d70.s22|50-56|during|drug
DDI-DrugBank.d70.s22|71-85|organogenesis.|drug
DDI-DrugBank.d70.s23|31-41|maintained|drug
DDI-DrugBank.d70.s23|56-65|following|drug
DDI-DrugBank.d70.s23|128-138|inadequate|drug
DDI-DrugBank.d70.s23|148-154|define|drug
DDI-DrugBank.d70.s23|208-218|clinically|drug
DDI-DrugBank.d70.s23|228-238|exposures.|group
DDI-DrugBank.d70.s24|0-7|Nursing|drug
DDI-DrugBank.d70.s24|95-103|12-fold)|drug_n
DDI-DrugBank.d70.s24|122-136|administration|drug
DDI-DrugBank.d70.s25|5-13|exposure|group
DDI-DrugBank.d70.s25|54-63|lactating|drug
DDI-DrugBank.d70.s25|97-109|administered|drug
DDI-DrugBank.d70.s27|111-119|FASLODEX|brand
DDI-DrugBank.d70.s27|123-130|nursing|drug
DDI-DrugBank.d70.s27|131-139|infants,|drug
DDI-DrugBank.d70.s27|177-188|discontinue|group
DDI-DrugBank.d70.s27|189-196|nursing|drug
DDI-DrugBank.d70.s27|203-214|discontinue|group
DDI-DrugBank.d70.s27|224-230|taking|drug
DDI-DrugBank.d70.s28|41-49|FASLODEX|brand
DDI-DrugBank.d70.s29|216-224|FASLODEX|brand
DDI-DrugBank.d87.s1|0-8|TAMBOCOR|brand
DDI-DrugBank.d87.s1|18-30|administered|drug
DDI-DrugBank.d87.s1|43-52|receiving|drug
DDI-DrugBank.d87.s1|95-103|blocking|drug
DDI-DrugBank.d87.s2|0-6|During|drug
DDI-DrugBank.d87.s2|7-21|administration|drug
DDI-DrugBank.d87.s2|48-56|TAMBOCOR|brand
DDI-DrugBank.d87.s2|93-104|maintenance|drug
DDI-DrugBank.d87.s2|113-121|digoxin,|drug
DDI-DrugBank.d87.s2|124-131|13%-19%|drug_n
DDI-DrugBank.d87.s2|132-140|increase|drug
DDI-DrugBank.d87.s2|151-158|digoxin|drug
DDI-DrugBank.d87.s3|11-20|involving|drug
DDI-DrugBank.d87.s3|38-47|receiving|drug
DDI-DrugBank.d87.s3|48-56|TAMBOCOR|brand
DDI-DrugBank.d87.s3|61-72|propranolol|drug
DDI-DrugBank.d87.s3|94-104|flecainide|drug
DDI-DrugBank.d87.s3|117-126|increased|drug
DDI-DrugBank.d87.s3|141-152|propranolol|drug
DDI-DrugBank.d87.s3|165-174|increased|drug
DDI-DrugBank.d87.s3|197-204|control|group
DDI-DrugBank.d87.s4|15-26|interaction|drug
DDI-DrugBank.d87.s4|34-42|TAMBOCOR|brand
DDI-DrugBank.d87.s4|47-58|propranolol|drug
DDI-DrugBank.d87.s4|92-101|inotropic|drug
DDI-DrugBank.d87.s5|20-32|administered|drug
DDI-DrugBank.d87.s6|27-41|administration|drug
DDI-DrugBank.d87.s6|45-53|TAMBOCOR|brand
DDI-DrugBank.d87.s6|58-69|propranolol|drug
DDI-DrugBank.d87.s6|80-88|interval|drug
DDI-DrugBank.d87.s7|3-11|TAMBOCOR|brand
DDI-DrugBank.d87.s7|12-20|clinical|drug
DDI-DrugBank.d87.s7|47-56|receiving|drug
DDI-DrugBank.d87.s7|106-115|increased|drug
DDI-DrugBank.d87.s7|116-125|incidence|drug
DDI-DrugBank.d87.s8|51-60|inotropic|drug
DDI-DrugBank.d87.s8|90-100|flecainide|drug
DDI-DrugBank.d87.s9|0-10|Flecainide|drug
DDI-DrugBank.d87.s9|46-55|proteins.|drug
DDI-DrugBank.d87.s10|49-61|administered|drug
DDI-DrugBank.d87.s10|102-112|flecainide|drug
DDI-DrugBank.d87.s10|113-120|binding|drug
DDI-DrugBank.d87.s10|137-145|proteins|drug
DDI-DrugBank.d87.s11|14-26|interactions|drug
DDI-DrugBank.d87.s11|61-68|protein|drug
DDI-DrugBank.d87.s11|82-96|anticoagulants|group
DDI-DrugBank.d87.s12|0-8|TAMBOCOR|brand
DDI-DrugBank.d87.s12|53-62|receiving|drug
DDI-DrugBank.d87.s12|63-72|diuretics|group
DDI-DrugBank.d87.s12|90-102|interaction.|drug
DDI-DrugBank.d87.s13|25-34|receiving|drug
DDI-DrugBank.d87.s13|48-56|inducers|drug
DDI-DrugBank.d87.s13|59-69|phenytoin,|drug
DDI-DrugBank.d87.s13|85-98|carbamazepine|drug
DDI-DrugBank.d87.s13|101-109|indicate|drug
DDI-DrugBank.d87.s13|121-129|increase|drug
DDI-DrugBank.d87.s13|145-155|flecainide|drug
DDI-DrugBank.d87.s13|156-168|elimination.|drug
DDI-DrugBank.d87.s14|20-29|receiving|drug
DDI-DrugBank.d87.s14|30-40|cimetidine|drug
DDI-DrugBank.d87.s14|75-85|flecainide|drug
DDI-DrugBank.d87.s14|93-102|increased|drug
DDI-DrugBank.d87.s14|130-139|increased|drug
DDI-DrugBank.d87.s15|28-38|flecainide|drug
DDI-DrugBank.d87.s15|55-65|flecainide|drug
DDI-DrugBank.d87.s15|77-85|increase|drug
DDI-DrugBank.d87.s15|124-134|flecainide|drug
DDI-DrugBank.d87.s16|11-18|inhibit|drug
DDI-DrugBank.d87.s16|30-39|P450IID6,|brand
DDI-DrugBank.d87.s16|48-57|quinidine|drug
DDI-DrugBank.d87.s16|66-74|increase|drug
DDI-DrugBank.d87.s16|104-114|flecainide|drug
DDI-DrugBank.d87.s16|147-157|flecainide|drug
DDI-DrugBank.d87.s18|42-58|coadministration|drug
DDI-DrugBank.d87.s18|62-70|TAMBOCOR|brand
DDI-DrugBank.d87.s18|82-94|disopyramide|drug
DDI-DrugBank.d87.s19|42-51|inotropic|drug
DDI-DrugBank.d87.s19|82-98|coadministration|drug
DDI-DrugBank.d87.s19|104-112|TAMBOCOR|brand
DDI-DrugBank.d87.s19|134-146|disopyramide|drug
DDI-DrugBank.d87.s19|171-183|administered|drug
DDI-DrugBank.d87.s19|202-210|TAMBOCOR|brand
DDI-DrugBank.d87.s19|274-285|combination|drug
DDI-DrugBank.d87.s20|46-62|coadministration|drug
DDI-DrugBank.d87.s20|66-74|TAMBOCOR|brand
DDI-DrugBank.d87.s20|80-90|nifedipine|drug
DDI-MedLine.d107.s1|54-62|exposure|group
DDI-MedLine.d107.s1|83-94|interaction|drug
DDI-MedLine.d107.s1|98-105|ethanol|drug
DDI-MedLine.d107.s1|143-153|coexisting|drug
DDI-MedLine.d107.s1|161-169|contents|group
DDI-MedLine.d107.s3|11-18|(SH/DA;|brand
DDI-MedLine.d107.s3|19-25|SH/FA)|brand
DDI-MedLine.d107.s3|75-89|hydroalcoholic|drug
DDI-MedLine.d107.s3|100-110|containing|group
DDI-MedLine.d107.s3|111-119|ethanol,|drug
DDI-MedLine.d107.s3|120-129|methanol,|drug
DDI-MedLine.d107.s4|16-23|(SH/EA)|brand
DDI-MedLine.d107.s4|43-57|hydroalcoholic|drug
DDI-MedLine.d107.s4|70-78|ethanol;|drug
DDI-MedLine.d107.s5|27-34|control|group
DDI-MedLine.d107.s7|108-115|control|group
DDI-MedLine.d107.s8|102-116|hydroalcoholic|drug
DDI-MedLine.d107.s9|47-54|ethanol|drug
DDI-MedLine.d107.s9|93-104|interaction|drug
DDI-MedLine.d20.s0|20-27|glycine|drug
DDI-MedLine.d20.s1|17-29|investigated|drug
DDI-MedLine.d20.s1|43-50|glycine|drug
DDI-MedLine.d20.s2|30-37|glycine|drug
DDI-MedLine.d20.s4|30-37|glycine|drug
DDI-MedLine.d20.s4|113-121|interval|drug
DDI-MedLine.d20.s4|136-145|increased|drug
DDI-MedLine.d20.s4|188-198|17-day-old|drug_n
DDI-MedLine.d20.s6|3-13|13-day-old|drug_n
DDI-MedLine.d20.s6|23-30|glycine|drug
DDI-MedLine.d20.s6|35-46|ineffective|drug
DDI-MedLine.d20.s7|65-72|glycine|drug
DDI-MedLine.d20.s7|137-148|incubation)|drug
DDI-MedLine.d20.s7|249-260|glycinergic|drug
DDI-MedLine.d20.s7|261-272|inhibition.|drug
DDI-MedLine.d82.s0|0-10|Intestinal|drug
DDI-MedLine.d82.s1|4-14|intestinal|drug
DDI-MedLine.d82.s1|54-66|investigated|drug
DDI-MedLine.d82.s2|8-18|procedure,|group
DDI-MedLine.d82.s2|156-165|declining|drug
DDI-MedLine.d82.s3|18-28|intestinal|drug
DDI-MedLine.d82.s4|96-103|remains|drug
DDI-MedLine.d82.s4|152-161|declines.|drug
DDI-MedLine.d82.s5|78-86|increase|drug
DDI-MedLine.d82.s5|92-98|linear|drug
DDI-MedLine.d82.s6|12-20|indicate|drug
DDI-MedLine.d82.s7|122-130|obtained|drug
DDI-MedLine.d82.s7|139-150|interaction|drug
DDI-MedLine.d82.s8|0-7|Vitamin|drug
DDI-MedLine.d82.s8|11-25|administration|drug
DDI-MedLine.d82.s8|76-85|elevating|drug
DDI-MedLine.d82.s8|116-122|acting|drug
DDI-DrugBank.d172.s0|21-33|interactions|drug
DDI-DrugBank.d172.s0|62-74|administered|drug
DDI-DrugBank.d172.s0|100-107|inhibit|drug
DDI-DrugBank.d172.s1|24-37|predominantly|drug
DDI-DrugBank.d172.s2|0-17|Co-administration|drug
DDI-DrugBank.d172.s2|60-67|inhibit|drug
DDI-DrugBank.d172.s3|17-25|indicate|drug
DDI-DrugBank.d172.s3|51-60|inhibitor|drug
DDI-DrugBank.d172.s4|22-30|indicate|drug
DDI-DrugBank.d172.s4|79-88|inhibitor|drug
DDI-DrugBank.d172.s5|52-63|interaction|drug
DDI-DrugBank.d172.s6|0-8|Clinical|drug
DDI-DrugBank.d172.s6|72-84|interactions|drug
DDI-DrugBank.d172.s6|90-101|fluconazole|drug
DDI-DrugBank.d172.s6|106-114|lithium.|drug
DDI-DrugBank.d172.s7|29-46|anti-inflammatory|group
DDI-DrugBank.d172.s7|89-101|interactions|drug
DDI-DrugBank.d172.s7|107-117|furosemide|drug
DDI-DrugBank.d172.s7|126-137|inhibitors.|drug
DDI-DrugBank.d172.s8|29-45|pharmacokinetics|drug
DDI-DrugBank.d172.s8|84-97|ketoconazole,|drug
DDI-DrugBank.d172.s8|112-122|phenytoin,|drug
DDI-DrugBank.d172.s8|140-148|warfarin|drug
DDI-DrugBank.d172.s8|179-189|clinically|drug
DDI-DrugBank.d172.s8|200-212|interactions|drug
DDI-DrugBank.d172.s9|4-15|inhibitors:|drug
DDI-DrugBank.d172.s9|48-56|diminish|drug
DDI-DrugBank.d172.s9|61-77|antihypertensive|group
DDI-DrugBank.d172.s9|88-99|Angiotensin|drug
DDI-DrugBank.d172.s9|100-110|Converting|drug
DDI-DrugBank.d172.s9|118-123|(ACE)|brand
DDI-DrugBank.d172.s9|124-135|inhibitors.|drug
DDI-DrugBank.d172.s10|5-16|interaction|drug
DDI-DrugBank.d172.s10|59-65|taking|drug
DDI-DrugBank.d172.s10|66-74|CELEBREX|brand
DDI-DrugBank.d172.s10|94-109|ACE-inhibitors.|drug
DDI-DrugBank.d172.s11|12-20|Clinical|drug
DDI-DrugBank.d172.s11|46-55|marketing|drug
DDI-DrugBank.d172.s11|108-119|natriuretic|group
DDI-DrugBank.d172.s11|130-140|furosemide|drug
DDI-DrugBank.d172.s11|145-154|thiazides|group
DDI-DrugBank.d172.s12|37-47|inhibition|drug
DDI-DrugBank.d172.s12|57-70|prostaglandin|drug
DDI-DrugBank.d172.s13|0-8|Aspirin:|brand
DDI-DrugBank.d172.s13|9-17|CELEBREX|brand
DDI-DrugBank.d172.s13|44-52|aspirin.|brand
DDI-DrugBank.d172.s14|21-35|administration|drug
DDI-DrugBank.d172.s14|39-46|aspirin|brand
DDI-DrugBank.d172.s14|52-60|CELEBREX|brand
DDI-DrugBank.d172.s14|78-87|increased|drug
DDI-DrugBank.d172.s14|153-161|CELEBREX|brand
DDI-DrugBank.d172.s15|41-49|CELEBREX|brand
DDI-DrugBank.d172.s15|74-81|aspirin|brand
DDI-DrugBank.d172.s16|0-12|Fluconazole:|drug
DDI-DrugBank.d172.s16|25-39|administration|drug
DDI-DrugBank.d172.s16|43-54|fluconazole|drug
DDI-DrugBank.d172.s16|91-99|increase|drug
DDI-DrugBank.d172.s17|5-13|increase|drug
DDI-DrugBank.d172.s17|28-38|inhibition|drug
DDI-DrugBank.d172.s17|79-90|fluconazole|drug
DDI-DrugBank.d172.s17|96-104|CLINICAL|brand
DDI-DrugBank.d172.s17|105-117|PHARMACOLOGY|brand
DDI-DrugBank.d172.s17|120-137|Pharmacokinetics:|drug
DDI-DrugBank.d172.s18|0-8|CELEBREX|brand
DDI-DrugBank.d172.s18|19-29|introduced|drug
DDI-DrugBank.d172.s18|73-82|receiving|drug
DDI-DrugBank.d172.s18|83-95|fluconazole.|drug
DDI-DrugBank.d172.s19|0-8|Lithium:|drug
DDI-DrugBank.d172.s19|69-76|lithium|drug
DDI-DrugBank.d172.s19|91-100|increased|drug
DDI-DrugBank.d172.s19|131-140|receiving|drug
DDI-DrugBank.d172.s19|141-148|lithium|drug
DDI-DrugBank.d172.s19|165-173|CELEBREX|brand
DDI-DrugBank.d172.s19|209-218|receiving|drug
DDI-DrugBank.d172.s19|219-226|lithium|drug
DDI-DrugBank.d172.s20|12-19|lithium|drug
DDI-DrugBank.d172.s20|63-71|CELEBREX|brand
DDI-DrugBank.d172.s20|75-85|introduced|drug
DDI-DrugBank.d172.s21|20-31|interaction|drug
DDI-DrugBank.d172.s21|71-77|taking|drug
DDI-DrugBank.d172.s21|92-100|CELEBREX|brand
DDI-DrugBank.d172.s21|142-158|pharmacokinetics|drug
DDI-DrugBank.d172.s22|0-9|Warfarin:|drug
DDI-DrugBank.d172.s22|41-55|anti-coagulant|group
DDI-DrugBank.d172.s22|66-74|warfarin|drug
DDI-DrugBank.d172.s22|118-127|receiving|drug
DDI-DrugBank.d172.s22|153-162|warfarin.|drug
DDI-DrugBank.d172.s23|47-60|anticoagulant|group
DDI-DrugBank.d172.s23|71-79|warfarin|drug
DDI-DrugBank.d172.s23|83-93|determined|drug
DDI-DrugBank.d172.s23|97-108|prothrombin|drug
DDI-DrugBank.d172.s24|37-50|administering|drug
DDI-DrugBank.d172.s24|51-59|CELEBREX|brand
DDI-DrugBank.d172.s24|65-73|warfarin|drug
DDI-DrugBank.d172.s24|74-79|since|drug
DDI-DrugBank.d172.s24|102-111|increased|drug
DDI-DrugBank.d172.s24|120-128|bleeding|drug
DDI-DrugBank.d135.s0|11-20|Lapatinib|drug
DDI-DrugBank.d135.s0|29-41|Metabolizing|drug
DDI-DrugBank.d135.s0|77-86|Lapatinib|drug
DDI-DrugBank.d135.s0|87-95|inhibits|drug
DDI-DrugBank.d135.s0|96-102|CYP3A4|brand
DDI-DrugBank.d135.s0|107-113|CYP2C8|brand
DDI-DrugBank.d135.s0|126-136|clinically|drug
DDI-DrugBank.d135.s1|107-113|dosing|drug
DDI-DrugBank.d135.s1|114-123|lapatinib|drug
DDI-DrugBank.d135.s1|178-185|windows|drug
DDI-DrugBank.d135.s1|209-215|CYP3A4|brand
DDI-DrugBank.d135.s1|219-226|CYP2C8.|brand
DDI-DrugBank.d135.s2|0-9|Lapatinib|drug
DDI-DrugBank.d135.s2|32-39|inhibit|drug
DDI-DrugBank.d135.s2|44-53|following|drug
DDI-DrugBank.d135.s2|89-96|CYP1A2,|brand
DDI-DrugBank.d135.s2|97-104|CYP2C9,|brand
DDI-DrugBank.d135.s2|105-113|CYP2C19,|brand
DDI-DrugBank.d135.s2|118-124|CYP2D6|brand
DDI-DrugBank.d135.s2|163-171|clinical|drug
DDI-DrugBank.d135.s3|0-9|Lapatinib|drug
DDI-DrugBank.d135.s3|10-18|inhibits|drug
DDI-DrugBank.d135.s3|25-40|P-glycoprotein.|drug
DDI-DrugBank.d135.s4|3-9|TYKERB|brand
DDI-DrugBank.d135.s4|13-25|administered|drug
DDI-DrugBank.d135.s4|65-74|increased|drug
DDI-DrugBank.d135.s5|57-66|Lapatinib|drug
DDI-DrugBank.d135.s5|101-108|CYP3A4,|brand
DDI-DrugBank.d135.s5|125-139|administration|drug
DDI-DrugBank.d135.s5|150-160|inhibitors|drug
DDI-DrugBank.d135.s5|164-172|inducers|drug
DDI-DrugBank.d135.s5|176-182|CYP3A4|brand
DDI-DrugBank.d135.s5|189-198|lapatinib|drug
DDI-DrugBank.d135.s6|19-28|lapatinib|drug
DDI-DrugBank.d135.s6|99-109|inhibitors|drug
DDI-DrugBank.d135.s6|132-140|inducers|drug
DDI-DrugBank.d135.s6|144-150|CYP3A4|brand
DDI-DrugBank.d135.s7|0-13|Ketoconazole:|drug
DDI-DrugBank.d135.s7|34-43|receiving|drug
DDI-DrugBank.d135.s7|44-57|ketoconazole,|drug
DDI-DrugBank.d135.s7|60-66|CYP3A4|brand
DDI-DrugBank.d135.s7|67-77|inhibitor,|drug
DDI-DrugBank.d135.s7|121-129|exposure|group
DDI-DrugBank.d135.s7|130-135|(AUC)|brand
DDI-DrugBank.d135.s7|139-148|lapatinib|drug
DDI-DrugBank.d135.s7|153-162|increased|drug
DDI-DrugBank.d135.s7|180-188|3.6-fold|drug_n
DDI-DrugBank.d135.s7|192-199|control|group
DDI-DrugBank.d135.s7|214-223|increased|drug
DDI-DrugBank.d135.s7|227-235|1.7-fold|drug_n
DDI-DrugBank.d135.s7|239-247|control.|group
DDI-DrugBank.d135.s8|0-14|Carbamazepine:|drug
DDI-DrugBank.d135.s8|35-44|receiving|drug
DDI-DrugBank.d135.s8|49-55|CYP3A4|brand
DDI-DrugBank.d135.s8|56-64|inducer,|drug
DDI-DrugBank.d135.s8|65-79|carbamazepine,|drug
DDI-DrugBank.d135.s8|158-166|exposure|group
DDI-DrugBank.d135.s8|167-172|(AUC)|brand
DDI-DrugBank.d135.s8|176-185|lapatinib|drug
DDI-DrugBank.d135.s9|42-51|Lapatinib|drug
DDI-DrugBank.d135.s9|93-107|P-glycoprotein|drug
DDI-DrugBank.d135.s9|114-121|ABCB1).|brand
DDI-DrugBank.d135.s10|3-9|TYKERB|brand
DDI-DrugBank.d135.s10|13-25|administered|drug
DDI-DrugBank.d135.s10|42-49|inhibit|drug
DDI-DrugBank.d135.s10|55-64|increased|drug
DDI-DrugBank.d135.s10|83-92|lapatinib|drug
DDI-DrugBank.d135.s11|59-73|administration|drug
DDI-DrugBank.d135.s11|77-86|lapatinib|drug
DDI-DrugBank.d135.s11|92-104|capecitabine|drug
DDI-DrugBank.d135.s11|113-125|meaningfully|drug
DDI-DrugBank.d135.s11|136-152|pharmacokinetics|drug
DDI-DrugBank.d135.s11|192-206|capecitabine).|drug
DDI-DrugBank.d484.s0|17-25|interact|drug
DDI-DrugBank.d484.s0|35-44|following|drug
DDI-DrugBank.d484.s0|58-71|acetaminophen|drug
DDI-DrugBank.d484.s0|83-94|antibiotics|group
DDI-DrugBank.d484.s0|103-113|ampicillin|drug
DDI-DrugBank.d484.s0|118-131|tetracycline,|drug
DDI-DrugBank.d484.s0|132-147|anticonvulsants|group
DDI-DrugBank.d484.s0|148-158|(Dilantin,|drug
DDI-DrugBank.d484.s0|215-226|antifungals|group
DDI-DrugBank.d484.s0|247-257|Sporanox),|drug
DDI-DrugBank.d484.s0|258-270|atorvastatin|drug
DDI-DrugBank.d484.s0|306-318|cyclosporine|drug
DDI-DrugBank.d484.s0|374-384|inhibitors|drug
DDI-DrugBank.d484.s0|456-464|morphine|drug
DDI-DrugBank.d484.s0|489-497|Contin),|drug
DDI-DrugBank.d484.s0|538-545|rifadin|drug
DDI-DrugBank.d484.s0|546-557|(rifampin),|drug
DDI-DrugBank.d484.s0|585-597|theophylline|drug
DDI-DrugBank.d484.s0|614-621|vitamin|drug
DDI-DrugBank.d92.s0|19-31|interactions|drug
DDI-DrugBank.d106.s0|12-20|increase|drug
DDI-DrugBank.d106.s0|40-51|nisoldipine|drug
DDI-DrugBank.d106.s0|82-96|administration|drug
DDI-DrugBank.d106.s0|100-110|cimetidine|drug
DDI-DrugBank.d106.s1|0-10|Ranitidine|drug
DDI-DrugBank.d106.s1|38-46|interact|drug
DDI-DrugBank.d106.s1|66-77|nisoldipine|drug
DDI-DrugBank.d106.s1|100-105|15-20|drug_n
DDI-DrugBank.d106.s2|37-46|histamine|drug
DDI-DrugBank.d106.s3|0-16|Coadministration|drug
DDI-DrugBank.d106.s3|20-29|phenytoin|drug
DDI-DrugBank.d106.s3|41-46|SULAR|brand
DDI-DrugBank.d106.s3|89-100|nisoldipine|drug
DDI-DrugBank.d106.s4|0-16|Coadministration|drug
DDI-DrugBank.d106.s4|20-25|SULAR|brand
DDI-DrugBank.d106.s4|31-40|phenytoin|drug
DDI-DrugBank.d106.s4|54-60|CYP3A4|brand
DDI-DrugBank.d106.s4|61-68|inducer|drug
DDI-DrugBank.d106.s4|103-119|antihypertensive|group
DDI-DrugBank.d106.s5|0-15|Pharmacokinetic|drug
DDI-DrugBank.d106.s5|16-28|interactions|drug
DDI-DrugBank.d106.s5|37-48|nisoldipine|drug
DDI-DrugBank.d106.s5|78-90|propranolol)|drug
DDI-DrugBank.d106.s6|0-11|Propranolol|drug
DDI-DrugBank.d106.s6|38-46|increase|drug
DDI-DrugBank.d106.s6|47-56|following|drug
DDI-DrugBank.d106.s6|57-71|administration|drug
DDI-DrugBank.d106.s6|93-105|nisoldipine.|drug
DDI-DrugBank.d106.s7|10-18|pressure|group
DDI-DrugBank.d106.s7|29-34|SULAR|brand
DDI-DrugBank.d106.s7|109-125|antihypertensive|group
DDI-DrugBank.d106.s8|0-9|Quinidine|drug
DDI-DrugBank.d106.s8|54-59|(AUC)|brand
DDI-DrugBank.d106.s8|63-74|nisoldipine|drug
DDI-DrugBank.d106.s9|60-71|nisoldipine|drug
DDI-DrugBank.d106.s9|72-81|increased|drug
DDI-DrugBank.d106.s9|89-98|quinidine|drug
DDI-DrugBank.d106.s10|5-16|interaction|drug
DDI-DrugBank.d106.s10|60-68|clinical|drug
DDI-DrugBank.d106.s11|15-27|interactions|drug
DDI-DrugBank.d106.s11|47-58|nisoldipine|drug
DDI-DrugBank.d106.s11|63-71|warfarin|drug
DDI-DrugBank.d106.s11|75-83|digoxin.|drug
DDI-DrugBank.d512.s0|45-53|CLINICAL|brand
DDI-DrugBank.d512.s0|54-67|PHARMACOLOGY,|brand
DDI-DrugBank.d512.s0|68-84|Pharmacokinetics|drug
DDI-DrugBank.d512.s1|76-85|(CYP2D6):|brand
DDI-DrugBank.d512.s1|117-126|inhibitor|drug
DDI-DrugBank.d512.s1|130-137|CYP2D6.|brand
DDI-DrugBank.d512.s2|64-77|predominantly|drug
DDI-DrugBank.d512.s2|93-99|CYP2D6|brand
DDI-DrugBank.d512.s2|130-135|index|drug
DDI-DrugBank.d512.s2|143-154|flecainide,|drug
DDI-DrugBank.d512.s2|155-167|vinblastine,|drug
DDI-DrugBank.d512.s2|168-180|thioridazine|drug
DDI-DrugBank.d512.s2|200-216|antidepressants)|group
DDI-DrugBank.d512.s3|0-14|Amitriptyline:|drug
DDI-DrugBank.d512.s3|26-40|administration|drug
DDI-DrugBank.d512.s3|60-70|cinacalcet|drug
DDI-DrugBank.d512.s3|82-95|amitriptyline|drug
DDI-DrugBank.d512.s3|96-105|increased|drug
DDI-DrugBank.d512.s3|106-119|amitriptyline|drug
DDI-DrugBank.d512.s3|120-128|exposure|group
DDI-DrugBank.d512.s3|133-146|nortriptyline|drug
DDI-DrugBank.d512.s3|167-175|exposure|group
DDI-DrugBank.d512.s3|200-206|CYP2D6|brand
DDI-DrugBank.d512.s4|108-115|CYP3A4,|brand
DDI-DrugBank.d512.s4|116-123|CYP2D6,|brand
DDI-DrugBank.d512.s4|128-135|CYP1A2.|brand
DDI-DrugBank.d512.s5|0-13|Ketoconazole:|drug
DDI-DrugBank.d512.s5|49-56|CYP3A4.|brand
DDI-DrugBank.d512.s6|0-17|Co-administration|drug
DDI-DrugBank.d512.s6|21-34|ketoconazole,|drug
DDI-DrugBank.d512.s6|44-53|inhibitor|drug
DDI-DrugBank.d512.s6|57-64|CYP3A4,|brand
DDI-DrugBank.d512.s6|65-74|increased|drug
DDI-DrugBank.d512.s6|75-85|cinacalcet|drug
DDI-DrugBank.d512.s6|86-94|exposure|group
DDI-DrugBank.d512.s6|95-104|following|drug
DDI-DrugBank.d512.s6|107-113|single|drug
DDI-DrugBank.d512.s7|62-69|calcium|drug
DDI-DrugBank.d512.s7|126-135|initiates|drug
DDI-DrugBank.d512.s7|139-151|discontinues|group
DDI-DrugBank.d512.s7|174-180|CYP3A4|brand
DDI-DrugBank.d512.s7|181-190|inhibitor|drug
DDI-DrugBank.d512.s7|198-211|ketoconazole,|drug
DDI-DrugBank.d512.s7|212-225|erythromycin,|drug
DDI-DrugBank.d512.s7|226-239|itraconazole;|drug
DDI-DrugBank.d512.s8|4-10|DOSAGE|brand
DDI-DrugBank.d512.s8|15-31|ADMINISTRATION).|brand
DDI-DrugBank.d261.s0|0-13|Tetracycline,|drug
DDI-DrugBank.d261.s0|31-42|antibiotic,|group
DDI-DrugBank.d261.s0|85-95|penicillin|drug
DDI-DrugBank.d344.s0|19-26|calcium|drug
DDI-DrugBank.d344.s0|43-51|L-lysine|drug
DDI-DrugBank.d344.s0|56-64|increase|drug
DDI-DrugBank.d344.s0|65-72|calcium|drug
DDI-DrugBank.d405.s0|14-22|warfarin|drug
DDI-DrugBank.d405.s0|36-55|hypoprothrombinemic|drug
DDI-DrugBank.d405.s1|92-104|administered|drug
DDI-DrugBank.d392.s0|17-25|applying|drug
DDI-DrugBank.d392.s0|26-34|Panretin|drug
DDI-DrugBank.d392.s0|81-88|contain|group
DDI-DrugBank.d392.s0|144-150|insect|drug
DDI-DrugBank.d392.s1|33-42|increased|drug
DDI-DrugBank.d392.s1|71-79|included|drug
DDI-DrugBank.d392.s2|22-30|clinical|drug
DDI-DrugBank.d392.s2|47-65|vehicle-controlled|group
DDI-DrugBank.d392.s2|82-94|interactions|drug
DDI-DrugBank.d392.s2|109-123|antiretroviral|group
DDI-DrugBank.d392.s2|132-141|including|drug
DDI-DrugBank.d392.s2|151-162|inhibitors,|drug
DDI-DrugBank.d392.s2|163-172|macrolide|drug
DDI-DrugBank.d392.s2|173-185|antibiotics,|group
DDI-DrugBank.d392.s2|190-195|azole|drug
DDI-DrugBank.d392.s2|196-208|antifungals,|group
DDI-DrugBank.d392.s2|223-231|Panretin|drug
DDI-DrugBank.d392.s3|8-19|interaction|drug
DDI-DrugBank.d392.s3|54-68|administration|drug
DDI-DrugBank.d392.s3|72-80|Panretin|drug
DDI-DrugBank.d392.s3|98-105|anti-KS|group
DDI-DrugBank.d348.s0|33-45|Desmopressin|drug
DDI-DrugBank.d348.s0|74-86|antidiuretic|group
DDI-DrugBank.d348.s0|112-124|Desmopressin|drug
DDI-DrugBank.d348.s0|200-211|monitoring.|drug
DDI-MedLine.d81.s0|18-23|index|drug
DDI-MedLine.d81.s0|31-49|disulfiram-ethanol|drug
DDI-MedLine.d81.s1|15-26|temperature|group
DDI-MedLine.d81.s1|46-58|investigated|drug
DDI-MedLine.d81.s1|75-80|index|drug
DDI-MedLine.d81.s1|88-106|disulfiram-ethanol|drug
DDI-MedLine.d81.s1|116-122|(DER).|brand
DDI-MedLine.d81.s2|5-16|temperature|group
DDI-MedLine.d81.s2|71-78|ethanol|drug
DDI-MedLine.d81.s2|83-95|administered|drug
DDI-MedLine.d81.s2|147-154|ethanol|drug
DDI-MedLine.d81.s3|16-27|temperature|group
DDI-MedLine.d81.s3|34-40|within|drug
DDI-MedLine.d81.s3|44-51|minutes|drug
DDI-MedLine.d81.s3|58-65|ethanol|drug
DDI-MedLine.d81.s3|66-81|administration,|drug
DDI-MedLine.d81.s3|82-90|reaching|drug
DDI-MedLine.d81.s3|129-136|minutes|drug
DDI-MedLine.d81.s3|142-150|ethanol.|drug
DDI-MedLine.d81.s4|9-20|temperature|group
DDI-MedLine.d81.s4|44-51|minutes|drug
DDI-MedLine.d81.s4|58-66|ethanol.|drug
DDI-MedLine.d81.s5|10-18|pressure|group
DDI-MedLine.d81.s5|71-83|temperature.|group
DDI-MedLine.d81.s6|34-41|minutes|drug
DDI-MedLine.d81.s6|47-55|ethanol,|drug
DDI-MedLine.d81.s6|83-90|minutes|drug
DDI-MedLine.d81.s6|97-105|ethanol.|drug
DDI-MedLine.d81.s7|11-20|increased|drug
DDI-MedLine.d81.s7|21-30|initially|drug
DDI-MedLine.d81.s7|57-64|minutes|drug
DDI-MedLine.d81.s7|71-78|ethanol|drug
DDI-DrugBank.d162.s0|28-37|following|drug
DDI-DrugBank.d162.s0|48-56|interact|drug
DDI-DrugBank.d162.s0|62-70|thiazide|group
DDI-DrugBank.d162.s0|71-81|diuretics.|group
DDI-DrugBank.d162.s2|37-45|insulin)|drug
DDI-DrugBank.d162.s2|73-85|antidiabetic|group
DDI-DrugBank.d162.s3|6-22|antihypertensive|group
DDI-DrugBank.d162.s4|0-14|Cholestyramine|drug
DDI-DrugBank.d162.s4|19-29|colestipol|drug
DDI-DrugBank.d162.s4|30-37|resins:|drug
DDI-DrugBank.d162.s4|52-71|hydrochlorothiazide|group
DDI-DrugBank.d162.s4|120-127|resins.|drug
DDI-DrugBank.d162.s5|0-6|Single|drug
DDI-DrugBank.d162.s5|23-37|cholestyramine|drug
DDI-DrugBank.d162.s5|41-51|colestipol|drug
DDI-DrugBank.d162.s5|52-58|resins|drug
DDI-DrugBank.d162.s5|68-87|hydrochlorothiazide|group
DDI-DrugBank.d162.s5|123-139|gastrointestinal|drug
DDI-DrugBank.d162.s6|0-16|Corticosteroids,|group
DDI-DrugBank.d162.s6|17-22|ACTH:|brand
DDI-DrugBank.d162.s6|23-34|intensified|drug
DDI-DrugBank.d162.s7|8-14|amines|drug
DDI-DrugBank.d162.s7|22-38|norepinephrine):|drug
DDI-DrugBank.d162.s7|78-84|amines|drug
DDI-DrugBank.d162.s8|27-42|nondepolarizing|drug
DDI-DrugBank.d162.s8|50-64|tubocurarine):|drug
DDI-DrugBank.d162.s8|74-83|increased|drug
DDI-DrugBank.d162.s9|0-8|Lithium:|drug
DDI-DrugBank.d162.s9|44-54|diuretics.|group
DDI-DrugBank.d162.s10|0-8|Diuretic|group
DDI-DrugBank.d162.s10|46-53|lithium|drug
DDI-DrugBank.d162.s10|77-84|lithium|drug
DDI-DrugBank.d162.s11|21-27|insert|drug
DDI-DrugBank.d162.s11|32-39|lithium|drug
DDI-DrugBank.d162.s11|90-110|Hydrochlorothiazide.|group
DDI-DrugBank.d162.s12|14-31|Anti-inflammatory|drug
DDI-DrugBank.d162.s12|61-75|administration|drug
DDI-DrugBank.d162.s12|95-112|anti-inflammatory|group
DDI-DrugBank.d162.s12|134-143|diuretic,|group
DDI-DrugBank.d162.s12|144-156|natriuretic,|group
DDI-DrugBank.d162.s12|161-177|antihypertensive|group
DDI-DrugBank.d162.s12|195-212|potassium-sparing|drug
DDI-DrugBank.d162.s12|217-225|thiazide|group
DDI-DrugBank.d162.s12|226-236|diuretics.|group
DDI-DrugBank.d162.s13|16-35|Hydrochlorothiazide|group
DDI-DrugBank.d162.s13|54-71|anti-inflammatory|group
DDI-DrugBank.d162.s13|145-154|determine|drug
DDI-DrugBank.d162.s13|184-192|diuretic|group
DDI-DrugBank.d162.s13|196-205|obtained.|drug
DDI-MedLine.d75.s0|16-24|biocytin|drug
DDI-MedLine.d75.s0|93-99|spinal|drug
DDI-MedLine.d75.s0|111-121|gelatinosa|drug
DDI-MedLine.d75.s1|19-30|preliminary|drug
DDI-MedLine.d75.s1|31-42|whole-cell,|drug
DDI-MedLine.d75.s1|54-64|recordings|drug
DDI-MedLine.d75.s1|72-78|spinal|drug
DDI-MedLine.d75.s1|90-100|gelatinosa|drug
DDI-MedLine.d75.s1|109-118|including|drug
DDI-MedLine.d75.s1|119-127|biocytin|drug
DDI-MedLine.d75.s1|261-271|recordings|drug
DDI-MedLine.d75.s1|280-289|biocytin.|drug
DDI-MedLine.d75.s2|14-26|investigated|drug
DDI-MedLine.d75.s2|42-50|biocytin|drug
DDI-MedLine.d75.s2|51-60|inclusion|drug
DDI-MedLine.d75.s2|111-117|during|drug
DDI-MedLine.d75.s2|118-129|whole-cell,|drug
DDI-MedLine.d75.s2|141-151|recordings|drug
DDI-MedLine.d75.s3|80-87|opioids|group
DDI-MedLine.d75.s4|9-17|biocytin|drug
DDI-MedLine.d75.s4|22-30|included|drug
DDI-MedLine.d75.s4|38-47|recording|drug
DDI-MedLine.d75.s4|96-105|biocytin.|drug
DDI-MedLine.d75.s5|102-110|0.05-0.2|drug_n
DDI-MedLine.d75.s5|117-125|biocytin|drug
DDI-MedLine.d75.s5|141-150|biocytin.|drug
DDI-MedLine.d75.s6|0-7|Resting|drug
DDI-MedLine.d75.s6|28-33|input|drug
DDI-MedLine.d75.s6|74-84|displaying|drug
DDI-MedLine.d75.s6|186-195|0.05-0.2%|drug_n
DDI-MedLine.d75.s6|196-205|biocytin.|drug
DDI-MedLine.d75.s7|70-79|potassium|drug
DDI-MedLine.d75.s8|18-26|labeling|drug
DDI-MedLine.d75.s8|53-61|biocytin|drug
DDI-MedLine.d75.s8|67-77|whole-cell|drug
DDI-MedLine.d75.s8|78-88|recording,|drug
DDI-MedLine.d75.s8|115-131|contraindicated.|group
DDI-MedLine.d68.s0|15-25|cimetidine|drug
DDI-MedLine.d68.s0|52-62|verografin|drug
DDI-MedLine.d68.s0|67-75|iodamide|drug
DDI-MedLine.d68.s0|90-101|intravenous|drug
DDI-MedLine.d68.s0|102-111|injection|drug
DDI-MedLine.d68.s0|115-125|cimetidine|drug
DDI-MedLine.d68.s0|157-168|verografine|drug
DDI-MedLine.d68.s0|173-181|iodamide|drug
DDI-MedLine.d68.s0|203-209|canine|drug
DDI-MedLine.d68.s1|11-22|verografine|drug
DDI-MedLine.d68.s1|27-35|iodamide|drug
DDI-MedLine.d68.s1|63-72|increased|drug
DDI-MedLine.d68.s2|9-19|cimetidine|drug
DDI-MedLine.d68.s3|44-54|cimetidine|drug
DDI-MedLine.d68.s3|58-69|verografine|drug
DDI-MedLine.d68.s3|74-82|iodamide|drug
DDI-MedLine.d68.s3|103-112|examined.|drug
DDI-DrugBank.d365.s0|30-41|L-histidine|drug
DDI-DrugBank.d365.s0|77-85|culture)|group
DDI-DrugBank.d365.s0|131-139|reducing|drug
DDI-DrugBank.d365.s1|44-56|L-histidine,|drug
DDI-DrugBank.d365.s1|79-89|histamine,|drug
DDI-DrugBank.d346.s0|29-41|interactions|drug
DDI-DrugBank.d346.s0|50-55|REVIA|brand
DDI-DrugBank.d346.s1|52-66|administration|drug
DDI-DrugBank.d346.s1|70-75|REVIA|brand
DDI-DrugBank.d346.s2|46-51|REVIA|brand
DDI-DrugBank.d346.s2|153-163|ordinarily|drug
DDI-DrugBank.d346.s3|13-23|somnolence|drug
DDI-DrugBank.d346.s3|43-52|following|drug
DDI-DrugBank.d346.s3|62-67|REVIA|brand
DDI-DrugBank.d346.s3|72-85|thioridazine.|drug
DDI-DrugBank.d346.s4|9-15|taking|drug
DDI-DrugBank.d346.s4|16-21|REVIA|brand
DDI-DrugBank.d346.s4|50-60|containing|group
DDI-DrugBank.d346.s4|61-71|medicines,|drug
DDI-DrugBank.d346.s4|109-122|antidiarrheal|group
DDI-DrugBank.d346.s5|56-68|administered|drug
DDI-DrugBank.d346.s5|82-91|receiving|drug
DDI-DrugBank.d346.s5|92-98|REVIA,|brand
DDI-DrugBank.d346.s5|164-173|resulting|drug
DDI-DrugBank.d397.s0|0-12|Erythromycin|drug
DDI-DrugBank.d397.s0|37-46|receiving|drug
DDI-DrugBank.d397.s0|61-73|theophylline|drug
DDI-DrugBank.d397.s0|100-108|increase|drug
DDI-DrugBank.d397.s0|118-130|theophylline|drug
DDI-DrugBank.d397.s0|152-164|theophylline|drug
DDI-DrugBank.d397.s1|11-23|theophylline|drug
DDI-DrugBank.d397.s1|55-67|theophylline|drug
DDI-DrugBank.d397.s1|88-100|theophylline|drug
DDI-DrugBank.d397.s1|140-149|receiving|drug
DDI-DrugBank.d397.s1|162-174|erythromycin|drug
DDI-DrugBank.d397.s2|12-26|administration|drug
DDI-DrugBank.d397.s2|30-42|erythromycin|drug
DDI-DrugBank.d397.s2|47-54|digoxin|drug
DDI-DrugBank.d397.s2|95-102|digoxin|drug
DDI-DrugBank.d397.s3|27-36|increased|drug
DDI-DrugBank.d397.s3|37-50|anticoagulant|group
DDI-DrugBank.d397.s3|64-76|erythromycin|drug
DDI-DrugBank.d397.s3|86-100|anticoagulants|group
DDI-DrugBank.d397.s4|10-25|anticoagulation|group
DDI-DrugBank.d397.s4|41-53|interactions|drug
DDI-DrugBank.d397.s4|57-69|erythromycin|drug
DDI-DrugBank.d397.s4|88-102|anticoagulents|group
DDI-DrugBank.d397.s5|18-30|erythromycin|drug
DDI-DrugBank.d397.s5|35-45|ergotamine|drug
DDI-DrugBank.d397.s5|49-66|dihydroergotamine|drug
DDI-DrugBank.d397.s6|0-12|Erythromycin|drug
DDI-DrugBank.d397.s6|60-69|triazolam|drug
DDI-DrugBank.d397.s6|74-83|midazolam|drug
DDI-DrugBank.d397.s6|97-105|increase|drug
DDI-DrugBank.d397.s6|140-156|benzodiazepines.|drug
DDI-DrugBank.d397.s7|11-23|erythromycin|drug
DDI-DrugBank.d397.s7|49-55|taking|drug
DDI-DrugBank.d397.s8|27-39|interactions|drug
DDI-DrugBank.d397.s8|43-55|erythromycin|drug
DDI-DrugBank.d397.s8|61-75|carbamazepine,|drug
DDI-DrugBank.d397.s8|76-89|cyclosporine,|drug
DDI-DrugBank.d397.s8|116-126|phenytoin,|drug
DDI-DrugBank.d397.s8|164-175|lovastatin,|drug
DDI-DrugBank.d397.s8|176-190|bromocriptine,|drug
DDI-DrugBank.d397.s8|202-214|terfenadine,|drug
DDI-DrugBank.d397.s8|219-230|astemizole.|drug
DDI-DrugBank.d397.s9|125-134|receiving|drug
DDI-DrugBank.d397.s9|135-148|erythromycin.|drug
DDI-DrugBank.d397.s10|0-12|Erythromycin|drug
DDI-DrugBank.d397.s10|72-83|nonsedating|drug
DDI-DrugBank.d397.s10|84-98|antihistamines|group
DDI-DrugBank.d397.s10|99-110|terfenadine|drug
DDI-DrugBank.d397.s10|115-125|astemizole|drug
DDI-DrugBank.d397.s11|53-62|including|drug
DDI-DrugBank.d397.s11|91-99|interval|drug
DDI-DrugBank.d397.s11|142-150|pointes,|drug
DDI-DrugBank.d397.s12|63-77|administration|drug
DDI-DrugBank.d397.s12|81-92|terfenadine|drug
DDI-DrugBank.d397.s12|97-110|erythromycin.|drug
DDI-DrugBank.d397.s13|16-29|postmarketing|drug
DDI-DrugBank.d397.s13|46-58|interactions|drug
DDI-DrugBank.d397.s13|64-76|erythromycin|drug
DDI-DrugBank.d397.s13|80-94|coadministered|drug
DDI-DrugBank.d397.s13|111-120|resulting|drug
DDI-DrugBank.d397.s13|227-235|pointes,|drug
DDI-DrugBank.d397.s13|253-263|inhibition|drug
DDI-DrugBank.d397.s13|289-298|cisapride|drug
DDI-DrugBank.d397.s13|302-315|erythromycin.|drug
DDI-DrugBank.d397.s15|9-18|receiving|drug
DDI-DrugBank.d397.s15|31-41|lovastatin|drug
DDI-DrugBank.d397.s15|46-58|erythromycin|drug
DDI-MedLine.d79.s0|23-32|indinavir|drug
DDI-MedLine.d79.s0|33-39|(IDV),|brand
DDI-MedLine.d79.s0|40-50|didanosine|drug
DDI-MedLine.d79.s0|71-80|exposure,|group
DDI-MedLine.d79.s0|100-109|buffering|drug
DDI-MedLine.d79.s1|11-25|administration|drug
DDI-MedLine.d79.s1|29-38|indinavir|drug
DDI-MedLine.d79.s1|43-53|didanosine|drug
DDI-MedLine.d79.s1|89-97|exposure|group
DDI-MedLine.d79.s1|101-111|indinavir,|drug
DDI-MedLine.d79.s1|145-155|didanosine|drug
DDI-MedLine.d79.s1|156-170|administration|drug
DDI-MedLine.d79.s1|171-180|indinavir|drug
DDI-MedLine.d79.s2|12-21|indinavir|drug
DDI-MedLine.d79.s2|22-38|pharmacokinetics|drug
DDI-MedLine.d79.s2|127-136|indinavir|drug
DDI-MedLine.d79.s2|160-169|indinavir|drug
DDI-MedLine.d79.s2|170-182|administered|drug
DDI-MedLine.d79.s2|193-203|didanosine|drug
DDI-MedLine.d79.s2|204-219|administration.|drug
DDI-MedLine.d79.s3|48-57|indinavir|drug
DDI-MedLine.d79.s3|74-84|didanosine|drug
DDI-MedLine.d79.s3|85-100|administration;|drug
DDI-MedLine.d79.s5|0-9|Indinavir|drug
DDI-MedLine.d79.s5|45-54|following|drug
DDI-MedLine.d79.s5|59-73|administration|drug
DDI-MedLine.d79.s5|87-98|didanosine.|drug
DDI-DrugBank.d40.s0|22-31|interfere|drug
DDI-DrugBank.d40.s0|55-67|fosphenytoin|drug
DDI-DrugBank.d40.s0|71-81|phenytoin.|drug
DDI-DrugBank.d40.s1|240-252|fosphenytoin|drug
DDI-DrugBank.d40.s1|256-266|phenytoin.|drug
DDI-DrugBank.d40.s2|22-29|albumin|drug
DDI-DrugBank.d40.s2|36-44|increase|drug
DDI-DrugBank.d40.s2|69-82|fosphenytoin.|drug
DDI-DrugBank.d40.s3|53-63|clinically|drug
DDI-DrugBank.d40.s3|109-122|administering|drug
DDI-DrugBank.d40.s3|181-189|albumin.|drug
DDI-DrugBank.d40.s4|4-20|pharmacokinetics|drug
DDI-DrugBank.d40.s4|25-32|protein|drug
DDI-DrugBank.d40.s4|33-40|binding|drug
DDI-DrugBank.d40.s4|44-57|fosphenytoin,|drug
DDI-DrugBank.d40.s4|58-68|phenytoin,|drug
DDI-DrugBank.d40.s4|143-155|administered|drug
DDI-DrugBank.d40.s4|159-165|single|drug
DDI-DrugBank.d40.s5|26-38|interactions|drug
DDI-DrugBank.d40.s5|39-48|following|drug
DDI-DrugBank.d40.s5|49-63|administration|drug
DDI-DrugBank.d40.s5|113-121|interact|drug
DDI-DrugBank.d40.s5|127-137|phenytoin.|drug
DDI-DrugBank.d40.s6|0-9|Phenytoin|drug
DDI-DrugBank.d40.s6|47-55|proteins|drug
DDI-DrugBank.d40.s7|0-9|Phenytoin|drug
DDI-DrugBank.d40.s7|95-105|inhibitory|drug
DDI-DrugBank.d40.s7|111-123|interactions|drug
DDI-DrugBank.d40.s8|49-58|increases|drug
DDI-DrugBank.d40.s8|62-73|circulating|drug
DDI-DrugBank.d40.s8|74-83|phenytoin|drug
DDI-DrugBank.d40.s9|0-9|Phenytoin|drug
DDI-DrugBank.d40.s9|22-29|inducer|drug
DDI-DrugBank.d40.s9|41-58|drug-metabolizing|drug
DDI-DrugBank.d40.s10|18-27|occurring|drug
DDI-DrugBank.d40.s10|33-45|interactions|drug
DDI-DrugBank.d40.s10|81-89|increase|drug
DDI-DrugBank.d40.s10|97-106|phenytoin|drug
DDI-DrugBank.d40.s10|122-130|include:|drug
DDI-DrugBank.d40.s10|145-152|intake,|drug
DDI-DrugBank.d40.s10|200-211|cimetidine,|drug
DDI-DrugBank.d40.s10|270-281|fluoxetine,|drug
DDI-DrugBank.d40.s10|337-352|phenothiazines,|drug
DDI-DrugBank.d40.s10|382-395|succinimides,|drug
DDI-DrugBank.d40.s12|33-42|phenytoin|drug
DDI-DrugBank.d40.s12|58-66|include:|drug
DDI-DrugBank.d40.s12|67-81|carbamazepine,|drug
DDI-DrugBank.d40.s12|105-114|reserpine|drug
DDI-DrugBank.d40.s14|24-32|increase|drug
DDI-DrugBank.d40.s14|52-61|phenytoin|drug
DDI-DrugBank.d40.s14|77-85|include:|drug
DDI-DrugBank.d40.s14|120-126|sodium|drug
DDI-DrugBank.d40.s15|26-35|phenytoin|drug
DDI-DrugBank.d40.s15|72-78|sodium|drug
DDI-DrugBank.d40.s17|27-39|interaction,|drug
DDI-DrugBank.d40.s17|50-65|antidepressants|group
DDI-DrugBank.d40.s17|82-90|seizures|group
DDI-DrugBank.d40.s19|38-47|phenytoin|drug
DDI-DrugBank.d40.s19|48-56|include:|drug
DDI-DrugBank.d40.s19|57-72|anticoagulants,|group
DDI-DrugBank.d40.s19|73-89|corticosteroids,|group
DDI-DrugBank.d40.s19|90-99|coumarin,|drug
DDI-DrugBank.d40.s19|100-110|digitoxin,|drug
DDI-DrugBank.d40.s19|111-123|doxycycline,|drug
DDI-DrugBank.d40.s19|152-167|contraceptives,|group
DDI-DrugBank.d40.s19|168-177|rifampin,|drug
DDI-DrugBank.d40.s19|178-188|quinidine,|drug
DDI-DrugBank.d40.s19|189-202|theophylline,|drug
DDI-DrugBank.d40.s19|203-210|vitamin|drug
DDI-DrugBank.d40.s20|0-10|Monitoring|drug
DDI-DrugBank.d40.s20|21-30|phenytoin|drug
DDI-DrugBank.d40.s20|80-92|interactions|drug
DDI-DrugBank.d40.s21|34-43|Phenytoin|drug
DDI-DrugBank.d40.s23|0-9|Phenytoin|drug
DDI-DrugBank.d40.s23|25-34|increased|drug
DDI-DrugBank.d40.s23|68-76|alkaline|drug
DDI-DrugBank.d40.s23|124-130|(GGT).|brand
DDI-DrugBank.d40.s24|26-31|using|drug
DDI-DrugBank.d40.s24|60-67|measure|group
DDI-DrugBank.d40.s24|75-84|phenytoin|drug
DDI-DrugBank.d40.s24|100-109|following|drug
DDI-DrugBank.d40.s24|118-133|administration.|drug
DDI-DrugBank.d381.s0|0-9|ERGAMISOL|brand
DDI-DrugBank.d381.s0|11-22|(levamisole|drug
DDI-DrugBank.d381.s0|23-37|hydrochloride)|drug
DDI-DrugBank.d381.s1|53-62|phenytoin|drug
DDI-DrugBank.d381.s2|42-53|prothrombin|drug
DDI-DrugBank.d381.s2|100-106|taking|drug
DDI-DrugBank.d381.s2|118-128|levamisole|drug
DDI-DrugBank.d381.s2|133-141|warfarin|drug
DDI-DrugBank.d381.s2|142-149|sodium,|drug
DDI-DrugBank.d381.s2|175-186|prothrombin|drug
DDI-DrugBank.d381.s2|232-240|warfarin|drug
DDI-DrugBank.d381.s2|241-247|sodium|drug
DDI-DrugBank.d381.s2|257-270|coumarin-like|drug
DDI-DrugBank.d381.s2|296-308|accordingly,|drug
DDI-DrugBank.d381.s2|321-327|taking|drug
DDI-DrugBank.d426.s0|0-16|Ergot-containing|group
DDI-DrugBank.d426.s1|47-59|interaction,|drug
DDI-DrugBank.d426.s1|67-88|ergotamine-containing|group
DDI-DrugBank.d426.s1|121-138|dihydroergotamine|drug
DDI-DrugBank.d426.s1|160-165|FROVA|brand
DDI-DrugBank.d426.s1|166-172|within|drug
DDI-DrugBank.d426.s1|244-263|CONTRAINDICATIONS).|brand
DDI-DrugBank.d426.s2|25-34|5-HT1B/1D|brand
DDI-DrugBank.d426.s2|44-50|within|drug
DDI-DrugBank.d426.s2|63-68|FROVA|brand
DDI-DrugBank.d426.s3|10-19|serotonin|drug
DDI-DrugBank.d426.s3|29-39|inhibitors|drug
DDI-DrugBank.d426.s3|55-66|fluoxetine,|drug
DDI-DrugBank.d426.s3|67-79|fluvoxamine,|drug
DDI-DrugBank.d426.s3|80-91|paroxetine,|drug
DDI-DrugBank.d426.s3|92-103|sertraline)|drug
DDI-DrugBank.d426.s3|170-184|incoordination|drug
DDI-DrugBank.d426.s3|190-204|coadministered|drug
DDI-DrugBank.d426.s3|210-215|5-HT1|brand
DDI-DrugBank.d426.s4|58-68|clinically|drug
DDI-DrugBank.d426.s5|34-39|FROVA|brand
DDI-DrugBank.d426.s5|56-65|interfere|drug
DDI-DrugBank.d426.s5|89-97|clinical|drug
DDI-MedLine.d119.s0|32-44|fluvastatin.|drug
DDI-MedLine.d119.s1|0-11|Fluvastatin|drug
DDI-MedLine.d119.s1|35-61|3-hydroxy-3-methylglutaryl|drug_n
DDI-MedLine.d119.s1|92-101|inhibitor|drug
DDI-MedLine.d119.s1|121-129|clinical|drug
DDI-MedLine.d119.s1|178-183|since|drug
DDI-MedLine.d119.s1|184-189|1986.|drug_n
DDI-MedLine.d119.s2|19-27|distinct|drug
DDI-MedLine.d119.s2|80-90|inhibitors|drug
DDI-MedLine.d119.s2|91-103|(lovastatin,|drug
DDI-MedLine.d119.s2|104-116|simvastatin,|drug
DDI-MedLine.d119.s2|121-134|pravastatin),|drug
DDI-MedLine.d119.s2|135-142|leading|drug
DDI-MedLine.d119.s3|14-25|fluvastatin|drug
DDI-MedLine.d119.s3|68-77|including|drug
DDI-MedLine.d119.s4|9-17|exposure|group
DDI-MedLine.d119.s4|33-44|fluvastatin|drug
DDI-MedLine.d119.s4|139-147|minutes.|drug
DDI-MedLine.d119.s5|14-20|single|drug
DDI-MedLine.d119.s5|31-42|fluvastatin|drug
DDI-MedLine.d119.s5|104-109|being|drug
DDI-MedLine.d119.s6|38-49|circulating|drug
DDI-MedLine.d119.s6|85-91|during|drug
DDI-MedLine.d119.s6|100-107|dosing.|drug
DDI-MedLine.d119.s7|37-53|pharmacokinetics|drug
DDI-MedLine.d119.s7|57-68|fluvastatin|drug
DDI-MedLine.d119.s8|25-36|fluvastatin|drug
DDI-MedLine.d119.s8|37-51|administration|drug
DDI-MedLine.d119.s8|61-68|evening|drug
DDI-MedLine.d119.s9|91-102|lipoprotein|drug
DDI-MedLine.d119.s9|103-114|cholesterol|drug
DDI-MedLine.d119.s9|132-143|ascertained|drug
DDI-MedLine.d119.s9|161-167|dosing|drug
DDI-MedLine.d119.s9|180-187|dosing.|drug
DDI-MedLine.d119.s10|4-20|pharmacokinetics|drug
DDI-MedLine.d119.s10|24-35|fluvastatin|drug
DDI-MedLine.d119.s11|61-72|fluvastatin|drug
DDI-MedLine.d119.s12|13-27|administration|drug
DDI-MedLine.d119.s12|65-78|insufficiency|drug
DDI-MedLine.d119.s12|93-101|2.5-fold|drug_n
DDI-MedLine.d119.s12|102-110|increase|drug
DDI-MedLine.d119.s12|170-179|controls.|group
DDI-MedLine.d119.s13|15-22|minimal|drug
DDI-MedLine.d119.s13|38-49|fluvastatin|drug
DDI-MedLine.d119.s13|83-96|insufficiency|drug
DDI-MedLine.d119.s13|101-112|anticipated|group
DDI-MedLine.d119.s13|205-212|examine|drug
DDI-MedLine.d119.s14|45-56|fluvastatin|drug
DDI-MedLine.d119.s14|98-113|coadministered.|drug
DDI-MedLine.d119.s15|0-15|Cholestyramine,|drug
DDI-MedLine.d119.s15|19-34|anionic-binding|drug
DDI-MedLine.d119.s15|35-41|resin,|drug
DDI-MedLine.d119.s15|71-79|lowering|drug
DDI-MedLine.d119.s15|103-114|fluvastatin|drug
DDI-MedLine.d119.s16|41-55|cholestyramine|drug
DDI-MedLine.d119.s16|83-95|fluvastatin,|drug
DDI-MedLine.d119.s16|127-137|diminished|drug
DDI-MedLine.d119.s17|30-38|warfarin|drug
DDI-MedLine.d119.s17|49-60|prothrombin|drug
DDI-MedLine.d119.s17|92-101|involving|drug
DDI-MedLine.d119.s17|114-128|administration|drug
DDI-MedLine.d119.s17|132-140|warfarin|drug
DDI-MedLine.d119.s17|145-157|fluvastatin.|drug
DDI-MedLine.d119.s18|21-32|interaction|drug
DDI-MedLine.d119.s18|46-52|niacin|drug
DDI-MedLine.d119.s18|57-68|propranolol|drug
DDI-MedLine.d119.s18|105-116|fluvastatin|drug
DDI-MedLine.d119.s18|136-150|administration|drug
DDI-MedLine.d119.s18|187-196|receiving|drug
DDI-MedLine.d119.s18|197-204|digoxin|drug
DDI-MedLine.d119.s18|267-274|digoxin|drug
DDI-MedLine.d119.s18|287-294|control|group
DDI-MedLine.d119.s19|33-41|clinical|drug
DDI-MedLine.d119.s19|42-57|pharmacokinetic|drug
DDI-MedLine.d119.s19|71-82|fluvastatin|drug
DDI-MedLine.d119.s19|129-150|hypercholesterolaemic|drug
DDI-DrugBank.d495.s0|20-29|receiving|drug
DDI-DrugBank.d495.s0|30-39|clonidine|drug
DDI-DrugBank.d495.s0|40-53|hydrochloride|drug
DDI-DrugBank.d495.s0|62-68|taking|drug
DDI-DrugBank.d495.s0|79-95|antidepressants,|group
DDI-DrugBank.d495.s0|110-119|clonidine|drug
DDI-DrugBank.d495.s0|141-154|necessitating|drug
DDI-DrugBank.d495.s0|158-166|increase|drug
DDI-DrugBank.d495.s1|0-9|Clonidine|drug
DDI-DrugBank.d495.s1|10-23|hydrochloride|drug
DDI-DrugBank.d495.s2|0-13|Amitriptyline|drug
DDI-DrugBank.d495.s2|17-28|combination|drug
DDI-DrugBank.d495.s2|34-43|clonidine|drug
DDI-DrugBank.d495.s2|117-126|Clonidine|drug
DDI-DrugBank.d495.s2|202-210|sedating|drug
DDI-DrugBank.d495.s3|62-72|clonidine.|drug
DDI-DrugBank.d495.s4|10-25|antidepressants|group
DDI-DrugBank.d495.s4|68-78|clonidine.|drug
DDI-DrugBank.d495.s5|25-40|antidepressants|group
DDI-DrugBank.d495.s5|44-54|clonidines|drug
DDI-DrugBank.d495.s6|65-74|clonidine|drug
DDI-DrugBank.d495.s7|115-124|receiving|drug
DDI-DrugBank.d495.s7|125-134|clonidine|drug
DDI-DrugBank.d495.s7|163-168|sinus|drug
DDI-DrugBank.d495.s7|224-231|calcium|drug
DDI-DrugBank.d495.s8|51-59|delirium|drug
DDI-DrugBank.d495.s8|100-112|fluphenazine|drug
DDI-DrugBank.d495.s8|122-132|clonidine.|drug
DDI-DrugBank.d495.s9|23-32|clonidine|drug
DDI-DrugBank.d495.s9|99-109|clonidine.|drug
DDI-DrugBank.d495.s10|9-18|clonidine|drug
DDI-DrugBank.d495.s10|100-109|including|drug
DDI-DrugBank.d27.s0|25-40|pharmacokinetic|drug
DDI-DrugBank.d27.s0|62-74|interactions|drug
DDI-DrugBank.d27.s0|94-105|interaction|drug
DDI-DrugBank.d27.s0|119-139|hydrochlorothiazide,|group
DDI-DrugBank.d27.s0|140-148|digoxin,|drug
DDI-DrugBank.d27.s0|149-158|warfarin,|drug
DDI-DrugBank.d27.s0|163-174|nifedipine.|drug
DDI-DrugBank.d27.s1|34-44|inhibition|drug
DDI-DrugBank.d27.s1|131-152|substrates/inhibitors|drug
DDI-DrugBank.d27.s1|153-166|sulphenazole,|drug
DDI-DrugBank.d27.s1|167-178|tolbutamide|drug
DDI-DrugBank.d27.s1|183-194|nifedipine.|drug
DDI-DrugBank.d27.s2|12-20|clinical|drug
DDI-DrugBank.d27.s2|99-107|warfarin|drug
DDI-DrugBank.d27.s3|27-38|interaction|drug
DDI-DrugBank.d27.s3|133-155|1A2,2A6,2B6,2D6,2E1,or|drug_n
DDI-DrugBank.d27.s4|32-41|receiving|drug
DDI-DrugBank.d27.s4|42-53|maintenance|drug
DDI-DrugBank.d27.s4|63-72|warfarin,|drug
DDI-DrugBank.d27.s4|73-93|hydrochlorothiazide,|group
DDI-DrugBank.d27.s4|97-105|digoxin,|drug
DDI-DrugBank.d27.s4|117-131|administration|drug
DDI-DrugBank.d27.s4|184-192|warfarin|drug
DDI-DrugBank.d27.s4|193-205|(prothrombin|drug
DDI-DrugBank.d27.s4|215-231|pharmacokinetics|drug
DDI-DrugBank.d27.s4|235-243|digoxin.|drug
DDI-DrugBank.d27.s5|4-20|pharmacokinetics|drug
DDI-DrugBank.d27.s5|56-72|coadministration|drug
DDI-DrugBank.d27.s5|76-86|nifedipine|drug
DDI-DrugBank.d27.s5|90-109|hydrochlorothiazide|group
DDI-MedLine.d117.s0|23-40|nucleophosmin/B23|drug
DDI-MedLine.d117.s0|44-58|anti-apoptotic|group
DDI-MedLine.d117.s0|73-79|during|drug
DDI-MedLine.d117.s1|3-11|obtained|drug
DDI-MedLine.d117.s1|26-35|increased|drug
DDI-MedLine.d117.s1|49-66|nucleophosmin/B23|drug
DDI-MedLine.d117.s1|70-78|involved|drug
DDI-MedLine.d117.s1|82-95|antiapoptotic|group
DDI-MedLine.d117.s1|110-116|during|drug
DDI-MedLine.d117.s2|0-17|Nucleophosmin/B23|drug
DDI-MedLine.d117.s2|47-54|NIH-3T3|brand
DDI-MedLine.d117.s3|3-12|contrast,|group
DDI-MedLine.d117.s3|13-30|nucleophosmin/B23|drug
DDI-MedLine.d117.s3|65-74|(RAS-3T3)|brand
DDI-MedLine.d117.s3|125-132|NIH-3T3|brand
DDI-MedLine.d117.s3|136-143|RAS-3T3|brand
DDI-MedLine.d117.s4|13-20|RAS-3T3|brand
DDI-MedLine.d117.s4|32-49|nucleophosmin/B23|drug
DDI-MedLine.d117.s4|50-59|antisense|group
DDI-MedLine.d117.s4|109-116|induced|drug
DDI-MedLine.d117.s5|81-88|RAS-3T3|brand
DDI-MedLine.d117.s5|146-153|NIH-3T3|brand
DDI-MedLine.d117.s6|25-34|inhibitor|drug
DDI-MedLine.d117.s6|48-54|medium|drug
DDI-MedLine.d117.s6|79-96|nucleophosmin/B23|drug
DDI-MedLine.d117.s6|111-118|induced|drug
DDI-MedLine.d117.s6|143-150|NIH-3T3|brand
DDI-MedLine.d117.s7|4-14|inhibitor,|drug
DDI-MedLine.d117.s7|67-80|nucleolin/C23|drug
DDI-MedLine.d117.s7|84-91|NIH-3T3|brand
DDI-MedLine.d117.s7|98-104|during|drug
DDI-MedLine.d117.s8|7-21|nucleolin/C23,|drug
DDI-MedLine.d117.s8|41-58|nucleophosmin/B23|drug
DDI-MedLine.d117.s9|12-20|indicate|drug
DDI-MedLine.d117.s9|56-74|nucleophosmin/B23,|drug
DDI-MedLine.d117.s9|104-113|induction|drug
DDI-DrugBank.d567.s0|0-6|CYP3A4|brand
DDI-DrugBank.d567.s1|0-10|Lovastatin|drug
DDI-DrugBank.d567.s1|29-35|CYP3A4|brand
DDI-DrugBank.d567.s1|47-53|CYP3A4|brand
DDI-DrugBank.d567.s1|54-64|inhibitory|drug
DDI-DrugBank.d567.s2|95-102|CYP3A4.|brand
DDI-DrugBank.d567.s3|7-17|inhibitors|drug
DDI-DrugBank.d567.s3|21-27|CYP3A4|brand
DDI-DrugBank.d567.s3|36-44|increase|drug
DDI-DrugBank.d567.s3|69-77|reducing|drug
DDI-DrugBank.d567.s3|82-93|elimination|drug
DDI-DrugBank.d567.s3|97-108|lovastatin.|drug
DDI-DrugBank.d567.s4|0-17|Pharmacokinetics.|drug
DDI-DrugBank.d567.s5|0-12|Itraconazole|drug
DDI-DrugBank.d567.s5|13-25|Ketoconazole|drug
DDI-DrugBank.d567.s5|26-38|Erythromycin|drug
DDI-DrugBank.d567.s5|39-53|Clarithromycin|drug
DDI-DrugBank.d567.s5|54-67|Telithromycin|drug
DDI-DrugBank.d567.s5|81-91|inhibitors|drug
DDI-DrugBank.d567.s5|103-115|Cyclosporine|drug
DDI-DrugBank.d567.s6|18-32|lipid-lowering|drug
DDI-DrugBank.d567.s7|29-38|increased|drug
DDI-DrugBank.d567.s7|46-55|following|drug
DDI-DrugBank.d567.s7|56-70|lipid-lowering|drug
DDI-DrugBank.d567.s7|97-103|CYP3A4|brand
DDI-DrugBank.d567.s7|104-115|inhibitors,|drug
DDI-DrugBank.d567.s8|4-13|WARNINGS,|brand
DDI-DrugBank.d567.s9|27-33|Niacin|drug
DDI-DrugBank.d567.s9|34-44|(nicotinic|drug
DDI-DrugBank.d567.s10|11-23|interactions|drug
DDI-DrugBank.d567.s11|48-57|increased|drug
DDI-DrugBank.d567.s11|73-87|administration|drug
DDI-DrugBank.d567.s11|133-143|lovastatin|drug
DDI-DrugBank.d567.s11|149-158|WARNINGS,|brand
DDI-DrugBank.d567.s12|64-73|increased|drug
DDI-DrugBank.d567.s12|187-196|inhibitor|drug
DDI-DrugBank.d567.s12|208-217|WARNINGS,|brand
DDI-DrugBank.d567.s13|0-8|Coumarin|drug
DDI-DrugBank.d567.s13|36-44|clinical|drug
DDI-DrugBank.d567.s13|60-70|lovastatin|drug
DDI-DrugBank.d567.s13|75-87|administered|drug
DDI-DrugBank.d567.s13|91-99|warfarin|drug
DDI-DrugBank.d567.s13|131-142|prothrombin|drug
DDI-DrugBank.d567.s14|9-16|another|drug
DDI-DrugBank.d567.s14|35-44|inhibitor|drug
DDI-DrugBank.d567.s14|94-102|increase|drug
DDI-DrugBank.d567.s14|106-117|prothrombin|drug
DDI-DrugBank.d567.s14|145-154|receiving|drug
DDI-DrugBank.d567.s14|168-177|warfarin.|drug
DDI-DrugBank.d567.s15|6-14|bleeding|drug
DDI-DrugBank.d567.s15|22-31|increased|drug
DDI-DrugBank.d567.s15|32-43|prothrombin|drug
DDI-DrugBank.d567.s15|86-92|taking|drug
DDI-DrugBank.d567.s15|93-101|coumarin|drug
DDI-DrugBank.d567.s15|102-116|anticoagulants|group
DDI-DrugBank.d567.s15|136-147|lovastatin.|drug
DDI-DrugBank.d567.s16|35-41|taking|drug
DDI-DrugBank.d567.s16|42-57|anticoagulants,|group
DDI-DrugBank.d567.s16|58-69|prothrombin|drug
DDI-DrugBank.d567.s16|78-88|determined|drug
DDI-DrugBank.d567.s16|96-104|starting|drug
DDI-DrugBank.d567.s16|105-115|lovastatin|drug
DDI-DrugBank.d567.s16|138-144|during|drug
DDI-DrugBank.d567.s16|162-168|insure|group
DDI-DrugBank.d567.s16|203-214|prothrombin|drug
DDI-DrugBank.d567.s17|14-25|prothrombin|drug
DDI-DrugBank.d567.s17|52-63|prothrombin|drug
DDI-DrugBank.d567.s17|94-103|intervals|drug
DDI-DrugBank.d567.s17|140-148|coumarin|drug
DDI-DrugBank.d567.s17|149-164|anticoagulants.|group
DDI-DrugBank.d567.s18|15-25|lovastatin|drug
DDI-DrugBank.d567.s18|47-56|procedure|group
DDI-DrugBank.d567.s19|0-10|Lovastatin|drug
DDI-DrugBank.d567.s19|48-56|bleeding|drug
DDI-DrugBank.d567.s19|76-87|prothrombin|drug
DDI-DrugBank.d567.s19|109-115|taking|drug
DDI-DrugBank.d567.s19|116-131|anticoagulants.|group
DDI-DrugBank.d567.s20|0-12|Propranolol:|drug
DDI-DrugBank.d567.s20|48-58|clinically|drug
DDI-DrugBank.d567.s20|71-86|pharmacokinetic|drug
DDI-DrugBank.d567.s20|106-117|interaction|drug
DDI-DrugBank.d567.s20|135-149|administration|drug
DDI-DrugBank.d567.s20|153-159|single|drug
DDI-DrugBank.d567.s20|169-179|lovastatin|drug
DDI-DrugBank.d567.s20|184-196|propranolol.|drug
DDI-DrugBank.d567.s21|0-8|Digoxin:|drug
DDI-DrugBank.d567.s21|26-47|hypercholesterolemia,|drug
DDI-DrugBank.d567.s21|60-74|administration|drug
DDI-DrugBank.d567.s21|78-88|lovastatin|drug
DDI-DrugBank.d567.s21|93-100|digoxin|drug
DDI-DrugBank.d567.s21|126-133|digoxin|drug
DDI-DrugBank.d567.s22|29-44|pharmacokinetic|drug
DDI-DrugBank.d567.s22|56-63|MEVACOR|brand
DDI-DrugBank.d567.s22|67-87|hypercholesterolemic|drug
DDI-DrugBank.d567.s22|88-98|noninsulin|drug
DDI-DrugBank.d567.s22|146-157|interaction|drug
DDI-DrugBank.d567.s22|163-172|glipizide|drug
DDI-DrugBank.d567.s22|181-195|chlorpropamide|drug
DDI-DrugBank.d562.s0|26-38|theophylline|drug
DDI-DrugBank.d562.s0|87-98|quinolones.|drug
DDI-DrugBank.d562.s1|27-47|theophylline-related|drug
DDI-DrugBank.d562.s1|88-110|theophylline-quinolone|drug
DDI-DrugBank.d562.s2|11-21|monitoring|drug
DDI-DrugBank.d562.s2|25-37|theophylline|drug
DDI-DrugBank.d562.s2|87-99|theophylline|drug
DDI-DrugBank.d562.s3|0-10|Quinolones|drug
DDI-DrugBank.d562.s3|35-44|interfere|drug
DDI-DrugBank.d562.s3|68-77|caffeine.|drug
DDI-DrugBank.d562.s4|38-46|caffeine|drug
DDI-DrugBank.d562.s5|14-25|interaction|drug
DDI-DrugBank.d562.s5|53-63|cinoxacin,|drug
DDI-DrugBank.d562.s5|97-106|cinoxacin|drug
DDI-DrugBank.d562.s5|135-154|caffeine-containing|group
DDI-DrugBank.d562.s6|0-8|Antacids|group
DDI-DrugBank.d562.s6|37-46|interfere|drug
DDI-DrugBank.d562.s6|75-86|quinolones,|drug
DDI-DrugBank.d562.s6|87-96|resulting|drug
DDI-DrugBank.d562.s6|104-109|urine|drug
DDI-DrugBank.d562.s7|18-32|administration|drug
DDI-DrugBank.d562.s7|36-46|quinolones|drug
DDI-DrugBank.d562.s7|61-71|containing|group
DDI-DrugBank.d562.s7|78-91|multivitamins|drug
DDI-DrugBank.d562.s7|92-102|containing|group
DDI-DrugBank.d562.s7|103-108|zinc,|drug
DDI-DrugBank.d562.s7|118-130|(didanosine)|drug
DDI-DrugBank.d562.s7|217-222|urine|drug
DDI-DrugBank.d562.s8|0-11|Quinolones,|drug
DDI-DrugBank.d562.s8|12-21|including|drug
DDI-DrugBank.d562.s8|22-32|cinoxacin,|drug
DDI-DrugBank.d562.s8|65-80|anticoagulants,|group
DDI-DrugBank.d562.s8|89-97|warfarin|drug
DDI-DrugBank.d562.s9|24-36|administered|drug
DDI-DrugBank.d562.s9|52-63|prothrombin|drug
DDI-DrugBank.d562.s10|0-8|Seizures|group
DDI-DrugBank.d562.s10|40-46|taking|drug
DDI-DrugBank.d562.s10|47-54|another|drug
DDI-DrugBank.d562.s10|55-64|quinolone|drug
DDI-DrugBank.d562.s10|71-84|antimicrobial|group
DDI-DrugBank.d562.s10|106-123|anti-inflammatory|group
DDI-DrugBank.d562.s11|31-40|increased|drug
DDI-DrugBank.d562.s11|55-63|seizures|group
DDI-DrugBank.d562.s13|29-40|information|drug
DDI-DrugBank.d562.s13|44-52|increase|drug
DDI-DrugBank.d562.s13|92-104|interactions|drug
DDI-DrugBank.d562.s13|110-119|cinoxacin|drug
DDI-DrugBank.d562.s13|124-131|certain|drug
DDI-DrugBank.d562.s13|145-162|anti-inflammatory|group
DDI-DrugBank.d562.s13|174-186|administered|drug
DDI-DrugBank.d562.s14|9-21|cyclosporine|drug
DDI-DrugBank.d562.s14|82-92|quinolones|drug
DDI-DrugBank.d562.s14|97-110|cyclosporine.|drug
DDI-DrugBank.d232.s0|15-22|dosing,|drug
DDI-DrugBank.d232.s0|23-33|interferon|drug
DDI-DrugBank.d232.s0|42-49|(AVONEX|brand
DDI-DrugBank.d232.s0|82-89|TYSABRI|brand
DDI-DrugBank.d232.s1|22-29|TYSABRI|brand
DDI-DrugBank.d232.s1|89-104|co-administered|drug
DDI-DrugBank.d232.s1|105-111|AVONEX|brand
DDI-DrugBank.d232.s1|132-147|co-administered|drug
DDI-DrugBank.d232.s1|148-154|AVONEX|brand
DDI-DrugBank.d232.s1|157-166|indicates|drug
DDI-DrugBank.d232.s1|239-246|TYSABRI|brand
DDI-DrugBank.d232.s1|256-264|maintain|drug
DDI-DrugBank.d232.s2|50-56|taking|drug
DDI-DrugBank.d232.s2|57-64|TYSABRI|brand
DDI-DrugBank.d232.s2|82-92|interferon|drug
DDI-DrugBank.d232.s2|101-108|(AVONEX|brand
DDI-DrugBank.d232.s2|160-172|inconclusive|drug
DDI-DrugBank.d232.s2|224-239|beta-interferon|drug
DDI-DrugBank.d413.s0|4-13|following|drug
DDI-DrugBank.d413.s0|19-31|interactions|drug
DDI-DrugBank.d413.s0|63-73|undergoing|drug
DDI-DrugBank.d413.s0|94-106|allopurinol.|drug
DDI-DrugBank.d413.s1|37-48|allopurinol|drug
DDI-DrugBank.d413.s1|49-57|includes|drug
DDI-DrugBank.d413.s1|135-141|gained|drug_n
DDI-DrugBank.d413.s2|0-28|Mercaptopurine/Azathioprine:|drug
DDI-DrugBank.d413.s2|29-40|Allopurinol|drug
DDI-DrugBank.d413.s2|41-49|inhibits|drug
DDI-DrugBank.d413.s2|77-91|mercaptopurine|drug
DDI-DrugBank.d413.s2|96-108|azathioprine|drug
DDI-DrugBank.d413.s2|112-122|6-thiouric|drug_n
DDI-DrugBank.d413.s3|38-46|xanthine|drug
DDI-DrugBank.d413.s3|56-67|inactivates|drug
DDI-DrugBank.d413.s3|68-83|mercaptopurine.|drug
DDI-DrugBank.d413.s4|12-21|receiving|drug
DDI-DrugBank.d413.s4|22-36|mercaptopurine|drug
DDI-DrugBank.d413.s4|37-49|(Purinethol)|drug
DDI-DrugBank.d413.s4|53-65|azathioprine|drug
DDI-DrugBank.d413.s4|92-106|administration|drug
DDI-DrugBank.d413.s4|110-117|300-600|drug_n
DDI-DrugBank.d413.s4|124-135|allopurinol|drug
DDI-DrugBank.d413.s4|239-253|mercaptopurine|drug
DDI-DrugBank.d413.s4|257-270|azathioprine.|drug
DDI-DrugBank.d413.s5|34-48|mercaptopurine|drug
DDI-DrugBank.d413.s5|52-64|azathioprine|drug
DDI-DrugBank.d413.s6|37-48|allopurinol|drug
DDI-DrugBank.d413.s6|79-93|anticoagulant,|group
DDI-DrugBank.d413.s7|4-12|clinical|drug
DDI-DrugBank.d413.s7|32-43|interaction|drug
DDI-DrugBank.d413.s7|94-105|allopurinol|drug
DDI-DrugBank.d413.s8|14-25|prothrombin|drug
DDI-DrugBank.d413.s8|77-86|receiving|drug
DDI-DrugBank.d413.s9|19-24|Since|drug
DDI-DrugBank.d413.s9|42-52|oxipurinol|drug
DDI-DrugBank.d413.s9|107-115|increase|drug
DDI-DrugBank.d413.s9|159-167|increase|drug
DDI-DrugBank.d413.s9|185-195|oxipurinol|drug
DDI-DrugBank.d413.s9|225-235|inhibition|drug
DDI-DrugBank.d413.s9|239-247|xanthine|drug
DDI-DrugBank.d413.s10|16-30|administration|drug
DDI-DrugBank.d413.s10|56-67|allopurinol|drug
DDI-DrugBank.d413.s10|124-134|oxypurines|drug
DDI-DrugBank.d413.s10|135-148|(hypoxanthine|drug
DDI-DrugBank.d413.s10|153-162|xanthine)|drug
DDI-DrugBank.d413.s10|170-178|increase|drug
DDI-DrugBank.d413.s10|182-189|urinary|drug
DDI-DrugBank.d413.s10|243-254|allopurinol|drug
DDI-DrugBank.d413.s11|9-17|clinical|drug
DDI-DrugBank.d413.s11|79-89|oxypurines|drug
DDI-DrugBank.d413.s11|112-123|allopurinol|drug
DDI-DrugBank.d413.s11|136-147|combination|drug
DDI-DrugBank.d413.s11|206-211|mind.|drug
DDI-DrugBank.d413.s12|0-8|Thiazide|drug
DDI-DrugBank.d413.s12|9-19|Diuretics:|group
DDI-DrugBank.d413.s12|60-71|allopurinol|drug
DDI-DrugBank.d413.s12|76-84|thiazide|group
DDI-DrugBank.d413.s12|85-94|diuretics|group
DDI-DrugBank.d413.s12|99-109|contribute|group
DDI-DrugBank.d413.s12|132-143|allopurinol|drug
DDI-DrugBank.d413.s13|29-38|indicates|drug
DDI-DrugBank.d413.s13|62-68|mainly|drug
DDI-DrugBank.d413.s13|69-78|receiving|drug
DDI-DrugBank.d413.s13|79-87|thiazide|group
DDI-DrugBank.d413.s13|88-97|diuretics|group
DDI-DrugBank.d413.s14|32-45|insufficiency|drug
DDI-DrugBank.d413.s14|111-122|allopurinol|drug
DDI-DrugBank.d413.s15|172-180|thiazide|group
DDI-DrugBank.d413.s15|181-190|diuretics|group
DDI-DrugBank.d413.s15|195-206|allopurinol|drug
DDI-DrugBank.d413.s15|236-244|failure,|group
DDI-DrugBank.d413.s15|333-341|combined|drug
DDI-DrugBank.d413.s15|353-363|diminished|drug
DDI-DrugBank.d413.s16|0-23|Ampicillin/Amoxicillin:|drug
DDI-DrugBank.d413.s16|27-35|increase|drug
DDI-DrugBank.d413.s16|99-108|receiving|drug
DDI-DrugBank.d413.s16|109-119|ampicillin|drug
DDI-DrugBank.d413.s16|123-134|amoxicillin|drug
DDI-DrugBank.d413.s16|153-164|allopurinol|drug
DDI-DrugBank.d413.s16|198-207|receiving|drug
DDI-DrugBank.d413.s18|54-70|cyclophosphamide|drug
DDI-DrugBank.d413.s18|192-204|allopurinol.|drug
DDI-DrugBank.d413.s19|14-29|well-controlled|group
DDI-DrugBank.d413.s19|65-76|combination|drug
DDI-DrugBank.d413.s19|86-97|allopurinol|drug
DDI-DrugBank.d413.s19|106-114|increase|drug
DDI-DrugBank.d413.s19|160-177|cyclophosphamide,|drug
DDI-DrugBank.d413.s19|178-190|doxorubicin,|drug
DDI-DrugBank.d413.s19|191-201|bleomycin,|drug
DDI-DrugBank.d413.s19|202-214|procarbazine|drug
DDI-DrugBank.d413.s19|222-238|mechlorethamine.|drug
DDI-DrugBank.d413.s20|69-81|allopurinol,|drug
DDI-DrugBank.d413.s20|82-87|since|drug
DDI-DrugBank.d413.s20|88-99|allopurinol|drug
DDI-DrugBank.d413.s20|104-118|chlorpropamide|drug
DDI-DrugBank.d413.s21|60-69|increased|drug
DDI-DrugBank.d413.s21|73-84|allopurinol|drug
DDI-DrugBank.d413.s21|89-103|chlorpropamide|drug
DDI-DrugBank.d413.s21|153-167|insufficiency.|drug
DDI-DrugBank.d413.s22|0-12|Cyclosporin:|drug
DDI-DrugBank.d413.s22|21-29|indicate|drug
DDI-DrugBank.d413.s22|35-47|cyclosporine|drug
DDI-DrugBank.d413.s22|62-71|increased|drug
DDI-DrugBank.d413.s22|72-78|during|drug
DDI-DrugBank.d413.s22|106-117|allopurinol|drug
DDI-DrugBank.d413.s22|118-124|sodium|drug
DDI-DrugBank.d413.s22|129-139|injection.|drug
DDI-DrugBank.d413.s23|0-10|Monitoring|drug
DDI-DrugBank.d413.s23|14-26|cyclosporine|drug
DDI-DrugBank.d413.s23|61-73|cyclosporine|drug
DDI-DrugBank.d413.s23|123-139|co-administered.|drug
DDI-DrugBank.d413.s24|27-35|inactive|drug
DDI-DrugBank.d413.s24|82-90|xanthine|drug
DDI-DrugBank.d413.s25|4-12|clinical|drug
DDI-DrugBank.d470.s0|25-40|pharmacokinetic|drug
DDI-DrugBank.d470.s0|51-63|interactions|drug
DDI-DrugBank.d470.s0|72-80|TRISENOX|brand
DDI-DrugBank.d470.s1|24-32|TRISENOX|brand
DDI-DrugBank.d470.s1|36-50|coadministered|drug
DDI-DrugBank.d470.s1|98-106|interval|drug
DDI-DrugBank.d470.s1|113-120|certain|drug
DDI-DrugBank.d470.s1|121-136|antiarrhythmics|group
DDI-DrugBank.d470.s1|140-153|thioridazine)|drug
DDI-DrugBank.d470.s1|200-209|diuretics|group
DDI-DrugBank.d470.s1|213-225|amphotericin|drug
DDI-MedLine.d49.s0|15-26|clindamycin|drug
DDI-MedLine.d49.s0|31-41|gentamicin|drug
DDI-MedLine.d49.s1|4-11|minimal|drug
DDI-MedLine.d49.s1|12-22|inhibitory|drug
DDI-MedLine.d49.s1|41-52|clindamycin|drug
DDI-MedLine.d49.s1|57-67|gentamicin|drug
DDI-MedLine.d49.s1|81-93|combinations|drug
DDI-MedLine.d49.s1|99-109|determined|drug
DDI-MedLine.d49.s1|180-188|clinical|drug
DDI-MedLine.d49.s2|7-14|strains|drug
DDI-MedLine.d49.s2|33-40|aureus,|group
DDI-MedLine.d49.s2|130-137|strains|drug
DDI-MedLine.d49.s2|141-153|Clostridium)|drug
DDI-MedLine.d49.s2|159-168|inhibited|drug
DDI-MedLine.d49.s2|191-202|clindamycin|drug
DDI-MedLine.d49.s3|0-10|Gentamicin|drug
DDI-MedLine.d49.s3|19-28|interfere|drug
DDI-MedLine.d49.s3|50-61|clindamycin|drug
DDI-MedLine.d49.s3|62-68|within|drug
DDI-MedLine.d49.s4|9-16|strains|drug
DDI-MedLine.d49.s4|17-29|combinations|drug
DDI-MedLine.d49.s5|22-29|strains|drug
DDI-MedLine.d49.s5|68-78|aeruginosa|drug
DDI-MedLine.d49.s5|84-93|inhibited|drug
DDI-MedLine.d49.s5|116-126|gentamicin|drug
DDI-MedLine.d49.s6|0-12|Combinations|drug
DDI-MedLine.d49.s6|16-27|clindamycin|drug
DDI-MedLine.d49.s6|32-42|gentamicin|drug
DDI-MedLine.d49.s6|48-59|indifferent|drug
DDI-MedLine.d49.s6|67-74|strains|drug
DDI-MedLine.d49.s6|98-106|strains.|drug
DDI-MedLine.d49.s7|7-14|strains|drug
DDI-MedLine.d49.s7|38-45|strains|drug
DDI-MedLine.d49.s7|49-61|Clostridium,|drug
DDI-MedLine.d49.s7|68-75|strains|drug
DDI-MedLine.d49.s7|105-111|strain|drug
DDI-MedLine.d49.s7|155-166|clindamycin|drug
DDI-MedLine.d49.s7|167-175|(minimal|drug
DDI-MedLine.d49.s7|176-186|inhibitory|drug
DDI-MedLine.d49.s7|230-240|gentamicin|drug
DDI-MedLine.d49.s7|241-249|(minimal|drug
DDI-MedLine.d49.s7|250-260|inhibitory|drug
DDI-MedLine.d49.s8|0-12|Combinations|drug
DDI-MedLine.d49.s8|16-27|clindamycin|drug
DDI-MedLine.d49.s8|32-42|gentamicin|drug
DDI-MedLine.d49.s8|48-59|indifferent|drug
DDI-MedLine.d49.s8|107-115|strains.|drug
DDI-MedLine.d49.s9|11-32|clindamycin-sensitive|drug
DDI-MedLine.d49.s9|138-148|obtainable|drug
DDI-DrugBank.d48.s0|15-23|increase|drug
DDI-DrugBank.d48.s0|24-33|dasatinib|drug
DDI-DrugBank.d48.s0|56-62|CYP3A4|brand
DDI-DrugBank.d48.s0|75-84|Dasatinib|drug
DDI-DrugBank.d48.s0|90-96|CYP3A4|brand
DDI-DrugBank.d48.s1|19-26|SPRYCEL|brand
DDI-DrugBank.d48.s1|42-49|inhibit|drug
DDI-DrugBank.d48.s1|50-56|CYP3A4|brand
DDI-DrugBank.d48.s1|62-75|ketoconazole,|drug
DDI-DrugBank.d48.s1|76-89|itraconazole,|drug
DDI-DrugBank.d48.s1|90-103|erythromycin,|drug
DDI-DrugBank.d48.s1|104-119|clarithromycin,|drug
DDI-DrugBank.d48.s1|143-153|indinavir,|drug
DDI-DrugBank.d48.s1|166-177|nelfinavir,|drug
DDI-DrugBank.d48.s1|178-189|saquinavir,|drug
DDI-DrugBank.d48.s1|190-204|telithromycin)|drug
DDI-DrugBank.d48.s1|209-217|increase|drug
DDI-DrugBank.d48.s1|218-226|exposure|group
DDI-DrugBank.d48.s1|230-239|dasatinib|drug
DDI-DrugBank.d48.s2|12-21|receiving|drug
DDI-DrugBank.d48.s2|37-45|SPRYCEL,|brand
DDI-DrugBank.d48.s2|52-62|monitoring|drug
DDI-DrugBank.d48.s2|82-89|SPRYCEL|brand
DDI-DrugBank.d48.s2|138-152|administration|drug
DDI-DrugBank.d48.s2|165-171|CYP3A4|brand
DDI-DrugBank.d48.s2|172-181|inhibitor|drug
DDI-DrugBank.d48.s3|24-33|dasatinib|drug
DDI-DrugBank.d48.s3|56-62|CYP3A4|brand
DDI-DrugBank.d48.s3|84-90|induce|drug
DDI-DrugBank.d48.s3|91-97|CYP3A4|brand
DDI-DrugBank.d48.s3|120-129|dasatinib|drug
DDI-DrugBank.d48.s4|20-26|CYP3A4|brand
DDI-DrugBank.d48.s4|27-35|inducers|drug
DDI-DrugBank.d48.s4|56-66|phenytoin,|drug
DDI-DrugBank.d48.s4|67-81|carbamazepine,|drug
DDI-DrugBank.d48.s4|82-93|rifampicin,|drug
DDI-DrugBank.d48.s4|113-123|indicated,|drug
DDI-DrugBank.d48.s4|160-169|induction|drug
DDI-DrugBank.d48.s5|3-10|SPRYCEL|brand
DDI-DrugBank.d48.s5|19-31|administered|drug
DDI-DrugBank.d48.s5|39-45|CYP3A4|brand
DDI-DrugBank.d48.s5|46-54|inducer,|drug
DDI-DrugBank.d48.s5|62-70|increase|drug
DDI-DrugBank.d48.s5|74-81|SPRYCEL|brand
DDI-DrugBank.d48.s6|51-58|SPRYCEL|brand
DDI-DrugBank.d48.s7|9-18|receiving|drug
DDI-DrugBank.d48.s7|19-26|SPRYCEL|brand
DDI-DrugBank.d48.s8|0-9|Antacids:|group
DDI-DrugBank.d48.s8|10-21|Nonclinical|drug
DDI-DrugBank.d48.s8|62-71|dasatinib|drug
DDI-DrugBank.d48.s9|13-27|administration|drug
DDI-DrugBank.d48.s9|31-38|SPRYCEL|brand
DDI-DrugBank.d48.s9|44-52|antacids|group
DDI-DrugBank.d48.s10|57-69|administered|drug
DDI-DrugBank.d48.s10|125-133|SPRYCEL.|brand
DDI-DrugBank.d48.s11|114-124|inhibitors|drug
DDI-DrugBank.d48.s11|130-140|famotidine|drug
DDI-DrugBank.d48.s11|145-156|omeprazole)|drug
DDI-DrugBank.d48.s11|177-186|dasatinib|drug
DDI-DrugBank.d48.s11|187-196|exposure.|group
DDI-DrugBank.d48.s12|50-60|inhibitors|drug
DDI-DrugBank.d48.s12|66-73|SPRYCEL|brand
DDI-DrugBank.d48.s13|11-19|antacids|group
DDI-DrugBank.d48.s13|80-90|inhibitors|drug
DDI-DrugBank.d48.s13|103-112|receiving|drug
DDI-DrugBank.d48.s13|113-120|SPRYCEL|brand
DDI-DrugBank.d48.s14|58-67|dasatinib|drug
DDI-DrugBank.d48.s14|68-74|CYP3A4|brand
DDI-DrugBank.d48.s14|87-96|Dasatinib|drug
DDI-DrugBank.d48.s14|117-126|inhibitor|drug
DDI-DrugBank.d48.s14|130-137|CYP3A4.|brand
DDI-DrugBank.d48.s15|11-17|CYP3A4|brand
DDI-DrugBank.d48.s15|64-69|index|drug
DDI-DrugBank.d48.s15|90-101|astemizole,|drug
DDI-DrugBank.d48.s15|102-114|terfenadine,|drug
DDI-DrugBank.d48.s15|126-139|cyclosporine,|drug
DDI-DrugBank.d48.s15|160-170|quinidine,|drug
DDI-DrugBank.d48.s15|203-212|alkaloids|group
DDI-DrugBank.d48.s15|213-225|(ergotamine,|drug
DDI-DrugBank.d48.s15|226-244|dihydroergotamine)|drug
DDI-DrugBank.d48.s15|255-267|administered|drug
DDI-DrugBank.d48.s15|293-302|receiving|drug
DDI-DrugBank.d48.s15|303-311|SPRYCEL.|brand
DDI-DrugBank.d48.s16|42-50|clinical|drug
DDI-DrugBank.d48.s16|64-71|SPRYCEL|brand
DDI-DrugBank.d48.s16|113-122|(clinical|drug
DDI-DrugBank.d48.s16|234-243|bilirubin|drug
DDI-DrugBank.d48.s17|14-23|dasatinib|drug
DDI-DrugBank.d48.s17|27-33|mainly|drug
DDI-DrugBank.d48.s19|40-48|clinical|drug
DDI-DrugBank.d48.s19|62-69|SPRYCEL|brand
DDI-DrugBank.d48.s19|111-120|(clinical|drug
DDI-DrugBank.d48.s19|163-173|creatinine|drug
DDI-DrugBank.d48.s20|0-9|Dasatinib|drug
DDI-DrugBank.d48.s20|34-43|minimally|drug
DDI-DrugBank.d48.s21|0-5|Since|drug
DDI-DrugBank.d48.s21|39-48|dasatinib|drug
DDI-DrugBank.d48.s21|151-165|insufficiency.|drug
DDI-DrugBank.d554.s0|0-7|Certain|drug
DDI-DrugBank.d554.s0|8-19|antibiotic,|group
DDI-DrugBank.d554.s0|20-30|cisplatin,|drug
DDI-DrugBank.d554.s0|31-44|cyclosporine,|drug
DDI-DrugBank.d554.s0|45-54|diuretic,|group
DDI-DrugBank.d554.s0|70-79|vaccines.|drug
DDI-DrugBank.d7.s0|54-70|cyclophosphamide|drug
DDI-DrugBank.d7.s0|86-95|increased|drug
DDI-DrugBank.d7.s0|107-121|administration|drug
DDI-DrugBank.d7.s1|43-51|combined|drug
DDI-DrugBank.d7.s1|92-101|involving|drug
DDI-DrugBank.d7.s1|102-118|cyclophosphamide|drug
DDI-DrugBank.d7.s1|131-147|cyclophosphamide|drug
DDI-DrugBank.d7.s1|206-215|including|drug
DDI-DrugBank.d7.s2|0-16|Cyclophosphamide|drug
DDI-DrugBank.d7.s2|65-75|inhibition|drug
DDI-DrugBank.d7.s2|79-93|cholinesterase|drug
DDI-DrugBank.d7.s2|130-145|succinylcholine|drug
DDI-DrugBank.d7.s3|35-51|cyclophosphamide|drug
DDI-DrugBank.d7.s3|52-58|within|drug
DDI-DrugBank.d355.s0|14-22|increase|drug
DDI-DrugBank.d355.s0|43-58|anticoagulahts.|group
DDI-DrugBank.d355.s1|14-27|anticoagulant|group
DDI-DrugBank.d355.s1|62-70|maintain|drug
DDI-DrugBank.d355.s1|96-116|hypoprothrombinemia.|drug
DDI-DrugBank.d355.s2|11-25|administration|drug
DDI-DrugBank.d355.s3|99-106|insulin|drug
DDI-DrugBank.d151.s0|47-60|antiepileptic|group
DDI-DrugBank.d151.s0|86-95|phenytoin|drug
DDI-DrugBank.d151.s0|115-123|increase|drug
DDI-DrugBank.d151.s0|141-149|seizures|group
DDI-DrugBank.d151.s1|0-11|Preliminary|drug
DDI-DrugBank.d151.s1|86-98|administered|drug
DDI-DrugBank.d151.s1|99-109|leucovorin|drug
DDI-DrugBank.d151.s1|137-162|5-methyltetrahydro-folate|drug_n
DDI-DrugBank.d151.s1|179-185|remain|drug
DDI-DrugBank.d151.s1|262-271|following|drug
DDI-DrugBank.d151.s1|272-283|intrathecal|drug
DDI-DrugBank.d151.s1|284-299|administration.|drug
DDI-DrugBank.d151.s2|23-33|leucovorin|drug
DDI-DrugBank.d151.s2|61-74|intrathecally|drug
DDI-DrugBank.d151.s2|75-87|administered|drug
DDI-DrugBank.d151.s3|0-10|Leucovorin|drug
DDI-DrugBank.d151.s3|39-54|5-fluorouracil.|drug_n
DDI-DrugBank.d174.s0|49-57|affinity|drug
DDI-DrugBank.d174.s0|62-70|protein,|drug
DDI-DrugBank.d174.s0|95-108|protein-bound|drug
DDI-DrugBank.d174.s0|126-133|binding|drug
DDI-DrugBank.d174.s1|33-46|administering|drug
DDI-DrugBank.d174.s1|63-71|warfarin|drug
DDI-DrugBank.d174.s1|72-77|since|drug
DDI-DrugBank.d174.s1|78-90|interactions|drug
DDI-DrugBank.d174.s2|12-26|administration|drug
DDI-DrugBank.d174.s2|33-52|aluminum-containing|group
DDI-DrugBank.d174.s2|113-118|6MNA.|brand
DDI-DrugBank.d174.s3|5-17|administered|drug
DDI-DrugBank.d314.s0|0-18|Aminoglutethimide:|drug
DDI-DrugBank.d314.s0|19-36|Aminoglutethimide|drug
DDI-DrugBank.d314.s0|41-49|diminish|drug
DDI-DrugBank.d314.s0|73-89|corticosteroids.|group
DDI-DrugBank.d314.s1|0-12|Amphotericin|drug
DDI-DrugBank.d314.s1|15-24|injection|drug
DDI-DrugBank.d314.s1|29-48|potassium-depleting|drug
DDI-DrugBank.d314.s1|62-77|corticosteroids|group
DDI-DrugBank.d314.s1|82-94|administered|drug
DDI-DrugBank.d314.s1|114-133|potassium-depleting|drug
DDI-DrugBank.d314.s1|148-160|amphotericin|drug
DDI-DrugBank.d314.s1|164-175|diuretics),|group
DDI-DrugBank.d314.s2|72-84|amphotericin|drug
DDI-DrugBank.d314.s2|91-105|hydrocortisone|drug
DDI-DrugBank.d314.s2|163-171|failure.|group
DDI-DrugBank.d314.s3|13-22|Macrolide|drug
DDI-DrugBank.d314.s3|23-34|antibiotics|group
DDI-DrugBank.d314.s4|0-20|Anticholinesterases:|drug
DDI-DrugBank.d314.s4|40-58|anticholinesterase|group
DDI-DrugBank.d314.s4|70-85|corticosteroids|group
DDI-DrugBank.d314.s5|13-31|anticholinesterase|group
DDI-DrugBank.d314.s5|84-94|initiating|drug
DDI-DrugBank.d314.s6|22-39|Co-administration|drug
DDI-DrugBank.d314.s6|43-58|corticosteroids|group
DDI-DrugBank.d314.s6|63-71|warfarin|drug
DDI-DrugBank.d314.s6|91-101|inhibition|drug
DDI-DrugBank.d314.s6|117-126|warfarin,|drug
DDI-DrugBank.d314.s6|157-168|conflicting|drug
DDI-DrugBank.d314.s7|23-30|indices|drug
DDI-DrugBank.d314.s7|65-73|maintain|drug
DDI-DrugBank.d314.s7|86-99|anticoagulant|group
DDI-DrugBank.d314.s8|23-38|corticosteroids|group
DDI-DrugBank.d314.s8|43-51|increase|drug
DDI-DrugBank.d314.s8|104-116|antidiabetic|group
DDI-DrugBank.d314.s10|0-15|Cholestyramine:|drug
DDI-DrugBank.d314.s10|16-30|Cholestyramine|drug
DDI-DrugBank.d314.s10|35-43|increase|drug
DDI-DrugBank.d314.s10|61-77|corticosteroids.|group
DDI-DrugBank.d314.s11|0-13|Cyclosporine:|drug
DDI-DrugBank.d314.s11|41-53|cyclosporine|drug
DDI-DrugBank.d314.s11|58-73|corticosteroids|group
DDI-DrugBank.d314.s13|31-37|(DST):|brand
DDI-DrugBank.d314.s13|99-104|(DST)|brand
DDI-DrugBank.d314.s13|117-122|being|drug
DDI-DrugBank.d314.s13|136-148|indomethacin|drug
DDI-DrugBank.d314.s14|35-46|interpreted|drug
DDI-DrugBank.d314.s15|65-74|increased|drug
DDI-DrugBank.d314.s16|0-10|Ephedrine:|drug
DDI-DrugBank.d314.s16|11-20|Ephedrine|drug
DDI-DrugBank.d314.s16|60-76|corticosteroids,|group
DDI-DrugBank.d314.s16|77-86|resulting|drug
DDI-DrugBank.d314.s16|153-162|requiring|drug
DDI-DrugBank.d314.s16|166-174|increase|drug
DDI-DrugBank.d314.s17|11-20|including|drug
DDI-DrugBank.d314.s17|26-41|contraceptives:|group
DDI-DrugBank.d314.s17|91-98|certain|drug
DDI-DrugBank.d314.s17|99-115|corticosteroids,|group
DDI-DrugBank.d314.s17|124-134|increasing|drug
DDI-DrugBank.d314.s18|64-70|induce|drug
DDI-DrugBank.d314.s18|138-148|phenytoin,|drug
DDI-DrugBank.d314.s18|149-163|carbamazepine,|drug
DDI-DrugBank.d314.s18|164-173|rifampin)|drug
DDI-DrugBank.d314.s18|204-219|corticosteroids|group
DDI-DrugBank.d314.s18|273-283|increased.|drug
DDI-DrugBank.d314.s19|12-19|inhibit|drug
DDI-DrugBank.d314.s19|35-48|ketoconazole,|drug
DDI-DrugBank.d314.s19|49-58|macrolide|drug
DDI-DrugBank.d314.s19|59-70|antibiotics|group
DDI-DrugBank.d314.s19|79-92|erythromycin)|drug
DDI-DrugBank.d314.s19|125-134|increased|drug
DDI-DrugBank.d314.s19|160-176|corticosteroids.|group
DDI-DrugBank.d314.s20|28-35|inducer|drug
DDI-DrugBank.d314.s21|0-17|Co-administration|drug
DDI-DrugBank.d314.s21|74-84|indinavir,|drug
DDI-DrugBank.d314.s21|85-98|erythromycin)|drug
DDI-DrugBank.d314.s21|103-111|increase|drug
DDI-DrugBank.d314.s21|129-138|resulting|drug
DDI-DrugBank.d314.s22|0-13|Ketoconazole:|drug
DDI-DrugBank.d314.s22|14-26|Ketoconazole|drug
DDI-DrugBank.d314.s22|75-82|certain|drug
DDI-DrugBank.d314.s22|83-98|corticosteroids|group
DDI-DrugBank.d314.s22|113-120|leading|drug
DDI-DrugBank.d314.s22|124-133|increased|drug
DDI-DrugBank.d314.s23|13-25|ketoconazole|drug
DDI-DrugBank.d314.s23|36-43|inhibit|drug
DDI-DrugBank.d314.s23|99-112|insufficiency|drug
DDI-DrugBank.d314.s23|113-119|during|drug
DDI-DrugBank.d314.s24|13-30|anti-inflammatory|group
DDI-DrugBank.d314.s24|38-47|(NSAIDS):|brand
DDI-DrugBank.d314.s24|67-74|aspirin|brand
DDI-DrugBank.d314.s24|98-114|antiinflammatory|group
DDI-DrugBank.d314.s24|127-142|corticosteroids|group
DDI-DrugBank.d314.s24|143-152|increases|drug
DDI-DrugBank.d314.s24|165-181|gastrointestinal|drug
DDI-DrugBank.d314.s25|0-7|Aspirin|brand
DDI-DrugBank.d314.s25|54-69|corticosteroids|group
DDI-DrugBank.d314.s25|73-93|hypoprothrombinemia.|drug
DDI-DrugBank.d314.s26|36-45|increased|drug
DDI-DrugBank.d314.s26|69-85|corticosteroids.|group
DDI-DrugBank.d314.s27|0-10|Phenytoin:|drug
DDI-DrugBank.d314.s27|14-28|post-marketing|drug
DDI-DrugBank.d314.s27|73-82|increases|drug
DDI-DrugBank.d314.s27|100-109|phenytoin|drug
DDI-DrugBank.d314.s27|136-154|co-administration,|drug
DDI-DrugBank.d314.s27|155-162|leading|drug
DDI-DrugBank.d314.s27|181-188|seizure|group
DDI-DrugBank.d314.s27|189-197|control.|group
DDI-DrugBank.d314.s28|12-27|Corticosteroids|group
DDI-DrugBank.d314.s29|13-30|Co-administration|drug
DDI-DrugBank.d314.s29|36-47|thalidomide|drug
DDI-DrugBank.d314.s30|0-9|Vaccines:|drug
DDI-DrugBank.d314.s30|59-69|diminished|drug
DDI-DrugBank.d314.s30|82-89|toxoids|group
DDI-DrugBank.d314.s30|102-113|inactivated|drug
DDI-DrugBank.d314.s30|114-122|vaccines|drug
DDI-DrugBank.d314.s30|130-140|inhibition|drug
DDI-DrugBank.d314.s30|144-152|antibody|group
DDI-DrugBank.d314.s31|0-15|Corticosteroids|group
DDI-DrugBank.d314.s31|70-79|contained|group
DDI-DrugBank.d314.s31|99-108|vaccines.|drug
DDI-DrugBank.d314.s32|0-7|Routine|drug
DDI-DrugBank.d314.s32|8-22|administration|drug
DDI-DrugBank.d314.s32|26-34|vaccines|drug
DDI-DrugBank.d314.s32|38-45|toxoids|group
DDI-DrugBank.d314.s32|97-109|discontinued|group
DDI-DrugBank.d118.s0|69-79|containing|group
DDI-DrugBank.d118.s0|106-118|latanoprost.|drug
DDI-DrugBank.d118.s1|38-50|administered|drug
DDI-DrugBank.d118.s1|59-67|interval|drug
DDI-DrugBank.d118.s1|82-89|minutes|drug
DDI-DrugBank.d491.s0|10-21|interaction|drug
DDI-DrugBank.d491.s1|27-36|following|drug
DDI-DrugBank.d491.s1|52-59|AMEVIVE|brand
DDI-DrugBank.d491.s1|88-96|starting|drug
DDI-DrugBank.d491.s2|0-15|Carcinogenesis,|drug
DDI-DrugBank.d491.s3|84-95|intravenous|drug
DDI-DrugBank.d491.s4|98-105|dosing.|drug
DDI-DrugBank.d491.s6|112-118|(LCV).|brand
DDI-DrugBank.d491.s7|11-20|infection|drug
DDI-DrugBank.d491.s8|159-167|germinal|drug
DDI-DrugBank.d491.s8|190-199|following|drug
DDI-DrugBank.d491.s8|202-209|116-day|drug_n
DDI-DrugBank.d491.s9|12-19|AMEVIVE|brand
DDI-DrugBank.d491.s10|193-202|including|drug
DDI-DrugBank.d491.s10|209-218|resulting|drug
DDI-DrugBank.d491.s11|3-18|carcinogenicity|drug
DDI-DrugBank.d491.s15|9-21|childbearing|drug
DDI-DrugBank.d491.s16|0-5|Since|drug
DDI-DrugBank.d491.s16|20-27|AMEVIVE|brand
DDI-DrugBank.d491.s16|64-73|including|drug
DDI-DrugBank.d491.s16|181-187|taking|drug
DDI-DrugBank.d491.s16|188-195|AMEVIVE|brand
DDI-DrugBank.d491.s16|254-261|calling|drug
DDI-DrugBank.d491.s16|262-275|1-866-AMEVIVE|brand
DDI-DrugBank.d491.s17|235-243|AMEVIVE.|brand
DDI-DrugBank.d491.s18|76-85|following|drug
DDI-DrugBank.d491.s18|86-97|intravenous|drug
DDI-DrugBank.d491.s18|104-114|injections|drug
DDI-DrugBank.d491.s18|118-125|AMEVIVE|brand
DDI-DrugBank.d491.s18|126-138|administered|drug
DDI-DrugBank.d491.s18|146-152|during|drug
DDI-DrugBank.d491.s18|167-180|organogenesis|drug
DDI-DrugBank.d491.s19|0-7|AMEVIVE|brand
DDI-DrugBank.d491.s19|64-72|exposure|group
DDI-DrugBank.d491.s19|80-90|developing|drug
DDI-DrugBank.d491.s20|26-34|exposure|group
DDI-DrugBank.d491.s21|30-39|including|drug
DDI-DrugBank.d491.s22|112-127|well-controlled|group
DDI-DrugBank.d491.s23|115-122|AMEVIVE|brand
DDI-DrugBank.d491.s23|139-145|during|drug
DDI-DrugBank.d491.s24|26-32|taking|drug
DDI-DrugBank.d491.s24|33-41|AMEVIVE,|brand
DDI-DrugBank.d491.s24|42-51|continued|group
DDI-DrugBank.d491.s25|0-7|Nursing|drug
DDI-DrugBank.d491.s26|24-31|AMEVIVE|brand
DDI-DrugBank.d491.s27|119-126|nursing|drug
DDI-DrugBank.d491.s27|127-134|infants|drug
DDI-DrugBank.d491.s27|140-148|AMEVIVE,|brand
DDI-DrugBank.d491.s27|186-197|discontinue|group
DDI-DrugBank.d491.s27|198-205|nursing|drug
DDI-DrugBank.d491.s27|212-218|taking|drug
DDI-DrugBank.d491.s27|234-245|discontinue|group
DDI-DrugBank.d491.s27|267-273|taking|drug
DDI-DrugBank.d491.s29|34-41|AMEVIVE|brand
DDI-DrugBank.d491.s29|45-53|clinical|drug
DDI-DrugBank.d491.s33|12-21|incidence|drug
DDI-DrugBank.d491.s33|25-35|infections|drug
DDI-DrugBank.d491.s33|40-47|certain|drug
DDI-DrugBank.d491.s33|136-144|treating|drug
DDI-DrugBank.d491.s35|27-34|AMEVIVE|brand
DDI-DrugBank.d491.s36|0-7|AMEVIVE|brand
DDI-DrugBank.d491.s36|15-24|indicated|drug
DDI-DrugBank.d137.s0|57-69|short-acting|drug
DDI-DrugBank.d137.s0|95-104|tolerated|drug
DDI-DrugBank.d137.s0|129-135|angina|drug
DDI-DrugBank.d137.s1|0-10|Sublingual|drug
DDI-DrugBank.d137.s1|11-24|nitroglycerin|drug
DDI-DrugBank.d137.s1|59-66|control|group
DDI-DrugBank.d137.s1|76-82|angina|drug
DDI-DrugBank.d137.s1|91-97|during|drug
DDI-DrugBank.d137.s2|0-13|Beta-blocking|drug
DDI-DrugBank.d137.s2|58-71|beta-blocking|drug
DDI-DrugBank.d137.s2|93-102|tolerated|drug
DDI-DrugBank.d137.s2|127-134|angina.|drug
DDI-DrugBank.d137.s4|0-8|Digoxin:|drug
DDI-DrugBank.d137.s4|12-22|controlled|group
DDI-DrugBank.d137.s4|63-76|hydrochloride|drug
DDI-DrugBank.d137.s4|140-150|increases,|drug
DDI-DrugBank.d137.s4|197-204|digoxin|drug
DDI-DrugBank.d137.s5|8-16|clinical|drug
DDI-DrugBank.d137.s5|25-31|angina|drug
DDI-DrugBank.d137.s5|41-50|receiving|drug
DDI-DrugBank.d137.s5|72-85|hydrochloride|drug
DDI-DrugBank.d137.s5|90-97|digoxin|drug
DDI-DrugBank.d137.s5|106-114|indicate|drug
DDI-DrugBank.d137.s5|147-154|digoxin|drug
DDI-DrugBank.d137.s6|59-68|increases|drug
DDI-DrugBank.d137.s6|78-85|digoxin|drug
DDI-DrugBank.d137.s6|150-163|interactions,|drug
DDI-DrugBank.d137.s6|237-245|WARNINGS|brand
DDI-DrugBank.d137.s6|263-272|Failure).|group
DDI-DrugBank.d137.s7|93-101|lowering|drug
DDI-DrugBank.d137.s7|132-140|altering|drug
DDI-DrugBank.d137.s7|156-163|insulin|drug
DDI-DrugBank.d137.s8|22-29|Certain|drug
DDI-DrugBank.d137.s8|42-50|increase|drug
DDI-DrugBank.d137.s8|119-133|hydrochloride.|drug
DDI-DrugBank.d137.s9|95-109|hydrochloride,|drug
DDI-DrugBank.d137.s9|110-119|including|drug
DDI-DrugBank.d137.s9|120-135|anti-arrhythmic|group
DDI-DrugBank.d137.s9|151-160|quinidine|drug
DDI-DrugBank.d137.s9|165-178|procainamide,|drug
DDI-DrugBank.d137.s9|212-229|anti-depressants.|group
DDI-DrugBank.d137.s10|31-47|anti-depressants|group
DDI-DrugBank.d137.s10|92-100|interval|drug
DDI-DrugBank.d137.s10|124-138|hydrochloride.|drug
DDI-DrugBank.d137.s11|97-111|hydrochloride.|drug
DDI-DrugBank.d9.s0|0-10|Azlocillin|drug
DDI-DrugBank.d9.s0|25-37|administered|drug
DDI-DrugBank.d9.s0|57-66|amikacin,|drug
DDI-DrugBank.d9.s0|67-81|ciprofloxacin,|drug
DDI-DrugBank.d9.s0|82-93|gentamicin,|drug
DDI-DrugBank.d9.s0|94-105|netilmicin,|drug
DDI-DrugBank.d9.s0|109-120|tobramycin.|drug
DDI-DrugBank.d274.s0|15-23|indicate|drug
DDI-DrugBank.d274.s0|29-39|dobutamine|drug
DDI-DrugBank.d274.s0|47-58|ineffective|drug
DDI-DrugBank.d274.s0|98-108|b-blocking|drug
DDI-DrugBank.d274.s1|55-64|increase.|drug
DDI-DrugBank.d274.s2|0-11|Preliminary|drug
DDI-DrugBank.d274.s2|20-28|indicate|drug
DDI-DrugBank.d274.s2|57-67|dobutamine|drug
DDI-DrugBank.d274.s2|72-85|nitroprusside|drug
DDI-DrugBank.d274.s2|159-167|pressure|group
DDI-DrugBank.d274.s3|30-42|interactions|drug
DDI-DrugBank.d274.s3|46-54|clinical|drug
DDI-DrugBank.d274.s3|72-82|dobutamine|drug
DDI-DrugBank.d274.s3|87-99|administered|drug
DDI-DrugBank.d274.s3|131-140|including|drug
DDI-DrugBank.d274.s3|193-203|lidocaine,|drug
DDI-DrugBank.d274.s3|213-224|trinitrate,|drug
DDI-DrugBank.d274.s3|225-235|isosorbide|drug
DDI-DrugBank.d274.s3|236-246|dinitrate,|drug
DDI-DrugBank.d274.s3|247-256|morphine,|drug
DDI-DrugBank.d274.s3|257-266|atropine,|drug
DDI-DrugBank.d274.s3|267-275|heparin,|drug
DDI-DrugBank.d274.s3|276-286|protamine,|drug
DDI-DrugBank.d274.s3|287-296|potassium|drug
DDI-DrugBank.d274.s3|323-337|acetaminophen.|drug
DDI-DrugBank.d469.s0|42-50|blocking|drug
DDI-DrugBank.d469.s0|61-69|TRACRIUM|brand
DDI-DrugBank.d469.s0|70-78|include:|drug
DDI-DrugBank.d469.s3|0-7|certain|drug
DDI-DrugBank.d469.s3|8-20|antibiotics,|group
DDI-DrugBank.d469.s3|36-51|aminoglycosides|drug
DDI-DrugBank.d469.s3|56-67|polymyxins;|drug
DDI-DrugBank.d469.s4|0-8|lithium;|drug
DDI-DrugBank.d469.s5|0-9|magnesium|drug
DDI-DrugBank.d469.s6|0-13|procainamide;|drug
DDI-DrugBank.d469.s7|42-50|blocking|drug
DDI-DrugBank.d469.s7|61-69|TRACRIUM|brand
DDI-DrugBank.d469.s7|70-78|include:|drug
DDI-DrugBank.d469.s7|79-117|enflurane;isoflurane;halothane;certain|drug
DDI-DrugBank.d469.s7|118-130|antibiotics,|group
DDI-DrugBank.d469.s7|146-161|aminoglycosides|drug
DDI-DrugBank.d469.s7|166-194|polymyxins;lithium;magnesium|drug
DDI-DrugBank.d469.s7|195-217|salts;procainamide;and|drug
DDI-DrugBank.d469.s7|218-228|quinidine.|drug
DDI-DrugBank.d469.s8|35-41|during|drug
DDI-DrugBank.d469.s8|51-61|procedure,|group
DDI-DrugBank.d469.s9|10-24|administration|drug
DDI-DrugBank.d469.s9|28-43|succinylcholine|drug
DDI-DrugBank.d469.s9|106-114|increase|drug
DDI-DrugBank.d469.s9|149-156|induced|drug
DDI-DrugBank.d469.s9|160-169|TRACRIUM.|brand
DDI-DrugBank.d469.s10|0-8|TRACRIUM|brand
DDI-DrugBank.d469.s10|23-35|administered|drug
DDI-DrugBank.d469.s10|71-94|succinylcholine-induced|drug
DDI-DrugBank.d464.s0|0-7|Codeine|drug
DDI-DrugBank.d464.s0|11-22|combination|drug
DDI-DrugBank.d464.s0|76-91|phenothiazines,|drug
DDI-DrugBank.d464.s0|152-162|(including|drug
DDI-DrugBank.d464.s2|0-11|combination|drug
DDI-DrugBank.d464.s2|23-36|contemplated,|group
DDI-DrugBank.d231.s0|0-10|Furosemide|drug
DDI-DrugBank.d231.s0|15-23|increase|drug
DDI-DrugBank.d231.s0|50-64|aminoglycoside|drug
DDI-DrugBank.d231.s0|65-77|antibiotics,|group
DDI-DrugBank.d231.s1|10-26|life-threatening|drug
DDI-DrugBank.d231.s1|50-62|combination.|drug
DDI-DrugBank.d231.s2|0-10|Furosemide|drug
DDI-DrugBank.d231.s3|9-18|receiving|drug
DDI-DrugBank.d231.s4|0-10|Furosemide|drug
DDI-DrugBank.d231.s4|60-68|relaxing|drug
DDI-DrugBank.d231.s4|79-91|tubocurarine|drug
DDI-DrugBank.d231.s4|125-141|succinylcholine.|drug
DDI-DrugBank.d231.s5|0-7|Lithium|drug
DDI-DrugBank.d231.s5|43-52|diuretics|group
DDI-DrugBank.d231.s5|73-81|lithiums|drug
DDI-DrugBank.d231.s5|121-128|lithium|drug
DDI-DrugBank.d231.s6|0-10|Furosemide|drug
DDI-DrugBank.d231.s6|68-84|antihypertensive|group
DDI-DrugBank.d231.s7|61-69|blocking|drug
DDI-DrugBank.d231.s8|0-10|Furosemide|drug
DDI-DrugBank.d231.s8|51-66|norepinephrine.|drug
DDI-DrugBank.d231.s9|9-23|norepinephrine|drug
DDI-DrugBank.d231.s10|21-35|administration|drug
DDI-DrugBank.d231.s10|54-64|furosemide|drug
DDI-DrugBank.d231.s10|88-99|natriuretic|group
DDI-DrugBank.d231.s10|104-120|antihypertensive|group
DDI-DrugBank.d231.s11|9-18|receiving|drug
DDI-DrugBank.d231.s11|60-69|determine|drug
DDI-DrugBank.d231.s11|85-93|diuretic|group
DDI-DrugBank.d231.s11|101-117|antihypertensive|group
DDI-DrugBank.d231.s11|128-138|furosemide|drug
DDI-DrugBank.d231.s12|4-10|intake|drug
DDI-DrugBank.d231.s12|14-24|furosemide|drug
DDI-DrugBank.d231.s13|86-97|combination|drug
DDI-DrugBank.d231.s13|101-111|furosemide|drug
DDI-DrugBank.d231.s13|157-167|creatinine|drug
DDI-DrugBank.d231.s13|209-223|insufficiency.|drug
DDI-DrugBank.d231.s14|49-58|increased|drug
DDI-DrugBank.d231.s14|70-80|creatinine|drug
DDI-DrugBank.d231.s14|91-100|potassium|drug
DDI-DrugBank.d231.s14|130-140|furosemide|drug
DDI-DrugBank.d231.s15|0-10|Literature|group
DDI-DrugBank.d231.s15|19-27|indicate|drug
DDI-DrugBank.d231.s15|33-49|coadministration|drug
DDI-DrugBank.d231.s15|53-65|indomethacin|drug
DDI-DrugBank.d231.s15|81-92|natriuretic|group
DDI-DrugBank.d231.s15|97-113|antihypertensive|group
DDI-DrugBank.d231.s15|125-135|furosemide|drug
DDI-DrugBank.d231.s15|156-166|inhibiting|drug
DDI-DrugBank.d231.s15|167-180|prostaglandin|drug
DDI-DrugBank.d231.s16|0-12|Indomethacin|drug
DDI-DrugBank.d231.s16|36-41|renin|drug
DDI-DrugBank.d231.s16|77-82|renin|drug
DDI-DrugBank.d231.s17|9-18|receiving|drug
DDI-DrugBank.d231.s17|24-36|indomethacin|drug
DDI-DrugBank.d231.s17|41-51|furosemide|drug
DDI-DrugBank.d231.s17|82-91|determine|drug
DDI-DrugBank.d231.s17|107-115|diuretic|group
DDI-DrugBank.d231.s17|123-139|antihypertensive|group
DDI-DrugBank.d231.s17|150-160|furosemide|drug
DDI-DrugBank.d193.s0|7-18|interaction|drug
DDI-DrugBank.d193.s0|48-55|ERBITUX|brand
DDI-DrugBank.d193.s0|60-72|administered|drug
DDI-DrugBank.d193.s0|76-87|combination|drug
DDI-DrugBank.d193.s0|93-104|irinotecan.|drug
DDI-DrugBank.d193.s1|29-44|pharmacokinetic|drug
DDI-DrugBank.d193.s1|45-57|interactions|drug
DDI-DrugBank.d193.s1|66-73|ERBITUX|brand
DDI-DrugBank.d193.s1|78-89|irinotecan.|drug
DDI-MedLine.d97.s0|61-77|trypanosomiasis,|drug
DDI-MedLine.d97.s0|86-96|1992-1993]|drug_n
DDI-MedLine.d97.s0|98-103|Since|drug
DDI-MedLine.d97.s0|104-109|1988,|drug_n
DDI-MedLine.d97.s0|154-160|decins|drug
DDI-MedLine.d97.s0|181-188|running|drug
DDI-MedLine.d97.s0|191-198|control|group
DDI-MedLine.d97.s0|224-239|trypanosomiasis|drug
DDI-MedLine.d97.s1|17-22|1993,|drug_n
DDI-MedLine.d97.s1|33-38|7,000|drug_n
DDI-MedLine.d97.s2|0-5|Since|drug
DDI-MedLine.d97.s2|6-11|1988,|drug_n
DDI-MedLine.d97.s2|35-44|incidence|drug
DDI-MedLine.d97.s2|73-82|increased|drug
DDI-MedLine.d97.s2|137-147|indicating|drug
DDI-MedLine.d97.s3|12-17|1993,|drug_n
DDI-MedLine.d97.s3|69-74|(ARE)|brand
DDI-MedLine.d97.s3|91-99|sleeping|drug
DDI-MedLine.d97.s4|4-13|incidence|drug
DDI-MedLine.d97.s4|82-88|during|drug
DDI-MedLine.d97.s4|115-120|1993.|drug_n
DDI-MedLine.d97.s8|46-54|increase|drug
DDI-MedLine.d97.s8|92-105|thiabendazole|drug
DDI-MedLine.d97.s8|132-138|during|drug
DDI-MedLine.d97.s8|180-188|clinical|drug
DDI-MedLine.d97.s9|62-70|involved|drug
DDI-MedLine.d97.s10|30-44|administration|drug
DDI-MedLine.d97.s10|59-74|anti-helminthic|group
DDI-MedLine.d97.s10|85-91|during|drug
DDI-MedLine.d97.s10|96-101|cure,|group
DDI-DrugBank.d388.s0|0-23|Catecholamine-depleting|drug
DDI-DrugBank.d388.s0|39-49|reserpine,|drug
DDI-DrugBank.d388.s0|94-107|beta-blocking|drug
DDI-DrugBank.d388.s1|38-51|catecholamine|drug
DDI-DrugBank.d388.s1|233-241|pressure|group
DDI-DrugBank.d388.s2|63-71|combined|drug
DDI-DrugBank.d388.s2|140-149|including|drug
DDI-DrugBank.d388.s2|156-165|contained|group
DDI-DrugBank.d388.s3|9-18|receiving|drug
DDI-DrugBank.d388.s4|0-8|Blunting|drug
DDI-DrugBank.d388.s4|16-32|antihypertensive|group
DDI-DrugBank.d388.s4|61-69|blocking|drug
DDI-DrugBank.d388.s4|93-110|anti-inflammatory|group
DDI-DrugBank.d388.s5|15-27|interactions|drug
DDI-DrugBank.d388.s5|33-41|digoxin,|drug
DDI-DrugBank.d388.s5|42-62|hydrochlorothiazide,|group
DDI-DrugBank.d388.s5|63-75|hydralazine,|drug
DDI-DrugBank.d388.s5|76-91|sulfinpyrazone,|drug
DDI-DrugBank.d388.s5|97-112|contraceptives,|group
DDI-DrugBank.d388.s5|129-137|warfarin|drug
DDI-MedLine.d14.s0|45-56|angiotensin|drug
DDI-MedLine.d14.s0|171-180|influence|drug
DDI-MedLine.d14.s0|184-195|angiotensin|drug
DDI-MedLine.d14.s0|202-213|angiotensin|drug
DDI-MedLine.d14.s0|219-232|pentagastrin-|drug
DDI-MedLine.d14.s0|237-254|histamine-induced|drug
DDI-MedLine.d14.s1|29-41|angiotensins|drug
DDI-MedLine.d14.s1|42-51|inhibited|drug
DDI-MedLine.d14.s1|89-101|pentagastrin|drug
DDI-MedLine.d14.s1|113-123|histamine.|drug
DDI-MedLine.d14.s2|55-65|inhibition|drug
DDI-MedLine.d14.s2|69-77|cholino-|drug
DDI-MedLine.d14.s2|106-116|inhibitory|drug
DDI-MedLine.d14.s2|127-139|angiotensins|drug
DDI-MedLine.d14.s2|167-178|angiotensin|drug
DDI-MedLine.d14.s2|179-188|influence|drug
DDI-MedLine.d14.s2|215-226|cholinergic|drug
DDI-MedLine.d85.s0|0-12|Misonidazole|drug
DDI-MedLine.d85.s0|80-85|CCNU.|brand
DDI-MedLine.d85.s1|12-23|nitrosourea|group
DDI-MedLine.d85.s1|119-129|antitumour|group
DDI-MedLine.d85.s1|159-175|pharmacokinetics|drug
DDI-MedLine.d85.s1|184-189|CCNU,|brand
DDI-MedLine.d85.s1|209-220|combination|drug
DDI-MedLine.d85.s1|246-259|misonidazole.|drug
DDI-MedLine.d85.s3|14-26|nitrosoureas|group
DDI-MedLine.d85.s3|38-45|1.4-1.5|drug_n
DDI-MedLine.d85.s5|64-74|antitumour|group
DDI-MedLine.d85.s6|3-12|contrast,|group
DDI-MedLine.d85.s6|113-126|dose-limiting|drug
DDI-MedLine.d85.s7|0-12|Misonidazole|drug
DDI-MedLine.d85.s7|25-35|antitumour|group
DDI-MedLine.d85.s7|66-75|modifying|drug
DDI-MedLine.d85.s7|84-89|(DMF)|brand
DDI-MedLine.d85.s7|93-103|0.58-0.71.|drug_n
DDI-MedLine.d85.s8|39-49|diminished|drug
DDI-MedLine.d85.s8|62-67|0.74.|drug_n
DDI-MedLine.d85.s9|0-12|Misonidazole|drug
DDI-MedLine.d85.s9|47-64|pharmacokinetics.|drug
DDI-MedLine.d85.s10|28-39|nitrosourea|group
DDI-MedLine.d85.s11|0-12|Misonidazole|drug
DDI-MedLine.d85.s12|0-11|nitrosourea|group
DDI-MedLine.d85.s12|50-59|depending|drug
DDI-MedLine.d85.s12|67-74|minimum|drug
DDI-MedLine.d85.s12|99-104|(MEC)|brand
DDI-MedLine.d85.s13|24-35|nitrosourea|group
DDI-MedLine.d85.s14|17-32|pharmacokinetic|drug
DDI-MedLine.d85.s14|51-61|underlying|drug
DDI-MedLine.d85.s14|119-132|misonidazole.|drug
DDI-MedLine.d85.s15|0-8|Clinical|drug
DDI-MedLine.d85.s15|24-36|combinations|drug
DDI-MedLine.d85.s15|71-86|pharmacokinetic|drug
DDI-DrugBank.d95.s0|0-12|Cyclosporine|drug
DDI-DrugBank.d95.s0|15-25|L-arginine|drug
DDI-DrugBank.d95.s0|45-58|antinaturetic|group
DDI-DrugBank.d95.s0|69-81|cyclosporin.|drug
DDI-DrugBank.d95.s1|12-22|L-arginine|drug
DDI-DrugBank.d95.s1|27-35|increase|drug
DDI-DrugBank.d95.s2|19-29|L-arginine|drug
DDI-DrugBank.d95.s3|36-46|L-arginine|drug
DDI-DrugBank.d155.s0|3-14|information|drug
DDI-DrugBank.d28.s0|21-29|COPAXONE|brand
DDI-DrugBank.d28.s1|13-21|existing|drug
DDI-DrugBank.d28.s1|22-30|clinical|drug
DDI-DrugBank.d28.s1|61-73|interactions|drug
DDI-DrugBank.d28.s1|82-90|COPAXONE|brand
DDI-DrugBank.d28.s1|142-151|including|drug
DDI-DrugBank.d28.s1|174-189|corticosteroids|group
DDI-DrugBank.d28.s2|0-8|COPAXONE|brand
DDI-DrugBank.d28.s2|45-56|combination|drug
DDI-DrugBank.d28.s3|71-79|COPAXONE|brand
DDI-MedLine.d76.s0|72-81|enhancing|drug
DDI-MedLine.d76.s0|92-99|peptide|drug
DDI-MedLine.d76.s1|56-62|sodium|drug
DDI-MedLine.d76.s1|86-93|(NaCMC)|drug_n
DDI-MedLine.d76.s1|98-129|carboxymethylcellulose-cysteine|drug
DDI-MedLine.d76.s1|130-139|(CMC-Cys)|drug_n
DDI-MedLine.d76.s1|158-168|intestinal|drug
DDI-MedLine.d76.s1|183-189|sodium|drug
DDI-MedLine.d76.s1|190-201|fluorescein|drug
DDI-MedLine.d76.s1|220-227|peptide|drug
DDI-MedLine.d76.s1|235-245|bacitracin|drug
DDI-MedLine.d76.s1|250-258|insulin.|drug
DDI-MedLine.d76.s2|0-8|Cysteine|drug
DDI-MedLine.d76.s2|24-30|linked|drug
DDI-MedLine.d76.s2|34-46|carbodiimide|drug
DDI-MedLine.d76.s2|57-63|NaCMC.|drug_n
DDI-MedLine.d76.s3|59-68|determine|drug
DDI-MedLine.d76.s3|95-104|cysteine.|drug
DDI-MedLine.d76.s4|37-43|guinea|drug
DDI-MedLine.d76.s4|54-64|intestinal|drug
DDI-MedLine.d76.s4|83-94|Ussing-type|drug
DDI-MedLine.d76.s5|11-16|NaCMC|drug_n
DDI-MedLine.d76.s5|96-104|control)|group
DDI-MedLine.d76.s5|134-139|NaCMC|drug_n
DDI-MedLine.d76.s5|156-164|cysteine|drug
DDI-MedLine.d76.s6|0-8|Cysteine|drug
DDI-MedLine.d76.s7|0-10|Decreasing|drug
DDI-MedLine.d76.s7|32-40|CMC-Cys,|drug_n
DDI-MedLine.d76.s7|41-51|exhibiting|drug
DDI-MedLine.d76.s7|78-86|cysteine|drug
DDI-MedLine.d76.s7|87-99|(CMC-Cys7.3)|drug_n
DDI-MedLine.d76.s8|0-5|NaCMC|drug_n
DDI-MedLine.d76.s8|42-50|cysteine|drug
DDI-MedLine.d76.s8|113-118|NaCMC|drug_n
DDI-MedLine.d76.s9|37-47|bacitracin|drug
DDI-MedLine.d76.s9|52-59|insulin|drug
DDI-MedLine.d76.s9|76-81|NaCMC|drug_n
DDI-MedLine.d76.s9|173-183|CMC-Cys7.3|drug_n
DDI-MedLine.d76.s9|237-242|1.3).|drug_n
DDI-MedLine.d76.s10|15-20|NaCMC|drug_n
DDI-MedLine.d76.s10|26-34|cysteine|drug
DDI-MedLine.d76.s10|71-81|intestinal|drug
DDI-MedLine.d76.s10|100-111|hydrophilic|drug
DDI-MedLine.d76.s10|112-120|molecule|drug
DDI-MedLine.d76.s10|141-148|peptide|drug
DDI-MedLine.d76.s10|155-165|bacitracin|drug
DDI-MedLine.d76.s10|170-177|insulin|drug
DDI-MedLine.d76.s10|246-260|administration|drug
DDI-MedLine.d76.s10|264-271|peptide|drug
DDI-MedLine.d76.s10|285-292|future.|group
DDI-DrugBank.d100.s0|43-52|following|drug
DDI-DrugBank.d100.s0|65-79|administration|drug
DDI-DrugBank.d100.s0|83-97|cephalosporins|drug
DDI-DrugBank.d100.s0|102-116|aminoglycoside|drug
DDI-DrugBank.d100.s0|117-129|antibiotics.|group
DDI-DrugBank.d100.s1|34-49|Cephalosporins,|drug
DDI-DrugBank.d100.s1|50-59|including|drug
DDI-DrugBank.d100.s1|71-78|sodium,|drug
DDI-DrugBank.d100.s1|105-111|induce|drug
DDI-DrugBank.d445.s0|3-13|clinically|drug
DDI-DrugBank.d445.s0|33-45|interactions|drug
DDI-DrugBank.d445.s0|89-104|co-administered|drug
DDI-DrugBank.d445.s0|110-124|anidulafungin.|drug
DDI-MedLine.d74.s0|13-21|arginine|drug
DDI-MedLine.d74.s0|75-82|Chinese|drug
DDI-MedLine.d74.s1|33-39|Cinese|drug
DDI-MedLine.d74.s1|75-82|insulin|drug
DDI-MedLine.d74.s2|57-64|insulin|drug
DDI-MedLine.d74.s2|90-98|measured|group
DDI-MedLine.d74.s2|160-167|Chinese|drug
DDI-MedLine.d74.s2|200-212|combinations|drug
DDI-MedLine.d74.s2|216-224|arginine|drug
DDI-MedLine.d74.s2|275-287|theophylline|drug
DDI-MedLine.d74.s3|0-12|Theophylline|drug
DDI-MedLine.d74.s3|36-43|insulin|drug
DDI-MedLine.d74.s4|38-51|theophylline,|drug
DDI-MedLine.d74.s4|69-76|insulin|drug
DDI-MedLine.d74.s5|0-9|Arginine,|drug
DDI-MedLine.d74.s5|41-54|theophylline,|drug
DDI-MedLine.d74.s5|107-114|insulin|drug
DDI-MedLine.d74.s6|0-9|Arginine,|drug
DDI-MedLine.d74.s6|39-52|theophylline,|drug
DDI-MedLine.d74.s6|121-128|insulin|drug
DDI-MedLine.d74.s7|11-18|content|group
DDI-MedLine.d74.s7|66-72|during|drug
DDI-MedLine.d74.s8|12-20|arginine|drug
DDI-MedLine.d74.s8|83-90|insulin|drug
DDI-MedLine.d74.s9|14-22|indicate|drug
DDI-MedLine.d74.s9|70-77|Chinese|drug
DDI-MedLine.d74.s9|110-119|arginine,|drug
DDI-MedLine.d74.s10|36-43|insulin|drug
DDI-MedLine.d74.s11|49-56|Chinese|drug
DDI-MedLine.d74.s11|108-121|theophylline,|drug
DDI-MedLine.d74.s11|141-152|insensitive|drug
DDI-DrugBank.d391.s0|12-23|information|drug
DDI-DrugBank.d301.s2|12-23|prothrombin|drug
DDI-DrugBank.d301.s2|38-52|thromboplastin|drug
DDI-DrugBank.d301.s3|0-9|increased|drug
DDI-DrugBank.d301.s4|0-9|increased|drug
DDI-DrugBank.d301.s4|26-34|antigen,|group
DDI-DrugBank.d301.s4|40-48|antigen,|group
DDI-DrugBank.d301.s4|86-91|VII-X|brand
DDI-DrugBank.d301.s4|101-109|II-VII-X|brand
DDI-DrugBank.d301.s4|123-144|beta-thromboglobulin;|drug
DDI-DrugBank.d301.s5|20-31|anti-factor|group
DDI-DrugBank.d301.s5|39-51|antithrombin|group
DDI-DrugBank.d301.s5|67-79|antithrombin|group
DDI-DrugBank.d301.s6|0-9|increased|drug
DDI-DrugBank.d301.s6|20-30|fibrinogen|drug
DDI-DrugBank.d301.s6|35-45|fibrinogen|drug
DDI-DrugBank.d301.s7|0-9|increased|drug
DDI-DrugBank.d301.s7|10-21|plasminogen|drug
DDI-DrugBank.d301.s7|22-29|antigen|group
DDI-DrugBank.d301.s9|10-25|thyroid-binding|drug
DDI-DrugBank.d301.s9|26-34|globulin|drug
DDI-DrugBank.d301.s9|35-40|(TBG)|brand
DDI-DrugBank.d301.s9|41-48|leading|drug
DDI-DrugBank.d301.s9|52-61|increased|drug
DDI-DrugBank.d301.s9|62-73|circulating|drug
DDI-DrugBank.d301.s9|107-115|measured|group
DDI-DrugBank.d301.s9|119-132|protein-bound|drug
DDI-DrugBank.d301.s9|133-139|iodine|drug
DDI-DrugBank.d301.s9|140-146|(PBI),|brand
DDI-DrugBank.d301.s10|3-8|resin|drug
DDI-DrugBank.d301.s10|30-40|reflecting|drug
DDI-DrugBank.d301.s14|6-13|binding|drug
DDI-DrugBank.d301.s14|14-22|proteins|drug
DDI-DrugBank.d301.s14|70-77|binding|drug
DDI-DrugBank.d301.s14|78-86|globulin|drug
DDI-DrugBank.d301.s14|87-93|(CBG),|brand
DDI-DrugBank.d301.s14|98-113|hormone-binding|drug
DDI-DrugBank.d301.s14|114-122|globulin|drug
DDI-DrugBank.d301.s14|123-130|(SHBG),|brand
DDI-DrugBank.d301.s14|131-138|leading|drug
DDI-DrugBank.d301.s14|142-151|increased|drug
DDI-DrugBank.d301.s14|158-169|circulating|drug
DDI-DrugBank.d301.s14|170-185|corticosteroids|group
DDI-DrugBank.d301.s14|194-203|steroids,|group
DDI-DrugBank.d301.s16|13-21|proteins|drug
DDI-DrugBank.d301.s16|29-38|increased|drug
DDI-DrugBank.d301.s16|39-61|(angiotensinogen/renin|drug
DDI-DrugBank.d301.s16|73-93|alpha-1-antitrypsin,|drug
DDI-DrugBank.d301.s16|94-109|ceruloplasmin).|drug
DDI-DrugBank.d301.s18|30-41|cholesterol|drug
DDI-DrugBank.d301.s18|82-93|cholesterol|drug
DDI-DrugBank.d301.s18|109-118|increased|drug
DDI-DrugBank.d301.s18|119-131|triglyceride|drug
DDI-DrugBank.d301.s20|17-27|tolerance.|drug
DDI-DrugBank.d400.s0|0-8|Aspirin:|brand
DDI-DrugBank.d400.s0|43-57|administration|drug
DDI-DrugBank.d400.s0|73-80|aspirin|brand
DDI-DrugBank.d400.s0|138-147|increased|drug
DDI-DrugBank.d400.s1|57-64|inhibit|drug
DDI-DrugBank.d400.s2|9-17|indicate|drug
DDI-DrugBank.d400.s3|39-51|administered|drug
DDI-DrugBank.d400.s4|4-15|inhibitors:|drug
DDI-DrugBank.d400.s4|48-56|diminish|drug
DDI-DrugBank.d400.s4|61-77|antihypertensive|group
DDI-DrugBank.d400.s4|92-103|inhibitors.|drug
DDI-DrugBank.d400.s5|5-16|interaction|drug
DDI-DrugBank.d400.s5|59-65|taking|drug
DDI-DrugBank.d400.s5|96-107|inhibitors.|drug
DDI-DrugBank.d400.s6|12-20|Clinical|drug
DDI-DrugBank.d400.s6|41-55|post-marketing|drug
DDI-DrugBank.d400.s6|108-119|natriuretic|group
DDI-DrugBank.d400.s6|130-140|furosemide|drug
DDI-DrugBank.d400.s6|145-154|thiazides|group
DDI-DrugBank.d400.s7|37-47|inhibition|drug
DDI-DrugBank.d400.s7|57-70|prostaglandin|drug
DDI-DrugBank.d400.s8|0-6|During|drug
DDI-DrugBank.d400.s8|113-121|failure,|group
DDI-DrugBank.d400.s8|136-142|assure|group
DDI-DrugBank.d400.s8|143-151|diuretic|group
DDI-DrugBank.d400.s9|0-8|Lithium:|drug
DDI-DrugBank.d400.s9|53-60|lithium|drug
DDI-DrugBank.d400.s9|93-100|lithium|drug
DDI-DrugBank.d400.s10|9-16|minimum|drug
DDI-DrugBank.d400.s10|17-24|lithium|drug
DDI-DrugBank.d400.s10|39-48|increased|drug
DDI-DrugBank.d400.s11|38-48|inhibition|drug
DDI-DrugBank.d400.s11|58-71|prostaglandin|drug
DDI-DrugBank.d400.s11|89-95|NSAID.|brand
DDI-DrugBank.d400.s12|22-29|lithium|drug
DDI-DrugBank.d400.s12|34-46|administered|drug
DDI-DrugBank.d400.s12|112-119|lithium|drug
DDI-DrugBank.d400.s13|0-9|Warfarin:|drug
DDI-DrugBank.d400.s13|25-33|warfarin|drug
DDI-DrugBank.d400.s13|51-59|bleeding|drug
DDI-DrugBank.d400.s13|142-150|bleeding|drug
DDI-DrugBank.d400.s14|0-9|Antacids:|group
DDI-DrugBank.d400.s14|15-21|single|drug
DDI-DrugBank.d400.s14|40-49|ingestion|drug
DDI-DrugBank.d400.s14|64-74|containing|group
DDI-DrugBank.d400.s14|75-83|1.7-gram|drug_n
DDI-DrugBank.d400.s14|87-96|magnesium|drug
DDI-DrugBank.d400.s14|97-106|hydroxide|drug
DDI-DrugBank.d400.s14|112-118|500-mg|drug_n
DDI-DrugBank.d400.s14|137-146|increased|drug
DDI-DrugBank.d400.s14|240-250|inhibitors|drug
DDI-DrugBank.d400.s14|254-260|CYP2C9|brand
DDI-DrugBank.d400.s14|261-270|including|drug
DDI-DrugBank.d400.s14|271-283|fluconazole,|drug
DDI-DrugBank.d400.s14|284-294|lovastatin|drug
DDI-DrugBank.d400.s15|5-16|interaction|drug
DDI-DrugBank.d272.s0|12-17|using|drug
DDI-DrugBank.d272.s0|18-31|bromocriptine|drug
DDI-DrugBank.d272.s0|44-55|combination|drug
DDI-DrugBank.d272.s0|159-172|bromocriptine|drug
DDI-DrugBank.d272.s1|0-13|Bromocriptine|drug
DDI-DrugBank.d272.s1|27-35|interact|drug
DDI-DrugBank.d272.s1|41-49|dopamine|drug
DDI-DrugBank.d272.s1|83-90|certain|drug
DDI-DrugBank.d272.s2|64-77|bromocriptine|drug
DDI-DrugBank.d272.s2|88-103|phenothiazines,|drug
DDI-DrugBank.d272.s3|19-32|bromocriptine|drug
DDI-DrugBank.d272.s3|59-68|alkaloids|group
DDI-DrugBank.d169.s0|51-62|nonclinical|drug
DDI-DrugBank.d169.s0|81-89|REVLIMID|brand
DDI-DrugBank.d169.s0|136-144|inhibits|drug
DDI-DrugBank.d169.s0|148-155|induces|drug
DDI-DrugBank.d169.s0|184-194|suggesting|drug
DDI-DrugBank.d169.s0|200-212|lenalidomide|drug
DDI-DrugBank.d169.s0|279-291|interactions|drug
DDI-DrugBank.d169.s1|0-17|Co-administration|drug
DDI-DrugBank.d169.s1|48-60|lenalidomide|drug
DDI-DrugBank.d169.s1|82-88|single|drug
DDI-DrugBank.d169.s1|94-110|pharmacokinetics|drug
DDI-DrugBank.d169.s1|124-133|warfarin.|drug
DDI-DrugBank.d169.s2|0-17|Co-administration|drug
DDI-DrugBank.d169.s2|21-27|single|drug
DDI-DrugBank.d169.s2|28-33|25-mg|drug_n
DDI-DrugBank.d169.s2|39-47|warfarin|drug
DDI-DrugBank.d169.s2|69-85|pharmacokinetics|drug
DDI-DrugBank.d169.s3|77-85|warfarin|drug
DDI-DrugBank.d169.s3|86-101|administration,|drug
DDI-DrugBank.d169.s3|153-165|lenalidomide|drug
DDI-DrugBank.d169.s3|166-181|administration.|drug
DDI-DrugBank.d104.s0|0-12|Fenfluramine|drug
DDI-DrugBank.d104.s0|17-25|increase|drug
DDI-DrugBank.d104.s0|49-65|antihypertensive|group
DDI-DrugBank.d104.s0|79-92|guanethidine,|drug
DDI-DrugBank.d104.s0|105-115|reserpine.|drug
DDI-DrugBank.d104.s1|67-73|taking|drug
DDI-DrugBank.d104.s1|74-87|fenfluramine,|drug
DDI-DrugBank.d104.s1|88-93|since|drug
DDI-DrugBank.d173.s0|4-12|interact|drug
DDI-DrugBank.d173.s0|49-58|medicines|drug
DDI-DrugBank.d173.s0|115-120|using|drug
DDI-DrugBank.d537.s0|0-11|Bentiromide|drug
DDI-DrugBank.d537.s0|16-24|interact|drug
DDI-DrugBank.d537.s0|30-43|acetaminophen|drug
DDI-DrugBank.d537.s0|84-99|Chloromycetin),|drug
DDI-DrugBank.d537.s0|125-135|benzocaine|drug
DDI-DrugBank.d537.s0|140-151|lidocaine),|drug
DDI-DrugBank.d537.s0|152-169|para-aminobenzoic|drug
DDI-DrugBank.d537.s0|175-192|(PABA)-containing|group
DDI-DrugBank.d537.s0|233-248|multivitamins),|drug
DDI-DrugBank.d537.s0|249-261|procainamide|drug
DDI-DrugBank.d537.s0|301-312|medicines),|drug
DDI-DrugBank.d537.s0|313-321|thiazide|group
DDI-DrugBank.d537.s0|322-331|diuretics|group
DDI-DrugBank.d537.s0|346-355|medicines|drug
DDI-DrugBank.d537.s0|356-362|during|drug
DDI-DrugBank.d234.s0|63-78|benzodiazepines|drug
DDI-DrugBank.d234.s1|24-36|interactions|drug
DDI-DrugBank.d234.s1|52-61|ROMAZICON|brand
DDI-DrugBank.d234.s1|66-78|administered|drug
DDI-DrugBank.d234.s1|96-108|inhalational|drug
DDI-DrugBank.d234.s1|171-183|administered|drug
DDI-DrugBank.d234.s2|37-42|using|drug
DDI-DrugBank.d234.s2|43-52|ROMAZICON|brand
DDI-DrugBank.d234.s2|87-92|since|drug
DDI-DrugBank.d234.s2|210-226|antidepressants)|group
DDI-DrugBank.d234.s2|263-277|benzodiazepine|drug
DDI-DrugBank.d234.s3|11-20|ROMAZICON|brand
DDI-DrugBank.d234.s3|76-85|receiving|drug
DDI-DrugBank.d234.s3|86-100|benzodiazepine|drug
DDI-DrugBank.d234.s4|9-18|ROMAZICON|brand
DDI-DrugBank.d234.s4|35-44|intrinsic|drug
DDI-DrugBank.d234.s4|45-59|anticonvulsant|group
DDI-DrugBank.d234.s4|121-135|benzodiazepine|drug
DDI-DrugBank.d234.s5|0-9|ROMAZICON|brand
DDI-DrugBank.d234.s5|40-55|benzodiazepines|drug
DDI-DrugBank.d234.s5|71-82|interaction|drug
DDI-DrugBank.d234.s6|15-32|nonbenzodiazepine|drug
DDI-DrugBank.d234.s6|45-59|benzodiazepine|drug
DDI-DrugBank.d234.s6|90-109|triazolopyridazines|drug
DDI-DrugBank.d234.s6|142-152|ROMAZICON.|brand
DDI-DrugBank.d234.s7|4-20|pharmacokinetics|drug
DDI-DrugBank.d234.s7|24-39|benzodiazepines|drug
DDI-DrugBank.d234.s8|12-27|pharmacokinetic|drug
DDI-DrugBank.d234.s8|28-39|interaction|drug
DDI-DrugBank.d234.s8|48-55|ethanol|drug
DDI-DrugBank.d234.s9|42-51|ROMAZICON|brand
DDI-DrugBank.d234.s9|74-85|long-acting|drug
DDI-DrugBank.d234.s9|86-100|benzodiazepine|drug
DDI-DrugBank.d234.s10|52-58|within|drug
DDI-DrugBank.d234.s11|82-93|long-acting|drug
DDI-DrugBank.d234.s11|94-109|benzodiazepines|drug
DDI-DrugBank.d234.s11|147-159|short-acting|drug
DDI-DrugBank.d234.s11|160-175|benzodiazepines|drug
DDI-DrugBank.d234.s12|15-24|increased|drug
DDI-DrugBank.d234.s12|77-83|taking|drug
DDI-DrugBank.d234.s12|84-99|benzodiazepines|drug
DDI-DrugBank.d234.s12|215-230|benzodiazepine,|drug
DDI-DrugBank.d234.s12|292-301|procedure|group
DDI-DrugBank.d234.s12|322-331|ROMAZICON|brand
DDI-DrugBank.d386.s1|68-80|metabolizing|drug
DDI-DrugBank.d386.s1|109-121|(debrisoquin|drug
DDI-DrugBank.d386.s1|122-134|hydroxylase)|drug
DDI-DrugBank.d386.s3|79-94|antidepressants|group
DDI-DrugBank.d386.s4|0-9|Depending|drug
DDI-DrugBank.d386.s4|63-71|increase|drug
DDI-DrugBank.d386.s4|133-141|increase|drug
DDI-DrugBank.d386.s4|163-168|TCA).|brand
DDI-DrugBank.d386.s5|13-20|certain|drug
DDI-DrugBank.d386.s5|27-34|inhibit|drug
DDI-DrugBank.d386.s7|3-13|individual|drug
DDI-DrugBank.d386.s7|101-111|inhibiting|drug
DDI-DrugBank.d386.s8|15-22|inhibit|drug
DDI-DrugBank.d386.s8|43-50|include|drug
DDI-DrugBank.d386.s8|95-106|(quinidine;|drug
DDI-DrugBank.d386.s9|0-11|cimetidine)|drug
DDI-DrugBank.d386.s9|66-82|antidepressants,|group
DDI-DrugBank.d386.s9|83-98|phenothiazines,|drug
DDI-DrugBank.d386.s9|115-131|antiarrhythrnics|group
DDI-DrugBank.d386.s9|148-160|flecainide).|drug
DDI-DrugBank.d386.s10|24-33|serotonin|drug
DDI-DrugBank.d386.s10|43-53|inhibitors|drug
DDI-DrugBank.d386.s10|69-80|fluoxetine,|drug
DDI-DrugBank.d386.s10|81-92|seriraline,|drug
DDI-DrugBank.d386.s10|97-108|paroxetine,|drug
DDI-DrugBank.d386.s10|109-116|inhibit|drug
DDI-DrugBank.d386.s10|158-169|inhibition.|drug
DDI-DrugBank.d386.s11|20-28|SSRI-TCA|brand
DDI-DrugBank.d386.s11|29-41|interactions|drug
DDI-DrugBank.d386.s11|51-59|clinical|drug
DDI-DrugBank.d386.s11|98-108|inhibition|drug
DDI-DrugBank.d386.s11|117-133|pharmacokinetics|drug
DDI-DrugBank.d386.s11|146-155|involved.|drug
DDI-DrugBank.d386.s12|25-34|indicated|drug
DDI-DrugBank.d386.s12|42-59|co-administration|drug
DDI-DrugBank.d386.s12|102-111|switching|drug
DDI-DrugBank.d386.s13|61-71|initiating|drug
DDI-DrugBank.d386.s13|99-104|being|drug
DDI-DrugBank.d386.s13|120-131|fluoxetine,|drug
DDI-DrugBank.d386.s14|29-44|antidepressants|group
DDI-DrugBank.d386.s14|65-72|inhibit|drug
DDI-DrugBank.d386.s14|166-180|antidepressant|group
DDI-DrugBank.d386.s15|80-89|increased|drug
DDI-DrugBank.d386.s15|108-122|antidepressant|group
DDI-DrugBank.d386.s16|63-68|going|drug
DDI-DrugBank.d386.s16|75-90|co-administered|drug
DDI-DrugBank.d386.s16|96-103|another|drug
DDI-DrugBank.d386.s16|124-133|inhibitor|drug
DDI-DrugBank.d386.s18|107-122|anticholinergic|group
DDI-DrugBank.d386.s20|0-8|Clinical|drug
DDI-DrugBank.d386.s20|38-52|administration|drug
DDI-DrugBank.d386.s20|64-78|antidepressant|group
DDI-DrugBank.d386.s21|57-66|increased|drug
DDI-DrugBank.d386.s23|3-14|desipramine|drug
DDI-DrugBank.d386.s23|15-28|hydrochloride|drug
DDI-DrugBank.d386.s23|38-46|combined|drug
DDI-DrugBank.d386.s23|204-209|since|drug
DDI-DrugBank.d386.s23|234-245|desipramine|drug
DDI-DrugBank.d386.s23|250-265|benzodiazepines|drug
DDI-DrugBank.d386.s23|273-289|chlordiazepoxide|drug
DDI-DrugBank.d386.s24|22-37|anticholinergic|group
DDI-DrugBank.d386.s24|103-115|desipramine.|drug
DDI-DrugBank.d386.s26|11-25|administration|drug
DDI-DrugBank.d386.s26|29-39|cimetidine|drug
DDI-DrugBank.d386.s26|54-69|antidepressants|group
DDI-DrugBank.d386.s26|82-92|clinically|drug
DDI-DrugBank.d386.s26|105-114|increases|drug
DDI-DrugBank.d386.s26|153-169|antidepressants.|group
DDI-DrugBank.d386.s27|56-71|antidepressants|group
DDI-DrugBank.d386.s27|96-111|discontinuation|group
DDI-DrugBank.d386.s27|115-125|cimetidine|drug
DDI-DrugBank.d386.s27|200-214|antidepressant|group
DDI-DrugBank.d386.s28|38-47|increases|drug
DDI-DrugBank.d386.s28|96-111|antidepressants|group
DDI-DrugBank.d386.s28|117-127|fluoxetine|drug
DDI-DrugBank.d386.s28|137-149|administered|drug
DDI-DrugBank.d386.s28|153-164|combination|drug
DDI-DrugBank.d195.s0|0-11|Anastrozole|drug
DDI-DrugBank.d195.s0|12-21|inhibited|drug
DDI-DrugBank.d195.s0|86-92|2C8/9,|brand
DDI-DrugBank.d195.s1|0-11|Anastrozole|drug
DDI-DrugBank.d195.s1|20-27|inhibit|drug
DDI-DrugBank.d195.s2|0-11|Anastrozole|drug
DDI-DrugBank.d195.s2|30-46|pharmacokinetics|drug
DDI-DrugBank.d195.s2|50-61|antipyrine.|group
DDI-DrugBank.d195.s3|35-46|interaction|drug
DDI-DrugBank.d195.s3|71-82|antipyrine,|group
DDI-DrugBank.d195.s3|148-165|co-administration|drug
DDI-DrugBank.d195.s3|184-192|ARIMIDEX|brand
DDI-DrugBank.d195.s3|225-235|clinically|drug
DDI-DrugBank.d195.s3|253-263|inhibition|drug
DDI-DrugBank.d195.s4|3-14|interaction|drug
DDI-DrugBank.d195.s4|26-34|warfarin|drug
DDI-DrugBank.d195.s4|45-55|clinically|drug
DDI-DrugBank.d195.s4|78-89|anastrozole|drug
DDI-DrugBank.d195.s4|93-101|warfarin|drug
DDI-DrugBank.d195.s4|102-118|pharmacokinetics|drug
DDI-DrugBank.d195.s4|122-135|anticoagulant|group
DDI-DrugBank.d195.s5|40-51|combination|drug
DDI-DrugBank.d195.s5|55-63|ARIMIDEX|brand
DDI-DrugBank.d195.s6|23-35|discontinued|group
DDI-DrugBank.d195.s7|9-17|clinical|drug
DDI-DrugBank.d195.s7|22-37|pharmacokinetic|drug
DDI-DrugBank.d195.s7|91-103|administered|drug
DDI-DrugBank.d195.s7|109-120|anastrozole|drug
DDI-DrugBank.d195.s7|126-134|CLINICAL|brand
DDI-DrugBank.d195.s7|135-147|PHARMACOLOGY|brand
DDI-DrugBank.d195.s7|172-180|CLINICAL|brand
DDI-DrugBank.d195.s7|181-193|PHARMACOLOGY|brand
DDI-DrugBank.d195.s7|196-204|Clinical|drug
DDI-DrugBank.d195.s8|0-17|Co-administration|drug
DDI-DrugBank.d195.s8|21-32|anastrozole|drug
DDI-DrugBank.d195.s8|74-85|anastrozole|drug
DDI-DrugBank.d195.s8|141-152|anastrozole|drug
DDI-DrugBank.d195.s9|0-19|Estrogen-containing|group
DDI-DrugBank.d195.s9|54-62|ARIMIDEX|brand
DDI-DrugBank.d195.s9|75-83|diminish|drug
DDI-DrugBank.d195.s10|37-47|clinically|drug
DDI-DrugBank.d195.s10|86-94|clinical|drug
DDI-DrugBank.d62.s0|0-18|Dexbrompheniramine|drug
DDI-DrugBank.d62.s0|23-31|interact|drug
DDI-DrugBank.d62.s0|144-160|antihistamines),|group
DDI-DrugBank.d62.s0|161-177|anticholinergics|group
DDI-DrugBank.d62.s0|204-219|anticholinergic|group
DDI-DrugBank.d62.s0|229-245|(anticholinergic|drug
DDI-DrugBank.d62.s0|323-339|antihistamines),|group
DDI-DrugBank.d62.s0|344-353|monoamine|drug
DDI-DrugBank.d62.s0|362-367|(MAO)|brand
DDI-DrugBank.d62.s0|368-378|inhibitors|drug
DDI-DrugBank.d62.s0|400-414|antihistamines|group
DDI-DrugBank.d62.s0|431-440|intensify|drug
DDI-DrugBank.d62.s0|445-460|anticholinergic|group
DDI-DrugBank.d62.s0|491-507|antihistamines).|group
DDI-DrugBank.d222.s0|5-13|atropine|drug
DDI-DrugBank.d222.s0|62-76|atropinization|drug
DDI-DrugBank.d222.s0|77-87|(flushing,|drug
DDI-DrugBank.d222.s0|194-202|atropine|drug
DDI-DrugBank.d222.s0|266-275|atropine.|drug
DDI-DrugBank.d222.s1|4-13|following|drug
DDI-DrugBank.d222.s1|69-87|anticholinesterase|group
DDI-DrugBank.d222.s1|88-97|poisoning|drug
DDI-DrugBank.d222.s1|147-155|atropine|drug
DDI-DrugBank.d222.s2|0-5|Since|drug
DDI-DrugBank.d222.s2|42-62|anticholinesterases,|group
DDI-DrugBank.d65.s0|0-13|Sulfacetamide|drug
DDI-DrugBank.d65.s0|31-43|incompatible|drug
DDI-DrugBank.d559.s0|49-58|monoamine|drug
DDI-DrugBank.d559.s0|67-72|(MAO)|brand
DDI-DrugBank.d559.s0|73-84|inhibitors.|drug
DDI-DrugBank.d559.s1|12-25|acetaminophen|drug
DDI-DrugBank.d559.s1|30-38|caffeine|drug
DDI-DrugBank.d559.s1|210-217|causing|drug
DDI-DrugBank.d559.s1|218-227|increased|drug
DDI-DrugBank.d559.s2|34-47|Acetaminophen|drug
DDI-DrugBank.d559.s2|92-99|urinary|drug
DDI-DrugBank.d559.s2|100-121|5-hydroxyindoleacetic|drug_n
DDI-MedLine.d102.s0|84-98|noradrenaline.|drug
DDI-MedLine.d102.s1|29-40|investigate|drug
DDI-MedLine.d102.s1|128-141|noradrenaline|drug
DDI-MedLine.d102.s3|0-9|injection|drug
DDI-MedLine.d102.s4|7-12|ninth|drug
DDI-MedLine.d102.s4|54-60|rings,|drug
DDI-MedLine.d102.s4|77-89|endothelium,|drug
DDI-MedLine.d102.s4|145-159|noradrenaline.|drug
DDI-MedLine.d102.s5|7-12|rings|drug
DDI-MedLine.d102.s5|18-24|intact|drug
DDI-MedLine.d102.s5|25-36|endothelium|drug
DDI-MedLine.d102.s5|109-122|noradrenaline|drug
DDI-MedLine.d102.s5|209-221|7.86+/-0.09,|drug_n
DDI-MedLine.d102.s5|222-233|7.30+/-0.11|drug_n
DDI-MedLine.d102.s5|238-250|7.35+/-0.04,|drug_n
DDI-MedLine.d102.s6|0-18|Endothelium-intact|drug
DDI-MedLine.d102.s6|26-31|rings|drug
DDI-MedLine.d102.s6|80-93|noradrenaline|drug
DDI-MedLine.d102.s6|196-208|7.77+/-0.12,|drug_n
DDI-MedLine.d102.s6|209-221|7.21+/-0.13,|drug_n
DDI-MedLine.d102.s6|222-233|6.93+/-0.04|drug_n
DDI-MedLine.d102.s6|238-250|7.22+/-0.18,|drug_n
DDI-MedLine.d102.s7|63-76|noradrenaline|drug
DDI-MedLine.d102.s7|87-92|rings|drug
DDI-MedLine.d102.s7|101-113|endothelium.|drug
DDI-MedLine.d102.s8|27-49|endothelium-dependent.|drug
DDI-DrugBank.d483.s0|19-29|creatinine|drug
DDI-DrugBank.d483.s0|49-56|CEFOTAN|brand
DDI-DrugBank.d483.s1|3-10|CEFOTAN|brand
DDI-DrugBank.d483.s1|18-32|aminoglycoside|drug
DDI-DrugBank.d483.s2|39-53|administration|drug
DDI-DrugBank.d483.s2|57-64|CEFOTAN|brand
DDI-DrugBank.d483.s2|124-129|urine|drug
DDI-DrugBank.d483.s2|130-135|using|drug
DDI-DrugBank.d483.s2|136-145|Clinitest|drug
DDI-DrugBank.d483.s2|172-180|Fehlings|drug
DDI-DrugBank.d483.s4|14-29|cephalosporins,|drug
DDI-DrugBank.d483.s4|67-76|interfere|drug
DDI-DrugBank.d483.s4|82-93|measurement|group
DDI-DrugBank.d483.s4|107-112|urine|drug
DDI-DrugBank.d483.s4|113-123|creatinine|drug
DDI-DrugBank.d483.s4|168-177|increases|drug
DDI-DrugBank.d483.s4|195-205|creatinine|drug
DDI-DrugBank.d242.s0|14-25|interaction|drug
DDI-DrugBank.d242.s0|63-76|Levofloxacin.|drug
DDI-DrugBank.d242.s1|22-36|administration|drug
DDI-DrugBank.d242.s1|45-55|quinolones|drug
DDI-DrugBank.d242.s1|107-120|theophylline,|drug
DDI-DrugBank.d242.s1|121-130|interfere|drug
DDI-DrugBank.d242.s1|154-163|caffeine,|drug
DDI-DrugBank.d242.s1|200-213|anticoagulant|group
DDI-DrugBank.d242.s1|214-222|warfarin|drug
DDI-DrugBank.d242.s1|303-313|creatinine|drug
DDI-DrugBank.d242.s1|326-335|receiving|drug
DDI-DrugBank.d242.s1|345-357|cyclosporine|drug
DDI-DrugBank.d257.s0|154-162|opioids,|group
DDI-DrugBank.d257.s0|208-224|antidepressants,|group
DDI-DrugBank.d257.s0|225-240|phenothiazines,|drug
DDI-DrugBank.d257.s0|286-301|antihistamines)|group
DDI-DrugBank.d257.s2|10-18|combined|drug
DDI-DrugBank.d257.s2|30-43|contemplated,|group
DDI-DrugBank.d257.s3|12-23|interaction|drug
DDI-DrugBank.d257.s3|36-46|inhibitors|drug
DDI-DrugBank.d257.s3|123-134|inhibitors.|drug
DDI-DrugBank.d257.s4|46-55|involving|drug
DDI-DrugBank.d257.s4|86-98|manufacturer|group
DDI-DrugBank.d257.s4|115-123|involved|drug
DDI-DrugBank.d257.s4|135-149|administration|drug
DDI-DrugBank.d257.s4|159-166|initial|drug
DDI-DrugBank.d257.s4|220-228|tolerant|drug
DDI-DrugBank.d257.s4|259-273|administration|drug
DDI-DrugBank.d257.s4|277-288|levorphanol|drug
DDI-DrugBank.d257.s4|306-315|affecting|drug
DDI-DrugBank.d257.s5|4-11|initial|drug
DDI-DrugBank.d257.s5|20-31|levorphanol|drug
DDI-DrugBank.d257.s5|119-126|another|drug
DDI-DrugBank.d257.s5|132-141|affecting|drug
DDI-DrugBank.d257.s6|97-109|pentazocine,|drug
DDI-DrugBank.d257.s6|110-121|nalbuphine,|drug
DDI-DrugBank.d257.s6|122-134|butorphanol,|drug
DDI-DrugBank.d257.s6|135-143|dezocine|drug
DDI-DrugBank.d257.s6|148-162|buprenorphine)|drug
DDI-DrugBank.d257.s6|177-189|administered|drug
DDI-DrugBank.d257.s6|226-235|receiving|drug
DDI-MedLine.d67.s0|23-32|midazolam|drug
DDI-MedLine.d67.s0|40-55|antinociceptive|group
DDI-MedLine.d67.s0|66-75|morphine,|drug
DDI-MedLine.d67.s0|90-102|indomethacin|drug
DDI-MedLine.d67.s1|4-13|influence|drug
DDI-MedLine.d67.s1|17-26|midazolam|drug
DDI-MedLine.d67.s1|43-58|antinociceptive|group
DDI-MedLine.d67.s1|69-77|morphine|drug
DDI-MedLine.d67.s1|116-128|indomethacin|drug
DDI-MedLine.d67.s1|144-156|investigated|drug
DDI-MedLine.d67.s1|174-179|using|drug
DDI-MedLine.d67.s2|15-23|injected|drug
DDI-MedLine.d67.s2|24-42|intraperitoneally.|drug
DDI-MedLine.d67.s3|0-15|Benzodiazepines|drug
DDI-MedLine.d67.s3|21-33|administered|drug
DDI-MedLine.d67.s3|56-64|applying|drug
DDI-MedLine.d67.s4|0-11|Measurement|group
DDI-MedLine.d67.s4|41-47|within|drug
DDI-MedLine.d67.s4|58-72|benzodiazepine|drug
DDI-MedLine.d67.s4|73-88|administration.|drug
DDI-MedLine.d67.s5|46-54|injected|drug
DDI-MedLine.d67.s5|60-68|morphine|drug
DDI-MedLine.d67.s5|95-110|antinociceptive|group
DDI-MedLine.d67.s5|121-130|morphine.|drug
DDI-MedLine.d67.s6|34-49|antinociceptive|group
DDI-MedLine.d67.s6|104-117|indomethacin.|drug
DDI-MedLine.d67.s7|0-9|Midazolam|drug
DDI-MedLine.d67.s7|66-81|antinociceptive|group
DDI-MedLine.d67.s7|92-101|morphine,|drug
DDI-MedLine.d67.s7|146-159|indomethacin.|drug
DDI-DrugBank.d178.s0|27-40|sulfonylureas|group
DDI-DrugBank.d178.s0|63-70|certain|drug
DDI-DrugBank.d178.s0|77-86|including|drug
DDI-DrugBank.d178.s0|100-117|anti-inflammatory|group
DDI-DrugBank.d178.s0|157-164|protein|drug
DDI-DrugBank.d178.s0|228-238|coumarins,|drug
DDI-DrugBank.d178.s0|239-248|monoamine|drug
DDI-DrugBank.d178.s0|257-268|inhibitors,|drug
DDI-DrugBank.d178.s0|289-297|blocking|drug
DDI-DrugBank.d178.s1|20-32|administered|drug
DDI-DrugBank.d178.s1|46-55|receiving|drug
DDI-DrugBank.d178.s1|56-66|MICRONASE,|brand
DDI-DrugBank.d178.s2|45-54|receiving|drug
DDI-DrugBank.d178.s2|55-65|MICRONASE,|brand
DDI-DrugBank.d178.s2|117-125|control.|group
DDI-DrugBank.d178.s3|0-7|Certain|drug
DDI-DrugBank.d178.s3|68-76|control.|group
DDI-DrugBank.d178.s4|12-19|include|drug
DDI-DrugBank.d178.s4|24-33|thiazides|group
DDI-DrugBank.d178.s4|44-54|diuretics,|group
DDI-DrugBank.d178.s4|55-71|corticosteroids,|group
DDI-DrugBank.d178.s4|72-88|phe-nothiazines,|drug
DDI-DrugBank.d178.s4|123-138|contraceptives,|group
DDI-DrugBank.d178.s4|139-149|phenytoin,|drug
DDI-DrugBank.d178.s4|150-159|nicotinic|drug
DDI-DrugBank.d178.s4|185-192|calcium|drug
DDI-DrugBank.d178.s4|201-209|blocking|drug
DDI-DrugBank.d178.s5|20-32|administered|drug
DDI-DrugBank.d178.s5|46-55|receiving|drug
DDI-DrugBank.d178.s5|56-66|MICRONASE,|brand
DDI-DrugBank.d178.s5|118-126|control.|group
DDI-DrugBank.d178.s6|45-54|receiving|drug
DDI-DrugBank.d178.s6|55-65|MICRONASE,|brand
DDI-DrugBank.d178.s7|11-22|interaction|drug
DDI-DrugBank.d178.s7|31-40|glyburide|drug
DDI-DrugBank.d178.s7|45-59|ciprofloxacin,|drug
DDI-DrugBank.d178.s7|62-77|fluoroquinolone|drug
DDI-DrugBank.d178.s7|78-89|antibiotic,|group
DDI-DrugBank.d178.s7|109-118|resulting|drug
DDI-DrugBank.d178.s8|23-34|interaction|drug
DDI-DrugBank.d178.s9|12-23|interaction|drug
DDI-DrugBank.d178.s9|37-47|miconazole|drug
DDI-DrugBank.d178.s9|77-84|leading|drug
DDI-DrugBank.d178.s10|13-24|interaction|drug
DDI-DrugBank.d178.s10|46-58|intravenous,|drug
DDI-DrugBank.d178.s10|70-77|vaginal|drug
DDI-DrugBank.d178.s10|94-104|miconazole|drug
DDI-DrugBank.d178.s11|0-10|Metformin:|drug
DDI-DrugBank.d178.s11|16-27|single-dose|drug
DDI-DrugBank.d178.s11|28-39|interaction|drug
DDI-DrugBank.d178.s11|49-54|NIDDM|brand
DDI-DrugBank.d178.s11|78-87|glyburide|drug
DDI-DrugBank.d178.s12|4-15|single-dose|drug
DDI-DrugBank.d178.s12|16-22|nature|group
DDI-DrugBank.d178.s12|73-82|glyburide|drug
DDI-DrugBank.d178.s12|136-144|clinical|drug
DDI-DrugBank.d178.s12|166-177|interaction|drug
DDI-DrugBank.d178.s12|178-188|uncertain.|drug
DDI-DrugBank.d178.s13|0-16|Coadministration|drug
DDI-DrugBank.d178.s13|20-30|gly-buride|drug
DDI-DrugBank.d178.s13|35-44|metformin|drug
DDI-DrugBank.d178.s13|85-94|metformin|drug
DDI-DrugBank.d178.s13|95-111|pharmacokinetics|drug
DDI-DrugBank.d368.s0|0-6|DIAMOX|brand
DDI-DrugBank.d368.s0|16-25|phenytoin|drug
DDI-DrugBank.d368.s0|42-51|increased|drug
DDI-DrugBank.d368.s0|68-78|phenytoin.|drug
DDI-DrugBank.d368.s1|9-17|increase|drug
DDI-DrugBank.d368.s1|77-86|receiving|drug
DDI-DrugBank.d368.s1|95-104|phenytoin|drug
DDI-DrugBank.d368.s2|31-40|receiving|drug
DDI-DrugBank.d368.s3|3-13|decreasing|drug
DDI-DrugBank.d368.s3|18-34|gastrointestinal|drug
DDI-DrugBank.d368.s3|60-66|DIAMOX|brand
DDI-DrugBank.d368.s3|174-188|anticonvulsant|group
DDI-DrugBank.d368.s4|24-34|beginning,|drug
DDI-DrugBank.d368.s4|35-49|discontinuing,|group
DDI-DrugBank.d368.s4|53-61|changing|drug
DDI-DrugBank.d368.s4|74-80|DIAMOX|brand
DDI-DrugBank.d368.s4|93-102|receiving|drug
DDI-DrugBank.d368.s5|57-66|anhydrase|drug
DDI-DrugBank.d368.s5|67-78|inhibitors,|drug
DDI-DrugBank.d368.s6|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s6|18-26|increase|drug
DDI-DrugBank.d368.s7|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s7|18-26|increase|drug
DDI-DrugBank.d368.s8|42-47|being|drug
DDI-DrugBank.d368.s8|61-73|antidiabetic|group
DDI-DrugBank.d368.s9|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s9|24-31|urinary|drug
DDI-DrugBank.d368.s9|45-56|amphetamine|drug
DDI-DrugBank.d368.s10|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s10|22-29|urinary|drug
DDI-DrugBank.d368.s10|43-52|quinidine|drug
DDI-DrugBank.d368.s11|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s11|30-37|urinary|drug
DDI-DrugBank.d368.s11|38-48|antiseptic|group
DDI-DrugBank.d368.s11|59-71|methenamine.|drug
DDI-DrugBank.d368.s12|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s12|14-23|increases|drug
DDI-DrugBank.d368.s12|24-31|lithium|drug
DDI-DrugBank.d368.s12|50-57|lithium|drug
DDI-DrugBank.d368.s13|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s13|18-24|sodium|drug
DDI-DrugBank.d368.s13|55-64|increases|drug
DDI-DrugBank.d368.s14|0-13|Acetazolamide|drug
DDI-DrugBank.d368.s14|26-38|cyclosporine|drug
DDI-DrugBank.d446.s0|21-29|interact|drug
DDI-DrugBank.d446.s0|35-51|antidepressants,|group
DDI-DrugBank.d446.s0|52-60|aspirin,|brand
DDI-DrugBank.d446.s0|75-89|bromocriptine,|drug
DDI-DrugBank.d446.s0|90-97|calcium|drug
DDI-DrugBank.d446.s0|111-127|corticosteroids,|group
DDI-DrugBank.d446.s0|128-142|corticotropin,|drug
DDI-DrugBank.d446.s0|143-156|cyclosporine,|drug
DDI-DrugBank.d446.s0|157-168|dantrolene,|drug
DDI-DrugBank.d446.s0|169-178|nicotine,|drug
DDI-DrugBank.d446.s0|179-190|somatropin,|drug
DDI-DrugBank.d446.s0|206-215|warfarin.|drug
DDI-DrugBank.d418.s0|15-26|interaction|drug
DDI-DrugBank.d418.s0|60-69|Cyanokit.|drug
DDI-DrugBank.d91.s0|6-15|medicines|drug
DDI-DrugBank.d91.s0|27-34|certain|drug
DDI-DrugBank.d91.s0|35-44|medicines|drug
DDI-DrugBank.d91.s0|110-119|medicines|drug
DDI-DrugBank.d91.s0|152-163|interaction|drug
DDI-DrugBank.d91.s2|13-18|using|drug
DDI-DrugBank.d91.s2|19-31|idoxuridine,|drug
DDI-DrugBank.d91.s2|110-115|using|drug
DDI-DrugBank.d91.s2|120-130|following:|drug
DDI-DrugBank.d91.s2|143-153|containing|group
DDI-DrugBank.d91.s3|15-23|interact|drug
DDI-DrugBank.d91.s3|33-44|idoxuridine|drug
DDI-DrugBank.d91.s3|57-64|causing|drug
DDI-DrugBank.d91.s3|99-107|interact|drug
DDI-DrugBank.d91.s3|137-148|idoxuridine|drug
DDI-DrugBank.d91.s3|161-168|causing|drug
DDI-DrugBank.d119.s0|4-13|following|drug
DDI-DrugBank.d119.s0|19-31|interactions|drug
DDI-DrugBank.d119.s3|0-9|Diazoxide|drug
DDI-DrugBank.d119.s4|0-10|Zimelidine|drug
DDI-DrugBank.d119.s5|31-46|antinociceptive|group
DDI-DrugBank.d119.s6|0-13|Aminophylline|drug
DDI-DrugBank.d119.s7|0-9|Midazolam|drug
DDI-DrugBank.d542.s0|17-24|Vitamin|drug
DDI-DrugBank.d542.s0|28-37|(Niacin):|drug
DDI-DrugBank.d542.s0|64-73|Nicotinic|drug
DDI-DrugBank.d542.s0|120-128|blocking|drug
DDI-DrugBank.d542.s0|157-166|resulting|drug
DDI-DrugBank.d542.s1|0-8|Aspirin:|brand
DDI-DrugBank.d542.s1|21-28|aspirin|brand
DDI-DrugBank.d542.s1|69-78|nicotinic|drug
DDI-DrugBank.d542.s2|4-12|clinical|drug
DDI-DrugBank.d542.s2|31-38|finding|drug
DDI-DrugBank.d542.s3|34-40|drinks|drug
DDI-DrugBank.d542.s3|45-53|increase|drug
DDI-DrugBank.d542.s3|74-82|flushing|drug
DDI-DrugBank.d542.s3|138-148|ingestion.|drug
DDI-DrugBank.d366.s0|4-12|interact|drug
DDI-DrugBank.d570.s0|35-42|Certain|drug
DDI-DrugBank.d570.s0|43-52|endocrine|drug
DDI-DrugBank.d570.s0|97-116|estrogen-containing|group
DDI-DrugBank.d570.s0|122-137|contraceptives.|group
DDI-DrugBank.d570.s1|4-13|following|drug
DDI-DrugBank.d570.s1|89-108|sulfobromophthalein|drug
DDI-DrugBank.d570.s3|12-23|prothrombin|drug
DDI-DrugBank.d570.s3|41-46|VIII,|brand
DDI-DrugBank.d570.s4|10-22|antithrombin|group
DDI-DrugBank.d570.s5|0-9|increased|drug
DDI-DrugBank.d570.s5|10-32|norepinephrine-induced|drug
DDI-DrugBank.d570.s7|12-27|thyroid-binding|drug
DDI-DrugBank.d570.s7|28-36|globulin|drug
DDI-DrugBank.d570.s7|37-42|(TBG)|brand
DDI-DrugBank.d570.s7|43-50|leading|drug
DDI-DrugBank.d570.s7|54-64|in-creased|drug
DDI-DrugBank.d570.s7|65-76|circulating|drug
DDI-DrugBank.d570.s8|3-11|measured|group
DDI-DrugBank.d570.s9|8-13|resin|drug
DDI-DrugBank.d570.s9|35-45|reflecting|drug
DDI-DrugBank.d570.s12|19-28|tolerance|drug
DDI-DrugBank.d570.s20|18-30|triglyceride|drug
DDI-MedLine.d32.s0|0-12|Prescribing.|drug
DDI-MedLine.d32.s1|8-18|maximizing|drug
DDI-MedLine.d32.s1|33-41|avoiding|drug
DDI-MedLine.d32.s2|5-16|prescribing|drug
DDI-MedLine.d32.s4|11-21|maximizing|drug
DDI-MedLine.d32.s4|38-53|individualizing|drug
DDI-MedLine.d32.s5|51-57|ensure|group
DDI-MedLine.d32.s5|86-91|being|drug
DDI-MedLine.d32.s6|12-19|include|drug
DDI-MedLine.d32.s6|101-114|understanding|drug
DDI-MedLine.d32.s6|154-161|certain|drug
DDI-MedLine.d32.s7|6-16|monitoring|drug
DDI-MedLine.d32.s7|38-46|minimize|drug
DDI-DrugBank.d479.s0|4-16|vasodilating|drug
DDI-DrugBank.d479.s0|28-38|isosorbide|drug
DDI-DrugBank.d479.s2|66-73|calcium|drug
DDI-DrugBank.d479.s2|125-137|combination.|drug
DDI-MedLine.d16.s0|15-23|ketamine|drug
DDI-MedLine.d16.s1|4-15|interaction|drug
DDI-MedLine.d16.s1|19-34|intramuscularly|drug
DDI-MedLine.d16.s1|35-43|injected|drug
DDI-MedLine.d16.s1|44-52|ketamine|drug
DDI-MedLine.d16.s2|29-37|ketamine|drug
DDI-MedLine.d16.s2|112-119|minutes|drug
DDI-MedLine.d16.s3|156-165|injection|drug
DDI-MedLine.d16.s3|169-178|ketamine,|drug
DDI-MedLine.d16.s4|41-46|brain|drug
DDI-MedLine.d16.s4|57-65|ketamine|drug
DDI-MedLine.d16.s4|83-93|suggesting|drug
DDI-MedLine.d16.s4|96-115|ketamine:metabolite|drug
DDI-MedLine.d16.s5|17-25|ketamine|drug
DDI-MedLine.d16.s5|40-45|brain|drug
DDI-MedLine.d16.s5|96-104|ketamine|drug
DDI-MedLine.d16.s6|21-29|ketamine|drug
DDI-MedLine.d16.s6|39-51|short-acting|drug
DDI-DrugBank.d522.s0|0-12|Terfenadine:|drug
DDI-DrugBank.d522.s0|36-45|involving|drug
DDI-DrugBank.d522.s0|75-88|dirithromycin|drug
DDI-DrugBank.d522.s0|122-134|terfenadine.|drug
DDI-DrugBank.d522.s1|30-41|terfenadine|drug
DDI-DrugBank.d522.s1|92-103|terfenadine|drug
DDI-DrugBank.d522.s1|107-118|combination|drug
DDI-DrugBank.d522.s1|124-137|dirithromycin|drug
DDI-DrugBank.d522.s3|4-20|pharmacokinetics|drug
DDI-DrugBank.d522.s3|24-35|terfenadine|drug
DDI-DrugBank.d522.s3|94-102|interval|drug
DDI-DrugBank.d522.s3|108-116|measured|group
DDI-DrugBank.d522.s3|117-123|during|drug
DDI-DrugBank.d522.s3|143-154|terfenadine|drug
DDI-DrugBank.d522.s3|171-182|terfenadine|drug
DDI-DrugBank.d522.s3|188-202|dirithromycin.|drug
DDI-DrugBank.d522.s4|13-24|terfenadine|drug
DDI-DrugBank.d522.s5|25-36|terfenadine|drug
DDI-DrugBank.d522.s5|56-67|terfenadine|drug
DDI-DrugBank.d522.s5|93-104|terfenadine|drug
DDI-DrugBank.d522.s5|110-124|dirithromycin.|drug
DDI-DrugBank.d522.s6|59-70|terfenadine|drug
DDI-DrugBank.d522.s7|14-22|interval|drug
DDI-DrugBank.d522.s7|43-54|terfenadine|drug
DDI-DrugBank.d522.s7|74-85|terfenadine|drug
DDI-DrugBank.d522.s7|91-105|dirithromycin.|drug
DDI-DrugBank.d522.s8|50-61|interaction|drug
DDI-DrugBank.d522.s8|70-83|dirithromycin|drug
DDI-DrugBank.d522.s8|88-100|terfenadine.|drug
DDI-DrugBank.d522.s9|10-21|interaction|drug
DDI-DrugBank.d522.s9|39-51|erythromycin|drug
DDI-DrugBank.d522.s9|56-67|terfenadine|drug
DDI-DrugBank.d522.s9|88-102|dirithromycin.|drug
DDI-DrugBank.d522.s10|35-44|resulting|drug
DDI-DrugBank.d522.s10|81-90|receiving|drug
DDI-DrugBank.d522.s10|91-102|terfenadine|drug
DDI-DrugBank.d522.s10|128-137|macrolide|drug
DDI-DrugBank.d522.s10|138-150|antibiotics.|group
DDI-DrugBank.d522.s11|33-48|contraindicated|group
DDI-DrugBank.d522.s11|61-70|receiving|drug
DDI-DrugBank.d522.s11|71-82|terfenadine|drug
DDI-DrugBank.d522.s11|100-112|pre-existing|drug
DDI-DrugBank.d522.s11|166-174|interval|drug
DDI-DrugBank.d522.s11|230-238|failure,|group
DDI-DrugBank.d522.s12|0-13|Theophylline:|drug
DDI-DrugBank.d522.s12|14-23|Following|drug
DDI-DrugBank.d522.s12|24-41|co-administration|drug
DDI-DrugBank.d522.s12|49-55|250-mg|drug_n
DDI-DrugBank.d522.s12|56-69|dirithromycin|drug
DDI-DrugBank.d522.s12|78-90|administered|drug
DDI-DrugBank.d522.s12|107-113|200-mg|drug_n
DDI-DrugBank.d522.s12|114-126|theophylline|drug
DDI-DrugBank.d522.s12|135-147|administered|drug
DDI-DrugBank.d522.s12|237-249|theophylline|drug
DDI-DrugBank.d522.s13|39-52|dirithromycin|drug
DDI-DrugBank.d522.s13|61-70|receiving|drug
DDI-DrugBank.d522.s13|83-95|theophylline|drug
DDI-DrugBank.d522.s13|142-154|theophylline|drug
DDI-DrugBank.d522.s13|165-175|monitoring|drug
DDI-DrugBank.d522.s13|179-191|theophylline|drug
DDI-DrugBank.d522.s14|9-21|theophylline|drug
DDI-DrugBank.d522.s14|149-160|maintaining|drug
DDI-DrugBank.d522.s14|169-181|theophylline|drug
DDI-DrugBank.d522.s14|254-266|theophylline|drug
DDI-DrugBank.d522.s15|0-8|Antacids|group
DDI-DrugBank.d522.s15|43-56|dirithromycin|drug
DDI-DrugBank.d522.s15|60-72|administered|drug
DDI-DrugBank.d522.s15|85-94|following|drug
DDI-DrugBank.d522.s15|95-103|antacids|group
DDI-DrugBank.d522.s15|152-165|dirithromycin|drug
DDI-DrugBank.d522.s16|4-13|following|drug
DDI-DrugBank.d522.s16|19-31|interactions|drug
DDI-DrugBank.d522.s16|56-68|erythromycin|drug
DDI-DrugBank.d522.s17|50-62|interactions|drug
DDI-DrugBank.d522.s17|74-88|dirithromycin.|drug
DDI-DrugBank.d522.s18|33-42|regarding|drug
DDI-DrugBank.d522.s18|57-68|interaction|drug
DDI-DrugBank.d522.s18|72-85|dirithromycin|drug
DDI-DrugBank.d522.s18|131-137|during|drug
DDI-DrugBank.d522.s18|138-155|coadministration.|drug
DDI-DrugBank.d522.s19|11-23|Erythromycin|drug
DDI-DrugBank.d522.s19|71-80|triazolam|drug
DDI-DrugBank.d522.s19|96-104|increase|drug
DDI-DrugBank.d522.s20|0-8|Digoxin:|drug
DDI-DrugBank.d522.s20|21-35|administration|drug
DDI-DrugBank.d522.s20|39-51|erythromycin|drug
DDI-DrugBank.d522.s20|56-63|digoxin|drug
DDI-DrugBank.d522.s20|104-111|digoxin|drug
DDI-DrugBank.d522.s21|43-52|increased|drug
DDI-DrugBank.d522.s21|53-66|anticoagulant|group
DDI-DrugBank.d522.s21|80-92|erythromycin|drug
DDI-DrugBank.d522.s21|102-116|anticoagulants|group
DDI-DrugBank.d522.s22|10-25|anticoagulation|group
DDI-DrugBank.d522.s22|48-59|interaction|drug
DDI-DrugBank.d522.s22|65-77|erythromycin|drug
DDI-DrugBank.d522.s23|0-11|Ergotamine:|drug
DDI-DrugBank.d522.s23|30-42|erythromycin|drug
DDI-DrugBank.d522.s23|47-57|ergotamine|drug
DDI-DrugBank.d522.s23|61-78|dihydroergotamine|drug
DDI-DrugBank.d522.s24|17-29|interactions|drug
DDI-DrugBank.d522.s24|66-80|administration|drug
DDI-DrugBank.d522.s24|84-96|erythromycin|drug
DDI-DrugBank.d522.s24|120-129|including|drug
DDI-DrugBank.d522.s24|130-143|cyclosporine,|drug
DDI-DrugBank.d522.s24|158-172|carbamazepine,|drug
DDI-DrugBank.d522.s24|199-209|phenytoin,|drug
DDI-DrugBank.d522.s24|210-224|bromocriptine,|drug
DDI-DrugBank.d522.s24|236-247|astemizole,|drug
DDI-DrugBank.d522.s24|252-263|lovastatin.|drug
DDI-MedLine.d34.s1|66-77|interaction|drug
DDI-MedLine.d34.s1|125-132|urinary|drug
DDI-MedLine.d34.s1|197-207|determined|drug
DDI-MedLine.d34.s1|211-216|using|drug
DDI-MedLine.d34.s1|228-238|containing|group
DDI-MedLine.d34.s3|32-39|urinary|drug
DDI-MedLine.d34.s3|137-142|being|drug
DDI-MedLine.d34.s5|26-35|increased|drug
DDI-MedLine.d34.s6|8-15|urinary|drug
DDI-MedLine.d34.s7|30-39|inhibited|drug
DDI-MedLine.d34.s8|43-52|receiving|drug
DDI-MedLine.d34.s8|63-70|instead|drug
DDI-MedLine.d34.s10|19-31|interactions|drug
DDI-MedLine.d34.s11|72-80|contents|group
DDI-MedLine.d34.s12|84-91|showing|drug
DDI-MedLine.d34.s12|202-211|TRUNCATED|brand
DDI-MedLine.d34.s12|219-225|WORDS)|brand
DDI-DrugBank.d275.s0|13-24|interaction|drug
DDI-DrugBank.d275.s1|16-29|toxicokinetic|drug
DDI-DrugBank.d275.s1|148-155|Kineret|drug
DDI-DrugBank.d275.s1|181-193|administered|drug
DDI-DrugBank.d275.s2|92-99|Kineret|drug
DDI-DrugBank.d275.s2|145-155|infections|drug
DDI-DrugBank.d275.s3|50-57|Kineret|drug
DDI-DrugBank.d275.s3|105-112|109/L).|brand
DDI-DrugBank.d121.s0|33-42|following|drug
DDI-DrugBank.d121.s0|55-69|administration|drug
DDI-DrugBank.d121.s0|73-87|aminoglycoside|drug
DDI-DrugBank.d121.s0|88-99|antibiotics|group
DDI-DrugBank.d121.s0|104-117|cephalosporin|drug
DDI-DrugBank.d121.s0|118-130|antibiotics.|group
DDI-DrugBank.d121.s1|12-26|administration|drug
DDI-DrugBank.d121.s2|82-94|administered|drug
DDI-DrugBank.d121.s2|97-104|minutes|drug
DDI-DrugBank.d121.s2|105-114|following|drug
DDI-DrugBank.d309.s0|39-53|antihistamines|group
DDI-DrugBank.d309.s0|58-70|administered|drug
DDI-DrugBank.d309.s0|112-121|including|drug
DDI-DrugBank.d309.s1|9-18|receiving|drug
DDI-DrugBank.d309.s1|19-33|antihistamines|group
DDI-DrugBank.d309.s1|52-59|against|drug_n
DDI-DrugBank.d309.s2|0-9|Monoamine|drug
DDI-DrugBank.d309.s2|18-23|(MAO)|brand
DDI-DrugBank.d309.s2|24-34|inhibitors|drug
DDI-DrugBank.d309.s2|47-56|intensify|drug
DDI-DrugBank.d309.s2|61-76|anticholinergic|group
DDI-DrugBank.d309.s2|88-103|antihistamines.|group
DDI-DrugBank.d369.s0|120-134|gonadotropins.|drug
DDI-DrugBank.d369.s1|12-19|include|drug
DDI-DrugBank.d369.s1|52-59|contain|group
DDI-DrugBank.d369.s1|82-93|progestins,|drug
DDI-DrugBank.d369.s1|97-113|glucocorticoids.|group
DDI-DrugBank.d369.s2|4-16|gonadotropin|drug
DDI-DrugBank.d369.s2|71-80|minimally|drug
DDI-DrugBank.d369.s2|126-140|contraceptives|group
DDI-DrugBank.d369.s2|145-153|digoxin.|drug
DDI-DrugBank.d369.s3|42-56|phenothiazines|drug
DDI-DrugBank.d369.s3|61-69|dopamine|drug
DDI-DrugBank.d369.s3|104-114|prolactin.|drug
DDI-DrugBank.d144.s0|17-31|administration|drug
DDI-DrugBank.d144.s0|35-47|ketoconazole|drug
DDI-DrugBank.d144.s0|57-66|inhibitor|drug
DDI-DrugBank.d144.s0|70-76|CYP3A4|brand
DDI-DrugBank.d144.s0|110-120|intestinal|drug
DDI-DrugBank.d144.s0|150-158|increase|drug
DDI-DrugBank.d144.s0|175-183|exposure|group
DDI-DrugBank.d144.s1|18-28|inhibitors|drug
DDI-DrugBank.d144.s1|32-38|CYP3A4|brand
DDI-DrugBank.d144.s1|57-70|ketoconazole,|drug
DDI-DrugBank.d144.s1|71-85|intraconazole,|drug
DDI-DrugBank.d144.s1|97-107|indinavir,|drug
DDI-DrugBank.d144.s1|108-119|saquinavir,|drug
DDI-DrugBank.d144.s1|120-133|erythromycin,|drug
DDI-DrugBank.d144.s1|143-153|indicated,|drug
DDI-DrugBank.d144.s1|171-181|budesonide|drug
DDI-DrugBank.d144.s2|16-22|intake|drug
DDI-DrugBank.d144.s2|50-58|inhibits|drug
DDI-DrugBank.d144.s2|59-65|CYP3A4|brand
DDI-DrugBank.d144.s2|75-88|predominantly|drug
DDI-DrugBank.d144.s2|96-106|intestinal|drug
DDI-DrugBank.d144.s2|129-137|exposure|group
DDI-DrugBank.d144.s2|147-157|budesonide|drug
DDI-DrugBank.d144.s2|158-167|increased|drug
DDI-DrugBank.d144.s3|30-35|being|drug
DDI-DrugBank.d144.s3|56-63|CYP3A4,|brand
DDI-DrugBank.d144.s3|64-73|ingestion|drug
DDI-DrugBank.d144.s3|145-155|budesonide|drug
DDI-DrugBank.d144.s3|156-171|administration.|drug
DDI-DrugBank.d105.s0|15-24|including|drug
DDI-DrugBank.d105.s0|25-33|coumarin|drug
DDI-DrugBank.d105.s0|47-57|indandione|drug
DDI-DrugBank.d105.s0|96-106|inhibitors|drug
DDI-DrugBank.d105.s0|128-145|anti-inflammatory|group
DDI-DrugBank.d105.s0|166-173|aspirin|brand
DDI-DrugBank.d105.s0|178-186|increase|drug
DDI-DrugBank.d105.s0|199-207|bleeding|drug
DDI-DrugBank.d105.s0|213-225|administered|drug
DDI-DrugBank.d105.s0|245-255|ardeparin.|drug
DDI-DrugBank.d30.s0|25-40|pharmacokinetic|drug
DDI-DrugBank.d30.s0|41-53|interactions|drug
DDI-DrugBank.d30.s0|73-84|interaction|drug
DDI-DrugBank.d30.s0|98-118|hydrochlorothiazide,|group
DDI-DrugBank.d30.s0|119-127|digoxin,|drug
DDI-DrugBank.d30.s0|128-137|warfarin,|drug
DDI-DrugBank.d30.s0|138-148|cimetidine|drug
DDI-DrugBank.d30.s1|0-9|Rifampin,|drug
DDI-DrugBank.d30.s1|13-20|inducer|drug
DDI-DrugBank.d30.s2|15-25|inhibitors|drug
DDI-DrugBank.d30.s3|0-12|Ketoconazole|drug
DDI-DrugBank.d30.s3|86-97|intravenous|drug
DDI-DrugBank.d30.s3|98-112|administration|drug
DDI-DrugBank.d30.s3|130-142|erythromycin|drug
DDI-DrugBank.d30.s3|150-160|clinically|drug
DDI-DrugBank.d30.s3|191-206|administration.|drug
DDI-DrugBank.d30.s4|0-12|Fluconazole,|drug
DDI-DrugBank.d30.s4|16-25|inhibitor|drug
DDI-DrugBank.d30.s4|85-94|increased|drug
DDI-DrugBank.d30.s5|68-78|inhibitors|drug
DDI-DrugBank.d30.s5|105-114|examined.|drug
DDI-DrugBank.d30.s8|31-42|angiotensin|drug
DDI-DrugBank.d30.s8|81-98|potassium-sparing|drug
DDI-DrugBank.d30.s8|99-108|diuretics|group
DDI-DrugBank.d30.s8|157-166|potassium|drug
DDI-DrugBank.d30.s8|200-210|containing|group
DDI-DrugBank.d30.s8|211-220|potassium|drug
DDI-DrugBank.d30.s8|233-242|increases|drug
DDI-DrugBank.d30.s8|252-262|potassium.|drug
DDI-DrugBank.d30.s9|14-30|antihypertensive|group
DDI-DrugBank.d30.s9|43-59|antihypertensive|group
DDI-DrugBank.d30.s9|115-132|anti-inflammatory|group
DDI-DrugBank.d30.s9|138-150|indomethacin|drug
DDI-DrugBank.d220.s0|10-22|interactions|drug
DDI-DrugBank.d220.s0|28-38|Mefloquine|drug
DDI-DrugBank.d220.s1|88-94|taking|drug
DDI-DrugBank.d220.s1|110-124|(propranolol).|drug
DDI-DrugBank.d220.s2|15-29|Mefloquineuine|drug
DDI-DrugBank.d220.s3|16-26|Mefloquine|drug
DDI-DrugBank.d220.s3|53-60|against|drug_n
DDI-DrugBank.d220.s4|69-78|interval,|drug
DDI-DrugBank.d220.s4|79-91|halofantrine|drug
DDI-DrugBank.d220.s4|147-158|Mefloquine.|drug
DDI-DrugBank.d220.s5|12-26|administration|drug
DDI-DrugBank.d220.s5|30-40|Mefloquine|drug
DDI-DrugBank.d220.s5|74-82|quinine,|drug
DDI-DrugBank.d220.s5|83-92|quinidine|drug
DDI-DrugBank.d220.s5|97-109|chloroquine)|drug
DDI-DrugBank.d220.s5|161-169|increase|drug
DDI-DrugBank.d220.s6|37-44|initial|drug
DDI-DrugBank.d220.s6|74-84|Mefloquine|drug
DDI-DrugBank.d220.s6|85-99|administration|drug
DDI-DrugBank.d220.s7|34-46|halofantrine|drug
DDI-DrugBank.d220.s7|53-67|Mefloquineuine|drug
DDI-DrugBank.d220.s7|89-100|lengthening|drug
DDI-DrugBank.d220.s7|112-121|interval.|drug
DDI-DrugBank.d220.s8|0-10|Clinically|drug
DDI-DrugBank.d220.s8|64-78|Mefloquineuine|drug
DDI-DrugBank.d220.s9|28-38|clinically|drug
DDI-DrugBank.d220.s9|48-59|interaction|drug
DDI-DrugBank.d220.s9|78-89|Mefloquine,|drug
DDI-DrugBank.d220.s9|114-130|coadministration|drug
DDI-DrugBank.d220.s9|185-200|anti-arrhythmic|group
DDI-DrugBank.d220.s9|220-228|blocking|drug
DDI-DrugBank.d220.s9|237-244|calcium|drug
DDI-DrugBank.d220.s9|263-277|antihistamines|group
DDI-DrugBank.d220.s9|281-292|H1-blocking|drug
DDI-DrugBank.d220.s9|311-326|antidepressants|group
DDI-DrugBank.d220.s9|331-346|phenothiazines)|drug
DDI-DrugBank.d220.s9|358-368|contribute|group
DDI-DrugBank.d220.s9|398-407|interval.|drug
DDI-DrugBank.d220.s10|70-84|administration|drug
DDI-DrugBank.d220.s10|88-102|Mefloquineuine|drug
DDI-DrugBank.d220.s11|12-18|taking|drug
DDI-DrugBank.d220.s11|22-36|anticonvulsant|group
DDI-DrugBank.d220.s11|57-71|carbamazepine,|drug
DDI-DrugBank.d220.s11|89-100|phenytoin),|drug
DDI-DrugBank.d220.s11|124-134|Mefloquine|drug
DDI-DrugBank.d220.s11|146-153|seizure|group
DDI-DrugBank.d220.s11|154-161|control|group
DDI-DrugBank.d220.s11|165-173|lowering|drug
DDI-DrugBank.d220.s11|199-214|anticonvulsant.|group
DDI-DrugBank.d220.s12|33-39|taking|drug
DDI-DrugBank.d220.s12|40-51|antiseizure|group
DDI-DrugBank.d220.s12|67-77|Mefloquine|drug
DDI-DrugBank.d220.s12|115-126|antiseizure|group
DDI-DrugBank.d220.s13|5-15|Mefloquine|drug
DDI-DrugBank.d220.s13|61-70|vaccines,|drug
DDI-DrugBank.d220.s14|0-12|Vaccinations|drug
DDI-DrugBank.d220.s14|114-125|Mefloquine.|drug
DDI-DrugBank.d220.s15|14-26|interactions|drug
DDI-DrugBank.d220.s16|29-39|Mefloquine|drug
DDI-DrugBank.d220.s16|53-62|receiving|drug
DDI-DrugBank.d220.s16|112-117|using|drug
DDI-DrugBank.d220.s16|118-133|anticoagulants,|group
DDI-DrugBank.d220.s16|159-169|departure.|group
DDI-DrugBank.d220.s17|3-11|clinical|drug
DDI-DrugBank.d220.s17|36-50|administration|drug
DDI-DrugBank.d220.s17|54-65|sulfadoxine|drug
DDI-DrugBank.d220.s17|70-83|pyrimethamine|drug
DDI-DrugBank.d345.s0|0-5|Since|drug
DDI-DrugBank.d345.s0|6-16|colestipol|drug
DDI-DrugBank.d345.s0|17-30|hydrochloride|drug
DDI-DrugBank.d345.s0|52-58|resin,|drug
DDI-DrugBank.d345.s0|80-88|affinity|drug
DDI-DrugBank.d345.s0|120-126|acids.|group
DDI-DrugBank.d345.s1|22-31|indicated|drug
DDI-DrugBank.d345.s1|37-47|colestipol|drug
DDI-DrugBank.d345.s1|48-61|hydrochloride|drug
DDI-DrugBank.d345.s1|62-67|binds|drug
DDI-DrugBank.d345.s3|4-12|interval|drug
DDI-DrugBank.d345.s3|25-39|administration|drug
DDI-DrugBank.d345.s3|43-51|COLESTID|brand
DDI-DrugBank.d345.s4|78-86|COLESTID|brand
DDI-DrugBank.d345.s4|104-112|impeding|drug
DDI-DrugBank.d345.s5|18-28|colestipol|drug
DDI-DrugBank.d345.s5|29-42|hydrochloride|drug
DDI-DrugBank.d345.s5|60-66|single|drug
DDI-DrugBank.d345.s5|75-86|propranolol|drug
DDI-DrugBank.d345.s5|134-145|propranolol|drug
DDI-DrugBank.d345.s6|50-61|single-dose|drug
DDI-DrugBank.d345.s6|62-76|administration|drug
DDI-DrugBank.d345.s6|80-90|colestipol|drug
DDI-DrugBank.d345.s6|91-104|hydrochloride|drug
DDI-DrugBank.d345.s6|109-120|propranolol|drug
DDI-DrugBank.d345.s6|137-151|administration|drug
DDI-DrugBank.d345.s6|207-218|propranolol|drug
DDI-DrugBank.d345.s7|69-77|minutes.|drug
DDI-DrugBank.d345.s8|63-74|determined.|drug
DDI-DrugBank.d345.s9|23-34|propranolol|drug
DDI-DrugBank.d345.s9|59-67|COLESTID|brand
DDI-DrugBank.d345.s10|46-60|chlorothiazide|group
DDI-DrugBank.d345.s10|77-84|urinary|drug
DDI-DrugBank.d345.s10|127-139|administered|drug
DDI-DrugBank.d345.s10|156-166|colestipol|drug
DDI-DrugBank.d345.s10|167-181|hydrochloride.|drug
DDI-DrugBank.d345.s11|18-31|tetracycline,|drug
DDI-DrugBank.d345.s11|44-54|penicillin|drug
DDI-DrugBank.d345.s11|58-78|hydrochlorothiazide,|group
DDI-DrugBank.d345.s11|154-164|colestipol|drug
DDI-DrugBank.d345.s11|165-179|hydrochloride;|drug
DDI-DrugBank.d345.s12|31-40|determine|drug
DDI-DrugBank.d345.s12|55-69|administration|drug
DDI-DrugBank.d345.s12|86-96|colestipol|drug
DDI-DrugBank.d345.s12|97-111|hydrochloride.|drug
DDI-DrugBank.d345.s13|62-72|colestipol|drug
DDI-DrugBank.d345.s13|73-86|hydrochloride|drug
DDI-DrugBank.d345.s13|91-103|administered|drug
DDI-DrugBank.d345.s13|120-129|following|drug
DDI-DrugBank.d345.s13|137-145|aspirin,|brand
DDI-DrugBank.d345.s13|146-158|clindamycin,|drug
DDI-DrugBank.d345.s13|183-192|nicotinic|drug
DDI-DrugBank.d345.s13|198-207|(niacin),|drug
DDI-DrugBank.d345.s13|221-230|phenytoin|drug
DDI-DrugBank.d345.s13|234-243|warfarin.|drug
DDI-DrugBank.d345.s14|66-71|since|drug
DDI-DrugBank.d345.s14|82-93|conflicting|drug
DDI-DrugBank.d345.s14|120-130|colestipol|drug
DDI-DrugBank.d345.s14|131-144|hydrochloride|drug
DDI-DrugBank.d345.s14|168-175|digoxin|drug
DDI-DrugBank.d345.s14|180-190|digitoxin.|drug
DDI-DrugBank.d345.s15|18-25|binding|drug
DDI-DrugBank.d345.s16|0-13|Discontinuing|group
DDI-DrugBank.d345.s16|14-24|colestipol|drug
DDI-DrugBank.d345.s16|25-38|hydrochloride|drug
DDI-DrugBank.d345.s16|132-137|resin|drug
DDI-DrugBank.d345.s16|161-172|maintenance|drug
DDI-DrugBank.d345.s16|201-207|taking|drug
DDI-DrugBank.d345.s16|208-218|colestipol|drug
DDI-DrugBank.d345.s16|219-233|hydrochloride.|drug
DDI-DrugBank.d345.s17|10-17|binding|drug
DDI-DrugBank.d345.s17|18-24|resins|drug
DDI-DrugBank.d345.s17|34-43|interfere|drug
DDI-DrugBank.d345.s17|98-113|hydrocortisone.|drug
DDI-DrugBank.d76.s0|31-40|Monoamine|drug
DDI-DrugBank.d76.s1|12-21|receiving|drug
DDI-DrugBank.d76.s1|22-29|another|drug
DDI-DrugBank.d76.s1|30-39|serotonin|drug
DDI-DrugBank.d76.s1|49-58|inhibitor|drug
DDI-DrugBank.d76.s1|67-78|combination|drug
DDI-DrugBank.d76.s1|84-93|monoamine|drug
DDI-DrugBank.d76.s1|102-112|inhibitors|drug
DDI-DrugBank.d76.s1|113-120|(MAOI),|brand
DDI-DrugBank.d76.s1|184-193|including|drug
DDI-DrugBank.d76.s1|239-250|instability|drug
DDI-DrugBank.d76.s1|331-338|include|drug
DDI-DrugBank.d76.s1|357-368|progressing|drug
DDI-DrugBank.d76.s1|372-380|delirium|drug
DDI-DrugBank.d76.s2|61-73|discontinued|group
DDI-DrugBank.d76.s2|111-116|MAOI.|brand
DDI-DrugBank.d76.s3|26-34|features|group
DDI-DrugBank.d76.s3|35-45|resembling|drug
DDI-DrugBank.d76.s3|46-57|neuroleptic|drug
DDI-DrugBank.d76.s4|34-45|Fluvoxamine|drug
DDI-DrugBank.d76.s4|69-80|combination|drug
DDI-DrugBank.d76.s4|96-102|within|drug
DDI-DrugBank.d76.s4|114-127|discontinuing|group
DDI-DrugBank.d76.s4|145-150|MAOI.|brand
DDI-DrugBank.d76.s5|6-14|stopping|drug
DDI-DrugBank.d76.s5|15-26|Fluvoxamine|drug
DDI-DrugBank.d76.s5|78-86|starting|drug
DDI-DrugBank.d76.s5|89-94|MAOI.|brand
DDI-DrugBank.d76.s6|10-22|Terfenadine,|drug
DDI-DrugBank.d76.s6|23-34|Astemizole,|drug
DDI-DrugBank.d76.s6|39-48|Cisapride|drug
DDI-DrugBank.d76.s7|0-12|Terfenadine,|drug
DDI-DrugBank.d76.s7|13-23|astemizole|drug
DDI-DrugBank.d76.s7|28-37|cisapride|drug
DDI-DrugBank.d76.s7|76-85|P450IIIA4|brand
DDI-DrugBank.d76.s7|129-142|ketoconazole,|drug
DDI-DrugBank.d76.s7|152-161|inhibitor|drug
DDI-DrugBank.d76.s7|165-171|IIIA4,|brand
DDI-DrugBank.d76.s7|210-219|resulting|drug
DDI-DrugBank.d76.s7|223-232|increased|drug
DDI-DrugBank.d76.s8|35-47|terfenadine,|drug
DDI-DrugBank.d76.s8|48-59|astemizole,|drug
DDI-DrugBank.d76.s8|64-73|cisapride|drug
DDI-DrugBank.d76.s8|138-150|pointes-type|drug
DDI-DrugBank.d76.s9|27-38|fluvoxamine|drug
DDI-DrugBank.d76.s9|42-53|combination|drug
DDI-DrugBank.d76.s9|117-122|IIIA4|brand
DDI-DrugBank.d76.s10|25-37|definitively|drug
DDI-DrugBank.d76.s10|56-67|fluvoxamine|drug
DDI-DrugBank.d76.s10|80-85|IIIA4|brand
DDI-DrugBank.d76.s10|86-96|inhibitor,|drug
DDI-DrugBank.d76.s10|139-150|interaction|drug
DDI-DrugBank.d76.s10|154-165|fluvoxamine|drug
DDI-DrugBank.d76.s11|37-48|fluvoxamine|drug
DDI-DrugBank.d76.s11|64-75|combination|drug
DDI-DrugBank.d76.s11|88-100|terbinafine,|drug
DDI-DrugBank.d76.s11|101-112|astemizole,|drug
DDI-DrugBank.d76.s12|47-63|Benzodiazepines:|drug
DDI-DrugBank.d76.s12|64-79|Benzodiazepines|drug
DDI-DrugBank.d76.s12|143-152|triazolam|drug
DDI-DrugBank.d76.s12|251-263|fluvoxamine.|drug
DDI-DrugBank.d76.s13|17-32|benzodiazepines|drug
DDI-DrugBank.d76.s13|134-146|fluvoxamine.|drug
DDI-DrugBank.d76.s14|17-28|fluvoxamine|drug
DDI-DrugBank.d76.s14|53-63|alprazolam|drug
DDI-DrugBank.d76.s14|80-95|co-administered|drug
DDI-DrugBank.d76.s14|144-160|pharmacokinetics|drug
DDI-DrugBank.d76.s14|172-177|(AUC,|brand
DDI-DrugBank.d76.s14|184-190|T1/2,)|brand
DDI-DrugBank.d76.s14|194-204|alprazolam|drug
DDI-DrugBank.d76.s14|250-260|alprazolam|drug
DDI-DrugBank.d76.s14|265-277|administered|drug
DDI-DrugBank.d76.s16|20-30|alprazolam|drug
DDI-DrugBank.d76.s17|5-17|interaction,|drug
DDI-DrugBank.d76.s17|37-49|investigated|drug
DDI-DrugBank.d76.s17|50-55|using|drug
DDI-DrugBank.d76.s17|72-84|fluvoxamine,|drug
DDI-DrugBank.d76.s17|134-150|co-administered,|drug
DDI-DrugBank.d76.s17|164-169|since|drug
DDI-DrugBank.d76.s17|170-181|fluvoxamine|drug
DDI-DrugBank.d76.s17|191-201|non-linear|drug
DDI-DrugBank.d76.s17|202-218|pharmacokinetics|drug
DDI-DrugBank.d76.s17|241-248|100-300|drug_n
DDI-DrugBank.d76.s17|256-266|alprazolam|drug
DDI-DrugBank.d76.s17|270-285|co-administered|drug
DDI-DrugBank.d76.s17|291-302|Fluvoxamine|drug
DDI-DrugBank.d76.s17|316-323|initial|drug
DDI-DrugBank.d76.s17|324-334|alprazolam|drug
DDI-DrugBank.d76.s18|37-48|Fluvoxamine|drug
DDI-DrugBank.d76.s19|14-31|co-administration|drug
DDI-DrugBank.d76.s19|35-46|Fluvoxamine|drug
DDI-DrugBank.d76.s20|8-19|fluvoxamine|drug
DDI-DrugBank.d76.s20|180-186|during|drug
DDI-DrugBank.d76.s20|195-213|co-administration.|drug
DDI-DrugBank.d76.s21|9-19|supporting|drug
DDI-DrugBank.d76.s21|46-57|inadvisable|drug
DDI-DrugBank.d76.s21|61-74|co-administer|drug
DDI-DrugBank.d76.s21|75-86|fluvoxamine|drug
DDI-DrugBank.d76.s21|152-158|taking|drug
DDI-DrugBank.d76.s21|173-184|fluvoxamine|drug
DDI-DrugBank.d76.s21|190-202|administered|drug
DDI-DrugBank.d76.s21|205-211|single|drug
DDI-DrugBank.d76.s22|134-141|measure|group
DDI-DrugBank.d76.s23|125-140|administration.|drug
DDI-DrugBank.d76.s24|50-61|fluvoxamine|drug
DDI-DrugBank.d76.s24|101-113|administered|drug
DDI-DrugBank.d76.s25|0-12|Accordingly,|drug
DDI-DrugBank.d76.s25|26-37|fluvoxamine|drug
DDI-DrugBank.d76.s25|49-59|ordinarily|drug
DDI-DrugBank.d76.s25|63-79|co-administered.|drug
DDI-DrugBank.d76.s26|0-13|Theophylline:|drug
DDI-DrugBank.d76.s26|41-52|fluvoxamine|drug
DDI-DrugBank.d76.s26|71-87|pharmacokinetics|drug
DDI-DrugBank.d76.s26|93-99|single|drug
DDI-DrugBank.d76.s26|108-120|Theophylline|drug
DDI-DrugBank.d76.s26|140-153|aminophylline|drug
DDI-DrugBank.d76.s26|182-194|non-smoking,|drug
DDI-DrugBank.d76.s27|17-29|theophylline|drug
DDI-DrugBank.d76.s27|58-65|3-fold.|drug_n
DDI-DrugBank.d76.s28|14-26|theophylline|drug
DDI-DrugBank.d76.s28|30-45|co-administered|drug
DDI-DrugBank.d76.s28|51-62|fluvoxamine|drug
DDI-DrugBank.d76.s28|131-142|maintenance|drug
DDI-DrugBank.d76.s28|177-189|theophylline|drug
DDI-DrugBank.d76.s29|37-48|Fluvoxamine|drug
DDI-DrugBank.d76.s30|0-9|Warfarin:|drug
DDI-DrugBank.d76.s30|15-26|fluvoxamine|drug
DDI-DrugBank.d76.s30|51-63|administered|drug
DDI-DrugBank.d76.s30|83-91|warfarin|drug
DDI-DrugBank.d76.s30|107-115|warfarin|drug
DDI-DrugBank.d76.s30|138-147|increased|drug
DDI-DrugBank.d76.s30|159-170|prothrombin|drug
DDI-DrugBank.d76.s31|14-23|receiving|drug
DDI-DrugBank.d76.s31|29-43|anticoagulants|group
DDI-DrugBank.d76.s31|48-59|Fluvoxamine|drug
DDI-DrugBank.d76.s31|86-97|prothrombin|drug
DDI-DrugBank.d76.s31|123-136|anticoagulant|group
DDI-DrugBank.d76.s31|151-163|accordingly.|drug
DDI-DrugBank.d76.s32|37-48|Fluvoxamine|drug
DDI-DrugBank.d265.s0|60-76|antihypertensive|group
DDI-DrugBank.d265.s1|58-66|blocking|drug
DDI-DrugBank.d265.s2|38-47|influence|drug
DDI-DrugBank.d265.s3|0-7|Warning|drug
DDI-DrugBank.d265.s3|89-100|drowsiness,|drug
DDI-DrugBank.d265.s3|122-127|pains|drug
DDI-DrugBank.d265.s3|197-213|gastrointestinal|drug
DDI-DrugBank.d265.s3|246-255|vomiting.|drug
DDI-DrugBank.d265.s4|0-7|Insulin|drug
DDI-DrugBank.d265.s4|49-59|increased,|drug
DDI-DrugBank.d265.s6|45-51|during|drug
DDI-DrugBank.d265.s6|67-82|administration.|drug
DDI-DrugBank.d265.s7|37-45|increase|drug
DDI-DrugBank.d265.s7|68-81|tubocurarine.|drug
DDI-DrugBank.d265.s8|73-88|norepinephrine.|drug
DDI-DrugBank.d265.s9|5-15|diminution|drug
DDI-DrugBank.d268.s1|39-48|ointments|drug
DDI-DrugBank.d303.s0|0-10|Metformin:|drug
DDI-DrugBank.d303.s0|37-43|single|drug
DDI-DrugBank.d303.s0|60-70|cephalexin|drug
DDI-DrugBank.d303.s0|75-85|metformin,|drug
DDI-DrugBank.d303.s0|93-102|metformin|drug
DDI-DrugBank.d303.s0|121-130|increased|drug
DDI-DrugBank.d303.s0|179-188|metformin|drug
DDI-DrugBank.d303.s1|3-14|information|drug
DDI-DrugBank.d303.s1|38-49|interaction|drug
DDI-DrugBank.d303.s1|53-63|cephalexin|drug
DDI-DrugBank.d303.s1|68-77|metformin|drug
DDI-DrugBank.d303.s1|78-87|following|drug
DDI-DrugBank.d303.s2|82-99|co-administration|drug
DDI-DrugBank.d303.s2|103-113|cephalexin|drug
DDI-DrugBank.d303.s2|118-127|metformin|drug
DDI-DrugBank.d303.s2|131-141|inhibition|drug
DDI-DrugBank.d303.s3|0-12|Accordingly,|drug
DDI-DrugBank.d303.s3|29-39|monitoring|drug
DDI-DrugBank.d303.s3|63-72|metformin|drug
DDI-DrugBank.d303.s3|114-120|taking|drug
DDI-DrugBank.d303.s3|121-131|cephalexin|drug
DDI-DrugBank.d303.s3|136-146|metformin.|drug
DDI-DrugBank.d303.s4|60-70|cephalexin|drug
DDI-DrugBank.d303.s4|74-83|inhibited|drug
DDI-DrugBank.d303.s5|51-65|administration|drug
DDI-DrugBank.d303.s5|122-127|urine|drug
DDI-DrugBank.d303.s6|43-50|Fehling|drug
DDI-DrugBank.d303.s6|77-86|Clinitest|drug
DDI-DrugBank.d94.s0|0-10|Clinically|drug
DDI-DrugBank.d94.s0|11-21|meaningful|drug
DDI-DrugBank.d94.s0|27-39|interactions|drug
DDI-DrugBank.d94.s0|87-95|include,|drug
DDI-DrugBank.d94.s0|123-133|following:|drug
DDI-DrugBank.d94.s0|164-171|Protein|drug
DDI-DrugBank.d94.s0|172-185|Carbamazepine|drug
DDI-DrugBank.d94.s0|216-225|proteins;|drug
DDI-DrugBank.d94.s1|11-25|administration|drug
DDI-DrugBank.d94.s1|29-38|EQUETROTM|brand
DDI-DrugBank.d94.s1|52-58|taking|drug
DDI-DrugBank.d94.s1|59-66|another|drug
DDI-DrugBank.d94.s1|87-94|protein|drug
DDI-DrugBank.d94.s1|118-127|increased|drug
DDI-DrugBank.d94.s2|54-61|Epoxide|drug
DDI-DrugBank.d94.s2|72-85|Carbamazepine|drug
DDI-DrugBank.d94.s2|101-107|mainly|drug
DDI-DrugBank.d94.s2|127-132|(CYP)|brand
DDI-DrugBank.d94.s2|151-164|carbamazepine|drug
DDI-DrugBank.d94.s2|165-179|10,11-epoxide,|drug_n
DDI-DrugBank.d94.s2|230-237|epoxide|drug
DDI-DrugBank.d94.s2|238-248|hydrolase.|drug
DDI-DrugBank.d94.s3|36-47|interaction|drug
DDI-DrugBank.d94.s3|56-69|carbamazepine|drug
DDI-DrugBank.d94.s3|89-97|inhibits|drug
DDI-DrugBank.d94.s3|98-104|CYP3A4|brand
DDI-DrugBank.d94.s3|112-119|epoxide|drug
DDI-DrugBank.d94.s3|120-130|hydrolase.|drug
DDI-DrugBank.d94.s4|16-22|CYP3A4|brand
DDI-DrugBank.d94.s4|23-33|inhibitors|drug
DDI-DrugBank.d94.s4|76-84|increase|drug
DDI-DrugBank.d94.s4|102-111|EQUETROTM|brand
DDI-DrugBank.d94.s4|120-130|following:|drug
DDI-DrugBank.d94.s4|146-151|azole|drug
DDI-DrugBank.d94.s4|152-164|antifungals,|group
DDI-DrugBank.d94.s4|165-176|cimetidine,|drug
DDI-DrugBank.d94.s4|177-195|clarithromycin(1),|drug
DDI-DrugBank.d94.s4|196-209|dalfopristin,|drug
DDI-DrugBank.d94.s4|219-231|delavirdine,|drug
DDI-DrugBank.d94.s4|243-259|erythromycin(1),|drug
DDI-DrugBank.d94.s4|260-271|fluoxetine,|drug
DDI-DrugBank.d94.s4|272-284|fluvoxamine,|drug
DDI-DrugBank.d94.s4|314-327|itraconazole,|drug
DDI-DrugBank.d94.s4|328-341|ketoconazole,|drug
DDI-DrugBank.d94.s4|342-353|loratadine,|drug
DDI-DrugBank.d94.s4|366-378|niacinamide,|drug
DDI-DrugBank.d94.s4|379-392|nicotinamide,|drug
DDI-DrugBank.d94.s4|402-413|inhibitors,|drug
DDI-DrugBank.d94.s4|428-436|quinine,|drug
DDI-DrugBank.d94.s4|437-450|quinupristin,|drug
DDI-DrugBank.d94.s4|451-466|troleandomycin,|drug
DDI-DrugBank.d94.s5|59-69|EQUETROTM,|brand
DDI-DrugBank.d94.s5|79-85|begins|drug
DDI-DrugBank.d94.s5|126-132|CYP3A4|brand
DDI-DrugBank.d94.s5|136-143|epoxide|drug
DDI-DrugBank.d94.s5|144-153|hydrolase|drug
DDI-DrugBank.d94.s5|154-165|inhibitors,|drug
DDI-DrugBank.d94.s5|219-228|EQUETROTM|brand
DDI-DrugBank.d94.s6|46-59|Carbamazepine|drug
DDI-DrugBank.d94.s6|78-85|CYP3A4.|brand
DDI-DrugBank.d94.s7|36-47|interaction|drug
DDI-DrugBank.d94.s7|56-69|carbamazepine|drug
DDI-DrugBank.d94.s7|89-96|induces|drug
DDI-DrugBank.d94.s7|97-104|CYP3A4.|brand
DDI-DrugBank.d94.s8|20-28|inducers|drug
DDI-DrugBank.d94.s8|97-106|EQUETROTM|brand
DDI-DrugBank.d94.s8|115-125|following:|drug
DDI-DrugBank.d94.s8|126-136|Cisplatin,|drug
DDI-DrugBank.d94.s8|137-148|doxorubicin|drug
DDI-DrugBank.d94.s8|165-174|rifampin,|drug
DDI-DrugBank.d94.s8|190-203|Phenytoin(2),|drug
DDI-DrugBank.d94.s8|233-245|theophylline|drug
DDI-DrugBank.d94.s8|305-315|EQUETROTM,|brand
DDI-DrugBank.d94.s8|325-331|begins|drug
DDI-DrugBank.d94.s8|372-378|CYP3A4|brand
DDI-DrugBank.d94.s8|379-388|inducers,|drug
DDI-DrugBank.d94.s8|428-436|increase|drug
DDI-DrugBank.d94.s8|441-450|EQUETROTM|brand
DDI-DrugBank.d94.s9|48-61|Carbamazepine|drug
DDI-DrugBank.d94.s9|106-119|Carbamazepine|drug
DDI-DrugBank.d94.s9|132-138|induce|drug
DDI-DrugBank.d94.s9|139-145|CYP1A2|brand
DDI-DrugBank.d94.s9|150-157|CYP3A4.|brand
DDI-DrugBank.d94.s10|36-47|interaction|drug
DDI-DrugBank.d94.s10|56-69|carbamazepine|drug
DDI-DrugBank.d94.s11|96-105|EQUETROTM|brand
DDI-DrugBank.d94.s11|113-122|induction|drug
DDI-DrugBank.d94.s11|146-156|following:|drug
DDI-DrugBank.d94.s11|157-171|Acetaminophen,|drug
DDI-DrugBank.d94.s11|184-198|amitriptyline,|drug
DDI-DrugBank.d94.s11|255-265|clozapine,|drug
DDI-DrugBank.d94.s11|266-278|cyclosporin,|drug
DDI-DrugBank.d94.s11|279-291|delavirdine,|drug
DDI-DrugBank.d94.s11|292-304|desipramine,|drug
DDI-DrugBank.d94.s11|326-338|doxycycline,|drug
DDI-DrugBank.d94.s11|364-375|felodipine,|drug
DDI-DrugBank.d94.s11|376-392|glucocorticoids,|group
DDI-DrugBank.d94.s11|406-419|itraconazole,|drug
DDI-DrugBank.d94.s11|420-432|lamotrigine,|drug
DDI-DrugBank.d94.s11|433-447|levothyroxine,|drug
DDI-DrugBank.d94.s11|481-493|mirtazapine,|drug
DDI-DrugBank.d94.s11|494-508|nortriptyline,|drug
DDI-DrugBank.d94.s11|509-520|olanzapine,|drug
DDI-DrugBank.d94.s11|526-544|contraceptives(3),|group
DDI-DrugBank.d94.s11|545-559|oxcarbazepine,|drug
DDI-DrugBank.d94.s11|560-573|Phenytoin(4),|drug
DDI-DrugBank.d94.s11|597-608|inhibitors,|drug
DDI-DrugBank.d94.s11|609-620|quetiapine,|drug
DDI-DrugBank.d94.s11|634-647|theophylline,|drug
DDI-DrugBank.d94.s11|660-670|tiagabine,|drug
DDI-DrugBank.d94.s11|703-714|warfarin(5)|drug
DDI-DrugBank.d94.s12|104-110|begins|drug
DDI-DrugBank.d94.s12|138-148|EQUETROTM,|brand
DDI-DrugBank.d94.s12|188-196|increase|drug
DDI-DrugBank.d94.s13|48-62|Carbamazepine:|drug
DDI-DrugBank.d94.s13|63-72|EQUETROTM|brand
DDI-DrugBank.d94.s13|73-82|increases|drug
DDI-DrugBank.d94.s13|108-117|following|drug
DDI-DrugBank.d94.s13|126-138|Clomipramine|drug
DDI-DrugBank.d94.s13|144-157|Phenytoin(6),|drug
DDI-DrugBank.d94.s13|276-282|begins|drug
DDI-DrugBank.d94.s13|314-324|EQUETROTM,|brand
DDI-DrugBank.d94.s14|50-63|Carbamazepine|drug
DDI-DrugBank.d94.s14|76-90|administration|drug
DDI-DrugBank.d94.s14|94-107|carbamazepine|drug
DDI-DrugBank.d94.s14|112-119|lithium|drug
DDI-DrugBank.d94.s14|124-132|increase|drug
DDI-DrugBank.d94.s15|10-24|anticonvulsant|group
DDI-DrugBank.d94.s15|39-53|carbamazepine,|drug
DDI-DrugBank.d94.s15|54-63|EQUETROTM|brand
DDI-DrugBank.d94.s15|128-144|anticonvulsants.|group
DDI-DrugBank.d94.s16|14-27|anti-malarial|group
DDI-DrugBank.d94.s16|43-54|chloroquine|drug
DDI-DrugBank.d94.s16|59-70|mefloquine,|drug
DDI-DrugBank.d94.s16|102-116|carbamazepine.|drug
DDI-DrugBank.d94.s17|103-109|begins|drug
DDI-DrugBank.d94.s17|137-147|EQUETROTM,|brand
DDI-DrugBank.d94.s18|63-72|EQUETROTM|brand
DDI-DrugBank.d94.s18|103-109|acting|drug
DDI-MedLine.d19.s0|30-38|pateint.|drug
DDI-MedLine.d19.s3|28-41|precipitating|drug
DDI-MedLine.d19.s3|42-56|anticonvulsant|group
DDI-MedLine.d19.s4|14-26|interactions|drug
DDI-MedLine.d19.s4|50-64|anticonvulsant|group
DDI-MedLine.d19.s4|100-110|phenytoin,|drug
DDI-MedLine.d19.s5|33-42|occurring|drug
DDI-MedLine.d19.s5|67-76|following|drug
DDI-MedLine.d19.s5|136-144|inducing|drug
DDI-DrugBank.d448.s0|4-14|inhibitors|drug
DDI-DrugBank.d448.s0|27-36|intensify|drug
DDI-DrugBank.d448.s0|52-67|antihistamines.|group
DDI-DrugBank.d448.s1|19-33|antihistamines|group
DDI-DrugBank.d448.s1|58-74|antidepressants,|group
DDI-DrugBank.d448.s2|49-58|receiving|drug
DDI-DrugBank.d448.s2|59-68|monoamine|drug
DDI-DrugBank.d448.s2|77-88|inhibitors,|drug
DDI-DrugBank.d448.s2|113-122|including|drug
DDI-DrugBank.d448.s3|4-20|antihypertensive|group
DDI-DrugBank.d448.s3|44-57|mecamylamine,|drug
DDI-DrugBank.d448.s3|58-68|reserpine,|drug
DDI-DrugBank.d448.s3|82-91|alkaloids|group
DDI-DrugBank.d448.s4|16-24|blocking|drug
DDI-DrugBank.d448.s4|41-49|interact|drug
DDI-DrugBank.d448.s5|52-67|pseudoephedrine|drug
DDI-DrugBank.d448.s6|0-8|Antacids|group
DDI-DrugBank.d448.s6|9-17|increase|drug
DDI-DrugBank.d448.s6|44-60|pseudoephedrine,|drug
DDI-DrugBank.d448.s6|67-73|kaolin|drug
DDI-DrugBank.d171.s0|41-48|certain|drug
DDI-DrugBank.d171.s0|130-143|warfarin-type|drug
DDI-DrugBank.d171.s0|144-159|anticoagulants,|group
DDI-DrugBank.d171.s0|160-170|phenytoin,|drug
DDI-DrugBank.d171.s0|171-183|propranolol,|drug
DDI-DrugBank.d171.s0|184-195|nifedipine,|drug
DDI-DrugBank.d171.s0|224-231|certain|drug
DDI-DrugBank.d171.s0|242-258|antidepressants,|group
DDI-DrugBank.d171.s0|259-269|lidocaine,|drug
DDI-DrugBank.d171.s0|270-282|theophylline|drug
DDI-DrugBank.d171.s0|287-301|metronidazole,|drug
DDI-DrugBank.d171.s0|310-318|delaying|drug
DDI-DrugBank.d171.s0|319-330|elimination|drug
DDI-DrugBank.d171.s0|335-345|increasing|drug
DDI-DrugBank.d171.s1|0-10|Clinically|drug
DDI-DrugBank.d171.s1|59-67|warfarin|drug
DDI-DrugBank.d171.s1|68-83|anticoagulants;|group
DDI-DrugBank.d171.s2|17-27|monitoring|drug
DDI-DrugBank.d171.s2|31-42|prothrombin|drug
DDI-DrugBank.d171.s2|86-99|anticoagulant|group
DDI-DrugBank.d171.s2|138-150|administered|drug
DDI-DrugBank.d171.s3|17-27|phenytoin,|drug
DDI-DrugBank.d171.s3|28-37|lidocaine|drug
DDI-DrugBank.d171.s3|42-54|theophylline|drug
DDI-DrugBank.d171.s3|97-105|clinical|drug
DDI-DrugBank.d171.s4|47-56|receiving|drug
DDI-DrugBank.d171.s4|146-158|theophylline|drug
DDI-DrugBank.d171.s4|243-255|theophylline|drug
DDI-DrugBank.d171.s6|20-29|receiving|drug
DDI-DrugBank.d171.s6|30-42|theophylline|drug
DDI-DrugBank.d171.s7|200-208|starting|drug
DDI-DrugBank.d171.s7|212-220|stopping|drug
DDI-DrugBank.d171.s7|235-247|administered|drug
DDI-DrugBank.d171.s7|259-267|maintain|drug
DDI-DrugBank.d171.s8|42-49|certain|drug
DDI-DrugBank.d171.s8|63-77|ketoconazole).|drug
DDI-DrugBank.d171.s9|75-85|cimetidine|drug
DDI-DrugBank.d171.s9|86-101|administration.|drug
DDI-DrugBank.d171.s10|11-19|clinical|drug
DDI-DrugBank.d171.s10|82-96|administration|drug
DDI-DrugBank.d376.s0|4-12|interact|drug
DDI-DrugBank.d376.s0|75-80|(CNS)|brand
DDI-DrugBank.d376.s0|98-109|habituating|drug
DDI-DrugBank.d376.s0|150-158|increase|drug
DDI-DrugBank.d376.s0|211-220|producing|drug
DDI-DrugBank.d376.s0|253-261|increase|drug
DDI-DrugBank.d376.s0|320-332|ethinamate).|drug
DDI-DrugBank.d238.s0|13-18|using|drug
DDI-DrugBank.d238.s0|32-43|combination|drug
DDI-DrugBank.d238.s1|66-71|using|drug
DDI-DrugBank.d238.s2|38-49|inhibitors.|drug
DDI-DrugBank.d238.s3|82-94|administered|drug
DDI-DrugBank.d238.s3|100-115|anticholinergic|group
DDI-DrugBank.d238.s4|18-33|antidepressants|group
DDI-DrugBank.d238.s4|91-104|guanethidine,|drug
DDI-DrugBank.d238.s4|105-115|clonidine,|drug
DDI-DrugBank.d238.s4|161-172|anticipated|group
DDI-DrugBank.d238.s4|238-254|antidepressants.|group
DDI-DrugBank.d238.s5|56-65|increased|drug
DDI-DrugBank.d238.s5|85-99|administration|drug
DDI-DrugBank.d238.s6|51-66|antidepressants|group
DDI-DrugBank.d238.s6|92-101|increased|drug
DDI-DrugBank.d238.s6|121-135|administration|drug
DDI-DrugBank.d238.s6|173-183|inhibitors|drug
DDI-DrugBank.d238.s6|191-202|cimetidine,|drug
DDI-DrugBank.d238.s6|203-214|fluoxetine)|drug
DDI-DrugBank.d238.s6|248-262|administration|drug
DDI-DrugBank.d238.s6|281-289|inducers|drug
DDI-DrugBank.d238.s6|311-322|phenytoin),|drug
DDI-DrugBank.d238.s6|349-360|anticipated|group
DDI-DrugBank.d238.s7|0-14|Administration|drug
DDI-DrugBank.d238.s7|43-51|increase|drug
DDI-DrugBank.d238.s8|68-80|metabolizing|drug
DDI-DrugBank.d238.s8|109-121|(debrisoquin|drug
DDI-DrugBank.d238.s8|122-134|hydroxylase)|drug
DDI-DrugBank.d238.s8|192-198|7%-10%|drug_n
DDI-DrugBank.d238.s10|78-93|antidepressants|group
DDI-DrugBank.d238.s11|0-9|Depending|drug
DDI-DrugBank.d238.s11|63-71|increase|drug
DDI-DrugBank.d238.s11|133-141|increase|drug
DDI-DrugBank.d238.s11|163-168|TCA).|brand
DDI-DrugBank.d238.s12|13-20|certain|drug
DDI-DrugBank.d238.s12|27-34|inhibit|drug
DDI-DrugBank.d238.s13|3-13|individual|drug
DDI-DrugBank.d238.s13|100-110|inhibiting|drug
DDI-DrugBank.d238.s14|15-22|inhibit|drug
DDI-DrugBank.d238.s14|43-50|include|drug
DDI-DrugBank.d238.s14|95-106|(quinidine;|drug
DDI-DrugBank.d238.s15|0-11|cimetidine)|drug
DDI-DrugBank.d238.s15|66-82|antidepressants,|group
DDI-DrugBank.d238.s15|83-98|phenothiazines,|drug
DDI-DrugBank.d238.s15|115-130|antiarrhythmics|group
DDI-DrugBank.d238.s15|147-159|flecainide).|drug
DDI-DrugBank.d238.s16|24-33|serotonin|drug
DDI-DrugBank.d238.s16|43-53|inhibitors|drug
DDI-DrugBank.d238.s16|69-80|fluoxetine,|drug
DDI-DrugBank.d238.s16|81-92|sertraline,|drug
DDI-DrugBank.d238.s16|93-104|paroxetine,|drug
DDI-DrugBank.d238.s16|109-121|fluvoxamine,|drug
DDI-DrugBank.d238.s16|122-129|inhibit|drug
DDI-DrugBank.d238.s16|171-182|inhibition.|drug
DDI-DrugBank.d238.s17|0-11|Fluvoxamine|drug
DDI-DrugBank.d238.s17|35-42|inhibit|drug
DDI-DrugBank.d238.s17|69-77|involved|drug
DDI-DrugBank.d238.s18|20-40|SSRI-TCAinteractions|drug
DDI-DrugBank.d238.s18|50-58|clinical|drug
DDI-DrugBank.d238.s18|97-107|inhibition|drug
DDI-DrugBank.d238.s18|116-132|pharmacokinetics|drug
DDI-DrugBank.d238.s18|145-154|involved.|drug
DDI-DrugBank.d238.s19|25-34|indicated|drug
DDI-DrugBank.d238.s19|42-59|co-administration|drug
DDI-DrugBank.d238.s19|102-111|switching|drug
DDI-DrugBank.d238.s20|61-71|initiating|drug
DDI-DrugBank.d238.s20|98-103|being|drug
DDI-DrugBank.d238.s20|119-130|fluoxetine,|drug
DDI-DrugBank.d238.s21|43-57|antidepressant|group
DDI-DrugBank.d238.s21|71-79|includes|drug
DDI-DrugBank.d238.s21|111-118|inhibit|drug
DDI-DrugBank.d238.s21|212-226|antidepressant|group
DDI-DrugBank.d238.s22|74-83|increased|drug
DDI-DrugBank.d238.s22|102-116|antidepressant|group
DDI-DrugBank.d238.s23|79-93|antidepressant|group
DDI-DrugBank.d238.s23|100-109|including|drug
DDI-DrugBank.d238.s23|123-128|going|drug
DDI-DrugBank.d238.s23|135-150|co-administered|drug
DDI-DrugBank.d238.s23|156-163|another|drug
DDI-DrugBank.d238.s23|184-193|inhibitor|drug
DDI-DrugBank.d238.s23|219-224|1A2).|brand
DDI-DrugBank.d238.s24|43-51|protein,|drug
DDI-DrugBank.d238.s24|56-70|administration|drug
DDI-DrugBank.d238.s24|96-102|taking|drug
DDI-DrugBank.d238.s24|140-147|protein|drug
DDI-DrugBank.d238.s24|155-164|warfarin,|drug
DDI-DrugBank.d238.s24|165-173|digoxin)|drug
DDI-DrugBank.d238.s24|187-195|increase|drug
DDI-DrugBank.d238.s24|249-258|resulting|drug
DDI-DrugBank.d238.s25|60-73|protein-bound|drug
DDI-DrugBank.d406.s0|4-12|interact|drug
DDI-DrugBank.d406.s0|18-29|cefamandole|drug
DDI-DrugBank.d406.s0|39-50|cephalothin|drug
DDI-DrugBank.d406.s0|51-58|sodium,|drug
DDI-DrugBank.d406.s0|59-68|magnesium|drug
DDI-DrugBank.d406.s0|91-97|sodium|drug
DDI-DrugBank.d406.s0|98-108|succinate,|drug
DDI-DrugBank.d406.s0|113-129|prochlorperazine|drug
DDI-DrugBank.d34.s0|73-81|clinical|drug
DDI-DrugBank.d34.s0|164-173|anhydrase|drug
DDI-DrugBank.d34.s0|174-184|inhibitors|drug
DDI-DrugBank.d34.s0|203-213|instances,|drug
DDI-DrugBank.d34.s0|231-243|interactions|drug
DDI-DrugBank.d34.s1|39-51|interactions|drug
DDI-DrugBank.d34.s1|85-94|receiving|drug
DDI-MedLine.d120.s0|0-9|Molecular|drug
DDI-MedLine.d120.s0|46-58|amphotericin|drug
DDI-MedLine.d120.s0|75-82|filipin|drug
DDI-MedLine.d120.s1|18-30|antibiotics,|group
DDI-MedLine.d120.s1|42-50|filipin,|drug
DDI-MedLine.d120.s1|66-76|clinically|drug
DDI-MedLine.d120.s2|0-12|amphotericin|drug
DDI-MedLine.d120.s2|62-72|infections|drug
DDI-MedLine.d120.s3|21-28|filipin|drug
DDI-MedLine.d120.s3|58-70|amphotericin|drug
DDI-MedLine.d120.s3|113-122|molecular|drug
DDI-MedLine.d120.s3|136-145|following|drug
DDI-MedLine.d120.s3|178-189|antibiotics|group
DDI-MedLine.d120.s4|0-7|filipin|drug
DDI-MedLine.d120.s4|27-33|lysing|drug
DDI-MedLine.d120.s4|65-77|amphotericin|drug
DDI-MedLine.d120.s4|99-109|inhibiting|drug
DDI-MedLine.d120.s5|24-31|filipin|drug
DDI-MedLine.d120.s5|54-63|inhibited|drug
DDI-MedLine.d120.s5|73-85|cholesterol,|drug
DDI-MedLine.d120.s5|151-163|amphotericin|drug
DDI-MedLine.d120.s5|188-197|inhibited|drug
DDI-MedLine.d120.s6|13-22|inference|drug
DDI-MedLine.d120.s6|78-88|determined|drug
DDI-MedLine.d120.s6|125-136|predominant|drug
DDI-DrugBank.d226.s0|22-33|(adenosine)|drug
DDI-DrugBank.d226.s0|55-67|administered|drug
DDI-DrugBank.d226.s0|121-131|quinidine,|drug
DDI-DrugBank.d226.s0|148-156|blocking|drug
DDI-DrugBank.d226.s0|165-172|calcium|drug
DDI-DrugBank.d226.s0|181-189|blocking|drug
DDI-DrugBank.d226.s0|202-213|angiotensin|drug
DDI-DrugBank.d226.s0|214-224|converting|drug
DDI-DrugBank.d226.s0|232-243|inhibitors,|drug
DDI-DrugBank.d226.s1|0-7|Digoxin|drug
DDI-DrugBank.d226.s1|86-94|combined|drug
DDI-DrugBank.d226.s3|33-42|receiving|drug
DDI-DrugBank.d226.s4|15-24|adenosine|drug
DDI-DrugBank.d226.s4|44-59|methylxanthines|drug
DDI-DrugBank.d226.s4|68-76|caffeine|drug
DDI-DrugBank.d226.s4|81-94|theophylline.|drug
DDI-DrugBank.d226.s5|25-41|methylxanthines,|drug
DDI-DrugBank.d226.s5|58-67|adenosine|drug
DDI-DrugBank.d226.s5|87-96|adenosine|drug
DDI-DrugBank.d226.s6|0-9|Adenosine|drug
DDI-DrugBank.d226.s6|37-50|dipyridamole.|drug
DDI-DrugBank.d226.s7|23-32|adenosine|drug
DDI-DrugBank.d226.s7|69-82|dipyridamole.|drug
DDI-DrugBank.d226.s8|0-13|Carbamazepine|drug
DDI-DrugBank.d226.s8|35-43|increase|drug
DDI-DrugBank.d226.s9|25-34|adenosine|drug
DDI-DrugBank.d226.s9|148-162|carbamazepine.|drug
DDI-DrugBank.d544.s0|92-101|including|drug
DDI-DrugBank.d544.s0|102-115|cyclosporine,|drug
DDI-DrugBank.d544.s0|116-132|corticosteroids,|group
DDI-DrugBank.d544.s0|144-156|azathioprine|drug
DDI-DrugBank.d544.s1|6-14|clinical|drug
DDI-DrugBank.d544.s1|27-39|investigated|drug
DDI-DrugBank.d544.s1|56-67|combination|drug
DDI-DrugBank.d544.s2|0-16|Pharmacokinetics|drug
DDI-DrugBank.d544.s3|76-88|azathioprine|drug
DDI-DrugBank.d544.s3|154-164|consisting|drug
DDI-DrugBank.d544.s3|168-181|cyclosporine,|drug
DDI-DrugBank.d544.s3|186-196|(MODIFIED)|brand
DDI-DrugBank.d544.s3|201-217|corticosteroids.|group
DDI-DrugBank.d544.s4|26-36|individual|drug
DDI-DrugBank.d544.s4|82-94|azathioprine|drug
DDI-DrugBank.d544.s4|160-167|outside|drug
DDI-DrugBank.d544.s5|4-13|following|drug
DDI-DrugBank.d544.s5|36-48|administered|drug
DDI-DrugBank.d544.s5|52-60|clinical|drug
DDI-DrugBank.d544.s5|90-98|increase|drug
DDI-DrugBank.d544.s5|121-129|ATG/ALG,|brand
DDI-DrugBank.d544.s5|130-143|azathioprine,|drug
DDI-DrugBank.d544.s5|144-160|corticosteroids,|group
DDI-DrugBank.d544.s5|161-174|cyclosporine,|drug
DDI-MedLine.d134.s0|72-78|sodium|drug
DDI-MedLine.d134.s0|91-100|following|drug
DDI-MedLine.d134.s0|110-121|intravenous|drug
DDI-MedLine.d134.s0|122-137|administration]|drug
DDI-MedLine.d134.s0|170-176|sodium|drug
DDI-MedLine.d134.s1|3-14|intravenous|drug
DDI-MedLine.d134.s1|102-115|concentrating|drug
DDI-MedLine.d134.s1|146-157|intravenous|drug
DDI-MedLine.d134.s1|224-233|injection|drug
DDI-MedLine.d134.s2|3-14|intravenous|drug
DDI-MedLine.d134.s2|15-24|injection|drug
DDI-MedLine.d134.s2|93-102|beginning|drug
DDI-MedLine.d134.s2|166-172|within|drug
DDI-MedLine.d134.s2|199-218|99m-TcO-4-injection|drug_n
DDI-MedLine.d134.s2|226-239|corresponding|drug
DDI-MedLine.d134.s2|240-248|increase|drug
DDI-MedLine.d134.s3|16-26|incomplete|drug
DDI-MedLine.d134.s4|4-15|intravenous|drug
DDI-MedLine.d134.s4|64-72|clinical|drug
DDI-DrugBank.d494.s0|27-45|calcium-containing|group
DDI-DrugBank.d494.s0|46-55|medicines|drug
DDI-DrugBank.d494.s0|56-66|(including|drug
DDI-DrugBank.d494.s0|67-76|antacids)|group
DDI-DrugBank.d494.s0|96-103|calcium|drug
DDI-DrugBank.d494.s0|120-126|urine,|drug
DDI-DrugBank.d494.s0|137-145|increase|drug
DDI-DrugBank.d494.s1|0-5|Using|drug
DDI-DrugBank.d494.s1|6-13|calcium|drug
DDI-DrugBank.d494.s1|55-64|medicine)|drug
DDI-DrugBank.d494.s1|99-106|calcium|drug
DDI-DrugBank.d494.s1|134-142|increase|drug
DDI-DrugBank.d494.s1|157-167|developing|drug
DDI-DrugBank.d403.s0|26-42|drug-interaction|drug
DDI-DrugBank.d403.s1|28-39|interaction|drug
DDI-DrugBank.d403.s3|25-34|interfere|drug
DDI-DrugBank.d403.s3|44-51|routine|drug
DDI-DrugBank.d0.s0|16-22|intake|drug
DDI-DrugBank.d0.s0|70-86|pharmacokinetics|drug
DDI-DrugBank.d0.s1|0-15|Pharmacokinetic|drug
DDI-DrugBank.d0.s1|24-32|indicate|drug
DDI-DrugBank.d0.s1|38-52|administration|drug
DDI-DrugBank.d0.s1|99-115|pharmacokinetics|drug
DDI-DrugBank.d0.s2|0-17|Co-administration|drug
DDI-DrugBank.d0.s2|64-72|increase|drug
DDI-DrugBank.d0.s2|90-98|increase|drug
DDI-DrugBank.d0.s4|4-20|pharmacokinetics|drug
DDI-DrugBank.d0.s4|60-76|6-beta-naltrexol|drug_n
DDI-DrugBank.d0.s4|93-102|following|drug
DDI-DrugBank.d0.s4|103-120|co-administration|drug
DDI-DrugBank.d0.s5|32-40|clinical|drug
DDI-DrugBank.d0.s5|161-171|(including|drug
DDI-DrugBank.d0.s5|172-189|benzodiazepines),|drug
DDI-DrugBank.d0.s5|247-253|taking|drug
DDI-DrugBank.d0.s6|9-15|taking|drug
DDI-DrugBank.d0.s6|47-62|antidepressants|group
DDI-DrugBank.d0.s6|143-149|taking|drug
DDI-MedLine.d99.s0|0-11|Fluvoxamine|drug
DDI-MedLine.d99.s0|12-20|inhibits|drug
DDI-MedLine.d99.s0|25-31|CYP2C9|brand
DDI-MedLine.d99.s1|0-10|OBJECTIVE:|brand
DDI-MedLine.d99.s1|32-39|examine|drug
DDI-MedLine.d99.s1|44-55|interaction|drug
DDI-MedLine.d99.s1|64-75|fluvoxamine|drug
DDI-MedLine.d99.s1|80-91|tolbutamide|drug
DDI-MedLine.d99.s1|108-119|fluvoxamine|drug
DDI-MedLine.d99.s1|120-128|inhibits|drug
DDI-MedLine.d99.s1|129-136|CYP2C9.|brand
DDI-MedLine.d99.s2|0-8|METHODS:|brand
DDI-MedLine.d99.s3|43-54|tolbutamide|drug
DDI-MedLine.d99.s5|42-53|fluvoxamine|drug
DDI-MedLine.d99.s6|31-42|tolbutamide|drug
DDI-MedLine.d99.s6|48-54|single|drug
DDI-MedLine.d99.s7|27-32|urine|drug
DDI-MedLine.d99.s7|57-67|intervals.|drug
DDI-MedLine.d99.s8|41-46|urine|drug
DDI-MedLine.d99.s8|64-75|tolbutamide|drug
DDI-MedLine.d99.s8|101-121|4-hydroxytolbutamide|drug_n
DDI-MedLine.d99.s8|126-144|carboxytolbutamide|drug
DDI-MedLine.d99.s8|157-162|HPLC.|brand
DDI-MedLine.d99.s9|0-8|RESULTS:|brand
DDI-MedLine.d99.s9|9-15|During|drug
DDI-MedLine.d99.s9|31-43|fluvoxamine,|drug
DDI-MedLine.d99.s10|35-45|borderline|drug
DDI-MedLine.d99.s11|26-46|4-hydroxytolbutamide|drug_n
DDI-MedLine.d99.s11|51-69|carboxytolbutamide|drug
DDI-MedLine.d99.s11|179-190|tolbutamide|drug
DDI-MedLine.d99.s11|265-276|tolbutamide|drug
DDI-MedLine.d99.s12|51-61|inhibition|drug
DDI-MedLine.d99.s12|69-84|4-hydroxylation|drug_n
DDI-MedLine.d99.s12|85-91|during|drug
DDI-MedLine.d99.s12|119-130|fluvoxamine|drug
DDI-MedLine.d99.s13|0-11|CONCLUSION:|brand
DDI-MedLine.d99.s13|12-23|Fluvoxamine|drug
DDI-MedLine.d99.s13|38-47|inhibitor|drug
DDI-MedLine.d99.s13|51-57|CYP2C9|brand
DDI-DrugBank.d480.s0|13-18|using|drug
DDI-DrugBank.d480.s0|19-28|Clozapine|drug
DDI-DrugBank.d480.s0|32-43|combination|drug
DDI-DrugBank.d480.s1|55-64|Clozapine|drug
DDI-DrugBank.d480.s1|65-72|induced|drug
DDI-DrugBank.d480.s2|56-64|interact|drug
DDI-DrugBank.d480.s2|84-92|increase|drug
DDI-DrugBank.d480.s3|11-20|Clozapine|drug
DDI-DrugBank.d480.s3|58-64|having|drug
DDI-DrugBank.d480.s4|33-43|Clozapine,|drug
DDI-DrugBank.d480.s4|66-71|using|drug
DDI-DrugBank.d480.s5|36-42|taking|drug
DDI-DrugBank.d480.s5|43-52|clozapine|drug
DDI-DrugBank.d480.s5|98-103|3,000|drug_n
DDI-DrugBank.d480.s6|64-70|during|drug
DDI-DrugBank.d480.s6|71-78|initial|drug
DDI-DrugBank.d480.s6|119-124|being|drug
DDI-DrugBank.d480.s6|125-137|administered|drug
DDI-DrugBank.d480.s6|138-154|benzodiazepines;|drug
DDI-DrugBank.d480.s7|46-52|taking|drug
DDI-DrugBank.d480.s7|86-95|Clozapine|drug
DDI-DrugBank.d480.s8|54-65|interaction|drug
DDI-DrugBank.d480.s8|74-83|Clozapine|drug
DDI-DrugBank.d480.s8|88-103|benzodiazepines|drug
DDI-DrugBank.d480.s8|152-161|clozapine|drug
DDI-DrugBank.d480.s8|165-174|initiated|drug
DDI-DrugBank.d480.s8|187-193|taking|drug
DDI-DrugBank.d480.s8|196-210|benzodiazepine|drug
DDI-DrugBank.d480.s9|0-9|Clozapine|drug
DDI-DrugBank.d480.s9|52-68|antihypertensive|group
DDI-DrugBank.d480.s9|83-98|anticholinergic|group
DDI-DrugBank.d480.s9|110-123|atropine-type|drug
DDI-DrugBank.d480.s10|4-18|administration|drug
DDI-DrugBank.d480.s10|22-33|epinephrine|drug
DDI-DrugBank.d480.s10|77-84|induced|drug
DDI-DrugBank.d480.s10|127-138|epinephrine|drug
DDI-DrugBank.d480.s11|0-23|Pharmacokinetic-related|drug
DDI-DrugBank.d480.s11|38-47|Clozapine|drug
DDI-DrugBank.d480.s12|22-34|interactions|drug
DDI-DrugBank.d480.s12|61-71|individual|drug
DDI-DrugBank.d480.s12|93-103|minimized.|drug
DDI-DrugBank.d480.s13|49-58|receiving|drug
DDI-DrugBank.d480.s13|114-124|inhibitors|drug
DDI-DrugBank.d480.s13|128-136|inducers|drug
DDI-DrugBank.d480.s14|12-26|administration|drug
DDI-DrugBank.d480.s14|45-51|induce|drug
DDI-DrugBank.d480.s14|110-120|clozapine.|drug
DDI-DrugBank.d480.s15|0-10|Phenytoin,|drug
DDI-DrugBank.d480.s15|11-20|nicotine,|drug
DDI-DrugBank.d480.s15|25-33|rifampin|drug
DDI-DrugBank.d480.s15|47-56|Clozapine|drug
DDI-DrugBank.d480.s15|72-81|resulting|drug
DDI-DrugBank.d480.s15|139-148|Clozapine|drug
DDI-DrugBank.d480.s16|12-26|administration|drug
DDI-DrugBank.d480.s16|45-52|inhibit|drug
DDI-DrugBank.d480.s16|98-106|increase|drug
DDI-DrugBank.d480.s16|128-138|clozapine.|drug
DDI-DrugBank.d480.s17|0-11|Cimetidine,|drug
DDI-DrugBank.d480.s17|12-21|caffeine,|drug
DDI-DrugBank.d480.s17|26-38|erythromycin|drug
DDI-DrugBank.d480.s17|43-51|increase|drug
DDI-DrugBank.d480.s17|69-79|Clozapine,|drug
DDI-DrugBank.d480.s17|92-101|resulting|drug
DDI-DrugBank.d480.s18|28-37|Clozapine|drug
DDI-DrugBank.d480.s18|42-55|carbamazepine|drug
DDI-DrugBank.d480.s18|100-115|discontinuation|group
DDI-DrugBank.d480.s18|131-144|carbamazepine|drug
DDI-DrugBank.d480.s18|145-159|administration|drug
DDI-DrugBank.d480.s18|177-185|increase|drug
DDI-DrugBank.d480.s18|189-198|Clozapine|drug
DDI-DrugBank.d480.s19|50-59|clozapine|drug
DDI-DrugBank.d480.s19|91-102|fluvoxamine|drug
DDI-DrugBank.d480.s19|106-116|paroxetine|drug
DDI-DrugBank.d480.s20|17-35|co-administration,|drug
DDI-DrugBank.d480.s20|66-75|clozapine|drug
DDI-DrugBank.d480.s20|97-117|N-desmethylclozapine|drug
DDI-DrugBank.d480.s20|122-131|clozapine|drug
DDI-DrugBank.d480.s20|160-171|fluvoxamine|drug
DDI-DrugBank.d480.s20|204-212|baseline|drug
DDI-DrugBank.d480.s21|0-10|Paroxetine|drug
DDI-DrugBank.d480.s21|25-30|minor|drug
DDI-DrugBank.d480.s21|56-65|clozapine|drug
DDI-DrugBank.d480.s22|84-93|clozapine|drug
DDI-DrugBank.d480.s22|129-138|clozapine|drug
DDI-DrugBank.d480.s22|154-165|paroxetine,|drug
DDI-DrugBank.d480.s22|166-177|fluoxetine,|drug
DDI-DrugBank.d480.s22|182-193|sertraline.|drug
DDI-DrugBank.d480.s23|16-24|combined|drug
DDI-DrugBank.d480.s23|115-124|Clozapine|drug
DDI-DrugBank.d480.s23|128-136|combined|drug
DDI-DrugBank.d480.s23|173-185|fluvoxamine.|drug
DDI-DrugBank.d480.s24|10-19|Clozapine|drug
DDI-DrugBank.d480.s25|60-67|certain|drug
DDI-DrugBank.d480.s25|73-85|metabolizing|drug
DDI-DrugBank.d480.s26|5-16|individuals|drug
DDI-DrugBank.d480.s26|71-83|debrisoquin,|drug
DDI-DrugBank.d480.s26|116-132|antidepressants,|group
DDI-DrugBank.d480.s26|137-147|clozapine.|drug
DDI-DrugBank.d480.s27|6-17|individuals|drug
DDI-DrugBank.d480.s27|76-85|clozapine|drug
DDI-DrugBank.d480.s28|13-20|certain|drug
DDI-DrugBank.d480.s28|65-74|including|drug
DDI-DrugBank.d480.s28|80-95|antidepressants|group
DDI-DrugBank.d480.s28|96-107|(clozapine,|drug
DDI-DrugBank.d480.s28|118-127|serotonin|drug
DDI-DrugBank.d480.s28|137-148|inhibitors,|drug
DDI-DrugBank.d480.s28|166-173|inhibit|drug
DDI-DrugBank.d480.s28|356-363|leading|drug
DDI-DrugBank.d480.s28|372-384|interaction.|drug
DDI-DrugBank.d480.s29|19-28|clozapine|drug
DDI-DrugBank.d480.s29|140-149|clozapine|drug
DDI-DrugBank.d480.s30|11-28|co-administration|drug
DDI-DrugBank.d480.s30|32-41|clozapine|drug
DDI-DrugBank.d480.s30|97-106|including|drug
DDI-DrugBank.d480.s30|107-123|antidepressants,|group
DDI-DrugBank.d480.s30|124-139|phenothiazines,|drug
DDI-DrugBank.d480.s30|140-154|carbamazepine,|drug
DDI-DrugBank.d480.s30|167-182|antiarrhythmics|group
DDI-DrugBank.d480.s30|203-213|flecainide|drug
DDI-DrugBank.d480.s30|218-229|encainide),|drug
DDI-DrugBank.d480.s30|238-245|inhibit|drug
DDI-DrugBank.d480.s30|265-276|quinidine),|drug
DDI-DrugBank.d379.s0|41-52|interaction|drug
DDI-DrugBank.d379.s0|56-63|LEVULAN|brand
DDI-DrugBank.d379.s0|64-73|KERASTICK|brand
DDI-DrugBank.d379.s0|138-150|interactions|drug
DDI-DrugBank.d379.s0|162-168|during|drug
DDI-DrugBank.d379.s0|180-190|controlled|group
DDI-DrugBank.d379.s0|191-199|clinical|drug
DDI-DrugBank.d379.s1|61-77|photosensitizing|drug
DDI-DrugBank.d379.s1|93-106|griseofulvin,|drug
DDI-DrugBank.d379.s1|107-115|thiazide|group
DDI-DrugBank.d379.s1|116-126|diuretics,|group
DDI-DrugBank.d379.s1|127-141|sulfonylureas,|group
DDI-DrugBank.d379.s1|142-157|phenothiazines,|drug
DDI-DrugBank.d379.s1|175-188|tetracyclines|drug
DDI-DrugBank.d379.s1|195-203|increase|drug
DDI-DrugBank.d379.s1|237-244|actinic|drug
DDI-DrugBank.d379.s1|272-279|LEVULAN|brand
DDI-DrugBank.d379.s1|280-289|KERASTICK|brand
DDI-DrugBank.d319.s0|11-18|inhibit|drug
DDI-DrugBank.d138.s0|23-34|interaction|drug
DDI-DrugBank.d138.s0|72-80|ALPHAGAN|brand
DDI-DrugBank.d138.s0|118-130|potentiating|drug
DDI-DrugBank.d138.s1|55-64|pressure.|group
DDI-DrugBank.d138.s2|11-16|using|drug
DDI-DrugBank.d138.s2|84-102|anti-hypertensives|group
DDI-DrugBank.d138.s3|10-25|antidepressants|group
DDI-DrugBank.d138.s3|89-101|clonidine.It|drug
DDI-DrugBank.d138.s3|163-171|ALPHAGAN|brand
DDI-DrugBank.d138.s3|196-205|resulting|drug
DDI-DrugBank.d138.s3|206-218|interference|drug
DDI-DrugBank.d138.s3|232-240|lowering|drug
DDI-DrugBank.d138.s4|24-35|circulating|drug
DDI-DrugBank.d138.s4|36-50|catecholamines|drug
DDI-DrugBank.d138.s4|57-65|ALPHAGAN|brand
DDI-DrugBank.d138.s4|68-82|administration|drug
DDI-DrugBank.d138.s5|41-47|taking|drug
DDI-DrugBank.d138.s5|58-73|antidepressants|group
DDI-DrugBank.d138.s5|120-131|circulating|drug
DDI-DrugBank.d138.s5|132-139|amines.|drug
DDI-DrugBank.d487.s0|4-19|pharmacokinetic|drug
DDI-DrugBank.d487.s0|20-32|interactions|drug
DDI-DrugBank.d487.s0|62-72|clinically|drug
DDI-DrugBank.d487.s1|11-17|induce|drug
DDI-DrugBank.d487.s1|57-66|phenytoin|drug
DDI-DrugBank.d487.s1|71-79|rifampin|drug
DDI-DrugBank.d487.s1|84-92|increase|drug
DDI-DrugBank.d487.s1|110-125|corticosteroids|group
DDI-DrugBank.d487.s1|142-151|increases|drug
DDI-DrugBank.d487.s2|14-28|troleandomycin|drug
DDI-DrugBank.d487.s2|33-45|ketoconazole|drug
DDI-DrugBank.d487.s2|50-57|inhibit|drug
DDI-DrugBank.d487.s2|76-91|corticosteroids|group
DDI-DrugBank.d487.s4|0-15|Corticosteroids|group
DDI-DrugBank.d487.s4|20-28|increase|drug
DDI-DrugBank.d487.s4|64-72|aspirin.|brand
DDI-DrugBank.d487.s5|56-64|increase|drug
DDI-DrugBank.d487.s6|0-7|Aspirin|brand
DDI-DrugBank.d487.s6|54-70|cortico-steroids|group
DDI-DrugBank.d487.s6|83-92|suffering|drug
DDI-DrugBank.d487.s6|98-119|hypopro-thrombinemia.|drug
DDI-DrugBank.d487.s7|14-29|corticosteroids|group
DDI-DrugBank.d487.s7|38-52|anticoagulants|group
DDI-DrugBank.d487.s8|41-51|diminished|drug
DDI-DrugBank.d487.s8|63-77|anticoagulants|group
DDI-DrugBank.d487.s8|107-123|corticosteroids.|group
DDI-DrugBank.d487.s9|23-30|indices|drug
DDI-DrugBank.d487.s9|54-62|maintain|drug
DDI-DrugBank.d487.s9|75-88|anticoagulant|group
DDI-DrugBank.d61.s0|3-11|clinical|drug
DDI-DrugBank.d61.s0|37-52|co-administered|drug
DDI-DrugBank.d61.s0|64-75|anti-asthma|group
DDI-DrugBank.d61.s0|89-98|including|drug
DDI-DrugBank.d61.s0|99-106|inhaled|drug
DDI-DrugBank.d61.s0|137-144|inhaled|drug
DDI-DrugBank.d61.s0|145-161|corticosteroids,|group
DDI-DrugBank.d61.s0|182-191|increased|drug
DDI-DrugBank.d61.s1|20-31|interaction|drug
DDI-DrugBank.d313.s0|65-72|insulin|drug
DDI-DrugBank.d313.s0|112-123|monitoring.|drug
DDI-DrugBank.d313.s1|4-13|following|drug
DDI-DrugBank.d313.s1|50-58|increase|drug
DDI-DrugBank.d313.s1|63-85|blood-glucose-lowering|drug
DDI-DrugBank.d313.s1|134-146|antidiabetic|group
DDI-DrugBank.d313.s1|161-172|inhibitors,|drug
DDI-DrugBank.d313.s1|197-208|fluoxetine,|drug
DDI-DrugBank.d313.s1|209-218|monoamine|drug
DDI-DrugBank.d313.s1|227-232|(MAO)|brand
DDI-DrugBank.d313.s1|233-244|inhibitors,|drug
DDI-DrugBank.d313.s1|272-284|somatostatin|drug
DDI-DrugBank.d313.s1|312-323|sulfonamide|drug
DDI-DrugBank.d313.s1|324-336|antibiotics.|group
DDI-DrugBank.d313.s2|4-13|following|drug
DDI-DrugBank.d313.s2|61-83|blood-glucose-lowering|drug
DDI-DrugBank.d313.s2|92-108|corticosteroids,|group
DDI-DrugBank.d313.s2|109-116|niacin,|drug
DDI-DrugBank.d313.s2|126-136|diuretics,|group
DDI-DrugBank.d313.s2|167-179|epinephrine,|drug
DDI-DrugBank.d313.s2|192-205|terbutaline),|drug
DDI-DrugBank.d313.s2|217-230|phenothiazine|drug
DDI-DrugBank.d313.s2|244-255|somatropin,|drug
DDI-DrugBank.d313.s2|313-329|contraceptives).|group
DDI-DrugBank.d313.s3|15-25|clonidine,|drug
DDI-DrugBank.d313.s3|26-33|lithium|drug
DDI-DrugBank.d313.s3|89-111|blood-glucose-lowering|drug
DDI-DrugBank.d313.s3|122-130|insulin.|drug
DDI-DrugBank.d313.s4|0-11|Pentamidine|drug
DDI-DrugBank.d313.s5|23-32|influence|drug
DDI-DrugBank.d313.s5|50-59|medicinal|drug
DDI-DrugBank.d313.s5|92-102|clonidine,|drug
DDI-DrugBank.d313.s5|103-116|guanethidine,|drug
DDI-DrugBank.d313.s5|121-131|reserpine,|drug
DDI-DrugBank.d313.s6|0-6|Mixing|drug
DDI-DrugBank.d313.s6|10-18|Insulins|drug
DDI-DrugBank.d313.s7|2-10|clinical|drug
DDI-DrugBank.d313.s7|69-75|mixing|drug
DDI-DrugBank.d313.s7|99-106|insulin|drug
DDI-DrugBank.d313.s7|126-135|injection|drug
DDI-DrugBank.d313.s8|35-43|insulin,|drug
DDI-DrugBank.d313.s8|77-84|syringe|drug
DDI-DrugBank.d313.s9|4-13|injection|drug
DDI-DrugBank.d313.s9|47-54|mixing.|drug
DDI-DrugBank.d313.s10|62-73|crystalline|drug
DDI-DrugBank.d313.s10|79-86|insulin|drug
DDI-DrugBank.d313.s11|15-21|mixing|drug
DDI-DrugBank.d313.s11|35-43|insulins|drug
DDI-DrugBank.d313.s11|64-71|insulin|drug
DDI-DrugBank.d313.s11|103-116|manufacturers|group
DDI-DrugBank.d313.s12|0-8|Mixtures|group
DDI-DrugBank.d313.s12|23-35|administered|drug
DDI-DrugBank.d313.s12|36-50|intravenously.|drug
DDI-DrugBank.d313.s13|35-43|infusion|drug
DDI-DrugBank.d313.s13|54-62|insulin,|drug
DDI-DrugBank.d313.s13|106-114|insulins|drug
DDI-DrugBank.d371.s0|26-34|clinical|drug
DDI-DrugBank.d371.s0|64-76|interactions|drug
DDI-DrugBank.d371.s0|80-88|TAXOTERE|brand
DDI-DrugBank.d371.s1|96-110|administration|drug
DDI-DrugBank.d371.s1|129-136|induce,|drug
DDI-DrugBank.d371.s1|137-145|inhibit,|drug
DDI-DrugBank.d371.s1|197-210|cyclosporine,|drug
DDI-DrugBank.d371.s1|211-223|terfenadine,|drug
DDI-DrugBank.d371.s1|224-237|ketoconazole,|drug
DDI-DrugBank.d371.s1|238-251|erythromycin,|drug
DDI-DrugBank.d371.s1|256-271|troleandomycin.|drug
DDI-DrugBank.d371.s2|50-58|treating|drug
DDI-DrugBank.d371.s2|68-77|receiving|drug
DDI-DrugBank.d371.s2|78-86|TAXOTERE|brand
DDI-DrugBank.d371.s2|129-141|interaction.|drug
DDI-DrugBank.d136.s0|8-18|(increases|drug
DDI-DrugBank.d136.s0|38-43|50%),|drug_n
DDI-DrugBank.d136.s0|44-55|cimetidine,|drug
DDI-DrugBank.d500.s0|8-21|tetracyclines|drug
DDI-DrugBank.d500.s0|56-67|prothrombin|drug
DDI-DrugBank.d500.s0|98-111|anticoagulant|group
DDI-DrugBank.d500.s0|161-174|anticoagulant|group
DDI-DrugBank.d500.s1|0-5|Since|drug
DDI-DrugBank.d500.s1|31-40|interfere|drug
DDI-DrugBank.d500.s1|73-84|penicillin,|drug
DDI-DrugBank.d500.s1|110-116|giving|drug
DDI-DrugBank.d500.s1|117-130|tetracyclines|drug
DDI-DrugBank.d500.s1|151-162|penicillin.|drug
DDI-DrugBank.d500.s2|14-27|tetracyclines|drug
DDI-DrugBank.d500.s2|43-51|antacids|group
DDI-DrugBank.d500.s2|52-62|containing|group
DDI-DrugBank.d500.s2|63-72|aluminum,|drug
DDI-DrugBank.d500.s2|73-81|calcium,|drug
DDI-DrugBank.d500.s2|85-95|magnesium,|drug
DDI-DrugBank.d500.s2|100-115|iron-containing|group
DDI-DrugBank.d500.s3|14-26|tetracycline|drug
DDI-DrugBank.d500.s4|14-28|carbamazepine,|drug
DDI-DrugBank.d500.s4|33-42|phenytoin|drug
DDI-DrugBank.d500.s4|69-81|doxycycline.|drug
DDI-DrugBank.d500.s5|22-34|tetracycline|drug
DDI-DrugBank.d500.s6|18-30|tetracycline|drug
DDI-DrugBank.d500.s6|47-61|contraceptives|group
DDI-DrugBank.d500.s7|54-61|urinary|drug
DDI-DrugBank.d500.s7|62-75|catecholamine|drug
DDI-DrugBank.d500.s7|100-112|interference|drug
DDI-DrugBank.d170.s0|7-16|Affecting|drug
DDI-DrugBank.d170.s0|78-84|mainly|drug
DDI-DrugBank.d170.s0|136-145|(CYP3A4),|brand
DDI-DrugBank.d170.s0|166-178|interactions|drug
DDI-DrugBank.d170.s0|194-203|DURAGESIC|brand
DDI-DrugBank.d170.s0|251-257|CYP3A4|brand
DDI-DrugBank.d170.s1|0-15|Coadminstration|drug
DDI-DrugBank.d170.s1|33-39|induce|drug
DDI-DrugBank.d170.s1|80-89|DURAGESIC|brand
DDI-DrugBank.d170.s2|49-58|ritonavir|drug
DDI-DrugBank.d170.s2|79-89|inhibitors|drug
DDI-DrugBank.d170.s2|98-111|ketoconazole,|drug
DDI-DrugBank.d170.s2|112-125|itraconazole,|drug
DDI-DrugBank.d170.s2|126-141|troleandomycin,|drug
DDI-DrugBank.d170.s2|142-157|clarithromycin,|drug
DDI-DrugBank.d170.s2|158-169|nelfinavir,|drug
DDI-DrugBank.d170.s2|202-210|increase|drug
DDI-DrugBank.d170.s3|29-35|CYP3A4|brand
DDI-DrugBank.d170.s3|36-46|inhibitors|drug
DDI-DrugBank.d170.s3|69-81|erythromycin|drug
DDI-DrugBank.d170.s3|130-138|increase|drug
DDI-DrugBank.d170.s3|186-194|increase|drug
DDI-DrugBank.d170.s5|59-68|DURAGESIC|brand
DDI-DrugBank.d170.s5|147-156|including|drug
DDI-DrugBank.d170.s5|182-190|opioids,|group
DDI-DrugBank.d170.s5|234-251|benzodiazepines),|drug
DDI-DrugBank.d170.s5|273-288|phenothiazines,|drug
DDI-DrugBank.d170.s6|10-18|combined|drug
DDI-DrugBank.d170.s6|30-43|contemplated,|group
DDI-DrugBank.d170.s7|16-25|DURAGESIC|brand
DDI-DrugBank.d170.s7|89-95|within|drug
DDI-DrugBank.d170.s7|157-167|inhibitors|drug
DDI-MedLine.d40.s0|38-49|miconazole:|drug
DDI-MedLine.d40.s0|60-70|miconazole|drug
DDI-MedLine.d40.s1|4-14|antifungal|group
DDI-MedLine.d40.s1|21-31|miconazole|drug
DDI-MedLine.d40.s1|41-49|inhibits|drug
DDI-MedLine.d40.s2|61-70|inhibited|drug
DDI-MedLine.d40.s3|149-158|inhibited|drug
DDI-MedLine.d40.s4|81-87|260-nm|drug_n
DDI-MedLine.d40.s4|88-97|absorbing|drug
DDI-MedLine.d40.s4|109-114|amino|drug
DDI-MedLine.d40.s4|115-121|acids,|group
DDI-MedLine.d40.s4|122-131|proteins,|drug
DDI-MedLine.d40.s4|136-145|inorganic|drug
DDI-DrugBank.d339.s0|0-14|Carbamazepine:|drug
DDI-DrugBank.d339.s0|24-37|carbamazepine|drug
DDI-DrugBank.d339.s0|67-80|postmarketing|drug
DDI-DrugBank.d339.s0|97-103|SUPRAX|brand
DDI-DrugBank.d339.s0|107-119|administered|drug
DDI-DrugBank.d339.s1|5-15|monitoring|drug
DDI-DrugBank.d339.s1|40-49|detecting|drug
DDI-DrugBank.d339.s1|65-78|carbamazepine|drug
DDI-DrugBank.d339.s2|0-8|Warfarin|drug
DDI-DrugBank.d339.s2|39-50|prothrombin|drug
DDI-DrugBank.d339.s2|73-81|clinical|drug
DDI-DrugBank.d339.s2|82-91|bleeding,|drug
DDI-DrugBank.d339.s2|127-139|administered|drug
DDI-DrugBank.d339.s3|79-84|urine|drug
DDI-DrugBank.d339.s3|106-111|using|drug
DDI-DrugBank.d339.s3|112-125|nitroprusside|drug
DDI-DrugBank.d339.s3|145-150|using|drug
DDI-DrugBank.d339.s4|4-18|administration|drug
DDI-DrugBank.d339.s4|22-28|SUPRAX|brand
DDI-DrugBank.d339.s4|88-93|urine|drug
DDI-DrugBank.d339.s4|94-99|using|drug
DDI-DrugBank.d339.s4|100-109|Clinitest|drug
DDI-DrugBank.d339.s4|138-145|Fehling|drug
DDI-DrugBank.d339.s5|91-100|Clinistix|drug
DDI-DrugBank.d339.s6|54-60|during|drug
DDI-DrugBank.d339.s6|82-95|cephalosporin|drug
DDI-DrugBank.d339.s6|96-108|antibiotics;|group
DDI-DrugBank.d373.s0|16-24|Blocking|drug
DDI-DrugBank.d373.s0|87-95|clinical|drug
DDI-DrugBank.d373.s0|129-143|administration|drug
DDI-DrugBank.d373.s0|147-157|nifedipine|drug
DDI-DrugBank.d373.s0|162-175|beta-blocking|drug
DDI-DrugBank.d373.s0|199-209|tolerated,|drug
DDI-DrugBank.d373.s0|241-251|literature|group
DDI-DrugBank.d373.s0|260-270|suggesting|drug
DDI-DrugBank.d373.s0|280-291|combination|drug
DDI-DrugBank.d373.s0|296-304|increase|drug
DDI-DrugBank.d373.s0|340-348|failure,|group
DDI-DrugBank.d373.s0|387-394|angina.|drug
DDI-DrugBank.d373.s1|5-11|Acting|drug
DDI-DrugBank.d373.s1|22-32|Nifedipine|drug
DDI-DrugBank.d373.s1|47-62|co-administered|drug
DDI-DrugBank.d373.s1|101-111|controlled|group
DDI-DrugBank.d373.s1|136-147|antianginal|group
DDI-DrugBank.d373.s1|170-182|combination.|drug
DDI-DrugBank.d373.s2|39-44|Since|drug
DDI-DrugBank.d373.s2|104-111|digoxin|drug
DDI-DrugBank.d373.s2|144-155|interaction|drug
DDI-DrugBank.d373.s2|164-171|digoxin|drug
DDI-DrugBank.d373.s2|176-187|nifedipine,|drug
DDI-DrugBank.d373.s2|211-218|digoxin|drug
DDI-DrugBank.d373.s2|244-255|initiating,|drug
DDI-DrugBank.d373.s2|256-266|adjusting,|drug
DDI-DrugBank.d373.s2|271-284|discontinuing|group
DDI-DrugBank.d373.s2|285-295|nifedipine|drug
DDI-DrugBank.d373.s3|26-40|Administration|drug
DDI-DrugBank.d373.s3|44-54|nifedipine|drug
DDI-DrugBank.d373.s3|60-67|digoxin|drug
DDI-DrugBank.d373.s3|68-77|increased|drug
DDI-DrugBank.d373.s3|78-85|digoxin|drug
DDI-DrugBank.d373.s4|12-20|increase|drug
DDI-DrugBank.d373.s5|8-20|investigator|drug
DDI-DrugBank.d373.s5|30-38|increase|drug
DDI-DrugBank.d373.s5|42-49|digoxin|drug
DDI-DrugBank.d373.s6|6-18|uncontrolled|group
DDI-DrugBank.d373.s6|68-75|failure|group
DDI-DrugBank.d373.s6|76-82|during|drug
DDI-DrugBank.d373.s6|89-96|digoxin|drug
DDI-DrugBank.d373.s6|119-128|measured,|group
DDI-DrugBank.d373.s7|0-5|Since|drug
DDI-DrugBank.d373.s7|65-72|digoxin|drug
DDI-DrugBank.d373.s7|104-111|digoxin|drug
DDI-DrugBank.d373.s7|137-148|initiating,|drug
DDI-DrugBank.d373.s7|149-159|adjusting,|drug
DDI-DrugBank.d373.s7|164-177|discontinuing|group
DDI-DrugBank.d373.s7|178-188|nifedipine|drug
DDI-DrugBank.d373.s8|0-10|Quinidine:|drug
DDI-DrugBank.d373.s8|74-85|interaction|drug
DDI-DrugBank.d373.s8|94-103|quinidine|drug
DDI-DrugBank.d373.s8|108-118|nifedipine|drug
DDI-DrugBank.d373.s8|153-164|quinidine).|drug
DDI-DrugBank.d373.s9|0-8|Coumarin|drug
DDI-DrugBank.d373.s9|57-66|increased|drug
DDI-DrugBank.d373.s9|67-78|prothrombin|drug
DDI-DrugBank.d373.s9|96-102|taking|drug
DDI-DrugBank.d373.s9|103-111|coumarin|drug
DDI-DrugBank.d373.s9|112-126|anticoagulants|group
DDI-DrugBank.d373.s9|135-145|nifedipine|drug
DDI-DrugBank.d373.s9|150-163|administered.|drug
DDI-DrugBank.d373.s10|29-39|nifedipine|drug
DDI-DrugBank.d373.s10|51-61|uncertain.|drug
DDI-DrugBank.d373.s11|0-11|Cimetidine:|drug
DDI-DrugBank.d373.s11|68-76|increase|drug
DDI-DrugBank.d373.s11|85-95|nifedipine|drug
DDI-DrugBank.d373.s11|172-182|cimetidine|drug
DDI-DrugBank.d373.s11|206-216|nifedipine|drug
DDI-DrugBank.d373.s12|0-10|Ranitidine|drug
DDI-DrugBank.d373.s12|45-55|increases.|drug
DDI-DrugBank.d373.s13|40-50|inhibition|drug
DDI-DrugBank.d373.s13|54-64|cimetidine|drug
DDI-DrugBank.d373.s13|87-93|P-450,|brand
DDI-DrugBank.d373.s13|166-177|nifedipine.|drug
DDI-DrugBank.d373.s14|3-13|nifedipine|drug
DDI-DrugBank.d373.s14|25-34|initiated|drug
DDI-DrugBank.d373.s14|58-67|receiving|drug
DDI-DrugBank.d373.s14|68-79|cimetidine,|drug
DDI-MedLine.d9.s0|0-16|Pharmacokinetics|drug
DDI-MedLine.d9.s0|20-33|calcium-entry|drug
DDI-MedLine.d9.s1|54-62|clinical|drug
DDI-MedLine.d9.s1|111-126|pharmacokinetic|drug
DDI-MedLine.d9.s2|5-16|information|drug
DDI-MedLine.d9.s2|48-54|dosing|drug
DDI-MedLine.d9.s2|88-96|handling|drug
DDI-MedLine.d9.s2|144-156|anticipation|group
DDI-MedLine.d9.s2|165-178|interactions.|drug
DDI-MedLine.d9.s3|8-21|calcium-entry|drug
DDI-MedLine.d9.s3|22-30|blocking|drug
DDI-MedLine.d9.s3|85-95|nifedipine|drug
DDI-MedLine.d9.s3|143-151|clinical|drug
DDI-MedLine.d9.s4|29-38|continues|group
DDI-MedLine.d9.s4|93-99|intact|drug
DDI-MedLine.d9.s4|150-162|elimination;|drug
DDI-MedLine.d9.s5|7-16|nonlinear|drug
DDI-MedLine.d9.s5|17-24|kinetic|drug
DDI-MedLine.d9.s5|87-98|nifedipine,|drug
DDI-MedLine.d9.s5|154-160|dosing|drug
DDI-MedLine.d9.s6|24-33|appearing|drug
DDI-MedLine.d9.s7|24-31|herein,|drug
DDI-MedLine.d9.s7|82-90|clinical|drug
DDI-MedLine.d9.s7|102-115|calcium-entry|drug
DDI-DrugBank.d185.s0|12-23|interaction|drug
DDI-DrugBank.d185.s0|65-71|ACZONE|brand
DDI-DrugBank.d185.s0|84-95|combination|drug
DDI-DrugBank.d185.s0|133-162|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d185.s0|163-173|(TMP/SMX).|brand
DDI-DrugBank.d185.s1|0-6|During|drug
DDI-DrugBank.d185.s1|7-25|co-administration,|drug
DDI-DrugBank.d185.s2|18-26|exposure|group
DDI-DrugBank.d185.s2|27-36|(AUC0-12)|brand
DDI-DrugBank.d185.s2|48-61|hydroxylamine|drug
DDI-DrugBank.d185.s2|62-67|(DHA)|brand
DDI-DrugBank.d185.s2|109-117|TMP/SMX.|brand
DDI-DrugBank.d185.s3|0-8|Exposure|group
DDI-DrugBank.d185.s3|97-112|co-administered|drug
DDI-DrugBank.d185.s3|118-126|TMP/SMX.|brand
DDI-DrugBank.d185.s4|0-7|Certain|drug
DDI-DrugBank.d185.s4|41-50|rifampin,|drug
DDI-DrugBank.d185.s4|51-67|anticonvulsants,|group
DDI-DrugBank.d185.s5|17-25|increase|drug
DDI-DrugBank.d185.s5|51-65|hydroxylamine,|drug
DDI-DrugBank.d185.s6|60-73|pyrimethamine|drug
DDI-DrugBank.d185.s6|102-110|increase|drug
DDI-DrugBank.d280.s0|12-23|information|drug
DDI-MedLine.d115.s0|12-29|cyclophosphamide,|drug
DDI-MedLine.d115.s0|30-42|doxorubicin,|drug
DDI-MedLine.d115.s0|43-55|vincristine,|drug
DDI-MedLine.d115.s0|103-117|antiretroviral|group
DDI-MedLine.d115.s0|181-192|non-Hodgkin|drug
DDI-MedLine.d115.s1|0-11|BACKGROUND:|brand
DDI-MedLine.d115.s1|87-101|antiretroviral|group
DDI-MedLine.d115.s1|110-117|(HAART)|brand
DDI-MedLine.d115.s2|44-49|HAART|brand
DDI-MedLine.d115.s2|57-65|clinical|drug
DDI-MedLine.d115.s2|113-124|non-Hodgkin|drug
DDI-MedLine.d115.s2|134-144|(HIV-NHL),|brand
DDI-MedLine.d115.s2|210-217|HIV-NHL|brand
DDI-MedLine.d115.s2|244-261|cyclophosphamide,|drug
DDI-MedLine.d115.s2|262-274|doxorubicin,|drug
DDI-MedLine.d115.s2|275-287|vincristine,|drug
DDI-MedLine.d115.s2|303-309|(CHOP)|brand
DDI-MedLine.d115.s2|336-341|HAART|brand
DDI-MedLine.d115.s2|440-457|cyclophosphamide,|drug
DDI-MedLine.d115.s2|458-470|doxorubicin,|drug
DDI-MedLine.d115.s2|503-514|vincristine|drug
DDI-MedLine.d115.s2|520-530|bleomycin)|drug
DDI-MedLine.d115.s2|539-548|receiving|drug
DDI-MedLine.d115.s2|549-563|antiretroviral|group
DDI-MedLine.d115.s3|0-8|METHODS:|brand
DDI-MedLine.d115.s3|78-84|Aviano|drug
DDI-MedLine.d115.s3|135-140|1998.|drug_n
DDI-MedLine.d115.s4|0-5|HAART|brand
DDI-MedLine.d115.s4|10-18|included|drug
DDI-MedLine.d115.s4|24-35|combination|drug
DDI-MedLine.d115.s4|57-62|1997.|drug_n
DDI-MedLine.d115.s5|63-73|inhibitors|drug
DDI-MedLine.d115.s5|91-101|inhibitor.|drug
DDI-MedLine.d115.s6|0-8|RESULTS:|brand
DDI-MedLine.d115.s8|25-34|according|drug
DDI-MedLine.d115.s8|133-143|CHOP-HAART|brand
DDI-MedLine.d115.s8|226-233|0.001).|drug_n
DDI-MedLine.d115.s9|58-69|stimulating|drug
DDI-MedLine.d115.s9|118-128|CHOP-HAART|brand
DDI-MedLine.d115.s9|147-154|control|group
DDI-MedLine.d115.s9|193-199|0.03).|drug_n
DDI-MedLine.d115.s10|21-31|CHOP-HAART|brand
DDI-MedLine.d115.s10|146-153|0.002).|drug_n
DDI-MedLine.d115.s11|43-52|infection|drug
DDI-MedLine.d115.s11|110-120|CHOP-HAART|brand
DDI-MedLine.d115.s11|188-193|0.05;|drug_n
DDI-MedLine.d115.s11|229-236|0.001).|drug_n
DDI-MedLine.d115.s12|24-34|CHOP-HAART|brand
DDI-MedLine.d115.s12|124-130|0.03).|drug_n
DDI-MedLine.d115.s13|0-12|CONCLUSIONS:|brand
DDI-MedLine.d115.s13|17-28|combination|drug
DDI-MedLine.d115.s13|42-47|HAART|brand
DDI-MedLine.d115.s13|101-108|HIV-NHL|brand
DDI-MedLine.d115.s14|75-90|pharmacokinetic|drug
DDI-MedLine.d115.s14|91-103|interactions|drug
DDI-MedLine.d115.s14|112-126|antiretroviral|group
DDI-MedLine.d115.s14|131-145|antineoplastic|group
DDI-MedLine.d115.s15|18-26|combined|drug
DDI-MedLine.d115.s15|45-50|HAART|brand
DDI-DrugBank.d424.s0|37-44|protein|drug
DDI-DrugBank.d424.s1|39-52|administering|drug
DDI-DrugBank.d424.s1|53-59|MEPRON|brand
DDI-DrugBank.d424.s1|98-106|protein-|drug
DDI-DrugBank.d424.s1|143-151|indices,|drug
DDI-DrugBank.d424.s1|171-178|binding|drug
DDI-DrugBank.d424.s2|21-28|protein|drug
DDI-DrugBank.d424.s2|29-36|binding|drug
DDI-DrugBank.d424.s2|132-141|phenytoin|drug
DDI-DrugBank.d424.s2|167-174|binding|drug
DDI-DrugBank.d424.s2|178-187|phenytoin|drug
DDI-DrugBank.d424.s3|0-9|Rifampin:|drug
DDI-DrugBank.d424.s3|10-26|Coadministration|drug
DDI-DrugBank.d424.s3|30-38|rifampin|drug
DDI-DrugBank.d424.s3|43-49|MEPRON|brand
DDI-DrugBank.d424.s4|16-24|rifampin|drug
DDI-DrugBank.d424.s4|46-52|during|drug
DDI-DrugBank.d424.s4|86-93|MEPRON.|brand
DDI-DrugBank.d424.s5|0-10|Rifabutin,|drug
DDI-DrugBank.d424.s5|11-18|another|drug
DDI-DrugBank.d424.s5|19-29|rifamycin,|drug
DDI-DrugBank.d424.s5|57-65|rifampin|drug
DDI-DrugBank.d424.s5|110-122|interactions|drug
DDI-DrugBank.d424.s5|126-135|rifampin.|drug
DDI-DrugBank.d424.s6|3-14|interaction|drug
DDI-DrugBank.d424.s6|47-53|MEPRON|brand
DDI-DrugBank.d424.s6|58-68|rifabutin.|drug
DDI-DrugBank.d424.s7|55-61|MEPRON|brand
DDI-DrugBank.d424.s7|62-72|interferes|drug
DDI-DrugBank.d424.s7|78-86|clinical|drug
DDI-DrugBank.d425.s0|17-26|interfere|drug
DDI-DrugBank.d425.s0|74-82|increase|drug
DDI-DrugBank.d425.s0|101-109|vitamin.|drug
DDI-DrugBank.d425.s1|16-25|interfere|drug
DDI-DrugBank.d425.s1|51-61|including:|drug
DDI-DrugBank.d425.s1|62-76|anticonvulsant|group
DDI-DrugBank.d425.s1|98-108|phenytoin,|drug
DDI-DrugBank.d425.s1|124-133|metformin|drug
DDI-DrugBank.d425.s1|159-166|control|group
DDI-DrugBank.d425.s1|199-212|sulfasalazine|drug
DDI-DrugBank.d425.s1|222-229|control|group
DDI-DrugBank.d425.s1|230-242|inflammation|drug
DDI-DrugBank.d425.s1|313-322|diuretic)|group
DDI-DrugBank.d425.s1|369-380|interaction|drug
DDI-DrugBank.d425.s1|389-396|vitamin|drug
DDI-DrugBank.d425.s2|62-69|vitamin|drug
DDI-DrugBank.d425.s3|90-97|vitamin|drug
DDI-DrugBank.d425.s4|52-59|vitamin|drug
DDI-DrugBank.d425.s5|11-17|intake|drug
DDI-DrugBank.d425.s5|134-141|masking|drug
DDI-DrugBank.d425.s5|154-161|vitamin|drug
DDI-DrugBank.d425.s6|88-95|vitamin|drug
DDI-DrugBank.d425.s6|136-142|having|drug
DDI-DrugBank.d425.s6|145-152|vitamin|drug
DDI-DrugBank.d425.s7|115-123|contains|group
DDI-DrugBank.d353.s0|0-16|Ethanol:Clinical|drug
DDI-DrugBank.d353.s0|41-51|etretinate|drug
DDI-DrugBank.d353.s0|82-91|ingestion|drug
DDI-DrugBank.d353.s0|95-104|acitretin|drug
DDI-DrugBank.d353.s0|109-117|ethanol.|drug
DDI-DrugBank.d353.s1|56-65|acitretin|drug
DDI-DrugBank.d353.s1|106-114|lowering|drug
DDI-DrugBank.d353.s1|125-138|glibenclamide|drug
DDI-DrugBank.d353.s1|142-154|sulfonylurea|group
DDI-DrugBank.d353.s2|0-9|Repeating|drug
DDI-DrugBank.d353.s2|69-82|glibenclamide|drug
DDI-DrugBank.d353.s2|111-120|acitretin|drug
DDI-DrugBank.d353.s2|132-142|tolerance.|drug
DDI-DrugBank.d353.s4|67-82|pharmacokinetic|drug
DDI-DrugBank.d353.s4|83-94|interaction|drug
DDI-DrugBank.d353.s4|103-112|acitretin|drug
DDI-DrugBank.d353.s4|117-125|combined|drug
DDI-DrugBank.d353.s4|131-146|contraceptives.|group
DDI-DrugBank.d353.s5|38-47|acitretin|drug
DDI-DrugBank.d353.s5|48-58|interferes|drug
DDI-DrugBank.d353.s5|68-81|contraceptive|group
DDI-DrugBank.d353.s5|103-112|progestin|drug
DDI-DrugBank.d353.s5|113-121|minipill|drug
DDI-DrugBank.d353.s6|11-19|minipill|drug
DDI-DrugBank.d353.s6|20-29|progestin|drug
DDI-DrugBank.d353.s7|45-60|contraceptives,|group
DDI-DrugBank.d353.s7|82-94|injectables,|drug
DDI-DrugBank.d353.s7|119-132|contraception|group
DDI-DrugBank.d353.s7|133-139|during|drug
DDI-DrugBank.d353.s7|140-149|acitretin|drug
DDI-DrugBank.d353.s8|17-26|increased|drug
DDI-DrugBank.d353.s8|78-86|combined|drug
DDI-DrugBank.d353.s8|111-122|etretinate.|drug
DDI-DrugBank.d353.s9|18-29|combination|drug
DDI-DrugBank.d353.s9|51-60|acitretin|drug
DDI-DrugBank.d353.s9|69-85|contraindicated.|group
DDI-DrugBank.d353.s10|0-10|Phenytoin:|drug
DDI-DrugBank.d353.s10|14-23|acitretin|drug
DDI-DrugBank.d353.s10|51-61|phenytoin,|drug
DDI-DrugBank.d353.s10|66-73|protein|drug
DDI-DrugBank.d353.s10|74-81|binding|drug
DDI-DrugBank.d353.s10|85-94|phenytoin|drug
DDI-DrugBank.d353.s11|0-14|Tetracyclines:|drug
DDI-DrugBank.d353.s11|15-20|Since|drug
DDI-DrugBank.d353.s11|26-35|acitretin|drug
DDI-DrugBank.d353.s11|40-53|tetracyclines|drug
DDI-DrugBank.d353.s11|64-73|increased|drug
DDI-DrugBank.d353.s11|74-86|intracranial|drug
DDI-DrugBank.d353.s11|87-96|pressure,|group
DDI-DrugBank.d353.s11|103-111|combined|drug
DDI-DrugBank.d353.s11|119-135|contraindicated.|group
DDI-DrugBank.d353.s12|0-7|Vitamin|drug
DDI-DrugBank.d353.s12|19-29|retinoids:|group
DDI-DrugBank.d353.s12|42-56|administration|drug
DDI-DrugBank.d353.s12|60-67|vitamin|drug
DDI-DrugBank.d353.s12|88-97|retinoids|group
DDI-DrugBank.d353.s12|103-112|acitretin|drug
DDI-DrugBank.d353.s12|152-168|hypervitaminosis|drug
DDI-DrugBank.d353.s13|30-45|pharmacokinetic|drug
DDI-DrugBank.d353.s13|46-57|interaction|drug
DDI-DrugBank.d353.s13|66-75|acitretin|drug
DDI-DrugBank.d353.s13|80-91|cimetidine,|drug
DDI-DrugBank.d353.s13|92-100|digoxin,|drug
DDI-DrugBank.d353.s14|34-43|acitretin|drug
DDI-DrugBank.d353.s14|51-58|protein|drug
DDI-DrugBank.d353.s14|59-66|binding|drug
DDI-DrugBank.d353.s14|70-84|anticoagulants|group
DDI-DrugBank.d353.s14|92-100|coumarin|drug
DDI-DrugBank.d353.s14|106-116|(warfarin)|drug
DDI-DrugBank.d353.s14|129-141|interaction.|drug
DDI-DrugBank.d353.s15|64-73|obtained,|drug
DDI-DrugBank.d353.s15|111-121|monitoring|drug
DDI-DrugBank.d353.s15|135-150|discontinuation|group
DDI-DrugBank.d353.s15|167-176|depending|drug
DDI-DrugBank.d353.s15|180-188|clinical|drug
DDI-DrugBank.d353.s16|27-36|receiving|drug
DDI-DrugBank.d353.s16|37-46|retinoids|group
DDI-DrugBank.d353.s16|90-98|control.|group
DDI-DrugBank.d353.s17|55-61|during|drug
DDI-DrugBank.d353.s17|62-70|retinoid|drug
DDI-DrugBank.d353.s17|80-89|including|drug
DDI-DrugBank.d353.s19|0-7|Lipids:|group
DDI-DrugBank.d353.s19|11-19|clinical|drug
DDI-DrugBank.d353.s19|33-42|incidence|drug
DDI-DrugBank.d353.s19|76-96|hypercholesterolemia|drug
DDI-DrugBank.d353.s20|27-39|measurements|group
DDI-DrugBank.d353.s20|50-58|obtained|drug
DDI-DrugBank.d353.s20|65-72|fasting|drug
DDI-DrugBank.d353.s22|40-47|(SGOT),|brand
DDI-DrugBank.d353.s22|52-58|(SGPT)|brand
DDI-DrugBank.d353.s23|57-67|initiation|drug
DDI-DrugBank.d353.s23|99-105|2-week|drug_n
DDI-DrugBank.d353.s23|106-115|intervals|drug
DDI-DrugBank.d353.s23|147-156|intervals|drug
DDI-DrugBank.d353.s23|160-170|clinically|drug
DDI-DrugBank.d353.s23|171-181|indicated.|drug
DDI-DrugBank.d307.s0|0-13|Oxcarbazepine|drug
DDI-DrugBank.d307.s0|18-25|inhibit|drug
DDI-DrugBank.d307.s0|26-33|CYP2C19|brand
DDI-DrugBank.d307.s0|38-44|induce|drug
DDI-DrugBank.d307.s0|45-53|CYP3A4/5|brand
DDI-DrugBank.d307.s1|52-60|inducers|drug
DDI-DrugBank.d307.s1|99-112|oxcarbazepine|drug
DDI-DrugBank.d307.s2|0-13|Oxcarbazepine|drug
DDI-DrugBank.d307.s2|57-66|determine|drug
DDI-DrugBank.d307.s2|83-90|inhibit|drug
DDI-DrugBank.d307.s3|25-38|oxcarbazepine|drug
DDI-DrugBank.d307.s3|72-86|10-monohydroxy|drug_n
DDI-DrugBank.d307.s3|98-103|(MHD)|brand
DDI-DrugBank.d307.s3|146-156|inhibitors|drug
DDI-DrugBank.d307.s3|213-221|(CYP1A2,|brand
DDI-DrugBank.d307.s3|222-229|CYP2A6,|brand
DDI-DrugBank.d307.s3|230-237|CYP2C9,|brand
DDI-DrugBank.d307.s3|238-245|CYP2D6,|brand
DDI-DrugBank.d307.s3|246-253|CYP2E1,|brand
DDI-DrugBank.d307.s3|254-260|CYP4A9|brand
DDI-DrugBank.d307.s3|265-273|CYP4A11)|brand
DDI-DrugBank.d307.s3|296-303|CYP2C19|brand
DDI-DrugBank.d307.s3|308-317|CYP3A4/5.|brand
DDI-DrugBank.d307.s4|9-19|inhibition|drug
DDI-DrugBank.d307.s4|27-32|3A4/5|brand
DDI-DrugBank.d307.s4|108-116|clinical|drug
DDI-DrugBank.d307.s5|4-14|inhibition|drug
DDI-DrugBank.d307.s5|18-26|CYP-2C19|brand
DDI-DrugBank.d307.s5|55-65|clinically|drug
DDI-DrugBank.d307.s6|51-61|increased,|drug
DDI-DrugBank.d307.s6|62-72|indicating|drug
DDI-DrugBank.d307.s6|73-82|induction|drug
DDI-DrugBank.d307.s7|39-52|oxcarbazepine|drug
DDI-DrugBank.d307.s8|12-23|predominant|drug
DDI-DrugBank.d307.s8|57-64|inducer|drug
DDI-DrugBank.d307.s8|147-153|mainly|drug
DDI-DrugBank.d307.s8|154-164|eliminated|drug
DDI-DrugBank.d307.s8|237-250|lamotrigine).|drug
DDI-DrugBank.d307.s9|13-26|oxcarbazepine|drug
DDI-DrugBank.d307.s9|35-41|induce|drug
DDI-DrugBank.d307.s9|86-93|(CYP3A4|brand
DDI-DrugBank.d307.s9|98-105|CYP3A5)|brand
DDI-DrugBank.d307.s9|140-155|dihydropyridine|drug
DDI-DrugBank.d307.s9|156-163|calcium|drug
DDI-DrugBank.d307.s9|185-200|contraceptives,|group
DDI-DrugBank.d307.s9|201-210|resulting|drug
DDI-DrugBank.d307.s10|3-10|binding|drug
DDI-DrugBank.d307.s10|28-36|proteins|drug
DDI-DrugBank.d307.s10|51-61|clinically|drug
DDI-DrugBank.d307.s10|74-86|interactions|drug
DDI-DrugBank.d307.s10|128-135|protein|drug
DDI-DrugBank.d307.s10|136-143|binding|drug
DDI-DrugBank.d307.s11|31-43|interactions|drug
DDI-DrugBank.d307.s11|94-102|clinical|drug
DDI-DrugBank.d307.s12|20-32|interactions|drug
DDI-DrugBank.d307.s12|106-118|interactions|drug
DDI-DrugBank.d307.s13|4-19|Co-administered|drug
DDI-DrugBank.d307.s18|0-13|Carbamazepine|drug
DDI-DrugBank.d307.s19|0-8|400-2000|drug_n
DDI-DrugBank.d307.s23|0-7|100-150|drug_n
DDI-DrugBank.d307.s24|0-8|600-1800|drug_n
DDI-DrugBank.d307.s25|4-12|increase|drug
DDI-DrugBank.d307.s25|21-30|increase,|drug
DDI-DrugBank.d307.s25|35-44|increase]|drug
DDI-DrugBank.d307.s26|0-9|Phenytoin|drug
DDI-DrugBank.d307.s27|0-7|250-500|drug_n
DDI-DrugBank.d307.s28|0-8|600-1800|drug_n
DDI-DrugBank.d307.s30|0-9|1200-2400|drug_n
DDI-DrugBank.d307.s30|20-29|increase3|drug
DDI-DrugBank.d307.s30|39-48|increase,|drug
DDI-DrugBank.d307.s30|54-63|increase]|drug
DDI-DrugBank.d307.s32|0-8|400-2800|drug_n
DDI-DrugBank.d307.s33|0-8|600-1800|drug_n
DDI-DrugBank.d307.s35|67-75|increase|drug
DDI-DrugBank.d307.s35|140-149|phenytoin|drug
DDI-DrugBank.d307.s35|150-159|increased|drug
DDI-DrugBank.d307.s36|16-21|using|drug
DDI-DrugBank.d307.s36|66-72|during|drug
DDI-DrugBank.d307.s36|119-128|phenytoin|drug
DDI-DrugBank.d307.s37|4-12|increase|drug
DDI-DrugBank.d307.s38|7-15|inducers|drug
DDI-DrugBank.d307.s38|49-63|carbamazepine,|drug
DDI-DrugBank.d307.s38|64-73|phenytoin|drug
DDI-DrugBank.d307.s39|3-16|autoinduction|drug
DDI-DrugBank.d307.s40|9-23|contraceptives|group
DDI-DrugBank.d307.s40|24-41|Co-administration|drug
DDI-DrugBank.d307.s40|68-81|contraceptive|group
DDI-DrugBank.d307.s40|100-109|influence|drug
DDI-DrugBank.d307.s40|168-184|ethinylestradiol|drug
DDI-DrugBank.d307.s40|209-215|(LNG).|brand
DDI-DrugBank.d307.s41|57-63|22-65]|drug_n
DDI-DrugBank.d307.s41|94-100|38-52]|drug_n
DDI-DrugBank.d307.s41|104-111|another|drug
DDI-DrugBank.d307.s42|58-64|20-45]|drug_n
DDI-DrugBank.d307.s42|95-101|42-52]|drug_n
DDI-DrugBank.d307.s42|105-112|another|drug
DDI-DrugBank.d307.s43|53-67|contraceptives|group
DDI-DrugBank.d307.s43|85-99|contraceptives|group
DDI-DrugBank.d307.s44|35-49|contraceptives|group
DDI-DrugBank.d307.s45|0-7|Calcium|drug
DDI-DrugBank.d307.s45|36-53|co-administration|drug
DDI-DrugBank.d307.s45|79-89|felodipine|drug
DDI-DrugBank.d307.s45|118-125|20-33].|drug_n
DDI-DrugBank.d307.s46|46-52|18-27]|drug_n
DDI-DrugBank.d307.s47|11-23|interactions|drug
DDI-DrugBank.d307.s47|24-35|Cimetidine,|drug
DDI-DrugBank.d307.s47|36-48|erythromycin|drug
DDI-DrugBank.d307.s47|93-109|pharmacokinetics|drug
DDI-DrugBank.d307.s48|13-21|warfarin|drug
DDI-DrugBank.d307.s48|43-54|interaction|drug
DDI-DrugBank.d307.s48|67-73|single|drug
DDI-DrugBank.d374.s0|0-9|Auranofin|drug
DDI-DrugBank.d374.s0|99-108|including|drug
DDI-DrugBank.d374.s0|122-134|Myochrysine.|drug
DDI-DrugBank.d374.s1|0-9|Auranofin|drug
DDI-DrugBank.d374.s1|43-56|penicillamine|drug
DDI-DrugBank.d374.s1|65-76|Cuprimine),|drug
DDI-DrugBank.d374.s1|77-84|another|drug
DDI-DrugBank.d374.s2|107-119|uncontrolled|group
DDI-DrugBank.d374.s3|62-70|itching,|drug
DDI-DrugBank.d374.s3|107-113|taking|drug
DDI-DrugBank.d374.s3|114-124|auranofin.|drug
DDI-DrugBank.d31.s0|4-14|inhibitors|drug
DDI-DrugBank.d31.s0|55-64|receiving|drug
DDI-DrugBank.d31.s0|65-77|hydralazine.|drug
DDI-DrugBank.d31.s1|27-43|antihypertensive|group
DDI-DrugBank.d31.s1|82-93|combination|drug
DDI-DrugBank.d31.s1|99-111|hydralazine,|drug
DDI-DrugBank.d31.s1|131-143|continuously|group
DDI-DrugBank.d31.s1|203-212|pressure.|group
DDI-DrugBank.d31.s2|45-54|diazoxide|drug
DDI-DrugBank.d31.s2|55-64|infection|drug
DDI-DrugBank.d31.s2|69-80|hydralazine|drug
DDI-DrugBank.d31.s3|27-39|propranolol)|drug
DDI-DrugBank.d31.s3|94-104|increased.|drug
DDI-DrugBank.d31.s5|0-11|Propranolol|drug
DDI-DrugBank.d31.s5|12-21|increases|drug
DDI-DrugBank.d31.s5|22-34|hydralazines|drug
DDI-DrugBank.d31.s7|47-59|hydralazine;|drug
DDI-DrugBank.d31.s8|82-94|interactions|drug
DDI-DrugBank.d538.s0|11-23|interactions|drug
DDI-DrugBank.d538.s0|24-31|include|drug
DDI-DrugBank.d538.s1|22-30|atropine|drug
DDI-DrugBank.d538.s1|43-51|interact|drug
DDI-DrugBank.d538.s1|61-71|inhibitors|drug
DDI-DrugBank.d538.s1|113-126|hydrochloride|drug
DDI-DrugBank.d538.s1|140-147|inhibit|drug
DDI-DrugBank.d538.s2|111-122|elimination|drug
DDI-DrugBank.d538.s2|159-171|metabolizing|drug
DDI-MedLine.d3.s0|0-15|Pharmacokinetic|drug
DDI-MedLine.d3.s0|36-46|amprenavir|drug
DDI-MedLine.d3.s0|51-60|rifabutin|drug
DDI-MedLine.d3.s0|64-72|rifampin|drug
DDI-MedLine.d3.s1|35-44|determine|drug
DDI-MedLine.d3.s1|59-74|pharmacokinetic|drug
DDI-MedLine.d3.s1|75-86|interaction|drug
DDI-MedLine.d3.s1|92-102|amprenavir|drug
DDI-MedLine.d3.s1|117-126|rifabutin|drug
DDI-MedLine.d3.s1|130-138|rifampin|drug
DDI-MedLine.d3.s1|146-155|determine|drug
DDI-MedLine.d3.s1|190-202|erythromycin|drug
DDI-MedLine.d3.s1|215-223|(ERMBT).|brand
DDI-MedLine.d3.s3|22-32|amprenavir|drug
DDI-MedLine.d3.s3|82-87|7-day|drug_n
DDI-MedLine.d3.s3|123-132|rifabutin|drug
DDI-MedLine.d3.s3|152-157|[QD])|brand
DDI-MedLine.d3.s3|172-180|rifampin|drug
DDI-MedLine.d3.s4|23-33|amprenavir|drug
DDI-MedLine.d3.s4|39-48|rifabutin|drug
DDI-MedLine.d3.s4|84-94|amprenavir|drug
DDI-MedLine.d3.s4|100-108|rifampin|drug
DDI-MedLine.d3.s5|18-23|urine|drug
DDI-MedLine.d3.s5|36-47|measurement|group
DDI-MedLine.d3.s5|63-73|rifabutin,|drug
DDI-MedLine.d3.s5|78-86|rifampin|drug
DDI-MedLine.d3.s5|97-111|25-O-desacetyl|drug_n
DDI-MedLine.d3.s5|130-138|measured|group
DDI-MedLine.d3.s6|0-9|Rifabutin|drug
DDI-MedLine.d3.s6|52-69|pharmacokinetics.|drug
DDI-MedLine.d3.s7|0-10|Amprenavir|drug
DDI-MedLine.d3.s7|25-34|increased|drug
DDI-MedLine.d3.s7|89-98|rifabutin|drug
DDI-MedLine.d3.s7|102-111|2.93-fold|drug_n
DDI-MedLine.d3.s7|131-154|25-O-desacetylrifabutin|drug_n
DDI-MedLine.d3.s7|158-168|13.3-fold.|drug_n
DDI-MedLine.d3.s8|0-8|Rifampin|drug
DDI-MedLine.d3.s8|48-58|amprenavir|drug
DDI-MedLine.d3.s8|71-81|amprenavir|drug
DDI-MedLine.d3.s8|99-107|rifampin|drug
DDI-MedLine.d3.s8|108-125|pharmacokinetics.|drug
DDI-MedLine.d3.s9|0-10|Amprenavir|drug
DDI-MedLine.d3.s9|40-45|ERMBT|brand
DDI-MedLine.d3.s10|19-24|ERMBT|brand
DDI-MedLine.d3.s10|42-51|rifabutin|drug
DDI-MedLine.d3.s10|56-64|rifampin|drug
DDI-MedLine.d3.s10|78-87|increased|drug
DDI-MedLine.d3.s10|96-101|156%,|drug_n
DDI-MedLine.d3.s11|0-10|Amprenavir|drug
DDI-MedLine.d3.s11|16-24|rifampin|drug
DDI-MedLine.d3.s11|34-44|tolerated.|drug
DDI-MedLine.d3.s12|0-10|Amprenavir|drug
DDI-MedLine.d3.s12|16-25|rifabutin|drug
DDI-MedLine.d3.s12|37-47|tolerated,|drug
DDI-MedLine.d3.s12|69-81|discontinued|group
DDI-MedLine.d3.s13|0-8|Rifampin|drug
DDI-MedLine.d3.s13|18-27|increases|drug
DDI-MedLine.d3.s13|71-87|coadministration|drug
DDI-MedLine.d3.s13|91-107|contraindicated.|group
DDI-MedLine.d3.s14|0-10|Amprenavir|drug
DDI-MedLine.d3.s14|48-57|rifabutin|drug
DDI-MedLine.d3.s14|62-86|25-O-desacetylrifabutin,|drug_n
DDI-MedLine.d3.s14|95-106|combination|drug
DDI-MedLine.d3.s14|117-127|tolerated.|drug
DDI-MedLine.d3.s15|0-10|Amprenavir|drug
DDI-MedLine.d3.s15|11-19|inhibits|drug
DDI-MedLine.d3.s15|24-30|ERMBT,|brand
DDI-MedLine.d3.s15|35-43|rifampin|drug
DDI-MedLine.d3.s15|48-57|rifabutin|drug
DDI-MedLine.d3.s15|73-81|inducers|drug
DDI-MedLine.d3.s15|89-95|ERMBT.|brand
DDI-DrugBank.d541.s0|4-12|interact|drug
DDI-DrugBank.d541.s0|22-32|following:|drug
DDI-DrugBank.d541.s0|49-57|blocking|drug
DDI-DrugBank.d541.s0|72-81|medicines|drug
DDI-DrugBank.d541.s0|160-167|working|drug
DDI-DrugBank.d541.s0|196-206|quinidine,|drug
DDI-DrugBank.d541.s0|207-222|phenothiazines,|drug
DDI-DrugBank.d541.s0|227-239|procainamide|drug
DDI-DrugBank.d541.s0|247-256|medicines|drug
DDI-DrugBank.d541.s0|261-269|increase|drug
DDI-DrugBank.d157.s0|0-8|Clinical|drug
DDI-DrugBank.d157.s0|9-20|interaction|drug
DDI-DrugBank.d157.s0|34-44|cimetidine|drug
DDI-DrugBank.d157.s0|49-57|warfarin|drug
DDI-DrugBank.d157.s0|58-67|indicated|drug
DDI-DrugBank.d157.s0|77-93|coadministration|drug
DDI-DrugBank.d157.s0|140-151|clinically-|drug
DDI-DrugBank.d157.s0|169-182|interactions.|drug
DDI-DrugBank.d157.s1|5-13|CLINICAL|brand
DDI-DrugBank.d157.s1|14-27|PHARMACOLOGY)|brand
DDI-DrugBank.d157.s1|28-44|Coadministration|drug
DDI-DrugBank.d157.s1|108-117|letrozole|drug
DDI-DrugBank.d157.s2|12-20|clinical|drug
DDI-DrugBank.d157.s2|64-75|combination|drug
DDI-DrugBank.d157.s2|87-97|anticancer|group
DDI-DrugBank.d429.s0|0-8|Antacids|group
DDI-DrugBank.d429.s0|13-20|kaolin:|drug
DDI-DrugBank.d429.s0|21-29|Antacids|group
DDI-DrugBank.d429.s0|34-40|kaolin|drug
DDI-DrugBank.d429.s0|66-78|chloroquine;|drug
DDI-DrugBank.d429.s1|3-11|interval|drug
DDI-DrugBank.d429.s1|40-46|intake|drug
DDI-DrugBank.d429.s1|67-78|chloroquine|drug
DDI-DrugBank.d429.s2|0-11|Cimetidine:|drug
DDI-DrugBank.d429.s2|12-22|Cimetidine|drug
DDI-DrugBank.d429.s2|27-34|inhibit|drug
DDI-DrugBank.d429.s2|53-65|chloroquine,|drug
DDI-DrugBank.d429.s2|66-76|increasing|drug
DDI-DrugBank.d429.s3|19-29|cimetidine|drug
DDI-DrugBank.d429.s4|0-11|Ampicillin:|drug
DDI-DrugBank.d429.s4|46-57|chloroquine|drug
DDI-DrugBank.d429.s4|103-114|ampicillin.|drug
DDI-DrugBank.d429.s5|3-11|interval|drug
DDI-DrugBank.d429.s5|42-48|intake|drug
DDI-DrugBank.d429.s5|67-78|chloroquine|drug
DDI-DrugBank.d429.s6|0-12|Cyclosporin:|drug
DDI-DrugBank.d429.s6|19-31|introduction|drug
DDI-DrugBank.d429.s6|35-46|chloroquine|drug
DDI-DrugBank.d429.s6|69-77|increase|drug
DDI-DrugBank.d429.s6|87-98|cyclosporin|drug
DDI-DrugBank.d429.s7|17-27|monitoring|drug
DDI-DrugBank.d429.s7|37-48|cyclosporin|drug
DDI-DrugBank.d429.s7|89-100|chloroquine|drug
DDI-DrugBank.d429.s7|111-124|discontinued.|group
DDI-DrugBank.d350.s0|27-38|caspofungin|drug
DDI-DrugBank.d350.s0|57-66|inhibitor|drug
DDI-DrugBank.d350.s0|104-109|(CYP)|brand
DDI-DrugBank.d350.s1|3-11|clinical|drug
DDI-DrugBank.d350.s1|21-32|caspofungin|drug
DDI-DrugBank.d350.s1|41-47|induce|drug
DDI-DrugBank.d350.s1|52-58|CYP3A4|brand
DDI-DrugBank.d350.s2|0-11|Caspofungin|drug
DDI-DrugBank.d350.s2|35-49|P-glycoprotein|drug
DDI-DrugBank.d350.s3|0-8|Clinical|drug
DDI-DrugBank.d350.s3|53-69|pharmacokinetics|drug
DDI-DrugBank.d350.s3|73-81|CANCIDAS|brand
DDI-DrugBank.d350.s3|101-114|itraconazole,|drug
DDI-DrugBank.d350.s3|115-127|amphotericin|drug
DDI-DrugBank.d350.s3|146-157|nelfinavir,|drug
DDI-DrugBank.d350.s4|0-8|CANCIDAS|brand
DDI-DrugBank.d350.s4|30-46|pharmacokinetics|drug
DDI-DrugBank.d350.s4|50-63|itraconazole,|drug
DDI-DrugBank.d350.s4|64-76|amphotericin|drug
DDI-DrugBank.d350.s5|0-8|CANCIDAS|brand
DDI-DrugBank.d350.s5|27-34|AUC0-12|brand
DDI-DrugBank.d350.s5|115-122|12-hour|drug_n
DDI-DrugBank.d350.s5|236-248|administered|drug
DDI-DrugBank.d350.s5|268-276|CANCIDAS|brand
DDI-DrugBank.d350.s5|320-327|control|group
DDI-DrugBank.d350.s5|359-371|administered|drug
DDI-DrugBank.d350.s6|13-22|receiving|drug
DDI-DrugBank.d350.s6|48-58|monitoring|drug
DDI-DrugBank.d350.s7|7-15|clinical|drug
DDI-DrugBank.d350.s7|25-37|cyclosporine|drug
DDI-DrugBank.d350.s7|78-87|increased|drug
DDI-DrugBank.d350.s7|99-110|caspofungin|drug
DDI-DrugBank.d350.s8|0-8|CANCIDAS|brand
DDI-DrugBank.d350.s8|17-25|increase|drug
DDI-DrugBank.d350.s8|47-60|cyclosporine.|drug
DDI-DrugBank.d350.s9|21-30|increases|drug
DDI-DrugBank.d350.s9|57-65|CANCIDAS|brand
DDI-DrugBank.d350.s9|70-82|cyclosporine|drug
DDI-DrugBank.d350.s9|88-104|co-administered.|drug
DDI-DrugBank.d350.s10|12-23|interaction|drug
DDI-DrugBank.d350.s10|35-43|rifampin|drug
DDI-DrugBank.d350.s10|94-105|caspofungin|drug
DDI-DrugBank.d350.s11|12-20|rifampin|drug
DDI-DrugBank.d350.s11|45-53|CANCIDAS|brand
DDI-DrugBank.d350.s12|57-72|pharmacokinetic|drug
DDI-DrugBank.d350.s12|91-108|co-administration|drug
DDI-DrugBank.d350.s12|118-126|inducers|drug
DDI-DrugBank.d350.s12|157-168|nevirapine,|drug
DDI-DrugBank.d350.s12|169-179|phenytoin,|drug
DDI-DrugBank.d350.s12|198-212|carbamazepine)|drug
DDI-DrugBank.d350.s12|218-226|CANCIDAS|brand
DDI-DrugBank.d350.s12|241-251|clinically|drug
DDI-DrugBank.d350.s12|252-262|meaningful|drug
DDI-DrugBank.d350.s12|277-288|caspofungin|drug
DDI-DrugBank.d350.s13|47-55|involved|drug
DDI-DrugBank.d350.s13|59-70|caspofungin|drug
DDI-DrugBank.d350.s13|90-100|inducible.|drug
DDI-DrugBank.d350.s14|5-13|CANCIDAS|brand
DDI-DrugBank.d350.s14|17-32|co-administered|drug
DDI-DrugBank.d350.s14|38-46|inducers|drug
DDI-DrugBank.d350.s14|85-96|nevirapine,|drug
DDI-DrugBank.d350.s14|97-107|phenytoin,|drug
DDI-DrugBank.d350.s14|126-140|carbamazepine,|drug
DDI-DrugBank.d350.s14|173-181|CANCIDAS|brand
DDI-DrugBank.d99.s0|69-81|metabolizing|drug
DDI-DrugBank.d99.s0|110-122|(debrisoquin|drug
DDI-DrugBank.d99.s0|123-135|hydroxylase)|drug
DDI-DrugBank.d99.s0|194-199|7-10%|drug_n
DDI-DrugBank.d99.s2|79-94|antidepressants|group
DDI-DrugBank.d99.s3|0-9|Depending|drug
DDI-DrugBank.d99.s3|63-71|increase|drug
DDI-DrugBank.d99.s3|133-141|increase|drug
DDI-DrugBank.d99.s3|163-168|TCA).|brand
DDI-DrugBank.d99.s4|13-20|certain|drug
DDI-DrugBank.d99.s4|27-34|inhibit|drug
DDI-DrugBank.d99.s5|3-13|individual|drug
DDI-DrugBank.d99.s5|101-111|inhibiting|drug
DDI-DrugBank.d99.s6|15-22|inhibit|drug
DDI-DrugBank.d99.s6|43-50|include|drug
DDI-DrugBank.d99.s6|95-106|(quinidine;|drug
DDI-DrugBank.d99.s7|0-11|cimetidine)|drug
DDI-DrugBank.d99.s7|66-82|antidepressants,|group
DDI-DrugBank.d99.s7|83-98|phenothiazines,|drug
DDI-DrugBank.d99.s7|115-130|antiarrhythmics|group
DDI-DrugBank.d99.s7|147-159|flecainide).|drug
DDI-DrugBank.d99.s8|24-33|serotonin|drug
DDI-DrugBank.d99.s8|43-53|inhibitors|drug
DDI-DrugBank.d99.s8|69-80|fluoxetine,|drug
DDI-DrugBank.d99.s8|81-92|sertraline,|drug
DDI-DrugBank.d99.s8|97-108|paroxetine,|drug
DDI-DrugBank.d99.s8|109-116|inhibit|drug
DDI-DrugBank.d99.s8|158-169|inhibition.|drug
DDI-DrugBank.d99.s9|20-28|SSRI-TCA|brand
DDI-DrugBank.d99.s9|29-41|interactions|drug
DDI-DrugBank.d99.s9|51-59|clinical|drug
DDI-DrugBank.d99.s9|98-108|inhibition|drug
DDI-DrugBank.d99.s9|117-133|pharmacokinetics|drug
DDI-DrugBank.d99.s9|146-155|involved.|drug
DDI-DrugBank.d99.s10|25-34|indicated|drug
DDI-DrugBank.d99.s10|42-58|coadministration|drug
DDI-DrugBank.d99.s10|101-110|switching|drug
DDI-DrugBank.d99.s11|61-71|initiating|drug
DDI-DrugBank.d99.s11|99-104|being|drug
DDI-DrugBank.d99.s11|120-131|fluoxetine,|drug
DDI-DrugBank.d99.s12|29-44|antidepressants|group
DDI-DrugBank.d99.s12|65-72|inhibit|drug
DDI-DrugBank.d99.s12|166-180|antidepressant|group
DDI-DrugBank.d99.s13|80-89|increased|drug
DDI-DrugBank.d99.s13|108-122|antidepressant|group
DDI-DrugBank.d99.s14|63-68|going|drug
DDI-DrugBank.d99.s14|75-89|coadministered|drug
DDI-DrugBank.d99.s14|95-102|another|drug
DDI-DrugBank.d99.s14|123-132|inhibitor|drug
DDI-DrugBank.d99.s15|0-9|Monoamine|drug
DDI-DrugBank.d99.s15|30-42|Guanethidine|drug
DDI-DrugBank.d99.s15|56-62|acting|drug
DDI-DrugBank.d99.s18|20-33|amitriptyline|drug
DDI-DrugBank.d99.s18|52-67|anticholinergic|group
DDI-DrugBank.d99.s18|101-110|including|drug
DDI-DrugBank.d99.s18|111-122|epinephrine|drug
DDI-DrugBank.d99.s18|123-131|combined|drug
DDI-DrugBank.d99.s19|36-49|amitriptyline|drug
DDI-DrugBank.d99.s19|57-69|administered|drug
DDI-DrugBank.d99.s19|75-90|anticholinergic|group
DDI-DrugBank.d99.s19|106-117|neuroleptic|drug
DDI-DrugBank.d99.s19|138-144|during|drug
DDI-DrugBank.d99.s20|38-44|taking|drug
DDI-DrugBank.d99.s20|55-70|antidepressants|group
DDI-DrugBank.d99.s20|74-85|combination|drug
DDI-DrugBank.d99.s20|91-111|anticholinergic-type|group
DDI-DrugBank.d99.s21|0-10|Cimetidine|drug
DDI-DrugBank.d99.s21|55-62|certain|drug
DDI-DrugBank.d99.s21|73-89|antidepressants,|group
DDI-DrugBank.d99.s21|98-106|delaying|drug
DDI-DrugBank.d99.s21|107-118|elimination|drug
DDI-DrugBank.d99.s21|123-133|increasing|drug
DDI-DrugBank.d99.s22|0-10|Clinically|drug
DDI-DrugBank.d99.s22|69-84|antidepressants|group
DDI-DrugBank.d99.s22|114-125|cimetidine.|drug
DDI-DrugBank.d99.s23|40-56|antidepressants,|group
DDI-DrugBank.d99.s23|121-137|anticholinergic,|group
DDI-DrugBank.d99.s23|162-172|cimetidine|drug
DDI-DrugBank.d99.s24|0-15|Discontinuation|group
DDI-DrugBank.d99.s24|19-29|cimetidine|drug
DDI-DrugBank.d99.s24|33-48|well-controlled|group
DDI-DrugBank.d99.s24|58-67|receiving|drug
DDI-DrugBank.d99.s24|78-93|antidepressants|group
DDI-DrugBank.d99.s24|98-108|cimetidine|drug
DDI-DrugBank.d99.s24|160-176|antidepressants.|group
DDI-DrugBank.d99.s26|10-18|delirium|drug
DDI-DrugBank.d99.s26|116-129|amitriptyline|drug
DDI-MedLine.d10.s1|30-38|becoming|drug
DDI-MedLine.d10.s1|39-51|increasingly|drug
DDI-MedLine.d10.s2|77-85|failure.|group
DDI-MedLine.d10.s4|20-33|insufficiency|drug
DDI-MedLine.d10.s4|43-50|failure|group
DDI-MedLine.d10.s4|128-140|interactions|drug
DDI-MedLine.d10.s5|31-41|escalating|drug
DDI-DrugBank.d557.s0|83-89|during|drug
DDI-DrugBank.d557.s0|109-122|cephalosporin|drug
DDI-DrugBank.d557.s0|123-135|antibiotics.|group
DDI-DrugBank.d557.s1|41-55|cross-matching|drug
DDI-DrugBank.d557.s1|56-66|procedures|group
DDI-DrugBank.d557.s1|72-85|anti-globulin|group
DDI-DrugBank.d557.s1|113-118|minor|drug
DDI-DrugBank.d557.s1|138-145|testing|drug
DDI-DrugBank.d557.s1|186-199|cephalosporin|drug
DDI-DrugBank.d557.s1|200-211|antibiotics|group
DDI-MedLine.d43.s0|88-97|initiated|drug
DDI-MedLine.d43.s0|98-104|murine|drug
DDI-MedLine.d43.s1|82-91|induction|drug
DDI-MedLine.d43.s2|34-45|initiation,|drug
DDI-MedLine.d43.s3|77-83|nature|group
DDI-MedLine.d43.s4|0-14|Vesselinovitch|drug
DDI-MedLine.d43.s5|18-28|2003-2010,|drug_n
DDI-MedLine.d43.s5|29-34|1978)|drug_n
DDI-MedLine.d43.s5|56-63|single,|drug
DDI-MedLine.d43.s5|79-89|carcinogen|drug
DDI-MedLine.d43.s5|94-100|induce|drug
DDI-MedLine.d43.s5|138-150|administered|drug
DDI-MedLine.d43.s6|41-47|strain|drug
DDI-MedLine.d43.s6|48-56|C57BL/6N|brand
DDI-MedLine.d43.s6|100-118|diethylnitrosamine|drug
DDI-MedLine.d43.s6|119-125|during|drug
DDI-MedLine.d43.s7|0-8|C57BL/6N|brand
DDI-MedLine.d43.s8|90-99|(C57BL/6N|brand
DDI-MedLine.d43.s8|140-151|carcinogen.|drug
DDI-MedLine.d43.s9|6-14|findings|drug
DDI-MedLine.d43.s9|93-103|carcinogen|drug
DDI-MedLine.d43.s10|4-13|initiated|drug
DDI-MedLine.d43.s11|51-60|initiated|drug
DDI-DrugBank.d201.s0|12-25|interactions.|drug
DDI-DrugBank.d441.s0|0-9|Monoamine|drug
DDI-DrugBank.d441.s0|30-39|Linezolid|drug
DDI-DrugBank.d441.s0|70-79|inhibitor|drug
DDI-DrugBank.d441.s0|83-92|monoamine|drug
DDI-DrugBank.d441.s1|11-20|linezolid|drug
DDI-DrugBank.d441.s1|43-54|interaction|drug
DDI-DrugBank.d441.s2|23-34|individuals|drug
DDI-DrugBank.d441.s2|35-44|receiving|drug
DDI-DrugBank.d441.s2|45-50|ZYVOX|brand
DDI-DrugBank.d441.s2|118-133|indirect-acting|drug
DDI-DrugBank.d441.s2|173-185|dopaminergic|drug
DDI-DrugBank.d441.s3|28-47|phenylpropanolamine|drug
DDI-DrugBank.d441.s3|52-67|pseudoephedrine|drug
DDI-DrugBank.d441.s4|44-52|dopamine|drug
DDI-DrugBank.d441.s4|56-68|epinephrine,|drug
DDI-DrugBank.d441.s5|21-38|Co-administration|drug
DDI-DrugBank.d441.s5|42-51|linezolid|drug
DDI-DrugBank.d441.s5|100-109|serotonin|drug
DDI-DrugBank.d441.s6|23-32|serotonin|drug
DDI-DrugBank.d441.s6|58-75|co-administration|drug
DDI-DrugBank.d441.s6|79-84|ZYVOX|brand
DDI-DrugBank.d441.s6|110-119|including|drug
DDI-DrugBank.d441.s6|120-135|antidepressants|group
DDI-DrugBank.d441.s6|154-163|serotonin|drug
DDI-DrugBank.d441.s6|173-183|inhibitors|drug
DDI-DrugBank.d441.s7|30-35|ZYVOX|brand
DDI-DrugBank.d441.s7|125-134|serotonin|drug
DDI-DrugBank.d441.s7|203-219|incoordination).|drug
DDI-DrugBank.d441.s8|58-73|discontinuation|group
DDI-DrugBank.d441.s8|103-109|(ZYVOX|brand
DDI-DrugBank.d441.s9|77-90|interactions.|drug
DDI-DrugBank.d414.s0|0-7|Lithium|drug
DDI-DrugBank.d414.s0|43-52|diuretics|group
DDI-DrugBank.d414.s0|116-123|lithium|drug
DDI-DrugBank.d414.s1|19-26|lithium|drug
DDI-DrugBank.d414.s2|0-7|EDECRIN|brand
DDI-DrugBank.d414.s2|12-20|increase|drug
DDI-DrugBank.d414.s2|67-81|aminoglycoside|drug
DDI-DrugBank.d414.s2|91-104|cephalosporin|drug
DDI-DrugBank.d414.s2|105-117|antibiotics.|group
DDI-DrugBank.d414.s4|19-28|including|drug
DDI-DrugBank.d414.s4|74-82|warfarin|drug
DDI-DrugBank.d414.s4|95-103|protein;|drug
DDI-DrugBank.d414.s5|25-38|anticoagulant|group
DDI-DrugBank.d414.s5|74-83|receiving|drug
DDI-DrugBank.d414.s6|22-36|administration|drug
DDI-DrugBank.d414.s6|57-73|antiinflammatory|group
DDI-DrugBank.d414.s6|95-104|diuretic,|group
DDI-DrugBank.d414.s6|105-117|natriuretic,|group
DDI-DrugBank.d414.s6|122-138|antihypertensive|group
DDI-DrugBank.d414.s6|156-166|potassium-|drug
DDI-DrugBank.d414.s6|167-174|sparing|drug
DDI-DrugBank.d414.s6|179-187|thiazide|group
DDI-DrugBank.d414.s6|188-198|diuretics.|group
DDI-DrugBank.d414.s7|16-23|EDECRIN|brand
DDI-DrugBank.d414.s7|43-48|anti-|group
DDI-DrugBank.d414.s7|49-61|inflammatory|drug
DDI-DrugBank.d414.s7|135-144|determine|drug
DDI-DrugBank.d414.s7|174-182|diuretic|group
DDI-DrugBank.d414.s7|186-195|obtained.|drug
DDI-DrugBank.d378.s0|62-77|aminoglycosides|drug
DDI-DrugBank.d378.s0|88-100|administered|drug
DDI-DrugBank.d378.s0|106-114|MAXIPIME|brand
DDI-DrugBank.d378.s0|130-139|increased|drug
DDI-DrugBank.d378.s0|187-201|aminoglycoside|drug
DDI-DrugBank.d378.s0|202-214|antibiotics.|group
DDI-DrugBank.d378.s1|33-42|following|drug
DDI-DrugBank.d378.s1|55-69|administration|drug
DDI-DrugBank.d378.s1|79-93|cephalosporins|drug
DDI-DrugBank.d378.s1|106-115|diuretics|group
DDI-DrugBank.d378.s2|38-52|administration|drug
DDI-DrugBank.d378.s2|124-129|urine|drug
DDI-DrugBank.d378.s2|135-140|using|drug
DDI-DrugBank.d378.s2|141-150|Clinitest|drug
DDI-DrugBank.d378.s3|91-100|Clinistix|drug
DDI-MedLine.d12.s0|18-25|retinyl|drug
DDI-MedLine.d12.s0|44-51|inhibit|drug
DDI-MedLine.d12.s0|74-89|insulin-induced|drug
DDI-MedLine.d12.s0|117-128|epithelium.|drug
DDI-MedLine.d12.s1|10-20|epithelium|drug
DDI-MedLine.d12.s1|39-46|defined|drug
DDI-MedLine.d12.s1|47-53|medium|drug
DDI-MedLine.d12.s1|54-64|consisting|drug
DDI-MedLine.d12.s1|74-80|medium|drug
DDI-MedLine.d12.s1|81-89|RPMI1640|brand
DDI-MedLine.d12.s1|90-100|containing|group
DDI-MedLine.d12.s1|101-112|transferrin|drug
DDI-MedLine.d12.s1|151-158|insulin|drug
DDI-MedLine.d12.s2|35-42|retinyl|drug
DDI-MedLine.d12.s2|91-101|epithelium|drug
DDI-MedLine.d12.s2|105-113|RPMI1640|brand
DDI-MedLine.d12.s2|114-124|containing|group
DDI-MedLine.d12.s2|125-136|transferrin|drug
DDI-MedLine.d12.s2|188-196|insulin.|drug
DDI-MedLine.d12.s3|17-24|10(-10)|drug_n
DDI-MedLine.d12.s3|30-37|retinyl|drug
DDI-MedLine.d12.s3|59-65|10(-9)|drug_n
DDI-MedLine.d12.s3|68-76|inhibits|drug
DDI-MedLine.d12.s4|49-55|10(-6)|drug_n
DDI-MedLine.d12.s4|62-69|retinyl|drug
DDI-MedLine.d12.s4|83-89|10(-8)|drug_n
DDI-MedLine.d12.s4|92-98|10(-7)|drug_n
DDI-MedLine.d12.s5|54-62|insulin.|drug
DDI-MedLine.d12.s6|9-16|retinyl|drug
DDI-MedLine.d12.s6|63-71|inhibit,|drug
DDI-MedLine.d12.s6|105-113|insulin.|drug
DDI-MedLine.d12.s7|50-57|retinyl|drug
DDI-MedLine.d12.s7|86-101|glucocorticoids|group
DDI-MedLine.d12.s7|106-116|retinoids,|group
DDI-MedLine.d12.s7|160-170|epithelium|drug
DDI-MedLine.d12.s7|223-230|insulin|drug
DDI-DrugBank.d440.s0|0-7|Calcium|drug
DDI-DrugBank.d440.s0|8-28|Supplements/Antacids|group
DDI-DrugBank.d440.s1|9-19|containing|group
DDI-DrugBank.d440.s1|20-27|calcium|drug
DDI-DrugBank.d440.s1|67-76|aluminum,|drug
DDI-DrugBank.d440.s1|77-87|magnesium,|drug
DDI-DrugBank.d440.s1|108-117|interfere|drug
DDI-DrugBank.d440.s2|40-47|minutes|drug
DDI-DrugBank.d440.s2|76-86|containing|group
DDI-DrugBank.d440.s2|107-117|(including|drug
DDI-DrugBank.d440.s2|118-127|antacids,|group
DDI-DrugBank.d440.s2|143-153|vitamins).|drug
DDI-DrugBank.d440.s4|106-117|anti-peptic|group
DDI-DrugBank.d440.s5|26-35|incidence|drug
DDI-DrugBank.d440.s5|45-61|gastrointestinal|drug
DDI-DrugBank.d440.s6|53-62|comparing|drug
DDI-DrugBank.d440.s6|87-93|dosing|drug
DDI-DrugBank.d440.s6|140-151|anti-peptic|group
DDI-DrugBank.d440.s7|26-35|incidence|drug
DDI-DrugBank.d440.s7|45-61|gastrointestinal|drug
DDI-DrugBank.d440.s8|0-20|Aspirin/Nonsteroidal|brand
DDI-DrugBank.d440.s8|21-37|Antiinflammatory|drug
DDI-DrugBank.d440.s9|14-32|placebo-controlled|group
DDI-DrugBank.d440.s9|63-70|aspirin|brand
DDI-DrugBank.d440.s9|88-105|anti-inflammatory|group
DDI-DrugBank.d440.s10|6-13|aspirin|brand
DDI-DrugBank.d440.s10|17-22|NSAID|brand
DDI-DrugBank.d440.s10|34-43|incidence|drug
DDI-DrugBank.d440.s10|53-69|gastrointestinal|drug
DDI-DrugBank.d440.s11|18-24|1-year|drug_n
DDI-DrugBank.d440.s11|51-58|aspirin|brand
DDI-DrugBank.d440.s11|76-93|anti-inflammatory|group
DDI-DrugBank.d440.s12|4-13|incidence|drug
DDI-DrugBank.d440.s12|23-39|gastrointestinal|drug
DDI-DrugBank.d440.s12|73-79|taking|drug
DDI-DrugBank.d440.s12|80-87|aspirin|brand
DDI-DrugBank.d440.s12|122-128|taking|drug
DDI-DrugBank.d440.s13|9-14|since|drug
DDI-DrugBank.d440.s13|15-23|aspirin,|brand
DDI-DrugBank.d440.s13|76-92|gastrointestinal|drug
DDI-DrugBank.d440.s13|159-166|aspirin|brand
DDI-DrugBank.d440.s15|29-38|interfere|drug
DDI-DrugBank.d440.s15|55-67|bone-imaging|drug
DDI-DrugBank.d251.s0|10-25|clarithromycin,|drug
DDI-DrugBank.d251.s0|26-37|Didanosine,|drug
DDI-DrugBank.d251.s0|38-50|Fluconazole,|drug
DDI-DrugBank.d251.s0|51-62|Fluoxetine,|drug
DDI-DrugBank.d251.s0|74-87|Ketoconazole,|drug
DDI-DrugBank.d251.s0|88-98|Phenytoin,|drug
DDI-DrugBank.d251.s0|114-128|carbamazepine,|drug
DDI-DrugBank.d251.s0|129-139|Rifabutin,|drug
DDI-DrugBank.d251.s0|140-149|Rifampin,|drug
DDI-DrugBank.d251.s0|150-160|Ritanovir,|drug
DDI-DrugBank.d251.s0|161-172|Saquinavir.|drug
DDI-DrugBank.d565.s0|99-108|receiving|drug
DDI-DrugBank.d565.s0|119-132|hydrochloride|drug
DDI-DrugBank.d565.s0|189-202|contractility|group
DDI-DrugBank.d565.s1|22-30|indicate|drug
DDI-DrugBank.d565.s1|69-79|prolonging|drug
DDI-DrugBank.d565.s1|99-104|using|drug
DDI-DrugBank.d565.s2|49-57|treating|drug
DDI-DrugBank.d565.s3|37-46|inhibitor|drug
DDI-DrugBank.d565.s3|65-70|P-450|brand
DDI-DrugBank.d565.s4|42-53|inhibitors,|drug
DDI-DrugBank.d565.s4|57-65|inducers|drug
DDI-DrugBank.d565.s5|9-15|taking|drug
DDI-DrugBank.d565.s5|51-57|CYP450|brand
DDI-DrugBank.d565.s5|156-164|starting|drug
DDI-DrugBank.d565.s5|168-176|stopping|drug
DDI-DrugBank.d565.s5|191-203|administered|drug
DDI-DrugBank.d565.s5|226-234|maintain|drug
DDI-DrugBank.d565.s7|15-27|uncontrolled|group
DDI-DrugBank.d565.s7|87-100|hydrochloride|drug
DDI-DrugBank.d565.s7|135-145|tolerated,|drug
DDI-DrugBank.d565.s8|0-14|Administration|drug
DDI-DrugBank.d565.s8|28-41|hydrochloride|drug
DDI-DrugBank.d565.s8|61-72|propranolol|drug
DDI-DrugBank.d565.s8|111-120|increased|drug
DDI-DrugBank.d565.s8|121-132|propranolol|drug
DDI-DrugBank.d565.s8|179-190|propranolol|drug
DDI-DrugBank.d565.s8|195-204|increased|drug
DDI-DrugBank.d565.s9|10-21|propranolol|drug
DDI-DrugBank.d565.s9|55-62|binding|drug
DDI-DrugBank.d565.s10|3-14|combination|drug
DDI-DrugBank.d565.s10|26-35|initiated|drug
DDI-DrugBank.d565.s10|69-81|propranolol,|drug
DDI-DrugBank.d565.s10|103-114|propranolol|drug
DDI-DrugBank.d565.s11|0-10|Cimetidine|drug
DDI-DrugBank.d565.s12|58-66|increase|drug
DDI-DrugBank.d565.s12|127-133|1-week|drug_n
DDI-DrugBank.d565.s12|144-154|cimetidine|drug
DDI-DrugBank.d565.s12|173-179|single|drug
DDI-DrugBank.d565.s12|198-203|60mg.|drug_n
DDI-DrugBank.d565.s13|0-10|Ranitidine|drug
DDI-DrugBank.d565.s13|44-54|increases.|drug
DDI-DrugBank.d565.s14|30-41|cimetidines|drug
DDI-DrugBank.d565.s14|48-58|inhibition|drug
DDI-DrugBank.d565.s14|81-87|P-450,|brand
DDI-DrugBank.d565.s15|19-28|receiving|drug
DDI-DrugBank.d565.s15|121-131|initiating|drug
DDI-DrugBank.d565.s15|136-149|discontinuing|group
DDI-DrugBank.d565.s15|163-174|cimetidine.|drug
DDI-DrugBank.d565.s18|0-14|Administration|drug
DDI-DrugBank.d565.s18|28-41|hydrochloride|drug
DDI-DrugBank.d565.s18|47-54|digoxin|drug
DDI-DrugBank.d565.s18|83-92|increased|drug
DDI-DrugBank.d565.s18|100-107|digoxin|drug
DDI-DrugBank.d565.s19|8-20|investigator|drug
DDI-DrugBank.d565.s19|30-38|increase|drug
DDI-DrugBank.d565.s19|42-49|digoxin|drug
DDI-DrugBank.d565.s20|0-5|Since|drug
DDI-DrugBank.d565.s20|22-33|conflicting|drug
DDI-DrugBank.d565.s20|42-51|regarding|drug
DDI-DrugBank.d565.s20|66-73|digoxin|drug
DDI-DrugBank.d565.s20|105-112|digoxin|drug
DDI-DrugBank.d565.s20|138-149|initiating,|drug
DDI-DrugBank.d565.s20|150-160|adjusting,|drug
DDI-DrugBank.d565.s20|165-178|discontinuing|group
DDI-DrugBank.d565.s20|189-202|hydrochloride|drug
DDI-DrugBank.d565.s22|26-40|contractility,|group
DDI-DrugBank.d565.s22|155-162|calcium|drug
DDI-DrugBank.d565.s23|41-48|calcium|drug
DDI-DrugBank.d565.s24|0-12|Cyclosporine|drug
DDI-DrugBank.d565.s25|2-17|pharmacokinetic|drug
DDI-DrugBank.d565.s25|18-29|interaction|drug
DDI-DrugBank.d565.s25|52-64|cyclosporine|drug
DDI-DrugBank.d565.s25|83-89|during|drug
DDI-DrugBank.d565.s25|98-107|involving|drug
DDI-DrugBank.d565.s26|59-71|cyclosporine|drug
DDI-DrugBank.d565.s26|77-84|ranging|drug
DDI-DrugBank.d565.s26|118-126|maintain|drug
DDI-DrugBank.d565.s26|127-139|cyclosporine|drug
DDI-DrugBank.d565.s27|26-38|administered|drug
DDI-DrugBank.d565.s27|53-65|cyclosporine|drug
DDI-DrugBank.d565.s27|139-149|initiated,|drug
DDI-DrugBank.d565.s27|163-176|discontinued.|group
DDI-DrugBank.d565.s28|14-26|cyclosporine|drug
DDI-DrugBank.d565.s29|0-13|Carbamazepine|drug
DDI-DrugBank.d565.s30|12-26|administration|drug
DDI-DrugBank.d565.s30|45-58|carbamazepine|drug
DDI-DrugBank.d565.s30|115-128|carbamazepine|drug
DDI-DrugBank.d565.s30|141-151|increase),|drug
DDI-DrugBank.d565.s30|152-161|resulting|drug
DDI-DrugBank.d565.s31|9-18|receiving|drug
DDI-DrugBank.d565.s31|85-97|interaction.|drug
DDI-DrugBank.d565.s32|0-15|Benzodiazepines|drug
DDI-DrugBank.d565.s33|30-39|increased|drug
DDI-DrugBank.d565.s33|51-60|midazolam|drug
DDI-DrugBank.d565.s33|65-74|triazolam|drug
DDI-DrugBank.d565.s33|103-110|2-fold,|drug_n
DDI-DrugBank.d565.s34|4-15|elimination|drug
DDI-DrugBank.d565.s34|29-38|midazolam|drug
DDI-DrugBank.d565.s34|43-52|triazolam|drug
DDI-DrugBank.d565.s34|58-67|increased|drug
DDI-DrugBank.d565.s34|83-89|during|drug
DDI-DrugBank.d565.s34|90-106|coadministration|drug
DDI-DrugBank.d565.s35|6-21|pharmacokinetic|drug
DDI-DrugBank.d565.s35|35-41|during|drug
DDI-DrugBank.d565.s35|52-68|coadministration|drug
DDI-DrugBank.d565.s35|83-92|increased|drug
DDI-DrugBank.d565.s35|93-101|clinical|drug
DDI-DrugBank.d565.s35|144-153|midazolam|drug
DDI-DrugBank.d565.s36|0-10|Lovastatin|drug
DDI-DrugBank.d565.s37|24-40|coadministration|drug
DDI-DrugBank.d565.s37|72-82|lovastatin|drug
DDI-DrugBank.d565.s37|107-115|increase|drug
DDI-DrugBank.d565.s37|124-134|lovastatin|drug
DDI-DrugBank.d565.s37|152-162|lovastatin|drug
DDI-DrugBank.d565.s38|13-24|pravastatin|drug
DDI-DrugBank.d565.s38|51-57|during|drug
DDI-DrugBank.d565.s38|68-85|coadministration.|drug
DDI-DrugBank.d565.s39|59-69|lovastatin|drug
DDI-DrugBank.d565.s39|73-85|pravastatin.|drug
DDI-DrugBank.d565.s40|0-8|Rifampin|drug
DDI-DrugBank.d565.s41|0-16|Coadministration|drug
DDI-DrugBank.d565.s41|20-28|rifampin|drug
DDI-DrugBank.d565.s42|0-16|Coadministration|drug
DDI-DrugBank.d565.s42|35-43|rifampin|drug
DDI-DrugBank.d565.s42|57-63|CYP3A4|brand
DDI-DrugBank.d565.s42|64-71|inducer|drug
DDI-DrugBank.d401.s0|31-46|anticholinergic|group
DDI-DrugBank.d401.s0|71-86|anticholinergic|group
DDI-DrugBank.d401.s0|102-110|AKINETON|brand
DDI-DrugBank.d401.s0|115-127|administered|drug
DDI-DrugBank.d401.s0|173-188|anticholinergic|group
DDI-DrugBank.d401.s0|204-211|certain|drug
DDI-DrugBank.d401.s0|240-251|meperidine,|drug
DDI-DrugBank.d401.s0|256-270|phenothiazines|drug
DDI-DrugBank.d401.s0|281-296|antipsychotics,|group
DDI-DrugBank.d401.s0|307-323|antidepressants,|group
DDI-DrugBank.d401.s0|324-331|certain|drug
DDI-DrugBank.d401.s0|332-347|antiarrhythmics|group
DDI-DrugBank.d401.s0|360-369|quinidine|drug
DDI-DrugBank.d401.s0|381-396|antihistamines.|group
DDI-DrugBank.d409.s0|12-25|tetracyclines|drug
DDI-DrugBank.d409.s0|60-71|prothrombin|drug
DDI-DrugBank.d409.s0|102-115|anticoagulant|group
DDI-DrugBank.d409.s0|165-178|anticoagulant|group
DDI-DrugBank.d409.s1|0-5|Since|drug
DDI-DrugBank.d409.s1|40-52|tetracycline|drug
DDI-DrugBank.d409.s1|62-74|antibiotics,|group
DDI-DrugBank.d409.s1|79-88|interfere|drug
DDI-DrugBank.d409.s1|121-133|penicillins,|drug
DDI-DrugBank.d409.s1|157-167|administer|drug
DDI-DrugBank.d409.s2|18-31|tetracyclines|drug
DDI-DrugBank.d409.s2|42-56|contraceptives|group
DDI-DrugBank.d409.s2|73-87|contraceptives|group
DDI-DrugBank.d409.s3|13-21|bleeding|drug
DDI-DrugBank.d225.s0|66-79|sulfonylureas|group
DDI-DrugBank.d225.s0|102-109|certain|drug
DDI-DrugBank.d225.s0|116-125|including|drug
DDI-DrugBank.d225.s0|139-156|anti-inflammatory|group
DDI-DrugBank.d225.s0|170-176|azoles|drug
DDI-DrugBank.d225.s0|209-216|protein|drug
DDI-DrugBank.d225.s0|280-290|coumarins,|drug
DDI-DrugBank.d225.s0|291-300|monoamine|drug
DDI-DrugBank.d225.s0|309-320|inhibitors,|drug
DDI-DrugBank.d225.s0|341-349|blocking|drug
DDI-DrugBank.d225.s1|20-32|administered|drug
DDI-DrugBank.d225.s1|46-55|receiving|drug
DDI-DrugBank.d225.s2|45-54|receiving|drug
DDI-DrugBank.d225.s2|117-125|control.|group
DDI-DrugBank.d225.s3|9-16|binding|drug
DDI-DrugBank.d225.s3|42-50|proteins|drug
DDI-DrugBank.d225.s3|51-59|indicate|drug
DDI-DrugBank.d225.s3|65-74|glipizide|drug
DDI-DrugBank.d225.s3|75-80|binds|drug
DDI-DrugBank.d225.s3|98-109|tolbutamide|drug
DDI-DrugBank.d225.s3|123-131|interact|drug
DDI-DrugBank.d225.s4|38-51|extrapolating|drug
DDI-DrugBank.d225.s4|58-66|findings|drug
DDI-DrugBank.d225.s4|74-82|clinical|drug
DDI-DrugBank.d225.s4|111-120|glipizide|drug
DDI-DrugBank.d225.s5|0-7|Certain|drug
DDI-DrugBank.d225.s5|68-76|control.|group
DDI-DrugBank.d225.s6|12-19|include|drug
DDI-DrugBank.d225.s6|24-33|thiazides|group
DDI-DrugBank.d225.s6|44-54|diuretics,|group
DDI-DrugBank.d225.s6|55-71|corticosteroids,|group
DDI-DrugBank.d225.s6|72-87|phenothiazines,|drug
DDI-DrugBank.d225.s6|122-137|contraceptives,|group
DDI-DrugBank.d225.s6|138-148|phenytoin,|drug
DDI-DrugBank.d225.s6|149-158|nicotinic|drug
DDI-DrugBank.d225.s6|183-190|calcium|drug
DDI-DrugBank.d225.s6|199-207|blocking|drug
DDI-DrugBank.d225.s7|20-32|administered|drug
DDI-DrugBank.d225.s7|46-55|receiving|drug
DDI-DrugBank.d225.s7|118-126|control.|group
DDI-DrugBank.d225.s8|45-54|receiving|drug
DDI-DrugBank.d225.s9|12-23|interaction|drug
DDI-DrugBank.d225.s9|37-47|miconazole|drug
DDI-DrugBank.d225.s9|77-84|leading|drug
DDI-DrugBank.d225.s10|13-24|interaction|drug
DDI-DrugBank.d225.s10|46-58|intravenous,|drug
DDI-DrugBank.d225.s10|71-78|vaginal|drug
DDI-DrugBank.d225.s10|95-105|miconazole|drug
DDI-DrugBank.d225.s11|26-40|administration|drug
DDI-DrugBank.d225.s11|44-55|fluconazole|drug
DDI-DrugBank.d225.s11|60-69|glipizide|drug
DDI-DrugBank.d225.s11|97-115|placebo-controlled|group
DDI-DrugBank.d225.s12|22-31|glipizide|drug
DDI-DrugBank.d225.s12|42-51|following|drug
DDI-DrugBank.d225.s12|77-88|fluconazole|drug
DDI-DrugBank.d225.s12|94-100|single|drug
DDI-DrugBank.d225.s13|20-28|increase|drug
DDI-DrugBank.d225.s13|36-45|glipizide|drug
DDI-DrugBank.d225.s13|56-67|fluconazole|drug
DDI-DrugBank.d225.s13|68-82|administration|drug
DDI-DrugBank.d225.s13|87-92|56.9%|drug_n
DDI-MedLine.d66.s0|11-18|urinary|drug
DDI-MedLine.d66.s0|19-31|homocysteine|drug
DDI-MedLine.d66.s0|32-41|following|drug
DDI-MedLine.d66.s0|87-101|administration|drug
DDI-MedLine.d66.s1|17-25|involved|drug
DDI-MedLine.d66.s1|30-44|administration|drug
DDI-MedLine.d66.s1|121-134|determination|drug
DDI-MedLine.d66.s1|142-154|homocysteine|drug
DDI-MedLine.d66.s1|173-179|urine.|drug
DDI-MedLine.d66.s2|12-20|indicate|drug
DDI-MedLine.d66.s2|103-115|homocysteine|drug
DDI-MedLine.d66.s2|123-128|urine|drug
DDI-MedLine.d66.s2|137-144|control|group
DDI-MedLine.d66.s3|95-103|indicate|drug
DDI-MedLine.d66.s3|109-121|homocysteine|drug
DDI-MedLine.d66.s3|131-144|precipitating|drug
DDI-MedLine.d66.s4|5-13|included|drug
DDI-MedLine.d66.s4|87-92|being|drug
DDI-MedLine.d66.s4|93-105|homocysteine|drug
DDI-MedLine.d66.s4|109-116|forming|drug
DDI-MedLine.d66.s4|161-182|sulphydryl-containing|group
DDI-MedLine.d66.s4|183-188|amino|drug
DDI-MedLine.d66.s4|204-213|analysing|drug
DDI-MedLine.d66.s4|218-227|resulting|drug
DDI-MedLine.d66.s4|228-235|mixture|group
DDI-DrugBank.d501.s0|11-19|clinical|drug
DDI-DrugBank.d501.s0|25-36|interaction|drug
DDI-DrugBank.d501.s4|12-17|using|drug
DDI-DrugBank.d501.s4|37-45|(digoxin|drug
DDI-DrugBank.d501.s4|76-84|calcium,|drug
DDI-DrugBank.d501.s4|85-94|potassium|drug
DDI-DrugBank.d501.s4|99-108|magnesium|drug
DDI-DrugBank.d501.s5|0-8|Insulin:|drug
DDI-DrugBank.d501.s5|11-19|clinical|drug
DDI-DrugBank.d501.s5|31-48|insulin-dependent|drug
DDI-DrugBank.d501.s5|93-102|EXTRANEAL|brand
DDI-DrugBank.d501.s5|106-113|insulin|drug
DDI-DrugBank.d501.s5|158-166|insulins|drug
DDI-DrugBank.d501.s5|178-185|control|group
DDI-DrugBank.d501.s5|205-212|insulin|drug
DDI-DrugBank.d501.s5|217-229|administered|drug
DDI-DrugBank.d501.s5|230-247|intraperitoneally|drug
DDI-DrugBank.d501.s5|253-263|EXTRANEAL.|brand
DDI-DrugBank.d501.s6|21-31|monitoring|drug
DDI-DrugBank.d501.s6|74-84|initiating|drug
DDI-DrugBank.d501.s6|85-94|EXTRANEAL|brand
DDI-DrugBank.d501.s6|120-127|insulin|drug
DDI-DrugBank.d501.s7|0-8|Heparin:|drug
DDI-DrugBank.d501.s7|23-34|interaction|drug
DDI-DrugBank.d501.s7|48-55|heparin|drug
DDI-DrugBank.d501.s8|45-60|incompatibility|drug
DDI-DrugBank.d501.s8|64-71|heparin|drug
DDI-DrugBank.d501.s8|77-87|EXTRANEAL.|brand
DDI-DrugBank.d501.s9|27-38|interaction|drug
DDI-DrugBank.d501.s9|52-63|antibiotics|group
DDI-DrugBank.d501.s10|17-27|evaluating|drug
DDI-DrugBank.d501.s10|32-39|minimum|drug
DDI-DrugBank.d501.s10|40-50|inhibitory|drug
DDI-DrugBank.d501.s10|65-70|(MIC)|brand
DDI-DrugBank.d501.s10|74-85|vancomycin,|drug
DDI-DrugBank.d501.s10|86-96|cefazolin,|drug
DDI-DrugBank.d501.s10|97-108|ampicillin,|drug
DDI-DrugBank.d501.s10|109-134|ampicillin/flucoxacillin,|drug
DDI-DrugBank.d501.s10|148-159|gentamicin,|drug
DDI-DrugBank.d501.s10|164-176|amphotericin|drug
DDI-DrugBank.d501.s10|205-220|incompatibility|drug
DDI-DrugBank.d501.s10|230-241|antibiotics|group
DDI-DrugBank.d501.s10|247-257|EXTRANEAL.|brand
DDI-DrugBank.d501.s11|62-73|measurement|group
DDI-DrugBank.d501.s11|137-149|interference|drug
DDI-DrugBank.d501.s12|0-5|Since|drug
DDI-DrugBank.d501.s12|76-86|monitoring|drug
DDI-DrugBank.d501.s12|128-141|dehydrogenase|drug
DDI-DrugBank.d501.s12|142-165|pyrroloquinolinequinone|drug
DDI-DrugBank.d501.s12|235-242|measure|group
DDI-DrugBank.d501.s12|270-282|administered|drug
DDI-DrugBank.d501.s12|283-294|EXTRANEAL..|brand
DDI-DrugBank.d501.s13|91-103|administered|drug
DDI-DrugBank.d501.s13|104-114|EXTRANEAL.|brand
DDI-DrugBank.d501.s14|0-11|Preliminary|drug
DDI-DrugBank.d501.s14|12-26|investigations|drug
DDI-DrugBank.d501.s14|27-35|indicate|drug
DDI-DrugBank.d501.s14|41-51|icodextrin|drug
DDI-DrugBank.d501.s14|72-81|interfere|drug
DDI-DrugBank.d501.s14|119-128|resulting|drug
DDI-DrugBank.d501.s14|132-144|inaccurately|drug
DDI-DrugBank.d501.s15|39-49|evaluating|drug
DDI-DrugBank.d501.s15|88-98|monitoring|drug
DDI-DrugBank.d501.s15|127-132|using|drug
DDI-DrugBank.d501.s15|133-143|EXTRANEAL.|brand
DDI-MedLine.d35.s2|82-91|increased|drug
DDI-MedLine.d35.s2|162-167|using|drug
DDI-MedLine.d35.s2|180-195|antidepressants|group
DDI-MedLine.d35.s3|33-41|proteins|drug
DDI-MedLine.d35.s3|42-53|interacting|drug
DDI-MedLine.d35.s4|17-32|antipsychotics.|group
DDI-MedLine.d35.s5|119-134|investigations.|drug
DDI-MedLine.d35.s6|53-65|examinations|drug
DDI-MedLine.d35.s6|70-80|insurances|drug
DDI-MedLine.d35.s6|89-102|appointments,|drug
DDI-MedLine.d35.s6|103-108|since|drug
DDI-MedLine.d35.s6|186-193|certain|drug
DDI-MedLine.d35.s7|44-53|instances|drug
DDI-DrugBank.d298.s0|19-28|interfere|drug
DDI-DrugBank.d298.s0|38-51|anti-glaucoma|group
DDI-DrugBank.d298.s0|75-87|pilocarpine;|drug
DDI-DrugBank.d298.s1|59-72|anti-glaucoma|group
DDI-DrugBank.d298.s1|106-120|cholinesterase|drug
DDI-DrugBank.d298.s1|121-132|inhibitors.|drug
DDI-DrugBank.d416.s0|16-28|measurements|group
DDI-DrugBank.d416.s0|93-102|receiving|drug
DDI-DrugBank.d416.s0|117-126|procaine,|drug
DDI-DrugBank.d416.s0|130-146|thiazolesulfone.|drug
DDI-DrugBank.d416.s1|16-25|interfere|drug
DDI-DrugBank.d416.s1|86-97|procedures.|group
DDI-DrugBank.d416.s2|42-49|certain|drug
DDI-DrugBank.d416.s2|55-60|acids|group
DDI-DrugBank.d416.s3|20-29|receiving|drug
DDI-DrugBank.d148.s0|0-8|Heparin:|drug
DDI-DrugBank.d148.s0|9-14|Since|drug
DDI-DrugBank.d148.s0|15-22|heparin|drug
DDI-DrugBank.d148.s0|26-41|contraindicated|group
DDI-DrugBank.d148.s0|59-74|heparin-induced|drug
DDI-DrugBank.d148.s0|97-114|co-administration|drug
DDI-DrugBank.d148.s0|133-140|heparin|drug
DDI-DrugBank.d148.s0|162-173|indication.|drug
DDI-DrugBank.d148.s1|32-41|initiated|drug
DDI-DrugBank.d148.s1|61-68|heparin|drug
DDI-DrugBank.d148.s1|104-112|heparins|drug
DDI-DrugBank.d148.s1|153-163|initiation|drug
DDI-DrugBank.d148.s2|0-22|Aspirin/Acetaminophen:|brand
DDI-DrugBank.d148.s2|23-38|Pharmacokinetic|drug
DDI-DrugBank.d148.s2|68-80|interactions|drug
DDI-DrugBank.d148.s2|145-157|administered|drug
DDI-DrugBank.d148.s2|158-165|aspirin|brand
DDI-DrugBank.d148.s2|213-223|initiation|drug
DDI-DrugBank.d148.s2|241-250|g/kg/min.|drug
DDI-DrugBank.d148.s2|268-281|acetaminophen|drug
DDI-DrugBank.d148.s2|366-376|initiation|drug
DDI-DrugBank.d148.s2|396-405|g/kg/min.|drug
DDI-DrugBank.d148.s3|5-18|anticoagulant|group
DDI-DrugBank.d148.s3|27-42|Pharmacokinetic|drug
DDI-DrugBank.d148.s3|53-65|interactions|drug
DDI-DrugBank.d148.s3|89-97|warfarin|drug
DDI-DrugBank.d148.s3|106-112|single|drug
DDI-DrugBank.d148.s4|47-55|warfarin|drug
DDI-DrugBank.d148.s4|66-73|initial|drug
DDI-DrugBank.d148.s4|96-101|2.5-6|drug_n
DDI-DrugBank.d148.s4|162-173|prothrombin|drug
DDI-DrugBank.d148.s4|219-225|(INR).|brand
DDI-DrugBank.d148.s6|0-18|Co-administration:|drug
DDI-DrugBank.d148.s6|54-66|antiplatelet|group
DDI-DrugBank.d148.s6|100-114|anticoagulants|group
DDI-DrugBank.d148.s6|119-127|increase|drug
DDI-DrugBank.d148.s6|140-149|bleeding.|drug
DDI-DrugBank.d148.s7|10-22|interactions|drug
DDI-DrugBank.d148.s7|69-76|digoxin|drug
DDI-DrugBank.d148.s7|80-93|erythromycin.|drug
DDI-DrugBank.d468.s0|18-28|controlled|group
DDI-DrugBank.d468.s0|29-37|clinical|drug
DDI-DrugBank.d468.s0|102-114|administered|drug
DDI-DrugBank.d468.s0|134-145|nicardipine|drug
DDI-DrugBank.d468.s1|4-15|combination|drug
DDI-DrugBank.d468.s1|24-34|tolerated.|drug
DDI-DrugBank.d468.s2|0-11|Cimetidine:|drug
DDI-DrugBank.d468.s2|12-22|Cimetidine|drug
DDI-DrugBank.d468.s2|23-32|increases|drug
DDI-DrugBank.d468.s2|33-44|nicardipine|drug
DDI-DrugBank.d468.s3|9-18|receiving|drug
DDI-DrugBank.d468.s4|0-8|Digoxin:|drug
DDI-DrugBank.d468.s4|14-21|calcium|drug
DDI-DrugBank.d468.s4|35-43|increase|drug
DDI-DrugBank.d468.s5|0-11|Nicardipine|drug
DDI-DrugBank.d468.s5|60-68|digoxin,|drug
DDI-DrugBank.d468.s5|84-91|digoxin|drug
DDI-DrugBank.d468.s5|150-161|nicardipine|drug
DDI-DrugBank.d468.s5|169-179|initiated.|drug
DDI-DrugBank.d468.s6|9-25|Coadministration|drug
DDI-DrugBank.d468.s6|56-67|nicardipine|drug
DDI-DrugBank.d468.s7|17-29|interactions|drug
DDI-DrugBank.d468.s7|44-50|during|drug
DDI-DrugBank.d468.s7|51-59|clinical|drug
DDI-DrugBank.d468.s7|73-84|nicardipine|drug
DDI-DrugBank.d468.s7|93-102|increased|drug
DDI-DrugBank.d468.s7|113-124|circulating|drug
DDI-DrugBank.d468.s7|125-131|fluids|group
DDI-DrugBank.d468.s7|161-172|interaction|drug
DDI-DrugBank.d468.s8|0-13|Cyclosporine:|drug
DDI-DrugBank.d468.s8|26-40|administration|drug
DDI-DrugBank.d468.s8|44-55|nicardipine|drug
DDI-DrugBank.d468.s8|60-72|cyclosporine|drug
DDI-DrugBank.d468.s9|25-37|cyclosporine|drug
DDI-DrugBank.d468.s9|100-112|accordingly,|drug
DDI-DrugBank.d468.s9|138-150|nicardipine.|drug
DDI-DrugBank.d468.s10|47-59|propranolol,|drug
DDI-DrugBank.d468.s10|60-73|dipyridamole,|drug
DDI-DrugBank.d468.s10|74-83|warfarin,|drug
DDI-DrugBank.d468.s10|84-94|quinidine,|drug
DDI-DrugBank.d468.s10|157-164|protein|drug
DDI-DrugBank.d468.s10|165-172|binding|drug
DDI-DrugBank.d468.s10|176-187|nicardipine|drug
DDI-MedLine.d136.s0|23-31|exposure|group
DDI-MedLine.d136.s0|131-139|exposure|group
DDI-MedLine.d136.s1|17-25|exposure|group
DDI-MedLine.d136.s1|30-43|toxicokinetic|drug
DDI-MedLine.d136.s1|44-57|interferences|drug
DDI-MedLine.d136.s2|15-23|exposure|group
DDI-MedLine.d136.s3|10-22|interference|drug
DDI-MedLine.d136.s3|87-97|indicators|drug
DDI-MedLine.d136.s4|14-26|interference|drug
DDI-MedLine.d136.s5|81-91|literature|group
DDI-MedLine.d136.s5|118-126|deriving|drug
DDI-MedLine.d136.s5|141-149|exposure|group
DDI-MedLine.d136.s6|73-81|combined|drug
DDI-MedLine.d136.s6|82-90|exposure|group
DDI-MedLine.d136.s7|32-40|exposure|group
DDI-MedLine.d136.s7|92-105|interferences|drug
DDI-MedLine.d90.s0|15-25|gentamycin|drug
DDI-MedLine.d90.s0|30-40|atracurium|drug
DDI-MedLine.d90.s1|60-70|maintained|drug
DDI-MedLine.d90.s1|81-89|baseline|drug
DDI-MedLine.d90.s1|101-111|atracurium|drug
DDI-MedLine.d90.s1|112-120|infusion|drug
DDI-MedLine.d90.s2|11-21|atracurium|drug
DDI-MedLine.d90.s2|26-38|discontinued|group
DDI-MedLine.d90.s3|0-10|Atracurium|drug
DDI-MedLine.d90.s3|15-20|again|drug_n
DDI-MedLine.d90.s3|30-38|infusion|drug
DDI-MedLine.d90.s3|42-50|maintain|drug
DDI-MedLine.d90.s3|91-104|gentamycin/kg|drug
DDI-MedLine.d90.s4|0-10|Atracurium|drug
DDI-MedLine.d90.s4|11-19|infusion|drug
DDI-MedLine.d90.s4|24-33|continued|group
DDI-MedLine.d90.s4|77-82|again|drug_n
DDI-MedLine.d90.s5|0-10|Gentamycin|drug
DDI-MedLine.d90.s5|78-84|within|drug
DDI-MedLine.d90.s5|106-112|0.02).|drug_n
DDI-MedLine.d90.s6|29-43|pre-gentamycin|drug
DDI-MedLine.d90.s7|65-75|atracurium|drug
DDI-MedLine.d90.s7|107-117|atracurium|drug
DDI-MedLine.d90.s7|123-133|gentamycin|drug
DDI-MedLine.d90.s7|139-145|0.03).|drug_n
DDI-MedLine.d90.s8|72-82|atracurium|drug
DDI-MedLine.d90.s8|114-124|atracurium|drug
DDI-MedLine.d90.s8|130-141|gentamycin.|drug
DDI-MedLine.d90.s9|55-65|atracurium|drug
DDI-MedLine.d90.s9|90-100|atracurium|drug
DDI-MedLine.d90.s9|106-117|gentamycin.|drug
DDI-MedLine.d90.s10|27-38|edrophonium|drug
DDI-MedLine.d90.s11|32-42|gentamycin|drug
DDI-MedLine.d90.s11|85-96|atracurium,|drug
DDI-MedLine.d90.s11|112-120|minimal.|drug
DDI-DrugBank.d354.s0|0-10|Tizoxanide|drug
DDI-DrugBank.d354.s0|37-44|protein|drug
DDI-DrugBank.d354.s0|47-54|99.9%).|drug_n
DDI-DrugBank.d354.s1|39-52|administering|drug
DDI-DrugBank.d354.s1|53-65|nitazoxanide|drug
DDI-DrugBank.d354.s1|104-117|protein-bound|drug
DDI-DrugBank.d354.s1|148-156|indices,|drug
DDI-DrugBank.d354.s1|176-183|binding|drug
DDI-DrugBank.d354.s1|207-217|warfarin).|drug
DDI-DrugBank.d354.s2|51-61|tizoxanide|drug
DDI-DrugBank.d354.s2|81-91|inhibitory|drug
DDI-DrugBank.d354.s3|22-33|interaction|drug
DDI-DrugBank.d354.s3|106-117|interaction|drug
DDI-DrugBank.d354.s3|135-147|nitazoxanide|drug
DDI-DrugBank.d354.s3|151-166|co-administered|drug
DDI-DrugBank.d354.s3|212-219|inhibit|drug
DDI-DrugBank.d447.s0|80-85|urine|drug
DDI-DrugBank.d447.s0|139-146|Fehling|drug
DDI-DrugBank.d447.s0|166-175|Clinitest|drug
DDI-DrugBank.d447.s1|44-56|ferricyanide|drug
DDI-DrugBank.d447.s1|116-126|hexokinase|drug
DDI-DrugBank.d447.s1|145-154|determine|drug
DDI-DrugBank.d447.s1|195-204|receiving|drug
DDI-DrugBank.d447.s2|20-29|interfere|drug
DDI-DrugBank.d447.s2|58-63|urine|drug
DDI-DrugBank.d447.s2|64-74|creatinine|drug
DDI-DrugBank.d447.s2|82-90|alkaline|drug
DDI-DrugBank.d408.s0|15-26|interaction|drug
DDI-DrugBank.d408.s0|60-68|ZEVALIN.|brand
DDI-DrugBank.d408.s1|117-126|interfere|drug
DDI-DrugBank.d408.s1|157-172|anticoagulation|group
DDI-DrugBank.d408.s1|191-198|against|drug_n
DDI-DrugBank.d408.s1|213-222|increased|drug
DDI-DrugBank.d408.s1|232-240|bleeding|drug
DDI-DrugBank.d408.s2|9-18|receiving|drug
DDI-DrugBank.d408.s2|36-45|interfere|drug
DDI-DrugBank.d408.s2|121-131|monitoring|drug
DDI-DrugBank.d408.s3|91-100|increased|drug
DDI-DrugBank.d408.s3|109-118|bleeding.|drug
DDI-DrugBank.d408.s4|12-20|clinical|drug
DDI-DrugBank.d408.s4|50-59|receiving|drug
DDI-DrugBank.d408.s4|109-116|ZEVALIN|brand
DDI-DrugBank.d408.s4|160-169|following|drug
DDI-MedLine.d113.s0|15-26|ethanolysis|drug
DDI-MedLine.d113.s0|43-52|anhydrous|drug
DDI-MedLine.d113.s0|65-72|ethanol|drug
DDI-MedLine.d113.s1|4-19|benzodiazepines|drug
DDI-MedLine.d113.s2|29-37|ethanol,|drug
DDI-MedLine.d113.s2|56-67|interaction|drug
DDI-MedLine.d113.s2|79-91|potentiating|drug
DDI-MedLine.d113.s3|36-48|interaction,|drug
DDI-MedLine.d113.s3|118-133|benzodiazepine)|drug
DDI-MedLine.d113.s3|138-145|ethanol|drug
DDI-MedLine.d113.s3|202-211|resulting|drug
DDI-MedLine.d113.s3|217-230|3-ethoxylated|drug_n
DDI-MedLine.d113.s4|20-29|kinetics,|drug
DDI-MedLine.d113.s4|30-42|equilibrium,|drug
DDI-MedLine.d113.s4|84-95|ethanolysis|drug
DDI-MedLine.d113.s5|43-54|ethanolysis|drug
DDI-MedLine.d113.s5|123-151|3-hydroxy-1,4-benzodiazepine|drug_n
DDI-MedLine.d113.s6|19-31|ethanol-drug|drug
DDI-DrugBank.d20.s0|46-59|predominantly|drug
DDI-DrugBank.d20.s0|73-80|CYP3A4.|brand
DDI-DrugBank.d20.s1|2-17|pharmacokinetic|drug
DDI-DrugBank.d20.s1|24-34|evaluating|drug
DDI-DrugBank.d20.s1|39-53|administration|drug
DDI-DrugBank.d20.s1|59-65|single|drug
DDI-DrugBank.d20.s1|74-80|INSPRA|brand
DDI-DrugBank.d20.s1|93-105|ketoconazole|drug
DDI-DrugBank.d20.s1|127-136|inhibitor|drug
DDI-DrugBank.d20.s1|144-150|CYP3A4|brand
DDI-DrugBank.d20.s1|169-177|1.7-fold|drug_n
DDI-DrugBank.d20.s1|178-186|increase|drug
DDI-DrugBank.d20.s1|215-223|5.4-fold|drug_n
DDI-DrugBank.d20.s1|224-232|increase|drug
DDI-DrugBank.d20.s2|0-6|INSPRA|brand
DDI-DrugBank.d20.s2|57-67|inhibitors|drug
DDI-DrugBank.d20.s2|71-77|CYP3A4|brand
DDI-DrugBank.d20.s2|87-96|labeling.|drug
DDI-DrugBank.d20.s3|0-14|Administration|drug
DDI-DrugBank.d20.s3|40-46|CYP3A4|brand
DDI-DrugBank.d20.s3|47-57|inhibitors|drug
DDI-DrugBank.d20.s3|65-77|erythromycin|drug
DDI-DrugBank.d20.s3|111-121|saquinavir|drug
DDI-DrugBank.d20.s3|135-146|fluconazole|drug
DDI-DrugBank.d20.s3|170-179|increases|drug
DDI-DrugBank.d20.s3|202-209|ranging|drug
DDI-DrugBank.d20.s4|19-30|Angiotensin|drug
DDI-DrugBank.d20.s4|73-80|Failure|group
DDI-DrugBank.d20.s4|113-121|EPHESUS,|brand
DDI-DrugBank.d20.s4|142-151|receiving|drug
DDI-DrugBank.d20.s4|152-158|INSPRA|brand
DDI-DrugBank.d20.s4|189-199|inhibitors|drug
DDI-DrugBank.d20.s4|203-214|angiotensin|drug
DDI-DrugBank.d20.s4|239-250|(ACEI/ARB).|brand
DDI-DrugBank.d20.s5|31-40|potassium|drug
DDI-DrugBank.d20.s5|97-106|ACEI/ARB.|brand
DDI-DrugBank.d20.s6|19-30|Angiotensin|drug
DDI-DrugBank.d20.s6|74-82|clinical|drug
DDI-DrugBank.d20.s6|138-144|INSPRA|brand
DDI-DrugBank.d20.s6|165-175|inhibitors|drug
DDI-DrugBank.d20.s6|180-191|angiotensin|drug
DDI-DrugBank.d20.s6|216-225|increased|drug
DDI-DrugBank.d20.s6|237-246|potassium|drug
DDI-DrugBank.d20.s6|263-272|0.09-0.13|drug_n
DDI-DrugBank.d20.s7|29-45|microalbuminuria|drug
DDI-DrugBank.d20.s7|46-52|INSPRA|brand
DDI-DrugBank.d20.s7|60-68|combined|drug
DDI-DrugBank.d20.s7|82-91|inhibitor|drug
DDI-DrugBank.d20.s7|108-117|increased|drug
DDI-DrugBank.d20.s7|155-164|potassium|drug
DDI-DrugBank.d20.s8|0-9|Lithium-A|drug
DDI-DrugBank.d20.s8|15-26|interaction|drug
DDI-DrugBank.d20.s8|52-59|lithium|drug
DDI-DrugBank.d20.s9|6-13|lithium|drug
DDI-DrugBank.d20.s9|55-61|INSPRA|brand
DDI-DrugBank.d20.s9|65-77|administered|drug
DDI-DrugBank.d20.s9|97-105|lithium.|drug
DDI-DrugBank.d20.s10|53-64|interaction|drug
DDI-DrugBank.d20.s10|93-98|NSAID|brand
DDI-DrugBank.d20.s11|4-18|administration|drug
DDI-DrugBank.d20.s11|28-45|potassium-sparing|drug
DDI-DrugBank.d20.s11|46-63|antihypertensives|group
DDI-DrugBank.d20.s11|105-121|antihypertensive|group
DDI-DrugBank.d20.s12|16-22|INSPRA|brand
DDI-DrugBank.d20.s12|89-98|determine|drug
DDI-DrugBank.d20.s12|135-143|pressure|group
DDI-DrugBank.d20.s12|147-156|obtained.|drug
DDI-DrugBank.d566.s0|0-14|Cholestyramine|drug
DDI-DrugBank.d566.s0|15-20|resin|drug
DDI-DrugBank.d566.s0|111-120|warfarin,|drug
DDI-DrugBank.d566.s0|121-129|thiazide|group
DDI-DrugBank.d566.s0|130-139|diuretics|group
DDI-DrugBank.d566.s0|152-163|propranolol|drug
DDI-DrugBank.d566.s0|184-196|tetracycline|drug
DDI-DrugBank.d566.s0|197-207|penicillin|drug
DDI-DrugBank.d566.s0|238-247|thyroxine|drug
DDI-DrugBank.d566.s0|276-287|progestins,|drug
DDI-DrugBank.d566.s1|86-93|another|drug
DDI-DrugBank.d566.s2|0-14|Cholestyramine|drug
DDI-DrugBank.d566.s2|15-20|resin|drug
DDI-DrugBank.d566.s2|25-34|interfere|drug
DDI-DrugBank.d566.s2|44-60|pharmacokinetics|drug
DDI-DrugBank.d566.s2|114-128|discontinuance|group
DDI-DrugBank.d566.s2|132-146|cholestyramine|drug
DDI-DrugBank.d566.s2|147-152|resin|drug
DDI-DrugBank.d566.s2|253-264|maintenance|drug
DDI-DrugBank.d566.s2|293-299|taking|drug
DDI-DrugBank.d566.s2|300-314|cholestyramine|drug
DDI-DrugBank.d566.s2|315-321|resin.|drug
DDI-DrugBank.d566.s3|8-22|cholestyramine|drug
DDI-DrugBank.d566.s3|23-28|binds|drug
DDI-DrugBank.d566.s3|34-40|acids,|group
DDI-DrugBank.d566.s3|41-55|cholestyramine|drug
DDI-DrugBank.d566.s3|56-61|resin|drug
DDI-DrugBank.d566.s3|66-75|interfere|drug
DDI-DrugBank.d566.s3|164-172|vitamins|drug
DDI-DrugBank.d566.s4|5-19|cholestyramine|drug
DDI-DrugBank.d566.s4|20-25|resin|drug
DDI-DrugBank.d566.s4|146-154|vitamins|drug
DDI-DrugBank.d566.s5|0-5|SINCE|brand
DDI-DrugBank.d566.s5|6-20|CHOLESTYRAMINE|brand
DDI-DrugBank.d566.s5|21-26|RESIN|brand
DDI-DrugBank.d566.s5|36-41|OTHER|brand
DDI-DrugBank.d566.s5|42-47|DRUGS|brand
DDI-DrugBank.d566.s5|48-53|GIVEN|brand
DDI-DrugBank.d566.s5|54-67|CONCURRENTLY,|brand
DDI-DrugBank.d566.s5|74-85|RECOMMENDED|brand
DDI-DrugBank.d566.s5|91-99|PATIENTS|brand
DDI-DrugBank.d566.s5|105-110|OTHER|brand
DDI-DrugBank.d566.s5|111-116|DRUGS|brand
DDI-DrugBank.d566.s5|120-125|LEAST|brand
DDI-DrugBank.d566.s5|133-139|BEFORE|brand
DDI-DrugBank.d566.s5|150-155|HOURS|brand
DDI-DrugBank.d566.s5|156-161|AFTER|brand
DDI-DrugBank.d566.s5|162-176|CHOLESTYRAMINE|brand
DDI-DrugBank.d566.s5|177-182|RESIN|brand
DDI-DrugBank.d566.s5|193-198|GREAT|brand
DDI-DrugBank.d566.s5|202-210|INTERVAL|brand
DDI-DrugBank.d566.s5|214-223|POSSIBLE)|brand
DDI-DrugBank.d566.s5|227-232|AVOID|brand
DDI-DrugBank.d566.s5|233-241|IMPEDING|brand
DDI-DrugBank.d566.s5|242-247|THEIR|brand
DDI-DrugBank.d566.s5|248-259|ABSORPTION.|brand
DDI-DrugBank.d489.s0|4-13|following|drug
DDI-DrugBank.d489.s0|30-44|coadministered|drug
DDI-DrugBank.d489.s0|83-100|pharmacokinetics:|drug
DDI-DrugBank.d489.s0|101-112|cimetidine,|drug
DDI-DrugBank.d489.s0|113-124|nifedipine,|drug
DDI-DrugBank.d489.s0|145-165|hydrochlorothiazide.|group
DDI-DrugBank.d489.s1|12-26|administration|drug
DDI-DrugBank.d489.s1|52-65|anticoagulant|group
DDI-DrugBank.d489.s1|66-74|warfarin|drug
DDI-DrugBank.d489.s1|112-125|anticoagulant|group
DDI-DrugBank.d489.s1|136-145|warfarin.|drug
DDI-DrugBank.d489.s2|0-23|Catecholamine-depleting|drug
DDI-DrugBank.d489.s2|37-47|reserpine)|drug
DDI-DrugBank.d489.s2|92-105|beta-blocking|drug
DDI-DrugBank.d489.s3|49-57|blocking|drug
DDI-DrugBank.d489.s3|71-84|catecholamine|drug
DDI-DrugBank.d489.s4|24-35|discontinue|group
DDI-DrugBank.d489.s4|56-65|receiving|drug
DDI-DrugBank.d489.s4|84-93|clonidine|drug
DDI-DrugBank.d489.s4|135-147|discontinued|group
DDI-DrugBank.d489.s4|206-216|clonidine.|drug
DDI-DrugBank.d489.s5|0-10|Literature|group
DDI-DrugBank.d489.s5|37-44|calcium|drug
DDI-DrugBank.d489.s5|72-83|combination|drug
DDI-DrugBank.d489.s5|105-113|blocking|drug
DDI-DrugBank.d489.s6|62-69|failure|group
DDI-DrugBank.d489.s6|106-115|receiving|drug
DDI-DrugBank.d489.s6|132-140|blocking|drug
DDI-DrugBank.d489.s6|161-168|calcium|drug
DDI-DrugBank.d489.s7|44-51|calcium|drug
DDI-DrugBank.d489.s7|70-85|dihydropyridine|drug
DDI-DrugBank.d489.s7|104-115|nifedipine,|drug
DDI-DrugBank.d489.s7|139-146|failure|group
DDI-DrugBank.d489.s7|179-188|including|drug
DDI-DrugBank.d489.s8|104-115|epinephrine|drug
DDI-DrugBank.d489.s8|188-197|interfere|drug
DDI-DrugBank.d489.s8|254-263|increased|drug
DDI-DrugBank.d489.s9|26-35|including|drug
DDI-DrugBank.d489.s9|157-165|contact,|group
DDI-DrugBank.d489.s9|214-223|receiving|drug
DDI-DrugBank.d489.s10|56-67|epinephrine|drug
DDI-DrugBank.d209.s0|8-20|interactions|drug
DDI-DrugBank.d209.s0|24-32|clinical|drug
DDI-DrugBank.d209.s1|0-11|Finasteride|drug
DDI-DrugBank.d209.s1|53-64|P450-linked|drug
DDI-DrugBank.d209.s1|65-82|drug-metabolizing|drug
DDI-DrugBank.d209.s2|39-46|include|drug
DDI-DrugBank.d209.s2|47-58|antipyrine,|group
DDI-DrugBank.d209.s2|59-67|digoxin,|drug
DDI-DrugBank.d209.s2|68-80|propranolol,|drug
DDI-DrugBank.d209.s2|81-94|theophylline,|drug
DDI-DrugBank.d209.s2|99-107|warfarin|drug
DDI-DrugBank.d209.s2|115-125|clinically|drug
DDI-DrugBank.d209.s2|126-136|meaningful|drug
DDI-DrugBank.d209.s2|137-149|interactions|drug
DDI-DrugBank.d209.s3|44-55|interaction|drug
DDI-DrugBank.d209.s3|84-95|finasteride|drug
DDI-DrugBank.d209.s3|145-153|clinical|drug
DDI-DrugBank.d209.s3|167-181|acetaminophen,|drug
DDI-DrugBank.d209.s3|228-250|angiotensin-converting|drug
DDI-DrugBank.d209.s3|258-263|(ACE)|brand
DDI-DrugBank.d209.s3|264-275|inhibitors,|drug
DDI-DrugBank.d209.s3|276-292|anticonvulsants,|group
DDI-DrugBank.d209.s3|293-309|benzodiazepines,|drug
DDI-DrugBank.d209.s3|325-340|calcium-channel|drug
DDI-DrugBank.d209.s3|369-379|diuretics,|group
DDI-DrugBank.d209.s3|414-425|inhibitors,|drug
DDI-DrugBank.d209.s3|426-439|prostaglandin|drug
DDI-DrugBank.d209.s3|451-461|inhibitors|drug
DDI-DrugBank.d209.s3|496-505|quinolone|drug
DDI-DrugBank.d209.s3|506-521|anti-infectives|group
DDI-DrugBank.d209.s3|542-552|clinically|drug
DDI-DrugBank.d209.s3|573-586|interactions.|drug
DDI-DrugBank.d209.s4|34-45|Finasteride|drug
DDI-DrugBank.d209.s4|63-74|circulating|drug
DDI-DrugBank.d209.s4|95-114|thyroid-stimulating|drug
DDI-DrugBank.d209.s4|127-137|thyroxine,|drug
DDI-DrugBank.d209.s4|194-206|cholesterol,|drug
DDI-DrugBank.d209.s4|219-232|lipoproteins,|drug
DDI-DrugBank.d209.s4|246-258|lipoproteins|drug
DDI-DrugBank.d209.s4|286-293|mineral|drug
DDI-DrugBank.d209.s5|16-28|finasteride,|drug
DDI-DrugBank.d209.s5|32-42|clinically|drug
DDI-DrugBank.d209.s5|43-53|meaningful|drug
DDI-DrugBank.d209.s5|65-76|luteinizing|drug
DDI-DrugBank.d209.s5|85-90|(LH),|brand
DDI-DrugBank.d209.s5|91-111|follicle-stimulating|drug
DDI-DrugBank.d209.s5|120-125|(FSH)|brand
DDI-DrugBank.d209.s5|129-138|prolactin|drug
DDI-DrugBank.d209.s6|38-49|finasteride|drug
DDI-DrugBank.d209.s6|94-116|gonadotropin-releasing|drug
DDI-DrugBank.d209.s6|125-135|indicating|drug
DDI-DrugBank.d209.s7|3-11|clinical|drug
DDI-DrugBank.d209.s7|25-33|PROPECIA|brand
DDI-DrugBank.d209.s7|34-47|(finasteride,|drug
DDI-DrugBank.d209.s7|61-66|18-41|drug_n
DDI-DrugBank.d209.s7|123-130|antigen|group
DDI-DrugBank.d209.s7|131-136|(PSA)|brand
DDI-DrugBank.d209.s7|165-173|baseline|drug
DDI-DrugBank.d209.s8|12-20|clinical|drug
DDI-DrugBank.d209.s8|34-41|PROSCAR|brand
DDI-DrugBank.d209.s8|42-55|(finasteride,|drug
DDI-DrugBank.d209.s8|123-129|(BPH),|brand
DDI-DrugBank.d209.s9|6-14|findings|drug
DDI-DrugBank.d209.s9|55-69|interpretation|drug
DDI-DrugBank.d209.s9|88-98|evaluating|drug
DDI-DrugBank.d209.s9|116-128|finasteride.|drug
DDI-DrugBank.d295.s0|0-5|Since|drug
DDI-DrugBank.d295.s0|6-15|entecavir|drug
DDI-DrugBank.d295.s0|29-39|eliminated|drug
DDI-DrugBank.d295.s0|56-72|coadministration|drug
DDI-DrugBank.d295.s0|76-85|BARACLUDE|brand
DDI-DrugBank.d295.s0|168-176|increase|drug
DDI-DrugBank.d295.s0|208-217|entecavir|drug
DDI-DrugBank.d295.s0|225-239|coadministered|drug
DDI-DrugBank.d295.s1|0-16|Coadministration|drug
DDI-DrugBank.d295.s1|20-29|entecavir|drug
DDI-DrugBank.d295.s1|35-46|lamivudine,|drug
DDI-DrugBank.d295.s1|134-147|interactions.|drug
DDI-DrugBank.d295.s2|15-31|coadministration|drug
DDI-DrugBank.d295.s2|35-44|BARACLUDE|brand
DDI-DrugBank.d295.s2|79-89|eliminated|drug
DDI-DrugBank.d295.s2|218-227|BARACLUDE|brand
DDI-DrugBank.d295.s2|231-245|coadministered|drug
DDI-MedLine.d29.s0|64-75|elimination|drug
DDI-MedLine.d29.s0|79-91|cloxacillin.|drug
DDI-MedLine.d29.s1|0-9|According|drug
DDI-MedLine.d29.s2|7-13|1970),|drug_n
DDI-MedLine.d29.s2|49-60|penicillins|drug
DDI-MedLine.d29.s2|65-78|cephaloridine|drug
DDI-MedLine.d29.s2|93-107|administration|drug
DDI-MedLine.d29.s2|155-166|elimination|drug
DDI-MedLine.d29.s3|3-12|determine|drug
DDI-MedLine.d29.s3|75-87|cloxacillin,|drug
DDI-MedLine.d29.s3|92-103|elimination|drug
DDI-MedLine.d29.s3|124-135|cloxacillin|drug
DDI-MedLine.d29.s3|170-177|lacking|drug
DDI-MedLine.d29.s4|93-104|cloxacillin|drug
DDI-MedLine.d29.s6|27-38|cloxacillin|drug
DDI-MedLine.d29.s6|51-58|lacking|drug
DDI-MedLine.d29.s7|61-72|elimination|drug
DDI-MedLine.d29.s7|151-156|0.326|drug_n
DDI-MedLine.d29.s7|160-169|0.263/h).|drug_n
DDI-MedLine.d29.s8|14-23|explained|drug
DDI-MedLine.d29.s8|59-70|elimination|drug
DDI-MedLine.d29.s8|74-85|cloxacillin|drug
DDI-MedLine.d45.s0|22-33|pentazocine|drug
DDI-MedLine.d45.s0|38-52|tripelennamine|drug
DDI-MedLine.d45.s0|68-78|aeruginosa|drug
DDI-MedLine.d45.s1|26-37|aeruginosa,|drug
DDI-MedLine.d45.s1|68-79|pentazocine|drug
DDI-MedLine.d45.s1|84-98|tripelennamine|drug
DDI-MedLine.d45.s2|75-84|infection|drug
DDI-MedLine.d45.s3|53-63|1,000-fold|drug_n
DDI-MedLine.d45.s3|91-98|strains|drug
DDI-MedLine.d45.s3|132-139|strains|drug
DDI-MedLine.d45.s4|47-54|strains|drug
DDI-MedLine.d45.s4|105-115|inhibitory|drug
DDI-MedLine.d45.s5|7-14|strains|drug
DDI-MedLine.d45.s5|33-39|aureus|group
DDI-MedLine.d45.s5|61-70|infection|drug
DDI-MedLine.d45.s5|74-81|heroin,|drug
DDI-MedLine.d45.s5|93-104|pentazocine|drug
DDI-MedLine.d45.s5|109-124|tripelennamine,|drug
DDI-MedLine.d45.s5|150-159|inhibited|drug
DDI-MedLine.d45.s5|172-184|combination.|drug
DDI-MedLine.d45.s6|50-55|using|drug
DDI-MedLine.d45.s6|105-119|tripelennamine|drug
DDI-MedLine.d45.s6|144-154|inhibitory|drug
DDI-MedLine.d45.s6|200-212|pentazocine.|drug
DDI-MedLine.d45.s8|0-10|aeruginosa|drug
DDI-MedLine.d45.s8|24-32|strains,|drug
DDI-MedLine.d45.s9|0-7|aureus,|group
DDI-MedLine.d45.s9|22-33|pentazocine|drug
DDI-MedLine.d45.s9|38-52|tripelennamine|drug
DDI-MedLine.d45.s9|57-64|explain|drug
DDI-MedLine.d45.s10|0-6|aureus|group
DDI-MedLine.d45.s11|0-10|aeruginosa|drug
DDI-MedLine.d45.s11|76-87|combination|drug
DDI-MedLine.d45.s11|101-111|increased.|drug
DDI-DrugBank.d450.s0|0-19|Potassium-depleting|drug
DDI-DrugBank.d450.s0|20-29|diuretics|group
DDI-DrugBank.d450.s0|42-54|contributing|group
DDI-DrugBank.d450.s1|0-8|Calcium,|drug
DDI-DrugBank.d450.s1|25-37|administered|drug
DDI-DrugBank.d450.s1|53-64|intravenous|drug
DDI-DrugBank.d450.s2|0-10|Quinidine,|drug
DDI-DrugBank.d450.s2|47-60|indomethacin,|drug
DDI-DrugBank.d450.s2|61-74|itraconazole,|drug
DDI-DrugBank.d450.s2|122-129|digoxin|drug
DDI-DrugBank.d450.s2|258-270|intoxication|drug
DDI-DrugBank.d450.s3|0-12|Erythromycin|drug
DDI-DrugBank.d450.s3|17-31|clarithromycin|drug
DDI-DrugBank.d450.s3|52-61|macrolide|drug
DDI-DrugBank.d450.s3|62-74|antibiotics)|group
DDI-DrugBank.d450.s3|79-91|tetracycline|drug
DDI-DrugBank.d450.s3|96-104|increase|drug
DDI-DrugBank.d450.s3|105-112|digoxin|drug
DDI-DrugBank.d450.s3|140-150|inactivate|drug
DDI-DrugBank.d450.s3|151-158|digoxin|drug
DDI-DrugBank.d450.s3|196-206|intestine,|drug
DDI-DrugBank.d450.s3|225-237|intoxication|drug
DDI-DrugBank.d450.s4|17-28|interaction|drug
DDI-DrugBank.d450.s4|47-54|digoxin|drug
DDI-DrugBank.d450.s5|0-13|Propantheline|drug
DDI-DrugBank.d450.s5|36-46|decreasing|drug
DDI-DrugBank.d450.s5|65-73|increase|drug
DDI-DrugBank.d450.s5|74-81|digoxin|drug
DDI-DrugBank.d450.s6|0-9|Antacids,|group
DDI-DrugBank.d450.s6|10-24|kaolin-pectin,|drug
DDI-DrugBank.d450.s6|25-39|sulfasalazine,|drug
DDI-DrugBank.d450.s6|40-49|neomycin,|drug
DDI-DrugBank.d450.s6|50-65|cholestyramine,|drug
DDI-DrugBank.d450.s6|66-73|certain|drug
DDI-DrugBank.d450.s6|74-84|anticancer|group
DDI-DrugBank.d450.s6|96-110|metoclopramide|drug
DDI-DrugBank.d450.s6|115-124|interfere|drug
DDI-DrugBank.d450.s6|130-140|intestinal|drug
DDI-DrugBank.d450.s6|141-148|digoxin|drug
DDI-DrugBank.d450.s6|161-170|resulting|drug
DDI-DrugBank.d450.s7|0-8|Rifampin|drug
DDI-DrugBank.d450.s7|28-35|digoxin|drug
DDI-DrugBank.d450.s7|101-111|increasing|drug
DDI-DrugBank.d450.s7|139-147|digoxin.|drug
DDI-DrugBank.d450.s8|16-28|inconsistent|drug
DDI-DrugBank.d450.s8|37-46|regarding|drug
DDI-DrugBank.d450.s8|81-89|quinine,|drug
DDI-DrugBank.d450.s8|90-104|penicillamine)|drug
DDI-DrugBank.d450.s8|114-121|digoxin|drug
DDI-DrugBank.d450.s9|8-22|administration|drug
DDI-DrugBank.d450.s9|65-73|increase|drug
DDI-DrugBank.d450.s9|98-106|digoxin.|drug
DDI-DrugBank.d450.s10|19-26|digoxin|drug
DDI-DrugBank.d450.s10|48-57|increases|drug
DDI-DrugBank.d450.s11|0-15|Succinylcholine|drug
DDI-DrugBank.d450.s11|48-57|potassium|drug
DDI-DrugBank.d450.s12|37-44|calcium|drug
DDI-DrugBank.d450.s12|66-73|digoxin|drug
DDI-DrugBank.d450.s12|91-102|combination|drug
DDI-DrugBank.d450.s12|106-113|control|group
DDI-DrugBank.d450.s13|45-58|interactions,|drug
DDI-DrugBank.d450.s13|73-80|digoxin|drug
DDI-DrugBank.d450.s13|91-105|individualized|drug
DDI-DrugBank.d450.s14|46-55|combining|drug
DDI-DrugBank.d450.s14|56-63|digoxin|drug
DDI-DrugBank.d450.s14|140-145|since|drug
DDI-DrugBank.d450.s14|148-155|decline|drug
DDI-DrugBank.d450.s14|230-238|digoxin.|drug
DDI-DrugBank.d282.s0|0-8|DOSTINEX|brand
DDI-DrugBank.d282.s0|23-35|administered|drug
DDI-DrugBank.d282.s0|78-93|phenothiazines,|drug
DDI-DrugBank.d282.s0|110-124|thioxanthines,|drug
DDI-DrugBank.d380.s0|0-13|Buprenorphine|drug
DDI-DrugBank.d380.s0|32-48|norbuprenorphine|drug
DDI-DrugBank.d380.s1|16-26|inhibitors|drug
DDI-DrugBank.d380.s1|31-39|increase|drug
DDI-DrugBank.d380.s1|65-79|buprenorphine,|drug
DDI-DrugBank.d380.s1|108-118|inhibitors|drug
DDI-DrugBank.d380.s1|127-132|azole|drug
DDI-DrugBank.d380.s1|133-144|antifungals|group
DDI-DrugBank.d380.s2|0-14|ketoconazole),|drug
DDI-DrugBank.d380.s2|15-24|macrolide|drug
DDI-DrugBank.d380.s2|25-36|antibiotics|group
DDI-DrugBank.d380.s2|43-57|erythromycin),|drug
DDI-DrugBank.d380.s2|75-85|inhibitors|drug
DDI-DrugBank.d380.s2|103-112|indinavir|drug
DDI-DrugBank.d380.s2|117-128|saquinavir)|drug
DDI-DrugBank.d380.s2|155-162|SUBUTEX|brand
DDI-DrugBank.d380.s2|166-174|SUBOXONE|brand
DDI-DrugBank.d380.s3|44-55|interaction|drug
DDI-DrugBank.d380.s3|64-77|buprenorphine|drug
DDI-DrugBank.d380.s3|82-98|benzodiazepines.|drug
DDI-DrugBank.d380.s4|43-57|post-marketing|drug
DDI-DrugBank.d380.s4|119-130|intravenous|drug
DDI-DrugBank.d380.s4|141-154|buprenorphine|drug
DDI-DrugBank.d380.s4|159-174|benzodiazepines|drug
DDI-DrugBank.d380.s5|24-37|buprenorphine|drug
DDI-DrugBank.d380.s5|53-67|self-injection|drug
DDI-DrugBank.d380.s5|79-86|SUBUTEX|brand
DDI-DrugBank.d380.s6|0-7|SUBUTEX|brand
DDI-DrugBank.d380.s6|12-20|SUBOXONE|brand
DDI-DrugBank.d380.s6|70-85|benzodiazepines|drug
DDI-DrugBank.d380.s7|57-68|intravenous|drug
DDI-DrugBank.d380.s7|69-88|self-administration|drug
DDI-DrugBank.d380.s7|92-107|benzodiazepines|drug
DDI-DrugBank.d380.s7|135-143|SUBOXONE|brand
DDI-DrugBank.d380.s7|147-155|SUBUTEX.|brand
DDI-MedLine.d50.s2|16-24|clinical|drug
DDI-MedLine.d50.s2|30-38|relating|drug
DDI-MedLine.d50.s3|173-182|findings,|drug
DDI-MedLine.d92.s0|9-19|antibiotic|group
DDI-MedLine.d92.s1|0-13|Understanding|drug
DDI-MedLine.d92.s1|38-51|antimicrobial|group
DDI-MedLine.d92.s1|149-161|interactions|drug
DDI-MedLine.d92.s1|173-182|clinician|drug
DDI-MedLine.d92.s1|245-255|infectious|drug
DDI-DrugBank.d498.s0|0-7|Certain|drug
DDI-DrugBank.d498.s0|8-20|antibiotics,|group
DDI-DrugBank.d498.s0|32-41|neomycin,|drug
DDI-DrugBank.d498.s0|42-54|streptomycin|drug
DDI-DrugBank.d498.s0|59-69|kanamycin,|drug
DDI-DrugBank.d498.s0|86-94|definite|drug
DDI-DrugBank.d498.s0|95-110|nondepolarizing|drug
DDI-DrugBank.d498.s0|111-119|blocking|drug
DDI-DrugBank.d498.s1|6-17|antibiotics|group
DDI-DrugBank.d498.s1|70-80|definitely|drug
DDI-DrugBank.d498.s1|81-91|indicated,|drug
DDI-DrugBank.d498.s1|149-167|anticholinesterase|group
DDI-DrugBank.d498.s2|36-50|antiarrhythmic|group
DDI-DrugBank.d498.s2|79-88|interfere|drug
DDI-DrugBank.d498.s3|12-22|Prostigmin|drug
DDI-DrugBank.d498.s3|38-47|increased|drug
DDI-DrugBank.d498.s3|48-60|accordingly.|drug
DDI-MedLine.d114.s0|22-31|ruthenium|drug
DDI-MedLine.d114.s0|39-47|inositol|drug
DDI-MedLine.d114.s0|53-76|5-trisphosphate-induced|drug_n
DDI-MedLine.d114.s1|15-24|ruthenium|drug
DDI-MedLine.d114.s1|37-45|inositol|drug
DDI-MedLine.d114.s1|46-65|1,4,5-trisphosphate|drug_n
DDI-MedLine.d114.s1|66-83|(InsP(3))-induced|drug
DDI-MedLine.d114.s1|162-172|whole-cell|drug
DDI-MedLine.d114.s1|173-182|recording|drug
DDI-MedLine.d114.s1|196-207|combination|drug
DDI-MedLine.d114.s2|45-54|increased|drug
DDI-MedLine.d114.s2|55-68|intracellular|drug
DDI-MedLine.d114.s3|0-13|Administering|drug
DDI-MedLine.d114.s3|56-65|inhibited|drug
DDI-MedLine.d114.s3|66-81|InsP(3)-induced|drug
DDI-MedLine.d114.s4|70-79|inhibited|drug
DDI-MedLine.d114.s4|80-95|InsP(3)-induced|drug
DDI-MedLine.d114.s5|58-69|ADP-induced|drug
DDI-MedLine.d114.s5|70-79|increases|drug
DDI-MedLine.d114.s6|3-12|contrast,|group
DDI-MedLine.d114.s6|25-31|single|drug
DDI-MedLine.d114.s6|43-49|acinar|drug
DDI-MedLine.d114.s6|77-92|InsP(3)-induced|drug
DDI-MedLine.d114.s7|59-69|inhibitory|drug
DDI-MedLine.d114.s7|137-146|proteins.|drug
DDI-MedLine.d114.s8|82-89|examine|drug
DDI-DrugBank.d89.s0|20-28|(CYP1A2)|brand
DDI-DrugBank.d89.s0|61-69|involved|drug
DDI-DrugBank.d89.s0|91-100|caffeine.|drug
DDI-DrugBank.d89.s1|11-19|caffeine|drug
DDI-DrugBank.d89.s1|41-49|interact|drug
DDI-DrugBank.d89.s1|85-92|CYP1A2,|brand
DDI-DrugBank.d89.s1|93-100|inhibit|drug
DDI-DrugBank.d89.s1|101-108|CYP1A2,|brand
DDI-DrugBank.d89.s1|112-118|induce|drug
DDI-DrugBank.d89.s1|119-126|CYP1A2.|brand
DDI-DrugBank.d89.s2|23-35|interactions|drug
DDI-DrugBank.d89.s2|41-49|caffeine|drug
DDI-DrugBank.d89.s3|36-44|caffeine|drug
DDI-DrugBank.d89.s3|59-68|following|drug
DDI-DrugBank.d89.s3|69-85|coadministration|drug
DDI-DrugBank.d89.s3|126-134|caffeine|drug
DDI-DrugBank.d89.s3|135-146|elimination|drug
DDI-DrugBank.d89.s3|154-164|cimetidine|drug
DDI-DrugBank.d89.s3|169-182|ketoconazole)|drug
DDI-DrugBank.d89.s3|194-202|caffeine|drug
DDI-DrugBank.d89.s3|223-232|following|drug
DDI-DrugBank.d89.s3|233-249|coadministration|drug
DDI-DrugBank.d89.s3|264-272|increase|drug
DDI-DrugBank.d89.s3|273-281|caffeine|drug
DDI-DrugBank.d89.s3|282-293|elimination|drug
DDI-DrugBank.d89.s3|319-330|phenytoin).|drug
DDI-DrugBank.d89.s4|0-8|Caffeine|drug
DDI-DrugBank.d89.s4|9-21|administered|drug
DDI-DrugBank.d89.s4|63-68|urine|drug
DDI-DrugBank.d89.s5|4-12|clinical|drug
DDI-DrugBank.d89.s5|34-45|interaction|drug
DDI-DrugBank.d89.s6|24-32|caffeine|drug
DDI-DrugBank.d89.s6|37-49|theophylline|drug
DDI-DrugBank.d347.s0|0-14|Administration|drug
DDI-DrugBank.d347.s0|34-41|FACTIVE|brand
DDI-DrugBank.d347.s0|75-91|pharmacokinetics|drug
DDI-DrugBank.d347.s0|95-108|theophylline,|drug
DDI-DrugBank.d347.s0|109-116|digoxin|drug
DDI-DrugBank.d347.s0|123-154|ethinylestradiol/levonorgestrol|drug
DDI-DrugBank.d347.s0|160-173|contraceptive|group
DDI-DrugBank.d347.s1|12-26|administration|drug
DDI-DrugBank.d347.s1|30-37|FACTIVE|brand
DDI-DrugBank.d347.s1|42-49|calcium|drug
DDI-DrugBank.d347.s1|61-72|cimetidine,|drug
DDI-DrugBank.d347.s1|73-84|omeprazole,|drug
DDI-DrugBank.d347.s1|118-131|contraceptive|group
DDI-DrugBank.d347.s1|141-146|minor|drug
DDI-DrugBank.d347.s1|162-178|pharmacokinetics|drug
DDI-DrugBank.d347.s1|182-195|gemifloxacin,|drug
DDI-DrugBank.d347.s1|232-240|clinical|drug
DDI-DrugBank.d347.s2|12-26|administration|drug
DDI-DrugBank.d347.s2|30-37|FACTIVE|brand
DDI-DrugBank.d347.s2|72-80|increase|drug
DDI-DrugBank.d347.s2|93-101|exposure|group
DDI-DrugBank.d347.s2|105-118|gemifloxacin.|drug
DDI-DrugBank.d347.s3|0-7|FACTIVE|brand
DDI-DrugBank.d347.s3|41-54|anticoagulant|group
DDI-DrugBank.d347.s3|65-73|warfarin|drug
DDI-DrugBank.d347.s3|104-112|warfarin|drug
DDI-DrugBank.d347.s4|22-32|quinolones|drug
DDI-DrugBank.d347.s4|67-80|anticoagulant|group
DDI-DrugBank.d347.s4|92-100|warfarin|drug
DDI-DrugBank.d347.s4|137-148|prothrombin|drug
DDI-DrugBank.d347.s4|222-231|quinolone|drug
DDI-DrugBank.d347.s4|232-245|antimicrobial|group
DDI-DrugBank.d347.s4|249-261|administered|drug
DDI-DrugBank.d347.s4|281-289|warfarin|drug
DDI-DrugBank.d347.s5|0-10|Quinolones|drug
DDI-DrugBank.d347.s5|30-38|alkaline|drug
DDI-DrugBank.d347.s6|23-35|gemifloxacin|drug
DDI-DrugBank.d347.s6|80-94|administration|drug
DDI-DrugBank.d347.s6|109-119|containing|group
DDI-DrugBank.d347.s6|120-128|aluminum|drug
DDI-DrugBank.d347.s6|133-143|magnesium.|drug
DDI-DrugBank.d347.s7|0-10|Magnesium-|drug
DDI-DrugBank.d347.s7|18-37|aluminum-containing|group
DDI-DrugBank.d347.s7|38-47|antacids,|group
DDI-DrugBank.d347.s7|57-67|containing|group
DDI-DrugBank.d347.s7|92-104|multivitamin|drug
DDI-DrugBank.d347.s7|118-128|containing|group
DDI-DrugBank.d347.s7|167-179|(didanosine)|drug
DDI-DrugBank.d347.s7|268-274|within|drug
DDI-DrugBank.d347.s7|307-315|FACTIVE.|brand
DDI-DrugBank.d347.s8|31-37|within|drug
DDI-DrugBank.d347.s8|49-57|FACTIVE.|brand
DDI-MedLine.d125.s0|32-41|pesticide|drug
DDI-MedLine.d125.s0|69-88|1,3-difluoroacetone|drug_n
DDI-MedLine.d125.s1|30-50|1,3-difluoroacetone,|drug_n
DDI-MedLine.d125.s1|83-93|ingredient|drug
DDI-MedLine.d125.s1|101-110|pesticide|drug
DDI-MedLine.d125.s1|119-145|(1,3-difluoro-2-propanol),|drug
DDI-MedLine.d125.s1|150-162|investigated|drug
DDI-MedLine.d125.s2|91-110|1,3-difluoroacetone|drug_n
DDI-MedLine.d125.s3|0-14|Administration|drug
DDI-MedLine.d125.s3|18-37|1,3-difluoroacetone|drug_n
DDI-MedLine.d125.s3|183-191|fluoride|drug
DDI-MedLine.d125.s4|19-38|1,3-difluoroacetone|drug_n
DDI-MedLine.d125.s4|142-150|fluoride|drug
DDI-MedLine.d125.s4|201-225|1,3-difluoro-2-propanol.|drug_n
DDI-MedLine.d125.s5|38-61|1,3-difluoro-2-propanol|drug_n
DDI-MedLine.d125.s5|65-84|1,3-difluoroacetone|drug_n
DDI-MedLine.d125.s5|123-136|rate-limiting|drug
DDI-MedLine.d125.s5|212-236|1,3-difluoro-2-propanol.|drug_n
DDI-MedLine.d125.s6|6-20|administration|drug
DDI-MedLine.d125.s6|24-40|4-methylpyrazole|drug_n
DDI-MedLine.d125.s6|107-130|1,3-difluoro-2-propanol|drug_n
DDI-MedLine.d125.s6|203-212|eliminate|drug
DDI-MedLine.d125.s6|217-225|fluoride|drug
DDI-MedLine.d125.s6|257-292|1,3-difluoro-2-propanol-intoxicated|drug_n
DDI-MedLine.d125.s7|9-23|administration|drug
DDI-MedLine.d125.s7|27-43|4-methylpyrazole|drug_n
DDI-MedLine.d125.s7|96-115|1,3-difluoroacetone|drug_n
DDI-MedLine.d125.s7|148-159|ineffective|drug
DDI-MedLine.d125.s7|163-173|preventing|drug
DDI-MedLine.d125.s7|222-230|diminish|drug
DDI-MedLine.d125.s7|231-239|fluoride|drug
DDI-MedLine.d125.s8|38-47|antidotal|group
DDI-MedLine.d125.s8|62-78|4-methylpyrazole|drug_n
DDI-MedLine.d125.s8|108-131|1,3-difluoro-2-propanol|drug_n
DDI-MedLine.d125.s8|160-167|inhibit|drug
DDI-MedLine.d125.s8|213-223|converting|drug
DDI-MedLine.d125.s8|224-247|1,3-difluoro-2-propanol|drug_n
DDI-MedLine.d125.s8|251-270|1,3-difluoroacetone|drug_n
DDI-MedLine.d65.s0|5-18|interactions:|drug
DDI-MedLine.d65.s1|63-75|increasingly|drug
DDI-MedLine.d65.s1|144-151|certain|drug
DDI-MedLine.d65.s1|184-200|life-endangering|drug
DDI-MedLine.d65.s2|39-48|resulting|drug
DDI-MedLine.d65.s2|54-66|interactions|drug
DDI-MedLine.d65.s2|91-102|physciains,|drug
DDI-MedLine.d65.s2|131-140|clinician|drug
DDI-MedLine.d65.s3|23-30|provide|drug
DDI-MedLine.d65.s3|47-60|understanding|drug
DDI-MedLine.d65.s3|99-112|interactions.|drug
DDI-MedLine.d65.s4|0-10|Guidelines|drug
DDI-MedLine.d65.s4|38-47|clinician|drug
DDI-MedLine.d65.s4|102-114|interactions|drug
DDI-MedLine.d65.s4|162-170|pateint.|drug
DDI-MedLine.d65.s5|27-38|interaction|drug
DDI-MedLine.d65.s5|87-94|provide|drug
DDI-MedLine.d65.s5|139-147|avoiding|drug
DDI-DrugBank.d506.s0|3-12|phenytoin|drug
DDI-DrugBank.d506.s0|37-45|inducers|drug
DDI-DrugBank.d506.s0|120-132|disopyramide|drug
DDI-DrugBank.d506.s1|0-10|Monitoring|drug
DDI-DrugBank.d506.s1|14-26|disopyramide|drug
DDI-DrugBank.d506.s1|88-99|ineffective|drug
DDI-DrugBank.d506.s2|6-20|antiarrhythmic|group
DDI-DrugBank.d506.s2|32-42|quinidine,|drug
DDI-DrugBank.d506.s2|43-56|procainamide,|drug
DDI-DrugBank.d506.s2|57-67|lidocaine,|drug
DDI-DrugBank.d506.s2|68-80|propranolol)|drug
DDI-DrugBank.d506.s3|10-18|widening|drug
DDI-DrugBank.d506.s3|69-77|interval|drug
DDI-DrugBank.d506.s4|46-57|interaction|drug
DDI-DrugBank.d506.s4|88-102|coadministered|drug
DDI-DrugBank.d506.s4|115-126|propranolol|drug
DDI-DrugBank.d506.s5|12-26|administration|drug
DDI-DrugBank.d506.s5|42-51|quinidine|drug
DDI-DrugBank.d506.s5|71-80|increases|drug
DDI-DrugBank.d506.s5|91-103|disopyramide|drug
DDI-DrugBank.d506.s5|142-151|quinidine|drug
DDI-DrugBank.d506.s6|17-25|increase|drug
DDI-DrugBank.d506.s6|32-39|digoxin|drug
DDI-DrugBank.d506.s7|9-15|taking|drug
DDI-DrugBank.d506.s7|16-28|disopyramide|drug
DDI-DrugBank.d506.s7|43-55|erythromycin|drug
DDI-DrugBank.d506.s7|82-91|increased|drug
DDI-DrugBank.d506.s7|116-128|disopyramide|drug
DDI-DrugBank.d506.s7|129-138|resulting|drug
DDI-DrugBank.d506.s7|152-160|widening|drug
DDI-DrugBank.d506.s7|211-220|interval.|drug
DDI-DrugBank.d506.s8|9-15|taking|drug
DDI-DrugBank.d506.s8|16-28|disopyramide|drug
DDI-DrugBank.d506.s8|58-68|inhibitors|drug
DDI-DrugBank.d506.s9|23-35|interactions|drug
DDI-DrugBank.d506.s9|58-70|disopyramide|drug
DDI-DrugBank.d506.s9|85-94|obtained,|drug
DDI-DrugBank.d506.s9|95-107|disopyramide|drug
DDI-DrugBank.d506.s9|122-134|administered|drug
DDI-DrugBank.d506.s9|135-141|within|drug
DDI-DrugBank.d506.s9|186-201|administration.|drug
DDI-DrugBank.d459.s0|18-25|ENABLEX|brand
DDI-DrugBank.d459.s0|56-70|coadministered|drug
DDI-DrugBank.d459.s0|83-89|CYP3A4|brand
DDI-DrugBank.d459.s0|90-100|inhibitors|drug
DDI-DrugBank.d459.s0|108-121|ketoconazole,|drug
DDI-DrugBank.d459.s0|122-135|itraconazole,|drug
DDI-DrugBank.d459.s0|147-158|nelfinavir,|drug
DDI-DrugBank.d459.s0|159-173|clarithromycin|drug
DDI-DrugBank.d459.s1|29-36|ENABLEX|brand
DDI-DrugBank.d459.s1|85-98|predominantly|drug
DDI-DrugBank.d459.s1|114-120|CYP2D6|brand
DDI-DrugBank.d459.s1|157-164|window,|drug
DDI-DrugBank.d459.s1|173-184|flecainide,|drug
DDI-DrugBank.d459.s1|185-197|thioridazine|drug
DDI-DrugBank.d459.s1|212-227|antidepressants|group
DDI-DrugBank.d459.s1|233-241|CLINICAL|brand
DDI-DrugBank.d459.s1|242-256|PHARMACOLOGY).|brand
DDI-DrugBank.d459.s2|23-30|ENABLEX|brand
DDI-DrugBank.d459.s2|42-57|anticholinergic|group
DDI-DrugBank.d459.s2|69-77|increase|drug
DDI-DrugBank.d459.s2|161-176|anticholinergic|group
DDI-DrugBank.d459.s3|0-15|Anticholinergic|drug
DDI-DrugBank.d459.s3|82-94|administered|drug
DDI-DrugBank.d459.s3|119-135|gastrointestinal|drug
DDI-DrugBank.d459.s4|55-66|darifenacin|drug
DDI-MedLine.d38.s0|6-20|hydrocortisone|drug
DDI-MedLine.d38.s0|21-35|administration|drug
DDI-MedLine.d38.s0|76-89|d-amphetamine|drug
DDI-MedLine.d38.s1|0-10|RATIONALE:|brand
DDI-MedLine.d38.s1|22-37|glucocorticoids|group
DDI-MedLine.d38.s1|53-62|reinstate|drug
DDI-MedLine.d38.s1|79-98|self-administration|drug
DDI-MedLine.d38.s2|35-50|glucocorticoids|group
DDI-MedLine.d38.s3|0-11|OBJECTIVES:|brand
DDI-MedLine.d38.s3|15-22|examine|drug
DDI-MedLine.d38.s3|44-58|hydrocortisone|drug
DDI-MedLine.d38.s3|116-130|d-amphetamine.|drug
DDI-MedLine.d38.s4|0-8|METHODS:|brand
DDI-MedLine.d38.s4|37-50|d-amphetamine|drug
DDI-MedLine.d38.s4|64-76|administered|drug
DDI-MedLine.d38.s4|144-163|placebo-controlled,|group
DDI-MedLine.d38.s4|164-179|within-subject,|drug
DDI-MedLine.d38.s5|49-58|rantidine|drug
DDI-MedLine.d38.s5|59-72|hydrochloride|drug
DDI-MedLine.d38.s6|10-18|measures|group
DDI-MedLine.d38.s6|19-27|included|drug
DDI-MedLine.d38.s6|97-107|inventory,|drug
DDI-MedLine.d38.s7|0-8|RESULTS:|brand
DDI-MedLine.d38.s7|119-126|wanting|drug
DDI-MedLine.d38.s8|9-23|hydrocortisone|drug
DDI-MedLine.d38.s8|115-129|d-amphetamine.|drug
DDI-MedLine.d38.s9|0-12|CONCLUSIONS:|brand
DDI-MedLine.d38.s9|16-24|contrast|group
DDI-MedLine.d38.s9|43-58|glucocorticoids|group
DDI-MedLine.d38.s9|92-100|indicate|drug
DDI-MedLine.d38.s9|115-123|increase|drug
DDI-MedLine.d38.s9|184-197|d-amphetamine|drug
DDI-DrugBank.d343.s0|0-8|Aspirin,|brand
DDI-DrugBank.d343.s0|9-18|warfarin,|drug
DDI-DrugBank.d343.s0|19-27|heparin,|drug
DDI-DrugBank.d569.s0|26-33|binding|drug
DDI-DrugBank.d569.s0|44-52|proteins|drug
DDI-DrugBank.d569.s0|65-74|thrombin)|drug
DDI-DrugBank.d569.s1|3-11|clinical|drug
DDI-DrugBank.d569.s1|31-41|undergoing|drug
DDI-DrugBank.d569.s1|42-51|PTCA/PCI,|brand
DDI-DrugBank.d569.s1|52-69|co-administration|drug
DDI-DrugBank.d569.s1|87-95|heparin,|drug
DDI-DrugBank.d569.s1|96-105|warfarin,|drug
DDI-DrugBank.d569.s1|123-135|glycoprotein|drug
DDI-DrugBank.d569.s1|145-155|inhibitors|drug
DDI-DrugBank.d569.s1|176-185|increased|drug
DDI-DrugBank.d569.s1|201-209|bleeding|drug
DDI-DrugBank.d569.s1|242-251|receiving|drug
DDI-DrugBank.d569.s2|28-45|co-administration|drug
DDI-DrugBank.d569.s3|88-97|increased|drug
DDI-DrugBank.d569.s3|106-115|bleeding.|drug
DDI-DrugBank.d569.s4|0-27|Immunogenicity/Re-exposure:|group
DDI-DrugBank.d569.s4|101-108|against|drug_n
DDI-DrugBank.d569.s4|146-156|HIT/HITTS.|brand
DDI-DrugBank.d569.s5|44-52|clinical|drug
DDI-DrugBank.d569.s5|80-91|antibodies,|group
DDI-DrugBank.d569.s5|135-146|bivalirudin|drug
DDI-DrugBank.d569.s5|147-155|antibody|group
DDI-DrugBank.d569.s6|29-37|clinical|drug
DDI-DrugBank.d569.s6|96-103|testing|drug
DDI-DrugBank.d569.s7|33-40|initial|drug
DDI-DrugBank.d569.s7|80-88|testing.|drug
DDI-DrugBank.d478.s0|0-16|Ergot-containing|group
DDI-DrugBank.d478.s1|80-101|ergotamine-containing|group
DDI-DrugBank.d478.s1|134-151|dihydroergotamine|drug
DDI-DrugBank.d478.s1|185-191|within|drug
DDI-DrugBank.d478.s1|204-220|contraindicated.|group
DDI-DrugBank.d478.s2|4-18|administration|drug
DDI-DrugBank.d478.s2|45-50|5-HT1|brand
DDI-DrugBank.d478.s2|86-94|migraine|drug
DDI-DrugBank.d478.s3|51-67|coadministration|drug
DDI-DrugBank.d478.s3|93-98|5-HT1|brand
DDI-DrugBank.d478.s3|108-114|within|drug
DDI-DrugBank.d478.s4|10-19|serotonin|drug
DDI-DrugBank.d478.s4|29-39|inhibitors|drug
DDI-DrugBank.d478.s4|55-66|fluoxetine,|drug
DDI-DrugBank.d478.s4|67-79|fluvoxamine,|drug
DDI-DrugBank.d478.s4|80-91|paroxetine,|drug
DDI-DrugBank.d478.s4|92-103|sertraline)|drug
DDI-DrugBank.d478.s4|170-184|incoordination|drug
DDI-DrugBank.d478.s4|190-204|coadministered|drug
DDI-DrugBank.d478.s4|210-215|5-HTv|drug_n
DDI-DrugBank.d478.s5|57-67|clinically|drug
DDI-DrugBank.d478.s6|35-41|AMERGE|brand
DDI-DrugBank.d478.s6|67-76|interfere|drug
DDI-DrugBank.d478.s6|100-108|clinical|drug
DDI-DrugBank.d212.s0|27-39|interactions|drug
DDI-DrugBank.d212.s0|40-48|indicate|drug
DDI-DrugBank.d212.s0|104-119|pharmacokinetic|drug
DDI-DrugBank.d212.s0|120-133|interactions.|drug
DDI-DrugBank.d212.s1|90-96|within|drug
DDI-DrugBank.d212.s1|137-147|inhibitors|drug
DDI-DrugBank.d212.s1|160-168|affinity|drug
DDI-DrugBank.d212.s1|222-229|epoxide|drug
DDI-DrugBank.d212.s1|230-239|hydrolase|drug
DDI-DrugBank.d212.s3|64-73|proteins;|drug
DDI-DrugBank.d212.s4|0-10|clinically|drug
DDI-DrugBank.d212.s4|23-35|interactions|drug
DDI-DrugBank.d212.s4|77-84|protein|drug
DDI-DrugBank.d212.s4|85-92|binding|drug
DDI-DrugBank.d212.s5|10-25|pharmacokinetic|drug
DDI-DrugBank.d212.s5|26-38|interactions|drug
DDI-DrugBank.d212.s5|56-64|clinical|drug
DDI-DrugBank.d212.s5|65-80|pharmacokinetic|drug
DDI-DrugBank.d212.s5|89-100|(phenytoin,|drug
DDI-DrugBank.d212.s5|117-131|contraceptive,|group
DDI-DrugBank.d212.s5|132-140|digoxin,|drug
DDI-DrugBank.d212.s5|141-150|warfarin,|drug
DDI-DrugBank.d212.s5|175-190|pharmacokinetic|drug
DDI-DrugBank.d212.s5|191-200|screening|drug
DDI-DrugBank.d212.s5|208-226|placebo-controlled|group
DDI-DrugBank.d212.s5|227-235|clinical|drug
DDI-DrugBank.d212.s6|76-85|Phenytoin|drug
DDI-DrugBank.d212.s6|131-146|pharmacokinetic|drug
DDI-DrugBank.d212.s6|162-171|phenytoin|drug
DDI-DrugBank.d212.s7|0-16|Pharmacokinetics|drug
DDI-DrugBank.d212.s7|60-70|phenytoin.|drug
DDI-DrugBank.d212.s8|58-74|pharmacokinetics|drug
DDI-DrugBank.d212.s9|118-125|urinary|drug
DDI-DrugBank.d212.s10|28-36|exposure|group
DDI-DrugBank.d212.s10|89-94|L057.|brand
DDI-DrugBank.d212.s11|15-27|interactions|drug
DDI-DrugBank.d212.s11|59-74|(carbamazepine,|drug
DDI-DrugBank.d212.s11|75-86|gabapentin,|drug
DDI-DrugBank.d212.s11|87-99|lamotrigine,|drug
DDI-DrugBank.d212.s11|115-125|phenytoin,|drug
DDI-DrugBank.d212.s11|173-183|evaluating|drug
DDI-DrugBank.d212.s11|241-247|during|drug
DDI-DrugBank.d212.s11|248-266|placebo-controlled|group
DDI-DrugBank.d212.s11|267-275|clinical|drug
DDI-DrugBank.d212.s12|11-19|indicate|drug
DDI-DrugBank.d212.s12|48-57|influence|drug
DDI-DrugBank.d212.s12|124-133|influence|drug
DDI-DrugBank.d212.s12|138-154|pharmacokinetics|drug
DDI-DrugBank.d212.s13|59-67|increase|drug
DDI-DrugBank.d212.s13|130-145|co-administered|drug
DDI-DrugBank.d212.s13|151-166|enzyme-inducing|drug
DDI-DrugBank.d212.s14|91-105|carbamazepine,|drug
DDI-DrugBank.d212.s14|132-144|lamotrigine.|drug
DDI-DrugBank.d212.s15|81-90|influence|drug
DDI-DrugBank.d212.s15|95-111|pharmacokinetics|drug
DDI-DrugBank.d212.s15|123-136|contraceptive|group
DDI-DrugBank.d212.s15|137-147|containing|group
DDI-DrugBank.d212.s15|156-163|ethinyl|drug
DDI-DrugBank.d212.s15|212-223|luteinizing|drug
DDI-DrugBank.d212.s15|257-267|indicating|drug
DDI-DrugBank.d212.s15|287-300|contraceptive|group
DDI-DrugBank.d212.s16|0-16|Coadministration|drug
DDI-DrugBank.d212.s16|30-43|contraceptive|group
DDI-DrugBank.d212.s16|52-61|influence|drug
DDI-DrugBank.d212.s16|66-82|pharmacokinetics|drug
DDI-DrugBank.d212.s17|0-7|Digoxin|drug
DDI-DrugBank.d212.s17|46-55|influence|drug
DDI-DrugBank.d212.s17|60-76|pharmacokinetics|drug
DDI-DrugBank.d212.s17|98-103|(ECG)|brand
DDI-DrugBank.d212.s17|107-114|digoxin|drug
DDI-DrugBank.d212.s18|0-16|Coadministration|drug
DDI-DrugBank.d212.s18|20-27|digoxin|drug
DDI-DrugBank.d212.s18|36-45|influence|drug
DDI-DrugBank.d212.s18|50-66|pharmacokinetics|drug
DDI-DrugBank.d212.s19|0-8|Warfarin|drug
DDI-DrugBank.d212.s19|47-56|influence|drug
DDI-DrugBank.d212.s19|61-77|pharmacokinetics|drug
DDI-DrugBank.d212.s19|89-98|warfarin.|drug
DDI-DrugBank.d212.s20|0-11|Prothrombin|drug
DDI-DrugBank.d212.s21|0-16|Coadministration|drug
DDI-DrugBank.d212.s21|20-28|warfarin|drug
DDI-DrugBank.d212.s21|48-64|pharmacokinetics|drug
DDI-DrugBank.d212.s22|50-58|blocking|drug
DDI-DrugBank.d212.s22|66-78|administered|drug
DDI-DrugBank.d212.s22|136-152|pharmacokinetics|drug
DDI-DrugBank.d212.s23|30-35|L057,|brand
DDI-DrugBank.d212.s23|145-150|urine|drug
DDI-DrugBank.d212.s23|151-159|remained|drug
DDI-DrugBank.d212.s24|105-115|inhibition|drug
DDI-DrugBank.d212.s24|144-149|L057.|brand
DDI-DrugBank.d250.s0|0-7|Certain|drug
DDI-DrugBank.d250.s0|14-25|antibiotics|group
DDI-DrugBank.d250.s0|26-42|(aminoglycosides|drug
DDI-DrugBank.d250.s0|47-57|polymyxin)|drug
DDI-DrugBank.d250.s0|85-94|interfere|drug
DDI-DrugBank.d250.s1|77-87|Coly-Mycin|drug
DDI-DrugBank.d250.s2|33-46|tubocurarine)|drug
DDI-DrugBank.d250.s2|64-73|including|drug
DDI-DrugBank.d250.s2|81-97|succinylcholine,|drug
DDI-DrugBank.d250.s2|98-108|gallamine,|drug
DDI-DrugBank.d250.s2|109-122|decamethonium|drug
DDI-DrugBank.d250.s2|127-133|sodium|drug
DDI-DrugBank.d250.s2|172-180|blocking|drug
DDI-DrugBank.d250.s2|240-245|being|drug
DDI-DrugBank.d250.s2|259-269|Coly-Mycin|drug
DDI-DrugBank.d250.s3|0-6|Sodium|drug
DDI-DrugBank.d250.s3|7-18|cephalothin|drug
DDI-DrugBank.d250.s3|53-63|Coly-Mycin|drug
DDI-DrugBank.d250.s4|23-29|sodium|drug
DDI-DrugBank.d250.s4|30-41|cephalothin|drug
DDI-DrugBank.d250.s4|46-56|Coly-Mycin|drug
DDI-DrugBank.d33.s0|93-102|following|drug
DDI-DrugBank.d33.s0|115-129|administration|drug
DDI-DrugBank.d33.s0|139-153|cephalosporins|drug
DDI-DrugBank.d33.s0|158-174|aminoglycosides.|drug
DDI-DrugBank.d244.s0|7-12|using|drug
DDI-DrugBank.d244.s0|138-153|aminoglycosides|drug
DDI-DrugBank.d244.s0|161-172|gentamicin,|drug
DDI-DrugBank.d244.s0|173-183|amikacin),|drug
DDI-DrugBank.d244.s0|184-196|amphotericin|drug
DDI-DrugBank.d244.s0|200-213|cyclosporine,|drug
DDI-DrugBank.d244.s0|228-245|anti-inflammatory|group
DDI-DrugBank.d244.s0|283-294|vancomycin.|drug
DDI-DrugBank.d244.s1|25-33|medicine|drug
DDI-DrugBank.d451.s0|5-17|interactions|drug
DDI-DrugBank.d362.s0|53-68|des-ciclesonide|drug
DDI-DrugBank.d362.s0|88-98|inhibitory|drug
DDI-DrugBank.d362.s0|102-111|induction|drug
DDI-DrugBank.d362.s1|4-14|inhibitory|drug
DDI-DrugBank.d362.s1|28-39|ciclesonide|drug
DDI-DrugBank.d362.s1|43-49|CYP450|brand
DDI-DrugBank.d362.s2|46-53|protein|drug
DDI-DrugBank.d362.s2|54-61|binding|drug
DDI-DrugBank.d362.s2|65-80|des-ciclesonide|drug
DDI-DrugBank.d362.s2|101-109|warfarin|drug
DDI-DrugBank.d362.s2|129-139|indicating|drug
DDI-DrugBank.d362.s2|157-164|protein|drug
DDI-DrugBank.d362.s2|165-178|binding-based|drug
DDI-DrugBank.d362.s2|184-197|interactions.|drug
DDI-DrugBank.d362.s3|10-21|interaction|drug
DDI-DrugBank.d362.s3|29-46|co-administration|drug
DDI-DrugBank.d362.s3|57-64|inhaled|drug
DDI-DrugBank.d362.s3|65-76|ciclesonide|drug
DDI-DrugBank.d362.s3|86-99|erythromycin,|drug
DDI-DrugBank.d362.s3|103-112|inhibitor|drug
DDI-DrugBank.d362.s3|158-174|pharmacokinetics|drug
DDI-DrugBank.d362.s3|185-200|des-ciclesonide|drug
DDI-DrugBank.d362.s3|204-217|erythromycin.|drug
DDI-DrugBank.d362.s4|3-10|another|drug
DDI-DrugBank.d362.s4|16-27|interaction|drug
DDI-DrugBank.d362.s4|35-52|co-administration|drug
DDI-DrugBank.d362.s4|63-70|inhaled|drug
DDI-DrugBank.d362.s4|71-82|ciclesonide|drug
DDI-DrugBank.d362.s4|92-105|ketoconazole,|drug
DDI-DrugBank.d362.s4|115-124|inhibitor|drug
DDI-DrugBank.d362.s4|149-158|increased|drug
DDI-DrugBank.d362.s4|163-171|exposure|group
DDI-DrugBank.d362.s4|172-177|(AUC)|brand
DDI-DrugBank.d362.s4|181-196|des-ciclesonide|drug
DDI-DrugBank.d362.s4|214-222|3.6-fold|drug_n
DDI-DrugBank.d362.s4|256-267|ciclesonide|drug
DDI-DrugBank.d362.s4|268-276|remained|drug
DDI-DrugBank.d362.s5|11-23|ketoconazole|drug
DDI-DrugBank.d362.s5|34-46|administered|drug
DDI-DrugBank.d362.s5|65-75|intranasal|drug
DDI-MedLine.d140.s0|0-12|Longitudinal|drug
DDI-MedLine.d140.s0|114-131|pharmacokinetics,|drug
DDI-MedLine.d140.s0|132-149|exposure-response|group
DDI-MedLine.d140.s0|169-178|influence|drug
DDI-MedLine.d140.s0|182-195|cyclosporine.|drug
DDI-MedLine.d140.s1|0-10|OBJECTIVE:|brand
DDI-MedLine.d140.s1|62-78|pharmacokinetics|drug
DDI-MedLine.d140.s1|97-109|cyclosporine|drug
DDI-MedLine.d140.s1|110-115|(INN,|brand
DDI-MedLine.d140.s1|116-128|ciclosporin)|drug
DDI-MedLine.d140.s1|134-148|coadministered|drug
DDI-MedLine.d140.s1|188-194|during|drug
DDI-MedLine.d140.s2|0-7|METHOD:|brand
DDI-MedLine.d140.s2|48-60|double-blind|drug
DDI-MedLine.d140.s2|110-115|1:1:1|drug_n
DDI-MedLine.d140.s2|197-209|cyclosporine|drug
DDI-MedLine.d140.s3|6-14|sampling|drug
DDI-MedLine.d140.s3|23-39|pharmacokinetics|drug
DDI-MedLine.d140.s3|58-70|cyclosporine|drug
DDI-MedLine.d140.s4|77-84|context|group
DDI-MedLine.d140.s4|88-94|linear|drug
DDI-MedLine.d140.s4|110-115|ANOVA|brand
DDI-MedLine.d140.s5|11-28|exposure-response|group
DDI-MedLine.d140.s5|97-102|(AUC)|brand
DDI-MedLine.d140.s5|145-151|lipids|group
DDI-MedLine.d140.s6|25-37|cyclosporine|drug
DDI-MedLine.d140.s6|38-44|dosing|drug
DDI-MedLine.d140.s6|49-65|pharmacokinetics|drug
DDI-MedLine.d140.s6|100-108|exposure|group
DDI-MedLine.d140.s6|130-137|context|group
DDI-MedLine.d140.s6|141-147|ANOVA.|brand
DDI-MedLine.d140.s7|0-8|RESULTS:|brand
DDI-MedLine.d140.s7|79-85|3-fold|drug_n
DDI-MedLine.d140.s7|107-115|exposure|group
DDI-MedLine.d140.s9|23-35|longitudinal|drug
DDI-MedLine.d140.s9|67-73|during|drug
DDI-MedLine.d140.s10|4-19|interindividual|drug
DDI-MedLine.d140.s10|20-35|pharmacokinetic|drug
DDI-MedLine.d140.s10|60-65|85.4%|drug_n
DDI-MedLine.d140.s10|70-86|intraindividual,|drug
DDI-MedLine.d140.s10|87-100|interoccasion|drug
DDI-MedLine.d140.s10|117-123|40.8%.|drug_n
DDI-MedLine.d140.s11|12-17|17-69|drug_n
DDI-MedLine.d140.s11|41-47|49-106|drug_n
DDI-MedLine.d140.s11|104-116|contributors|group
DDI-MedLine.d140.s12|13-23|increasing|drug
DDI-MedLine.d140.s12|24-33|incidence|drug
DDI-MedLine.d140.s12|75-83|10(9)/L)|brand
DDI-MedLine.d140.s12|89-99|increasing|drug
DDI-MedLine.d140.s13|0-12|Cyclosporine|drug
DDI-MedLine.d140.s13|87-93|during|drug
DDI-MedLine.d140.s13|136-151|co-administered|drug
DDI-MedLine.d140.s14|0-12|CONCLUSIONS:|brand
DDI-MedLine.d140.s14|60-68|exposure|group
DDI-MedLine.d140.s14|69-75|during|drug
DDI-MedLine.d140.s15|6-12|4-fold|drug_n
DDI-MedLine.d140.s15|77-89|cyclosporine|drug
DDI-MedLine.d140.s15|90-96|dosing|drug
DDI-MedLine.d140.s15|100-117|pharmacokinetics.|drug
DDI-DrugBank.d510.s0|22-29|Robinul|drug
DDI-DrugBank.d510.s0|51-67|anticholinergics|group
DDI-DrugBank.d510.s0|88-103|anticholinergic|group
DDI-DrugBank.d510.s0|122-137|phenothiazines,|drug
DDI-DrugBank.d510.s0|138-151|antiparkinson|group
DDI-DrugBank.d510.s0|172-188|antidepressants,|group
DDI-DrugBank.d510.s0|193-202|intensify|drug
DDI-DrugBank.d510.s0|207-221|antimuscarinic|group
DDI-DrugBank.d510.s0|251-259|increase|drug
DDI-DrugBank.d510.s0|263-278|anticholinergic|group
DDI-DrugBank.d510.s1|12-26|administration|drug
DDI-DrugBank.d510.s1|30-37|Robinul|drug
DDI-DrugBank.d510.s1|52-61|potassium|drug
DDI-DrugBank.d510.s1|62-70|chloride|drug
DDI-DrugBank.d510.s1|91-99|increase|drug
DDI-DrugBank.d510.s1|116-125|potassium|drug
DDI-DrugBank.d510.s1|126-142|chloride-induced|drug
DDI-DrugBank.d510.s1|143-159|gastrointestinal|drug
DDI-DrugBank.d510.s1|192-208|gastrointestinal|drug
DDI-DrugBank.d102.s0|3-14|information|drug
DDI-DrugBank.d547.s0|20-32|interactions|drug
DDI-DrugBank.d547.s0|130-141|nifedipine,|drug
DDI-DrugBank.d547.s0|142-150|digoxin,|drug
DDI-DrugBank.d547.s0|151-160|warfarin,|drug
DDI-DrugBank.d547.s0|161-181|hydrochlorothiazide,|group
DDI-DrugBank.d547.s0|191-205|contraceptives|group
DDI-DrugBank.d547.s0|276-283|failure|group
DDI-DrugBank.d547.s0|284-289|(NYHA|brand
DDI-DrugBank.d547.s0|303-308|III).|brand
DDI-DrugBank.d547.s1|149-161|interactions|drug
DDI-DrugBank.d547.s1|178-185|inhibit|drug
DDI-DrugBank.d547.s2|0-7|Lithium|drug
DDI-DrugBank.d547.s2|19-28|increases|drug
DDI-DrugBank.d547.s2|38-45|lithium|drug
DDI-DrugBank.d547.s2|93-99|during|drug
DDI-DrugBank.d547.s2|112-126|administration|drug
DDI-DrugBank.d547.s2|130-137|lithium|drug
DDI-DrugBank.d547.s2|147-158|inhibitors,|drug
DDI-DrugBank.d547.s2|173-184|angiotensin|drug
DDI-DrugBank.d547.s3|3-11|increase|drug
DDI-DrugBank.d547.s3|21-28|lithium|drug
DDI-DrugBank.d547.s3|61-67|during|drug
DDI-DrugBank.d547.s3|80-94|administration|drug
DDI-DrugBank.d547.s3|98-105|lithium|drug
DDI-DrugBank.d547.s3|111-119|ATACAND,|brand
DDI-DrugBank.d547.s3|131-141|monitoring|drug
DDI-DrugBank.d547.s3|151-158|lithium|drug
DDI-DrugBank.d547.s3|181-187|during|drug
DDI-MedLine.d41.s0|11-21|induction:|drug
DDI-MedLine.d41.s0|31-43|establishing|drug
DDI-MedLine.d41.s0|44-56|interactions|drug
DDI-MedLine.d41.s1|22-34|interactions|drug
DDI-MedLine.d41.s1|106-116|interferon|drug
DDI-MedLine.d41.s1|117-126|induction|drug
DDI-MedLine.d41.s1|132-140|obtained|drug
DDI-MedLine.d41.s1|206-214|cultures|group
DDI-MedLine.d41.s1|215-227|superinduced|drug
DDI-MedLine.d41.s1|241-252|inhibitors.|drug
DDI-DrugBank.d114.s0|0-9|PROLEUKIN|brand
DDI-DrugBank.d114.s1|11-23|interactions|drug
DDI-DrugBank.d114.s1|36-45|following|drug
DDI-DrugBank.d114.s1|58-72|administration|drug
DDI-DrugBank.d114.s1|125-137|antiemetics,|group
DDI-DrugBank.d114.s2|11-25|administration|drug
DDI-DrugBank.d114.s2|35-45|possessing|drug
DDI-DrugBank.d114.s2|65-81|aminoglycosides,|drug
DDI-DrugBank.d114.s2|82-96|indomethacin),|drug
DDI-DrugBank.d114.s2|159-171|doxorubicin)|drug
DDI-DrugBank.d114.s2|208-221|asparaginase)|drug
DDI-DrugBank.d114.s2|235-244|PROLEUKIN|brand
DDI-DrugBank.d114.s2|249-257|increase|drug
DDI-DrugBank.d114.s3|27-36|PROLEUKIN|brand
DDI-DrugBank.d114.s3|40-51|combination|drug
DDI-DrugBank.d114.s3|61-75|antineoplastic|group
DDI-DrugBank.d114.s4|60-69|PROLEUKIN|brand
DDI-DrugBank.d114.s4|90-101|elimination|drug
DDI-DrugBank.d114.s4|133-141|increase|drug
DDI-DrugBank.d114.s5|58-67|receiving|drug
DDI-DrugBank.d114.s5|68-79|combination|drug
DDI-DrugBank.d114.s5|89-99|containing|group
DDI-DrugBank.d114.s5|121-130|PROLEUKIN|brand
DDI-DrugBank.d114.s5|135-149|antineoplastic|group
DDI-DrugBank.d114.s5|172-184|dacarbazine,|drug
DDI-DrugBank.d114.s5|185-198|cis-platinum,|drug
DDI-DrugBank.d114.s5|213-229|interferon-alfa.|drug
DDI-DrugBank.d114.s6|78-84|within|drug
DDI-DrugBank.d114.s6|94-108|administration|drug
DDI-DrugBank.d114.s7|30-42|intervention|drug
DDI-DrugBank.d114.s8|11-18|injury,|drug
DDI-DrugBank.d114.s8|19-28|including|drug
DDI-DrugBank.d114.s8|40-51|infarction,|drug
DDI-DrugBank.d114.s8|77-89|hypokinesia,|drug
DDI-DrugBank.d114.s8|129-138|increased|drug
DDI-DrugBank.d114.s8|151-160|receiving|drug
DDI-DrugBank.d114.s8|161-170|PROLEUKIN|brand
DDI-DrugBank.d114.s8|175-190|interferon-alfa|drug
DDI-DrugBank.d114.s9|20-27|initial|drug
DDI-DrugBank.d114.s9|71-83|inflammatory|drug
DDI-DrugBank.d114.s9|112-121|following|drug
DDI-DrugBank.d114.s9|140-155|interferon-alfa|drug
DDI-DrugBank.d114.s9|160-170|PROLEUKIN,|brand
DDI-DrugBank.d114.s9|171-180|including|drug
DDI-DrugBank.d114.s9|248-260|inflammatory|drug
DDI-DrugBank.d114.s10|9-24|glucocorticoids|group
DDI-DrugBank.d114.s10|51-68|PROLEUKIN-induced|drug
DDI-DrugBank.d114.s10|82-91|including|drug
DDI-DrugBank.d114.s10|105-119|insufficiency,|drug
DDI-DrugBank.d114.s10|120-139|hyperbilirubinemia,|drug
DDI-DrugBank.d114.s10|176-190|administration|drug
DDI-DrugBank.d114.s10|212-221|PROLEUKIN|brand
DDI-DrugBank.d114.s10|237-246|antitumor|group
DDI-DrugBank.d114.s10|264-273|PROLEUKIN|brand
DDI-DrugBank.d114.s10|329-346|antihypertensives|group
DDI-DrugBank.d114.s10|388-398|PROLEUKIN.|brand
DDI-DrugBank.d114.s11|29-38|Iodinated|drug
DDI-DrugBank.d114.s11|71-81|literature|group
DDI-DrugBank.d114.s11|96-101|12.6%|drug_n
DDI-DrugBank.d114.s11|109-116|11-28%)|drug_n
DDI-DrugBank.d114.s11|154-167|interleukin-2|drug
DDI-DrugBank.d114.s11|168-178|containing|group
DDI-DrugBank.d114.s11|210-222|administered|drug
DDI-DrugBank.d114.s11|236-245|iodinated|drug
DDI-DrugBank.d114.s11|246-254|contrast|group
DDI-DrugBank.d114.s12|39-45|within|drug
DDI-DrugBank.d114.s12|81-90|following|drug
DDI-DrugBank.d114.s12|95-109|administration|drug
DDI-DrugBank.d114.s12|113-121|contrast|group
DDI-DrugBank.d114.s13|16-23|include|drug
DDI-DrugBank.d114.s13|47-56|vomiting,|drug
DDI-DrugBank.d114.s14|5-15|clinicians|drug
DDI-DrugBank.d114.s14|94-107|interleukin-2|drug
DDI-DrugBank.d114.s14|108-123|administration,|drug
DDI-DrugBank.d114.s14|145-153|contrast|group
DDI-DrugBank.d114.s14|170-183|interleukin-2|drug
DDI-DrugBank.d114.s15|40-48|contrast|group
DDI-DrugBank.d114.s15|65-71|within|drug
DDI-DrugBank.d114.s15|103-117|interleukin-2.|drug
DDI-DrugBank.d114.s16|46-54|contrast|group
DDI-DrugBank.d114.s16|92-105|interleukin-2|drug
DDI-DrugBank.d127.s0|15-26|interaction|drug
DDI-DrugBank.d127.s0|60-65|DOXIL|brand
DDI-DrugBank.d127.s1|76-81|DOXIL|brand
DDI-DrugBank.d127.s2|0-5|DOXIL|brand
DDI-DrugBank.d127.s2|11-19|interact|drug
DDI-DrugBank.d127.s2|40-48|interact|drug
DDI-DrugBank.d127.s2|86-97|doxorubicin|drug
DDI-DrugBank.d189.s0|61-71|clinically|drug
DDI-DrugBank.d189.s0|82-97|pharmacokinetic|drug
DDI-DrugBank.d189.s0|98-110|interactions|drug
DDI-DrugBank.d189.s0|142-153|felodipine,|drug
DDI-DrugBank.d189.s0|154-162|digoxin,|drug
DDI-DrugBank.d189.s0|163-172|warfarin,|drug
DDI-DrugBank.d189.s0|173-183|isosorbide|drug
DDI-DrugBank.d189.s0|209-216|ethanol|drug
DDI-DrugBank.d189.s0|220-233|itraconazole.|drug
DDI-DrugBank.d361.s0|0-11|Combination|drug
DDI-DrugBank.d361.s0|82-92|interferes|drug
DDI-DrugBank.d361.s0|147-155|increase|drug
DDI-DrugBank.d361.s0|172-184|Floxuridine.|drug
DDI-DrugBank.d223.s0|68-80|metabolizing|drug
DDI-DrugBank.d223.s0|109-121|(debrisoquin|drug
DDI-DrugBank.d223.s0|122-134|hydroxylase)|drug
DDI-DrugBank.d223.s0|193-198|7-10%|drug_n
DDI-DrugBank.d223.s2|79-94|antidepressants|group
DDI-DrugBank.d223.s3|0-9|Depending|drug
DDI-DrugBank.d223.s3|63-71|increase|drug
DDI-DrugBank.d223.s3|133-141|increase|drug
DDI-DrugBank.d223.s3|163-168|TCA).|brand
DDI-DrugBank.d223.s4|13-20|certain|drug
DDI-DrugBank.d223.s4|27-34|inhibit|drug
DDI-DrugBank.d223.s5|3-13|individual|drug
DDI-DrugBank.d223.s5|101-111|inhibiting|drug
DDI-DrugBank.d223.s6|15-22|inhibit|drug
DDI-DrugBank.d223.s6|43-50|include|drug
DDI-DrugBank.d223.s6|95-106|(quinidine;|drug
DDI-DrugBank.d223.s7|0-11|cimetidine)|drug
DDI-DrugBank.d223.s7|66-82|antidepressants,|group
DDI-DrugBank.d223.s7|83-98|phenothiazines,|drug
DDI-DrugBank.d223.s7|115-130|antiarrhythmics|group
DDI-DrugBank.d223.s7|147-159|flecainide).|drug
DDI-DrugBank.d223.s8|24-33|serotonin|drug
DDI-DrugBank.d223.s8|43-53|inhibitors|drug
DDI-DrugBank.d223.s8|95-106|fluoxetine,|drug
DDI-DrugBank.d223.s8|107-118|sertraline,|drug
DDI-DrugBank.d223.s8|123-134|paroxetine,|drug
DDI-DrugBank.d223.s8|135-142|inhibit|drug
DDI-DrugBank.d223.s8|184-195|inhibition.|drug
DDI-DrugBank.d223.s9|20-28|SSRI-TCA|brand
DDI-DrugBank.d223.s9|29-41|interactions|drug
DDI-DrugBank.d223.s9|51-59|clinical|drug
DDI-DrugBank.d223.s9|98-108|inhibition|drug
DDI-DrugBank.d223.s9|117-133|pharmacokinetics|drug
DDI-DrugBank.d223.s9|146-155|involved.|drug
DDI-DrugBank.d223.s10|25-34|indicated|drug
DDI-DrugBank.d223.s10|42-59|co-administration|drug
DDI-DrugBank.d223.s10|102-111|switching|drug
DDI-DrugBank.d223.s11|61-71|initiating|drug
DDI-DrugBank.d223.s11|99-104|being|drug
DDI-DrugBank.d223.s11|120-131|fluoxetine,|drug
DDI-DrugBank.d223.s12|29-44|antidepressants|group
DDI-DrugBank.d223.s12|65-72|inhibit|drug
DDI-DrugBank.d223.s12|166-180|antidepressant|group
DDI-DrugBank.d223.s13|80-89|increased|drug
DDI-DrugBank.d223.s13|108-122|antidepressant|group
DDI-DrugBank.d223.s14|63-68|going|drug
DDI-DrugBank.d223.s14|75-90|co-administered|drug
DDI-DrugBank.d223.s14|96-103|another|drug
DDI-DrugBank.d223.s14|124-133|inhibitor|drug
DDI-DrugBank.d223.s15|0-7|Doxepin|drug
DDI-DrugBank.d223.s15|36-42|CYP2D6|brand
DDI-DrugBank.d223.s15|49-55|CYP1A2|brand
DDI-DrugBank.d223.s15|62-68|CYP3A4|brand
DDI-DrugBank.d223.s15|72-77|minor|drug
DDI-DrugBank.d223.s16|28-34|CYP2D6|brand
DDI-DrugBank.d223.s16|42-52|quinidine,|drug
DDI-DrugBank.d223.s16|63-72|serotonin|drug
DDI-DrugBank.d223.s16|82-92|inhibitors|drug
DDI-DrugBank.d223.s16|106-114|increase|drug
DDI-DrugBank.d223.s16|143-150|doxepin|drug
DDI-DrugBank.d223.s16|156-168|administered|drug
DDI-DrugBank.d223.s17|14-25|interaction|drug
DDI-DrugBank.d223.s17|66-73|CYP2D6.|brand
DDI-DrugBank.d223.s18|4-12|clinical|drug
DDI-DrugBank.d223.s18|34-45|interaction|drug
DDI-DrugBank.d223.s18|51-58|doxepin|drug
DDI-DrugBank.d223.s19|71-80|following|drug
DDI-DrugBank.d223.s19|104-111|certain|drug
DDI-DrugBank.d223.s19|127-138|inhibitors.|drug
DDI-DrugBank.d223.s20|15-25|inhibitors|drug
DDI-DrugBank.d223.s20|36-48|discontinued|group
DDI-DrugBank.d223.s20|90-100|initiation|drug
DDI-DrugBank.d223.s20|117-126|SINEQUAN.|brand
DDI-DrugBank.d223.s21|75-84|inhibitor|drug
DDI-DrugBank.d223.s21|85-90|being|drug
DDI-DrugBank.d223.s21|128-141|administered,|drug
DDI-DrugBank.d223.s21|157-166|involved.|drug
DDI-DrugBank.d223.s22|0-11|Cimetidine:|drug
DDI-DrugBank.d223.s22|12-22|Cimetidine|drug
DDI-DrugBank.d223.s22|52-62|clinically|drug
DDI-DrugBank.d223.s22|146-162|antidepressants.|group
DDI-DrugBank.d223.s23|8-23|anticholinergic|group
DDI-DrugBank.d223.s23|58-65|urinary|drug
DDI-DrugBank.d223.s23|166-180|antidepressant|group
DDI-DrugBank.d223.s23|186-196|cimetidine|drug
DDI-DrugBank.d223.s23|208-218|initiated.|drug
DDI-DrugBank.d223.s24|45-59|antidepressant|group
DDI-DrugBank.d223.s24|126-132|taking|drug
DDI-DrugBank.d223.s24|133-144|cimetidine.|drug
DDI-DrugBank.d223.s25|46-56|controlled|group
DDI-DrugBank.d223.s25|70-85|antidepressants|group
DDI-DrugBank.d223.s25|86-95|receiving|drug
DDI-DrugBank.d223.s25|107-117|cimetidine|drug
DDI-DrugBank.d223.s25|127-142|discontinuation|group
DDI-DrugBank.d223.s25|146-156|cimetidine|drug
DDI-DrugBank.d223.s25|228-242|antidepressant|group
DDI-DrugBank.d223.s26|49-58|ingestion|drug
DDI-DrugBank.d223.s26|63-71|increase|drug
DDI-DrugBank.d223.s26|83-91|inherent|drug
DDI-DrugBank.d223.s26|99-110|intentional|drug
DDI-DrugBank.d223.s26|114-127|unintentional|drug
DDI-DrugBank.d223.s26|128-136|SINEQUAN|brand
DDI-DrugBank.d223.s28|90-100|maintained|drug
DDI-DrugBank.d223.s28|104-114|tolazamide|drug
DDI-DrugBank.d223.s28|156-163|doxepin|drug
DDI-MedLine.d31.s0|41-49|clinical|drug
DDI-MedLine.d31.s1|4-13|incidence|drug
DDI-MedLine.d31.s1|24-33|increases|drug
DDI-MedLine.d31.s2|64-70|aging.|drug
DDI-MedLine.d31.s3|106-113|explain|drug
DDI-MedLine.d31.s3|118-127|increased|drug
DDI-MedLine.d31.s4|4-12|clinical|drug
DDI-MedLine.d31.s4|80-86|aging.|drug
DDI-MedLine.d31.s5|60-68|examines|drug
DDI-MedLine.d31.s5|163-174|information|drug
DDI-MedLine.d31.s5|190-199|influence|drug
DDI-MedLine.d137.s0|12-19|insulin|drug
DDI-MedLine.d137.s1|0-16|AIMS/HYPOTHESIS:|brand
DDI-MedLine.d137.s1|40-47|insulin|drug
DDI-MedLine.d137.s2|54-62|combined|drug
DDI-MedLine.d137.s2|82-99|hyperinsulinaemia|drug
DDI-MedLine.d137.s2|164-171|insulin|drug
DDI-MedLine.d137.s3|0-8|METHODS:|brand
DDI-MedLine.d137.s3|38-43|3-way|drug_n
DDI-MedLine.d137.s4|93-99|during|drug
DDI-MedLine.d137.s4|111-118|insulin|drug
DDI-MedLine.d137.s4|130-140|mU/kg/min;|drug
DDI-MedLine.d137.s4|151-161|mU/kg/min)|drug
DDI-MedLine.d137.s4|162-171|infusion.|drug
DDI-MedLine.d137.s5|46-53|insulin|drug
DDI-MedLine.d137.s5|81-94|somatostatin.|drug
DDI-MedLine.d137.s6|90-98|measured|group
DDI-MedLine.d137.s6|99-104|using|drug
DDI-MedLine.d137.s6|109-127|paraaminohippurate|drug
DDI-MedLine.d137.s6|140-146|inulin|drug
DDI-MedLine.d137.s6|166-181|interferometric|drug
DDI-MedLine.d137.s6|182-193|measurement|group
DDI-MedLine.d137.s7|0-8|RESULTS:|brand
DDI-MedLine.d137.s7|9-16|Insulin|drug
DDI-MedLine.d137.s7|17-26|increased|drug
DDI-MedLine.d137.s8|15-24|increased|drug
DDI-MedLine.d137.s9|36-43|insulin|drug
DDI-MedLine.d137.s9|63-75|somatostatin|drug
DDI-MedLine.d137.s9|80-95|co-administered|drug
DDI-MedLine.d137.s10|0-27|CONCLUSIONS/INTERPRETATION:|brand
DDI-MedLine.d137.s10|40-47|insulin|drug
DDI-MedLine.d137.s11|55-64|increased|drug
DDI-MedLine.d137.s11|96-108|longitudinal|drug
DDI-MedLine.d137.s11|141-160|(insulin-dependent)|drug
DDI-DrugBank.d68.s0|12-27|pharmacokinetic|drug
DDI-DrugBank.d68.s0|49-60|interaction|drug
DDI-DrugBank.d68.s1|0-8|Digoxin:|drug
DDI-DrugBank.d68.s1|92-99|digoxin|drug
DDI-DrugBank.d68.s2|80-87|digoxin|drug
DDI-DrugBank.d68.s3|0-16|Coadministration|drug
DDI-DrugBank.d68.s3|20-27|digoxin|drug
DDI-DrugBank.d68.s3|85-94|ibutilide|drug
DDI-DrugBank.d68.s3|102-110|clinical|drug
DDI-DrugBank.d68.s4|0-7|Calcium|drug
DDI-DrugBank.d68.s4|16-24|blocking|drug
DDI-DrugBank.d68.s4|33-49|Coadministration|drug
DDI-DrugBank.d68.s4|53-60|calcium|drug
DDI-DrugBank.d68.s4|138-147|ibutilide|drug
DDI-DrugBank.d68.s4|155-163|clinical|drug
DDI-DrugBank.d68.s5|16-24|blocking|drug
DDI-DrugBank.d68.s5|33-49|Coadministration|drug
DDI-DrugBank.d68.s5|69-77|blocking|drug
DDI-DrugBank.d68.s5|145-154|ibutilide|drug
DDI-DrugBank.d68.s5|162-170|clinical|drug
DDI-DrugBank.d180.s0|44-51|initial|drug
DDI-DrugBank.d180.s0|63-77|norepinephrine|drug
DDI-DrugBank.d180.s0|88-97|Bretylium|drug
DDI-DrugBank.d180.s1|23-37|catecholamines|drug
DDI-DrugBank.d180.s1|46-54|dopamine|drug
DDI-DrugBank.d180.s1|58-72|norepinephrine|drug
DDI-DrugBank.d180.s1|89-98|Bretylium|drug
DDI-DrugBank.d180.s2|5-19|catecholamines|drug
DDI-DrugBank.d180.s2|24-37|administered,|drug
DDI-DrugBank.d180.s2|80-88|pressure|group
DDI-DrugBank.d180.s3|35-46|information|drug
DDI-DrugBank.d180.s3|62-76|administration|drug
DDI-DrugBank.d180.s3|80-89|lidocaine|drug
DDI-DrugBank.d180.s3|94-103|Bretylium|drug
DDI-DrugBank.d180.s3|136-148|administered|drug
DDI-DrugBank.d180.s3|186-198|interactions|drug
DDI-DrugBank.d180.s3|199-208|resulting|drug
DDI-DrugBank.d180.s3|231-241|diminished|drug
DDI-DrugBank.d536.s0|0-7|Certain|drug
DDI-DrugBank.d536.s0|82-90|control.|group
DDI-DrugBank.d536.s1|12-19|include|drug
DDI-DrugBank.d536.s1|24-33|thiazides|group
DDI-DrugBank.d536.s1|44-54|diuretics,|group
DDI-DrugBank.d536.s1|55-71|corticosteroids,|group
DDI-DrugBank.d536.s1|72-87|phenothiazines,|drug
DDI-DrugBank.d536.s1|122-137|contraceptives,|group
DDI-DrugBank.d536.s1|138-148|phenytoin,|drug
DDI-DrugBank.d536.s1|149-158|nicotinic|drug
DDI-DrugBank.d536.s1|183-190|calcium|drug
DDI-DrugBank.d536.s1|191-207|channel-blocking|drug
DDI-DrugBank.d536.s2|20-32|administered|drug
DDI-DrugBank.d536.s2|46-55|receiving|drug
DDI-DrugBank.d536.s2|131-139|control.|group
DDI-DrugBank.d536.s3|44-53|receiving|drug
DDI-DrugBank.d536.s3|66-77|combination|drug
DDI-DrugBank.d536.s3|83-96|sulfonylureas|group
DDI-DrugBank.d536.s3|100-108|insulin,|drug
DDI-DrugBank.d536.s4|0-10|Intestinal|drug
DDI-DrugBank.d536.s4|74-84|containing|group
DDI-DrugBank.d536.s4|85-107|carbohydrate-splitting|drug
DDI-DrugBank.d536.s4|133-144|pancreatin)|drug
DDI-DrugBank.d536.s5|54-61|digoxin|drug
DDI-DrugBank.d536.s5|76-92|co-administered,|drug
DDI-DrugBank.d536.s5|111-118|digoxin|drug
DDI-DrugBank.d536.s6|83-99|pharmacokinetics|drug
DDI-DrugBank.d536.s6|123-131|digoxin,|drug
DDI-DrugBank.d536.s6|132-143|nifedipine,|drug
DDI-DrugBank.d536.s6|144-156|propranolol,|drug
DDI-DrugBank.d536.s6|160-171|ranitidine.|drug
DDI-DrugBank.d536.s7|17-26|interfere|drug
DDI-DrugBank.d536.s7|69-81|sulfonylurea|group
DDI-DrugBank.d536.s7|82-91|glyburide|drug
DDI-DrugBank.d536.s8|20-27|digoxin|drug
DDI-DrugBank.d536.s8|79-86|digoxin|drug
DDI-DrugBank.d536.s8|110-119|interval:|drug
DDI-DrugBank.d536.s8|120-127|8-23%),|drug_n
DDI-DrugBank.d536.s8|148-155|digoxin|drug
DDI-DrugBank.d536.s8|179-188|interval:|drug
DDI-DrugBank.d536.s8|189-196|16-34%)|drug_n
DDI-DrugBank.d536.s8|240-247|digoxin|drug
DDI-DrugBank.d536.s8|296-306|increase).|drug
DDI-DrugBank.d536.s9|14-23|metformin|drug
DDI-DrugBank.d536.s9|39-45|taking|drug
DDI-DrugBank.d536.s9|101-107|taking|drug
DDI-DrugBank.d536.s9|120-129|indicated|drug
DDI-DrugBank.d536.s10|34-43|metformin|drug
DDI-DrugBank.d536.s10|82-88|taking|drug
DDI-DrugBank.d536.s10|141-151|metformin.|drug
DDI-DrugBank.d536.s11|23-33|clinically|drug
DDI-DrugBank.d536.s11|46-57|interaction|drug
DDI-DrugBank.d536.s11|79-89|metformin.|drug
DDI-MedLine.d126.s0|0-20|Cypermethrin-induced|drug
DDI-MedLine.d126.s0|45-50|brain|drug
DDI-MedLine.d126.s0|77-84|vitamin|drug
DDI-MedLine.d126.s0|90-102|allopurinol.|drug
DDI-MedLine.d126.s1|0-11|Considering|drug
DDI-MedLine.d126.s1|21-32|involvement|drug
DDI-MedLine.d126.s1|60-65|(ROS)|brand
DDI-MedLine.d126.s1|152-163|investigate|drug
DDI-MedLine.d126.s1|200-209|induction|drug
DDI-MedLine.d126.s1|213-226|cypermethrin,|drug
DDI-MedLine.d126.s2|7-13|single|drug
DDI-MedLine.d126.s2|73-87|administration|drug
DDI-MedLine.d126.s2|91-103|cypermethrin|drug
DDI-MedLine.d126.s2|283-290|(TBARS)|brand
DDI-MedLine.d126.s3|44-54|increasing|drug
DDI-MedLine.d126.s3|107-114|control|group
DDI-MedLine.d126.s3|127-133|single|drug
DDI-MedLine.d126.s4|55-60|GSH),|brand
DDI-MedLine.d126.s4|128-134|single|drug
DDI-MedLine.d126.s4|153-162|indicated|drug
DDI-MedLine.d126.s4|192-199|insult.|drug
DDI-MedLine.d126.s5|26-31|(GST)|brand
DDI-MedLine.d126.s5|71-78|control|group
DDI-MedLine.d126.s5|114-119|point|drug
DDI-MedLine.d126.s6|26-37|allopurinol|drug
DDI-MedLine.d126.s6|57-64|Vitamin|drug
DDI-MedLine.d126.s6|173-180|against|drug_n
DDI-MedLine.d126.s6|198-203|TBARS|brand
DDI-MedLine.d126.s6|244-251|induced|drug
DDI-MedLine.d126.s6|255-261|single|drug
DDI-MedLine.d126.s6|280-292|cypermethrin|drug
DDI-MedLine.d126.s6|293-307|administration|drug
DDI-MedLine.d126.s6|308-314|within|drug
DDI-MedLine.d126.s7|31-43|cypermethrin|drug
DDI-MedLine.d126.s7|44-52|exposure|group
DDI-MedLine.d126.s7|112-121|indicated|drug
DDI-MedLine.d126.s7|198-209|allopurinol|drug
DDI-MedLine.d126.s7|214-221|Vitamin|drug
DDI-DrugBank.d13.s0|36-44|interact|drug
DDI-DrugBank.d13.s0|67-76|Monoamine|drug
DDI-DrugBank.d13.s0|85-95|inhibitors|drug
DDI-DrugBank.d13.s0|96-103|(MAOI):|brand
DDI-DrugBank.d13.s0|168-177|Arecoline|drug
DDI-DrugBank.d13.s0|180-191|Eproxindine|drug
DDI-DrugBank.d13.s0|194-202|Ethanol:|drug
DDI-DrugBank.d13.s0|220-227|Ethanol|drug
DDI-DrugBank.d13.s0|270-286|antidepressants:|group
DDI-DrugBank.d13.s0|300-309|increases|drug
DDI-DrugBank.d13.s0|334-349|antidepressants|group
DDI-DrugBank.d205.s0|0-5|Since|drug
DDI-DrugBank.d205.s0|6-14|Zarontin|drug
DDI-DrugBank.d205.s0|34-42|interact|drug
DDI-DrugBank.d205.s0|61-73|administered|drug
DDI-DrugBank.d205.s0|74-87|antiepileptic|group
DDI-DrugBank.d205.s0|116-130|determinations|drug
DDI-DrugBank.d205.s0|168-180|ethosuximide|drug
DDI-DrugBank.d205.s0|193-202|phenytoin|drug
DDI-DrugBank.d205.s0|260-268|increase|drug
DDI-DrugBank.d205.s0|282-294|ethosuximide|drug
DDI-MedLine.d122.s0|22-32|underlying|drug
DDI-MedLine.d122.s0|50-57|smoking|drug
DDI-MedLine.d122.s0|62-71|drinking.|drug
DDI-MedLine.d122.s1|33-41|nicotine|drug
DDI-MedLine.d122.s2|102-108|brain,|drug
DDI-MedLine.d122.s2|151-158|certain|drug
DDI-MedLine.d122.s3|4-14|initiation|drug
DDI-MedLine.d122.s3|29-37|nicotine|drug
DDI-MedLine.d122.s3|148-156|seeking.|drug
DDI-MedLine.d122.s4|25-35|underlying|drug
DDI-MedLine.d122.s4|97-106|nicotine.|drug
DDI-MedLine.d122.s5|6-13|certain|drug
DDI-MedLine.d122.s5|31-42|reinforcing|drug
DDI-MedLine.d122.s5|57-69|conditioning|drug
DDI-MedLine.d122.s5|117-126|influence|drug
DDI-MedLine.d122.s6|23-32|tolerance|drug
DDI-MedLine.d122.s6|126-136|contribute|group
DDI-MedLine.d122.s7|54-61|certain|drug
DDI-MedLine.d122.s7|62-67|brain|drug
DDI-MedLine.d122.s7|167-176|interact.|drug
DDI-MedLine.d131.s0|19-34|antinociceptive|group
DDI-MedLine.d131.s0|50-61|neurotensin|drug
DDI-MedLine.d131.s0|66-77|enkephalins|drug
DDI-MedLine.d131.s0|81-89|tuftsin.|drug
DDI-MedLine.d131.s1|39-50|interaction|drug
DDI-MedLine.d131.s1|59-70|neurotensin|drug
DDI-MedLine.d131.s1|80-91|enkephalins|drug
DDI-MedLine.d131.s1|118-144|D-Ala2-metenkephalinamide,|drug
DDI-MedLine.d131.s1|148-156|tuftsin,|drug
DDI-MedLine.d131.s1|164-180|antinonciceptive|group
DDI-MedLine.d131.s1|220-234|intracisternal|drug
DDI-MedLine.d131.s1|235-245|injection.|drug
DDI-MedLine.d131.s2|0-15|Antinociception|drug
DDI-MedLine.d131.s2|20-28|measured|group
DDI-MedLine.d131.s3|18-29|neurotensin|drug
DDI-MedLine.d131.s3|56-71|antinociceptive|group
DDI-MedLine.d131.s3|82-93|enkephalins|drug
DDI-MedLine.d131.s4|7-16|contrary,|group
DDI-MedLine.d131.s4|17-28|neurotensin|drug
DDI-MedLine.d131.s4|33-40|tuftsin|drug
DDI-MedLine.d131.s4|58-67|induction|drug
DDI-MedLine.d131.s5|21-32|neurotensin|drug
DDI-MedLine.d131.s5|82-97|enkephalinergic|drug
DDI-MedLine.d131.s5|132-140|tuftsin.|drug
DDI-DrugBank.d360.s0|21-30|increased|drug
DDI-DrugBank.d360.s0|31-40|incidence|drug
DDI-DrugBank.d360.s0|57-65|bleeding|drug
DDI-DrugBank.d360.s0|140-149|rifampin.|drug
DDI-DrugBank.d360.s1|97-106|phenytoin|drug
DDI-DrugBank.d360.s1|107-114|sodium,|drug
DDI-DrugBank.d360.s1|115-129|carbamazepine,|drug
DDI-DrugBank.d360.s1|130-143|griseofulvin,|drug
DDI-DrugBank.d360.s1|174-184|ampicillin|drug
DDI-DrugBank.d360.s1|189-202|tetracyclines|drug
DDI-DrugBank.d360.s2|11-22|interaction|drug
DDI-DrugBank.d360.s2|56-70|contraceptives|group
DDI-DrugBank.d360.s2|142-155|contraceptive|group
DDI-DrugBank.d360.s2|162-174|experiencing|drug
DDI-DrugBank.d360.s2|188-196|bleeding|drug
DDI-DrugBank.d360.s2|211-219|starting|drug
DDI-DrugBank.d360.s3|43-51|combined|drug
DDI-DrugBank.d360.s3|61-75|contraceptives|group
DDI-DrugBank.d360.s4|58-65|inserts|drug
DDI-DrugBank.d360.s4|80-92|administered|drug
DDI-DrugBank.d360.s4|117-132|contraceptives.|group
DDI-DrugBank.d74.s0|0-9|FLUOTHANE|brand
DDI-DrugBank.d74.s0|33-49|non-depolarising|drug
DDI-DrugBank.d74.s0|102-118|aminoglycosides.|drug
DDI-DrugBank.d74.s1|0-9|FLUOTHANE|brand
DDI-DrugBank.d74.s1|52-71|ganglionic-blocking|drug
DDI-DrugBank.d74.s1|82-95|tubocurarine.|drug
DDI-DrugBank.d74.s2|28-34|during|drug
DDI-DrugBank.d74.s2|39-53|administration|drug
DDI-DrugBank.d74.s2|57-67|adrenaline|drug
DDI-DrugBank.d74.s2|99-108|FLUOTHANE|brand
DDI-DrugBank.d74.s3|28-38|adrenaline|drug
DDI-DrugBank.d74.s3|67-81|antiarrhythmic|group
DDI-DrugBank.d74.s3|88-100|administered|drug
DDI-DrugBank.d74.s4|67-80|aminophylline|drug
DDI-DrugBank.d74.s4|85-97|theophylline|drug
DDI-DrugBank.d74.s4|112-128|antidepressants,|group
DDI-DrugBank.d237.s0|0-9|Cisapride|drug
DDI-DrugBank.d237.s0|25-31|mainly|drug
DDI-DrugBank.d237.s1|86-93|pointes|drug
DDI-DrugBank.d237.s1|113-122|cisapride|drug
DDI-DrugBank.d237.s1|184-195|inhibitors,|drug
DDI-DrugBank.d237.s1|211-220|cisapride|drug
DDI-DrugBank.d237.s2|52-67|clarithromycin,|drug
DDI-DrugBank.d237.s2|68-81|erythromycin,|drug
DDI-DrugBank.d237.s2|86-100|troleandomycin|drug
DDI-DrugBank.d237.s2|110-117|inhibit|drug
DDI-DrugBank.d237.s2|170-178|increase|drug
DDI-DrugBank.d237.s2|189-198|cisapride|drug
DDI-DrugBank.d237.s2|233-241|interval|drug
DDI-DrugBank.d237.s3|0-17|Anticholinergics:|drug
DDI-DrugBank.d237.s3|29-43|administration|drug
DDI-DrugBank.d237.s3|47-54|certain|drug
DDI-DrugBank.d237.s3|55-70|anticholinergic|group
DDI-DrugBank.d237.s3|101-110|alkaloids|group
DDI-DrugBank.d237.s3|115-127|dicyclomine,|drug
DDI-DrugBank.d237.s4|35-44|receiving|drug
DDI-DrugBank.d237.s4|50-65|anticoagulants,|group
DDI-DrugBank.d237.s4|93-102|increased|drug
DDI-DrugBank.d237.s5|42-48|within|drug
DDI-DrugBank.d237.s5|88-103|discontinuation|group
DDI-DrugBank.d237.s5|107-116|cisapride|drug
DDI-DrugBank.d237.s5|164-177|anticoagulant|group
DDI-DrugBank.d237.s6|31-39|indicate|drug
DDI-DrugBank.d237.s6|56-64|inhibits|drug
DDI-DrugBank.d237.s6|117-125|increase|drug
DDI-DrugBank.d237.s6|136-145|cisapride|drug
DDI-DrugBank.d237.s6|180-188|interval|drug
DDI-DrugBank.d237.s7|42-50|indicate|drug
DDI-DrugBank.d237.s7|56-68|fluconazole,|drug
DDI-DrugBank.d237.s7|69-82|itraconazole,|drug
DDI-DrugBank.d237.s7|92-104|ketoconazole|drug
DDI-DrugBank.d237.s7|114-121|inhibit|drug
DDI-DrugBank.d237.s7|174-182|increase|drug
DDI-DrugBank.d237.s7|193-202|cisapride|drug
DDI-DrugBank.d237.s7|237-245|interval|drug
DDI-DrugBank.d237.s8|6-21|pharmacokinetic|drug
DDI-DrugBank.d237.s8|27-35|indicate|drug
DDI-DrugBank.d237.s8|46-58|ketoconazole|drug
DDI-DrugBank.d237.s8|68-76|inhibits|drug
DDI-DrugBank.d237.s8|106-115|resulting|drug
DDI-DrugBank.d237.s8|137-145|increase|drug
DDI-DrugBank.d237.s9|62-78|coadministration|drug
DDI-DrugBank.d237.s9|82-91|cisapride|drug
DDI-DrugBank.d237.s9|96-108|ketoconazole|drug
DDI-DrugBank.d237.s9|146-154|interval|drug
DDI-DrugBank.d237.s10|25-35|Cimetidine|drug
DDI-DrugBank.d237.s10|36-52|coadministration|drug
DDI-DrugBank.d237.s10|65-74|increased|drug
DDI-DrugBank.d237.s10|145-154|cisapride|drug
DDI-DrugBank.d237.s10|177-191|coadministered|drug
DDI-DrugBank.d237.s10|197-208|ranitidine.|drug
DDI-DrugBank.d237.s11|4-20|gastrointestinal|drug
DDI-DrugBank.d237.s11|35-45|cimetidine|drug
DDI-DrugBank.d237.s11|50-60|ranitidine|drug
DDI-DrugBank.d237.s11|90-104|coadministered|drug
DDI-DrugBank.d237.s12|35-43|indicate|drug
DDI-DrugBank.d237.s12|49-58|indinavir|drug
DDI-DrugBank.d237.s12|63-72|ritonavir|drug
DDI-DrugBank.d237.s12|82-89|inhibit|drug
DDI-DrugBank.d237.s12|108-117|cisapride|drug
DDI-DrugBank.d237.s12|141-149|increase|drug
DDI-DrugBank.d237.s12|160-169|cisapride|drug
DDI-DrugBank.d237.s12|204-212|interval|drug
DDI-DrugBank.d237.s13|7-23|Coadministration|drug
DDI-DrugBank.d237.s13|49-58|cisapride|drug
DDI-DrugBank.d237.s13|59-68|increases|drug
DDI-DrugBank.d237.s13|92-101|cisapride|drug
DDI-DrugBank.d237.s14|0-9|Cisapride|drug
DDI-DrugBank.d237.s14|84-93|interval:|drug
DDI-DrugBank.d237.s14|94-101|certain|drug
DDI-DrugBank.d237.s14|102-118|antiarrhythmics,|group
DDI-DrugBank.d237.s14|119-128|including|drug
DDI-DrugBank.d237.s14|156-165|quinidine|drug
DDI-DrugBank.d237.s14|170-183|procainamide)|drug
DDI-DrugBank.d237.s15|10-25|antidepressants|group
DDI-DrugBank.d237.s15|35-50|amitriptyline);|drug
DDI-DrugBank.d237.s16|0-7|certain|drug
DDI-DrugBank.d237.s16|20-35|antidepressants|group
DDI-DrugBank.d237.s16|45-58|maprotiline);|drug
DDI-DrugBank.d237.s17|0-7|certain|drug
DDI-DrugBank.d237.s17|8-21|antipsychotic|group
DDI-DrugBank.d237.s17|43-55|sertindole);|drug
DDI-DrugBank.d237.s18|0-11|astemizole,|drug
DDI-DrugBank.d237.s18|22-35|sparfloxacin,|drug
DDI-DrugBank.d237.s18|40-51|terodiline.|drug
DDI-DrugBank.d237.s19|4-13|preceding|drug
DDI-DrugBank.d237.s20|28-36|emptying|drug
DDI-DrugBank.d237.s20|40-49|cisapride|drug
DDI-DrugBank.d237.s21|9-18|receiving|drug
DDI-DrugBank.d237.s22|21-26|being|drug
DDI-DrugBank.d134.s0|24-36|interactions|drug
DDI-DrugBank.d134.s0|42-51|LEUSTATIN|brand
DDI-DrugBank.d134.s1|31-40|LEUSTATIN|brand
DDI-DrugBank.d134.s1|54-66|administered|drug
DDI-DrugBank.d452.s0|0-14|Administration|drug
DDI-DrugBank.d452.s0|18-26|thiazide|group
DDI-DrugBank.d452.s0|27-36|diuretics|group
DDI-DrugBank.d452.s0|86-91|being|drug
DDI-DrugBank.d452.s0|105-123|dihydrotachysterol|drug
DDI-MedLine.d87.s0|4-11|8-2698,|drug_n
DDI-MedLine.d87.s0|14-52|trans-3,4-dimethyl-4-(3-hydroxyphenyl)|drug
DDI-MedLine.d87.s0|53-64|piperidine,|drug
DDI-MedLine.d87.s0|74-90|gastrointestinal|drug
DDI-MedLine.d87.s0|102-113|intravenous|drug
DDI-MedLine.d87.s0|114-122|morphine|drug
DDI-MedLine.d87.s0|131-140|affecting|drug
DDI-MedLine.d87.s1|0-10|ADL-8-2698|brand
DDI-MedLine.d87.s1|93-107|opioid-induced|drug
DDI-MedLine.d87.s1|108-124|gastrointestinal|drug
DDI-MedLine.d87.s1|141-150|reversing|drug
DDI-MedLine.d87.s2|0-16|Gastrointestinal|drug
DDI-MedLine.d87.s2|41-49|hydrogen|drug
DDI-MedLine.d87.s2|67-75|measured|group
DDI-MedLine.d87.s2|107-118|intravenous|drug
DDI-MedLine.d87.s2|145-156|intravenous|drug
DDI-MedLine.d87.s2|157-165|morphine|drug
DDI-MedLine.d87.s2|199-205|8-2698|drug_n
DDI-MedLine.d87.s2|217-228|intravenous|drug
DDI-MedLine.d87.s2|229-237|morphine|drug
DDI-MedLine.d87.s2|269-275|blind,|drug
DDI-MedLine.d87.s3|0-8|Morphine|drug
DDI-MedLine.d87.s3|19-35|gastrointestinal|drug
DDI-MedLine.d87.s3|64-71|minutes|drug
DDI-MedLine.d87.s4|0-8|Morphine|drug
DDI-MedLine.d87.s4|19-35|gastrointestinal|drug
DDI-MedLine.d87.s4|64-71|minutes|drug
DDI-MedLine.d87.s4|110-116|8-2698|drug_n
DDI-MedLine.d87.s5|57-69|double-blind|drug
DDI-MedLine.d87.s5|93-99|8-2698|drug_n
DDI-MedLine.d87.s5|122-133|intravenous|drug
DDI-MedLine.d87.s5|134-142|morphine|drug
DDI-MedLine.d87.s5|179-190|intravenous|drug
DDI-MedLine.d87.s6|38-47|measured.|group
DDI-MedLine.d87.s7|0-8|Morphine|drug
DDI-MedLine.d87.s7|65-71|8-2698|drug_n
DDI-MedLine.d87.s8|21-27|8-2698|drug_n
DDI-MedLine.d87.s8|37-53|morphine-induced|drug
DDI-MedLine.d87.s8|54-63|increases|drug
DDI-MedLine.d87.s8|67-83|gastrointestinal|drug
DDI-MedLine.d87.s8|157-166|affecting|drug
DDI-MedLine.d118.s0|31-40|rapamycin|drug
DDI-MedLine.d118.s0|41-50|inhibitor|drug
DDI-MedLine.d118.s2|92-101|increased|drug
DDI-MedLine.d118.s2|231-243|cyclosporine|drug
DDI-MedLine.d118.s3|41-48|initial|drug
DDI-MedLine.d118.s3|49-57|clinical|drug
DDI-MedLine.d118.s3|111-122|combination|drug
DDI-MedLine.d118.s3|128-140|cyclosporine|drug
DDI-MedLine.d118.s3|249-261|cyclosporine|drug
DDI-MedLine.d118.s3|322-328|1999).|drug_n
DDI-DrugBank.d163.s0|0-7|Vitamin|drug
DDI-DrugBank.d163.s0|54-61|vitamin|drug
DDI-DrugBank.d163.s0|92-99|against|drug_n
DDI-DrugBank.d163.s0|100-106|taking|drug
DDI-DrugBank.d163.s0|107-114|vitamin|drug
DDI-DrugBank.d163.s0|127-137|containing|group
DDI-DrugBank.d163.s0|138-145|vitamin|drug
DDI-DrugBank.d163.s2|0-14|Tetracyclines:|drug
DDI-DrugBank.d163.s2|55-68|tetracyclines|drug
DDI-DrugBank.d163.s2|182-194|intracranial|drug
DDI-DrugBank.d163.s2|224-232|involved|drug
DDI-DrugBank.d163.s2|252-265|tetracyclines|drug
DDI-DrugBank.d163.s4|77-87|(minipills|drug
DDI-DrugBank.d163.s4|100-107|contain|group
DDI-DrugBank.d163.s4|131-141|inadequate|drug
DDI-DrugBank.d163.s4|152-165|contraception|group
DDI-DrugBank.d163.s4|166-172|during|drug
DDI-DrugBank.d163.s5|24-38|contraceptives|group
DDI-DrugBank.d163.s5|123-131|combined|drug
DDI-DrugBank.d163.s5|137-152|contraceptives,|group
DDI-DrugBank.d163.s5|164-205|topical/injectable/implantable/insertable|drug
DDI-DrugBank.d163.s5|221-228|control|group
DDI-DrugBank.d163.s6|57-63|single|drug
DDI-DrugBank.d163.s6|74-88|contraception.|group
DDI-DrugBank.d163.s7|28-42|contraceptives|group
DDI-DrugBank.d163.s8|51-63|childbearing|drug
DDI-DrugBank.d163.s8|123-136|contraception|group
DDI-DrugBank.d163.s8|213-223|abstinence|drug
DDI-DrugBank.d163.s10|0-10|Phenytoin:|drug
DDI-DrugBank.d163.s10|52-68|pharmacokinetics|drug
DDI-DrugBank.d163.s10|72-81|phenytoin|drug
DDI-DrugBank.d163.s11|47-54|finding|drug
DDI-DrugBank.d163.s11|68-80|isotretinoin|drug
DDI-DrugBank.d163.s11|101-107|induce|drug
DDI-DrugBank.d163.s11|111-118|inhibit|drug
DDI-DrugBank.d163.s12|0-9|Phenytoin|drug
DDI-DrugBank.d163.s13|10-18|clinical|drug
DDI-DrugBank.d163.s13|72-83|interactive|drug
DDI-DrugBank.d163.s13|112-121|phenytoin|drug
DDI-DrugBank.d163.s14|44-49|using|drug
DDI-DrugBank.d163.s16|9-25|Corticosteroids:|group
DDI-DrugBank.d163.s16|35-50|corticosteroids|group
DDI-DrugBank.d163.s17|10-18|clinical|drug
DDI-DrugBank.d163.s17|72-83|interactive|drug
DDI-DrugBank.d163.s17|121-136|corticosteroids|group
DDI-DrugBank.d163.s18|44-49|using|drug
DDI-DrugBank.d163.s19|47-53|insert|drug
DDI-DrugBank.d163.s19|68-80|administered|drug
DDI-DrugBank.d163.s19|109-124|contraceptives,|group
DDI-DrugBank.d163.s19|125-130|since|drug
DDI-DrugBank.d163.s19|194-201|control|group
DDI-DrugBank.d163.s21|43-51|combined|drug
DDI-DrugBank.d163.s21|61-75|contraceptives|group
DDI-DrugBank.d163.s22|51-63|childbearing|drug
DDI-DrugBank.d163.s22|108-113|urine|drug
DDI-DrugBank.d163.s22|187-196|receiving|drug
DDI-DrugBank.d163.s22|201-208|initial|drug
DDI-DrugBank.d163.s23|18-26|obtained|drug
DDI-DrugBank.d163.s23|126-135|screening|drug
DDI-DrugBank.d163.s24|63-69|during|drug
DDI-DrugBank.d163.s24|123-132|preceding|drug
DDI-DrugBank.d163.s24|137-146|beginning|drug
DDI-DrugBank.d163.s25|119-130|intercourse|drug
DDI-DrugBank.d163.s25|140-145|using|drug
DDI-DrugBank.d163.s25|167-182|contraception).|group
DDI-DrugBank.d163.s26|70-75|urine|drug
DDI-DrugBank.d163.s27|73-82|receiving|drug
DDI-DrugBank.d163.s29|0-7|Lipids:|group
DDI-DrugBank.d163.s29|41-47|lipids|group
DDI-DrugBank.d163.s29|58-66|obtained|drug
DDI-DrugBank.d163.s29|73-80|fasting|drug
DDI-DrugBank.d163.s30|75-89|determinations|drug
DDI-DrugBank.d163.s31|70-79|intervals|drug
DDI-DrugBank.d163.s32|4-13|incidence|drug
DDI-DrugBank.d163.s34|22-27|Since|drug
DDI-DrugBank.d163.s34|75-81|during|drug
DDI-DrugBank.d163.s34|82-90|clinical|drug
DDI-DrugBank.d163.s34|222-231|intervals|drug
DDI-DrugBank.d163.s36|23-32|receiving|drug
DDI-DrugBank.d163.s36|75-82|control|group
DDI-DrugBank.d163.s37|55-61|during|drug
DDI-DrugBank.d163.s39|19-29|undergoing|drug
DDI-DrugBank.d163.s40|13-21|clinical|drug
DDI-DrugBank.d163.s41|21-34|postmarketing|drug
DDI-DrugBank.d163.s42|5-13|clinical|drug
DDI-DrugBank.d163.s42|164-173|including|drug
DDI-DrugBank.d163.s42|180-190|undergoing|drug
DDI-DrugBank.d163.s42|292-297|pain,|drug
DDI-DrugBank.d163.s42|315-322|injury,|drug
DDI-DrugBank.d163.s42|333-340|sprain.|drug
DDI-DrugBank.d163.s43|79-85|within|drug
DDI-DrugBank.d163.s43|122-128|within|drug
DDI-DrugBank.d556.s0|43-52|following|drug
DDI-DrugBank.d556.s0|65-79|administration|drug
DDI-DrugBank.d556.s0|83-97|cephalosporins|drug
DDI-DrugBank.d556.s0|102-116|aminoglycoside|drug
DDI-DrugBank.d556.s0|117-129|antibiotics.|group
DDI-DrugBank.d556.s1|42-54|cephalothin,|drug
DDI-DrugBank.d556.s1|78-87|cefoxitin|drug
DDI-DrugBank.d556.s1|113-122|interfere|drug
DDI-DrugBank.d556.s1|128-139|measurement|group
DDI-DrugBank.d556.s1|153-158|urine|drug
DDI-DrugBank.d556.s1|159-169|creatinine|drug
DDI-DrugBank.d556.s1|218-227|increases|drug
DDI-DrugBank.d556.s1|262-272|creatinine|drug
DDI-DrugBank.d556.s2|41-50|cefoxitin|drug
DDI-DrugBank.d556.s2|78-88|creatinine|drug
DDI-DrugBank.d556.s2|102-108|within|drug
DDI-DrugBank.d556.s2|125-140|administration.|drug
DDI-DrugBank.d556.s3|23-32|cefoxitin|drug
DDI-DrugBank.d556.s3|40-45|urine|drug
DDI-DrugBank.d556.s3|50-59|interfere|drug
DDI-DrugBank.d556.s3|65-76|measurement|group
DDI-DrugBank.d556.s3|80-87|urinary|drug
DDI-DrugBank.d556.s3|88-114|17-hydroxy-corticosteroids|drug_n
DDI-DrugBank.d556.s3|164-173|increases|drug
DDI-DrugBank.d556.s4|45-50|urine|drug
DDI-DrugBank.d556.s5|28-37|CLINITEST|brand
DDI-DrugBank.d25.s0|0-13|Corticotropin|drug
DDI-DrugBank.d25.s0|66-74|diuretic|group
DDI-DrugBank.d528.s0|0-13|Acetaminophen|drug
DDI-DrugBank.d528.s0|33-45|L-methionine|drug
DDI-DrugBank.d528.s0|90-103|acetaminophen|drug
DDI-DrugBank.d528.s0|127-133|taking|drug
DDI-DrugBank.d528.s2|0-10|Gentamicin|drug
DDI-DrugBank.d528.s2|13-23|Methionine|drug
DDI-DrugBank.d528.s2|36-43|against|drug_n
DDI-DrugBank.d528.s2|68-79|gentamicin.|drug
DDI-DrugBank.d287.s0|0-10|Cevimeline|drug
DDI-DrugBank.d287.s0|21-33|administered|drug
DDI-DrugBank.d287.s0|59-65|taking|drug
DDI-DrugBank.d287.s1|39-51|administered|drug
DDI-DrugBank.d287.s1|70-80|cevimeline|drug
DDI-DrugBank.d287.s2|0-10|Cevimeline|drug
DDI-DrugBank.d287.s2|17-26|interfere|drug
DDI-DrugBank.d287.s2|42-56|antimuscarinic|group
DDI-DrugBank.d287.s3|12-19|inhibit|drug
DDI-DrugBank.d287.s3|20-26|CYP2D6|brand
DDI-DrugBank.d287.s3|31-39|CYP3A3/4|brand
DDI-DrugBank.d287.s3|45-52|inhibit|drug
DDI-DrugBank.d287.s3|71-82|cevimeline.|drug
DDI-DrugBank.d287.s4|0-10|Cevimeline|drug
DDI-DrugBank.d287.s4|42-53|individuals|drug
DDI-DrugBank.d287.s4|92-98|CYP2D6|brand
DDI-DrugBank.d287.s5|62-67|2C19,|brand
DDI-DrugBank.d287.s5|95-104|inhibited|drug
DDI-DrugBank.d287.s5|108-116|exposure|group
DDI-DrugBank.d287.s5|120-131|cevimeline.|drug
DDI-DrugBank.d458.s0|0-12|Ketoconazole|drug
DDI-DrugBank.d458.s0|25-34|inhibitor|drug
DDI-DrugBank.d458.s1|0-16|Coadministration|drug
DDI-DrugBank.d458.s1|20-27|NIZORAL|brand
DDI-DrugBank.d458.s1|124-133|increased|drug
DDI-DrugBank.d458.s1|180-188|increase|drug
DDI-DrugBank.d458.s3|4-13|following|drug
DDI-DrugBank.d458.s3|19-31|interactions|drug
DDI-DrugBank.d458.s3|53-62|involving|drug
DDI-DrugBank.d458.s3|63-70|NIZORAL|brand
DDI-DrugBank.d458.s3|149-161|Ketoconazole|drug
DDI-DrugBank.d458.s3|170-177|inhibit|drug
DDI-DrugBank.d458.s3|196-208|terfenadine,|drug
DDI-DrugBank.d458.s3|209-218|resulting|drug
DDI-DrugBank.d458.s3|225-234|increased|drug
DDI-DrugBank.d458.s3|259-270|terfenadine|drug
DDI-DrugBank.d458.s3|290-301|elimination|drug
DDI-DrugBank.d458.s4|4-13|increased|drug
DDI-DrugBank.d458.s4|38-49|terfenadine|drug
DDI-DrugBank.d458.s4|95-105|intervals.|drug
DDI-DrugBank.d458.s5|0-15|Pharmacokinetic|drug
DDI-DrugBank.d458.s5|21-29|indicate|drug
DDI-DrugBank.d458.s5|40-52|ketoconazole|drug
DDI-DrugBank.d458.s5|53-61|inhibits|drug
DDI-DrugBank.d458.s5|80-91|astemizole,|drug
DDI-DrugBank.d458.s5|92-101|resulting|drug
DDI-DrugBank.d458.s5|131-141|astemizole|drug
DDI-DrugBank.d458.s5|168-187|desmethylastemizole|drug
DDI-DrugBank.d458.s5|209-219|intervals.|drug
DDI-DrugBank.d458.s6|0-16|Coadministration|drug
DDI-DrugBank.d458.s6|20-30|astemizole|drug
DDI-DrugBank.d458.s6|36-48|ketoconazole|drug
DDI-DrugBank.d458.s6|70-86|contraindicated.|group
DDI-DrugBank.d458.s7|6-22|pharmacokinetics|drug
DDI-DrugBank.d458.s7|28-36|indicate|drug
DDI-DrugBank.d458.s7|47-59|ketoconazole|drug
DDI-DrugBank.d458.s7|69-77|inhibits|drug
DDI-DrugBank.d458.s7|96-105|cisapride|drug
DDI-DrugBank.d458.s7|106-115|resulting|drug
DDI-DrugBank.d458.s7|137-145|increase|drug
DDI-DrugBank.d458.s8|18-34|coadministration|drug
DDI-DrugBank.d458.s8|43-55|ketoconazole|drug
DDI-DrugBank.d458.s8|60-69|cisapride|drug
DDI-DrugBank.d458.s8|107-115|interval|drug
DDI-DrugBank.d458.s9|22-36|administration|drug
DDI-DrugBank.d458.s9|40-52|ketoconazole|drug
DDI-DrugBank.d458.s9|66-75|cisapride|drug
DDI-DrugBank.d458.s9|79-95|contraindicated.|group
DDI-DrugBank.d458.s10|0-12|Ketoconazole|drug
DDI-DrugBank.d458.s10|49-62|cyclosporine,|drug
DDI-DrugBank.d458.s10|99-108|resulting|drug
DDI-DrugBank.d458.s11|37-50|cyclosporine,|drug
DDI-DrugBank.d458.s11|114-121|NIZORAL|brand
DDI-DrugBank.d458.s12|0-16|Coadministration|drug
DDI-DrugBank.d458.s12|20-27|NIZORAL|brand
DDI-DrugBank.d458.s12|42-51|midazolam|drug
DDI-DrugBank.d458.s12|55-64|triazolam|drug
DDI-DrugBank.d458.s13|88-94|dosing|drug
DDI-DrugBank.d458.s13|106-120|administration|drug
DDI-DrugBank.d458.s14|57-64|NIZORAL|brand
DDI-DrugBank.d458.s15|3-12|midazolam|drug
DDI-DrugBank.d458.s15|16-28|administered|drug
DDI-DrugBank.d458.s15|74-79|since|drug
DDI-DrugBank.d458.s16|48-55|digoxin|drug
DDI-DrugBank.d458.s17|44-55|combination|drug
DDI-DrugBank.d458.s18|39-46|digoxin|drug
DDI-DrugBank.d458.s18|74-83|receiving|drug
DDI-DrugBank.d458.s18|84-97|ketoconazole.|drug
DDI-DrugBank.d458.s19|20-29|imidazole|drug
DDI-DrugBank.d458.s19|45-57|ketoconazole|drug
DDI-DrugBank.d458.s19|74-87|anticoagulant|group
DDI-DrugBank.d458.s19|98-111|coumarin-like|drug
DDI-DrugBank.d458.s20|31-40|imidazole|drug
DDI-DrugBank.d458.s20|51-59|coumarin|drug
DDI-DrugBank.d458.s20|71-84|anticoagulant|group
DDI-DrugBank.d458.s21|72-81|receiving|drug
DDI-DrugBank.d458.s21|87-97|miconazole|drug
DDI-DrugBank.d458.s21|102-112|imidazole)|drug
DDI-DrugBank.d458.s21|160-171|interaction|drug
DDI-DrugBank.d458.s21|172-181|involving|drug
DDI-DrugBank.d458.s21|229-241|ketoconazole|drug
DDI-DrugBank.d458.s21|254-264|imidazole)|drug
DDI-DrugBank.d458.s22|12-26|administration|drug
DDI-DrugBank.d458.s22|30-42|ketoconazole|drug
DDI-DrugBank.d458.s22|56-65|phenytoin|drug
DDI-DrugBank.d458.s23|32-44|ketoconazole|drug
DDI-DrugBank.d458.s23|49-59|phenytoin.|drug
DDI-DrugBank.d458.s24|12-26|administration|drug
DDI-DrugBank.d458.s24|30-38|rifampin|drug
DDI-DrugBank.d458.s24|44-56|ketoconazole|drug
DDI-DrugBank.d458.s25|43-55|ketoconazole|drug
DDI-DrugBank.d458.s27|10-26|coadministration|drug
DDI-DrugBank.d458.s27|42-54|ketoconazole|drug
DDI-DrugBank.d458.s27|89-99|loratadine|drug
DDI-DrugBank.d458.s27|136-146|loratadine|drug
DDI-DrugBank.d458.s27|168-173|S.D.)|brand
DDI-DrugBank.d458.s27|189-195|S.D.),|brand
DDI-DrugBank.d458.s27|219-227|obtained|drug
DDI-DrugBank.d458.s28|20-45|descarboethoxyloratadine,|drug
DDI-DrugBank.d458.s28|88-93|S.D.)|brand
DDI-DrugBank.d458.s28|109-115|S.D.),|brand
DDI-DrugBank.d458.s29|95-112|coadministration.|drug
DDI-DrugBank.d458.s30|20-30|clinically|drug
DDI-DrugBank.d458.s30|78-88|loratadine|drug
DDI-DrugBank.d458.s30|93-105|administered|drug
DDI-DrugBank.d458.s30|122-135|ketoconazole.|drug
DDI-DrugBank.d458.s32|45-54|flushing,|drug
DDI-DrugBank.d458.s33|18-24|within|drug
DDI-MedLine.d26.s0|24-34|individual|drug
DDI-MedLine.d26.s0|39-44|joint|drug
DDI-MedLine.d26.s0|45-53|exposure|group
DDI-MedLine.d26.s1|12-25|administering|drug
DDI-MedLine.d26.s1|39-50|combination|drug
DDI-MedLine.d26.s1|64-73|enhancing|drug
DDI-MedLine.d26.s1|101-109|limiting|drug
DDI-MedLine.d26.s2|46-56|developing|drug
DDI-MedLine.d26.s2|93-98|joint|drug
DDI-MedLine.d26.s2|164-173|designing|drug
DDI-MedLine.d26.s2|190-199|assessing|drug
DDI-MedLine.d26.s2|200-205|joint|drug
DDI-MedLine.d26.s3|135-146|literature.|group
DDI-MedLine.d26.s4|27-36|nonlinear|drug
DDI-MedLine.d26.s4|71-80|nonlinear|drug
DDI-MedLine.d26.s4|148-157|designing|drug
DDI-MedLine.d26.s5|52-60|settings|drug
DDI-MedLine.d26.s5|86-91|joint|drug
DDI-MedLine.d26.s5|105-114|including|drug
DDI-MedLine.d26.s5|115-125|continuous|group
DDI-MedLine.d26.s5|168-179|structures,|group
DDI-MedLine.d26.s6|90-100|individual|drug
DDI-MedLine.d26.s6|144-153|providing|drug
DDI-MedLine.d26.s7|43-50|minimal|drug
DDI-MedLine.d26.s7|96-102|single|drug
DDI-MedLine.d26.s7|115-127|administered|drug
DDI-MedLine.d26.s8|38-46|deriving|drug
DDI-MedLine.d26.s8|90-99|nonlinear|drug
DDI-MedLine.d26.s8|173-184|independent|drug
DDI-MedLine.d26.s8|185-190|joint|drug
DDI-MedLine.d26.s8|198-203|(IJA)|brand
DDI-MedLine.d26.s8|215-225|individual|drug
DDI-MedLine.d26.s8|230-238|combined|drug
DDI-MedLine.d26.s8|239-248|exposures|group
DDI-DrugBank.d330.s0|174-183|neomycin.|drug
DDI-DrugBank.d330.s1|66-81|aminoglycosides|drug
DDI-DrugBank.d330.s1|86-96|polymyxins|drug
DDI-DrugBank.d330.s1|122-130|neomycin|drug
DDI-DrugBank.d330.s1|182-190|neomycin|drug
DDI-DrugBank.d330.s1|213-221|blocking|drug
DDI-DrugBank.d330.s2|5-13|neomycin|drug
DDI-DrugBank.d330.s2|14-22|inhibits|drug
DDI-DrugBank.d330.s2|27-43|gastrointestinal|drug
DDI-DrugBank.d330.s2|58-68|penicillin|drug
DDI-DrugBank.d330.s2|77-84|vitamin|drug
DDI-DrugBank.d330.s2|85-90|B-12,|brand
DDI-DrugBank.d330.s2|108-123|5-fluorouracil.|drug_n
DDI-DrugBank.d330.s3|4-20|gastrointestinal|drug
DDI-DrugBank.d330.s3|35-42|digoxin|drug
DDI-DrugBank.d330.s3|62-72|inhibited.|drug
DDI-DrugBank.d330.s4|11-18|digoxin|drug
DDI-DrugBank.d330.s5|5-13|neomycin|drug
DDI-DrugBank.d330.s5|48-56|coumarin|drug
DDI-DrugBank.d330.s5|60-74|anticoagulants|group
DDI-DrugBank.d330.s5|78-88|decreasing|drug
DDI-DrugBank.d330.s5|89-96|vitamin|drug
DDI-DrugBank.d412.s0|32-38|taking|drug
DDI-DrugBank.d412.s0|56-67|combination|drug
DDI-DrugBank.d412.s0|83-98|antidepressants|group
DDI-DrugBank.d412.s1|4-16|contribution|group
DDI-DrugBank.d412.s1|109-120|interaction|drug
DDI-DrugBank.d412.s2|6-16|possessing|drug
DDI-DrugBank.d412.s2|17-30|beta-blocking|drug
DDI-DrugBank.d412.s3|41-54|antiasthmatic|group
DDI-DrugBank.d412.s4|0-10|Cimetidine|drug
DDI-DrugBank.d412.s4|29-37|increase|drug
DDI-DrugBank.d412.s5|0-5|Since|drug
DDI-DrugBank.d412.s5|20-29|explained|drug
DDI-DrugBank.d412.s5|151-163|establishing|drug
DDI-DrugBank.d412.s5|192-200|pressure|group
DDI-DrugBank.d412.s5|201-208|control|group
DDI-DrugBank.d412.s6|58-71|intravenously|drug
DDI-DrugBank.d412.s6|72-84|administered|drug
DDI-DrugBank.d412.s7|0-6|During|drug
DDI-DrugBank.d412.s7|7-17|controlled|group
DDI-DrugBank.d412.s7|41-46|using|drug
DDI-DrugBank.d412.s7|200-209|increased|drug
DDI-DrugBank.d412.s7|287-295|increase|drug
DDI-DrugBank.d412.s7|314-323|pressure.|group
DDI-DrugBank.d412.s8|31-39|informed|drug
DDI-DrugBank.d412.s8|58-67|receiving|drug
DDI-DrugBank.d412.s9|56-69|nitroglycerin|drug
DDI-DrugBank.d412.s9|78-88|preventing|drug
DDI-DrugBank.d412.s10|30-43|nitroglycerin|drug
DDI-DrugBank.d412.s10|61-67|angina|drug
DDI-DrugBank.d412.s10|89-105|antihypertensive|group
DDI-DrugBank.d412.s11|61-68|calcium|drug
DDI-DrugBank.d412.s12|36-42|taking|drug
DDI-DrugBank.d412.s13|56-67|epinephrine|drug
DDI-DrugBank.d412.s14|79-84|urine|drug
DDI-DrugBank.d412.s14|126-133|urinary|drug
DDI-DrugBank.d412.s14|134-149|catecholamines,|drug
DDI-DrugBank.d412.s14|150-163|metanephrine,|drug
DDI-DrugBank.d412.s14|164-179|normetanephrine|drug
DDI-DrugBank.d412.s14|211-219|measured|group
DDI-DrugBank.d412.s15|3-12|screening|drug
DDI-DrugBank.d412.s15|35-41|having|drug
DDI-DrugBank.d412.s15|65-70|being|drug
DDI-DrugBank.d412.s15|222-235|385:241,1987)|drug_n
DDI-DrugBank.d412.s15|258-269|determining|drug
DDI-DrugBank.d412.s15|280-295|catecholamines.|drug
DDI-DrugBank.d412.s16|74-85|amphetamine|drug
DDI-DrugBank.d412.s16|91-100|screening|drug
DDI-DrugBank.d412.s16|101-106|urine|drug
DDI-DrugBank.d412.s16|133-138|using|drug
DDI-DrugBank.d412.s16|192-203|(thin-layer|drug
DDI-DrugBank.d412.s17|14-19|being|drug
DDI-DrugBank.d412.s17|59-64|urine|drug
DDI-DrugBank.d412.s17|74-85|amphetamine|drug
DDI-DrugBank.d412.s17|86-91|using|drug
DDI-DrugBank.d412.s17|140-145|using|drug
DDI-MedLine.d128.s0|12-39|16,16-dimethylprostaglandin|drug_n
DDI-MedLine.d128.s0|40-50|E2-induced|drug
DDI-MedLine.d128.s1|4-31|16,16-dimethylprostaglandin|drug_n
DDI-MedLine.d128.s1|35-51|(dmPGE2)-induced|drug
DDI-MedLine.d128.s1|107-116|resecting|drug
DDI-MedLine.d128.s1|135-146|vasculature|group
DDI-MedLine.d128.s1|155-165|disturbing|drug
DDI-MedLine.d128.s3|17-26|increased|drug
DDI-MedLine.d128.s3|65-72|induced|drug
DDI-MedLine.d128.s4|18-35|diarrhea-inducing|drug
DDI-MedLine.d128.s4|99-106|control|group
DDI-MedLine.d128.s5|36-43|induced|drug
DDI-MedLine.d128.s5|79-86|control|group
DDI-MedLine.d128.s5|144-157|short-lasting|drug
DDI-MedLine.d128.s5|178-193|administration.|drug
DDI-MedLine.d128.s7|5-12|induced|drug
DDI-MedLine.d128.s8|51-58|control|group
DDI-MedLine.d128.s8|79-89|intestinal|drug
DDI-MedLine.d128.s8|124-137|p.o.)-induced|drug
DDI-MedLine.d128.s9|24-38|dmPGE2-induced|drug
DDI-MedLine.d128.s9|104-111|control|group
DDI-MedLine.d128.s10|76-91|intraluminally,|drug
DDI-MedLine.d128.s10|117-124|control|group
DDI-MedLine.d128.s10|151-168|transit-enhancing|drug
DDI-MedLine.d128.s10|235-242|control|group
DDI-MedLine.d128.s10|282-297|administration.|drug
DDI-MedLine.d128.s11|24-32|contents|group
DDI-MedLine.d128.s11|83-90|control|group
DDI-MedLine.d128.s12|0-10|Loperamide|drug
DDI-MedLine.d128.s12|15-23|morphine|drug
DDI-MedLine.d128.s13|0-10|Loperamide|drug
DDI-MedLine.d128.s13|15-23|morphine|drug
DDI-MedLine.d128.s13|50-59|inhibited|drug
DDI-MedLine.d128.s13|83-96|p.o.)-induced|drug
DDI-MedLine.d128.s15|64-74|inhibitory|drug
DDI-MedLine.d128.s15|85-95|loperamide|drug
DDI-MedLine.d128.s15|133-142|morphine.|drug
DDI-MedLine.d128.s16|32-46|administration|drug
DDI-MedLine.d128.s16|57-64|induces|drug
DDI-MedLine.d128.s16|126-133|control|group
DDI-MedLine.d128.s17|46-56|evaluating|drug
DDI-MedLine.d128.s17|61-74|antidiarrheal|group
DDI-DrugBank.d443.s0|19-26|Aspirin|brand
DDI-DrugBank.d443.s0|67-82|sulfinpyrazone,|drug
DDI-DrugBank.d443.s1|39-46|aspirin|brand
DDI-DrugBank.d443.s1|50-57|causing|drug
DDI-DrugBank.d443.s1|58-74|gastrointestinal|drug
DDI-DrugBank.d443.s1|75-84|bleeding.|drug
DDI-DrugBank.d443.s2|0-16|Corticosteroids:|group
DDI-DrugBank.d443.s2|29-43|administration|drug
DDI-DrugBank.d443.s2|49-56|aspirin|brand
DDI-DrugBank.d443.s2|61-69|increase|drug
DDI-DrugBank.d443.s2|82-98|gastrointestinal|drug
DDI-DrugBank.d443.s3|93-107|administration|drug
DDI-DrugBank.d443.s3|113-120|aspirin|brand
DDI-DrugBank.d443.s3|125-133|increase|drug
DDI-DrugBank.d443.s3|146-162|gastrointestinal|drug
DDI-DrugBank.d443.s4|13-29|Antiinflammatory|drug
DDI-DrugBank.d443.s4|38-45|Aspirin|brand
DDI-DrugBank.d443.s4|49-64|contraindicated|group
DDI-DrugBank.d443.s4|116-133|anti-inflammatory|group
DDI-DrugBank.d443.s5|0-7|Urinary|drug
DDI-DrugBank.d443.s5|8-21|Alkalinizers:|drug
DDI-DrugBank.d443.s5|31-38|aspirin|brand
DDI-DrugBank.d443.s5|56-66|increasing|drug
DDI-DrugBank.d443.s6|25-32|aspirin|brand
DDI-DrugBank.d443.s6|57-67|induction.|drug
DDI-DrugBank.d443.s7|0-10|Phenytoin:|drug
DDI-DrugBank.d443.s7|17-26|phenytoin|drug
DDI-DrugBank.d443.s7|41-50|increased|drug
DDI-DrugBank.d443.s7|54-62|aspirin.|brand
DDI-DrugBank.d443.s8|0-12|Propranolol:|drug
DDI-DrugBank.d443.s8|26-34|aspirins|brand
DDI-DrugBank.d443.s8|35-52|anti-inflammatory|group
DDI-DrugBank.d443.s8|63-72|competing|drug
DDI-DrugBank.d443.s9|0-9|Antacids:|group
DDI-DrugBank.d443.s9|25-32|Aspirin|brand
DDI-DrugBank.d443.s9|71-80|antacids,|group
DDI-DrugBank.d443.s9|81-86|since|drug
DDI-DrugBank.d443.s9|90-98|increase|drug
DDI-DrugBank.d443.s9|147-154|coating|drug
DDI-DrugBank.d18.s0|13-29|benzodiazepines,|drug
DDI-DrugBank.d18.s0|30-39|including|drug
DDI-DrugBank.d18.s0|87-99|administered|drug
DDI-DrugBank.d18.s1|21-31|injection,|drug
DDI-DrugBank.d18.s1|43-53|injectable|drug
DDI-DrugBank.d18.s1|54-70|benzodiazepines,|drug
DDI-DrugBank.d18.s1|126-138|administered|drug
DDI-DrugBank.d18.s1|159-174|phenothiazines,|drug
DDI-DrugBank.d18.s1|193-204|inhibitors,|drug
DDI-DrugBank.d18.s1|215-235|antidepressants.When|group
DDI-DrugBank.d18.s1|236-247|scopolamine|drug
DDI-DrugBank.d18.s1|275-285|injectable|drug
DDI-DrugBank.d18.s1|300-309|increased|drug
DDI-DrugBank.d18.s1|310-319|incidence|drug
DDI-DrugBank.d18.s1|333-348|hallucinations,|drug
DDI-DrugBank.d435.s0|54-70|coadministration|drug
DDI-DrugBank.d435.s0|74-87|ketoconazole,|drug
DDI-DrugBank.d435.s0|97-106|inhibitor|drug
DDI-DrugBank.d435.s0|159-176|pharmacokinetics.|drug
DDI-DrugBank.d435.s1|12-27|pharmacokinetic|drug
DDI-DrugBank.d435.s1|28-40|interactions|drug
DDI-DrugBank.d435.s1|53-63|inhibition|drug
DDI-DrugBank.d435.s2|20-26|induce|drug
DDI-DrugBank.d435.s2|42-53|rifampicin,|drug
DDI-DrugBank.d435.s2|54-64|phenytoin,|drug
DDI-DrugBank.d435.s2|65-79|carbamazepine,|drug
DDI-DrugBank.d435.s2|142-150|exposure|group
DDI-DrugBank.d435.s3|59-68|receiving|drug
DDI-DrugBank.d435.s3|86-94|inducer.|drug
DDI-DrugBank.d435.s4|38-48|clinically|drug
DDI-DrugBank.d435.s4|84-92|clinical|drug
DDI-DrugBank.d482.s0|17-25|medicine|drug
DDI-DrugBank.d482.s0|31-44|thioridizine,|drug
DDI-DrugBank.d482.s0|48-54|within|drug
DDI-DrugBank.d482.s0|66-72|taking|drug
DDI-DrugBank.d482.s0|73-84|fluoxetine.|drug
DDI-DrugBank.d482.s1|31-37|taking|drug
DDI-DrugBank.d482.s1|38-45|certain|drug
DDI-DrugBank.d482.s1|46-57|antibiotics|group
DDI-DrugBank.d482.s1|66-79|erythromycin,|drug
DDI-DrugBank.d482.s1|80-94|clarithromycin|drug
DDI-DrugBank.d482.s1|98-111|azithromycin.|drug
DDI-DrugBank.d482.s2|5-13|medicine|drug
DDI-DrugBank.d482.s2|43-54|inhibitors.|drug
DDI-DrugBank.d482.s3|33-39|taking|drug
DDI-DrugBank.d482.s3|45-53|medicine|drug
DDI-DrugBank.d482.s3|54-61|certain|drug
DDI-DrugBank.d482.s3|62-74|antibiotics,|group
DDI-DrugBank.d482.s3|83-96|erythromycin,|drug
DDI-DrugBank.d482.s3|97-112|clarithromycin,|drug
DDI-DrugBank.d482.s3|116-129|azithromycin.|drug
DDI-DrugBank.d482.s4|5-13|medicine|drug
DDI-DrugBank.d482.s4|43-54|inhibitors.|drug
DDI-DrugBank.d482.s5|7-12|think|drug
DDI-DrugBank.d482.s5|21-27|taking|drug
DDI-DrugBank.d482.s5|35-44|inhibitor|drug
DDI-DrugBank.d482.s6|17-25|medicine|drug
DDI-DrugBank.d482.s6|81-90|sertonin.|drug
DDI-DrugBank.d482.s7|45-56|inhibitors.|drug
DDI-DrugBank.d482.s8|44-55|information|drug
DDI-DrugBank.d482.s8|63-74|inhibitors.|drug
DDI-DrugBank.d482.s9|19-27|stopping|drug
DDI-DrugBank.d482.s9|48-56|starting|drug
DDI-DrugBank.d482.s9|77-87|inhibitor.|drug
DDI-DrugBank.d482.s10|19-27|stopping|drug
DDI-DrugBank.d482.s10|35-44|inhibitor|drug
DDI-DrugBank.d482.s10|52-60|starting|drug
DDI-DrugBank.d482.s11|11-17|taking|drug
DDI-DrugBank.d482.s11|34-43|migraines|drug
DDI-DrugBank.d482.s11|88-96|starting|drug
DDI-DrugBank.d482.s11|102-111|medicine.|drug
DDI-DrugBank.d482.s12|11-17|taking|drug
DDI-DrugBank.d482.s12|30-45|antidepressant,|group
DDI-DrugBank.d482.s12|73-79|taking|drug
DDI-DrugBank.d482.s12|85-94|medicine.|drug
DDI-DrugBank.d482.s13|41-47|taking|drug
DDI-DrugBank.d482.s13|53-61|medicine|drug
DDI-DrugBank.d482.s13|93-103|serotonin.|drug
DDI-DrugBank.d482.s14|28-34|taking|drug
DDI-DrugBank.d482.s14|46-55|following|drug
DDI-DrugBank.d482.s14|69-77|thinners|drug
DDI-DrugBank.d482.s14|78-88|(Coumadin)|drug
DDI-DrugBank.d482.s14|95-110|antidepressants|group
DDI-DrugBank.d482.s14|122-136|antihistamines|group
DDI-DrugBank.d482.s14|137-150|carbamazepine|drug
DDI-DrugBank.d482.s14|162-172|cimetidine|drug
DDI-DrugBank.d482.s14|193-203|fluoxetine|drug
DDI-DrugBank.d482.s14|213-226|intraconazole|drug
DDI-DrugBank.d482.s14|227-237|(Sporanox)|drug
DDI-DrugBank.d482.s14|238-250|ketoconazole|drug
DDI-DrugBank.d482.s14|270-277|lithium|drug
DDI-DrugBank.d482.s14|301-308|control|group
DDI-DrugBank.d482.s14|315-323|sleeping|drug
DDI-DrugBank.d320.s0|0-10|Chirocaine|drug
DDI-DrugBank.d320.s0|53-62|receiving|drug
DDI-DrugBank.d320.s0|150-155|since|drug
DDI-DrugBank.d320.s1|17-25|indicate|drug
DDI-DrugBank.d320.s1|26-32|CYP3A4|brand
DDI-DrugBank.d320.s1|45-51|CYP1A2|brand
DDI-DrugBank.d320.s1|86-101|levobupivacaine|drug
DDI-DrugBank.d320.s1|114-129|levobupivacaine|drug
DDI-DrugBank.d320.s1|134-143|3-hydroxy|drug_n
DDI-DrugBank.d320.s1|144-160|levobupivacaine,|drug
DDI-DrugBank.d320.s2|39-51|administered|drug
DDI-DrugBank.d320.s2|57-67|Chirocaine|drug
DDI-DrugBank.d320.s2|130-138|interact|drug
DDI-DrugBank.d320.s2|144-155|Chirocaine.|drug
DDI-DrugBank.d320.s3|12-20|clinical|drug
DDI-DrugBank.d320.s3|86-101|levobupivacaine|drug
DDI-DrugBank.d320.s3|131-137|CYP3A4|brand
DDI-DrugBank.d320.s3|138-146|inducers|drug
DDI-DrugBank.d320.s3|156-166|phenytoin,|drug
DDI-DrugBank.d320.s3|182-192|rifampin),|drug
DDI-DrugBank.d320.s3|193-199|CYP3A4|brand
DDI-DrugBank.d320.s3|200-210|inhibitors|drug
DDI-DrugBank.d320.s3|211-217|(azole|drug
DDI-DrugBank.d320.s3|218-230|antimycotics|group
DDI-DrugBank.d320.s3|237-250|ketoconazole;|drug
DDI-DrugBank.d320.s4|0-7|certain|drug
DDI-DrugBank.d320.s4|17-27|inhibitors|drug
DDI-DrugBank.d320.s4|34-44|ritanovir;|drug
DDI-DrugBank.d320.s5|0-9|macrolide|drug
DDI-DrugBank.d320.s5|10-21|antibiotics|group
DDI-DrugBank.d320.s5|28-41|erythromycin;|drug
DDI-DrugBank.d320.s6|4-11|calcium|drug
DDI-DrugBank.d320.s6|50-56|CYP1A2|brand
DDI-DrugBank.d320.s6|57-65|inducers|drug
DDI-DrugBank.d320.s6|66-78|(omeprazole)|drug
DDI-DrugBank.d320.s6|83-89|CYP1A2|brand
DDI-DrugBank.d320.s6|90-100|inhibitors|drug
DDI-DrugBank.d320.s6|101-113|(furafylline|drug
DDI-DrugBank.d320.s6|118-134|clarithromycin).|drug
DDI-DrugBank.d320.s7|40-55|levobupivacaine|drug
DDI-DrugBank.d320.s7|72-84|administered|drug
DDI-DrugBank.d320.s7|90-96|CYP3A4|brand
DDI-DrugBank.d320.s7|97-107|inhibitors|drug
DDI-DrugBank.d320.s7|112-118|CYP1A2|brand
DDI-DrugBank.d320.s7|119-129|inhibitors|drug
DDI-DrugBank.d320.s7|142-157|levobupivacaine|drug
DDI-DrugBank.d320.s7|174-183|resulting|drug
DDI-DrugBank.d2.s0|0-7|PROSTIN|brand
DDI-DrugBank.d394.s0|26-32|sodium|drug
DDI-DrugBank.d394.s0|33-46|nitroprusside|drug
DDI-DrugBank.d394.s0|101-110|including|drug
DDI-DrugBank.d394.s0|122-130|blocking|drug
DDI-DrugBank.d394.s0|148-157|inotropic|drug
DDI-DrugBank.d394.s0|170-177|inhaled|drug
DDI-DrugBank.d208.s0|0-12|Benzthiazide|group
DDI-DrugBank.d208.s0|17-25|interact|drug
DDI-DrugBank.d208.s0|46-55|thinners,|drug
DDI-DrugBank.d208.s0|95-100|sinus|drug
DDI-DrugBank.d208.s0|101-112|medicines),|drug
DDI-DrugBank.d208.s0|129-137|lithium,|drug
DDI-DrugBank.d208.s0|138-153|norepinephrine,|drug
DDI-DrugBank.d208.s0|201-209|pressure|group
DDI-DrugBank.d26.s0|9-18|receiving|drug
DDI-DrugBank.d26.s0|67-82|phenothiazines,|drug
DDI-DrugBank.d26.s0|128-143|antidepressants|group
DDI-DrugBank.d26.s0|169-179|(including|drug
DDI-DrugBank.d26.s0|208-216|DILAUDID|brand
DDI-DrugBank.d26.s1|10-18|combined|drug
DDI-DrugBank.d26.s1|30-43|contemplated,|group
DDI-DrugBank.d387.s0|15-27|interactions|drug
DDI-DrugBank.d387.s0|32-42|doxylamine|drug
DDI-DrugBank.d387.s0|43-51|include,|drug
DDI-DrugBank.d387.s0|52-61|increased|drug
DDI-DrugBank.d387.s0|74-84|doxylamine|drug
DDI-DrugBank.d387.s0|88-96|combined|drug
DDI-DrugBank.d387.s1|0-14|Antihistamines|drug
DDI-DrugBank.d387.s1|44-59|anticoagulation|group
DDI-DrugBank.d387.s1|71-78|heparin|drug
DDI-DrugBank.d387.s1|82-91|warfarin.|drug
DDI-DrugBank.d387.s2|0-10|Doxylamine|drug
DDI-DrugBank.d387.s2|38-50|epinephrine.|drug
DDI-DrugBank.d383.s0|3-14|information|drug
DDI-DrugBank.d128.s0|4-12|interact|drug
DDI-DrugBank.d128.s0|18-29|wthionamide|drug
DDI-DrugBank.d423.s0|12-21|receiving|drug
DDI-DrugBank.d423.s0|35-44|monoamine|drug
DDI-DrugBank.d423.s0|53-63|inhibitors|drug
DDI-DrugBank.d423.s0|79-89|selegiline|drug
DDI-DrugBank.d423.s0|90-104|hydrochloride)|drug
DDI-DrugBank.d423.s0|108-119|combination|drug
DDI-DrugBank.d423.s0|125-139|serotoninergic|drug
DDI-DrugBank.d423.s0|154-165|fluoxetine,|drug
DDI-DrugBank.d423.s0|166-178|fluvoxamine,|drug
DDI-DrugBank.d423.s0|179-190|paroxetine,|drug
DDI-DrugBank.d423.s0|191-202|sertraline,|drug
DDI-DrugBank.d423.s0|203-216|venlafaxine),|drug
DDI-DrugBank.d423.s1|8-23|dexfenfluramine|drug
DDI-DrugBank.d423.s1|29-38|serotonin|drug
DDI-DrugBank.d423.s1|61-71|inhibitor,|drug
DDI-DrugBank.d423.s1|72-87|dexfenfluramine|drug
DDI-DrugBank.d423.s1|132-142|inhibitor.|drug
DDI-DrugBank.d423.s2|39-54|discontinuation|group
DDI-DrugBank.d423.s2|64-73|inhibitor|drug
DDI-DrugBank.d423.s2|78-88|initiation|drug
DDI-DrugBank.d423.s2|107-123|dexfenfluramine.|drug
DDI-DrugBank.d423.s3|39-54|discontinuation|group
DDI-DrugBank.d423.s3|58-73|dexfenfluramine|drug
DDI-DrugBank.d423.s3|78-88|initiation|drug
DDI-DrugBank.d423.s3|113-123|inhibitor.|drug
DDI-DrugBank.d423.s4|55-64|serotonin|drug
DDI-DrugBank.d423.s4|131-140|serotonin|drug
DDI-DrugBank.d423.s4|150-160|inhibitors|drug
DDI-DrugBank.d423.s4|184-192|migraine|drug
DDI-DrugBank.d423.s4|231-241|succinate)|drug
DDI-DrugBank.d423.s4|246-264|dihydroergotamine.|drug
DDI-DrugBank.d423.s5|58-65|include|drug
DDI-DrugBank.d423.s5|85-94|following|drug
DDI-DrugBank.d423.s5|297-312|incoordination,|drug
DDI-DrugBank.d423.s5|327-337|shivering,|drug
DDI-DrugBank.d423.s6|0-15|Dexfenfluramine|drug
DDI-DrugBank.d423.s6|30-42|administered|drug
DDI-DrugBank.d423.s6|54-68|serotoninergic|drug
DDI-DrugBank.d423.s7|16-24|interval|drug
DDI-DrugBank.d423.s7|33-47|administration|drug
DDI-DrugBank.d423.s7|68-83|dexfenfluramine|drug
DDI-DrugBank.d423.s8|11-26|dexfenfluramine|drug
DDI-DrugBank.d423.s9|36-51|dexfenfluramine|drug
DDI-DrugBank.d518.s0|94-103|ketamine.|drug
DDI-DrugBank.d518.s1|0-8|Ketamine|drug
DDI-DrugBank.d518.s1|12-22|clinically|drug
DDI-DrugBank.d518.s1|134-145|maintained.|drug
DDI-MedLine.d1.s1|0-5|Since|drug
DDI-MedLine.d1.s1|26-45|erection-supporting|drug
DDI-MedLine.d1.s1|149-155|during|drug
DDI-MedLine.d1.s1|163-182|erection-supporting|drug
DDI-MedLine.d1.s2|7-18|intercourse|drug
DDI-MedLine.d1.s2|113-121|ironing,|drug
DDI-MedLine.d1.s2|138-145|walking|drug
DDI-MedLine.d1.s2|154-163|climbing,|drug
DDI-MedLine.d1.s2|164-177|paperhanging,|drug
DDI-MedLine.d1.s2|178-185|playing|drug
DDI-MedLine.d1.s2|194-204|gardening.|drug
DDI-MedLine.d1.s3|32-42|infarction|drug
DDI-MedLine.d1.s3|43-49|during|drug
DDI-MedLine.d1.s4|4-13|incidence|drug
DDI-MedLine.d1.s5|14-29|contraindicated|group
DDI-MedLine.d1.s5|42-47|using|drug
DDI-MedLine.d1.s5|48-59|long-acting|drug
DDI-MedLine.d1.s5|92-104|short-acting|drug
DDI-MedLine.d1.s5|127-138|combination|drug
DDI-MedLine.d1.s5|175-184|pressure.|group
DDI-MedLine.d1.s6|3-15|interactions|drug
DDI-MedLine.d1.s6|64-71|calcium|drug
DDI-MedLine.d1.s6|85-93|thiazide|group
DDI-MedLine.d1.s6|103-112|diuretics|group
DDI-MedLine.d1.s6|121-132|inhibitors.|drug
DDI-MedLine.d1.s7|7-18|prescribing|drug
DDI-MedLine.d1.s8|92-100|pressure|group
DDI-MedLine.d1.s8|186-193|(giving|drug
DDI-MedLine.d1.s8|197-205|smoking,|drug
DDI-MedLine.d1.s8|206-214|adapting|drug
DDI-MedLine.d1.s9|63-70|refrain|drug
DDI-DrugBank.d21.s0|7-14|culture|group
DDI-DrugBank.d21.s0|34-42|indicate|drug
DDI-DrugBank.d21.s0|48-54|ELSPAR|brand
DDI-DrugBank.d21.s0|59-67|diminish|drug
DDI-DrugBank.d21.s0|192-202|asparagine|drug
DDI-DrugBank.d21.s1|36-43|against|drug_n
DDI-DrugBank.d21.s1|48-56|clinical|drug
DDI-DrugBank.d21.s1|82-89|ELSPAR,|brand
DDI-DrugBank.d21.s1|93-99|during|drug
DDI-DrugBank.d21.s1|111-120|following|drug
DDI-DrugBank.d21.s1|121-127|ELSPAR|brand
DDI-DrugBank.d21.s1|148-158|asparagine|drug
DDI-DrugBank.d492.s0|4-14|inhibitors|drug
DDI-DrugBank.d492.s0|27-36|intensify|drug
DDI-DrugBank.d492.s0|41-56|anticholinergic|group
DDI-DrugBank.d492.s0|68-83|antihistamines.|group
DDI-DrugBank.d492.s1|0-14|Antihistamines|drug
DDI-DrugBank.d492.s1|124-135|antianxiety|group
DDI-DrugBank.d228.s0|49-62|dehydrogenase|drug
DDI-DrugBank.d228.s0|63-74|inhibition,|drug
DDI-DrugBank.d228.s0|109-120|elimination|drug
DDI-DrugBank.d228.s0|124-131|ethanol|drug
DDI-DrugBank.d228.s1|11-18|ethanol|drug
DDI-DrugBank.d228.s1|41-52|elimination|drug
DDI-DrugBank.d228.s2|11-23|interactions|drug
DDI-DrugBank.d228.s2|81-89|increase|drug
DDI-DrugBank.d228.s2|93-100|inhibit|drug
DDI-DrugBank.d228.s2|135-145|phenytoin,|drug
DDI-DrugBank.d228.s2|146-160|carbamazepine,|drug
DDI-DrugBank.d228.s2|161-172|cimetidine,|drug
DDI-DrugBank.d228.s2|173-187|ketoconazole),|drug
DDI-DrugBank.d462.s0|0-16|Aminoglycosides:|drug
DDI-DrugBank.d462.s0|21-27|mixing|drug
DDI-DrugBank.d462.s0|31-43|piperacillin|drug
DDI-DrugBank.d462.s0|52-66|aminoglycoside|drug
DDI-DrugBank.d462.s0|102-114|inactivation|drug
DDI-DrugBank.d462.s0|122-137|aminoglycoside.|drug
DDI-DrugBank.d462.s1|0-11|Vecuronium:|drug
DDI-DrugBank.d462.s1|51-63|piperacillin|drug
DDI-DrugBank.d462.s1|137-148|vecuronium.|drug
DDI-DrugBank.d462.s2|11-20|indicated|drug
DDI-DrugBank.d462.s2|26-38|piperacillin|drug
DDI-DrugBank.d462.s3|7-17|controlled|group
DDI-DrugBank.d462.s3|18-26|clinical|drug
DDI-DrugBank.d462.s3|38-56|ureidopenicillins,|group
DDI-DrugBank.d462.s3|57-66|including|drug
DDI-DrugBank.d462.s3|67-80|piperacillin,|drug
DDI-DrugBank.d462.s3|120-131|vecuronium.|drug
DDI-DrugBank.d462.s4|112-128|non-depolarizing|drug
DDI-DrugBank.d462.s4|184-197|piperacillin.|drug
DDI-DrugBank.d462.s5|21-32|combination|drug
DDI-DrugBank.d462.s5|54-67|intramuscular|drug
DDI-DrugBank.d462.s5|68-77|injection|drug
DDI-DrugBank.d462.s5|81-89|PIPRACIL|brand
DDI-DrugBank.d462.s5|102-110|increase|drug
DDI-DrugBank.d462.s5|114-126|piperacillin|drug
DDI-DrugBank.d462.s6|96-102|during|drug
DDI-DrugBank.d462.s6|116-130|administration|drug
DDI-DrugBank.d462.s6|148-156|heparin,|drug
DDI-DrugBank.d462.s6|162-177|anticoagulants,|group
DDI-DrugBank.d462.s7|14-26|Piperacillin|drug
DDI-DrugBank.d462.s7|27-33|sodium|drug
DDI-DrugBank.d462.s9|48-60|penicillins,|drug
DDI-DrugBank.d462.s9|65-79|administration|drug
DDI-DrugBank.d462.s9|83-91|PIPRACIL|brand
DDI-DrugBank.d462.s9|151-156|urine|drug
DDI-DrugBank.d462.s9|157-162|using|drug
DDI-DrugBank.d462.s11|49-54|using|drug
DDI-DrugBank.d462.s11|122-131|receiving|drug
DDI-DrugBank.d462.s11|132-155|piperacillin/tazobactam|drug
DDI-DrugBank.d462.s11|156-165|injection|drug
DDI-DrugBank.d462.s11|220-230|infection.|drug
DDI-DrugBank.d462.s12|57-70|polyfuranoses|drug
DDI-DrugBank.d462.s13|45-54|receiving|drug
DDI-DrugBank.d462.s13|55-67|piperacillin|drug
DDI-DrugBank.d462.s13|78-89|interpreted|drug
DDI-MedLine.d58.s0|10-22|ginsenosides|drug
DDI-MedLine.d58.s0|71-77|bovine|drug
DDI-MedLine.d58.s0|78-88|chromaffin|drug
DDI-MedLine.d58.s1|39-51|ginsenosides|drug
DDI-MedLine.d58.s1|52-59|inhibit|drug
DDI-MedLine.d58.s2|44-64|ginsenosides-induced|drug
DDI-MedLine.d58.s2|65-75|inhibition|drug
DDI-MedLine.d58.s2|95-108|discriminates|drug
DDI-MedLine.d58.s3|17-29|investigated|drug
DDI-MedLine.d58.s3|44-56|ginsenosides|drug
DDI-MedLine.d58.s3|117-122|using|drug
DDI-MedLine.d58.s3|163-173|nimodipine|drug
DDI-MedLine.d58.s3|184-199|omega-conotoxin|drug
DDI-MedLine.d58.s3|218-232|omega-agatoxin|drug
DDI-MedLine.d58.s3|249-255|bovine|drug
DDI-MedLine.d58.s3|256-266|chromaffin|drug
DDI-MedLine.d58.s4|22-34|ginsenosides|drug
DDI-MedLine.d58.s4|35-44|inhibited|drug
DDI-MedLine.d58.s5|4-10|IC(50)|brand
DDI-MedLine.d58.s6|0-10|Nimodipine|drug
DDI-MedLine.d58.s6|28-40|ginsenosides|drug
DDI-MedLine.d58.s7|24-36|ginsenosides|drug
DDI-MedLine.d58.s7|78-85|calcium|drug
DDI-MedLine.d58.s7|98-104|bovine|drug
DDI-MedLine.d58.s7|105-115|chromaffin|drug
DDI-MedLine.d58.s7|122-131|including|drug
DDI-MedLine.d58.s7|135-150|omega-conotoxin|drug
DDI-MedLine.d58.s7|187-201|omega-agatoxin|drug
DDI-MedLine.d58.s7|202-215|IVA-sensitive|brand
DDI-MedLine.d58.s7|237-263|nimodipine/omega-conotoxin|drug
DDI-MedLine.d58.s7|264-283|GVIA/omega-agatoxin|drug
DDI-MedLine.d58.s8|71-83|ginsenosides|drug
DDI-MedLine.d58.s8|87-93|bovine|drug
DDI-MedLine.d58.s8|94-104|chromaffin|drug
DDI-MedLine.d58.s8|141-151|antistress|group
DDI-MedLine.d58.s8|160-167|induced|drug
DDI-MedLine.d58.s8|171-179|ginseng.|drug
DDI-DrugBank.d367.s0|21-30|doxazosin|drug
DDI-DrugBank.d367.s0|34-41|protein|drug
DDI-DrugBank.d367.s1|30-38|indicate|drug
DDI-DrugBank.d367.s1|44-53|doxazosin|drug
DDI-DrugBank.d367.s1|80-87|protein|drug
DDI-DrugBank.d367.s1|88-95|binding|drug
DDI-DrugBank.d367.s1|99-107|digoxin,|drug
DDI-DrugBank.d367.s1|108-117|warfarin,|drug
DDI-DrugBank.d367.s1|118-127|phenytoin|drug
DDI-DrugBank.d367.s1|131-144|indomethacin.|drug
DDI-DrugBank.d367.s2|12-23|information|drug
DDI-DrugBank.d367.s2|61-68|protein|drug
DDI-DrugBank.d367.s2|84-93|doxazosin|drug
DDI-DrugBank.d367.s2|94-102|binding.|drug
DDI-DrugBank.d367.s3|0-9|Doxazosin|drug
DDI-DrugBank.d367.s3|28-40|administered|drug
DDI-DrugBank.d367.s3|81-92|interaction|drug
DDI-DrugBank.d367.s3|105-114|receiving|drug
DDI-DrugBank.d367.s3|115-123|thiazide|group
DDI-DrugBank.d367.s3|124-134|diuretics,|group
DDI-DrugBank.d367.s3|135-148|beta-blocking|drug
DDI-DrugBank.d367.s3|174-191|anti-inflammatory|group
DDI-DrugBank.d367.s4|5-23|placebo-controlled|group
DDI-DrugBank.d367.s4|56-70|administration|drug
DDI-DrugBank.d367.s4|76-82|single|drug
DDI-DrugBank.d367.s4|96-105|doxazosin|drug
DDI-DrugBank.d367.s4|145-155|cimetidine|drug
DDI-DrugBank.d367.s4|195-203|increase|drug
DDI-DrugBank.d367.s4|219-228|doxazosin|drug
DDI-DrugBank.d367.s4|287-295|increase|drug
DDI-DrugBank.d367.s4|331-341|doxazosin.|drug
DDI-DrugBank.d367.s5|4-12|clinical|drug
DDI-DrugBank.d367.s5|34-42|increase|drug
DDI-DrugBank.d367.s5|46-55|doxazosin|drug
DDI-DrugBank.d367.s6|3-11|clinical|drug
DDI-DrugBank.d367.s6|20-29|doxazosin|drug
DDI-DrugBank.d367.s6|57-69|administered|drug
DDI-DrugBank.d367.s7|16-27|interaction|drug
DDI-DrugBank.d367.s7|60-72|interactions|drug
DDI-DrugBank.d367.s8|0-9|Doxazosin|drug
DDI-DrugBank.d367.s8|51-60|following|drug
DDI-DrugBank.d367.s9|0-27|Analgesic/anti-inflammatory|drug
DDI-DrugBank.d367.s9|35-49|acetaminophen,|drug
DDI-DrugBank.d367.s9|50-58|aspirin,|brand
DDI-DrugBank.d367.s9|59-66|codeine|drug
DDI-DrugBank.d367.s9|71-78|codeine|drug
DDI-DrugBank.d367.s9|79-92|combinations,|drug
DDI-DrugBank.d367.s9|104-118|indomethacin).|drug
DDI-DrugBank.d367.s11|19-32|erythromycin,|drug
DDI-DrugBank.d367.s11|50-67|sulfamethoxazole,|drug
DDI-DrugBank.d367.s11|68-81|amoxicillin).|drug
DDI-DrugBank.d367.s13|0-14|Antihistamines|drug
DDI-DrugBank.d367.s13|22-40|chlorpheniramine).|drug
DDI-DrugBank.d367.s15|39-59|hydrochlorothiazide,|group
DDI-DrugBank.d367.s15|60-73|propranolol).|drug
DDI-DrugBank.d367.s17|0-16|Corticosteroids.|group
DDI-DrugBank.d367.s19|0-16|Gastrointestinal|drug
DDI-DrugBank.d367.s19|31-41|antacids).|group
DDI-DrugBank.d367.s21|18-27|endocrine|drug
DDI-DrugBank.d342.s0|14-22|interact|drug
DDI-DrugBank.d342.s0|135-151|antihistamines),|group
DDI-DrugBank.d342.s0|152-168|anticholinergics|group
DDI-DrugBank.d342.s0|195-210|anticholinergic|group
DDI-DrugBank.d342.s0|220-236|(anticholinergic|drug
DDI-DrugBank.d342.s0|314-330|antihistamines),|group
DDI-DrugBank.d342.s0|335-344|monoamine|drug
DDI-DrugBank.d342.s0|353-358|(MAO)|brand
DDI-DrugBank.d342.s0|359-369|inhibitors|drug
DDI-DrugBank.d342.s0|391-405|antihistamines|group
DDI-DrugBank.d342.s0|422-431|intensify|drug
DDI-DrugBank.d342.s0|436-451|anticholinergic|group
DDI-DrugBank.d342.s0|482-498|antihistamines).|group
DDI-DrugBank.d145.s0|17-31|anticonvulsant|group
DDI-DrugBank.d145.s0|65-71|during|drug
DDI-DrugBank.d145.s0|72-81|cisplatin|drug
DDI-DrugBank.d284.s0|41-53|administered|drug
DDI-DrugBank.d284.s0|166-173|BROVANA|brand
DDI-DrugBank.d284.s1|5-16|paroxetine,|drug
DDI-DrugBank.d284.s1|26-35|inhibitor|drug
DDI-DrugBank.d284.s1|39-46|CYP2D6,|brand
DDI-DrugBank.d284.s1|51-66|co-administered|drug
DDI-DrugBank.d284.s1|72-79|BROVANA|brand
DDI-DrugBank.d284.s1|97-105|exposure|group
DDI-DrugBank.d284.s2|22-29|BROVANA|brand
DDI-DrugBank.d284.s2|97-103|CYP2D6|brand
DDI-DrugBank.d284.s2|104-115|inhibitors.|drug
DDI-DrugBank.d284.s3|27-42|methylxanthines|drug
DDI-DrugBank.d284.s3|43-58|(aminophylline,|drug
DDI-DrugBank.d284.s3|59-73|theophylline),|drug
DDI-DrugBank.d284.s3|74-83|steroids,|group
DDI-DrugBank.d284.s3|87-96|diuretics|group
DDI-DrugBank.d284.s4|60-74|administration|drug
DDI-DrugBank.d284.s4|78-91|non-potassium|drug
DDI-DrugBank.d284.s4|92-99|sparing|drug
DDI-DrugBank.d284.s4|100-109|diuretics|group
DDI-DrugBank.d284.s4|127-135|thiazide|group
DDI-DrugBank.d284.s4|136-146|diuretics)|group
DDI-DrugBank.d284.s5|13-21|clinical|drug
DDI-DrugBank.d284.s5|92-109|co-administration|drug
DDI-DrugBank.d284.s5|132-145|non-potassium|drug
DDI-DrugBank.d284.s5|146-153|sparing|drug
DDI-DrugBank.d284.s5|154-164|diuretics.|group
DDI-DrugBank.d284.s6|0-8|BROVANA,|brand
DDI-DrugBank.d284.s6|49-61|administered|drug
DDI-DrugBank.d284.s6|95-100|being|drug
DDI-DrugBank.d284.s6|114-123|monoamine|drug
DDI-DrugBank.d284.s6|132-143|inhibitors,|drug
DDI-DrugBank.d284.s6|154-170|antidepressants,|group
DDI-DrugBank.d284.s6|205-213|interval|drug
DDI-DrugBank.d284.s7|40-48|interval|drug
DDI-DrugBank.d284.s7|57-66|increased|drug
DDI-DrugBank.d284.s8|22-35|intravenously|drug
DDI-DrugBank.d284.s8|46-58|administered|drug
DDI-DrugBank.d284.s8|59-74|methylxanthines|drug
DDI-DrugBank.d284.s8|82-96|aminophylline,|drug
DDI-DrugBank.d284.s8|97-110|theophylline)|drug
DDI-DrugBank.d284.s8|123-132|receiving|drug
DDI-DrugBank.d284.s8|133-140|BROVANA|brand
DDI-DrugBank.d284.s9|7-15|combined|drug
DDI-DrugBank.d284.s9|16-23|12-week|drug_n
DDI-DrugBank.d284.s9|32-42|controlled|group
DDI-DrugBank.d284.s9|55-63|included|drug
DDI-DrugBank.d284.s9|64-71|BROVANA|brand
DDI-DrugBank.d284.s9|154-161|BROVANA|brand
DDI-DrugBank.d284.s9|201-213|theophylline|drug
DDI-DrugBank.d284.s10|5-13|12-month|drug_n
DDI-DrugBank.d284.s10|14-24|controlled|group
DDI-DrugBank.d284.s10|36-44|included|drug
DDI-DrugBank.d284.s10|65-72|BROVANA|brand
DDI-DrugBank.d284.s10|93-100|BROVANA|brand
DDI-DrugBank.d284.s10|140-152|theophylline|drug
DDI-DrugBank.d284.s11|47-55|pressure|group
DDI-DrugBank.d284.s11|146-158|theophylline|drug
DDI-DrugBank.d284.s12|57-64|BROVANA|brand
DDI-DrugBank.d284.s12|69-78|interfere|drug
DDI-DrugBank.d284.s12|114-126|administered|drug
DDI-DrugBank.d284.s15|15-22|certain|drug
DDI-DrugBank.d284.s15|76-87|infarction,|drug
DDI-DrugBank.d284.s15|173-178|COPD.|brand
DDI-DrugBank.d284.s16|8-16|setting,|drug
DDI-DrugBank.d284.s16|92-104|administered|drug
DDI-MedLine.d132.s0|4-12|emerging|drug
DDI-MedLine.d132.s0|13-18|roles|drug
DDI-MedLine.d132.s0|22-36|non-nucleoside|drug
DDI-MedLine.d132.s0|59-69|inhibitors|drug
DDI-MedLine.d132.s0|73-87|antiretroviral|group
DDI-MedLine.d132.s1|27-41|non-nucleoside|drug
DDI-MedLine.d132.s1|64-73|inhibitor|drug
DDI-MedLine.d132.s1|101-115|antiretroviral|group
DDI-MedLine.d132.s1|137-146|regarding|drug
DDI-MedLine.d132.s1|156-165|inhibitor|drug
DDI-MedLine.d132.s1|263-273|infection.|drug
DDI-MedLine.d132.s2|75-82|initial|drug
DDI-MedLine.d132.s2|105-114|including|drug
DDI-MedLine.d132.s2|131-145|administration|drug
DDI-MedLine.d132.s2|188-201|interactions,|drug
DDI-MedLine.d132.s3|25-33|clinical|drug
DDI-MedLine.d132.s3|57-66|comparing|drug
DDI-MedLine.d132.s3|101-111|nevirapine|drug
DDI-MedLine.d132.s3|115-128|delavirdine).|drug
DDI-MedLine.d132.s4|19-29|nevirapine|drug
DDI-MedLine.d132.s4|79-88|indinavir|drug
DDI-MedLine.d132.s4|106-113|initial|drug
DDI-MedLine.d132.s4|146-151|being|drug
DDI-MedLine.d132.s4|166-176|nevirapine|drug
DDI-MedLine.d132.s5|10-17|24-week|drug_n
DDI-MedLine.d132.s5|38-48|nevirapine|drug
DDI-MedLine.d132.s5|75-86|nelfinavir.|drug
DDI-MedLine.d132.s6|72-83|nevirapine-|drug
DDI-MedLine.d132.s6|87-104|delavirdine-based|drug
DDI-MedLine.d132.s7|52-60|clinical|drug
DDI-MedLine.d132.s8|34-49|indinavir-based|drug
DDI-MedLine.d132.s9|45-57|uncontrolled|group
DDI-MedLine.d132.s9|84-94|contribute|group
DDI-MedLine.d132.s10|44-54|nelfinavir|drug
DDI-MedLine.d132.s10|100-109|combining|drug
DDI-MedLine.d132.s11|4-16|tolerability|drug
DDI-MedLine.d132.s11|59-70|individuals|drug
DDI-MedLine.d132.s11|71-84|discontinuing|group
DDI-MedLine.d132.s11|88-96|clinical|drug
DDI-MedLine.d132.s12|49-55|within|drug
DDI-MedLine.d132.s12|124-137|interruption.|drug
DDI-DrugBank.d294.s0|33-45|Dactinomycin|drug
DDI-DrugBank.d294.s0|50-59|interfere|drug
DDI-DrugBank.d294.s0|74-84|procedures|group
DDI-DrugBank.d294.s0|93-106|determination|drug
DDI-DrugBank.d294.s0|110-123|antibacterial|group
DDI-DrugBank.d488.s0|28-37|Enhancing|drug
DDI-DrugBank.d488.s0|38-45|Heparin|drug
DDI-DrugBank.d488.s0|59-74|anticoagulants:|group
DDI-DrugBank.d488.s0|75-82|Heparin|drug
DDI-DrugBank.d488.s0|83-89|sodium|drug
DDI-DrugBank.d488.s0|116-127|prothrombin|drug
DDI-DrugBank.d488.s1|16-23|heparin|drug
DDI-DrugBank.d488.s1|24-30|sodium|drug
DDI-DrugBank.d488.s1|58-66|warfarin|drug
DDI-DrugBank.d488.s1|67-74|sodium,|drug
DDI-DrugBank.d488.s1|119-130|intravenous|drug
DDI-DrugBank.d488.s1|228-239|prothrombin|drug
DDI-DrugBank.d488.s1|254-263|obtained.|drug
DDI-DrugBank.d488.s2|9-20|inhibitors:|drug
DDI-DrugBank.d488.s2|93-106|indomethacin,|drug
DDI-DrugBank.d488.s2|107-120|dipyridamole,|drug
DDI-DrugBank.d488.s2|121-139|hydroxychloroquine|drug
DDI-DrugBank.d488.s2|156-165|interfere|drug
DDI-DrugBank.d488.s2|234-245|heparinized|drug
DDI-DrugBank.d488.s2|260-266|induce|drug
DDI-DrugBank.d488.s2|267-275|bleeding|drug
DDI-DrugBank.d488.s2|320-329|receiving|drug
DDI-DrugBank.d488.s2|330-337|heparin|drug
DDI-DrugBank.d488.s2|338-345|sodium.|drug
DDI-DrugBank.d488.s3|4-17|anticoagulant|group
DDI-DrugBank.d488.s3|28-35|heparin|drug
DDI-DrugBank.d488.s3|77-89|antithrombin|group
DDI-DrugBank.d488.s3|130-142|antithrombin|group
DDI-DrugBank.d488.s4|23-32|bleeding,|drug
DDI-DrugBank.d488.s4|51-58|heparin|drug
DDI-DrugBank.d488.s4|74-80|during|drug
DDI-DrugBank.d488.s4|96-108|antithrombin|group
DDI-DrugBank.d488.s6|6-16|Decreasing|drug
DDI-DrugBank.d488.s6|17-24|Heparin|drug
DDI-DrugBank.d488.s6|44-58|tetracyclines,|drug
DDI-DrugBank.d488.s6|59-68|nicotine,|drug
DDI-DrugBank.d488.s6|72-86|antihistamines|group
DDI-DrugBank.d488.s6|116-129|anticoagulant|group
DDI-DrugBank.d488.s6|140-147|heparin|drug
DDI-DrugBank.d488.s6|148-155|sodium.|drug
DDI-DrugBank.d488.s7|0-7|Heparin|drug
DDI-DrugBank.d488.s7|8-14|Sodium|drug
DDI-DrugBank.d488.s7|50-62|doxorubicin,|drug
DDI-DrugBank.d488.s7|75-89|ciprofloxacin,|drug
DDI-DrugBank.d488.s7|107-112|since|drug
DDI-DrugBank.d488.s7|155-167|incompatible|drug
DDI-DrugBank.d488.s7|173-180|heparin|drug
DDI-DrugBank.d488.s8|36-61|Hyperaminotransferasemia:|drug
DDI-DrugBank.d488.s8|88-104|aminotransferase|drug
DDI-DrugBank.d488.s8|105-110|(SGOT|brand
DDI-DrugBank.d488.s8|111-118|[S-AST]|brand
DDI-DrugBank.d488.s8|128-136|[S-ALT])|brand
DDI-DrugBank.d488.s8|232-239|heparin|drug
DDI-DrugBank.d488.s8|240-247|sodium.|drug
DDI-DrugBank.d488.s9|0-5|Since|drug
DDI-DrugBank.d488.s9|6-22|aminotransferase|drug
DDI-DrugBank.d488.s9|23-37|determinations|drug
DDI-DrugBank.d488.s9|96-107|infarction,|drug
DDI-DrugBank.d488.s9|180-188|(heparin|drug
DDI-DrugBank.d488.s9|189-196|sodium)|drug
DDI-DrugBank.d488.s9|207-218|interpreted|drug
DDI-MedLine.d91.s0|50-57|cocaine|drug
DDI-MedLine.d91.s1|30-37|cocaine|drug
DDI-MedLine.d91.s1|103-110|defined|drug
DDI-MedLine.d91.s1|135-145|abstinence|drug
DDI-MedLine.d91.s2|27-34|defined|drug
DDI-MedLine.d91.s2|58-65|control|group
DDI-MedLine.d91.s2|70-79|continued|group
DDI-MedLine.d91.s2|118-125|cocaine|drug
DDI-MedLine.d91.s3|16-23|cocaine|drug
DDI-MedLine.d91.s3|43-51|involves|drug
DDI-MedLine.d91.s4|20-26|within|drug
DDI-MedLine.d91.s4|35-42|leaving|drug
DDI-MedLine.d91.s5|3-10|contend|group
DDI-MedLine.d91.s7|5-12|cocaine|drug
DDI-MedLine.d91.s7|113-123|recovering|drug
DDI-MedLine.d91.s7|124-131|cocaine|drug
DDI-MedLine.d91.s8|3-14|incorporate|drug
DDI-MedLine.d91.s8|19-29|principles|drug
DDI-MedLine.d91.s8|46-52|define|drug
DDI-MedLine.d91.s8|95-102|dealing|drug
DDI-MedLine.d91.s8|108-115|cocaine|drug
DDI-MedLine.d91.s9|41-48|involve|drug
DDI-MedLine.d91.s9|49-59|individual|drug
DDI-MedLine.d91.s9|101-107|nature|group
DDI-MedLine.d91.s10|73-81|reducing|drug
DDI-MedLine.d91.s10|106-112|during|drug
DDI-MedLine.d2.s0|0-7|Failure|group
DDI-MedLine.d2.s0|11-19|neomycin|drug
DDI-MedLine.d2.s0|35-42|induced|drug
DDI-MedLine.d2.s1|32-40|neomycin|drug
DDI-MedLine.d2.s1|41-55|administration|drug
DDI-MedLine.d2.s1|67-74|certain|drug
DDI-MedLine.d2.s1|131-140|including|drug
DDI-MedLine.d2.s2|20-28|neomycin|drug
DDI-MedLine.d2.s2|37-44|induced|drug
DDI-MedLine.d2.s2|63-71|examined|drug
DDI-MedLine.d2.s3|0-8|Neomycin|drug
DDI-MedLine.d2.s3|36-44|pressure|group
DDI-DrugBank.d203.s0|8-20|interactions|drug
DDI-DrugBank.d203.s1|13-23|famotidine|drug
DDI-DrugBank.d203.s1|89-101|interference|drug
DDI-DrugBank.d203.s2|24-31|include|drug
DDI-DrugBank.d203.s2|32-41|warfarin,|drug
DDI-DrugBank.d203.s2|42-55|theophylline,|drug
DDI-DrugBank.d203.s2|56-66|phenytoin,|drug
DDI-DrugBank.d203.s2|77-88|aminopyrine|drug
DDI-DrugBank.d203.s2|93-104|antipyrine.|group
DDI-DrugBank.d203.s3|0-11|Indocyanine|drug
DDI-DrugBank.d203.s3|24-29|index|drug
DDI-DrugBank.d255.s0|29-41|interactions|drug
DDI-DrugBank.d571.s0|15-26|interaction|drug
DDI-DrugBank.d571.s0|60-68|VELCADE.|brand
DDI-DrugBank.d571.s1|45-53|indicate|drug
DDI-DrugBank.d571.s1|120-125|2C19,|brand
DDI-DrugBank.d571.s2|31-40|receiving|drug
DDI-DrugBank.d571.s2|41-48|VELCADE|brand
DDI-DrugBank.d571.s2|68-78|inhibitors|drug
DDI-DrugBank.d571.s2|82-90|inducers|drug
DDI-DrugBank.d571.s3|0-6|During|drug
DDI-DrugBank.d571.s3|7-15|clinical|drug
DDI-DrugBank.d571.s3|90-99|receiving|drug
DDI-DrugBank.d571.s4|17-29|antidiabetic|group
DDI-DrugBank.d571.s4|37-46|receiving|drug
DDI-DrugBank.d571.s4|47-54|VELCADE|brand
DDI-DrugBank.d571.s4|83-93|monitoring|drug
DDI-DrugBank.d571.s4|160-172|antidiabetic|group
DDI-DrugBank.d252.s0|9-16|BETAGAN|brand
DDI-DrugBank.d252.s0|77-86|resulting|drug
DDI-DrugBank.d252.s0|117-124|BETAGAN|brand
DDI-DrugBank.d252.s0|129-140|epinephrine|drug
DDI-DrugBank.d252.s1|71-83|administered|drug
DDI-DrugBank.d252.s1|96-105|receiving|drug
DDI-DrugBank.d252.s1|106-129|catecholamine-depleting|drug
DDI-DrugBank.d252.s1|144-154|reserpine,|drug
DDI-DrugBank.d252.s2|9-18|receiving|drug
DDI-DrugBank.d252.s2|35-43|blocking|drug
DDI-DrugBank.d252.s2|77-88|intravenous|drug
DDI-DrugBank.d252.s2|89-96|calcium|drug
DDI-DrugBank.d252.s2|201-208|failure|group
DDI-DrugBank.d252.s4|39-47|blocking|drug
DDI-DrugBank.d252.s4|74-81|calcium|drug
DDI-DrugBank.d252.s4|123-133|prolonging|drug
DDI-DrugBank.d252.s5|0-21|Phenothiazine-related|drug
DDI-DrugBank.d252.s5|52-60|blocking|drug
DDI-DrugBank.d252.s5|117-127|inhibition|drug
DDI-MedLine.d0.s0|27-36|phenytoin|drug
DDI-MedLine.d0.s0|37-51|administration|drug
DDI-MedLine.d0.s0|72-88|pharmacokinetics|drug
DDI-MedLine.d0.s0|92-103|quetiapine.|drug
DDI-MedLine.d0.s1|0-10|Quetiapine|drug
DDI-MedLine.d0.s1|44-54|introduced|drug
DDI-MedLine.d0.s1|64-77|antipsychotic|group
DDI-MedLine.d0.s2|31-44|predominantly|drug
DDI-MedLine.d0.s3|22-36|administration|drug
DDI-MedLine.d0.s3|51-57|induce|drug
DDI-MedLine.d0.s3|61-68|inhibit|drug
DDI-MedLine.d0.s3|92-102|quetiapine|drug
DDI-MedLine.d0.s3|103-120|pharmacokinetics.|drug
DDI-MedLine.d0.s4|56-70|enzyme-inducer|drug
DDI-MedLine.d0.s4|71-80|phenytoin|drug
DDI-MedLine.d0.s4|85-91|indeed|drug
DDI-MedLine.d0.s4|134-145|quetiapine,|drug
DDI-MedLine.d0.s4|146-155|resulting|drug
DDI-MedLine.d0.s4|161-167|5-fold|drug_n
DDI-MedLine.d0.s4|168-176|increase|drug
DDI-MedLine.d0.s4|195-207|administered|drug
DDI-MedLine.d0.s5|14-22|indicate|drug
DDI-MedLine.d0.s5|49-59|quetiapine|drug
DDI-MedLine.d0.s5|157-170|administering|drug
DDI-MedLine.d0.s5|188-195|inhibit|drug
DDI-MedLine.d0.s5|199-205|induce|drug
DDI-DrugBank.d16.s0|41-52|hydroxyurea|group
DDI-DrugBank.d16.s0|56-64|interact|drug
DDI-DrugBank.d16.s1|18-29|hydroxyurea|group
DDI-DrugBank.d16.s1|89-97|increase|drug
DDI-DrugBank.d16.s2|0-5|Since|drug
DDI-DrugBank.d16.s2|6-17|hydroxyurea|group
DDI-MedLine.d109.s0|27-43|pharmacokinetics|drug
DDI-MedLine.d109.s0|47-54|digoxin|drug
DDI-MedLine.d109.s1|12-20|examined|drug
DDI-MedLine.d109.s1|39-55|cyclooxygenase-2|drug
DDI-MedLine.d109.s1|56-63|(COX-2)|brand
DDI-MedLine.d109.s1|64-74|inhibitor,|drug
DDI-MedLine.d109.s1|109-125|pharmacokinetics|drug
DDI-MedLine.d109.s1|129-136|digoxin|drug
DDI-MedLine.d109.s1|137-146|following|drug
DDI-MedLine.d109.s1|149-155|single|drug
DDI-MedLine.d109.s2|96-109|double-blind,|drug
DDI-MedLine.d109.s3|2-8|single|drug
DDI-MedLine.d109.s3|29-36|digoxin|drug
DDI-MedLine.d109.s3|48-60|administered|drug
DDI-MedLine.d109.s3|84-90|11-day|drug_n
DDI-MedLine.d109.s5|23-28|urine|drug
DDI-MedLine.d109.s5|44-51|digoxin|drug
DDI-MedLine.d109.s5|100-109|following|drug
DDI-MedLine.d109.s5|114-121|digoxin|drug
DDI-MedLine.d109.s6|106-113|digoxin|drug
DDI-MedLine.d109.s6|114-129|pharmacokinetic|drug
DDI-MedLine.d109.s7|4-11|digoxin|drug
DDI-MedLine.d109.s7|12-28|AUC(0-infinity),|drug
DDI-MedLine.d109.s7|29-39|AUC(0-24),|brand
DDI-MedLine.d109.s7|92-101|interval)|drug
DDI-MedLine.d109.s7|119-134|digoxin/placebo|drug
DDI-MedLine.d109.s7|137-145|digoxin)|drug
DDI-MedLine.d109.s7|163-169|1.14),|drug_n
DDI-MedLine.d109.s7|182-188|1.09),|drug_n
DDI-MedLine.d109.s7|205-211|1.10),|drug_n
DDI-MedLine.d109.s8|4-11|digoxin|drug
DDI-MedLine.d109.s9|18-29|elimination|drug
DDI-MedLine.d109.s9|80-87|digoxin|drug
DDI-MedLine.d109.s9|102-109|digoxin|drug
DDI-MedLine.d109.s10|0-7|Digoxin|drug
DDI-MedLine.d109.s10|11-21|eliminated|drug
DDI-MedLine.d109.s11|25-32|urinary|drug
DDI-MedLine.d109.s11|61-68|digoxin|drug
DDI-MedLine.d109.s11|126-131|228.2|drug_n
DDI-MedLine.d109.s11|137-142|30.8)|drug_n
DDI-MedLine.d109.s11|147-152|235.1|drug_n
DDI-MedLine.d109.s11|158-163|39.1)|drug_n
DDI-MedLine.d109.s12|14-19|minor|drug
DDI-MedLine.d109.s13|18-27|influence|drug
DDI-MedLine.d109.s13|39-55|pharmacokinetics|drug
DDI-MedLine.d109.s13|65-76|elimination|drug
DDI-MedLine.d109.s13|82-88|single|drug
DDI-MedLine.d109.s13|102-110|digoxin.|drug
DDI-DrugBank.d90.s0|8-19|interaction|drug
DDI-DrugBank.d449.s0|0-17|Co-administration|drug
DDI-DrugBank.d449.s0|23-33|antifungal|group
DDI-DrugBank.d449.s0|49-61|ketoconazole|drug
DDI-DrugBank.d449.s0|65-77|itraconazole|drug
DDI-DrugBank.d449.s1|12-24|fluvoxamine,|drug
DDI-DrugBank.d449.s1|25-35|cimetidine|drug
DDI-DrugBank.d449.s2|0-11|Fluoxetine,|drug
DDI-DrugBank.d449.s2|17-28|sertraline,|drug
DDI-DrugBank.d449.s2|40-49|macrolide|drug
DDI-DrugBank.d449.s2|50-61|antibiotics|group
DDI-DrugBank.d444.s0|11-18|FLUDARA|brand
DDI-DrugBank.d444.s0|23-32|INJECTION|brand
DDI-DrugBank.d444.s0|36-47|combination|drug
DDI-DrugBank.d444.s0|53-64|pentostatin|drug
DDI-DrugBank.d224.s0|0-13|Apraclonidine|drug
DDI-DrugBank.d224.s0|45-54|receiving|drug
DDI-DrugBank.d224.s0|59-71|inhibitors..|drug
DDI-DrugBank.d224.s1|26-38|interactions|drug
DDI-DrugBank.d224.s1|110-118|clinical|drug
DDI-DrugBank.d224.s1|130-138|IOPIDINE|brand
DDI-DrugBank.d224.s1|199-211|potentiating|drug
DDI-DrugBank.d224.s2|10-25|antidepressants|group
DDI-DrugBank.d224.s2|89-99|clonidine.|drug
DDI-DrugBank.d224.s3|64-77|apraclonidine|drug
DDI-DrugBank.d224.s3|109-117|lowering|drug
DDI-DrugBank.d224.s4|24-35|circulating|drug
DDI-DrugBank.d224.s4|36-50|catecholamines|drug
DDI-DrugBank.d224.s4|57-70|apraclonidine|drug
DDI-DrugBank.d224.s5|41-47|taking|drug
DDI-DrugBank.d224.s5|58-73|antidepressants|group
DDI-DrugBank.d224.s5|120-131|circulating|drug
DDI-DrugBank.d224.s5|132-139|amines.|drug
DDI-DrugBank.d224.s6|58-69|combination|drug
DDI-DrugBank.d224.s6|82-91|clonidine|drug
DDI-DrugBank.d224.s6|96-107|neuroleptic|drug
DDI-DrugBank.d224.s7|9-18|clonidine|drug
DDI-DrugBank.d224.s7|23-30|inhibit|drug
DDI-DrugBank.d224.s7|49-63|catecholamines|drug
DDI-DrugBank.d224.s7|79-94|insulin-induced|drug
DDI-DrugBank.d224.s8|0-5|Since|drug
DDI-DrugBank.d224.s8|6-19|apraclonidine|drug
DDI-DrugBank.d224.s8|47-56|pressure,|group
DDI-DrugBank.d224.s8|68-73|using|drug
DDI-DrugBank.d224.s8|129-147|antihypertensives,|group
DDI-DrugBank.d224.s9|9-14|using|drug
DDI-DrugBank.d224.s9|54-62|IOPIDINE|brand
DDI-DrugBank.d224.s9|116-125|pressures|group
DDI-DrugBank.d224.s10|53-62|clonidine|drug
DDI-DrugBank.d318.s0|5-17|administered|drug
DDI-DrugBank.d318.s0|36-45|following|drug
DDI-DrugBank.d318.s0|56-64|interact|drug
DDI-DrugBank.d318.s0|70-82|amphotericin|drug
DDI-DrugBank.d318.s0|86-100|Antineoplastic|drug
DDI-DrugBank.d318.s1|0-14|Antineoplastic|drug
DDI-DrugBank.d318.s2|0-15|Corticosteroids|group
DDI-DrugBank.d318.s2|20-33|Corticotropin|drug
DDI-DrugBank.d318.s2|34-41|(ACTH):|brand
DDI-DrugBank.d318.s2|57-69|amphotericin|drug
DDI-DrugBank.d318.s2|73-80|induced|drug
DDI-DrugBank.d318.s3|42-49|control|group
DDI-DrugBank.d318.s3|66-78|amphotericin|drug
DDI-DrugBank.d318.s5|22-34|amphotericin|drug
DDI-DrugBank.d318.s5|35-44|B-induced|drug
DDI-DrugBank.d318.s6|6-15|potassium|drug
DDI-DrugBank.d318.s7|0-12|Flucytosine:|drug
DDI-DrugBank.d318.s7|51-63|amphotericin|drug
DDI-DrugBank.d318.s7|105-113|increase|drug
DDI-DrugBank.d318.s7|130-141|flucytosine|drug
DDI-DrugBank.d318.s7|154-164|increasing|drug
DDI-DrugBank.d318.s7|192-201|impairing|drug
DDI-DrugBank.d318.s8|0-10|Imidazoles|drug
DDI-DrugBank.d318.s8|19-32|ketoconazole,|drug
DDI-DrugBank.d318.s8|33-44|miconazole,|drug
DDI-DrugBank.d318.s8|45-58|clotrimazole,|drug
DDI-DrugBank.d318.s8|59-71|fluconazole,|drug
DDI-DrugBank.d318.s8|116-127|combination|drug
DDI-DrugBank.d318.s8|131-143|amphotericin|drug
DDI-DrugBank.d318.s8|150-160|imidazoles|drug
DDI-DrugBank.d318.s8|174-184|imidazoles|drug
DDI-DrugBank.d318.s8|189-195|induce|drug
DDI-DrugBank.d318.s8|217-229|amphotericin|drug
DDI-DrugBank.d318.s9|0-11|Combination|drug
DDI-DrugBank.d318.s9|30-42|administered|drug
DDI-DrugBank.d318.s10|46-62|aminoglycosides,|drug
DDI-DrugBank.d318.s10|63-76|cyclosporine,|drug
DDI-DrugBank.d318.s10|81-92|pentamidine|drug
DDI-DrugBank.d318.s10|123-135|drug-induced|drug
DDI-DrugBank.d318.s11|10-20|monitoring|drug
DDI-DrugBank.d318.s11|66-75|requiring|drug
DDI-DrugBank.d318.s11|80-91|combination|drug
DDI-DrugBank.d318.s12|27-39|amphotericin|drug
DDI-DrugBank.d318.s12|40-49|B-induced|drug
DDI-DrugBank.d318.s12|132-146|tubocurarine).|drug
DDI-DrugBank.d318.s13|6-15|potassium|drug
DDI-DrugBank.d318.s14|79-88|receiving|drug
DDI-DrugBank.d318.s14|89-100|intravenous|drug
DDI-DrugBank.d318.s14|101-113|amphotericin|drug
DDI-DrugBank.d527.s0|65-72|insulin|drug
DDI-DrugBank.d527.s0|112-123|monitoring.|drug
DDI-DrugBank.d527.s1|4-13|following|drug
DDI-DrugBank.d527.s1|50-58|increase|drug
DDI-DrugBank.d527.s1|63-85|blood-glucose-lowering|drug
DDI-DrugBank.d527.s1|134-146|antidiabetes|group
DDI-DrugBank.d527.s1|161-172|inhibitors,|drug
DDI-DrugBank.d527.s1|197-208|fluoxetine,|drug
DDI-DrugBank.d527.s1|213-224|inhibitors,|drug
DDI-DrugBank.d527.s1|252-264|somatostatin|drug
DDI-DrugBank.d527.s1|292-303|sulfonamide|drug
DDI-DrugBank.d527.s1|304-316|antibiotics.|group
DDI-DrugBank.d527.s2|4-13|following|drug
DDI-DrugBank.d527.s2|61-83|blood-glucose-lowering|drug
DDI-DrugBank.d527.s2|94-102|insulin:|drug
DDI-DrugBank.d527.s2|103-119|corticosteroids,|group
DDI-DrugBank.d527.s2|129-139|diuretics,|group
DDI-DrugBank.d527.s2|170-182|epinephrine,|drug
DDI-DrugBank.d527.s2|194-207|terbutaline),|drug
DDI-DrugBank.d527.s2|219-232|phenothiazine|drug
DDI-DrugBank.d527.s2|246-257|somatropin,|drug
DDI-DrugBank.d527.s2|315-331|contraceptives).|group
DDI-DrugBank.d527.s3|15-25|clonidine,|drug
DDI-DrugBank.d527.s3|26-33|lithium|drug
DDI-DrugBank.d527.s3|89-111|blood-glucose-lowering|drug
DDI-DrugBank.d527.s3|122-130|insulin.|drug
DDI-DrugBank.d527.s4|0-11|Pentamidine|drug
DDI-DrugBank.d527.s5|23-32|influence|drug
DDI-DrugBank.d527.s5|50-59|medicinal|drug
DDI-DrugBank.d527.s5|92-102|clonidine,|drug
DDI-DrugBank.d527.s5|103-116|guanethidine,|drug
DDI-DrugBank.d527.s5|121-131|reserpine,|drug
DDI-DrugBank.d63.s0|0-9|Monoamine|drug
DDI-DrugBank.d63.s0|18-23|(MAO)|brand
DDI-DrugBank.d63.s0|24-34|inhibitors|drug
DDI-DrugBank.d63.s0|74-84|phenelzine|drug
DDI-DrugBank.d63.s0|101-113|procarbazine|drug
DDI-DrugBank.d63.s0|132-142|selegiline|drug
DDI-DrugBank.d63.s0|165-180|tranylcypromine|drug
DDI-DrugBank.d63.s0|198-203|Using|drug
DDI-DrugBank.d63.s0|210-219|medicines|drug
DDI-DrugBank.d63.s0|242-250|increase|drug
DDI-DrugBank.d213.s0|0-6|Iodine|drug
DDI-DrugBank.d213.s0|10-16|iodine|drug
DDI-DrugBank.d213.s0|51-63|Carbimazole,|drug
DDI-DrugBank.d213.s0|71-77|iodine|drug
DDI-DrugBank.d213.s0|93-101|increase|drug
DDI-DrugBank.d213.s0|116-128|Carbimazole.|drug
DDI-DrugBank.d213.s1|23-30|digoxin|drug
DDI-DrugBank.d213.s1|35-44|digitoxin|drug
DDI-DrugBank.d213.s1|49-57|increase|drug
DDI-DrugBank.d213.s1|77-88|antithyroid|group
DDI-DrugBank.d213.s3|52-58|sodium|drug
DDI-DrugBank.d213.s3|59-65|iodide|drug
DDI-DrugBank.d213.s3|66-71|I131,|brand
DDI-DrugBank.d213.s3|142-154|Carbimazole.|drug
DDI-DrugBank.d213.s4|26-40|anticoagulants|group
DDI-DrugBank.d213.s5|17-28|prothrombin|drug
DDI-DrugBank.d213.s5|55-68|anticoagulant|group
DDI-DrugBank.d552.s0|19-31|administered|drug
DDI-DrugBank.d552.s0|65-71|taking|drug
DDI-DrugBank.d552.s0|117-126|including|drug
DDI-DrugBank.d552.s0|225-235|(including|drug
DDI-DrugBank.d552.s1|113-120|sodium,|drug
DDI-DrugBank.d552.s1|132-140|codeine.|drug
DDI-DrugBank.d43.s0|0-16|Coadministration|drug
DDI-DrugBank.d43.s0|20-25|VIDEX|brand
DDI-DrugBank.d43.s0|78-86|increase|drug
DDI-DrugBank.d43.s0|118-127|WARNINGS)|brand
DDI-DrugBank.d43.s0|235-245|indicated.|drug
DDI-DrugBank.d43.s1|109-118|including|drug
DDI-DrugBank.d43.s1|119-129|stavudine,|drug
DDI-DrugBank.d43.s1|159-168|increased|drug
DDI-DrugBank.d43.s1|188-194|during|drug
DDI-DrugBank.d43.s1|195-200|VIDEX|brand
DDI-DrugBank.d43.s1|214-221|ADVERSE|brand
DDI-DrugBank.d43.s1|222-233|REACTIONS).|brand
DDI-DrugBank.d43.s2|0-12|Allopurinol:|drug
DDI-DrugBank.d43.s2|24-34|didanosine|drug
DDI-DrugBank.d43.s2|39-48|increased|drug
DDI-DrugBank.d43.s2|55-61|4-fold|drug_n
DDI-DrugBank.d43.s2|67-78|allopurinol|drug
DDI-DrugBank.d43.s2|97-111|coadministered|drug
DDI-DrugBank.d43.s2|119-125|single|drug
DDI-DrugBank.d43.s2|126-132|200-mg|drug_n
DDI-DrugBank.d43.s2|141-146|VIDEX|brand
DDI-DrugBank.d43.s2|201-209|mL/min).|drug
DDI-DrugBank.d43.s3|15-26|allopurinol|drug
DDI-DrugBank.d43.s3|30-40|didanosine|drug
DDI-DrugBank.d43.s3|41-57|pharmacokinetics|drug
DDI-DrugBank.d43.s4|0-9|Antacids:|group
DDI-DrugBank.d43.s4|22-36|administration|drug
DDI-DrugBank.d43.s4|40-48|antacids|group
DDI-DrugBank.d43.s4|49-59|containing|group
DDI-DrugBank.d43.s4|60-69|magnesium|drug
DDI-DrugBank.d43.s4|73-81|aluminum|drug
DDI-DrugBank.d43.s4|87-92|VIDEX|brand
DDI-DrugBank.d43.s5|93-105|ketoconazole|drug
DDI-DrugBank.d43.s5|110-122|itraconazole|drug
DDI-DrugBank.d43.s5|133-145|administered|drug
DDI-DrugBank.d43.s5|172-178|dosing|drug
DDI-DrugBank.d43.s5|184-190|VIDEX.|brand
DDI-DrugBank.d43.s6|13-27|Administration|drug
DDI-DrugBank.d43.s6|31-36|VIDEX|brand
DDI-DrugBank.d43.s6|123-131|increase|drug
DDI-DrugBank.d43.s6|159-169|didanosine|drug
DDI-DrugBank.d43.s7|77-82|VIDEX|brand
DDI-DrugBank.d43.s7|87-99|administered|drug
DDI-DrugBank.d43.s7|162-174|administered|drug
DDI-DrugBank.d43.s8|0-9|Quinolone|drug
DDI-DrugBank.d43.s8|23-28|VIDEX|brand
DDI-DrugBank.d43.s8|39-51|administered|drug
DDI-DrugBank.d43.s8|93-99|dosing|drug
DDI-DrugBank.d43.s8|105-118|ciprofloxacin|drug
DDI-DrugBank.d43.s8|152-165|ciprofloxacin|drug
DDI-DrugBank.d43.s8|185-197|administered|drug
DDI-DrugBank.d43.s8|203-211|antacids|group
DDI-DrugBank.d43.s8|212-222|containing|group
DDI-DrugBank.d43.s8|223-233|magnesium,|drug
DDI-DrugBank.d43.s8|234-242|calcium,|drug
DDI-DrugBank.d43.s8|246-255|aluminum.|drug
DDI-DrugBank.d43.s9|9-21|HIV-infected|drug
DDI-DrugBank.d43.s9|56-69|ciprofloxacin|drug
DDI-DrugBank.d43.s9|127-140|ciprofloxacin|drug
DDI-DrugBank.d43.s9|145-157|administered|drug
DDI-DrugBank.d43.s9|229-235|VIDEX.|brand
DDI-DrugBank.d43.s10|11-24|ciprofloxacin|drug
DDI-DrugBank.d43.s10|53-60|15-fold|drug_n
DDI-DrugBank.d43.s10|90-103|ciprofloxacin|drug
DDI-DrugBank.d43.s10|108-126|didanosine-placebo|drug
DDI-DrugBank.d43.s11|5-11|single|drug
DDI-DrugBank.d43.s11|38-51|ciprofloxacin|drug
DDI-DrugBank.d43.s11|76-94|didanosine-placebo|drug
DDI-DrugBank.d43.s11|147-160|ciprofloxacin|drug
DDI-DrugBank.d43.s12|25-34|quinolone|drug
DDI-DrugBank.d43.s12|35-46|antibiotics|group
DDI-DrugBank.d43.s12|66-78|administered|drug
DDI-DrugBank.d43.s12|84-92|antacids|group
DDI-DrugBank.d43.s12|93-103|containing|group
DDI-DrugBank.d43.s12|104-114|magnesium,|drug
DDI-DrugBank.d43.s12|115-123|calcium,|drug
DDI-DrugBank.d43.s12|127-136|aluminum.|drug
DDI-DrugBank.d43.s13|12-18|dosing|drug
DDI-DrugBank.d43.s13|19-27|interval|drug
DDI-DrugBank.d43.s13|32-48|coadministration|drug
DDI-DrugBank.d43.s13|54-59|VIDEX|brand
DDI-DrugBank.d43.s13|70-80|determined|drug
DDI-DrugBank.d43.s13|84-94|consulting|drug
DDI-DrugBank.d43.s13|111-120|quinolone|drug
DDI-DrugBank.d43.s13|129-136|insert.|drug
DDI-DrugBank.d43.s14|82-93|delavirdine|drug
DDI-DrugBank.d43.s14|104-113|indinavir|drug
DDI-DrugBank.d43.s14|129-138|following|drug
DDI-DrugBank.d43.s14|152-166|administration|drug
DDI-DrugBank.d43.s14|188-194|VIDEX.|brand
DDI-DrugBank.d43.s15|14-26|interaction,|drug
DDI-DrugBank.d43.s15|27-38|delavirdine|drug
DDI-DrugBank.d43.s15|42-51|indinavir|drug
DDI-DrugBank.d43.s15|84-90|dosing|drug
DDI-DrugBank.d43.s15|96-102|VIDEX.|brand
DDI-DrugBank.d43.s16|4-20|pharmacokinetics|drug
DDI-DrugBank.d43.s16|24-34|nelfinavir|drug
DDI-DrugBank.d43.s16|56-66|clinically|drug
DDI-DrugBank.d43.s16|97-109|administered|drug
DDI-DrugBank.d43.s16|141-147|VIDEX.|brand
DDI-DrugBank.d139.s0|42-53|antibiotics|group
DDI-DrugBank.d139.s0|95-102|vitamin|drug
DDI-DrugBank.d139.s0|105-117|contribution|group
DDI-DrugBank.d139.s0|137-147|intestinal|drug
DDI-DrugBank.d139.s1|0-29|Cephalosporins-Cephalosporins|drug
DDI-DrugBank.d139.s1|30-40|containing|group
DDI-DrugBank.d139.s1|46-52|chains|drug
DDI-DrugBank.d139.s1|56-77|N-methylthiotetrazole|drug
DDI-DrugBank.d139.s1|117-129|cefamandole,|drug
DDI-DrugBank.d139.s1|144-161|methylthiadiazole|drug
DDI-DrugBank.d139.s1|162-173|(cefazolin)|drug
DDI-DrugBank.d139.s1|184-191|vitamin|drug
DDI-DrugBank.d139.s1|209-229|hypoprothrombinemia.|drug
DDI-DrugBank.d139.s2|6-20|cephalosporins|drug
DDI-DrugBank.d139.s2|25-35|inhibitors|drug
DDI-DrugBank.d139.s2|47-54|vitamin|drug
DDI-DrugBank.d139.s2|57-64|epoxide|drug
DDI-DrugBank.d139.s3|0-26|Cholestyramine-Concomitant|drug
DDI-DrugBank.d139.s3|27-33|intake|drug
DDI-DrugBank.d139.s3|37-51|cholestyramine|drug
DDI-DrugBank.d139.s3|56-63|vitamin|drug
DDI-DrugBank.d139.s3|95-102|vitamin|drug
DDI-DrugBank.d139.s4|0-22|Colestipol-Concomitant|drug
DDI-DrugBank.d139.s4|23-29|intake|drug
DDI-DrugBank.d139.s4|33-43|colestipol|drug
DDI-DrugBank.d139.s4|48-55|vitamin|drug
DDI-DrugBank.d139.s4|87-94|vitamin|drug
DDI-DrugBank.d139.s5|0-7|Mineral|drug
DDI-DrugBank.d139.s5|24-30|intake|drug
DDI-DrugBank.d139.s5|34-41|mineral|drug
DDI-DrugBank.d139.s5|50-57|vitamin|drug
DDI-DrugBank.d139.s5|89-96|vitamin|drug
DDI-DrugBank.d139.s6|49-56|vitamin|drug
DDI-DrugBank.d139.s7|43-50|inhibit|drug
DDI-DrugBank.d139.s7|51-58|vitamin|drug
DDI-DrugBank.d139.s7|61-68|epoxide|drug
DDI-DrugBank.d139.s7|79-88|resulting|drug
DDI-DrugBank.d139.s7|92-99|vitamin|drug
DDI-DrugBank.d139.s8|0-16|Warfarin-Vitamin|drug
DDI-DrugBank.d139.s8|48-56|warfarin|drug
DDI-MedLine.d57.s0|21-37|antihistaminics.|group
DDI-MedLine.d57.s1|4-14|literature|group
DDI-MedLine.d57.s1|46-56|indicating|drug
DDI-MedLine.d57.s1|83-99|antihistaminics,|group
DDI-MedLine.d57.s1|104-110|indeed|drug
DDI-MedLine.d57.s2|42-50|includes|drug
DDI-MedLine.d57.s2|51-67|diphenhydramine,|drug
DDI-MedLine.d57.s2|68-80|hydroxyzine,|drug
DDI-MedLine.d57.s2|81-94|orphenadrine,|drug
DDI-MedLine.d57.s2|95-106|pyrilamine,|drug
DDI-MedLine.d57.s2|107-124|phenyltoloxamine,|drug
DDI-MedLine.d57.s2|125-138|promethazine,|drug
DDI-MedLine.d57.s2|139-152|methdilazine,|drug
DDI-MedLine.d57.s2|157-172|tripelennamine.|drug
DDI-MedLine.d57.s3|47-62|antihistaminics|group
DDI-MedLine.d57.s4|4-14|literature|group
DDI-MedLine.d57.s5|31-41|suggesting|drug
DDI-MedLine.d57.s5|47-60|histaminergic|drug
DDI-MedLine.d57.s5|65-79|serotoninergic|drug
DDI-MedLine.d57.s5|101-109|involved|drug
DDI-MedLine.d57.s5|134-148|antihistaminic|group
DDI-MedLine.d57.s6|28-42|norepinephrine|drug
DDI-MedLine.d57.s6|47-55|dopamine|drug
DDI-MedLine.d57.s6|75-90|antihistaminics|group
DDI-MedLine.d57.s8|10-23|understanding|drug
DDI-MedLine.d57.s8|55-66|elucidating|drug
DDI-MedLine.d57.s8|79-94|antihistaminics|group
DDI-MedLine.d28.s0|67-74|insulin|drug
DDI-MedLine.d28.s1|30-37|growing|drug
DDI-MedLine.d28.s2|34-43|intensive|drug
DDI-MedLine.d28.s2|44-51|control|group
DDI-MedLine.d28.s2|140-152|retinopathy,|drug
DDI-MedLine.d28.s4|5-14|increased|drug
DDI-MedLine.d28.s4|15-24|incidence|drug
DDI-MedLine.d28.s4|55-66|intricately|drug
DDI-MedLine.d28.s4|83-90|insulin|drug
DDI-MedLine.d28.s5|30-37|insulin|drug
DDI-MedLine.d28.s5|52-60|involved|drug
DDI-MedLine.d28.s6|60-67|insulin|drug
DDI-MedLine.d28.s7|4-22|thiazolidinediones|drug
DDI-MedLine.d28.s7|77-89|antidiabetic|group
DDI-MedLine.d28.s7|102-110|"insulin|drug
DDI-MedLine.d28.s8|46-53|insulin|drug
DDI-MedLine.d28.s9|31-38|insulin|drug
DDI-MedLine.d28.s9|64-71|control|group
DDI-MedLine.d28.s9|85-92|insulin|drug
DDI-MedLine.d28.s10|32-41|determine|drug
DDI-MedLine.d28.s10|54-73|insulin-sensitizing|drug
DDI-MedLine.d28.s10|121-130|premature|group
DDI-DrugBank.d103.s0|0-12|Short-Acting|drug
DDI-DrugBank.d103.s0|60-72|short-acting|drug
DDI-DrugBank.d103.s0|153-158|using|drug
DDI-DrugBank.d103.s1|9-19|increasing|drug
DDI-DrugBank.d103.s1|48-55|control|group
DDI-DrugBank.d103.s1|65-74|indicates|drug
DDI-DrugBank.d103.s1|99-106|control|group
DDI-DrugBank.d103.s2|12-26|administration|drug
DDI-DrugBank.d103.s2|101-109|FORADIL.|brand
DDI-DrugBank.d103.s3|0-9|Monoamine|drug
DDI-DrugBank.d103.s3|60-67|FORADIL|brand
DDI-DrugBank.d103.s3|78-90|administered|drug
DDI-DrugBank.d103.s3|124-129|being|drug
DDI-DrugBank.d103.s3|143-152|monoamine|drug
DDI-DrugBank.d103.s3|161-171|inhibitors|drug
DDI-DrugBank.d103.s3|185-200|antidepressants|group
DDI-DrugBank.d103.s4|0-16|Corticosteroids,|group
DDI-DrugBank.d103.s4|17-32|Methylxanthines|drug
DDI-DrugBank.d103.s4|37-47|Diuretics:|group
DDI-DrugBank.d103.s4|75-83|xanthine|drug
DDI-DrugBank.d103.s4|97-106|steroids,|group
DDI-DrugBank.d103.s4|110-119|diuretics|group
DDI-DrugBank.d103.s5|16-24|increase|drug
DDI-DrugBank.d103.s6|83-91|FORADIL.|brand
DDI-DrugBank.d103.s7|10-17|FORADIL|brand
DDI-DrugBank.d103.s7|74-84|(including|drug
DDI-DrugBank.d103.s7|113-123|compelling|drug
DDI-DrugBank.d103.s8|26-36|quinidine,|drug
DDI-DrugBank.d103.s8|51-64|procainamide,|drug
DDI-DrugBank.d103.s8|65-80|phenothiazines,|drug
DDI-DrugBank.d103.s8|81-96|antihistamines,|group
DDI-DrugBank.d103.s8|111-126|antidepressants|group
DDI-DrugBank.d103.s8|150-161|QT-interval|drug
DDI-DrugBank.d103.s8|182-191|increased|drug
DDI-DrugBank.d103.s9|0-11|INFORMATION|brand
DDI-DrugBank.d103.s9|18-26|PROVIDED|brand
DDI-DrugBank.d103.s9|34-41|PATIENT|brand
DDI-DrugBank.d103.s9|45-53|GUARDIAN|brand
DDI-DrugBank.d103.s10|52-59|FORADIL|brand
DDI-DrugBank.d103.s10|122-132|inhalation|drug
DDI-DrugBank.d103.s10|223-230|taking.|drug
DDI-DrugBank.d103.s11|39-48|following|drug
DDI-DrugBank.d103.s11|49-61|information:|drug
DDI-DrugBank.d103.s12|57-64|morning|drug
DDI-DrugBank.d103.s12|69-77|evening)|drug
DDI-DrugBank.d103.s14|0-7|FORADIL|brand
DDI-DrugBank.d103.s15|40-53|short-acting,|drug
DDI-DrugBank.d103.s15|54-61|inhaled|drug
DDI-DrugBank.d103.s15|118-125|provide|drug
DDI-DrugBank.d103.s15|163-171|instruct|drug
DDI-DrugBank.d103.s17|59-68|following|drug
DDI-DrugBank.d103.s17|120-129|worsening|drug
DDI-DrugBank.d103.s17|167-180|short-acting,|drug
DDI-DrugBank.d103.s17|181-188|inhaled|drug
DDI-DrugBank.d103.s18|14-25|inhalations|drug
DDI-DrugBank.d103.s18|40-53|short-acting,|drug
DDI-DrugBank.d103.s18|54-61|inhaled|drug
DDI-DrugBank.d103.s20|0-7|FORADIL|brand
DDI-DrugBank.d103.s20|55-62|inhaled|drug
DDI-DrugBank.d103.s20|63-79|corticosteroids.|group
DDI-DrugBank.d103.s21|93-103|consulting|drug
DDI-DrugBank.d103.s21|158-168|initiating|drug
DDI-DrugBank.d103.s21|184-192|FORADIL.|brand
DDI-DrugBank.d103.s22|32-41|regarding|drug
DDI-DrugBank.d103.s22|114-119|pain.|drug
DDI-DrugBank.d103.s24|12-21|receiving|drug
DDI-DrugBank.d103.s24|22-30|FORADIL,|brand
DDI-DrugBank.d103.s24|37-44|inhaled|drug
DDI-DrugBank.d103.s26|47-54|FORADIL|brand
DDI-DrugBank.d103.s26|96-105|regarding|drug
DDI-DrugBank.d103.s26|155-172|anti-inflammatory|group
DDI-DrugBank.d103.s26|196-208|short-acting|drug
DDI-MedLine.d141.s0|12-19|cadmium|drug
DDI-MedLine.d141.s1|16-24|cadmium,|drug
DDI-MedLine.d141.s1|34-46|cadmium/zinc|drug
DDI-MedLine.d141.s1|47-55|mixtures|group
DDI-MedLine.d141.s1|74-81|ranging|drug
DDI-MedLine.d141.s1|95-100|50000|drug_n
DDI-MedLine.d141.s1|115-127|investigated|drug
DDI-MedLine.d141.s1|128-135|against|drug_n
DDI-MedLine.d141.s1|186-194|obtained|drug
DDI-MedLine.d141.s2|42-47|25000|drug_n
DDI-MedLine.d141.s4|0-8|Mixtures|group
DDI-MedLine.d141.s4|12-19|cadmium|drug
DDI-MedLine.d141.s4|68-74|single|drug
DDI-MedLine.d141.s4|102-107|50000|drug_n
DDI-MedLine.d141.s5|76-88|cadmium/zinc|drug
DDI-MedLine.d141.s5|89-97|mixtures|group
DDI-MedLine.d141.s5|105-115|encysting.|drug
DDI-MedLine.d141.s6|14-23|exposures|group
DDI-DrugBank.d288.s0|19-24|using|drug
DDI-DrugBank.d288.s0|25-35|escalating|drug
DDI-DrugBank.d288.s0|45-50|TAXOL|brand
DDI-DrugBank.d288.s0|71-80|cisplatin|drug
DDI-DrugBank.d288.s0|118-128|infusions,|drug
DDI-DrugBank.d288.s0|169-174|TAXOL|brand
DDI-DrugBank.d288.s0|191-200|cisplatin|drug
DDI-DrugBank.d288.s0|239-244|TAXOL|brand
DDI-DrugBank.d288.s0|252-263|cisplatin).|drug
DDI-DrugBank.d288.s1|0-15|Pharmacokinetic|drug
DDI-DrugBank.d288.s1|115-120|TAXOL|brand
DDI-DrugBank.d288.s1|125-137|administered|drug
DDI-DrugBank.d288.s1|138-147|following|drug
DDI-DrugBank.d288.s1|148-158|cisplatin.|drug
DDI-DrugBank.d288.s2|18-23|TAXOL|brand
DDI-DrugBank.d288.s2|68-74|CYP2C8|brand
DDI-DrugBank.d288.s2|79-86|CYP3A4.|brand
DDI-DrugBank.d288.s3|25-33|clinical|drug
DDI-DrugBank.d288.s3|39-50|interaction|drug
DDI-DrugBank.d288.s3|93-106|administering|drug
DDI-DrugBank.d288.s3|107-112|TAXOL|brand
DDI-DrugBank.d288.s3|152-162|inhibitors|drug
DDI-DrugBank.d288.s3|197-203|CYP2C8|brand
DDI-DrugBank.d288.s3|208-215|CYP3A4.|brand
DDI-DrugBank.d288.s4|10-22|interactions|drug
DDI-DrugBank.d288.s4|31-37|TAXOL,|brand
DDI-DrugBank.d288.s4|53-60|CYP3A4,|brand
DDI-DrugBank.d288.s4|74-84|inhibitors|drug
DDI-DrugBank.d288.s4|97-108|saquinavir,|drug
DDI-DrugBank.d288.s4|109-119|indinavir,|drug
DDI-DrugBank.d288.s4|124-136|nelfinavir),|drug
DDI-DrugBank.d288.s4|165-175|inhibitors|drug
DDI-DrugBank.d288.s4|179-186|CYP3A4,|brand
DDI-DrugBank.d288.s4|214-222|clinical|drug
DDI-DrugBank.d288.s5|15-25|literature|group
DDI-DrugBank.d288.s5|56-67|doxorubicin|drug
DDI-DrugBank.d288.s5|95-109|doxorubicinol)|drug
DDI-DrugBank.d288.s5|117-126|increased|drug
DDI-DrugBank.d288.s5|147-158|doxorubicin|drug
DDI-DrugBank.d288.s5|171-183|combination.|drug
DDI-DrugBank.d288.s6|12-17|TAXOL|brand
DDI-DrugBank.d288.s6|40-52|administered|drug
DDI-DrugBank.d288.s6|70-78|baseline|drug
DDI-DrugBank.d288.s6|110-115|1,500|drug_n
DDI-DrugBank.d288.s7|143-152|receiving|drug
DDI-DrugBank.d288.s7|153-159|TAXOL.|brand
DDI-DrugBank.d288.s8|60-65|TAXOL|brand
DDI-DrugBank.d288.s8|153-160|100,000|drug_n
DDI-DrugBank.d288.s9|74-80|during|drug
DDI-DrugBank.d288.s9|93-98|TAXOL|brand
DDI-DrugBank.d288.s10|84-90|TAXOL,|brand
DDI-DrugBank.d288.s10|140-149|initiated|drug
DDI-DrugBank.d288.s11|101-111|containing|group
DDI-DrugBank.d288.s11|131-142|cyclosporin|drug
DDI-DrugBank.d288.s11|147-156|injection|drug
DDI-DrugBank.d288.s11|173-183|teniposide|drug
DDI-DrugBank.d288.s11|188-197|injection|drug
DDI-DrugBank.d288.s11|238-244|TAXOL.|brand
DDI-DrugBank.d288.s12|97-102|TAXOL|brand
DDI-DrugBank.d288.s12|131-146|corticosteroids|group
DDI-DrugBank.d288.s12|172-188|diphen-hydramine|drug
DDI-DrugBank.d288.s12|217-227|cimetidine|drug
DDI-DrugBank.d288.s12|231-243|ranitidine).|drug
DDI-DrugBank.d288.s13|0-5|Minor|drug
DDI-DrugBank.d288.s13|23-32|flushing,|drug
DDI-DrugBank.d288.s13|101-113|interruption|drug
DDI-DrugBank.d288.s14|47-56|requiring|drug
DDI-DrugBank.d288.s14|76-85|requiring|drug
DDI-DrugBank.d288.s14|158-173|discontinuation|group
DDI-DrugBank.d288.s14|177-182|TAXOL|brand
DDI-DrugBank.d288.s15|94-100|TAXOL.|brand
DDI-DrugBank.d288.s16|78-84|during|drug
DDI-DrugBank.d288.s16|85-99|administration|drug
DDI-DrugBank.d288.s16|103-109|TAXOL,|brand
DDI-DrugBank.d288.s17|13-18|TAXOL|brand
DDI-DrugBank.d288.s17|19-28|infusions|drug
DDI-DrugBank.d288.s17|37-48|interrupted|drug
DDI-DrugBank.d288.s17|52-64|discontinued|group
DDI-DrugBank.d288.s17|76-83|initial|drug
DDI-DrugBank.d288.s18|20-31|monitoring,|drug
DDI-DrugBank.d288.s18|45-51|during|drug
DDI-DrugBank.d288.s18|70-75|TAXOL|brand
DDI-DrugBank.d288.s18|76-85|infusion,|drug
DDI-DrugBank.d288.s19|0-10|Continuous|drug
DDI-DrugBank.d288.s19|19-29|monitoring|drug
DDI-DrugBank.d288.s20|196-202|TAXOL.|brand
DDI-DrugBank.d288.s21|0-5|TAXOL|brand
DDI-DrugBank.d288.s21|6-14|contains|group
DDI-DrugBank.d288.s21|15-25|dehydrated|drug
DDI-DrugBank.d288.s23|61-66|TAXOL|brand
DDI-DrugBank.d288.s23|115-124|bilirubin|drug
DDI-DrugBank.d288.s24|41-54|administering|drug
DDI-DrugBank.d288.s24|55-60|TAXOL|brand
DDI-DrugBank.d288.s24|117-123|DOSAGE|brand
DDI-DrugBank.d288.s24|128-143|ADMINISTRATION,|brand
DDI-DrugBank.d288.s25|50-59|including|drug
DDI-DrugBank.d288.s25|178-186|swelling|drug
DDI-DrugBank.d288.s25|194-203|injection|drug
DDI-DrugBank.d288.s26|60-67|24-hour|drug_n
DDI-DrugBank.d288.s26|68-76|infusion|drug
DDI-DrugBank.d288.s26|91-97|3-hour|drug_n
DDI-DrugBank.d288.s26|98-107|infusion.|drug
DDI-DrugBank.d288.s27|65-74|following|drug
DDI-DrugBank.d288.s27|75-89|administration|drug
DDI-DrugBank.d288.s27|93-98|TAXOL|brand
DDI-DrugBank.d288.s28|66-77|induration,|drug
DDI-DrugBank.d288.s28|153-163|continuing|group
DDI-DrugBank.d288.s28|180-185|TAXOL|brand
DDI-DrugBank.d288.s29|31-40|injection|drug
DDI-DrugBank.d288.s29|71-77|during|drug
DDI-DrugBank.d288.s29|90-98|infusion|drug
DDI-DrugBank.d288.s31|79-87|infusion|drug
DDI-DrugBank.d288.s31|106-118|infiltration|drug
DDI-DrugBank.d288.s31|119-125|during|drug
DDI-DrugBank.d288.s31|131-146|administration.|drug
DDI-DrugBank.d184.s0|32-42|following:|drug
DDI-DrugBank.d184.s0|43-59|adrenocorticoids|group
DDI-DrugBank.d184.s0|76-86|medicine),|drug
DDI-DrugBank.d184.s0|87-101|anticoagulants|group
DDI-DrugBank.d184.s0|109-119|thinners),|drug
DDI-DrugBank.d184.s0|120-134|carbamazepine,|drug
DDI-DrugBank.d184.s0|135-148|corticotropin|drug
DDI-DrugBank.d184.s0|197-208|medicines),|drug
DDI-DrugBank.d184.s0|232-237|(CNS)|brand
DDI-DrugBank.d184.s0|250-256|(using|drug
DDI-DrugBank.d184.s0|263-272|medicines|drug
DDI-DrugBank.d184.s0|305-314|increased|drug
DDI-DrugBank.d184.s0|351-358|sodium,|drug
DDI-DrugBank.d184.s0|373-379|(using|drug
DDI-DrugBank.d184.s0|386-395|medicines|drug
DDI-DrugBank.d184.s0|446-454|medicine|drug
DDI-DrugBank.d184.s0|488-502|contraceptives|group
DDI-DrugBank.d184.s0|503-513|containing|group
DDI-DrugBank.d184.s0|583-598|contraceptives,|group
DDI-DrugBank.d184.s0|655-664|control).|group
DDI-DrugBank.d59.s0|15-22|ERGOMAR|brand
DDI-DrugBank.d59.s0|45-66|triacetyloleandomycin|drug
DDI-DrugBank.d59.s0|73-81|inhibits|drug
DDI-DrugBank.d59.s0|100-111|ergotamine.|drug
DDI-DrugBank.d59.s1|23-30|ERGOMAR|brand
DDI-DrugBank.d59.s1|67-74|combine|drug
DDI-DrugBank.d256.s0|0-11|Clindamycin|drug
DDI-DrugBank.d256.s0|49-57|blocking|drug
DDI-DrugBank.d256.s0|120-128|blocking|drug
DDI-DrugBank.d256.s1|54-63|receiving|drug
DDI-DrugBank.d256.s2|41-52|clindamycin|drug
DDI-DrugBank.d256.s2|57-69|erythromycin|drug
DDI-DrugBank.d256.s3|20-28|clinical|drug
DDI-DrugBank.d256.s3|73-85|administered|drug
DDI-DrugBank.d167.s0|23-35|interactions|drug
DDI-DrugBank.d167.s0|51-65|coadministered|drug
DDI-DrugBank.d167.s0|71-79|digoxin,|drug
DDI-DrugBank.d167.s1|0-19|Anticholinesterases|drug
DDI-DrugBank.d167.s1|20-32|(neostgmine,|drug
DDI-DrugBank.d167.s1|33-48|physostigmine),|drug
DDI-DrugBank.d167.s1|49-60|lignocaine,|drug
DDI-DrugBank.d167.s1|61-69|quinine,|drug
DDI-DrugBank.d167.s1|70-82|procainamide|drug
DDI-DrugBank.d167.s2|27-35|blocking|drug
DDI-DrugBank.d167.s2|102-112|lidocaine,|drug
DDI-DrugBank.d167.s2|113-122|procaine,|drug
DDI-DrugBank.d167.s2|154-161|lithium|drug
DDI-DrugBank.d167.s2|177-189|terbutaline.|drug
DDI-DrugBank.d305.s0|0-8|Dantrium|drug
DDI-DrugBank.d305.s0|125-131|induce|drug
DDI-DrugBank.d305.s1|62-70|Dantrium|drug
DDI-DrugBank.d305.s2|0-7|Binding|drug
DDI-DrugBank.d305.s2|18-25|protein|drug
DDI-DrugBank.d305.s2|68-86|diphenylhydantoin,|drug
DDI-DrugBank.d305.s3|0-7|Binding|drug
DDI-DrugBank.d305.s3|18-26|proteins|drug
DDI-DrugBank.d305.s3|41-49|warfarin|drug
DDI-DrugBank.d305.s3|69-78|increased|drug
DDI-DrugBank.d305.s4|78-88|dantrolene|drug
DDI-DrugBank.d305.s4|89-95|sodium|drug
DDI-DrugBank.d305.s5|4-15|combination|drug
DDI-DrugBank.d305.s5|40-51|intravenous|drug
DDI-DrugBank.d305.s5|52-62|dantrolene|drug
DDI-DrugBank.d305.s5|63-69|sodium|drug
DDI-DrugBank.d305.s5|123-128|swine|drug
DDI-DrugBank.d305.s6|27-38|combination|drug
DDI-DrugBank.d305.s6|42-53|intravenous|drug
DDI-DrugBank.d305.s6|54-64|dantrolene|drug
DDI-DrugBank.d305.s6|65-71|sodium|drug
DDI-DrugBank.d305.s6|76-83|calcium|drug
DDI-DrugBank.d305.s6|142-148|during|drug
DDI-DrugBank.d305.s6|226-234|findings|drug
DDI-DrugBank.d305.s7|0-14|Administration|drug
DDI-DrugBank.d305.s7|18-28|dantrolene|drug
DDI-DrugBank.d305.s7|44-62|vecuronium-induced|drug
DDI-DrugBank.d334.s0|26-34|Diuretic|group
DDI-DrugBank.d334.s0|56-66|diuretics,|group
DDI-DrugBank.d334.s0|96-104|diuretic|group
DDI-DrugBank.d334.s0|126-137|instituted,|drug
DDI-DrugBank.d334.s0|198-206|pressure|group
DDI-DrugBank.d334.s0|213-223|initiation|drug
DDI-DrugBank.d334.s0|240-249|PRINIVIL.|brand
DDI-DrugBank.d334.s1|44-52|PRINIVIL|brand
DDI-DrugBank.d334.s1|60-69|minimized|drug
DDI-DrugBank.d334.s1|80-93|discontinuing|group
DDI-DrugBank.d334.s1|98-106|diuretic|group
DDI-DrugBank.d334.s1|110-120|increasing|drug
DDI-DrugBank.d334.s1|130-136|intake|drug
DDI-DrugBank.d334.s1|146-156|initiation|drug
DDI-DrugBank.d334.s1|175-184|PRINIVIL.|brand
DDI-DrugBank.d334.s2|22-30|continue|group
DDI-DrugBank.d334.s2|35-44|diuretic,|group
DDI-DrugBank.d334.s2|45-53|initiate|drug
DDI-DrugBank.d334.s2|67-75|PRINIVIL|brand
DDI-DrugBank.d334.s2|105-112|provide|drug
DDI-DrugBank.d334.s2|149-156|initial|drug
DDI-DrugBank.d334.s2|174-182|pressure|group
DDI-DrugBank.d334.s3|7-15|diuretic|group
DDI-DrugBank.d334.s3|53-62|receiving|drug
DDI-DrugBank.d334.s3|63-72|PRINIVIL,|brand
DDI-DrugBank.d334.s3|87-103|antihypertensive|group
DDI-DrugBank.d334.s4|17-27|inhibitors|drug
DDI-DrugBank.d334.s4|31-42|combination|drug
DDI-DrugBank.d334.s4|48-57|diuretics|group
DDI-DrugBank.d334.s4|58-66|indicate|drug
DDI-DrugBank.d334.s4|92-101|inhibitor|drug
DDI-DrugBank.d334.s4|141-150|diuretic.|group
DDI-DrugBank.d334.s5|14-31|Anti-inflammatory|drug
DDI-DrugBank.d334.s5|97-102|being|drug
DDI-DrugBank.d334.s5|130-147|anti-inflammatory|group
DDI-DrugBank.d334.s5|159-176|co-administration|drug
DDI-DrugBank.d334.s5|180-190|lisinopril|drug
DDI-DrugBank.d334.s7|32-40|diminish|drug
DDI-DrugBank.d334.s7|45-61|antihypertensive|group
DDI-DrugBank.d334.s7|76-87|inhibitors,|drug
DDI-DrugBank.d334.s7|88-97|including|drug
DDI-DrugBank.d334.s7|98-109|lisinopril.|drug
DDI-DrugBank.d334.s8|5-16|interaction|drug
DDI-DrugBank.d334.s8|59-65|taking|drug
DDI-DrugBank.d334.s8|96-107|inhibitors.|drug
DDI-DrugBank.d334.s9|71-87|antihypertensive|group
DDI-DrugBank.d334.s9|99-107|PRINIVIL|brand
DDI-DrugBank.d334.s9|131-139|PRINIVIL|brand
DDI-DrugBank.d334.s9|165-178|indomethacin,|drug
DDI-DrugBank.d334.s9|190-202|indomethacin|drug
DDI-DrugBank.d334.s9|233-249|antihypertensive|group
DDI-DrugBank.d334.s10|14-22|PRINIVIL|brand
DDI-DrugBank.d334.s10|72-79|digoxin|drug
DDI-DrugBank.d334.s10|100-110|clinically|drug
DDI-DrugBank.d334.s10|131-144|interactions.|drug
DDI-DrugBank.d334.s11|5-13|included|drug
DDI-DrugBank.d334.s11|30-40|infarction|drug
DDI-DrugBank.d334.s11|59-68|receiving|drug
DDI-DrugBank.d334.s11|69-80|intravenous|drug
DDI-DrugBank.d334.s11|96-110|nitroglycerin.|drug
DDI-DrugBank.d334.s12|3-13|clinically|drug
DDI-DrugBank.d334.s12|24-39|pharmacokinetic|drug
DDI-DrugBank.d334.s12|40-52|interactions|drug
DDI-DrugBank.d334.s12|67-75|PRINIVIL|brand
DDI-DrugBank.d334.s12|104-115|propranolol|drug
DDI-DrugBank.d334.s12|119-139|hydrochlorothiazide.|group
DDI-DrugBank.d334.s13|74-83|PRINIVIL.|brand
DDI-DrugBank.d334.s14|7-17|Increasing|drug
DDI-DrugBank.d334.s14|24-34|Potassium:|drug
DDI-DrugBank.d334.s14|35-43|PRINIVIL|brand
DDI-DrugBank.d334.s14|55-64|potassium|drug
DDI-DrugBank.d334.s14|80-93|thiazide-type|group
DDI-DrugBank.d334.s14|94-104|diuretics.|group
DDI-DrugBank.d334.s15|7-15|PRINIVIL|brand
DDI-DrugBank.d334.s15|21-38|potassium-sparing|drug
DDI-DrugBank.d334.s15|39-48|diuretics|group
DDI-DrugBank.d334.s15|100-109|potassium|drug
DDI-DrugBank.d334.s15|126-146|potassium-containing|group
DDI-DrugBank.d334.s15|188-197|increases|drug
DDI-DrugBank.d334.s15|207-217|potassium.|drug
DDI-DrugBank.d334.s16|49-58|indicated|drug
DDI-DrugBank.d334.s16|147-157|monitoring|drug
DDI-DrugBank.d334.s16|167-177|potassium.|drug
DDI-DrugBank.d334.s17|0-9|Potassium|drug
DDI-DrugBank.d334.s17|10-17|sparing|drug
DDI-DrugBank.d334.s17|77-84|failure|group
DDI-DrugBank.d334.s17|93-102|receiving|drug
DDI-DrugBank.d334.s17|103-112|PRINIVIL.|brand
DDI-DrugBank.d334.s18|0-8|Lithium:|drug
DDI-DrugBank.d334.s18|9-16|Lithium|drug
DDI-DrugBank.d334.s18|56-65|receiving|drug
DDI-DrugBank.d334.s18|66-73|lithium|drug
DDI-DrugBank.d334.s18|111-122|elimination|drug
DDI-DrugBank.d334.s18|126-133|sodium,|drug
DDI-DrugBank.d334.s18|134-143|including|drug
DDI-DrugBank.d334.s18|148-159|inhibitors.|drug
DDI-DrugBank.d334.s19|0-7|Lithium|drug
DDI-DrugBank.d334.s19|45-60|discontinuation|group
DDI-DrugBank.d334.s19|64-71|lithium|drug
DDI-DrugBank.d334.s19|84-94|inhibitor.|drug
DDI-DrugBank.d334.s20|29-36|lithium|drug
DDI-DrugBank.d334.s20|71-79|PRINIVIL|brand
DDI-DrugBank.d334.s20|83-95|administered|drug
DDI-DrugBank.d334.s20|115-123|lithium.|drug
DDI-DrugBank.d311.s0|0-6|Taking|drug
DDI-DrugBank.d311.s0|42-48|taking|drug
DDI-DrugBank.d311.s0|52-58|within|drug
DDI-DrugBank.d311.s0|70-76|taking|drug
DDI-DrugBank.d311.s0|81-91|inhibitors|drug
DDI-DrugBank.d311.s0|96-104|increase|drug
DDI-DrugBank.d311.s0|184-192|pressure|group
DDI-DrugBank.d230.s0|0-10|LABORATORY|brand
DDI-DrugBank.d230.s0|16-24|FINDINGS|brand
DDI-DrugBank.d230.s1|4-12|clinical|drug
DDI-DrugBank.d230.s2|9-19|interferes|drug
DDI-DrugBank.d230.s2|31-38|calcium|drug
DDI-DrugBank.d230.s2|39-51|measurements|group
DDI-DrugBank.d230.s2|128-137|resulting|drug
DDI-DrugBank.d230.s2|147-154|calcium|drug
DDI-DrugBank.d230.s3|52-57|12-24|drug_n
DDI-DrugBank.d230.s3|70-84|administration|drug
DDI-DrugBank.d230.s4|8-20|measurements|group
DDI-DrugBank.d230.s5|46-54|remained|drug
DDI-MedLine.d110.s0|0-22|18-Methoxycoronaridine|drug_n
DDI-MedLine.d110.s0|23-30|(18-MC)|brand
DDI-MedLine.d110.s0|35-44|ibogaine:|drug_n
DDI-MedLine.d110.s0|59-72|antiaddictive|group
DDI-MedLine.d110.s1|0-6|18-MC,|brand
DDI-MedLine.d110.s1|43-48|being|drug
DDI-MedLine.d110.s2|5-13|ibogaine|drug_n
DDI-MedLine.d110.s2|26-31|18-MC|brand
DDI-MedLine.d110.s2|57-68|intravenous|drug
DDI-MedLine.d110.s2|69-88|self-administration|drug
DDI-MedLine.d110.s2|92-100|morphine|drug
DDI-MedLine.d110.s2|105-112|cocaine|drug
DDI-MedLine.d110.s2|126-145|self-administration|drug
DDI-MedLine.d110.s2|149-156|ethanol|drug
DDI-MedLine.d110.s2|161-169|nicotine|drug
DDI-MedLine.d110.s3|7-16|ibogaine,|drug_n
DDI-MedLine.d110.s3|17-22|18-MC|brand
DDI-MedLine.d110.s3|39-49|responding|drug
DDI-MedLine.d110.s3|64-74|reinforcer|drug
DDI-MedLine.d110.s4|5-13|ibogaine|drug_n
DDI-MedLine.d110.s4|18-23|18-MC|brand
DDI-MedLine.d110.s5|5-13|ibogaine|drug_n
DDI-MedLine.d110.s5|18-23|18-MC|brand
DDI-MedLine.d110.s5|57-65|dopamine|drug
DDI-MedLine.d110.s5|101-109|ibogaine|drug_n
DDI-MedLine.d110.s5|110-119|increases|drug
DDI-MedLine.d110.s5|144-153|serotonin|drug
DDI-MedLine.d110.s6|5-13|ibogaine|drug_n
DDI-MedLine.d110.s6|18-23|18-MC|brand
DDI-MedLine.d110.s6|30-46|morphine-induced|drug
DDI-MedLine.d110.s6|51-67|nicotine-induced|drug
DDI-MedLine.d110.s6|68-76|dopamine|drug
DDI-MedLine.d110.s7|5-13|ibogaine|drug_n
DDI-MedLine.d110.s7|23-38|cocaine-induced|drug
DDI-MedLine.d110.s7|39-48|increases|drug
DDI-MedLine.d110.s7|61-70|dopamine.|drug
DDI-MedLine.d110.s8|5-13|ibogaine|drug_n
DDI-MedLine.d110.s8|18-23|18-MC|brand
DDI-MedLine.d110.s9|0-8|Ibogaine|drug_n
DDI-MedLine.d110.s9|25-30|18-MC|brand
DDI-MedLine.d110.s9|75-84|morphine;|drug
DDI-MedLine.d110.s10|25-41|morphine-induced|drug
DDI-MedLine.d110.s10|56-76|morphine-experienced|drug
DDI-MedLine.d110.s11|0-8|Ibogaine|drug_n
DDI-MedLine.d110.s11|18-23|whole|drug
DDI-MedLine.d110.s12|0-5|18-MC|brand
DDI-MedLine.d110.s13|0-9|Ibogaine,|drug_n
DDI-MedLine.d110.s13|18-24|18-MC,|brand
DDI-MedLine.d110.s14|6-11|18-MC|brand
DDI-MedLine.d110.s14|16-24|ibogaine|drug_n
DDI-MedLine.d110.s14|38-48|affinities|drug
DDI-MedLine.d110.s14|79-88|nicotinic|drug
DDI-MedLine.d110.s14|100-105|18-MC|brand
DDI-MedLine.d110.s14|121-131|affinities|drug
DDI-MedLine.d110.s14|137-145|ibogaine|drug_n
DDI-MedLine.d110.s14|178-184|sodium|drug
DDI-MedLine.d110.s15|5-10|18-MC|brand
DDI-MedLine.d110.s15|15-23|ibogaine|drug_n
DDI-MedLine.d110.s15|57-66|ibogaine,|drug_n
DDI-MedLine.d110.s15|67-72|18-MC|brand
DDI-MedLine.d110.s16|22-27|18-MC|brand
DDI-MedLine.d110.s16|113-118|index|drug
DDI-MedLine.d110.s16|124-133|ibogaine.|drug_n
DDI-DrugBank.d84.s0|16-30|administration|drug
DDI-DrugBank.d84.s0|45-64|aluminum-containing|group
DDI-DrugBank.d84.s1|33-41|affinity|drug
DDI-DrugBank.d84.s1|46-54|aluminum|drug
DDI-DrugBank.d84.s1|102-121|aluminum-containing|group
DDI-DrugBank.d84.s2|51-67|pharmacokinetics|drug
DDI-DrugBank.d84.s2|71-79|digoxin.|drug
DDI-DrugBank.d84.s3|14-21|digoxin|drug
DDI-DrugBank.d84.s3|32-48|pharmacokinetics|drug
DDI-DrugBank.d84.s4|16-30|administration|drug
DDI-DrugBank.d84.s4|45-52|vitamin|drug
DDI-DrugBank.d84.s5|9-16|vitamin|drug
DDI-DrugBank.d84.s5|48-56|clinical|drug
DDI-DrugBank.d84.s6|4-15|interaction|drug
DDI-DrugBank.d84.s6|31-42|hydroxyurea|group
DDI-DrugBank.d84.s7|3-13|inhibition|drug
DDI-DrugBank.d84.s7|43-54|hydroxyurea|group
DDI-DrugBank.d84.s8|21-29|combined|drug
DDI-DrugBank.d84.s8|84-96|combinations|drug
DDI-DrugBank.d84.s9|43-48|(AUC)|brand
DDI-DrugBank.d84.s9|77-86|increased|drug
DDI-DrugBank.d84.s10|51-58|minutes|drug
DDI-DrugBank.d84.s10|66-73|eating.|drug
DDI-DrugBank.d12.s0|33-47|anticoagulants|group
DDI-DrugBank.d12.s1|27-40|anticoagulant|group
DDI-DrugBank.d12.s1|71-81|(depending|drug
DDI-DrugBank.d12.s1|89-99|individual|drug
DDI-DrugBank.d12.s1|109-117|maintain|drug
DDI-DrugBank.d12.s1|122-133|prothrombin|drug
DDI-DrugBank.d12.s1|171-179|bleeding|drug
DDI-DrugBank.d12.s2|9-20|prothrombin|drug
DDI-DrugBank.d12.s2|21-35|determinations|drug
DDI-DrugBank.d12.s2|68-78|determined|drug
DDI-DrugBank.d12.s2|79-89|definitely|drug
DDI-DrugBank.d12.s2|99-110|prothrombin|drug
DDI-DrugBank.d12.s3|44-53|phenytoin|drug
DDI-DrugBank.d12.s3|57-68|tolbutamide|drug
DDI-DrugBank.d12.s3|80-87|binding|drug
DDI-DrugBank.d12.s4|33-41|treating|drug
DDI-DrugBank.d12.s4|94-107|protein-bound|drug
DDI-DrugBank.d12.s5|27-38|tolbutamide|drug
DDI-DrugBank.d12.s5|60-68|increase|drug
DDI-DrugBank.d12.s6|0-9|Fulminant|drug
DDI-DrugBank.d12.s6|69-79|initiation|drug
DDI-DrugBank.d12.s6|83-91|combined|drug
DDI-DrugBank.d12.s6|105-112|another|drug
DDI-DrugBank.d12.s6|125-135|lovastatin|drug
DDI-DrugBank.d12.s7|146-154|combined|drug
DDI-DrugBank.d12.s7|168-178|lovastatin|drug
DDI-DrugBank.d12.s7|271-279|failure.|group
DDI-DrugBank.d12.s8|35-46|interaction|drug
DDI-DrugBank.d12.s8|186-195|including|drug
DDI-DrugBank.d12.s9|15-23|combined|drug
DDI-DrugBank.d12.s9|31-41|lovastatin|drug
DDI-DrugBank.d477.s0|55-61|amines|drug
DDI-DrugBank.d477.s0|91-99|within14|drug
DDI-DrugBank.d477.s0|105-114|following|drug
DDI-DrugBank.d477.s0|122-131|monoamine|drug
DDI-DrugBank.d477.s0|140-151|inhibitors.|drug
DDI-DrugBank.d477.s1|0-6|DIDREX|brand
DDI-DrugBank.d477.s2|0-12|Amphetamines|drug
DDI-DrugBank.d477.s2|52-70|antihypertensives.|group
DDI-DrugBank.d477.s3|0-12|Amphetamines|drug
DDI-DrugBank.d477.s3|50-66|antidepressants.|group
DDI-DrugBank.d477.s4|0-7|Urinary|drug
DDI-DrugBank.d477.s4|8-20|alkalinizing|drug
DDI-DrugBank.d477.s4|28-36|increase|drug
DDI-DrugBank.d477.s4|76-89|amphetamines.|drug
DDI-DrugBank.d477.s5|0-7|Urinary|drug
DDI-DrugBank.d477.s5|8-18|acidifying|drug
DDI-DrugBank.d477.s5|52-60|increase|drug
DDI-DrugBank.d477.s5|74-87|amphetamines.|drug
DDI-DrugBank.d235.s0|13-19|CYP2D6|brand
DDI-DrugBank.d235.s0|20-28|(minor),|drug
DDI-DrugBank.d235.s1|9-15|CYP2D6|brand
DDI-DrugBank.d235.s2|58-69|inhibitors,|drug
DDI-DrugBank.d235.s2|80-96|antidepressants,|group
DDI-DrugBank.d235.s2|97-112|phenothiazines.|drug
DDI-DrugBank.d235.s3|0-6|CYP3A4|brand
DDI-DrugBank.d235.s3|7-18|inhibitors:|drug
DDI-DrugBank.d235.s3|23-31|increase|drug
DDI-DrugBank.d235.s3|54-71|chlorpheniramine.|drug
DDI-DrugBank.d235.s4|8-18|inhibitors|drug
DDI-DrugBank.d235.s4|19-26|include|drug
DDI-DrugBank.d235.s4|27-32|azole|drug
DDI-DrugBank.d235.s4|33-45|antifungals,|group
DDI-DrugBank.d235.s4|46-60|ciprofloxacin,|drug
DDI-DrugBank.d235.s4|61-76|clarithromycin,|drug
DDI-DrugBank.d235.s4|89-101|doxycycline,|drug
DDI-DrugBank.d235.s4|102-115|erythromycin,|drug
DDI-DrugBank.d235.s4|116-125|imatinib,|drug
DDI-DrugBank.d235.s4|149-161|nicardipine,|drug
DDI-DrugBank.d235.s4|181-192|inhibitors,|drug
DDI-DrugBank.d235.s4|193-203|quinidine,|drug
DDI-MedLine.d72.s0|15-27|interactions|drug
DDI-MedLine.d72.s0|62-70|measures|group
DDI-MedLine.d72.s0|124-135|OBJECTIVES:|brand
DDI-MedLine.d72.s0|168-180|interactions|drug
DDI-MedLine.d72.s0|184-192|clinical|drug
DDI-MedLine.d72.s0|203-209|(PICR)|brand
DDI-MedLine.d72.s0|248-253|(MAC)|brand
DDI-MedLine.d72.s0|308-316|minimise|drug
DDI-MedLine.d72.s1|0-7|DESIGN:|brand
DDI-MedLine.d72.s2|0-8|SETTING:|brand
DDI-MedLine.d72.s3|0-9|PATIENTS:|brand
DDI-MedLine.d72.s3|53-58|1306.|drug_n
DDI-MedLine.d72.s4|0-12|MEASUREMENTS|brand
DDI-MedLine.d72.s4|22-30|RESULTS:|brand
DDI-MedLine.d72.s4|43-48|1998,|drug_n
DDI-MedLine.d72.s4|53-62|following|drug
DDI-MedLine.d72.s4|152-161|intrinsic|drug
DDI-MedLine.d72.s4|218-230|interactions|drug
DDI-MedLine.d72.s4|231-236|(PI),|brand
DDI-MedLine.d72.s4|248-254|(using|drug
DDI-MedLine.d72.s4|276-281|1996)|drug_n
DDI-MedLine.d72.s4|297-307|clinically|drug
DDI-MedLine.d72.s5|47-53|0.05).|drug_n
DDI-MedLine.d72.s6|41-46|1.2).|drug_n
DDI-MedLine.d72.s7|48-53|0.2).|drug_n
DDI-MedLine.d72.s8|7-16|affecting|drug
DDI-MedLine.d72.s9|0-5|24.9%|drug_n
DDI-MedLine.d72.s9|29-34|PICR,|brand
DDI-MedLine.d72.s9|47-52|11.7%|drug_n
DDI-MedLine.d72.s10|87-93|0.01).|drug_n
DDI-MedLine.d72.s11|35-44|intrinsic|drug
DDI-MedLine.d72.s11|70-75|2.8).|drug_n
DDI-MedLine.d72.s12|0-5|74.1%|drug_n
DDI-MedLine.d72.s13|8-17|remaining|drug
DDI-MedLine.d72.s13|18-23|25.9%|drug_n
DDI-MedLine.d72.s13|45-55|monitoring|drug
DDI-MedLine.d72.s14|0-12|CONCLUSIONS:|brand
DDI-MedLine.d72.s14|71-79|involved|drug
DDI-MedLine.d72.s14|122-130|measures|group
DDI-MedLine.d72.s14|134-142|minimise|drug
DDI-MedLine.d72.s14|153-160|arising|drug
DDI-DrugBank.d198.s1|119-124|(CYP)|brand
DDI-DrugBank.d198.s1|134-140|3A4/5,|brand
DDI-DrugBank.d198.s1|167-174|CYP2C9.|brand
DDI-DrugBank.d198.s2|11-21|inhibitors|drug
DDI-DrugBank.d198.s4|0-10|Cimetidine|drug
DDI-DrugBank.d198.s4|71-76|(AUC)|brand
DDI-DrugBank.d198.s4|129-144|co-administered|drug
DDI-DrugBank.d198.s5|0-12|Erythromycin|drug
DDI-DrugBank.d198.s5|39-45|4-fold|drug_n
DDI-DrugBank.d198.s5|46-54|increase|drug
DDI-DrugBank.d198.s5|79-85|3-fold|drug_n
DDI-DrugBank.d198.s5|86-94|increase|drug
DDI-DrugBank.d198.s5|108-123|co-administered|drug
DDI-DrugBank.d198.s6|34-40|single|drug
DDI-DrugBank.d198.s6|70-77|24-hour|drug_n
DDI-DrugBank.d198.s6|98-109|combination|drug
DDI-DrugBank.d198.s6|115-128|erythromycin.|drug
DDI-DrugBank.d198.s7|0-12|Ketoconazole|drug
DDI-DrugBank.d198.s7|44-51|10-fold|drug_n
DDI-DrugBank.d198.s7|52-60|increase|drug
DDI-DrugBank.d198.s7|85-91|4-fold|drug_n
DDI-DrugBank.d198.s7|92-100|increase|drug
DDI-DrugBank.d198.s7|114-129|co-administered|drug
DDI-DrugBank.d198.s8|59-70|combination|drug
DDI-DrugBank.d198.s8|94-107|ketoconazole.|drug
DDI-DrugBank.d198.s9|0-5|Since|drug
DDI-DrugBank.d198.s9|22-34|ketoconazole|drug
DDI-DrugBank.d198.s9|71-80|increases|drug
DDI-DrugBank.d198.s9|100-106|single|drug
DDI-DrugBank.d198.s9|161-168|24-hour|drug_n
DDI-DrugBank.d198.s9|189-200|combination|drug
DDI-DrugBank.d198.s9|206-218|ketoconazole|drug
DDI-DrugBank.d198.s10|25-34|Indinavir|drug
DDI-DrugBank.d198.s10|51-66|co-administered|drug
DDI-DrugBank.d198.s10|103-110|16-fold|drug_n
DDI-DrugBank.d198.s10|111-119|increase|drug
DDI-DrugBank.d198.s10|141-147|7-fold|drug_n
DDI-DrugBank.d198.s10|148-156|increase|drug
DDI-DrugBank.d198.s10|182-188|2-fold|drug_n
DDI-DrugBank.d198.s10|189-197|increase|drug
DDI-DrugBank.d198.s11|34-40|single|drug
DDI-DrugBank.d198.s11|69-76|24-hour|drug_n
DDI-DrugBank.d198.s11|97-108|combination|drug
DDI-DrugBank.d198.s11|114-124|indinavir.|drug
DDI-DrugBank.d198.s12|0-9|Ritonavir|drug
DDI-DrugBank.d198.s12|26-41|co-administered|drug
DDI-DrugBank.d198.s12|77-84|49-fold|drug_n
DDI-DrugBank.d198.s12|85-93|increase|drug
DDI-DrugBank.d198.s12|118-125|13-fold|drug_n
DDI-DrugBank.d198.s12|126-134|increase|drug
DDI-DrugBank.d198.s13|4-15|interaction|drug
DDI-DrugBank.d198.s13|36-44|blocking|drug
DDI-DrugBank.d198.s13|108-114|CYP3A4|brand
DDI-DrugBank.d198.s13|115-125|inhibitor,|drug
DDI-DrugBank.d198.s13|137-145|inhibits|drug
DDI-DrugBank.d198.s13|146-153|CYP2C9.|brand
DDI-DrugBank.d198.s14|0-9|Ritonavir|drug
DDI-DrugBank.d198.s15|48-54|single|drug
DDI-DrugBank.d198.s15|83-90|72-hour|drug_n
DDI-DrugBank.d198.s15|111-122|combination|drug
DDI-DrugBank.d198.s16|28-43|pharmacokinetic|drug
DDI-DrugBank.d198.s16|44-56|interactions|drug
DDI-DrugBank.d198.s16|98-107|following|drug
DDI-DrugBank.d198.s16|126-135|warfarin,|drug
DDI-DrugBank.d198.s16|136-144|digoxin,|drug
DDI-DrugBank.d198.s16|157-168|ranitidine.|drug
DDI-DrugBank.d198.s17|7-15|warfarin|drug
DDI-DrugBank.d198.s17|55-66|prothrombin|drug
DDI-DrugBank.d198.s19|66-73|CYP1A2,|brand
DDI-DrugBank.d198.s19|93-100|100uM).|drug_n
DDI-DrugBank.d198.s20|5-15|inhibitory|drug
DDI-DrugBank.d198.s20|46-54|(CYP2C8,|brand
DDI-DrugBank.d198.s20|60-65|2C19,|brand
DDI-DrugBank.d198.s20|151-160|following|drug
DDI-DrugBank.d198.s20|161-168|dosing.|drug
DDI-DrugBank.d198.s21|16-26|inhibitory|drug
DDI-DrugBank.d198.s21|111-118|CYP3A4,|brand
DDI-DrugBank.d198.s22|37-45|pressure|group
DDI-DrugBank.d198.s22|46-54|lowering|drug
DDI-DrugBank.d198.s22|66-76|sublingual|drug
DDI-DrugBank.d198.s22|136-145|increases|drug
DDI-DrugBank.d198.s24|167-183|contraindicated.|group
DDI-DrugBank.d198.s25|0-11|Nifedipine:|drug
DDI-DrugBank.d198.s25|35-50|co-administered|drug
DDI-DrugBank.d198.s25|69-79|nifedipine|drug
DDI-DrugBank.d198.s25|151-156|(AUC)|brand
DDI-DrugBank.d198.s25|192-203|nifedipine,|drug
DDI-DrugBank.d198.s25|235-242|CYP3A4.|brand
DDI-DrugBank.d198.s26|0-10|Nifedipine|drug
DDI-DrugBank.d198.s26|71-83|combination.|drug
DDI-DrugBank.d198.s27|41-51|controlled|group
DDI-DrugBank.d198.s27|57-68|nifedipine,|drug
DDI-DrugBank.d198.s27|111-117|supine|drug
DDI-DrugBank.d198.s27|143-151|pressure|group
DDI-DrugBank.d198.s28|131-141|terazosin,|drug
DDI-DrugBank.d198.s29|18-24|dosing|drug
DDI-DrugBank.d198.s29|49-58|terazosin|drug
DDI-DrugBank.d198.s29|96-104|standing|drug
DDI-DrugBank.d198.s29|120-128|pressure|group
DDI-DrugBank.d198.s30|18-24|dosing|drug
DDI-DrugBank.d198.s30|49-58|terazosin|drug
DDI-DrugBank.d198.s30|96-104|standing|drug
DDI-DrugBank.d198.s30|120-128|pressure|group
DDI-DrugBank.d198.s31|16-22|dosing|drug
DDI-DrugBank.d198.s31|42-51|terazosin|drug
DDI-DrugBank.d198.s31|146-154|standing|drug
DDI-DrugBank.d198.s31|170-178|pressure|group
DDI-DrugBank.d198.s32|24-34|tamsulosin|drug
DDI-DrugBank.d198.s32|107-117|tamsulosin|drug
DDI-DrugBank.d198.s32|160-168|standing|drug
DDI-DrugBank.d198.s32|184-192|pressure|group
DDI-DrugBank.d198.s33|66-76|tamsulosin|drug
DDI-DrugBank.d198.s33|98-106|standing|drug
DDI-DrugBank.d198.s33|122-130|pressure|group
DDI-DrugBank.d198.s34|4-18|administration|drug
DDI-DrugBank.d198.s34|105-114|determine|drug
DDI-DrugBank.d198.s34|137-149|administered|drug
DDI-DrugBank.d198.s36|0-9|Ritonavir|drug
DDI-DrugBank.d198.s36|14-24|indinavir:|drug
DDI-DrugBank.d198.s36|42-56|administration|drug
DDI-DrugBank.d198.s36|126-135|ritonavir|drug
DDI-DrugBank.d198.s37|5-19|administration|drug
DDI-DrugBank.d198.s37|59-69|indinavir,|drug
DDI-DrugBank.d198.s37|90-99|indinavir|drug
DDI-DrugBank.d198.s39|73-79|during|drug
DDI-DrugBank.d198.s39|84-90|4-hour|drug_n
DDI-DrugBank.d198.s39|137-149|administered|drug
DDI-DrugBank.d198.s40|0-8|Aspirin:|brand
DDI-DrugBank.d198.s40|61-69|increase|drug
DDI-DrugBank.d198.s40|73-81|bleeding|drug
DDI-DrugBank.d198.s40|97-104|aspirin|brand
DDI-DrugBank.d198.s41|6-19|interactions:|drug
DDI-DrugBank.d198.s41|72-81|glyburide|drug
DDI-DrugBank.d198.s41|95-102|insulin|drug
DDI-DrugBank.d198.s41|123-131|warfarin|drug
DDI-DrugBank.d198.s41|132-144|(prothrombin|drug
DDI-DrugBank.d390.s0|28-42|phenothiazines|drug
DDI-DrugBank.d390.s1|10-26|antidepressants.|group
DDI-DrugBank.d8.s0|106-113|ALFENTA|brand
DDI-DrugBank.d8.s0|117-129|administered|drug
DDI-DrugBank.d8.s0|133-144|combination|drug
DDI-DrugBank.d8.s0|209-217|opioids,|group
DDI-DrugBank.d8.s0|221-231|inhalation|drug
DDI-DrugBank.d8.s2|17-25|combined|drug
DDI-DrugBank.d8.s3|8-16|clinical|drug
DDI-DrugBank.d8.s3|28-37|indicates|drug
DDI-DrugBank.d8.s3|69-79|inhalation|drug
DDI-DrugBank.d8.s3|142-149|minutes|drug
DDI-DrugBank.d8.s3|150-159|following|drug
DDI-DrugBank.d8.s3|160-167|ALFENTA|brand
DDI-DrugBank.d8.s3|168-177|induction|drug
DDI-DrugBank.d8.s3|201-213|erythromycin|drug
DDI-DrugBank.d8.s3|219-226|ALFENTA|brand
DDI-DrugBank.d8.s3|245-252|inhibit|drug
DDI-DrugBank.d8.s3|253-260|ALFENTA|brand
DDI-DrugBank.d8.s3|279-287|increase|drug
DDI-DrugBank.d8.s4|0-10|Cimetidine|drug
DDI-DrugBank.d8.s4|36-44|ALFENTA.|brand
DDI-DrugBank.d8.s5|18-25|ALFENTA|brand
DDI-DrugBank.d8.s5|64-78|administration|drug
DDI-DrugBank.d8.s5|109-116|ALFENTA|brand
DDI-DrugBank.d8.s6|14-28|administration|drug
DDI-DrugBank.d8.s6|38-47|affecting|drug
DDI-DrugBank.d358.s0|0-5|Since|drug
DDI-DrugBank.d358.s0|6-12|PLETAL|brand
DDI-DrugBank.d358.s0|54-59|P-450|brand
DDI-DrugBank.d358.s0|105-111|PLETAL|brand
DDI-DrugBank.d358.s0|115-129|coadministered|drug
DDI-DrugBank.d358.s0|135-145|inhibitors|drug
DDI-DrugBank.d358.s0|149-155|C.P.A.|brand
DDI-DrugBank.d358.s0|164-176|ketoconazole|drug
DDI-DrugBank.d358.s0|181-193|erythromycin|drug
DDI-DrugBank.d358.s0|197-207|inhibitors|drug
DDI-DrugBank.d358.s0|211-218|CYP2C19|brand
DDI-DrugBank.d358.s0|227-238|omeprazole.|drug
DDI-DrugBank.d358.s1|0-15|Pharmacokinetic|drug
DDI-DrugBank.d358.s1|47-57|omeprazole|drug
DDI-DrugBank.d358.s1|62-74|erythromycin|drug
DDI-DrugBank.d358.s1|89-98|increased|drug
DDI-DrugBank.d358.s1|112-120|exposure|group
DDI-DrugBank.d358.s2|11-26|pharmacokinetic|drug
DDI-DrugBank.d358.s2|133-142|inhibitor|drug
DDI-DrugBank.d358.s2|146-153|C.P.A..|brand
DDI-DrugBank.d358.s3|42-51|increased|drug
DDI-DrugBank.d358.s3|89-96|CYP3A4,|brand
DDI-DrugBank.d358.s3|120-131|lovastatin,|drug
DDI-DrugBank.d358.s3|173-179|C.P.A.|brand
DDI-DrugBank.d358.s3|180-191|inhibition.|drug
DDI-DrugBank.d517.s0|0-13|Tetracycline,|drug
DDI-DrugBank.d517.s0|31-42|antibiotic,|group
DDI-DrugBank.d517.s0|84-94|penicillin|drug
DDI-DrugBank.d35.s0|51-58|aspirin|brand
DDI-DrugBank.d35.s0|83-100|anti-inflammatory|group
DDI-DrugBank.d35.s0|132-139|(Allium|drug
DDI-DrugBank.d35.s0|153-159|ginkgo|drug
DDI-DrugBank.d35.s0|160-167|(Ginkgo|drug
DDI-DrugBank.d35.s1|5-17|interactions|drug
DDI-DrugBank.d35.s1|41-50|increased|drug
DDI-DrugBank.d35.s1|69-78|bruising,|drug
DDI-DrugBank.d35.s3|52-65|discontinued.|group
DDI-DrugBank.d35.s4|0-11|Conflicting|drug
DDI-DrugBank.d35.s4|39-48|regarding|drug
DDI-DrugBank.d35.s4|92-99|control|group
DDI-DrugBank.d35.s4|130-142|intolerance,|drug
DDI-DrugBank.d35.s5|19-28|indicated|drug
DDI-DrugBank.d35.s7|78-88|tolerance,|drug
DDI-DrugBank.d35.s7|89-96|insulin|drug
DDI-DrugBank.d35.s7|110-117|insulin|drug
DDI-DrugBank.d35.s8|126-134|control.|group
DDI-DrugBank.d476.s0|0-6|ZEBETA|brand
DDI-DrugBank.d476.s0|21-29|combined|drug
DDI-DrugBank.d476.s0|41-54|beta-blocking|drug
DDI-DrugBank.d476.s1|9-18|receiving|drug
DDI-DrugBank.d476.s1|19-42|catecholamine-depleting|drug
DDI-DrugBank.d476.s1|58-67|reserpine|drug
DDI-DrugBank.d476.s1|71-84|guanethidine,|drug
DDI-DrugBank.d476.s1|148-156|blocking|drug
DDI-DrugBank.d476.s1|167-173|ZEBETA|brand
DDI-DrugBank.d476.s2|12-21|receiving|drug
DDI-DrugBank.d476.s2|46-56|clonidine,|drug
DDI-DrugBank.d476.s2|77-90|discontinued,|group
DDI-DrugBank.d476.s2|112-118|ZEBETA|brand
DDI-DrugBank.d476.s2|122-134|discontinued|group
DDI-DrugBank.d476.s2|177-187|clonidine.|drug
DDI-DrugBank.d476.s3|0-6|ZEBETA|brand
DDI-DrugBank.d476.s3|63-73|inhibitors|drug
DDI-DrugBank.d476.s3|100-107|certain|drug
DDI-DrugBank.d476.s3|108-115|calcium|drug
DDI-DrugBank.d476.s3|149-165|phenylalkylamine|drug
DDI-DrugBank.d476.s3|182-197|benzothiazepine|drug
DDI-DrugBank.d476.s3|223-237|antiarrhythmic|group
DDI-DrugBank.d476.s4|18-26|rifampin|drug
DDI-DrugBank.d476.s4|27-36|increases|drug
DDI-DrugBank.d476.s4|64-71|ZEBETA,|brand
DDI-DrugBank.d476.s4|72-81|resulting|drug
DDI-DrugBank.d476.s4|97-108|elimination|drug
DDI-DrugBank.d476.s4|122-129|ZEBETA.|brand
DDI-DrugBank.d476.s5|9-16|initial|drug
DDI-DrugBank.d476.s6|0-15|Pharmacokinetic|drug
DDI-DrugBank.d476.s6|36-46|clinically|drug
DDI-DrugBank.d476.s6|56-68|interactions|drug
DDI-DrugBank.d476.s6|108-117|including|drug
DDI-DrugBank.d476.s6|118-126|thiazide|group
DDI-DrugBank.d476.s6|127-137|diuretics,|group
DDI-DrugBank.d476.s6|138-146|digoxin,|drug
DDI-DrugBank.d476.s6|151-162|cimetidine.|drug
DDI-DrugBank.d476.s7|23-29|ZEBETA|brand
DDI-DrugBank.d476.s7|33-44|prothrombin|drug
DDI-DrugBank.d476.s7|81-90|warfarin.|drug
DDI-DrugBank.d476.s8|37-43|taking|drug
DDI-DrugBank.d476.s9|56-67|epinephrine|drug
DDI-DrugBank.d219.s0|0-14|ACE-inhibitors|drug
DDI-DrugBank.d219.s0|47-55|diminish|drug
DDI-DrugBank.d219.s0|60-76|antihypertensive|group
DDI-DrugBank.d219.s0|87-102|ACE-inhibitors.|drug
DDI-DrugBank.d219.s1|5-16|interaction|drug
DDI-DrugBank.d219.s1|59-65|taking|drug
DDI-DrugBank.d219.s1|92-107|ACE-inhibitors.|drug
DDI-DrugBank.d219.s2|0-9|Antacids:|group
DDI-DrugBank.d219.s2|26-40|administration|drug
DDI-DrugBank.d219.s2|44-52|antacids|group
DDI-DrugBank.d219.s2|107-114|Lodine.|drug
DDI-DrugBank.d219.s3|9-17|antacids|group
DDI-DrugBank.d219.s4|0-8|Aspirin:|brand
DDI-DrugBank.d219.s4|14-20|Lodine|drug
DDI-DrugBank.d219.s4|24-36|administered|drug
DDI-DrugBank.d219.s4|42-50|aspirin,|brand
DDI-DrugBank.d219.s4|55-62|protein|drug
DDI-DrugBank.d219.s4|63-70|binding|drug
DDI-DrugBank.d219.s5|4-12|clinical|drug
DDI-DrugBank.d219.s5|34-45|interaction|drug
DDI-DrugBank.d219.s6|43-57|administration|drug
DDI-DrugBank.d219.s6|61-67|Lodine|drug
DDI-DrugBank.d219.s6|72-79|aspirin|brand
DDI-DrugBank.d219.s6|137-146|increased|drug
DDI-DrugBank.d219.s7|0-13|Cyclosporine,|drug
DDI-DrugBank.d219.s7|14-22|Digoxin,|drug
DDI-DrugBank.d219.s7|36-43|Lodine,|drug
DDI-DrugBank.d219.s7|88-103|prostaglandins,|drug
DDI-DrugBank.d219.s7|129-140|elimination|drug
DDI-DrugBank.d219.s7|156-163|leading|drug
DDI-DrugBank.d219.s7|192-205|cyclosporine,|drug
DDI-DrugBank.d219.s7|206-214|digoxin,|drug
DDI-DrugBank.d219.s7|233-242|increased|drug
DDI-DrugBank.d219.s8|31-43|cyclosporine|drug
DDI-DrugBank.d219.s9|9-18|receiving|drug
DDI-DrugBank.d219.s9|45-52|Lodine,|drug
DDI-DrugBank.d219.s9|66-72|NSAID,|brand
DDI-DrugBank.d219.s10|0-10|Diuretics:|group
DDI-DrugBank.d219.s10|36-51|pharmacokinetic|drug
DDI-DrugBank.d219.s10|52-63|interaction|drug
DDI-DrugBank.d219.s10|69-81|administered|drug
DDI-DrugBank.d219.s10|87-97|furosemide|drug
DDI-DrugBank.d219.s10|101-121|hydrochlorothiazide.|group
DDI-DrugBank.d219.s11|14-22|clinical|drug
DDI-DrugBank.d219.s11|43-56|postmarketing|drug
DDI-DrugBank.d219.s11|86-92|Lodine|drug
DDI-DrugBank.d219.s11|108-119|natriuretic|group
DDI-DrugBank.d219.s11|130-140|furosemide|drug
DDI-DrugBank.d219.s11|145-154|thiazides|group
DDI-DrugBank.d219.s12|37-47|inhibition|drug
DDI-DrugBank.d219.s12|57-70|prostaglandin|drug
DDI-DrugBank.d219.s13|0-6|During|drug
DDI-DrugBank.d219.s13|98-106|failure,|group
DDI-DrugBank.d219.s13|121-127|assure|group
DDI-DrugBank.d219.s13|128-136|diuretic|group
DDI-DrugBank.d219.s14|36-51|pharmacokinetic|drug
DDI-DrugBank.d219.s14|52-63|interaction|drug
DDI-DrugBank.d219.s14|69-81|administered|drug
DDI-DrugBank.d219.s15|0-8|Lithium:|drug
DDI-DrugBank.d219.s15|53-60|lithium|drug
DDI-DrugBank.d219.s15|93-100|lithium|drug
DDI-DrugBank.d219.s16|9-16|minimum|drug
DDI-DrugBank.d219.s16|17-24|lithium|drug
DDI-DrugBank.d219.s16|39-48|increased|drug
DDI-DrugBank.d219.s17|38-48|inhibition|drug
DDI-DrugBank.d219.s17|58-71|prostaglandin|drug
DDI-DrugBank.d219.s17|89-95|NSAID.|brand
DDI-DrugBank.d219.s18|22-29|lithium|drug
DDI-DrugBank.d219.s18|34-46|administered|drug
DDI-DrugBank.d219.s18|112-119|lithium|drug
DDI-DrugBank.d219.s19|38-46|increase|drug
DDI-DrugBank.d219.s20|87-103|coadministration|drug
DDI-DrugBank.d219.s20|158-173|coadministered.|drug
DDI-DrugBank.d219.s21|0-10|Phenytoin:|drug
DDI-DrugBank.d219.s21|36-51|pharmacokinetic|drug
DDI-DrugBank.d219.s21|52-63|interaction|drug
DDI-DrugBank.d219.s21|69-81|administered|drug
DDI-DrugBank.d219.s21|87-97|phenytoin.|drug
DDI-DrugBank.d219.s22|0-9|Warfarin:|drug
DDI-DrugBank.d219.s22|25-33|warfarin|drug
DDI-DrugBank.d219.s22|51-59|bleeding|drug
DDI-DrugBank.d219.s22|142-150|bleeding|drug
DDI-DrugBank.d219.s23|11-26|pharmacokinetic|drug
DDI-DrugBank.d219.s23|70-84|administration|drug
DDI-DrugBank.d219.s23|88-96|warfarin|drug
DDI-DrugBank.d219.s23|101-107|Lodine|drug
DDI-DrugBank.d219.s23|160-167|protein|drug
DDI-DrugBank.d219.s23|168-175|binding|drug
DDI-DrugBank.d219.s23|179-188|warfarin,|drug
DDI-DrugBank.d219.s23|238-247|warfarin.|drug
DDI-DrugBank.d219.s24|69-77|warfarin|drug
DDI-DrugBank.d219.s24|78-90|administered|drug
DDI-DrugBank.d219.s24|101-109|warfarin|drug
DDI-DrugBank.d219.s24|110-122|administered|drug
DDI-DrugBank.d219.s24|128-134|Lodine|drug
DDI-DrugBank.d219.s24|138-146|measured|group
DDI-DrugBank.d219.s24|150-161|prothrombin|drug
DDI-DrugBank.d219.s25|31-39|warfarin|drug
DDI-DrugBank.d219.s25|44-50|Lodine|drug
DDI-DrugBank.d219.s26|100-111|prothrombin|drug
DDI-DrugBank.d219.s26|135-144|bleeding,|drug
DDI-DrugBank.d219.s26|174-183|receiving|drug
DDI-DrugBank.d219.s26|196-204|warfarin|drug
DDI-DrugBank.d219.s27|38-43|urine|drug
DDI-DrugBank.d219.s27|65-71|Lodine|drug
DDI-DrugBank.d219.s27|111-118|urinary|drug
DDI-DrugBank.d219.s27|119-128|bilirubin|drug
DDI-DrugBank.d219.s27|129-139|(urobilin)|drug
DDI-DrugBank.d219.s28|66-72|urine,|drug
DDI-DrugBank.d219.s28|104-112|findings|drug
DDI-DrugBank.d219.s28|143-150|Lodine.|drug
DDI-DrugBank.d219.s29|62-72|clinically|drug
DDI-DrugBank.d219.s31|0-6|Lodine|drug
DDI-DrugBank.d219.s32|3-11|clinical|drug
DDI-DrugBank.d219.s32|87-96|receiving|drug
DDI-DrugBank.d219.s33|18-26|remained|drug
DDI-DrugBank.d131.s0|4-20|benzodiazepines,|drug
DDI-DrugBank.d131.s0|21-30|including|drug
DDI-DrugBank.d131.s0|88-103|co-administered|drug
DDI-DrugBank.d131.s0|141-157|anticonvulsants,|group
DDI-DrugBank.d131.s0|158-174|antihistaminics,|group
DDI-DrugBank.d131.s0|175-183|ethanol,|drug
DDI-DrugBank.d131.s1|42-52|imipramine|drug
DDI-DrugBank.d131.s1|57-68|desipramine|drug
DDI-DrugBank.d131.s1|94-103|increased|drug
DDI-DrugBank.d131.s1|164-178|administration|drug
DDI-DrugBank.d131.s1|182-192|alprazolam|drug
DDI-DrugBank.d131.s2|4-12|clinical|drug
DDI-DrugBank.d131.s3|19-29|Alprazolam|drug
DDI-DrugBank.d131.s3|69-76|initial|drug
DDI-DrugBank.d131.s3|85-95|alprazolam|drug
DDI-DrugBank.d131.s3|110-123|hydroxylation|drug
DDI-DrugBank.d131.s4|12-19|inhibit|drug
DDI-DrugBank.d131.s4|90-100|alprazolam|drug
DDI-DrugBank.d131.s5|55-63|Clinical|drug
DDI-DrugBank.d131.s5|93-101|Clinical|drug
DDI-DrugBank.d131.s5|110-119|Involving|drug
DDI-DrugBank.d131.s5|120-130|Alprazolam|drug
DDI-DrugBank.d131.s5|155-161|during|drug
DDI-DrugBank.d131.s5|162-178|coadministration|drug
DDI-DrugBank.d131.s5|197-213|Coadministration|drug
DDI-DrugBank.d131.s5|217-227|fluoxetine|drug
DDI-DrugBank.d131.s5|233-243|alprazolam|drug
DDI-DrugBank.d131.s5|244-253|increased|drug
DDI-DrugBank.d131.s5|290-300|alprazolam|drug
DDI-DrugBank.d131.s5|337-346|increased|drug
DDI-DrugBank.d131.s5|379-387|measured|group
DDI-DrugBank.d131.s6|0-16|Coadministration|drug
DDI-DrugBank.d131.s6|79-89|alprazolam|drug
DDI-DrugBank.d131.s6|129-138|increased|drug
DDI-DrugBank.d131.s7|0-16|Coadministration|drug
DDI-DrugBank.d131.s7|25-39|contraceptives|group
DDI-DrugBank.d131.s7|40-49|increased|drug
DDI-DrugBank.d131.s7|86-96|alprazolam|drug
DDI-DrugBank.d131.s7|137-146|increased|drug
DDI-DrugBank.d131.s8|53-63|inhibitors|drug
DDI-DrugBank.d131.s8|80-88|clinical|drug
DDI-DrugBank.d131.s8|97-106|involving|drug
DDI-DrugBank.d131.s8|107-122|benzodiazepines|drug
DDI-DrugBank.d131.s8|148-158|alprazolam|drug
DDI-DrugBank.d131.s8|200-210|alprazolam|drug
DDI-DrugBank.d131.s8|220-235|benzodiazepines|drug
DDI-DrugBank.d131.s8|260-266|during|drug
DDI-DrugBank.d131.s8|267-283|coadministration|drug
DDI-DrugBank.d131.s8|322-330|clinical|drug
DDI-DrugBank.d131.s8|342-357|benzodiazepines|drug
DDI-DrugBank.d131.s8|369-379|alprazolam|drug
DDI-DrugBank.d131.s8|404-415|interaction|drug
DDI-DrugBank.d131.s8|421-431|alprazolam|drug
DDI-DrugBank.d131.s8|440-450|following:|drug
DDI-DrugBank.d131.s8|473-482|macrolide|drug
DDI-DrugBank.d131.s8|483-494|antibiotics|group
DDI-DrugBank.d131.s8|503-515|erythromycin|drug
DDI-DrugBank.d131.s8|520-535|clarithromycin,|drug
DDI-DrugBank.d131.s9|30-40|alprazolam|drug
DDI-DrugBank.d131.s9|65-76|interaction|drug
DDI-DrugBank.d131.s9|82-92|alprazolam|drug
DDI-DrugBank.d131.s9|101-111|following:|drug
DDI-DrugBank.d131.s9|112-122|sertraline|drug
DDI-DrugBank.d131.s9|127-138|paroxetine.|drug
DDI-DrugBank.d131.s10|30-45|benzodiazepines|drug
DDI-DrugBank.d131.s10|57-67|alprazolam|drug
DDI-DrugBank.d131.s10|92-103|interaction|drug
DDI-DrugBank.d131.s10|112-122|following:|drug
DDI-DrugBank.d131.s10|123-134|ergotamine,|drug
DDI-DrugBank.d131.s10|135-148|cyclosporine,|drug
DDI-DrugBank.d131.s10|161-173|nicardipine,|drug
DDI-DrugBank.d131.s10|178-189|nifedipine.|drug
DDI-DrugBank.d131.s11|23-29|during|drug
DDI-DrugBank.d131.s11|34-50|coadministration|drug
DDI-MedLine.d37.s1|29-35|taking|drug
DDI-MedLine.d37.s1|36-50|anticoagulants|group
DDI-MedLine.d37.s2|39-47|bleeding|drug
DDI-DrugBank.d177.s0|10-20|nilutamide|drug
DDI-DrugBank.d177.s0|39-46|inhibit|drug
DDI-DrugBank.d177.s0|80-85|P-450|brand
DDI-DrugBank.d177.s0|151-160|requiring|drug
DDI-DrugBank.d177.s1|43-50|margin,|drug
DDI-DrugBank.d177.s1|59-66|vitamin|drug
DDI-DrugBank.d177.s1|82-92|phenytoin,|drug
DDI-DrugBank.d177.s1|97-110|theophylline,|drug
DDI-DrugBank.d177.s1|132-143|elimination|drug
DDI-DrugBank.d177.s1|148-157|increases|drug
DDI-DrugBank.d177.s1|183-190|leading|drug
DDI-DrugBank.d177.s2|98-110|administered|drug
DDI-DrugBank.d177.s3|18-25|vitamin|drug
DDI-DrugBank.d177.s3|44-56|administered|drug
DDI-DrugBank.d177.s3|88-99|prothrombin|drug
DDI-DrugBank.d177.s3|167-174|vitamin|drug
DDI-DrugBank.d505.s0|3-18|pharmacokinetic|drug
DDI-DrugBank.d505.s0|29-40|interaction|drug
DDI-DrugBank.d505.s0|69-79|PERSANTINE|brand
DDI-DrugBank.d505.s0|81-94|(dipyridamole|drug
DDI-DrugBank.d505.s1|4-13|following|drug
DDI-DrugBank.d505.s1|14-25|information|drug
DDI-DrugBank.d505.s1|30-38|obtained|drug
DDI-DrugBank.d505.s1|48-59|literature.|group
DDI-DrugBank.d505.s2|0-10|Adenosine:|drug
DDI-DrugBank.d505.s2|11-23|Dipyridamole|drug
DDI-DrugBank.d505.s2|45-53|increase|drug
DDI-DrugBank.d505.s2|102-112|adenosine.|drug
DDI-DrugBank.d505.s3|14-23|adenosine|drug
DDI-DrugBank.d505.s4|0-14|Cholinesterase|drug
DDI-DrugBank.d505.s4|27-39|Dipyridamole|drug
DDI-DrugBank.d505.s4|59-77|anticholinesterase|group
DDI-DrugBank.d505.s4|88-102|cholinesterase|drug
DDI-DrugBank.d505.s4|103-114|inhibitors,|drug
DDI-DrugBank.d505.s4|135-146|aggravating|drug
DDI-DrugBank.d442.s0|13-24|prothrombin|drug
DDI-DrugBank.d442.s0|58-67|receiving|drug
DDI-DrugBank.d442.s0|79-87|warfarin|drug
DDI-DrugBank.d442.s0|102-111|flutamide|drug
DDI-DrugBank.d442.s0|116-126|initiated.|drug
DDI-DrugBank.d442.s1|17-27|monitoring|drug
DDI-DrugBank.d442.s1|31-42|prothrombin|drug
DDI-DrugBank.d442.s1|85-98|anticoagulant|group
DDI-DrugBank.d442.s1|126-133|EULEXIN|brand
DDI-DrugBank.d442.s1|147-159|administered|drug
DDI-DrugBank.d442.s1|179-188|warfarin.|drug
DDI-DrugBank.d417.s0|0-10|Netilmicin|drug
DDI-DrugBank.d417.s0|25-37|administered|drug
DDI-DrugBank.d417.s0|69-78|diuretics|group
DDI-DrugBank.d417.s0|87-97|furosemide|drug
DDI-DrugBank.d417.s0|170-182|combination.|drug
DDI-DrugBank.d241.s0|31-39|pressure|group
DDI-DrugBank.d241.s0|55-61|FLOLAN|brand
DDI-DrugBank.d241.s0|65-77|administered|drug
DDI-DrugBank.d241.s0|83-93|diuretics,|group
DDI-DrugBank.d241.s0|94-110|antihypertensive|group
DDI-DrugBank.d241.s1|11-23|antiplatelet|group
DDI-DrugBank.d241.s1|34-48|anticoagulants|group
DDI-DrugBank.d241.s1|100-106|FLOLAN|brand
DDI-DrugBank.d241.s1|110-118|increase|drug
DDI-DrugBank.d241.s1|131-140|bleeding.|drug
DDI-DrugBank.d241.s2|18-27|receiving|drug
DDI-DrugBank.d241.s2|28-37|infusions|drug
DDI-DrugBank.d241.s2|41-47|FLOLAN|brand
DDI-DrugBank.d241.s2|51-59|clinical|drug
DDI-DrugBank.d241.s2|72-82|maintained|drug
DDI-DrugBank.d241.s2|86-100|anticoagulants|group
DDI-DrugBank.d241.s2|121-130|increased|drug
DDI-DrugBank.d241.s2|131-140|bleeding.|drug
DDI-DrugBank.d241.s3|3-11|clinical|drug
DDI-DrugBank.d241.s3|20-26|FLOLAN|brand
DDI-DrugBank.d241.s3|41-49|digoxin,|drug
DDI-DrugBank.d241.s3|50-60|diuretics,|group
DDI-DrugBank.d241.s3|61-76|anticoagulants,|group
DDI-DrugBank.d241.s3|125-140|pharmacokinetic|drug
DDI-DrugBank.d241.s3|184-191|failure|group
DDI-DrugBank.d241.s3|192-201|receiving|drug
DDI-DrugBank.d241.s3|202-212|furosemide|drug
DDI-DrugBank.d241.s3|216-223|digoxin|drug
DDI-DrugBank.d241.s3|245-251|FLOLAN|brand
DDI-DrugBank.d241.s3|256-266|initiated,|drug
DDI-DrugBank.d241.s3|302-312|furosemide|drug
DDI-DrugBank.d241.s3|326-333|digoxin|drug
DDI-DrugBank.d241.s3|437-445|baseline|drug
DDI-DrugBank.d241.s4|14-24|furosemide|drug
DDI-DrugBank.d241.s4|61-71|clinically|drug
DDI-DrugBank.d241.s5|21-28|digoxin|drug
DDI-DrugBank.d241.s5|52-59|digoxin|drug
DDI-DrugBank.d241.s5|81-91|initiation|drug
DDI-DrugBank.d241.s5|108-115|FLOLAN,|brand
DDI-DrugBank.d241.s5|129-139|clinically|drug
DDI-DrugBank.d241.s5|173-180|digoxin|drug
DDI-DrugBank.d107.s0|25-33|Diuretic|group
DDI-DrugBank.d107.s0|55-64|diuretics|group
DDI-DrugBank.d107.s0|94-102|diuretic|group
DDI-DrugBank.d107.s0|124-135|instituted,|drug
DDI-DrugBank.d107.s0|196-204|pressure|group
DDI-DrugBank.d107.s0|211-221|initiation|drug
DDI-DrugBank.d107.s1|76-85|minimized|drug
DDI-DrugBank.d107.s1|96-109|discontinuing|group
DDI-DrugBank.d107.s1|114-122|diuretic|group
DDI-DrugBank.d107.s1|126-136|increasing|drug
DDI-DrugBank.d107.s1|146-152|intake|drug
DDI-DrugBank.d107.s1|162-172|initiation|drug
DDI-DrugBank.d107.s2|22-30|continue|group
DDI-DrugBank.d107.s2|35-44|diuretic,|group
DDI-DrugBank.d107.s2|45-52|provide|drug
DDI-DrugBank.d107.s2|89-96|initial|drug
DDI-DrugBank.d107.s2|141-149|pressure|group
DDI-DrugBank.d107.s3|7-14|Causing|drug
DDI-DrugBank.d107.s3|15-20|Renin|drug
DDI-DrugBank.d107.s3|34-50|antihypertensive|group
DDI-DrugBank.d107.s3|104-120|antihypertensive|group
DDI-DrugBank.d107.s3|139-144|renin|drug
DDI-DrugBank.d107.s3|160-171|diuretics).|group
DDI-DrugBank.d107.s4|14-31|Anti-inflammatory|drug
DDI-DrugBank.d107.s4|97-102|being|drug
DDI-DrugBank.d107.s4|129-146|anti-inflammatory|group
DDI-DrugBank.d107.s4|158-175|co-administration|drug
DDI-DrugBank.d107.s6|5-13|clinical|drug
DDI-DrugBank.d107.s6|34-46|indomethacin|drug
DDI-DrugBank.d107.s6|50-58|sulindac|drug
DDI-DrugBank.d107.s6|63-75|administered|drug
DDI-DrugBank.d107.s6|101-110|receiving|drug
DDI-DrugBank.d107.s6|111-119|VASOTEC.|brand
DDI-DrugBank.d107.s7|41-49|blunting|drug
DDI-DrugBank.d107.s7|57-73|antihypertensive|group
DDI-DrugBank.d107.s7|84-92|VASOTEC.|brand
DDI-DrugBank.d107.s8|41-49|diminish|drug
DDI-DrugBank.d107.s8|54-70|antihypertensive|group
DDI-DrugBank.d107.s8|85-96|inhibitors.|drug
DDI-DrugBank.d107.s9|5-16|interaction|drug
DDI-DrugBank.d107.s9|59-65|taking|drug
DDI-DrugBank.d107.s9|96-107|inhibitors.|drug
DDI-DrugBank.d107.s10|95-114|adrenergic-blocking|drug
DDI-DrugBank.d107.s10|145-161|calcium-blocking|drug
DDI-DrugBank.d107.s10|170-182|hydralazine,|drug
DDI-DrugBank.d107.s10|183-191|prazosin|drug
DDI-DrugBank.d107.s10|196-203|digoxin|drug
DDI-DrugBank.d107.s10|224-234|clinically|drug
DDI-DrugBank.d107.s10|255-268|interactions.|drug
DDI-DrugBank.d107.s11|76-86|clinically|drug
DDI-DrugBank.d107.s12|7-17|Increasing|drug
DDI-DrugBank.d107.s12|24-34|Potassium:|drug
DDI-DrugBank.d107.s12|72-81|potassium|drug
DDI-DrugBank.d107.s12|97-110|thiazide-type|group
DDI-DrugBank.d107.s12|111-121|diuretics.|group
DDI-DrugBank.d107.s13|0-17|Potassium-sparing|drug
DDI-DrugBank.d107.s13|18-27|diuretics|group
DDI-DrugBank.d107.s13|79-88|potassium|drug
DDI-DrugBank.d107.s13|105-125|potassium-containing|group
DDI-DrugBank.d107.s13|167-176|increases|drug
DDI-DrugBank.d107.s13|186-196|potassium.|drug
DDI-DrugBank.d107.s14|49-58|indicated|drug
DDI-DrugBank.d107.s14|147-157|monitoring|drug
DDI-DrugBank.d107.s14|167-177|potassium.|drug
DDI-DrugBank.d107.s15|0-9|Potassium|drug
DDI-DrugBank.d107.s15|10-17|sparing|drug
DDI-DrugBank.d107.s15|77-84|failure|group
DDI-DrugBank.d107.s15|85-94|receiving|drug
DDI-DrugBank.d107.s16|0-8|Lithium:|drug
DDI-DrugBank.d107.s16|9-16|Lithium|drug
DDI-DrugBank.d107.s16|56-65|receiving|drug
DDI-DrugBank.d107.s16|66-73|lithium|drug
DDI-DrugBank.d107.s16|111-122|elimination|drug
DDI-DrugBank.d107.s16|126-133|sodium,|drug
DDI-DrugBank.d107.s16|134-143|including|drug
DDI-DrugBank.d107.s16|148-159|inhibitors.|drug
DDI-DrugBank.d107.s17|29-36|lithium|drug
DDI-DrugBank.d107.s17|84-96|administered|drug
DDI-DrugBank.d107.s17|116-124|lithium.|drug
DDI-DrugBank.d546.s1|122-132|inhibition|drug
DDI-DrugBank.d546.s2|63-74|interaction|drug
DDI-DrugBank.d546.s2|84-95|intravenous|drug
DDI-DrugBank.d546.s2|116-128|administered|drug
DDI-DrugBank.d546.s2|169-179|sublingual|drug
DDI-DrugBank.d546.s2|180-194|nitroglycerin.|drug
DDI-DrugBank.d546.s3|45-61|antihypertensive|group
DDI-DrugBank.d546.s3|93-100|calcium|drug
DDI-DrugBank.d546.s3|123-134|inhibitors,|drug
DDI-DrugBank.d546.s3|139-148|diuretics|group
DDI-DrugBank.d546.s3|155-168|thiazide-like|group
DDI-DrugBank.d336.s0|9-17|clinical|drug
DDI-DrugBank.d336.s0|193-202|receiving|drug
DDI-DrugBank.d336.s0|208-222|anticoagulants|group
DDI-DrugBank.d493.s0|14-20|HUMIRA|brand
DDI-DrugBank.d493.s0|71-77|taking|drug
DDI-DrugBank.d493.s1|63-69|HUMIRA|brand
DDI-DrugBank.d493.s2|0-9|Anakinra:|drug
DDI-DrugBank.d493.s2|21-35|administration|drug
DDI-DrugBank.d493.s2|39-47|anakinra|drug
DDI-DrugBank.d493.s2|52-65|interleukin-1|drug
DDI-DrugBank.d493.s2|82-89|another|drug
DDI-DrugBank.d493.s2|90-102|TNF-blocking|drug
DDI-DrugBank.d493.s2|137-146|increased|drug
DDI-DrugBank.d493.s2|163-174|infections,|drug
DDI-DrugBank.d493.s2|178-187|increased|drug
DDI-DrugBank.d493.s2|252-261|medicinal|drug
DDI-DrugBank.d493.s3|27-35|anakinra|drug
DDI-DrugBank.d493.s3|44-55|combination|drug
DDI-DrugBank.d493.s3|61-67|HUMIRA|brand
DDI-DrugBank.d493.s4|15-26|combination|drug
DDI-DrugBank.d493.s4|30-38|anakinra|drug
DDI-DrugBank.d493.s4|50-62|TNF-blocking|drug
DDI-DrugBank.d493.s4|71-80|including|drug
DDI-DrugBank.d493.s4|81-88|HUMIRA,|brand
DDI-DrugBank.d159.s0|8-20|interactions|drug
DDI-DrugBank.d159.s1|40-47|retinal|drug
DDI-DrugBank.d509.s0|56-69|aripiprazole,|drug
DDI-DrugBank.d509.s0|98-105|ABILIFY|brand
DDI-DrugBank.d509.s0|118-129|combination|drug
DDI-DrugBank.d509.s0|151-157|acting|drug
DDI-DrugBank.d509.s2|35-47|aripiprazole|drug
DDI-DrugBank.d509.s2|91-98|certain|drug
DDI-DrugBank.d509.s2|99-115|antihypertensive|group
DDI-DrugBank.d509.s3|36-43|ABILIFY|brand
DDI-DrugBank.d509.s3|44-56|Aripiprazole|drug
DDI-DrugBank.d509.s3|79-86|CYP1A1,|brand
DDI-DrugBank.d509.s3|87-94|CYP1A2,|brand
DDI-DrugBank.d509.s3|95-102|CYP2A6,|brand
DDI-DrugBank.d509.s3|103-110|CYP2B6,|brand
DDI-DrugBank.d509.s3|111-118|CYP2C8,|brand
DDI-DrugBank.d509.s3|119-126|CYP2C9,|brand
DDI-DrugBank.d509.s3|127-135|CYP2C19,|brand
DDI-DrugBank.d509.s3|139-145|CYP2E1|brand
DDI-DrugBank.d509.s4|0-12|Aripiprazole|drug
DDI-DrugBank.d509.s5|22-33|interaction|drug
DDI-DrugBank.d509.s5|37-49|aripiprazole|drug
DDI-DrugBank.d509.s5|55-65|inhibitors|drug
DDI-DrugBank.d509.s5|69-77|inducers|drug
DDI-DrugBank.d509.s5|119-127|smoking,|drug
DDI-DrugBank.d509.s6|5-11|CYP3A4|brand
DDI-DrugBank.d509.s6|16-22|CYP2D6|brand
DDI-DrugBank.d509.s6|43-55|aripiprazole|drug
DDI-DrugBank.d509.s7|12-18|induce|drug
DDI-DrugBank.d509.s7|19-25|CYP3A4|brand
DDI-DrugBank.d509.s7|31-45|carbamazepine)|drug
DDI-DrugBank.d509.s7|61-69|increase|drug
DDI-DrugBank.d509.s7|73-85|aripiprazole|drug
DDI-DrugBank.d509.s8|14-20|CYP3A4|brand
DDI-DrugBank.d509.s8|26-39|ketoconazole)|drug
DDI-DrugBank.d509.s8|43-49|CYP2D6|brand
DDI-DrugBank.d509.s8|55-65|quinidine,|drug
DDI-DrugBank.d509.s8|66-77|fluoxetine,|drug
DDI-DrugBank.d509.s8|81-92|paroxetine)|drug
DDI-DrugBank.d509.s8|97-104|inhibit|drug
DDI-DrugBank.d509.s8|105-117|aripiprazole|drug
DDI-DrugBank.d509.s8|118-129|elimination|drug
DDI-DrugBank.d509.s8|140-149|increased|drug
DDI-DrugBank.d509.s9|0-13|Ketoconazole:|drug
DDI-DrugBank.d509.s9|14-30|Coadministration|drug
DDI-DrugBank.d509.s9|34-46|ketoconazole|drug
DDI-DrugBank.d509.s9|79-84|15-mg|drug_n
DDI-DrugBank.d509.s9|85-91|single|drug
DDI-DrugBank.d509.s9|100-112|aripiprazole|drug
DDI-DrugBank.d509.s9|113-122|increased|drug
DDI-DrugBank.d509.s9|134-146|aripiprazole|drug
DDI-DrugBank.d509.s10|23-35|ketoconazole|drug
DDI-DrugBank.d509.s11|17-31|administration|drug
DDI-DrugBank.d509.s11|35-47|ketoconazole|drug
DDI-DrugBank.d509.s11|53-65|aripiprazole|drug
DDI-DrugBank.d509.s11|74-86|aripiprazole|drug
DDI-DrugBank.d509.s12|13-23|inhibitors|drug
DDI-DrugBank.d509.s12|27-33|CYP3A4|brand
DDI-DrugBank.d509.s12|34-48|(itraconazole)|drug
DDI-DrugBank.d509.s13|7-17|inhibitors|drug
DDI-DrugBank.d509.s13|18-32|(erythromycin,|drug
DDI-DrugBank.d509.s14|9-15|CYP3A4|brand
DDI-DrugBank.d509.s14|16-25|inhibitor|drug
DDI-DrugBank.d509.s14|48-59|combination|drug
DDI-DrugBank.d509.s14|69-81|aripiprazole|drug
DDI-DrugBank.d509.s14|102-112|increased.|drug
DDI-DrugBank.d509.s15|0-10|Quinidine:|drug
DDI-DrugBank.d509.s15|11-27|Coadministration|drug
DDI-DrugBank.d509.s15|33-38|10-mg|drug_n
DDI-DrugBank.d509.s15|39-45|single|drug
DDI-DrugBank.d509.s15|54-66|aripiprazole|drug
DDI-DrugBank.d509.s15|72-81|quinidine|drug
DDI-DrugBank.d509.s15|117-126|inhibitor|drug
DDI-DrugBank.d509.s15|130-137|CYP2D6,|brand
DDI-DrugBank.d509.s15|138-147|increased|drug
DDI-DrugBank.d509.s15|159-171|aripiprazole|drug
DDI-DrugBank.d509.s15|228-248|dehydroaripiprazole,|drug
DDI-DrugBank.d509.s16|0-12|Aripiprazole|drug
DDI-DrugBank.d509.s16|84-98|administration|drug
DDI-DrugBank.d509.s16|102-111|quinidine|drug
DDI-DrugBank.d509.s16|117-129|aripiprazole|drug
DDI-DrugBank.d509.s17|18-28|inhibitors|drug
DDI-DrugBank.d509.s17|32-39|CYP2D6,|brand
DDI-DrugBank.d509.s17|48-58|fluoxetine|drug
DDI-DrugBank.d509.s17|62-73|paroxetine,|drug
DDI-DrugBank.d509.s18|9-15|CYP2D6|brand
DDI-DrugBank.d509.s18|16-25|inhibitor|drug
DDI-DrugBank.d509.s18|48-59|combination|drug
DDI-DrugBank.d509.s18|69-81|aripiprazole|drug
DDI-DrugBank.d509.s18|102-112|increased.|drug
DDI-DrugBank.d509.s19|0-14|Carbamazepine:|drug
DDI-DrugBank.d509.s19|15-31|Coadministration|drug
DDI-DrugBank.d509.s19|35-48|carbamazepine|drug
DDI-DrugBank.d509.s19|57-62|BID),|brand
DDI-DrugBank.d509.s19|72-78|CYP3A4|brand
DDI-DrugBank.d509.s19|79-87|inducer,|drug
DDI-DrugBank.d509.s19|93-105|aripiprazole|drug
DDI-DrugBank.d509.s19|188-200|aripiprazole|drug
DDI-DrugBank.d509.s19|228-249|dehydro-aripiprazole.|drug
DDI-DrugBank.d509.s20|5-18|carbamazepine|drug
DDI-DrugBank.d509.s20|31-43|aripiprazole|drug
DDI-DrugBank.d509.s20|53-65|aripiprazole|drug
DDI-DrugBank.d509.s21|16-25|increases|drug
DDI-DrugBank.d509.s21|45-53|clinical|drug
DDI-DrugBank.d509.s22|5-18|carbamazepine|drug
DDI-DrugBank.d509.s22|41-52|combination|drug
DDI-DrugBank.d509.s22|62-74|aripiprazole|drug
DDI-DrugBank.d509.s23|3-13|clinically|drug
DDI-DrugBank.d509.s23|36-47|famotidine,|drug
DDI-DrugBank.d509.s23|62-69|lithium|drug
DDI-DrugBank.d509.s23|86-102|pharmacokinetics|drug
DDI-DrugBank.d509.s23|106-118|aripiprazole|drug
DDI-DrugBank.d509.s23|124-132|CLINICAL|brand
DDI-DrugBank.d509.s23|133-146|PHARMACOLOGY:|brand
DDI-DrugBank.d509.s24|14-21|ABILIFY|brand
DDI-DrugBank.d509.s24|44-56|Aripiprazole|drug
DDI-DrugBank.d509.s24|78-88|clinically|drug
DDI-DrugBank.d509.s24|99-114|pharmacokinetic|drug
DDI-DrugBank.d509.s24|115-127|interactions|drug
DDI-DrugBank.d509.s25|27-36|30-mg/day|drug_n
DDI-DrugBank.d509.s25|46-58|aripiprazole|drug
DDI-DrugBank.d509.s25|102-108|CYP2D6|brand
DDI-DrugBank.d509.s25|129-135|CYP2C9|brand
DDI-DrugBank.d509.s25|136-147|(warfarin),|drug
DDI-DrugBank.d509.s25|148-155|CYP2C19|brand
DDI-DrugBank.d509.s25|156-168|(omeprazole,|drug
DDI-DrugBank.d509.s25|169-179|warfarin),|drug
DDI-DrugBank.d509.s25|184-190|CYP3A4|brand
DDI-DrugBank.d509.s26|14-26|aripiprazole|drug
DDI-DrugBank.d509.s26|31-50|dehydroaripiprazole|drug
DDI-DrugBank.d509.s26|78-86|altering|drug
DDI-DrugBank.d509.s27|53-65|aripiprazole|drug
DDI-DrugBank.d509.s27|66-80|coadministered|drug
DDI-DrugBank.d509.s27|86-93|ethanol|drug
DDI-DrugBank.d509.s27|106-120|coadministered|drug
DDI-DrugBank.d509.s27|126-133|ethanol|drug
DDI-DrugBank.d509.s28|89-95|taking|drug
DDI-DrugBank.d509.s28|96-103|ABILIFY|brand
DDI-DrugBank.d310.s0|55-62|calcium|drug
DDI-DrugBank.d310.s1|49-58|intensify|drug
DDI-DrugBank.d310.s1|73-89|antihypertensive|group
DDI-DrugBank.d310.s1|132-141|suffering|drug
DDI-DrugBank.d310.s2|51-59|clinical|drug
DDI-DrugBank.d310.s3|52-60|increase|drug
DDI-DrugBank.d310.s3|74-84|nimodipine|drug
DDI-DrugBank.d310.s3|117-125|increase|drug
DDI-DrugBank.d310.s3|183-193|cimetidine|drug
DDI-DrugBank.d310.s3|197-202|1,000|drug_n
DDI-DrugBank.d310.s3|214-224|nimodipine|drug
DDI-DrugBank.d310.s4|41-51|inhibition|drug
DDI-DrugBank.d310.s4|84-95|cimetidine,|drug
DDI-DrugBank.d310.s4|142-153|nimodipine.|drug
DDI-DrugBank.d108.s0|24-36|administered|drug
DDI-DrugBank.d108.s0|62-71|receiving|drug
DDI-DrugBank.d108.s1|5-11|single|drug
DDI-DrugBank.d108.s1|35-50|intraperitoneal|drug
DDI-DrugBank.d108.s1|67-76|inhibitor|drug
DDI-DrugBank.d108.s1|122-131|including|drug
DDI-DrugBank.d108.s2|112-124|potentiating|drug
DDI-DrugBank.d108.s4|3-14|combination|drug
DDI-DrugBank.d108.s5|4-13|monoamine|drug
DDI-DrugBank.d108.s5|22-32|inhibitory|drug
DDI-DrugBank.d108.s5|101-116|discontinuation|group
DDI-DrugBank.d108.s5|168-175|another|drug
DDI-DrugBank.d108.s5|195-204|following|drug
DDI-DrugBank.d108.s6|37-44|wishing|drug
DDI-DrugBank.d108.s6|48-57|terminate|drug
DDI-DrugBank.d108.s6|91-96|begin|drug
DDI-DrugBank.d108.s6|110-117|another|drug
DDI-DrugBank.d108.s6|144-152|interval|drug
DDI-DrugBank.d321.s0|53-64|albendazole|drug
DDI-DrugBank.d321.s0|65-74|sulfoxide|drug
DDI-DrugBank.d321.s0|125-139|coadministered|drug
DDI-DrugBank.d321.s0|158-169|albendazole|drug
DDI-DrugBank.d321.s1|56-65|increased|drug
DDI-DrugBank.d321.s1|128-139|albendazole|drug
DDI-DrugBank.d321.s1|140-149|sulfoxide|drug
DDI-DrugBank.d321.s1|245-256|albendazole|drug
DDI-DrugBank.d321.s2|27-38|elimination|drug
DDI-DrugBank.d321.s2|52-63|albendazole|drug
DDI-DrugBank.d321.s2|64-73|sulfoxide|drug
DDI-DrugBank.d321.s3|4-20|pharmacokinetics|drug
DDI-DrugBank.d321.s3|52-61|following|drug
DDI-DrugBank.d321.s3|62-78|coadministration|drug
DDI-DrugBank.d321.s3|84-95|albendazole|drug
DDI-DrugBank.d321.s4|0-11|Cimetidine:|drug
DDI-DrugBank.d321.s4|12-23|Albendazole|drug
DDI-DrugBank.d321.s4|24-33|sulfoxide|drug
DDI-DrugBank.d321.s4|79-88|increased|drug
DDI-DrugBank.d321.s4|96-103|2-fold)|drug_n
DDI-DrugBank.d321.s4|142-152|cimetidine|drug
DDI-DrugBank.d321.s4|188-199|albendazole|drug
DDI-DrugBank.d321.s5|0-11|Albendazole|drug
DDI-DrugBank.d321.s5|12-21|sulfoxide|drug
DDI-DrugBank.d321.s5|73-80|dosing.|drug
DDI-DrugBank.d321.s6|0-13|Theophylline:|drug
DDI-DrugBank.d321.s6|18-34|pharmacokinetics|drug
DDI-DrugBank.d321.s6|38-50|theophylline|drug
DDI-DrugBank.d321.s6|51-65|(aminophylline|drug
DDI-DrugBank.d321.s6|76-83|infused|drug
DDI-DrugBank.d321.s6|92-100|minutes)|drug
DDI-DrugBank.d321.s6|116-125|following|drug
DDI-DrugBank.d321.s6|128-134|single|drug
DDI-DrugBank.d321.s6|148-159|albendazole|drug
DDI-DrugBank.d519.s0|20-31|interaction|drug
DDI-DrugBank.d519.s1|11-16|P-450|brand
DDI-DrugBank.d519.s1|36-44|involved|drug
DDI-DrugBank.d519.s2|35-43|proteins|drug
DDI-DrugBank.d519.s2|51-56|99%).|drug_n
DDI-DrugBank.d519.s3|61-70|measuring|drug
DDI-DrugBank.d519.s3|125-139|administration|drug
DDI-DrugBank.d519.s4|6-18|transaminase|drug
DDI-DrugBank.d519.s4|36-44|obtained|drug
DDI-DrugBank.d519.s4|52-60|starting|drug
DDI-DrugBank.d519.s4|102-108|during|drug
DDI-DrugBank.d519.s5|9-20|measurement|group
DDI-DrugBank.d467.s0|35-47|interactions|drug
DDI-DrugBank.d467.s2|69-82|ketoconazole,|drug
DDI-DrugBank.d467.s2|83-96|itraconazole,|drug
DDI-DrugBank.d467.s2|97-110|erythromycin,|drug
DDI-DrugBank.d467.s2|152-162|inhibitors|drug
DDI-DrugBank.d467.s2|218-226|increase|drug
DDI-DrugBank.d467.s3|13-22|rifampin,|drug
DDI-DrugBank.d467.s3|23-33|phenytoin,|drug
DDI-DrugBank.d467.s3|59-67|inducers|drug
DDI-DrugBank.d467.s4|12-26|administration|drug
DDI-DrugBank.d467.s4|30-39|Targretin|drug
DDI-DrugBank.d467.s4|89-98|increases|drug
DDI-DrugBank.d467.s4|198-208|inhibition|drug
DDI-DrugBank.d467.s5|85-97|atorvastatin|drug
DDI-DrugBank.d467.s5|98-113|administration.|drug
DDI-DrugBank.d467.s6|12-26|administration|drug
DDI-DrugBank.d467.s6|47-56|Targretin|drug
DDI-DrugBank.d286.s0|0-13|Ethoxzolamide|drug
DDI-DrugBank.d286.s0|18-26|increase|drug
DDI-DrugBank.d286.s0|53-66|amphetamines,|drug
DDI-DrugBank.d286.s0|67-80|procainamide,|drug
DDI-DrugBank.d286.s0|85-95|quinidine.|drug
DDI-DrugBank.d286.s1|7-15|increase|drug
DDI-DrugBank.d286.s1|43-51|lithium,|drug
DDI-DrugBank.d286.s1|73-81|increase|drug
DDI-DrugBank.d286.s2|0-16|Coadministration|drug
DDI-DrugBank.d286.s2|20-33|ethoxzolamide|drug
DDI-DrugBank.d286.s2|45-55|diuretics,|group
DDI-DrugBank.d286.s2|56-68|amphotericin|drug
DDI-DrugBank.d286.s2|76-91|corticosteroids|group
DDI-DrugBank.d317.s0|0-15|DRUG/LABORATORY|brand
DDI-DrugBank.d317.s0|21-33|INTERACTIONS|brand
DDI-DrugBank.d317.s1|12-23|prothrombin|drug
DDI-DrugBank.d317.s1|38-52|thromboplastin|drug
DDI-DrugBank.d317.s2|0-9|increased|drug
DDI-DrugBank.d317.s3|0-9|increased|drug
DDI-DrugBank.d317.s3|26-34|antigen,|group
DDI-DrugBank.d317.s3|40-48|antigen,|group
DDI-DrugBank.d317.s3|86-91|VII-X|brand
DDI-DrugBank.d317.s3|101-109|II-VII-X|brand
DDI-DrugBank.d317.s3|123-144|beta-thromboglobulin;|drug
DDI-DrugBank.d317.s4|20-31|anti-factor|group
DDI-DrugBank.d317.s4|39-51|antithrombin|group
DDI-DrugBank.d317.s4|67-79|antithrombin|group
DDI-DrugBank.d317.s5|0-9|increased|drug
DDI-DrugBank.d317.s5|20-30|fibrinogen|drug
DDI-DrugBank.d317.s5|35-45|fibrinogen|drug
DDI-DrugBank.d317.s6|0-9|increased|drug
DDI-DrugBank.d317.s6|10-21|plasminogen|drug
DDI-DrugBank.d317.s6|22-29|antigen|group
DDI-DrugBank.d317.s8|10-25|thyroid-binding|drug
DDI-DrugBank.d317.s8|26-34|globulin|drug
DDI-DrugBank.d317.s8|35-40|(TBG)|brand
DDI-DrugBank.d317.s8|48-55|leading|drug
DDI-DrugBank.d317.s8|59-68|increased|drug
DDI-DrugBank.d317.s8|69-80|circulating|drug
DDI-DrugBank.d317.s8|113-121|measured|group
DDI-DrugBank.d317.s8|125-138|protein-bound|drug
DDI-DrugBank.d317.s8|139-145|iodine|drug
DDI-DrugBank.d317.s8|146-152|(PBI),|brand
DDI-DrugBank.d317.s9|3-8|resin|drug
DDI-DrugBank.d317.s9|30-40|reflecting|drug
DDI-DrugBank.d317.s13|6-13|binding|drug
DDI-DrugBank.d317.s13|14-22|proteins|drug
DDI-DrugBank.d317.s13|71-78|binding|drug
DDI-DrugBank.d317.s13|79-87|globulin|drug
DDI-DrugBank.d317.s13|88-94|(CBG),|brand
DDI-DrugBank.d317.s13|107-114|binding|drug
DDI-DrugBank.d317.s13|115-123|globulin|drug
DDI-DrugBank.d317.s13|124-131|(SHBG))|brand
DDI-DrugBank.d317.s13|132-139|leading|drug
DDI-DrugBank.d317.s13|143-152|increased|drug
DDI-DrugBank.d317.s13|159-170|circulating|drug
DDI-DrugBank.d317.s13|171-186|corticosteroids|group
DDI-DrugBank.d317.s13|195-204|steroids,|group
DDI-DrugBank.d317.s15|13-21|proteins|drug
DDI-DrugBank.d317.s15|29-38|increased|drug
DDI-DrugBank.d317.s15|39-61|(angiotensinogen/renin|drug
DDI-DrugBank.d317.s15|73-93|alpha-1-antitrypsin,|drug
DDI-DrugBank.d317.s15|94-109|ceruloplasmin).|drug
DDI-DrugBank.d317.s17|30-41|cholesterol|drug
DDI-DrugBank.d317.s17|82-93|cholesterol|drug
DDI-DrugBank.d317.s17|109-118|increased|drug
DDI-DrugBank.d317.s17|119-131|triglyceride|drug
DDI-DrugBank.d317.s19|17-27|tolerance.|drug
DDI-MedLine.d70.s0|12-19|cadmium|drug
DDI-MedLine.d70.s1|74-83|hatching,|drug
DDI-MedLine.d70.s2|16-24|cadmium,|drug
DDI-MedLine.d70.s2|25-30|zinc,|drug
DDI-MedLine.d70.s2|35-47|cadmium/zinc|drug
DDI-MedLine.d70.s2|48-56|mixtures|group
DDI-MedLine.d70.s2|75-82|ranging|drug
DDI-MedLine.d70.s2|88-93|10000|drug_n
DDI-MedLine.d70.s2|113-126|investigated.|drug
DDI-MedLine.d70.s3|6-13|mixture|group
DDI-MedLine.d70.s3|23-36|investigation|drug
DDI-MedLine.d70.s4|4-12|hatching|drug
DDI-MedLine.d70.s4|40-49|inhibited|drug
DDI-MedLine.d70.s4|71-81|1000-10000|drug_n
DDI-MedLine.d70.s4|94-100|single|drug
DDI-MedLine.d70.s5|6-14|mixtures|group
DDI-MedLine.d70.s5|36-45|hatching.|drug
DDI-MedLine.d70.s6|37-47|increasing|drug
DDI-MedLine.d70.s6|112-118|single|drug
DDI-MedLine.d70.s6|153-162|increased|drug
DDI-MedLine.d70.s6|173-181|control.|group
DDI-DrugBank.d289.s0|27-33|CYP2C9|brand
DDI-DrugBank.d289.s0|38-45|CYP3A4.|brand
DDI-DrugBank.d289.s1|35-43|increase|drug
DDI-DrugBank.d289.s2|15-22|inducer|drug
DDI-DrugBank.d289.s2|26-32|CYP3A4|brand
DDI-DrugBank.d289.s2|37-44|CYP2C9.|brand
DDI-DrugBank.d289.s3|104-112|TRACLEER|brand
DDI-DrugBank.d289.s3|116-132|co-administered.|drug
DDI-DrugBank.d289.s4|25-35|inhibitory|drug
DDI-DrugBank.d289.s4|72-80|(CYP1A2,|brand
DDI-DrugBank.d289.s4|81-88|CYP2C9,|brand
DDI-DrugBank.d289.s4|89-97|CYP2C19,|brand
DDI-DrugBank.d289.s4|98-105|CYP2D6,|brand
DDI-DrugBank.d289.s4|106-114|CYP3A4).|brand
DDI-DrugBank.d289.s5|14-22|TRACLEER|brand
DDI-DrugBank.d289.s5|42-50|increase|drug
DDI-DrugBank.d289.s6|25-34|Including|drug
DDI-DrugBank.d289.s6|101-112|interaction|drug
DDI-DrugBank.d289.s6|137-154|co-administration|drug
DDI-DrugBank.d289.s6|189-202|contraceptive|group
DDI-DrugBank.d289.s6|245-258|norethindrone|drug
DDI-DrugBank.d289.s6|263-270|ethinyl|drug
DDI-DrugBank.d289.s7|22-30|exposure|group
DDI-DrugBank.d289.s7|77-87|individual|drug
DDI-DrugBank.d289.s8|20-35|contraceptives,|group
DDI-DrugBank.d289.s8|36-45|including|drug
DDI-DrugBank.d289.s8|52-63|injectable,|drug
DDI-DrugBank.d289.s8|125-133|TRACLEER|brand
DDI-DrugBank.d289.s8|137-153|co-administered.|drug
DDI-DrugBank.d289.s9|44-57|contraception|group
DDI-DrugBank.d289.s9|83-96|contraception|group
DDI-DrugBank.d289.s9|108-114|taking|drug
DDI-DrugBank.d289.s9|115-124|TRACLEER.|brand
DDI-DrugBank.d289.s10|9-20|interaction|drug
DDI-DrugBank.d289.s10|51-61|following:|drug
DDI-DrugBank.d289.s10|62-74|Cyclosporine|drug
DDI-DrugBank.d289.s10|78-84|During|drug
DDI-DrugBank.d289.s10|114-129|administration,|drug
DDI-DrugBank.d289.s10|169-178|increased|drug
DDI-DrugBank.d289.s10|188-196|30-fold.|drug_n
DDI-DrugBank.d289.s11|55-61|4-fold|drug_n
DDI-DrugBank.d289.s11|92-104|cyclosporine|drug
DDI-DrugBank.d289.s12|16-30|administration|drug
DDI-DrugBank.d289.s12|47-59|cyclosporine|drug
DDI-DrugBank.d289.s12|65-81|contraindicated.|group
DDI-DrugBank.d289.s13|0-17|Co-administration|drug
DDI-DrugBank.d289.s13|69-81|cyclosporine|drug
DDI-DrugBank.d289.s13|87-93|CYP3A4|brand
DDI-DrugBank.d289.s14|12-29|Co-administration|drug
DDI-DrugBank.d289.s15|0-17|Co-administration|drug
DDI-DrugBank.d289.s15|66-75|increased|drug
DDI-DrugBank.d289.s17|14-23|increased|drug
DDI-DrugBank.d289.s17|47-64|aminotransferases|drug
DDI-DrugBank.d289.s17|90-99|receiving|drug
DDI-DrugBank.d289.s18|27-41|administration|drug
DDI-DrugBank.d289.s18|45-53|TRACLEER|brand
DDI-DrugBank.d289.s18|58-67|glyburide|drug
DDI-DrugBank.d289.s18|71-87|contraindicated,|group
DDI-DrugBank.d289.s19|0-17|Co-administration|drug
DDI-DrugBank.d289.s19|69-78|glyburide|drug
DDI-DrugBank.d289.s21|101-114|predominantly|drug
DDI-DrugBank.d289.s21|130-136|CYP2C9|brand
DDI-DrugBank.d289.s21|140-147|CYP3A4.|brand
DDI-DrugBank.d289.s22|36-43|control|group
DDI-DrugBank.d289.s22|56-61|using|drug
DDI-DrugBank.d289.s23|0-13|Ketoconazole:|drug
DDI-DrugBank.d289.s23|14-31|Co-administration|drug
DDI-DrugBank.d289.s23|62-75|ketoconazole,|drug
DDI-DrugBank.d289.s23|85-91|CYP3A4|brand
DDI-DrugBank.d289.s23|92-102|inhibitor,|drug
DDI-DrugBank.d289.s23|103-112|increased|drug
DDI-DrugBank.d289.s23|168-175|2-fold.|drug_n
DDI-DrugBank.d289.s24|49-58|increased|drug
DDI-DrugBank.d289.s25|0-11|Simvastatin|drug
DDI-DrugBank.d289.s25|22-30|Statins:|drug
DDI-DrugBank.d289.s25|31-48|Co-administration|drug
DDI-DrugBank.d289.s25|100-111|simvastatin|drug
DDI-DrugBank.d289.s25|115-121|CYP3A4|brand
DDI-DrugBank.d289.s25|150-158|-hydroxy|drug
DDI-DrugBank.d289.s27|67-74|statins|drug
DDI-DrugBank.d289.s27|111-118|CYP3A4,|brand
DDI-DrugBank.d289.s27|127-137|lovastatin|drug
DDI-DrugBank.d289.s27|142-155|atorvastatin.|drug
DDI-DrugBank.d289.s28|27-33|statin|drug
DDI-DrugBank.d289.s29|9-14|using|drug
DDI-DrugBank.d289.s29|15-21|CYP3A4|brand
DDI-DrugBank.d289.s29|34-41|statins|drug
DDI-DrugBank.d289.s29|54-65|cholesterol|drug
DDI-DrugBank.d289.s29|89-97|TRACLEER|brand
DDI-DrugBank.d289.s29|101-110|initiated|drug
DDI-DrugBank.d289.s29|130-136|statin|drug
DDI-DrugBank.d289.s30|0-9|Warfarin:|drug
DDI-DrugBank.d289.s30|10-27|Co-administration|drug
DDI-DrugBank.d289.s30|109-119|S-warfarin|drug
DDI-DrugBank.d289.s30|123-129|CYP2C9|brand
DDI-DrugBank.d289.s30|145-155|R-warfarin|drug
DDI-DrugBank.d289.s30|159-165|CYP3A4|brand
DDI-DrugBank.d289.s31|0-8|Clinical|drug
DDI-DrugBank.d289.s31|37-51|administration|drug
DDI-DrugBank.d289.s31|68-76|warfarin|drug
DDI-DrugBank.d289.s31|139-149|clinically|drug
DDI-DrugBank.d289.s31|177-185|warfarin|drug
DDI-DrugBank.d289.s31|191-200|(baseline|drug
DDI-DrugBank.d289.s31|216-224|clinical|drug
DDI-DrugBank.d289.s31|262-270|warfarin|drug
DDI-DrugBank.d289.s31|276-282|during|drug
DDI-DrugBank.d289.s32|0-8|Digoxin,|drug
DDI-DrugBank.d289.s32|9-19|Nimodipine|drug
DDI-DrugBank.d289.s32|62-77|pharmacokinetic|drug
DDI-DrugBank.d289.s32|78-90|interactions|drug
DDI-DrugBank.d289.s32|96-103|digoxin|drug
DDI-DrugBank.d289.s32|108-119|nimodipine,|drug
DDI-DrugBank.d473.s0|12-20|clinical|drug
DDI-DrugBank.d473.s0|31-42|interaction|drug
DDI-DrugBank.d473.s0|134-144|inhibitors|drug
DDI-DrugBank.d473.s0|149-157|inducers|drug
DDI-DrugBank.d473.s0|199-211|clofarabine.|drug
DDI-DrugBank.d473.s1|14-25|clofarabine|drug
DDI-DrugBank.d473.s2|54-64|clinically|drug
DDI-DrugBank.d473.s2|77-89|interactions|drug
DDI-DrugBank.d473.s2|93-99|CLOLAR|brand
DDI-DrugBank.d473.s3|31-42|interaction|drug
DDI-DrugBank.d473.s3|76-82|CLOLAR|brand
DDI-DrugBank.d116.s0|37-47|amantadine|drug
DDI-DrugBank.d116.s0|51-63|administered|drug
DDI-DrugBank.d116.s1|0-16|Coadministration|drug
DDI-DrugBank.d116.s1|20-32|thioridazine|drug
DDI-DrugBank.d116.s1|97-107|Parkinsons|drug
DDI-DrugBank.d116.s2|34-48|phenothiazines|drug
DDI-DrugBank.d96.s0|0-14|Dimenhydrinate|drug
DDI-DrugBank.d96.s0|47-59|apomorphine.|drug
DDI-DrugBank.d14.s0|4-16|vasodilating|drug
DDI-DrugBank.d14.s0|28-41|nitroglycerin|drug
DDI-DrugBank.d14.s2|66-73|calcium|drug
DDI-DrugBank.d14.s2|125-137|combination.|drug
DDI-MedLine.d96.s0|0-8|Jacalin:|drug
DDI-MedLine.d96.s0|12-23|IgA-binding|drug
DDI-MedLine.d96.s0|24-31|lectin.|drug
DDI-MedLine.d96.s1|48-60|integrifolia|drug
DDI-MedLine.d96.s1|73-80|contain|group
DDI-MedLine.d96.s1|83-90|lectin,|drug
DDI-MedLine.d96.s1|105-113|jacalin,|drug
DDI-MedLine.d96.s1|171-187|cell-independent|drug
DDI-MedLine.d96.s1|236-252|immunoglobulins.|drug
DDI-MedLine.d96.s2|0-6|During|drug
DDI-MedLine.d96.s2|70-78|cultures|group
DDI-MedLine.d96.s2|138-145|lectin.|drug
DDI-MedLine.d96.s3|64-75|interaction|drug
DDI-MedLine.d96.s3|79-86|jacalin|drug
DDI-MedLine.d96.s3|101-108|protein|drug
DDI-MedLine.d96.s3|122-129|culture|group
DDI-MedLine.d96.s3|130-137|medium.|drug
DDI-MedLine.d96.s4|102-108|lectin|drug
DDI-MedLine.d96.s5|49-56|protein|drug
DDI-MedLine.d96.s5|73-81|jacalin.|drug
DDI-MedLine.d96.s6|67-75|affinity|drug
DDI-MedLine.d96.s6|91-100|procedure|group
DDI-MedLine.d96.s7|0-7|Jacalin|drug
DDI-MedLine.d96.s7|19-26|binding|drug
DDI-MedLine.d96.s7|27-33|lectin|drug
DDI-MedLine.d96.s7|66-74|studying|drug
DDI-DrugBank.d186.s0|204-209|brain|drug
DDI-DrugBank.d186.s0|261-268|lithium|drug
DDI-DrugBank.d186.s0|274-281|HALDOL.|brand
DDI-DrugBank.d186.s1|63-77|administration|drug
DDI-DrugBank.d186.s1|81-88|lithium|drug
DDI-DrugBank.d186.s1|93-99|HALDOL|brand
DDI-DrugBank.d186.s2|18-27|receiving|drug
DDI-DrugBank.d186.s2|33-41|combined|drug
DDI-DrugBank.d186.s2|136-148|discontinued|group
DDI-DrugBank.d186.s3|14-27|antipsychotic|group
DDI-DrugBank.d186.s3|60-66|HALDOL|brand
DDI-DrugBank.d186.s3|85-97|potentiating|drug
DDI-DrugBank.d186.s4|40-54|coadministered|drug
DDI-DrugBank.d186.s4|76-85|rifampin,|drug
DDI-DrugBank.d186.s4|185-191|Rating|drug
DDI-DrugBank.d186.s4|203-212|increased|drug
DDI-DrugBank.d186.s4|218-227|baseline.|drug
DDI-DrugBank.d186.s5|68-77|rifampin,|drug
DDI-DrugBank.d186.s5|78-93|discontinuation|group
DDI-DrugBank.d186.s5|97-105|rifampin|drug
DDI-DrugBank.d186.s5|122-130|3.3-fold|drug_n
DDI-DrugBank.d186.s5|131-139|increase|drug
DDI-DrugBank.d186.s6|14-24|monitoring|drug
DDI-DrugBank.d186.s6|28-36|clinical|drug
DDI-DrugBank.d186.s6|62-70|rifampin|drug
DDI-DrugBank.d186.s6|74-86|administered|drug
DDI-DrugBank.d186.s6|90-102|discontinued|group
DDI-DrugBank.d524.s0|11-26|Antihistamines,|drug
DDI-DrugBank.d524.s0|27-39|antidiabetic|group
DDI-DrugBank.d524.s0|47-57|diuretics,|group
DDI-DrugBank.d253.s0|16-24|blocking|drug
DDI-DrugBank.d253.s0|74-85|arbutamine.|drug
DDI-DrugBank.d253.s1|16-24|blocking|drug
DDI-DrugBank.d253.s1|77-87|conducting|drug
DDI-DrugBank.d253.s1|91-110|arbutamine-mediated|drug
DDI-DrugBank.d253.s2|40-51|flecainide,|drug
DDI-DrugBank.d253.s2|52-62|lidocaine,|drug
DDI-DrugBank.d253.s2|66-77|quinidine):|drug
DDI-DrugBank.d253.s2|98-108|arbutamine|drug
DDI-DrugBank.d253.s3|29-37|atropine|drug
DDI-DrugBank.d253.s3|47-62|anticholinergic|group
DDI-DrugBank.d253.s3|116-126|arbutamine|drug
DDI-DrugBank.d253.s3|148-157|inotropic|drug
DDI-DrugBank.d101.s0|20-29|digitoxin|drug
DDI-DrugBank.d101.s1|11-21|monitoring|drug
DDI-DrugBank.d101.s1|32-39|digoxin|drug
DDI-DrugBank.d101.s1|54-63|indicated|drug
DDI-DrugBank.d101.s1|76-85|receiving|drug
DDI-DrugBank.d101.s1|94-105|combination|drug
DDI-DrugBank.d101.s2|19-28|digitoxin|drug
DDI-DrugBank.d101.s3|5-17|flucytosine.|drug
DDI-DrugBank.d393.s0|0-15|Pharmacokinetic|drug
DDI-DrugBank.d393.s0|16-27|interaction|drug
DDI-DrugBank.d393.s0|41-51|cetirizine|drug
DDI-DrugBank.d393.s0|82-98|pseudoephedrine,|drug
DDI-DrugBank.d393.s0|99-110|antipyrine,|group
DDI-DrugBank.d393.s0|111-124|ketoconazole,|drug
DDI-DrugBank.d393.s0|125-137|erythromycin|drug
DDI-DrugBank.d393.s0|142-155|azithromycin.|drug
DDI-DrugBank.d393.s1|3-15|interactions|drug
DDI-DrugBank.d393.s2|28-40|theophylline|drug
DDI-DrugBank.d393.s2|76-86|cetirizine|drug
DDI-DrugBank.d393.s2|153-163|cetirizine|drug
DDI-DrugBank.d393.s3|19-31|theophylline|drug
DDI-DrugBank.d393.s3|63-73|cetirizine|drug
DDI-DrugBank.d393.s3|74-89|administration.|drug
DDI-DrugBank.d393.s4|27-37|clinically|drug
DDI-DrugBank.d393.s4|55-67|interactions|drug
DDI-DrugBank.d393.s4|89-101|theophylline|drug
DDI-DrugBank.d393.s4|117-130|azithromycin,|drug
DDI-DrugBank.d393.s4|131-147|pseudoephedrine,|drug
DDI-DrugBank.d393.s4|148-161|ketoconazole,|drug
DDI-DrugBank.d393.s4|165-178|erythromycin.|drug
DDI-DrugBank.d393.s5|47-57|cetirizine|drug
DDI-DrugBank.d393.s5|70-76|400-mg|drug_n
DDI-DrugBank.d393.s5|85-98|theophylline;|drug
DDI-DrugBank.d393.s6|27-39|theophylline|drug
DDI-DrugBank.d395.s0|57-65|enoxacin|drug
DDI-DrugBank.d395.s0|72-79|minutes|drug
DDI-DrugBank.d395.s0|80-89|following|drug
DDI-DrugBank.d395.s0|90-98|enoxacin|drug
DDI-DrugBank.d395.s0|99-114|administration,|drug
DDI-DrugBank.d395.s0|125-133|enoxacin|drug
DDI-DrugBank.d395.s1|18-32|administration|drug
DDI-DrugBank.d395.s1|36-44|enoxacin|drug
DDI-DrugBank.d395.s2|0-9|Caffeine:|drug
DDI-DrugBank.d395.s2|10-18|Enoxacin|drug
DDI-DrugBank.d395.s2|31-40|inhibitor|drug
DDI-DrugBank.d395.s2|59-64|P-450|brand
DDI-DrugBank.d395.s2|108-124|methylxanthines.|drug
DDI-DrugBank.d395.s3|26-34|enoxacin|drug
DDI-DrugBank.d395.s3|57-65|increase|drug
DDI-DrugBank.d395.s3|78-89|elimination|drug
DDI-DrugBank.d395.s3|103-112|caffeine,|drug
DDI-DrugBank.d395.s3|121-131|decreasing|drug
DDI-DrugBank.d395.s3|149-157|caffeine|drug
DDI-DrugBank.d395.s3|175-182|leading|drug
DDI-DrugBank.d395.s3|198-206|increase|drug
DDI-DrugBank.d395.s3|239-248|caffeine.|drug
DDI-DrugBank.d395.s4|14-22|enoxacin|drug
DDI-DrugBank.d395.s4|56-64|caffeine|drug
DDI-DrugBank.d395.s4|69-77|enoxacin|drug
DDI-DrugBank.d395.s4|83-95|administered|drug
DDI-DrugBank.d395.s5|0-16|Caffeine-related|drug
DDI-DrugBank.d395.s5|59-68|consuming|drug
DDI-DrugBank.d395.s5|69-77|caffeine|drug
DDI-DrugBank.d395.s5|100-109|enoxacin.|drug
DDI-DrugBank.d395.s6|0-13|Cyclosporine:|drug
DDI-DrugBank.d395.s6|39-51|cyclosporine|drug
DDI-DrugBank.d395.s6|95-107|cyclosporine|drug
DDI-DrugBank.d395.s6|134-143|quinolone|drug
DDI-DrugBank.d395.s7|0-8|Digoxin:|drug
DDI-DrugBank.d395.s7|9-17|Enoxacin|drug
DDI-DrugBank.d395.s7|34-41|digoxin|drug
DDI-DrugBank.d395.s7|57-69|individuals.|drug
DDI-DrugBank.d395.s8|36-43|digoxin|drug
DDI-DrugBank.d395.s8|64-72|enoxacin|drug
DDI-DrugBank.d395.s8|77-84|digoxin|drug
DDI-DrugBank.d395.s8|136-142|obtain|drug
DDI-DrugBank.d395.s8|149-156|digoxin|drug
DDI-DrugBank.d395.s8|175-182|digoxin|drug
DDI-DrugBank.d395.s9|14-31|anti-inflammatory|group
DDI-DrugBank.d395.s9|40-48|Seizures|group
DDI-DrugBank.d395.s9|80-86|taking|drug
DDI-DrugBank.d395.s9|87-95|enoxacin|drug
DDI-DrugBank.d395.s9|132-149|anti-inflammatory|group
DDI-DrugBank.d395.s10|31-40|increased|drug
DDI-DrugBank.d395.s10|55-63|seizures|group
DDI-DrugBank.d395.s12|15-24|antacids:|group
DDI-DrugBank.d395.s12|25-35|Quinolones|drug
DDI-DrugBank.d395.s13|11-25|administration|drug
DDI-DrugBank.d395.s13|29-39|quinolones|drug
DDI-DrugBank.d395.s13|45-53|antacids|group
DDI-DrugBank.d395.s13|54-64|containing|group
DDI-DrugBank.d395.s13|65-73|calcium,|drug
DDI-DrugBank.d395.s13|74-84|magnesium,|drug
DDI-DrugBank.d395.s13|88-97|aluminum;|drug
DDI-DrugBank.d395.s16|8-21|multivitamins|drug
DDI-DrugBank.d395.s16|22-32|containing|group
DDI-DrugBank.d395.s16|56-65|interfere|drug
DDI-DrugBank.d395.s16|101-113|insufficient|drug
DDI-DrugBank.d395.s16|132-141|quinolone|drug
DDI-DrugBank.d395.s17|0-8|Antacids|group
DDI-DrugBank.d395.s17|9-19|containing|group
DDI-DrugBank.d395.s17|20-28|aluminum|drug
DDI-DrugBank.d395.s17|29-38|hydroxide|drug
DDI-DrugBank.d395.s17|43-52|magnesium|drug
DDI-DrugBank.d395.s17|53-62|hydroxide|drug
DDI-DrugBank.d395.s17|93-101|enoxacin|drug
DDI-DrugBank.d395.s18|28-36|enoxacin|drug
DDI-DrugBank.d395.s18|60-76|coadministration|drug
DDI-DrugBank.d395.s18|80-91|ranitidine.|drug
DDI-DrugBank.d395.s19|73-81|enoxacin|drug
DDI-DrugBank.d395.s19|82-97|administration.|drug
DDI-DrugBank.d395.s20|0-13|Theophylline:|drug
DDI-DrugBank.d395.s20|14-22|Enoxacin|drug
DDI-DrugBank.d395.s20|35-44|inhibitor|drug
DDI-DrugBank.d395.s20|63-68|P-450|brand
DDI-DrugBank.d395.s20|112-128|methylxanthines.|drug
DDI-DrugBank.d395.s21|0-8|Enoxacin|drug
DDI-DrugBank.d395.s21|9-19|interferes|drug
DDI-DrugBank.d395.s21|43-55|theophylline|drug
DDI-DrugBank.d395.s21|56-65|resulting|drug
DDI-DrugBank.d395.s21|107-119|theophylline|drug
DDI-DrugBank.d395.s21|160-168|increase|drug
DDI-DrugBank.d395.s21|178-190|theophylline|drug
DDI-DrugBank.d395.s22|0-20|Theophylline-related|drug
DDI-DrugBank.d395.s22|68-80|theophylline|drug
DDI-DrugBank.d395.s22|85-93|enoxacin|drug
DDI-DrugBank.d395.s22|99-114|coadministered.|drug
DDI-DrugBank.d395.s23|0-9|Warfarin:|drug
DDI-DrugBank.d395.s23|10-21|Quinolones,|drug
DDI-DrugBank.d395.s23|22-31|including|drug
DDI-DrugBank.d395.s23|32-41|enoxacin,|drug
DDI-DrugBank.d395.s23|68-79|R-warfarin,|drug
DDI-DrugBank.d395.s23|114-123|warfarin.|drug
DDI-DrugBank.d395.s24|0-8|Enoxacin|drug
DDI-DrugBank.d395.s24|78-86|clotting|drug
DDI-DrugBank.d395.s24|120-128|enoxacin|drug
DDI-DrugBank.d395.s24|133-141|warfarin|drug
DDI-DrugBank.d395.s24|147-162|coadministered.|drug
DDI-DrugBank.d395.s25|18-29|prothrombin|drug
DDI-DrugBank.d395.s25|95-103|warfarin|drug
DDI-DrugBank.d395.s25|127-135|enoxacin|drug
DDI-DrugBank.d299.s0|0-16|Ergot-Containing|drug
DDI-DrugBank.d299.s1|80-101|ergotamine-containing|group
DDI-DrugBank.d299.s1|134-151|dihydroergotamine|drug
DDI-DrugBank.d299.s1|173-178|AXERT|brand
DDI-DrugBank.d299.s1|179-185|within|drug
DDI-DrugBank.d299.s2|0-9|Monoamine|drug
DDI-DrugBank.d299.s2|30-46|Coadministration|drug
DDI-DrugBank.d299.s2|50-61|moclobemide|drug
DDI-DrugBank.d299.s2|121-129|increase|drug
DDI-DrugBank.d299.s4|6-15|5-HT1B/1D|brand
DDI-DrugBank.d299.s4|50-59|5-HT1B/1D|brand
DDI-DrugBank.d299.s4|69-75|within|drug
DDI-DrugBank.d299.s4|103-108|AXERT|brand
DDI-DrugBank.d299.s4|112-128|contraindicated.|group
DDI-DrugBank.d299.s5|0-11|Propanolol:|drug
DDI-DrugBank.d299.s5|16-32|pharmacokinetics|drug
DDI-DrugBank.d299.s5|69-85|coadministration|drug
DDI-DrugBank.d299.s5|89-101|propranolol.|drug
DDI-DrugBank.d299.s6|10-19|Serotonin|drug
DDI-DrugBank.d299.s6|62-73|fluoxetine,|drug
DDI-DrugBank.d299.s6|74-86|fluvoxamine,|drug
DDI-DrugBank.d299.s6|87-98|paroxetine,|drug
DDI-DrugBank.d299.s6|99-110|sertraline)|drug
DDI-DrugBank.d299.s6|175-189|incoordination|drug
DDI-DrugBank.d299.s6|195-209|coadministered|drug
DDI-DrugBank.d299.s6|215-220|5-HT1|brand
DDI-DrugBank.d299.s7|30-35|AXERT|brand
DDI-DrugBank.d299.s7|51-61|clinically|drug
DDI-DrugBank.d299.s8|11-27|Coadministration|drug
DDI-DrugBank.d299.s8|75-83|increase|drug
DDI-DrugBank.d299.s10|0-16|Coadministration|drug
DDI-DrugBank.d299.s10|47-53|CYP3A4|brand
DDI-DrugBank.d299.s10|54-63|inhibitor|drug
DDI-DrugBank.d299.s10|64-76|ketoconazole|drug
DDI-DrugBank.d299.s10|135-143|increase|drug
DDI-DrugBank.d299.s11|13-24|interaction|drug
DDI-DrugBank.d299.s11|62-68|CYP3A4|brand
DDI-DrugBank.d299.s11|69-79|inhibitors|drug
DDI-DrugBank.d299.s11|87-100|itraconazole,|drug
DDI-DrugBank.d299.s11|116-129|erythromycin)|drug
DDI-DrugBank.d299.s11|152-161|increased|drug
DDI-DrugBank.d299.s11|162-171|exposures|group
DDI-DrugBank.d299.s12|0-5|AXERT|brand
DDI-DrugBank.d299.s12|22-31|interfere|drug
DDI-DrugBank.d299.s12|55-63|clinical|drug
DDI-DrugBank.d543.s0|4-13|following|drug
DDI-DrugBank.d543.s0|25-33|increase|drug
DDI-DrugBank.d543.s0|34-41|certain|drug
DDI-DrugBank.d543.s0|69-84|anticholinergic|group
DDI-DrugBank.d543.s0|92-102|amantadine|drug
DDI-DrugBank.d543.s0|103-117|antiarrhythmic|group
DDI-DrugBank.d543.s0|140-151|quinidine),|drug
DDI-DrugBank.d543.s0|152-166|antihistamines|group
DDI-DrugBank.d543.s0|167-180|antipsychotic|group
DDI-DrugBank.d543.s0|194-210|phenothiazines),|drug
DDI-DrugBank.d543.s0|211-227|benzodiazepines.|drug
DDI-DrugBank.d543.s1|4-15|inhibitors,|drug
DDI-DrugBank.d543.s1|43-55|meperidine),|drug
DDI-DrugBank.d543.s1|113-129|antidepressants,|group
DDI-DrugBank.d543.s1|146-152|having|drug
DDI-DrugBank.d543.s1|153-168|anticholinergic|group
DDI-DrugBank.d543.s2|0-16|Anticholinergics|drug
DDI-DrugBank.d543.s2|43-55|antiglaucoma|group
DDI-DrugBank.d543.s3|0-15|Anticholinergic|drug
DDI-DrugBank.d543.s3|41-50|increased|drug
DDI-DrugBank.d543.s3|51-62|intraocular|drug
DDI-DrugBank.d543.s3|63-71|pressure|group
DDI-DrugBank.d543.s3|139-151|costeroids..|group
DDI-DrugBank.d543.s4|0-15|Anticholinergic|drug
DDI-DrugBank.d543.s4|34-50|gastrointestinal|drug
DDI-DrugBank.d543.s4|95-105|dissolving|drug
DDI-DrugBank.d543.s4|122-130|digoxin;|drug
DDI-DrugBank.d543.s5|0-9|increased|drug
DDI-DrugBank.d543.s5|16-23|digoxin|drug
DDI-DrugBank.d543.s6|0-15|Anticholinergic|drug
DDI-DrugBank.d543.s6|73-89|gastrointestinal|drug
DDI-DrugBank.d543.s7|8-16|antacids|group
DDI-DrugBank.d543.s7|21-30|interfere|drug
DDI-DrugBank.d543.s7|54-69|anticholinergic|group
DDI-DrugBank.d543.s8|4-14|inhibiting|drug
DDI-DrugBank.d543.s8|26-41|anticholinergic|group
DDI-DrugBank.d543.s8|59-71|hydrochloric|drug
DDI-DrugBank.d543.s8|127-139|achlorhydria|drug
DDI-MedLine.d11.s2|83-95|increasingly|drug
DDI-MedLine.d11.s2|196-208|inflammation|drug
DDI-MedLine.d11.s3|15-25|broadening|drug
DDI-MedLine.d11.s3|26-37|indications|drug
DDI-MedLine.d11.s3|127-132|being|drug
DDI-MedLine.d11.s4|73-90|(corticosteroids,|group
DDI-MedLine.d11.s4|91-103|cyclosporin,|drug
DDI-MedLine.d11.s4|104-117|azathioprine,|drug
DDI-MedLine.d11.s4|132-150|cyclophosphamide),|drug
DDI-MedLine.d11.s4|151-161|discussing|drug
DDI-MedLine.d11.s4|166-171|main,|drug
DDI-MedLine.d11.s4|172-186|non-infection,|drug
DDI-MedLine.d11.s5|18-27|infection|drug
DDI-DrugBank.d486.s0|8-19|interaction|drug
DDI-DrugBank.d486.s0|52-60|COLAZAL,|brand
DDI-DrugBank.d486.s0|87-99|administered|drug
DDI-DrugBank.d486.s0|100-111|antibiotics|group
DDI-DrugBank.d486.s0|134-143|interfere|drug
DDI-DrugBank.d486.s0|164-174|mesalamine|drug
DDI-DrugBank.d49.s0|5-16|interaction|drug
DDI-DrugBank.d44.s0|15-26|interaction|drug
DDI-DrugBank.d44.s0|60-68|RAPTIVA.|brand
DDI-DrugBank.d44.s1|0-7|RAPTIVA|brand
DDI-DrugBank.d44.s2|36-44|vaccines|drug
DDI-DrugBank.d44.s2|59-71|administered|drug
DDI-DrugBank.d44.s2|72-78|during|drug
DDI-DrugBank.d44.s2|79-86|RAPTIVA|brand
DDI-DrugBank.d44.s3|138-144|during|drug
DDI-DrugBank.d44.s3|145-152|RAPTIVA|brand
DDI-DrugBank.d112.s0|60-70|eliminated|drug
DDI-DrugBank.d112.s0|119-128|increased|drug
DDI-DrugBank.d112.s1|18-25|6-deoxy|drug_n
DDI-DrugBank.d192.s0|0-18|Dexbrompheniramine|drug
DDI-DrugBank.d192.s0|23-31|interact|drug
DDI-DrugBank.d192.s0|144-160|antihistamines),|group
DDI-DrugBank.d192.s0|161-177|anticholinergics|group
DDI-DrugBank.d192.s0|204-219|anticholinergic|group
DDI-DrugBank.d192.s0|229-245|(anticholinergic|drug
DDI-DrugBank.d192.s0|323-339|antihistamines),|group
DDI-DrugBank.d192.s0|344-353|monoamine|drug
DDI-DrugBank.d192.s0|362-367|(MAO)|brand
DDI-DrugBank.d192.s0|368-378|inhibitors|drug
DDI-DrugBank.d192.s0|400-414|antihistamines|group
DDI-DrugBank.d192.s0|431-440|intensify|drug
DDI-DrugBank.d192.s0|445-460|anticholinergic|group
DDI-DrugBank.d192.s0|491-507|antihistamines).|group
DDI-DrugBank.d196.s0|15-22|PEGASYS|brand
DDI-DrugBank.d196.s0|90-100|inhibition|drug
DDI-DrugBank.d196.s0|123-131|increase|drug
DDI-DrugBank.d196.s0|135-147|theophylline|drug
DDI-DrugBank.d196.s1|0-12|Theophylline|drug
DDI-DrugBank.d196.s1|114-126|theophylline|drug
DDI-DrugBank.d196.s1|131-139|PEGASYS.|brand
DDI-DrugBank.d196.s2|27-43|pharmacokinetics|drug
DDI-DrugBank.d196.s2|96-101|2C19,|brand
DDI-DrugBank.d196.s3|50-57|PEGASYS|brand
DDI-DrugBank.d196.s3|61-72|combination|drug
DDI-DrugBank.d196.s3|78-86|COPEGUS,|brand
DDI-DrugBank.d196.s3|87-94|PEGASYS|brand
DDI-DrugBank.d196.s3|120-129|ribavirin|drug
DDI-DrugBank.d196.s4|0-10|Nucleoside|drug
DDI-DrugBank.d196.s4|21-31|Didanosine|drug
DDI-DrugBank.d196.s4|32-49|Co-administration|drug
DDI-DrugBank.d196.s4|53-60|COPEGUS|brand
DDI-DrugBank.d196.s4|65-75|didanosine|drug
DDI-DrugBank.d196.s5|25-33|failure,|group
DDI-DrugBank.d196.s5|152-160|clinical|drug
DDI-DrugBank.d196.s6|0-9|Stavudine|drug
DDI-DrugBank.d196.s6|14-24|Zidovudine|drug
DDI-DrugBank.d196.s6|25-34|Ribavirin|drug
DDI-DrugBank.d196.s6|63-72|antiviral|group
DDI-DrugBank.d196.s6|85-94|stavudine|drug
DDI-DrugBank.d196.s6|99-109|zidovudine|drug
DDI-DrugBank.d196.s6|110-117|against|drug_n
DDI-DrugBank.d196.s7|30-39|ribavirin|drug
DDI-DrugBank.d196.s8|0-15|Carcinogenesis,|drug
DDI-DrugBank.d196.s8|53-67|Carcinogenesis|drug
DDI-DrugBank.d196.s8|68-75|PEGASYS|brand
DDI-DrugBank.d196.s8|104-116|carcinogenic|drug
DDI-DrugBank.d196.s9|12-19|PEGASYS|brand
DDI-DrugBank.d196.s10|9-18|Ribavirin|drug
DDI-DrugBank.d196.s10|19-28|Ribavirin|drug
DDI-DrugBank.d196.s11|4-16|carcinogenic|drug
DDI-DrugBank.d196.s11|30-39|ribavirin|drug
DDI-DrugBank.d196.s11|59-70|determined.|drug
DDI-DrugBank.d196.s12|21-36|carcinogenicity|drug
DDI-DrugBank.d196.s12|70-79|tolerated|drug
DDI-DrugBank.d196.s12|102-111|ribavirin|drug
DDI-DrugBank.d196.s13|89-96|24-hour|drug_n
DDI-DrugBank.d196.s13|105-115|ribavirin.|drug
DDI-DrugBank.d196.s14|30-42|carcinogenic|drug
DDI-DrugBank.d196.s14|56-65|ribavirin|drug
DDI-DrugBank.d196.s14|69-77|ongoing.|drug
DDI-DrugBank.d196.s15|36-43|PEGASYS|brand
DDI-DrugBank.d196.s16|97-107|injections|drug
DDI-DrugBank.d196.s16|149-156|PEGASYS|brand
DDI-DrugBank.d196.s17|128-137|following|drug
DDI-DrugBank.d196.s17|138-152|administration|drug
DDI-DrugBank.d196.s17|156-163|PEGASYS|brand
DDI-DrugBank.d196.s19|16-22|dosing|drug
DDI-DrugBank.d196.s19|51-58|PEGASYS|brand
DDI-DrugBank.d196.s20|15-22|PEGASYS|brand
DDI-DrugBank.d196.s21|105-115|interferon|drug
DDI-DrugBank.d196.s22|32-39|PEGASYS|brand
DDI-DrugBank.d196.s23|14-24|interferon|drug
DDI-DrugBank.d196.s23|165-173|increase|drug
DDI-DrugBank.d196.s24|40-49|offspring|drug
DDI-DrugBank.d196.s25|0-7|PEGASYS|brand
DDI-DrugBank.d196.s26|26-41|well-controlled|group
DDI-DrugBank.d196.s26|53-60|PEGASYS|brand
DDI-DrugBank.d196.s27|0-7|PEGASYS|brand
DDI-DrugBank.d196.s27|22-28|during|drug
DDI-DrugBank.d196.s28|0-7|PEGASYS|brand
DDI-DrugBank.d196.s28|43-55|childbearing|drug
DDI-DrugBank.d196.s28|85-90|using|drug
DDI-DrugBank.d196.s28|101-114|contraception|group
DDI-DrugBank.d196.s28|115-121|during|drug
DDI-DrugBank.d196.s29|32-41|Ribavirin|drug
DDI-DrugBank.d196.s29|47-65|CONTRAINDICATIONS)|brand
DDI-DrugBank.d196.s29|173-183|ribavirin.|drug
DDI-DrugBank.d196.s30|0-7|COPEGUS|brand
DDI-DrugBank.d196.s30|19-34|contraindicated|group
DDI-DrugBank.d196.s31|57-63|during|drug
DDI-DrugBank.d196.s31|77-83|during|drug
DDI-DrugBank.d196.s31|161-168|COPEGUS|brand
DDI-DrugBank.d196.s31|191-206|1-800-526-6367.|drug_n
DDI-DrugBank.d196.s32|0-7|Nursing|drug
DDI-DrugBank.d196.s32|40-53|peginterferon|drug
DDI-DrugBank.d196.s32|57-66|ribavirin|drug
DDI-DrugBank.d196.s33|21-29|ingested|drug
DDI-DrugBank.d196.s33|30-43|peginterferon|drug
DDI-DrugBank.d196.s33|47-56|ribavirin|drug
DDI-DrugBank.d196.s33|81-88|nursing|drug
DDI-DrugBank.d196.s33|89-95|infant|drug
DDI-DrugBank.d196.s34|65-72|nursing|drug
DDI-DrugBank.d196.s34|73-81|infants,|drug
DDI-DrugBank.d196.s34|117-128|discontinue|group
DDI-DrugBank.d196.s34|129-136|nursing|drug
DDI-DrugBank.d196.s34|140-151|discontinue|group
DDI-DrugBank.d196.s34|152-159|PEGASYS|brand
DDI-DrugBank.d196.s34|164-171|COPEGUS|brand
DDI-DrugBank.d196.s35|46-54|PEGASYS,|brand
DDI-DrugBank.d196.s35|67-78|combination|drug
DDI-DrugBank.d196.s35|84-91|COPEGUS|brand
DDI-DrugBank.d196.s36|0-7|PEGASYS|brand
DDI-DrugBank.d196.s36|8-16|contains|group
DDI-DrugBank.d196.s37|58-67|increased|drug
DDI-DrugBank.d196.s37|68-77|incidence|drug
DDI-DrugBank.d196.s37|134-142|infants,|drug
DDI-DrugBank.d196.s39|0-8|Clinical|drug
DDI-DrugBank.d196.s39|20-27|PEGASYS|brand
DDI-DrugBank.d196.s39|40-51|combination|drug
DDI-DrugBank.d196.s39|57-64|COPEGUS|brand
DDI-DrugBank.d196.s39|73-80|include|drug
DDI-DrugBank.d196.s39|131-140|determine|drug
DDI-DrugBank.d196.s40|35-47|interferons,|drug
DDI-DrugBank.d196.s40|186-193|PEGASYS|brand
DDI-DrugBank.d196.s41|0-7|PEGASYS|brand
DDI-DrugBank.d196.s41|12-19|COPEGUS|brand
DDI-DrugBank.d196.s43|0-7|PEGASYS|brand
DDI-DrugBank.d196.s43|53-63|creatinine|drug
DDI-DrugBank.d196.s43|78-84|mL/min|drug
DDI-DrugBank.d196.s43|89-96|COPEGUS|brand
DDI-DrugBank.d196.s43|111-123|administered|drug
DDI-DrugBank.d196.s43|141-151|creatinine|drug
DDI-DrugBank.d196.s43|166-172|mL/min|drug
DDI-MedLine.d61.s0|0-15|Pharmacokinetic|drug
DDI-MedLine.d61.s0|34-52|digoxin-amiodarone|drug
DDI-MedLine.d61.s0|53-65|interaction.|drug
DDI-MedLine.d61.s1|35-42|digoxin|drug
DDI-MedLine.d61.s2|40-55|pharmacokinetic|drug
DDI-MedLine.d61.s2|70-81|interaction|drug
DDI-MedLine.d61.s3|4-19|pharmacokinetic|drug
DDI-MedLine.d61.s3|34-41|digoxin|drug
DDI-MedLine.d61.s3|47-57|determined|drug
DDI-MedLine.d61.s3|73-84|intravenous|drug
DDI-MedLine.d61.s3|93-100|digoxin|drug
DDI-MedLine.d61.s4|0-6|During|drug
DDI-MedLine.d61.s4|18-33|administration,|drug
DDI-MedLine.d61.s4|56-63|digoxin|drug
DDI-MedLine.d61.s4|92-98|ml/min|drug
DDI-MedLine.d61.s4|143-149|ml/min|drug
DDI-MedLine.d61.s4|163-169|0.01).|drug_n
DDI-MedLine.d61.s5|81-88|ml/min)|drug
DDI-MedLine.d61.s5|102-107|0.05)|drug_n
DDI-MedLine.d61.s5|161-168|ml/min)|drug
DDI-MedLine.d61.s5|182-188|0.01).|drug_n
DDI-MedLine.d61.s6|0-7|Digoxin|drug
DDI-MedLine.d61.s6|21-32|elimination|drug
DDI-MedLine.d61.s6|94-100|0.05).|drug_n
DDI-MedLine.d61.s7|0-7|Digoxin|drug
DDI-MedLine.d61.s8|39-47|increase|drug
DDI-MedLine.d61.s8|65-81|triiodothyronine|drug
DDI-MedLine.d61.s8|172-179|digoxin|drug
DDI-MedLine.d61.s8|180-197|pharmacokinetics.|drug
DDI-MedLine.d61.s9|21-28|digoxin|drug
DDI-MedLine.d61.s9|29-45|pharmacokinetics|drug
DDI-MedLine.d61.s9|69-76|explain|drug
DDI-MedLine.d61.s9|81-89|increase|drug
DDI-MedLine.d61.s9|99-106|digoxin|drug
DDI-MedLine.d61.s9|151-162|combination|drug
DDI-MedLine.d61.s9|177-188|clinically.|drug
DDI-DrugBank.d51.s0|0-8|ATROVENT|brand
DDI-DrugBank.d51.s0|74-83|including|drug
DDI-DrugBank.d51.s0|117-133|methylxanthines,|drug
DDI-DrugBank.d51.s0|138-147|steroids,|group
DDI-DrugBank.d51.s1|67-77|evaluating|drug
DDI-DrugBank.d51.s1|82-93|interaction|drug
DDI-DrugBank.d51.s1|105-113|ATROVENT|brand
DDI-DrugBank.d51.s2|0-15|Anticholinergic|drug
DDI-DrugBank.d51.s2|33-44|ipratropium|drug
DDI-DrugBank.d51.s2|45-52|bromide|drug
DDI-DrugBank.d51.s2|56-65|minimally|drug
DDI-DrugBank.d51.s2|146-157|interaction|drug
DDI-DrugBank.d51.s2|182-197|anticholinergic|group
DDI-DrugBank.d51.s3|36-52|coadministration|drug
DDI-DrugBank.d51.s3|56-64|ATROVENT|brand
DDI-DrugBank.d51.s3|95-121|anticholinergic-containing|group
DDI-DrugBank.d72.s0|0-12|Itraconazole|drug
DDI-DrugBank.d72.s1|0-12|Fluconazole,|drug
DDI-DrugBank.d72.s1|21-26|5-HT3|brand
DDI-DrugBank.d72.s1|27-38|antiemetics|group
DDI-DrugBank.d72.s1|109-118|BUSULFEX.|brand
DDI-DrugBank.d72.s2|0-9|Phenytoin|drug
DDI-DrugBank.d72.s2|10-19|increases|drug
DDI-DrugBank.d72.s2|82-91|induction|drug
DDI-DrugBank.d72.s3|0-5|Since|drug
DDI-DrugBank.d72.s3|10-26|pharmacokinetics|drug
DDI-DrugBank.d72.s3|30-38|BUSULFEX|brand
DDI-DrugBank.d72.s3|77-87|phenytoin,|drug
DDI-DrugBank.d72.s3|105-113|BUSULFEX|brand
DDI-DrugBank.d72.s3|155-163|exposure|group
DDI-DrugBank.d72.s3|164-169|(AUC)|brand
DDI-DrugBank.d72.s3|206-216|phenytoin.|drug
DDI-DrugBank.d72.s4|20-30|eliminated|drug
DDI-DrugBank.d72.s4|86-99|acetaminophen|drug
DDI-DrugBank.d72.s4|140-148|BUSULFEX|brand
DDI-DrugBank.d72.s4|223-236|acetaminophen|drug
DDI-DrugBank.d308.s0|4-16|POTENTIATING|brand
DDI-DrugBank.d308.s0|17-23|ACTION|brand
DDI-DrugBank.d308.s0|27-38|HYDROXYZINE|brand
DDI-DrugBank.d308.s0|47-57|CONSIDERED|brand
DDI-DrugBank.d308.s0|83-94|CONJUNCTION|brand
DDI-DrugBank.d308.s0|100-107|CENTRAL|brand
DDI-DrugBank.d308.s0|108-115|NERVOUS|brand
DDI-DrugBank.d308.s0|116-122|SYSTEM|brand
DDI-DrugBank.d308.s0|123-134|DEPRESSANTS|brand
DDI-DrugBank.d308.s0|143-153|NARCOTICS,|brand
DDI-DrugBank.d308.s0|154-166|NON-NARCOTIC|brand
DDI-DrugBank.d308.s0|167-177|ANALGESICS|brand
DDI-DrugBank.d308.s0|182-195|BARBITURATES.|brand
DDI-DrugBank.d308.s1|54-66|administered|drug
DDI-DrugBank.d308.s1|86-97|hydroxyzine|drug
DDI-DrugBank.d308.s2|0-5|Since|drug
DDI-DrugBank.d308.s2|6-16|drowsiness|drug
DDI-DrugBank.d308.s2|110-117|against|drug_n
DDI-DrugBank.d308.s2|118-125|driving|drug
DDI-DrugBank.d308.s2|135-144|operating|drug
DDI-DrugBank.d308.s2|155-164|machinery|drug
DDI-DrugBank.d308.s2|171-177|taking|drug
DDI-DrugBank.d308.s3|27-34|against|drug_n
DDI-DrugBank.d308.s3|135-145|increased.|drug
DDI-MedLine.d60.s0|0-9|Phenytoin|drug
DDI-MedLine.d60.s0|10-22|intoxication|drug
DDI-MedLine.d60.s0|23-30|induced|drug
DDI-MedLine.d60.s0|34-46|fluvoxamine.|drug
DDI-MedLine.d60.s1|14-23|phenytoin|drug
DDI-MedLine.d60.s1|24-36|intoxication|drug
DDI-MedLine.d60.s1|43-57|administration|drug
DDI-MedLine.d60.s1|61-73|fluvoxamine,|drug
DDI-MedLine.d60.s1|86-95|serotonin|drug
DDI-MedLine.d60.s1|105-115|inhibitor.|drug
DDI-MedLine.d60.s2|27-36|phenytoin|drug
DDI-MedLine.d60.s2|37-46|increased|drug
DDI-MedLine.d60.s2|93-104|fluvoxamine|drug
DDI-MedLine.d60.s2|109-124|coadministered,|drug
DDI-MedLine.d60.s2|154-163|phenytoin|drug
DDI-MedLine.d60.s3|0-6|During|drug
DDI-MedLine.d60.s3|7-16|phenytoin|drug
DDI-MedLine.d60.s3|21-32|fluvoxamine|drug
DDI-MedLine.d60.s3|77-87|phenytoin,|drug
DDI-MedLine.d60.s4|17-23|CYP2C9|brand
DDI-MedLine.d60.s4|28-33|2C19,|brand
DDI-MedLine.d60.s4|62-71|phenytoin|drug
DDI-MedLine.d60.s4|126-138|(CYP2C9*1/*1|brand
DDI-MedLine.d60.s4|143-150|2C19*1/|brand
DDI-MedLine.d60.s5|4-15|interaction|drug
DDI-MedLine.d60.s5|35-45|inhibition|drug
DDI-MedLine.d60.s5|54-60|CYP2C9|brand
DDI-MedLine.d60.s5|73-85|fluvoxamine.|drug
DDI-MedLine.d129.s0|45-67|glucocorticoid-induced|drug
DDI-MedLine.d129.s1|54-76|glucocorticoid-induced|drug
DDI-MedLine.d129.s1|110-115|using|drug
DDI-MedLine.d129.s2|4-26|glucocorticoid-induced|drug
DDI-MedLine.d129.s3|41-51|inhibition|drug
DDI-MedLine.d129.s3|57-67|inhibition|drug
DDI-MedLine.d129.s4|45-56|inhibition,|drug
DDI-MedLine.d129.s4|101-111|suggesting|drug
DDI-MedLine.d129.s4|133-144|hydrophobic|drug
DDI-MedLine.d129.s4|150-155|chain|drug
DDI-MedLine.d129.s5|19-32|surprisingly,|drug
DDI-MedLine.d129.s5|43-58|gallocatechins,|drug
DDI-MedLine.d129.s5|59-91|(-)-epigallocatechin-3-O-gallate|drug
DDI-MedLine.d129.s5|96-108|theasinensin|drug
DDI-MedLine.d129.s6|35-57|glucocorticoid-induced|drug
DDI-MedLine.d129.s6|81-94|antioxidative|group
DDI-MedLine.d129.s6|116-124|interest|drug
DDI-MedLine.d129.s6|144-149|point|drug
DDI-DrugBank.d41.s0|0-14|Cholestyramine|drug
DDI-DrugBank.d41.s0|28-42|Administration|drug
DDI-DrugBank.d41.s0|46-60|cholestyramine|drug
DDI-DrugBank.d41.s1|56-67|leflunomide|drug
DDI-DrugBank.d41.s2|35-46|leflunomide|drug
DDI-DrugBank.d41.s2|98-109|elimination|drug
DDI-DrugBank.d41.s2|110-120|procedure.|group
DDI-DrugBank.d41.s3|18-29|combination|drug
DDI-DrugBank.d41.s3|39-44|ARAVA|brand
DDI-DrugBank.d41.s3|72-78|3-fold|drug_n
DDI-DrugBank.d41.s4|32-44|continuation|group
DDI-DrugBank.d41.s4|71-86|discontinuation|group
DDI-DrugBank.d41.s5|3-9|3-fold|drug_n
DDI-DrugBank.d41.s5|10-18|increase|drug
DDI-DrugBank.d41.s5|31-38|another|drug
DDI-DrugBank.d41.s6|35-47|continuation|group
DDI-DrugBank.d41.s6|74-89|discontinuation|group
DDI-DrugBank.d41.s8|3-18|pharmacokinetic|drug
DDI-DrugBank.d41.s8|19-30|interaction|drug
DDI-DrugBank.d41.s9|51-60|increases|drug
DDI-DrugBank.d41.s9|61-68|ranging|drug
DDI-DrugBank.d41.s9|157-165|clinical|drug
DDI-DrugBank.d41.s10|4-12|clinical|drug
DDI-DrugBank.d41.s10|34-41|finding|drug
DDI-DrugBank.d41.s11|58-66|clinical|drug
DDI-DrugBank.d41.s12|56-65|increases|drug
DDI-DrugBank.d41.s12|66-73|ranging|drug
DDI-DrugBank.d41.s12|112-123|tolbutamide|drug
DDI-DrugBank.d41.s12|149-157|clinical|drug
DDI-DrugBank.d41.s13|4-12|clinical|drug
DDI-DrugBank.d41.s13|34-41|finding|drug
DDI-DrugBank.d41.s14|0-9|Rifampin:|drug
DDI-DrugBank.d41.s14|10-19|Following|drug
DDI-DrugBank.d41.s14|32-46|administration|drug
DDI-DrugBank.d41.s14|52-58|single|drug
DDI-DrugBank.d41.s14|67-72|ARAVA|brand
DDI-DrugBank.d41.s14|85-94|receiving|drug
DDI-DrugBank.d41.s14|113-122|rifampin,|drug
DDI-DrugBank.d41.s14|143-152|increased|drug
DDI-DrugBank.d41.s14|181-186|ARAVA|brand
DDI-DrugBank.d41.s15|29-34|ARAVA|brand
DDI-DrugBank.d41.s15|45-53|continue|group
DDI-DrugBank.d41.s15|57-65|increase|drug
DDI-DrugBank.d41.s15|80-87|dosing,|drug
DDI-DrugBank.d41.s15|133-142|receiving|drug
DDI-DrugBank.d41.s15|148-153|ARAVA|brand
DDI-DrugBank.d41.s15|158-167|rifampin.|drug
DDI-DrugBank.d41.s16|0-9|Warfarin:|drug
DDI-DrugBank.d41.s16|62-67|ARAVA|brand
DDI-DrugBank.d41.s16|72-80|warfarin|drug
DDI-DrugBank.d41.s16|86-101|co-administered|drug
DDI-DrugBank.d38.s0|0-8|ZINECARD|brand
DDI-DrugBank.d38.s0|18-27|influence|drug
DDI-DrugBank.d38.s0|32-48|pharmacokinetics|drug
DDI-DrugBank.d38.s0|52-64|doxorubicin.|drug
DDI-DrugBank.d38.s1|0-15|Carcinogenesis,|drug
DDI-DrugBank.d38.s1|66-81|carcinogenicity|drug
DDI-DrugBank.d38.s3|32-40|ZINECARD|brand
DDI-DrugBank.d38.s4|45-59|administration|drug
DDI-DrugBank.d555.s0|3-14|information|drug
DDI-DrugBank.d457.s0|52-67|contraceptives,|group
DDI-DrugBank.d457.s0|68-75|certain|drug
DDI-DrugBank.d457.s0|76-88|antibiotics,|group
DDI-DrugBank.d457.s0|89-99|quinidine,|drug
DDI-DrugBank.d457.s0|100-113|theophylline,|drug
DDI-DrugBank.d457.s0|114-130|corticosteroids,|group
DDI-DrugBank.d457.s0|131-146|anticoagulants,|group
DDI-DrugBank.d236.s0|0-10|Acidifying|drug
DDI-DrugBank.d236.s0|19-35|Gastrointestinal|drug
DDI-DrugBank.d236.s0|36-46|acidifying|drug
DDI-DrugBank.d236.s0|54-68|(guanethidine,|drug
DDI-DrugBank.d236.s0|69-79|reserpine,|drug
DDI-DrugBank.d236.s0|154-167|amphetamines.|drug
DDI-DrugBank.d236.s1|0-7|Urinary|drug
DDI-DrugBank.d236.s1|8-18|acidifying|drug
DDI-DrugBank.d236.s1|26-35|(ammonium|drug
DDI-DrugBank.d236.s1|46-52|sodium|drug
DDI-DrugBank.d236.s1|75-83|increase|drug
DDI-DrugBank.d236.s1|132-143|amphetamine|drug
DDI-DrugBank.d236.s1|144-153|molecule,|drug
DDI-DrugBank.d236.s1|162-172|increasing|drug
DDI-DrugBank.d236.s1|173-180|urinary|drug
DDI-DrugBank.d236.s2|57-70|amphetamines.|drug
DDI-DrugBank.d236.s3|45-54|inhibited|drug
DDI-DrugBank.d236.s3|58-71|amphetamines.|drug
DDI-DrugBank.d236.s4|0-12|Alkalinizing|drug
DDI-DrugBank.d236.s4|21-37|Gastrointestinal|drug
DDI-DrugBank.d236.s4|38-50|alkalinizing|drug
DDI-DrugBank.d236.s4|58-65|(sodium|drug
DDI-DrugBank.d236.s4|85-93|increase|drug
DDI-DrugBank.d236.s4|108-121|amphetamines.|drug
DDI-DrugBank.d236.s5|0-7|Urinary|drug
DDI-DrugBank.d236.s5|8-20|alkalinizing|drug
DDI-DrugBank.d236.s5|49-59|thiazides)|group
DDI-DrugBank.d236.s5|60-68|increase|drug
DDI-DrugBank.d236.s5|121-132|amphetamine|drug
DDI-DrugBank.d236.s5|133-142|molecule,|drug
DDI-DrugBank.d236.s5|151-161|decreasing|drug
DDI-DrugBank.d236.s5|162-169|urinary|drug
DDI-DrugBank.d236.s6|22-30|increase|drug
DDI-DrugBank.d236.s6|84-97|amphetamines.|drug
DDI-DrugBank.d236.s7|28-40|Amphetamines|drug
DDI-DrugBank.d236.s8|0-13|d-amphetamine|drug
DDI-DrugBank.d236.s8|19-30|desipramine|drug
DDI-DrugBank.d236.s8|34-47|protriptyline|drug
DDI-DrugBank.d236.s8|84-92|striking|drug
DDI-DrugBank.d236.s8|97-106|sustained|drug
DDI-DrugBank.d236.s8|107-116|increases|drug
DDI-DrugBank.d236.s8|141-154|d-amphetamine|drug
DDI-DrugBank.d236.s8|162-168|brain;|drug
DDI-DrugBank.d236.s10|4-15|inhibitors:|drug
DDI-DrugBank.d236.s10|21-37|antidepressants,|group
DDI-DrugBank.d236.s10|84-95|amphetamine|drug
DDI-DrugBank.d236.s11|5-12|slowing|drug
DDI-DrugBank.d236.s11|25-38|amphetamines,|drug
DDI-DrugBank.d236.s11|39-49|increasing|drug
DDI-DrugBank.d236.s11|81-95|norepinephrine|drug
DDI-DrugBank.d236.s11|106-116|monoamines|drug
DDI-DrugBank.d236.s11|139-147|endings;|drug
DDI-DrugBank.d236.s14|0-15|Antihistamines:|drug
DDI-DrugBank.d236.s14|16-28|Amphetamines|drug
DDI-DrugBank.d236.s14|67-82|antihistamines.|group
DDI-DrugBank.d236.s15|19-31|Amphetamines|drug
DDI-DrugBank.d236.s15|74-92|antihypertensives.|group
DDI-DrugBank.d236.s16|0-15|Chlorpromazine:|drug
DDI-DrugBank.d236.s16|16-30|Chlorpromazine|drug
DDI-DrugBank.d236.s16|38-46|dopamine|drug
DDI-DrugBank.d236.s16|51-65|norepinephrine|drug
DDI-DrugBank.d236.s16|81-91|inhibiting|drug
DDI-DrugBank.d236.s16|125-138|amphetamines,|drug
DDI-DrugBank.d236.s16|164-175|amphetamine|drug
DDI-DrugBank.d236.s16|176-186|poisoning.|drug
DDI-DrugBank.d236.s17|14-26|Amphetamines|drug
DDI-DrugBank.d236.s17|37-47|intestinal|drug
DDI-DrugBank.d236.s18|32-40|dopamine|drug
DDI-DrugBank.d236.s18|45-59|norepinephrine|drug
DDI-DrugBank.d236.s18|75-85|inhibiting|drug
DDI-DrugBank.d236.s18|119-132|amphetamines.|drug
DDI-DrugBank.d236.s19|0-7|Lithium|drug
DDI-DrugBank.d236.s19|46-58|amphetamines|drug
DDI-DrugBank.d236.s19|66-75|inhibited|drug
DDI-DrugBank.d236.s19|79-86|lithium|drug
DDI-DrugBank.d236.s20|0-11|Meperidine:|drug
DDI-DrugBank.d236.s20|12-24|Amphetamines|drug
DDI-DrugBank.d236.s20|60-71|meperidine.|drug
DDI-DrugBank.d236.s21|0-11|Methenamine|drug
DDI-DrugBank.d236.s21|21-28|Urinary|drug
DDI-DrugBank.d236.s21|42-54|amphetamines|drug
DDI-DrugBank.d236.s21|58-68|increased,|drug
DDI-DrugBank.d236.s21|97-107|acidifying|drug
DDI-DrugBank.d236.s21|123-134|methenamine|drug
DDI-DrugBank.d236.s22|0-15|Norepinephrine:|drug
DDI-DrugBank.d236.s22|16-28|Amphetamines|drug
DDI-DrugBank.d236.s22|62-77|norepinephrine.|drug
DDI-DrugBank.d236.s23|15-27|Amphetamines|drug
DDI-DrugBank.d236.s23|38-48|intestinal|drug
DDI-DrugBank.d236.s24|0-17|co-administration|drug
DDI-DrugBank.d236.s24|61-75|anticonvulsant|group
DDI-DrugBank.d236.s25|0-10|Phenytoin:|drug
DDI-DrugBank.d236.s25|11-23|Amphetamines|drug
DDI-DrugBank.d236.s25|34-44|intestinal|drug
DDI-DrugBank.d236.s25|59-69|phenytoin;|drug
DDI-DrugBank.d236.s26|0-17|co-administration|drug
DDI-DrugBank.d236.s26|21-30|phenytoin|drug
DDI-DrugBank.d236.s26|57-71|anticonvulsant|group
DDI-DrugBank.d236.s27|51-62|amphetamine|drug
DDI-DrugBank.d236.s28|9-19|alkaloids:|group
DDI-DrugBank.d236.s28|20-32|Amphetamines|drug
DDI-DrugBank.d236.s28|33-40|inhibit|drug
DDI-DrugBank.d236.s28|76-86|alkaloids.|group
DDI-DrugBank.d236.s29|35-47|Amphetamines|drug
DDI-DrugBank.d236.s30|5-13|increase|drug
DDI-DrugBank.d236.s30|33-41|evening.|drug
DDI-DrugBank.d236.s31|0-12|Amphetamines|drug
DDI-DrugBank.d236.s31|17-26|interfere|drug
DDI-DrugBank.d236.s31|32-39|urinary|drug
DDI-DrugBank.d236.s31|48-63|determinations.|drug
DDI-DrugBank.d297.s0|12-23|interaction|drug
DDI-DrugBank.d297.s0|61-69|ORENCIA.|brand
DDI-DrugBank.d297.s1|11-26|pharmacokinetic|drug
DDI-DrugBank.d297.s1|63-79|corticosteroids,|group
DDI-DrugBank.d297.s1|88-96|blocking|drug
DDI-DrugBank.d297.s1|112-121|influence|drug
DDI-DrugBank.d297.s2|31-39|clinical|drug
DDI-DrugBank.d297.s2|76-85|following|drug
DDI-DrugBank.d297.s2|115-123|ORENCIA:|brand
DDI-DrugBank.d297.s2|137-153|corticosteroids,|group
DDI-DrugBank.d297.s2|158-166|blocking|drug
DDI-DrugBank.d297.s2|175-188|azathioprine,|drug
DDI-DrugBank.d297.s2|189-201|chloroquine,|drug
DDI-DrugBank.d297.s2|208-227|hydroxychloroquine,|drug
DDI-DrugBank.d297.s2|241-255|sulfasalazine,|drug
DDI-DrugBank.d297.s2|260-269|anakinra.|drug
DDI-DrugBank.d297.s3|11-25|administration|drug
DDI-DrugBank.d297.s3|51-58|ORENCIA|brand
DDI-DrugBank.d297.s3|87-96|increased|drug
DDI-DrugBank.d297.s3|113-123|infections|drug
DDI-DrugBank.d297.s4|24-31|ORENCIA|brand
DDI-DrugBank.d297.s5|9-21|insufficient|drug
DDI-DrugBank.d297.s5|70-77|ORENCIA|brand
DDI-DrugBank.d297.s5|78-90|administered|drug
DDI-DrugBank.d297.s5|109-118|anakinra,|drug
DDI-MedLine.d84.s0|26-35|Ganoderma|drug
DDI-MedLine.d84.s0|65-76|combination|drug
DDI-MedLine.d84.s0|87-99|antibiotics.|group
DDI-MedLine.d84.s1|74-83|Ganoderma|drug
DDI-MedLine.d84.s1|92-102|(FR)KARST)|brand
DDI-MedLine.d84.s1|123-130|against|drug_n
DDI-MedLine.d84.s1|213-226|antimicrobial|group
DDI-MedLine.d84.s1|253-260|minimal|drug
DDI-MedLine.d84.s1|261-271|inhibitory|drug
DDI-MedLine.d84.s1|286-292|(MIC).|brand
DDI-MedLine.d84.s2|46-59|antimicrobial|group
DDI-MedLine.d84.s2|95-102|against|drug_n
DDI-MedLine.d84.s2|122-127|(MIC,|brand
DDI-MedLine.d84.s3|3-14|investigate|drug
DDI-MedLine.d84.s3|30-43|antimicrobial|group
DDI-MedLine.d84.s3|44-56|combinations|drug
DDI-MedLine.d84.s3|73-78|kinds|drug
DDI-MedLine.d84.s3|82-93|antibiotics|group
DDI-MedLine.d84.s3|94-106|(ampicillin,|drug
DDI-MedLine.d84.s3|107-117|cefazolin,|drug
DDI-MedLine.d84.s3|118-133|oxytetracycline|drug
DDI-MedLine.d84.s3|171-181|inhibitory|drug
DDI-MedLine.d84.s3|196-201|index|drug
DDI-MedLine.d84.s3|202-208|(FICI)|brand
DDI-MedLine.d84.s3|213-223|determined|drug
DDI-MedLine.d84.s3|255-262|strain.|drug
DDI-MedLine.d84.s4|4-17|antimicrobial|group
DDI-MedLine.d84.s4|18-30|combinations|drug
DDI-MedLine.d84.s4|47-58|antibiotics|group
DDI-MedLine.d84.s4|95-105|instances,|drug
DDI-MedLine.d84.s4|123-133|instances,|drug
DDI-MedLine.d84.s4|156-166|instances.|drug
DDI-MedLine.d84.s5|35-43|combined|drug
DDI-MedLine.d84.s5|49-58|cefazolin|drug
DDI-MedLine.d84.s5|59-66|against|drug_n
DDI-DrugBank.d181.s0|0-8|Oxytocin|drug
DDI-DrugBank.d181.s0|49-58|dinoprost|drug
DDI-DrugBank.d181.s0|73-80|uterine|drug
DDI-DrugBank.d181.s0|102-109|causing|drug
DDI-DrugBank.d181.s0|110-117|uterine|drug
DDI-DrugBank.d181.s0|118-125|rupture|group
DDI-DrugBank.d181.s1|9-21|combinations|drug
DDI-DrugBank.d10.s1|29-36|examine|drug
DDI-DrugBank.d10.s1|42-54|interactions|drug
DDI-DrugBank.d10.s1|176-188|administered|drug
DDI-DrugBank.d10.s1|201-208|(N=180)|brand
DDI-DrugBank.d10.s1|209-218|receiving|drug
DDI-DrugBank.d10.s2|10-24|administration|drug
DDI-DrugBank.d10.s2|71-76|0.025|drug_n
DDI-DrugBank.d10.s2|114-124|inhibition|drug
DDI-DrugBank.d10.s2|128-138|antipyrine|group
DDI-DrugBank.d10.s2|139-153|elimination.14|drug
DDI-DrugBank.d10.s2|182-196|administration|drug
DDI-MedLine.d105.s0|21-33|azithromycin|drug
DDI-MedLine.d105.s0|56-66|zidovudine|drug
DDI-MedLine.d105.s0|71-85|dideoxyinosine|drug
DDI-MedLine.d105.s0|89-101|HIV-infected|drug
DDI-MedLine.d105.s1|30-42|HIV-infected|drug
DDI-MedLine.d105.s1|80-92|azithromycin|drug
DDI-MedLine.d105.s1|96-104|interact|drug
DDI-MedLine.d105.s1|110-120|zidovudine|drug
DDI-MedLine.d105.s1|125-140|dideoxyinosine.|drug
DDI-MedLine.d105.s3|4-14|zidovudine|drug
DDI-MedLine.d105.s3|56-68|azithromycin|drug
DDI-MedLine.d105.s3|137-143|21-day|drug_n
DDI-MedLine.d105.s3|180-191|zidovudine.|drug
DDI-MedLine.d105.s4|32-46|dideoxyinosine|drug
DDI-MedLine.d105.s4|91-103|azithromycin|drug
DDI-MedLine.d105.s5|26-31|urine|drug
DDI-MedLine.d105.s5|32-40|sampling|drug
DDI-MedLine.d105.s5|81-91|zidovudine|drug
DDI-MedLine.d105.s5|117-132|dideoxyinosine.|drug
DDI-MedLine.d105.s6|84-95|zidovudine.|drug
DDI-MedLine.d105.s7|0-12|Azithromycin|drug
DDI-MedLine.d105.s7|62-73|zidovudine,|drug
DDI-MedLine.d105.s7|114-124|zidovudine|drug
DDI-MedLine.d105.s7|141-150|increased|drug
DDI-MedLine.d105.s7|155-168|intracellular|drug
DDI-MedLine.d105.s7|169-177|exposure|group
DDI-MedLine.d105.s7|196-206|zidovudine|drug
DDI-MedLine.d105.s7|210-215|110%.|drug_n
DDI-MedLine.d105.s8|0-12|Azithromycin|drug
DDI-MedLine.d105.s8|42-56|dideoxyinosine|drug
DDI-MedLine.d105.s8|57-74|pharmacokinetics.|drug
DDI-MedLine.d105.s9|60-72|azithromycin|drug
DDI-MedLine.d105.s9|87-101|coadministered|drug
DDI-MedLine.d105.s9|112-122|zidovudine|drug
DDI-MedLine.d105.s9|127-142|dideoxyinosine.|drug
DDI-DrugBank.d550.s0|78-94|pharmacokinetics|drug
DDI-DrugBank.d550.s0|98-105|ethinyl|drug
DDI-DrugBank.d550.s0|155-170|contraceptives.|group
DDI-DrugBank.d550.s1|13-21|clinical|drug
DDI-DrugBank.d550.s1|123-132|antacids.|group
DDI-DrugBank.d550.s2|25-42|Co-administration|drug
DDI-DrugBank.d550.s2|48-54|single|drug
DDI-DrugBank.d550.s2|63-76|intravenously|drug
DDI-DrugBank.d550.s2|77-89|administered|drug
DDI-DrugBank.d550.s2|90-100|famotidine|drug
DDI-DrugBank.d550.s2|142-148|single|drug
DDI-DrugBank.d550.s2|183-195|administered|drug
DDI-DrugBank.d550.s2|196-205|following|drug
DDI-DrugBank.d550.s3|13-21|clinical|drug
DDI-DrugBank.d550.s4|35-47|antibiotics,|group
DDI-DrugBank.d550.s4|48-65|co-administration|drug
DDI-DrugBank.d550.s4|119-127|increase|drug
DDI-DrugBank.d550.s4|142-150|exposure|group
DDI-DrugBank.d550.s4|177-185|increase|drug
DDI-DrugBank.d550.s4|207-215|increase|drug
DDI-DrugBank.d550.s4|239-247|increase|drug
DDI-DrugBank.d550.s5|34-48|Cephalosporins|drug
DDI-DrugBank.d550.s5|75-81|induce|drug
DDI-DrugBank.d550.s6|45-50|urine|drug
DDI-DrugBank.d550.s6|103-111|Fehlings|drug
DDI-DrugBank.d550.s6|129-138|CLINITEST|brand
DDI-DrugBank.d550.s6|203-213|CLINISTIX,|brand
DDI-DrugBank.d550.s6|214-224|TES-TAPE).|brand
DDI-DrugBank.d550.s7|44-56|ferricyanide|drug
DDI-DrugBank.d550.s7|116-126|hexokinase|drug
DDI-DrugBank.d550.s7|145-154|determine|drug
DDI-DrugBank.d550.s7|195-204|receiving|drug
DDI-DrugBank.d245.s0|27-39|sulfonylurea|group
DDI-DrugBank.d245.s0|62-69|certain|drug
DDI-DrugBank.d245.s0|76-85|including|drug
DDI-DrugBank.d245.s0|99-116|anti-inflammatory|group
DDI-DrugBank.d245.s0|156-163|protein|drug
DDI-DrugBank.d245.s0|227-237|coumarins,|drug
DDI-DrugBank.d245.s0|238-247|monoamine|drug
DDI-DrugBank.d245.s0|256-267|inhibitors,|drug
DDI-DrugBank.d245.s0|288-296|blocking|drug
DDI-DrugBank.d245.s1|20-32|administered|drug
DDI-DrugBank.d245.s1|46-55|receiving|drug
DDI-DrugBank.d245.s1|56-66|DIABINESE,|brand
DDI-DrugBank.d245.s2|45-54|receiving|drug
DDI-DrugBank.d245.s2|55-65|DIABINESE,|brand
DDI-DrugBank.d245.s2|117-125|control.|group
DDI-DrugBank.d245.s3|0-7|Certain|drug
DDI-DrugBank.d245.s3|68-76|control.|group
DDI-DrugBank.d245.s4|12-19|include|drug
DDI-DrugBank.d245.s4|24-33|thiazides|group
DDI-DrugBank.d245.s4|44-54|diuretics,|group
DDI-DrugBank.d245.s4|55-71|corticosteroids,|group
DDI-DrugBank.d245.s4|72-87|phenothiazines,|drug
DDI-DrugBank.d245.s4|122-137|contraceptives,|group
DDI-DrugBank.d245.s4|138-148|phenytoin,|drug
DDI-DrugBank.d245.s4|149-158|nicotinic|drug
DDI-DrugBank.d245.s4|183-190|calcium|drug
DDI-DrugBank.d245.s4|199-207|blocking|drug
DDI-DrugBank.d245.s5|20-32|administered|drug
DDI-DrugBank.d245.s5|46-55|receiving|drug
DDI-DrugBank.d245.s5|56-66|DIABINESE,|brand
DDI-DrugBank.d245.s5|118-126|control.|group
DDI-DrugBank.d245.s6|45-54|receiving|drug
DDI-DrugBank.d245.s6|55-65|DIABINESE,|brand
DDI-DrugBank.d245.s7|0-5|Since|drug
DDI-DrugBank.d245.s8|68-77|ingestion|drug
DDI-DrugBank.d245.s9|12-23|interaction|drug
DDI-DrugBank.d245.s9|37-47|miconazole|drug
DDI-DrugBank.d245.s9|77-84|leading|drug
DDI-DrugBank.d245.s10|13-24|interaction|drug
DDI-DrugBank.d245.s10|46-58|intravenous,|drug
DDI-DrugBank.d245.s10|71-78|vaginal|drug
DDI-DrugBank.d245.s10|95-105|miconazole|drug
DDI-MedLine.d62.s0|54-70|methamphetamine.|drug
DDI-MedLine.d62.s1|71-80|mediating|drug
DDI-MedLine.d62.s1|81-97|stimulus-induced|drug
DDI-MedLine.d62.s1|130-137|induced|drug
DDI-MedLine.d62.s1|141-156|methamphetamine|drug
DDI-MedLine.d62.s1|157-163|(METH)|brand
DDI-MedLine.d62.s1|190-196|define|drug
DDI-MedLine.d62.s1|250-262|long-lasting|drug
DDI-MedLine.d62.s3|14-22|examined|drug
DDI-MedLine.d62.s3|36-50|administration|drug
DDI-MedLine.d62.s3|154-161|protein|drug
DDI-MedLine.d62.s3|179-188|spectrin.|drug
DDI-MedLine.d62.s4|0-5|Using|drug
DDI-MedLine.d62.s4|95-103|increase|drug
DDI-MedLine.d62.s4|202-210|dopamine|drug
DDI-MedLine.d62.s4|234-243|SCH-23390|brand
DDI-MedLine.d62.s4|267-278|neuroleptic|drug
DDI-MedLine.d62.s4|279-289|clozapine.|drug
DDI-MedLine.d62.s5|5-12|induced|drug
DDI-MedLine.d62.s5|62-70|dopamine|drug
DDI-MedLine.d62.s6|92-100|involved|drug
DDI-MedLine.d62.s6|141-151|underlying|drug
DDI-MedLine.d62.s6|183-188|METH.|brand
DDI-DrugBank.d42.s0|18-28|clinically|drug
DDI-DrugBank.d42.s0|51-63|interactions|drug
DDI-DrugBank.d42.s0|88-103|hydrodolasetron|drug
DDI-DrugBank.d42.s0|182-197|hydrodolasetron|drug
DDI-DrugBank.d42.s0|201-211|eliminated|drug
DDI-DrugBank.d42.s1|16-31|hydrodolasetron|drug
DDI-DrugBank.d42.s1|32-41|increased|drug
DDI-DrugBank.d42.s1|66-80|coadministered|drug
DDI-DrugBank.d42.s1|86-96|cimetidine|drug
DDI-DrugBank.d42.s1|111-120|inhibitor|drug
DDI-DrugBank.d42.s1|135-141|P-450)|brand
DDI-DrugBank.d42.s1|177-193|coadministration|drug
DDI-DrugBank.d42.s1|197-205|rifampin|drug
DDI-DrugBank.d42.s1|214-221|inducer|drug
DDI-DrugBank.d42.s1|236-242|P-450)|brand
DDI-DrugBank.d42.s2|27-41|coadministered|drug
DDI-DrugBank.d42.s3|39-49|intervals,|drug
DDI-DrugBank.d42.s3|90-96|taking|drug
DDI-DrugBank.d42.s3|121-131|intervals,|drug
DDI-DrugBank.d42.s4|12-18|taking|drug
DDI-DrugBank.d42.s4|31-42|nifedipine,|drug
DDI-DrugBank.d42.s4|58-69|inhibitors,|drug
DDI-DrugBank.d42.s4|92-104|propranolol,|drug
DDI-DrugBank.d42.s4|178-194|hydrodolasetron.|drug
DDI-DrugBank.d42.s5|13-28|hydrodolasetron|drug
DDI-DrugBank.d42.s5|81-93|administered|drug
DDI-DrugBank.d42.s5|94-107|intravenously|drug
DDI-DrugBank.d42.s6|20-29|influence|drug
DDI-DrugBank.d42.s7|28-35|inhibit|drug
DDI-DrugBank.d42.s7|40-49|antitumor|group
DDI-DrugBank.d42.s7|91-102|(cisplatin,|drug
DDI-DrugBank.d42.s7|103-118|5-fluorouracil,|drug_n
DDI-DrugBank.d42.s7|119-131|doxorubicin,|drug
DDI-DrugBank.d42.s7|132-149|cyclophosphamide)|drug
DDI-DrugBank.d42.s7|158-164|murine|drug
DDI-DrugBank.d187.s0|30-42|administered|drug
DDI-DrugBank.d187.s1|87-99|administered|drug
DDI-DrugBank.d187.s2|0-14|Acetaminophen:|drug
DDI-DrugBank.d187.s2|34-47|acetaminophen|drug
DDI-DrugBank.d187.s2|83-92|receiving|drug
DDI-DrugBank.d187.s3|82-93|interaction|drug
DDI-DrugBank.d187.s3|116-129|acetaminophen|drug
DDI-DrugBank.d187.s3|136-145|molecular|drug
DDI-DrugBank.d187.s3|161-172|interaction|drug
DDI-DrugBank.d187.s4|55-61|induce|drug
DDI-DrugBank.d187.s4|62-72|P-450IIE1,|brand
DDI-DrugBank.d187.s5|60-69|induction|drug
DDI-DrugBank.d187.s5|73-82|P-450IIE1|brand
DDI-DrugBank.d187.s5|161-169|ingested|drug
DDI-DrugBank.d187.s5|170-183|acetaminophen|drug
DDI-DrugBank.d187.s5|184-189|being|drug
DDI-DrugBank.d187.s6|73-85|cetaminophen|drug
DDI-DrugBank.d187.s7|0-14|Carbamazepine:|drug
DDI-DrugBank.d187.s7|60-73|carbamazepine|drug
DDI-DrugBank.d187.s7|78-86|increase|drug
DDI-DrugBank.d187.s7|104-117|Carbamazepine|drug
DDI-DrugBank.d187.s7|135-145|determined|drug
DDI-DrugBank.d187.s7|166-180|administration|drug
DDI-DrugBank.d187.s7|219-232|carbamazepine|drug
DDI-DrugBank.d187.s7|312-326|anticonvulsant|group
DDI-DrugBank.d187.s8|0-13|Ketoconazole:|drug
DDI-DrugBank.d187.s8|24-35|interaction|drug
DDI-DrugBank.d187.s8|39-51|Ketoconazole|drug
DDI-DrugBank.d187.s9|0-10|Phenytoin:|drug
DDI-DrugBank.d187.s9|25-33|increase|drug
DDI-DrugBank.d187.s9|50-60|phenytoin.|drug
DDI-DrugBank.d187.s10|9-18|phenytoin|drug
DDI-DrugBank.d187.s10|19-32|intoxication,|drug
DDI-DrugBank.d187.s10|63-77|anticonvulsant|group
DDI-DrugBank.d187.s11|0-14|Therophylline:|drug
DDI-DrugBank.d187.s11|56-70|administration|drug
DDI-DrugBank.d187.s11|88-100|theophylline|drug
DDI-DrugBank.d187.s11|137-150|theophylline,|drug
DDI-DrugBank.d187.s11|163-172|instances|drug
DDI-DrugBank.d187.s11|198-209|elimination|drug
DDI-DrugBank.d187.s12|0-5|Since|drug
DDI-DrugBank.d187.s12|31-43|theophylline|drug
DDI-DrugBank.d187.s12|54-66|theophylline|drug
DDI-DrugBank.d187.s12|147-159|theophylline|drug
DDI-DrugBank.d187.s13|52-60|increase|drug
DDI-DrugBank.d187.s13|102-114|administered|drug
DDI-DrugBank.d187.s14|87-100|administered,|drug
DDI-DrugBank.d124.s0|5-17|INTERACTIONS|brand
DDI-DrugBank.d124.s1|13-24|interaction|drug
DDI-DrugBank.d124.s1|63-71|INVIRASE|brand
DDI-DrugBank.d124.s1|76-86|FORTOVASE.|brand
DDI-DrugBank.d124.s2|23-34|interaction|drug
DDI-DrugBank.d124.s2|48-57|FORTOVASE|brand
DDI-DrugBank.d124.s2|84-93|INVIRASE.|brand
DDI-DrugBank.d124.s3|8-17|ritonavir|drug
DDI-DrugBank.d124.s3|21-36|coadministered,|drug
DDI-DrugBank.d124.s3|74-85|prescribing|drug
DDI-DrugBank.d124.s3|86-97|information|drug
DDI-DrugBank.d124.s3|102-111|ritonavir|drug
DDI-DrugBank.d124.s3|112-121|regarding|drug
DDI-DrugBank.d124.s3|127-139|interactions|drug
DDI-DrugBank.d124.s4|18-28|saquinavir|drug
DDI-DrugBank.d124.s4|55-60|P450,|brand
DDI-DrugBank.d124.s4|89-95|CYP3A4|brand
DDI-DrugBank.d124.s5|14-24|saquinavir|drug
DDI-DrugBank.d124.s5|44-58|P-Glycoprotein|drug
DDI-DrugBank.d124.s6|29-35|CYP3A4|brand
DDI-DrugBank.d124.s6|63-79|pharmacokinetics|drug
DDI-DrugBank.d124.s6|83-94|saquinavir.|drug
DDI-DrugBank.d124.s7|11-21|saquinavir|drug
DDI-DrugBank.d124.s7|44-60|pharmacokinetics|drug
DDI-DrugBank.d124.s7|100-106|CYP3A4|brand
DDI-DrugBank.d124.s8|15-30|contraindicated|group
DDI-DrugBank.d124.s8|77-88|interaction|drug
DDI-DrugBank.d124.s8|141-159|CONTRAINDICATIONS.|brand
DDI-DrugBank.d124.s9|46-62|coadministration|drug
DDI-DrugBank.d124.s9|68-76|INVIRASE|brand
DDI-DrugBank.d124.s9|81-90|ritonavir|drug
DDI-DrugBank.d124.s9|95-103|included|drug
DDI-DrugBank.d124.s10|47-58|interaction|drug
DDI-DrugBank.d124.s10|80-92|interactions|drug
DDI-DrugBank.d124.s10|126-137|interaction|drug
DDI-DrugBank.d124.s11|40-48|induced,|drug
DDI-DrugBank.d124.s11|49-58|resulting|drug
DDI-DrugBank.d124.s12|25-39|Coadministered|drug
DDI-DrugBank.d124.s12|45-63|INVIRASE/Ritonavir|drug
DDI-DrugBank.d124.s13|22-30|Clinical|drug
DDI-DrugBank.d124.s14|39-50|flecainide,|drug
DDI-DrugBank.d124.s14|64-73|quinidine|drug
DDI-DrugBank.d124.s14|74-89|CONTRAINDICATED|brand
DDI-DrugBank.d124.s14|126-142|life-threatening|drug
DDI-DrugBank.d124.s15|0-15|Antihistamines:|drug
DDI-DrugBank.d124.s15|16-28|astemizole*,|drug
DDI-DrugBank.d124.s15|29-41|terfenadine*|drug
DDI-DrugBank.d124.s15|42-57|CONTRAINDICATED|brand
DDI-DrugBank.d124.s15|94-110|life-threatening|drug
DDI-DrugBank.d124.s16|19-37|Dihydroergotamine,|drug
DDI-DrugBank.d124.s16|38-49|ergonovine,|drug
DDI-DrugBank.d124.s16|50-61|ergotamine,|drug
DDI-DrugBank.d124.s16|62-78|methylergonovine|drug
DDI-DrugBank.d124.s16|79-94|CONTRAINDICATED|brand
DDI-DrugBank.d124.s16|128-144|life-threatening|drug
DDI-DrugBank.d124.s17|26-34|rifampin|drug
DDI-DrugBank.d124.s17|35-50|CONTRAINDICATED|brand
DDI-DrugBank.d124.s17|51-56|since|drug
DDI-DrugBank.d124.s17|61-77|coadministration|drug
DDI-DrugBank.d124.s17|99-109|saquinavir|drug
DDI-DrugBank.d124.s17|116-130|antiretroviral|group
DDI-DrugBank.d124.s17|176-187|saquinavir.|drug
DDI-DrugBank.d124.s18|57-63|taking|drug
DDI-DrugBank.d124.s18|64-74|saquinavir|drug
DDI-DrugBank.d124.s18|75-86|(FORTOVASE)|brand
DDI-DrugBank.d124.s18|108-117|inhibitor|drug
DDI-DrugBank.d124.s18|147-157|saquinavir|drug
DDI-DrugBank.d124.s19|30-46|coadministration|drug
DDI-DrugBank.d124.s19|50-68|INVIRASE/ritonavir|drug
DDI-DrugBank.d124.s19|72-91|FORTOVASE/ritonavir|drug
DDI-DrugBank.d124.s20|30-45|CONTRAINDICATED|brand
DDI-DrugBank.d124.s20|82-98|life-threatening|drug
DDI-DrugBank.d124.s21|56-63|WARNING|brand
DDI-DrugBank.d124.s21|64-80|coadministration|drug
DDI-DrugBank.d124.s21|147-155|INVIRASE|brand
DDI-DrugBank.d124.s21|184-195|inhibitors.|drug
DDI-DrugBank.d124.s22|30-41|lovastatin,|drug
DDI-DrugBank.d124.s22|42-53|simvastatin|drug
DDI-DrugBank.d124.s22|54-61|WARNING|brand
DDI-DrugBank.d124.s22|119-128|including|drug
DDI-DrugBank.d124.s23|32-41|midazolam|drug
DDI-DrugBank.d124.s23|42-57|CONTRAINDICATED|brand
DDI-DrugBank.d124.s23|94-110|life-threatening|drug
DDI-DrugBank.d124.s23|142-151|increased|drug
DDI-DrugBank.d124.s25|15-21|Mainly|drug
DDI-DrugBank.d124.s25|37-43|CYP3A4|brand
DDI-DrugBank.d124.s26|51-67|coadministration|drug
DDI-DrugBank.d124.s26|88-94|mainly|drug
DDI-DrugBank.d124.s26|110-116|CYP3A4|brand
DDI-DrugBank.d124.s26|122-129|calcium|drug
DDI-DrugBank.d124.s26|171-179|quinine,|drug
DDI-DrugBank.d124.s26|192-202|quinidine,|drug
DDI-DrugBank.d124.s26|203-212|warfarin,|drug
DDI-DrugBank.d124.s26|225-238|cyclosporine,|drug
DDI-DrugBank.d124.s26|268-282|carbamazepine,|drug
DDI-DrugBank.d124.s26|377-391|coadministered|drug
DDI-DrugBank.d124.s26|397-408|saquinavir;|drug
DDI-DrugBank.d124.s27|17-29|combinations|drug
DDI-DrugBank.d124.s28|0-5|Since|drug
DDI-DrugBank.d124.s28|6-14|INVIRASE|brand
DDI-DrugBank.d124.s28|18-32|coadministered|drug
DDI-DrugBank.d124.s28|53-62|ritonavir|drug
DDI-DrugBank.d124.s28|128-143|coadministered.|drug
DDI-DrugBank.d124.s29|12-18|CYP3A4|brand
DDI-DrugBank.d124.s30|0-16|Coadministration|drug
DDI-DrugBank.d124.s30|48-56|inducers|drug
DDI-DrugBank.d124.s30|60-66|CYP3A4|brand
DDI-DrugBank.d124.s30|87-97|phenytoin,|drug
DDI-DrugBank.d124.s30|113-127|carbamazepine)|drug
DDI-DrugBank.d124.s30|169-180|saquinavir.|drug
DDI-DrugBank.d370.s0|3-11|DIFFERIN|brand
DDI-DrugBank.d370.s0|117-127|irritating|drug
DDI-DrugBank.d370.s0|228-234|drying|drug
DDI-DrugBank.d370.s0|293-305|astringents,|drug
DDI-DrugBank.d370.s1|42-47|using|drug
DDI-DrugBank.d370.s1|61-71|containing|group
DDI-DrugBank.d370.s1|80-91|resorcinol,|drug
DDI-DrugBank.d370.s1|113-124|combination|drug
DDI-DrugBank.d370.s1|130-138|DIFFERIN|brand
DDI-DrugBank.d370.s2|79-87|DIFFERIN|brand
DDI-DrugBank.d563.s0|45-59|administration|drug
DDI-DrugBank.d563.s0|63-69|ETHYOL|brand
DDI-DrugBank.d563.s0|82-91|receiving|drug
DDI-DrugBank.d563.s0|92-108|antihypertensive|group
DDI-DrugBank.d502.s0|57-66|receiving|drug
DDI-DrugBank.d502.s0|85-93|blocking|drug
DDI-DrugBank.d502.s1|71-83|administered|drug
DDI-DrugBank.d502.s1|96-105|receiving|drug
DDI-DrugBank.d502.s1|106-129|catecholamine-depleting|drug
DDI-DrugBank.d502.s1|144-154|reserpine,|drug
DDI-DrugBank.d199.s0|21-35|coadministered|drug
DDI-DrugBank.d199.s0|41-49|MONUROL,|brand
DDI-DrugBank.d199.s0|79-88|increases|drug
DDI-DrugBank.d199.s0|89-105|gastrointestinal|drug
DDI-DrugBank.d199.s0|151-158|urinary|drug
DDI-DrugBank.d199.s0|172-183|fosfomycin.|drug
DDI-DrugBank.d199.s1|17-25|increase|drug
DDI-DrugBank.d199.s1|26-42|gastrointestinal|drug
DDI-DrugBank.d199.s2|0-11|Cimetidine:|drug
DDI-DrugBank.d199.s2|12-22|Cimetidine|drug
DDI-DrugBank.d199.s2|43-59|pharmacokinetics|drug
DDI-DrugBank.d199.s2|63-73|fosfomycin|drug
DDI-DrugBank.d199.s2|79-93|coadministered|drug
DDI-DrugBank.d199.s2|99-107|MONUROL.|brand
DDI-DrugBank.d188.s0|11-25|administration|drug
DDI-DrugBank.d188.s0|29-36|HEXALEN|brand
DDI-DrugBank.d188.s0|41-56|antidepressants|group
DDI-DrugBank.d188.s0|68-77|inhibitor|drug
DDI-DrugBank.d188.s0|113-136|hypotension.Cimetidine,|drug
DDI-DrugBank.d188.s0|140-149|inhibitor|drug
DDI-DrugBank.d188.s0|181-190|increased|drug
DDI-DrugBank.d188.s0|191-203|altretamines|drug
DDI-DrugBank.d188.s1|32-39|HEXALEN|brand
DDI-DrugBank.d188.s1|44-53|cisplatin|drug
DDI-DrugBank.d188.s1|62-67|minus|drug
DDI-DrugBank.d188.s1|68-78|pyridoxine|drug
DDI-DrugBank.d188.s1|97-106|indicated|drug
DDI-DrugBank.d188.s1|112-122|pyridoxine|drug
DDI-DrugBank.d188.s2|49-59|suggesting|drug
DDI-DrugBank.d188.s2|65-75|pyridoxine|drug
DDI-DrugBank.d188.s2|90-102|administered|drug
DDI-DrugBank.d188.s2|108-115|HEXALEN|brand
DDI-DrugBank.d188.s2|123-134|cisplatin.1|drug
DDI-DrugBank.d521.s0|11-20|medicines|drug
DDI-DrugBank.d521.s0|25-33|increase|drug
DDI-DrugBank.d521.s0|61-72|glimepiride|drug
DDI-DrugBank.d521.s1|7-13|taking|drug
DDI-DrugBank.d521.s1|55-61|taking|drug
DDI-DrugBank.d521.s1|73-82|following|drug
DDI-DrugBank.d521.s1|83-93|medicines:|drug
DDI-DrugBank.d521.s1|96-103|aspirin|brand
DDI-DrugBank.d521.s1|107-114|another|drug
DDI-DrugBank.d521.s1|134-151|magnesium/choline|drug
DDI-DrugBank.d521.s1|206-213|choline|drug
DDI-DrugBank.d521.s1|238-247|magnesium|drug
DDI-DrugBank.d521.s2|17-34|anti-inflammatory|group
DDI-DrugBank.d521.s2|40-47|(NSAID)|brand
DDI-DrugBank.d521.s2|66-74|(Motrin,|drug
DDI-DrugBank.d521.s2|82-89|Nuprin,|drug
DDI-DrugBank.d521.s2|182-191|(Lodine),|drug
DDI-DrugBank.d521.s2|192-204|indomethacin|drug
DDI-DrugBank.d521.s2|205-215|(Indocin),|drug
DDI-DrugBank.d521.s2|238-247|oxaprozin|drug
DDI-DrugBank.d521.s3|29-58|sulfamethoxazole-trimethoprim|drug
DDI-DrugBank.d521.s3|78-91|sulfisoxazole|drug
DDI-DrugBank.d521.s3|92-104|(Gantrisin),|drug
DDI-DrugBank.d521.s3|108-121|sulfasalazine|drug
DDI-DrugBank.d521.s3|122-135|(Azulfidine);|drug
DDI-DrugBank.d521.s4|4-13|monoamine|drug
DDI-DrugBank.d521.s4|22-31|inhibitor|drug
DDI-DrugBank.d521.s4|32-38|(MAOI)|brand
DDI-DrugBank.d521.s4|72-87|tranylcypromine|drug
DDI-DrugBank.d521.s4|102-112|phenelzine|drug
DDI-DrugBank.d521.s5|25-36|propranolol|drug
DDI-DrugBank.d521.s5|57-68|(Tenormin),|drug
DDI-DrugBank.d521.s6|4-12|diuretic|group
DDI-DrugBank.d521.s6|34-53|hydrochlorothiazide|group
DDI-DrugBank.d521.s6|54-60|(HCTZ,|brand
DDI-DrugBank.d521.s6|75-89|chlorothiazide|group
DDI-DrugBank.d521.s7|12-20|medicine|drug
DDI-DrugBank.d521.s8|4-17|phenothiazine|drug
DDI-DrugBank.d521.s8|26-40|chlorpromazine|drug
DDI-DrugBank.d521.s8|41-53|(Thorazine),|drug
DDI-DrugBank.d521.s8|54-66|fluphenazine|drug
DDI-DrugBank.d521.s8|67-77|(Prolixin,|drug
DDI-DrugBank.d521.s8|89-105|prochlorperazine|drug
DDI-DrugBank.d521.s8|106-118|(Compazine),|drug
DDI-DrugBank.d521.s8|119-131|promethazine|drug
DDI-DrugBank.d521.s9|2-11|phenytoin|drug
DDI-DrugBank.d521.s9|12-23|(Dilantin);|drug
DDI-DrugBank.d521.s11|2-10|rifampin|drug
DDI-DrugBank.d521.s11|11-20|(Rifadin,|drug
DDI-DrugBank.d521.s13|47-57|monitoring|drug
DDI-DrugBank.d521.s13|69-75|taking|drug
DDI-DrugBank.d521.s13|87-96|medicines|drug
DDI-DrugBank.d521.s14|44-52|interact|drug
DDI-DrugBank.d521.s14|58-69|glimepiride|drug
DDI-DrugBank.d521.s15|42-48|taking|drug
DDI-DrugBank.d521.s15|86-96|medicines,|drug
DDI-DrugBank.d521.s15|97-106|including|drug
DDI-DrugBank.d233.s0|9-21|Allopurinol:|drug
DDI-DrugBank.d233.s0|26-35|principal|drug
DDI-DrugBank.d233.s0|66-78|azathioprine|drug
DDI-DrugBank.d233.s0|82-91|inhibited|drug
DDI-DrugBank.d233.s0|95-107|allopurinol.|drug
DDI-DrugBank.d233.s1|9-18|receiving|drug
DDI-DrugBank.d233.s1|19-31|azathioprine|drug
DDI-DrugBank.d233.s1|36-47|allopurinol|drug
DDI-DrugBank.d233.s1|94-107|azathioprine,|drug
DDI-DrugBank.d233.s2|22-31|Affecting|drug
DDI-DrugBank.d233.s2|90-99|including|drug
DDI-DrugBank.d233.s2|100-115|co-trimoxazole,|drug
DDI-DrugBank.d233.s3|21-31|Converting|drug
DDI-DrugBank.d233.s3|62-73|angiotensin|drug
DDI-DrugBank.d233.s3|74-84|converting|drug
DDI-DrugBank.d233.s3|92-102|inhibitors|drug
DDI-DrugBank.d233.s3|106-113|control|group
DDI-DrugBank.d233.s3|142-154|azathioprine|drug
DDI-DrugBank.d233.s3|176-182|induce|drug
DDI-DrugBank.d37.s0|12-23|information|drug
DDI-DrugBank.d168.s0|14-22|interact|drug
DDI-DrugBank.d168.s0|135-151|antihistamines),|group
DDI-DrugBank.d168.s0|152-168|anticholinergics|group
DDI-DrugBank.d168.s0|195-210|anticholinergic|group
DDI-DrugBank.d168.s0|220-236|(anticholinergic|drug
DDI-DrugBank.d168.s0|314-330|antihistamines),|group
DDI-DrugBank.d168.s0|335-344|monoamine|drug
DDI-DrugBank.d168.s0|353-358|(MAO)|brand
DDI-DrugBank.d168.s0|359-369|inhibitors|drug
DDI-DrugBank.d168.s0|391-405|antihistamines|group
DDI-DrugBank.d168.s0|422-431|intensify|drug
DDI-DrugBank.d168.s0|436-451|anticholinergic|group
DDI-DrugBank.d168.s0|482-498|antihistamines).|group
DDI-DrugBank.d57.s0|9-15|mixing|drug
DDI-DrugBank.d57.s0|22-36|aminoglycoside|drug
DDI-DrugBank.d57.s0|58-69|antibiotics|group
DDI-DrugBank.d57.s0|70-82|(penicillins|drug
DDI-DrugBank.d57.s0|86-101|cephalosporins)|drug
DDI-DrugBank.d57.s0|137-150|inactivation.|drug
DDI-DrugBank.d57.s1|13-27|aminoglycoside|drug
DDI-DrugBank.d57.s1|34-49|penicillin-type|drug
DDI-DrugBank.d57.s1|59-71|administered|drug
DDI-DrugBank.d57.s1|119-133|aminoglycoside|drug
DDI-DrugBank.d57.s2|14-26|inactivation|drug
DDI-DrugBank.d57.s2|34-48|aminoglycoside|drug
DDI-DrugBank.d57.s2|52-62|clinically|drug
DDI-DrugBank.d529.s0|0-9|Antacids:|group
DDI-DrugBank.d529.s0|10-24|Administration|drug
DDI-DrugBank.d529.s0|61-68|fasting|drug
DDI-DrugBank.d529.s2|53-70|anti-inflammatory|group
DDI-DrugBank.d529.s2|103-111|bleeding|drug
DDI-DrugBank.d529.s2|135-144|receiving|drug
DDI-DrugBank.d529.s2|145-161|anti-coagulants,|group
DDI-DrugBank.d529.s2|174-182|clinical|drug
DDI-DrugBank.d529.s2|183-191|bleeding|drug
DDI-DrugBank.d529.s3|38-51|administering|drug
DDI-DrugBank.d529.s3|77-83|taking|drug
DDI-DrugBank.d529.s3|84-99|anticoagulants.|group
DDI-DrugBank.d529.s4|0-8|Aspirin:|brand
DDI-DrugBank.d529.s4|20-34|administration|drug
DDI-DrugBank.d529.s4|38-45|aspirin|brand
DDI-DrugBank.d529.s5|15-22|aspirin|brand
DDI-DrugBank.d529.s5|85-102|anti-inflammatory|group
DDI-DrugBank.d529.s6|35-42|aspirin|brand
DDI-DrugBank.d529.s7|16-24|Blocking|drug
DDI-DrugBank.d529.s7|69-77|pressure|group
DDI-DrugBank.d529.s7|90-101|propranolol|drug
DDI-DrugBank.d529.s8|65-71|single|drug
DDI-DrugBank.d529.s8|80-91|propranolol|drug
DDI-DrugBank.d529.s10|32-47|pharmacokinetic|drug
DDI-DrugBank.d529.s10|96-101|lying|drug
DDI-DrugBank.d529.s10|106-118|interference|drug
DDI-DrugBank.d529.s10|124-136|propranolols|drug
DDI-DrugBank.d529.s11|9-15|taking|drug
DDI-DrugBank.d529.s11|76-82|ensure|group
DDI-DrugBank.d529.s12|0-11|Cimetidine,|drug
DDI-DrugBank.d529.s12|12-23|Ranitidine:|drug
DDI-DrugBank.d529.s12|70-80|cimetidine|drug
DDI-DrugBank.d529.s12|84-94|ranitidine|drug
DDI-DrugBank.d529.s12|123-139|pharmacokinetics|drug
DDI-DrugBank.d529.s12|197-205|increase|drug
DDI-DrugBank.d529.s12|284-295|cimetidine.|drug
DDI-DrugBank.d529.s13|0-8|Digoxin:|drug
DDI-DrugBank.d529.s13|32-46|administration|drug
DDI-DrugBank.d529.s13|67-74|digoxin|drug
DDI-DrugBank.d529.s14|0-10|Diuretics:|group
DDI-DrugBank.d529.s14|93-110|anti-inflammatory|group
DDI-DrugBank.d529.s14|122-131|interfere|drug
DDI-DrugBank.d529.s15|99-108|diuresis,|group
DDI-DrugBank.d529.s15|109-121|natriuresis,|group
DDI-DrugBank.d529.s15|126-137|kaliuresis.|group
DDI-DrugBank.d529.s16|19-36|anti-inflammatory|group
DDI-DrugBank.d529.s16|48-55|inhibit|drug
DDI-DrugBank.d529.s16|56-69|prostaglandin|drug
DDI-DrugBank.d529.s16|99-108|interfere|drug
DDI-DrugBank.d529.s16|114-122|thiazide|group
DDI-DrugBank.d529.s16|123-132|diuretics|group
DDI-DrugBank.d529.s16|158-175|potassium-sparing|drug
DDI-DrugBank.d529.s16|176-186|diuretics.|group
DDI-DrugBank.d529.s17|9-18|receiving|drug
DDI-DrugBank.d529.s17|36-46|furosemide|drug
DDI-DrugBank.d529.s17|56-65|diuretics|group
DDI-DrugBank.d529.s17|96-105|determine|drug
DDI-DrugBank.d529.s17|131-140|obtained.|drug
DDI-DrugBank.d529.s18|99-108|receiving|drug
DDI-DrugBank.d529.s18|109-118|glyburide|drug
DDI-DrugBank.d529.s18|126-135|metformin|drug
DDI-DrugBank.d529.s18|142-156|chlorpropamide|drug
DDI-DrugBank.d529.s18|162-172|phenformin|drug
DDI-DrugBank.d529.s18|183-192|glyburide|drug
DDI-DrugBank.d529.s18|198-208|phenformin|drug
DDI-DrugBank.d529.s19|68-74|during|drug
DDI-DrugBank.d529.s19|87-101|administration|drug
DDI-MedLine.d98.s0|33-40|cocaine|drug
DDI-MedLine.d98.s0|41-49|exposure|group
DDI-MedLine.d98.s1|39-44|lines|drug
DDI-MedLine.d98.s1|82-103|pentobarbital-induced|drug
DDI-MedLine.d98.s1|139-145|(LST),|brand
DDI-MedLine.d98.s1|166-172|(SST),|brand
DDI-MedLine.d98.s1|191-198|control|group
DDI-MedLine.d98.s1|199-205|(RBC)]|brand
DDI-MedLine.d98.s1|225-240|cocaine-induced|drug
DDI-MedLine.d98.s2|6-11|lines|drug
DDI-MedLine.d98.s2|75-83|cocaine.|drug
DDI-MedLine.d98.s3|9-16|cocaine|drug
DDI-MedLine.d98.s3|97-103|14-day|drug_n
DDI-MedLine.d98.s3|137-146|tolerance|drug
DDI-MedLine.d98.s4|15-23|cocaine,|drug
DDI-MedLine.d98.s5|91-96|3-day|drug_n
DDI-MedLine.d98.s6|46-53|induced|drug
DDI-MedLine.d98.s6|57-64|cocaine|drug
DDI-MedLine.d98.s6|113-124|determining|drug
DDI-MedLine.d98.s7|0-8|Dopamine|drug
DDI-MedLine.d98.s7|69-74|(STR)|brand
DDI-MedLine.d98.s7|96-101|(NAC)|brand
DDI-MedLine.d98.s7|110-125|cocaine-treated|drug
DDI-MedLine.d98.s7|143-156|corresponding|drug
DDI-MedLine.d98.s7|157-171|saline-treated|drug
DDI-MedLine.d98.s7|172-181|controls.|group
DDI-MedLine.d98.s8|4-12|affinity|drug
DDI-MedLine.d98.s8|102-117|cocaine-treated|drug
DDI-MedLine.d98.s9|37-44|binding|drug
DDI-MedLine.d98.s9|108-117|increased|drug
DDI-MedLine.d98.s9|121-136|cocaine-treated|drug
DDI-MedLine.d98.s11|22-30|findings|drug
DDI-MedLine.d98.s11|117-127|contribute|group
DDI-MedLine.d98.s11|173-180|cocaine|drug
DDI-MedLine.d98.s11|181-189|exposure|group
DDI-MedLine.d98.s11|205-211|lines.|drug
DDI-DrugBank.d243.s0|46-58|interactions|drug
DDI-DrugBank.d285.s0|21-30|increased|drug
DDI-DrugBank.d285.s0|31-40|incidence|drug
DDI-DrugBank.d285.s0|57-65|bleeding|drug
DDI-DrugBank.d285.s0|140-149|rifampin.|drug
DDI-DrugBank.d285.s1|98-107|phenytoin|drug
DDI-DrugBank.d285.s1|108-115|sodium,|drug
DDI-DrugBank.d285.s1|116-129|carbamazepine|drug
DDI-DrugBank.d285.s1|148-161|griseofulvin,|drug
DDI-DrugBank.d285.s1|162-173|ampicillin,|drug
DDI-DrugBank.d285.s1|178-191|tetracyclines|drug
DDI-DrugBank.d183.s0|10-26|drug-interaction|drug
DDI-DrugBank.d183.s0|62-72|clinically|drug
DDI-DrugBank.d183.s0|85-96|interaction|drug
DDI-DrugBank.d183.s0|165-172|failure|group
DDI-DrugBank.d183.s1|16-28|administered|drug
DDI-DrugBank.d183.s1|34-45|tolazoline,|drug
DDI-DrugBank.d183.s1|46-55|dopamine,|drug
DDI-DrugBank.d183.s1|56-67|dobutamine,|drug
DDI-DrugBank.d183.s1|68-77|steroids,|group
DDI-DrugBank.d183.s2|69-74|oxide|drug
DDI-DrugBank.d183.s2|92-101|including|drug
DDI-DrugBank.d183.s2|102-108|sodium|drug
DDI-DrugBank.d183.s2|109-122|nitroprusside|drug
DDI-DrugBank.d183.s2|127-141|nitroglycerin,|drug
DDI-DrugBank.d183.s2|197-207|developing|drug
DDI-DrugBank.d183.s2|208-226|methemoglobinemia.|drug
DDI-DrugBank.d183.s3|23-33|prilocaine|drug
DDI-DrugBank.d183.s3|41-50|increased|drug
DDI-DrugBank.d183.s3|59-79|methaemoglobinaemia,|drug
DDI-DrugBank.d183.s3|96-104|infants,|drug
DDI-DrugBank.d183.s3|142-152|literature|group
DDI-DrugBank.d183.s4|43-55|administered|drug
DDI-MedLine.d5.s0|14-28|administration|drug
DDI-MedLine.d5.s0|52-64|interactions|drug
DDI-MedLine.d5.s0|83-102|bishydroxycoumarin,|drug
DDI-MedLine.d5.s0|134-141|sodium.|drug
DDI-MedLine.d5.s1|48-66|bishydroxycoumarin|drug
DDI-MedLine.d5.s1|71-86|anticoagulant),|group
DDI-MedLine.d5.s1|103-120|organophosphorous|drug
DDI-MedLine.d5.s1|150-156|sodium|drug
DDI-MedLine.d5.s1|161-168|inducer|drug
DDI-MedLine.d5.s1|197-209|investigated|drug
DDI-MedLine.d5.s2|104-123|antiprothrombinemic|group
DDI-MedLine.d5.s2|134-153|bishydroxy-coumarin|drug
DDI-MedLine.d5.s3|30-41|intravenous|drug
DDI-MedLine.d5.s3|47-56|injection|drug
DDI-MedLine.d5.s3|73-85|insufficient|drug
DDI-MedLine.d5.s3|109-119|inhibition|drug
DDI-MedLine.d5.s3|135-155|acetylcholinesterase|drug
DDI-MedLine.d5.s4|37-46|sodium/kg|drug
DDI-MedLine.d5.s4|58-75|intraperitoneally|drug
DDI-MedLine.d5.s4|76-81|(IP),|brand
DDI-MedLine.d5.s4|86-104|anticholinesterase|group
DDI-MedLine.d5.s5|81-99|anticholinesterase|group
DDI-DrugBank.d166.s1|53-68|antituberculous|group
DDI-DrugBank.d166.s1|75-87|administered|drug
DDI-DrugBank.d166.s2|51-62|ethionamide|drug
DDI-DrugBank.d166.s2|66-78|administered|drug
DDI-DrugBank.d166.s2|84-95|cycloserine|drug
DDI-DrugBank.d166.s2|156-164|includes|drug
DDI-DrugBank.d166.s3|10-17|ethanol|drug
DDI-DrugBank.d166.s3|18-27|ingestion|drug
DDI-DrugBank.d315.s0|0-8|Digoxin:|drug
DDI-DrugBank.d315.s0|9-25|Coadministration|drug
DDI-DrugBank.d315.s0|29-37|digoxin,|drug
DDI-DrugBank.d315.s0|40-54|P-glycoprotein|drug
DDI-DrugBank.d315.s0|131-139|increase|drug
DDI-DrugBank.d315.s0|143-150|digoxin|drug
DDI-DrugBank.d315.s1|14-21|digoxin|drug
DDI-DrugBank.d315.s1|25-37|administered|drug
DDI-DrugBank.d315.s1|43-52|VAPRISOL,|brand
DDI-DrugBank.d315.s1|57-66|clinician|drug
DDI-DrugBank.d315.s1|105-114|increases|drug
DDI-DrugBank.d315.s1|118-125|digoxin|drug
DDI-MedLine.d46.s0|13-29|coadministration|drug
DDI-MedLine.d46.s0|33-43|fluoxetine|drug
DDI-MedLine.d46.s0|47-56|cisapride|drug
DDI-MedLine.d46.s0|57-73|pharmacokinetics|drug
DDI-MedLine.d46.s0|82-91|intervals|drug
DDI-MedLine.d46.s1|0-5|STUDY|brand
DDI-MedLine.d46.s1|6-16|OBJECTIVE:|brand
DDI-MedLine.d46.s1|43-53|fluoxetine|drug
DDI-MedLine.d46.s1|61-77|pharmacokinetics|drug
DDI-MedLine.d46.s1|107-116|cisapride|drug
DDI-MedLine.d46.s2|0-7|DESIGN:|brand
DDI-MedLine.d46.s3|0-8|SETTING:|brand
DDI-MedLine.d46.s3|9-17|Clinical|drug
DDI-MedLine.d46.s5|0-14|INTERVENTIONS:|brand
DDI-MedLine.d46.s5|40-49|according|drug
DDI-MedLine.d46.s5|57-66|following|drug
DDI-MedLine.d46.s5|77-86|baseline;|drug
DDI-MedLine.d46.s6|14-19|1-6):|drug_n
DDI-MedLine.d46.s6|20-29|cisapride|drug
DDI-MedLine.d46.s7|14-20|7-13);|drug_n
DDI-MedLine.d46.s8|14-21|14-44):|drug_n
DDI-MedLine.d46.s8|22-32|fluoxetine|drug
DDI-MedLine.d46.s9|18-25|45-52):|drug_n
DDI-MedLine.d46.s9|26-35|cisapride|drug
DDI-MedLine.d46.s9|60-66|45-51)|drug_n
DDI-MedLine.d46.s9|72-82|fluoxetine|drug
DDI-MedLine.d46.s9|99-106|45-52).|drug_n
DDI-MedLine.d46.s10|0-12|MEASUREMENTS|brand
DDI-MedLine.d46.s10|22-30|RESULTS:|brand
DDI-MedLine.d46.s10|60-67|12-lead|drug_n
DDI-MedLine.d46.s10|115-121|points|drug
DDI-MedLine.d46.s10|137-144|morning|drug
DDI-MedLine.d46.s10|153-162|cisapride|drug
DDI-MedLine.d46.s11|37-44|morning|drug
DDI-MedLine.d46.s12|32-40|baseline|drug
DDI-MedLine.d46.s13|0-16|Coadministration|drug
DDI-MedLine.d46.s13|20-30|fluoxetine|drug
DDI-MedLine.d46.s13|55-64|cisapride|drug
DDI-MedLine.d46.s14|14-24|clinically|drug
DDI-MedLine.d46.s14|61-70|intervals|drug
DDI-MedLine.d46.s14|71-77|during|drug
DDI-MedLine.d46.s14|78-92|administration|drug
DDI-MedLine.d46.s14|96-105|cisapride|drug
DDI-MedLine.d46.s14|120-131|fluoxetine.|drug
DDI-MedLine.d46.s15|0-9|Cisapride|drug
DDI-MedLine.d46.s15|19-28|tolerated|drug
DDI-MedLine.d46.s15|34-46|administered|drug
DDI-MedLine.d46.s15|61-72|fluoxetine.|drug
DDI-MedLine.d46.s16|0-11|CONCLUSION:|brand
DDI-MedLine.d46.s16|12-21|Cisapride|drug
DDI-MedLine.d46.s16|29-41|administered|drug
DDI-MedLine.d46.s16|61-70|receiving|drug
DDI-MedLine.d46.s16|98-109|fluoxetine.|drug
DDI-DrugBank.d142.s0|25-34|resulting|drug
DDI-DrugBank.d142.s0|40-51|cholinergic|drug
DDI-DrugBank.d142.s0|76-82|LEVSIN|brand
DDI-DrugBank.d142.s0|86-98|administered|drug
DDI-DrugBank.d142.s0|124-140|antimuscarinics,|group
DDI-DrugBank.d142.s0|141-152|amantadine,|drug
DDI-DrugBank.d142.s0|166-181|phenothiazines,|drug
DDI-DrugBank.d142.s0|182-191|monoamine|drug
DDI-DrugBank.d142.s0|200-205|(MAO)|brand
DDI-DrugBank.d142.s0|206-217|inhibitors,|drug
DDI-DrugBank.d142.s0|228-243|antidepressants|group
DDI-DrugBank.d142.s0|252-267|antihistamines.|group
DDI-DrugBank.d142.s1|0-8|Antacids|group
DDI-DrugBank.d142.s1|13-22|interfere|drug
DDI-DrugBank.d142.s1|46-53|LEVSIN.|brand
DDI-DrugBank.d142.s2|0-10|Administer|drug
DDI-DrugBank.d142.s2|11-17|LEVSIN|brand
DDI-DrugBank.d142.s3|0-8|antacids|group
DDI-MedLine.d112.s0|10-21|dofetillide|drug
DDI-MedLine.d112.s0|29-45|pharmacokinetics|drug
DDI-MedLine.d112.s0|49-57|digoxin.|drug
DDI-MedLine.d112.s1|14-24|dofetilide|drug
DDI-MedLine.d112.s1|45-61|pharmacokinetics|drug
DDI-MedLine.d112.s1|65-72|digoxin|drug
DDI-MedLine.d112.s1|104-116|double-blind|drug
DDI-MedLine.d112.s2|13-23|dofetilide|drug
DDI-MedLine.d112.s2|76-91|pharmacokinetic|drug
DDI-MedLine.d112.s2|105-112|digoxin|drug
DDI-MedLine.d112.s3|22-32|dofetilide|drug
DDI-MedLine.d112.s3|71-78|digoxin|drug
DDI-MedLine.d112.s3|87-95|maintain|drug
DDI-MedLine.d112.s3|108-115|digoxin|drug
DDI-DrugBank.d427.s0|26-38|theophylline|drug
DDI-DrugBank.d427.s0|75-84|quinolone|drug
DDI-DrugBank.d427.s1|27-47|theophylline-related|drug
DDI-DrugBank.d427.s1|101-111|quinolones|drug
DDI-DrugBank.d427.s1|116-129|theophylline.|drug
DDI-DrugBank.d427.s2|11-21|monitoring|drug
DDI-DrugBank.d427.s2|25-37|theophylline|drug
DDI-DrugBank.d427.s2|87-99|theophylline|drug
DDI-DrugBank.d427.s3|0-10|Quinolones|drug
DDI-DrugBank.d427.s3|30-39|interfere|drug
DDI-DrugBank.d427.s3|63-72|caffeine.|drug
DDI-DrugBank.d427.s4|38-46|caffeine|drug
DDI-DrugBank.d427.s5|0-11|Quinolones,|drug
DDI-DrugBank.d427.s5|12-21|including|drug
DDI-DrugBank.d427.s5|74-87|anticoagulant|group
DDI-DrugBank.d427.s5|88-96|warfarin|drug
DDI-DrugBank.d427.s6|24-36|administered|drug
DDI-DrugBank.d427.s6|52-63|prothrombin|drug
DDI-DrugBank.d427.s7|0-14|Nitrofurantoin|drug
DDI-DrugBank.d427.s7|15-25|interferes|drug
DDI-DrugBank.d427.s8|0-8|Antacids|group
DDI-DrugBank.d427.s8|9-19|containing|group
DDI-DrugBank.d427.s8|20-30|magnesium,|drug
DDI-DrugBank.d427.s8|31-40|aluminum,|drug
DDI-DrugBank.d427.s8|44-52|calcium;|drug
DDI-DrugBank.d427.s10|0-13|multivitamins|drug
DDI-DrugBank.d427.s10|14-24|containing|group
DDI-DrugBank.d427.s10|25-30|zinc;|drug
DDI-DrugBank.d427.s11|12-25|(Didanosine),|drug
DDI-DrugBank.d427.s11|112-121|interfere|drug
DDI-DrugBank.d427.s11|145-156|quinolones,|drug
DDI-DrugBank.d427.s11|157-166|resulting|drug
DDI-DrugBank.d427.s12|33-39|within|drug
DDI-DrugBank.d427.s12|70-76|within|drug
DDI-DrugBank.d427.s12|118-133|administration.|drug
DDI-DrugBank.d427.s13|25-37|cyclosporine|drug
DDI-DrugBank.d427.s13|90-100|quinolones|drug
DDI-DrugBank.d427.s13|105-118|cyclosporine.|drug
DDI-DrugBank.d427.s14|11-23|cyclosporine|drug
DDI-DrugBank.d427.s14|73-85|cyclosporine|drug
DDI-DrugBank.d52.s0|55-69|streptokinase)|drug
DDI-DrugBank.d52.s0|77-85|increase|drug
DDI-DrugBank.d52.s0|98-106|bleeding|drug
DDI-DrugBank.d52.s0|158-166|REFLUDAN|brand
DDI-DrugBank.d52.s1|27-35|coumarin|drug
DDI-DrugBank.d52.s1|48-56|(vitamin|drug
DDI-DrugBank.d52.s1|121-129|increase|drug
DDI-DrugBank.d52.s1|142-151|bleeding.|drug
DDI-DrugBank.d428.s0|0-7|ELLENCE|brand
DDI-DrugBank.d428.s0|21-32|combination|drug
DDI-DrugBank.d428.s0|128-144|gastrointestinal|drug
DDI-DrugBank.d428.s1|19-26|ELLENCE|brand
DDI-DrugBank.d428.s1|84-91|failure|group
DDI-DrugBank.d428.s1|99-106|calcium|drug
DDI-DrugBank.d428.s1|141-151|monitoring|drug
DDI-DrugBank.d428.s2|19-28|regarding|drug
DDI-DrugBank.d428.s2|33-49|coadministration|drug
DDI-DrugBank.d428.s2|75-86|epirubicin.|drug
DDI-DrugBank.d428.s3|22-43|epirubicin-containing|group
DDI-DrugBank.d428.s3|44-51|CEF-120|brand
DDI-DrugBank.d428.s3|55-62|FEC-100|brand
DDI-DrugBank.d428.s4|38-46|increase|drug
DDI-DrugBank.d428.s4|119-130|literature.|group
DDI-DrugBank.d428.s5|36-52|epirubicin-based|drug
DDI-DrugBank.d428.s5|124-135|interrupted|drug
DDI-DrugBank.d428.s5|164-175|overlapping|drug
DDI-DrugBank.d428.s6|25-35|epirubicin|drug
DDI-DrugBank.d428.s7|0-14|Administration|drug
DDI-DrugBank.d428.s7|18-25|ELLENCE|brand
DDI-DrugBank.d428.s7|63-69|induce|drug
DDI-DrugBank.d428.s7|73-85|inflammatory|drug
DDI-DrugBank.d428.s8|0-10|Epirubicin|drug
DDI-DrugBank.d428.s9|28-35|induced|drug
DDI-DrugBank.d428.s9|72-82|epirubicin|drug
DDI-DrugBank.d428.s9|95-112|pharmacokinetics,|drug
DDI-DrugBank.d428.s10|0-10|Cimetidine|drug
DDI-DrugBank.d428.s10|11-20|increased|drug
DDI-DrugBank.d428.s10|32-42|epirubicin|drug
DDI-DrugBank.d428.s11|0-10|Cimetidine|drug
DDI-DrugBank.d428.s11|39-45|during|drug
DDI-DrugBank.d428.s11|61-69|ELLENCE.|brand
DDI-DrugBank.d428.s12|53-65|interactions|drug
DDI-DrugBank.d428.s12|74-81|ELLENCE|brand
DDI-DrugBank.d190.s0|5-16|interaction|drug
DDI-DrugBank.d190.s1|9-14|since|drug
DDI-DrugBank.d190.s1|27-36|increased|drug
DDI-DrugBank.d190.s1|45-53|bleeding|drug
DDI-DrugBank.d190.s2|93-100|heparin|drug
DDI-DrugBank.d190.s2|117-124|heparin|drug
DDI-DrugBank.d190.s2|131-137|15,000|drug_n
DDI-DrugBank.d190.s2|178-187|molecular|drug
DDI-DrugBank.d190.s2|195-203|heparins|drug
DDI-DrugBank.d190.s2|207-216|indicated|drug
DDI-DrugBank.d190.s2|224-235|prescribing|drug
DDI-DrugBank.d190.s2|236-247|information|drug
DDI-DrugBank.d190.s3|41-48|heparin|drug
DDI-DrugBank.d190.s3|172-187|well-controlled|group
DDI-DrugBank.d190.s3|188-196|clinical|drug
DDI-DrugBank.d190.s4|112-121|interfere|drug
DDI-DrugBank.d190.s4|190-195|VIII,|brand
DDI-DrugBank.d190.s5|5-17|interference|drug
DDI-DrugBank.d190.s6|42-51|interfere|drug
DDI-DrugBank.d410.s0|18-24|D.H.E.|brand
DDI-DrugBank.d410.s0|29-47|(dihydroergotamine|drug
DDI-DrugBank.d410.s0|137-148|combination|drug
DDI-DrugBank.d410.s0|190-199|pressure.|group
DDI-DrugBank.d410.s1|117-123|D.H.E.|brand
DDI-DrugBank.d410.s1|128-146|(dihydroergotamine|drug
DDI-DrugBank.d410.s2|16-22|D.H.E.|brand
DDI-DrugBank.d410.s2|27-45|(dihydroergotamine|drug
DDI-DrugBank.d410.s2|91-97|within|drug
DDI-DrugBank.d410.s3|41-49|clinical|drug
DDI-DrugBank.d410.s3|64-72|indicate|drug
DDI-DrugBank.d410.s3|108-122|administration|drug
DDI-DrugBank.d410.s3|126-132|D.H.E.|brand
DDI-DrugBank.d410.s3|137-155|(dihydroergotamine|drug
DDI-DrugBank.d410.s3|201-210|receiving|drug
DDI-DrugBank.d410.s3|211-223|propranolol,|drug
DDI-DrugBank.d410.s3|253-264|propranolol|drug
DDI-DrugBank.d410.s3|311-321|ergotamine|drug
DDI-DrugBank.d410.s3|325-333|blocking|drug
DDI-DrugBank.d410.s3|338-350|vasodilating|drug
DDI-DrugBank.d410.s3|363-375|epinephrine.|drug
DDI-DrugBank.d410.s4|0-9|Nicotine:|drug
DDI-DrugBank.d410.s4|10-18|Nicotine|drug
DDI-DrugBank.d410.s4|66-78|predisposing|drug
DDI-DrugBank.d410.s5|0-9|Macrolide|drug
DDI-DrugBank.d410.s5|29-41|erythromycin|drug
DDI-DrugBank.d410.s5|46-62|troleandomycin):|drug
DDI-DrugBank.d410.s5|108-114|D.H.E.|brand
DDI-DrugBank.d410.s5|119-137|(dihydroergotamine|drug
DDI-DrugBank.d410.s5|195-203|interact|drug
DDI-DrugBank.d410.s5|209-220|antibiotics|group
DDI-DrugBank.d410.s5|228-237|macrolide|drug
DDI-DrugBank.d410.s5|245-254|resulting|drug
DDI-DrugBank.d410.s5|258-267|increased|drug
DDI-DrugBank.d410.s5|295-304|alkaloids|group
DDI-DrugBank.d410.s6|67-88|ergotamine-containing|group
DDI-DrugBank.d410.s6|100-115|co-administered|drug
DDI-DrugBank.d410.s6|127-139|antibiotics.|group
DDI-DrugBank.d410.s7|35-49|incoordination|drug
DDI-DrugBank.d410.s7|81-86|5-HT1|brand
DDI-DrugBank.d410.s7|106-121|co-administered|drug
DDI-DrugBank.d410.s8|0-11|fluoxetine,|drug
DDI-DrugBank.d410.s8|12-24|fluvoxamine,|drug
DDI-DrugBank.d410.s8|25-36|paroxetine,|drug
DDI-DrugBank.d410.s8|37-49|sertraline).|drug
DDI-DrugBank.d410.s9|67-78|interaction|drug
DDI-DrugBank.d410.s9|97-103|D.H.E.|brand
DDI-DrugBank.d410.s9|108-126|(dihydroergotamine|drug
DDI-DrugBank.d410.s10|40-54|contraceptives|group
DDI-DrugBank.d410.s10|62-78|pharmacokinetics|drug
DDI-DrugBank.d410.s10|82-88|D.H.E.|brand
DDI-DrugBank.d410.s10|93-111|(dihydroergotamine|drug
DDI-DrugBank.d165.s0|5-17|itraconazole|drug
DDI-DrugBank.d165.s0|44-64|hydroxyitraconazole,|drug
DDI-DrugBank.d165.s0|69-79|inhibitors|drug
DDI-DrugBank.d165.s1|0-16|Coadministration|drug
DDI-DrugBank.d165.s1|20-32|Itraconazole|drug
DDI-DrugBank.d165.s1|120-129|increased|drug
DDI-DrugBank.d165.s1|176-184|increase|drug
DDI-DrugBank.d165.s3|0-16|Coadministration|drug
DDI-DrugBank.d165.s3|20-31|terfenadine|drug
DDI-DrugBank.d165.s3|37-49|Itraconazole|drug
DDI-DrugBank.d165.s3|95-107|terfenadine,|drug
DDI-DrugBank.d165.s3|108-117|resulting|drug
DDI-DrugBank.d165.s3|126-135|instances|drug
DDI-DrugBank.d165.s3|145-156|threatening|drug
DDI-DrugBank.d165.s4|13-18|azole|drug
DDI-DrugBank.d165.s4|19-30|antifungal,|group
DDI-DrugBank.d165.s4|31-44|ketoconazole,|drug
DDI-DrugBank.d165.s4|45-53|inhibits|drug
DDI-DrugBank.d165.s4|72-83|astemizole,|drug
DDI-DrugBank.d165.s4|84-93|resulting|drug
DDI-DrugBank.d165.s4|131-141|astemizole|drug
DDI-DrugBank.d165.s4|168-188|desmethylastermizole|drug
DDI-DrugBank.d165.s4|210-220|intervals.|drug
DDI-DrugBank.d165.s5|27-40|itraconazole,|drug
DDI-DrugBank.d165.s5|58-71|ketoconazole,|drug
DDI-DrugBank.d165.s5|167-178|astemizole.|drug
DDI-DrugBank.d165.s6|37-49|itraconazole|drug
DDI-DrugBank.d165.s6|54-67|ketoconazole,|drug
DDI-DrugBank.d165.s6|68-84|coadministration|drug
DDI-DrugBank.d165.s6|88-98|astemizole|drug
DDI-DrugBank.d165.s6|104-116|itraconazole|drug
DDI-DrugBank.d165.s6|120-136|contraindicated.|group
DDI-DrugBank.d165.s7|6-22|pharmacokinetics|drug
DDI-DrugBank.d165.s7|28-36|indicate|drug
DDI-DrugBank.d165.s7|47-59|ketoconazole|drug
DDI-DrugBank.d165.s7|69-77|inhibits|drug
DDI-DrugBank.d165.s7|96-105|cisapride|drug
DDI-DrugBank.d165.s7|106-115|resulting|drug
DDI-DrugBank.d165.s7|133-141|increase|drug
DDI-DrugBank.d165.s8|18-34|coadministration|drug
DDI-DrugBank.d165.s8|43-55|ketoconazole|drug
DDI-DrugBank.d165.s8|60-69|cisapride|drug
DDI-DrugBank.d165.s8|107-115|interval|drug
DDI-DrugBank.d165.s9|27-39|itraconazole|drug
DDI-DrugBank.d165.s9|54-62|inhibits|drug
DDI-DrugBank.d165.s9|92-98|mainly|drug
DDI-DrugBank.d165.s10|22-36|administration|drug
DDI-DrugBank.d165.s10|40-52|Itraconazole|drug
DDI-DrugBank.d165.s10|58-67|cisapride|drug
DDI-DrugBank.d165.s10|71-87|contraindicated.|group
DDI-DrugBank.d165.s11|0-16|Coadministration|drug
DDI-DrugBank.d165.s11|20-32|Itraconazole|drug
DDI-DrugBank.d165.s11|43-52|midazolam|drug
DDI-DrugBank.d165.s11|56-65|triazolam|drug
DDI-DrugBank.d165.s13|57-70|Itraconazole.|drug
DDI-DrugBank.d165.s14|3-12|midazolam|drug
DDI-DrugBank.d165.s14|16-28|administered|drug
DDI-DrugBank.d165.s14|74-79|since|drug
DDI-DrugBank.d165.s15|0-16|Coadministration|drug
DDI-DrugBank.d165.s15|20-32|Itraconazole|drug
DDI-DrugBank.d165.s15|37-50|cyclosporine,|drug
DDI-DrugBank.d165.s15|65-72|digoxin|drug
DDI-DrugBank.d165.s15|84-93|increased|drug
DDI-DrugBank.d165.s16|0-13|Cyclosporine,|drug
DDI-DrugBank.d165.s16|29-36|digoxin|drug
DDI-DrugBank.d165.s16|79-89|initiation|drug
DDI-DrugBank.d165.s16|93-105|Itraconazole|drug
DDI-DrugBank.d165.s17|45-54|receiving|drug
DDI-DrugBank.d165.s17|73-83|inhibitors|drug
DDI-DrugBank.d165.s17|84-96|administered|drug
DDI-DrugBank.d165.s17|174-183|including|drug
DDI-DrugBank.d165.s17|184-197|cyclosporine.|drug
DDI-DrugBank.d165.s18|5-17|Itraconazole|drug
DDI-DrugBank.d165.s18|22-36|coadministered|drug
DDI-DrugBank.d165.s18|42-52|phenytoin,|drug
DDI-DrugBank.d165.s18|53-62|rifampin,|drug
DDI-DrugBank.d165.s18|114-126|itraconazole|drug
DDI-DrugBank.d165.s19|65-77|itraconazole|drug
DDI-DrugBank.d165.s19|132-140|increase|drug
DDI-DrugBank.d165.s19|153-165|Itraconazole|drug
DDI-DrugBank.d165.s20|53-67|administration|drug
DDI-DrugBank.d165.s20|71-83|Itraconazole|drug
DDI-DrugBank.d165.s20|88-97|phenytoin|drug
DDI-DrugBank.d165.s20|126-136|phenytoin;|drug
DDI-DrugBank.d165.s21|36-45|phenytoin|drug
DDI-DrugBank.d165.s21|106-119|Itraconazole.|drug
DDI-DrugBank.d165.s22|26-38|Itraconazole|drug
DDI-DrugBank.d165.s22|52-65|anticoagulant|group
DDI-DrugBank.d165.s22|76-89|coumarin-like|drug
DDI-DrugBank.d165.s23|11-22|prothrombin|drug
DDI-DrugBank.d165.s23|70-79|receiving|drug
DDI-DrugBank.d165.s23|80-92|Itraconazole|drug
DDI-DrugBank.d165.s23|97-110|coumarin-like|drug
DDI-DrugBank.d165.s24|25-30|azole|drug
DDI-DrugBank.d165.s24|31-41|antifungal|group
DDI-DrugBank.d165.s25|0-12|Itraconazole|drug
DDI-DrugBank.d165.s25|60-72|Itraconazole|drug
DDI-DrugBank.d165.s25|91-106|coadministered.|drug
DDI-DrugBank.d165.s26|64-73|receiving|drug
DDI-DrugBank.d165.s26|74-79|azole|drug
DDI-DrugBank.d165.s26|80-90|antifungal|group
DDI-DrugBank.d165.s27|64-76|Itraconazole|drug
DDI-DrugBank.d165.s27|110-125|coadministered.|drug
DDI-DrugBank.d165.s28|0-8|Tinnitus|drug
DDI-DrugBank.d165.s28|23-30|hearing|drug
DDI-DrugBank.d165.s28|76-85|receiving|drug
DDI-DrugBank.d165.s28|86-98|Itraconazole|drug
DDI-DrugBank.d165.s28|103-113|quinidine.|drug
DDI-DrugBank.d165.s29|50-59|receiving|drug
DDI-DrugBank.d165.s29|60-72|Itraconazole|drug
DDI-DrugBank.d165.s29|77-92|dihydropyridine|drug
DDI-DrugBank.d165.s29|93-100|calcium|drug
DDI-DrugBank.d165.s31|40-52|HIV-infected|drug
DDI-DrugBank.d165.s31|53-64|individuals|drug
DDI-DrugBank.d165.s31|83-94|zidovudine,|drug
DDI-DrugBank.d165.s31|132-148|pharmacokinetics|drug
DDI-DrugBank.d165.s31|152-162|zidovudine|drug
DDI-DrugBank.d165.s31|181-187|during|drug
DDI-DrugBank.d165.s31|200-214|administration|drug
DDI-DrugBank.d165.s31|218-231|Itraconazole,|drug
DDI-DrugBank.d402.s0|13-24|interaction|drug
DDI-DrugBank.d194.s0|33-46|administering|drug
DDI-DrugBank.d194.s0|47-56|ETOPOPHOS|brand
DDI-DrugBank.d194.s0|86-93|inhibit|drug
DDI-DrugBank.d194.s0|124-134|levamisole|drug
DDI-DrugBank.d194.s0|135-150|hydrochloride).|drug
DDI-DrugBank.d194.s1|10-21|cyclosporin|drug
DDI-DrugBank.d194.s1|24-33|resulting|drug
DDI-DrugBank.d194.s1|69-81|administered|drug
DDI-DrugBank.d194.s1|92-101|etoposide|drug
DDI-DrugBank.d194.s1|120-128|increase|drug
DDI-DrugBank.d194.s1|132-141|etoposide|drug
DDI-DrugBank.d194.s1|142-150|exposure|group
DDI-DrugBank.d194.s1|198-207|etoposide|drug
DDI-DrugBank.d194.s1|220-229|etoposide|drug
DDI-MedLine.d101.s4|56-72|pharmacokinetics|drug
DDI-MedLine.d101.s4|112-122|clinically|drug
DDI-MedLine.d101.s4|133-145|interactions|drug
DDI-DrugBank.d45.s0|11-25|administration|drug
DDI-DrugBank.d45.s0|40-48|(another|drug
DDI-DrugBank.d45.s0|53-62|-blocking|drug
DDI-DrugBank.d45.s0|74-82|anakinra|drug
DDI-DrugBank.d45.s0|87-100|interleukin-1|drug
DDI-DrugBank.d45.s0|141-150|increased|drug
DDI-DrugBank.d45.s0|167-178|infections,|drug
DDI-DrugBank.d45.s0|183-192|increased|drug
DDI-DrugBank.d45.s0|257-266|medicinal|drug
DDI-DrugBank.d45.s1|6-19|TNFa-blocking|drug
DDI-DrugBank.d45.s1|27-37|(including|drug
DDI-DrugBank.d45.s1|38-47|REMICADE)|brand
DDI-DrugBank.d45.s1|56-67|combination|drug
DDI-DrugBank.d45.s1|73-81|anakinra|drug
DDI-DrugBank.d45.s2|14-25|interaction|drug
DDI-DrugBank.d45.s2|35-44|including|drug
DDI-DrugBank.d45.s2|45-57|interactions|drug
DDI-DrugBank.d45.s3|68-76|clinical|drug
DDI-DrugBank.d45.s4|79-96|anti-inflammatory|group
DDI-DrugBank.d45.s4|117-132|corticosteroids|group
DDI-DrugBank.d45.s5|45-57|antibiotics,|group
DDI-DrugBank.d45.s5|58-69|antivirals,|group
DDI-DrugBank.d45.s5|70-86|corticosteroids,|group
DDI-DrugBank.d45.s5|87-95|6-MP/AZA|brand
DDI-DrugBank.d45.s5|100-117|aminosalicylates.|drug
DDI-DrugBank.d45.s6|23-31|clinical|drug
DDI-DrugBank.d45.s6|64-72|included|drug
DDI-DrugBank.d45.s6|139-156|anti-inflammatory|group
DDI-DrugBank.d45.s6|180-196|corticosteroids.|group
DDI-DrugBank.d45.s7|89-97|infusion|drug
DDI-DrugBank.d45.s8|6-16|infliximab|drug
DDI-DrugBank.d45.s8|61-69|baseline|drug
DDI-DrugBank.d45.s8|126-135|including|drug
DDI-DrugBank.d45.s8|136-152|corticosteroids,|group
DDI-DrugBank.d45.s8|153-164|antibiotics|group
DDI-DrugBank.d45.s8|165-179|(metronidazole|drug
DDI-DrugBank.d45.s8|183-197|ciprofloxacin)|drug
DDI-DrugBank.d45.s8|202-219|aminosalicylates.|drug
DDI-DrugBank.d75.s0|29-42|investigating|drug
DDI-DrugBank.d75.s0|52-64|interactions|drug
DDI-DrugBank.d75.s0|73-83|anagrelide|drug
DDI-DrugBank.d75.s0|94-103|medicinal|drug
DDI-DrugBank.d75.s1|8-19|interaction|drug
DDI-DrugBank.d75.s1|61-68|digoxin|drug
DDI-DrugBank.d75.s1|73-81|warfarin|drug
DDI-DrugBank.d75.s1|138-148|anagrelide|drug
DDI-DrugBank.d75.s1|177-184|digoxin|drug
DDI-DrugBank.d75.s1|188-197|warfarin.|drug
DDI-DrugBank.d75.s2|25-36|interaction|drug
DDI-DrugBank.d75.s2|122-132|anagrelide|drug
DDI-DrugBank.d75.s2|136-144|clinical|drug
DDI-DrugBank.d75.s2|157-165|aspirin,|brand
DDI-DrugBank.d75.s2|166-180|acetaminophen,|drug
DDI-DrugBank.d75.s2|199-210|ranitidine,|drug
DDI-DrugBank.d75.s2|211-223|hydroxyurea,|group
DDI-DrugBank.d75.s2|228-240|allopurinol.|drug
DDI-DrugBank.d75.s3|12-20|clinical|drug
DDI-DrugBank.d75.s3|46-56|anagrelide|drug
DDI-DrugBank.d75.s3|57-66|interacts|drug
DDI-DrugBank.d75.s4|11-22|interaction|drug
DDI-DrugBank.d75.s4|59-65|single|drug
DDI-DrugBank.d75.s4|78-88|anagrelide|drug
DDI-DrugBank.d75.s4|89-101|administered|drug
DDI-DrugBank.d75.s4|123-129|single|drug
DDI-DrugBank.d75.s4|145-152|aspirin|brand
DDI-DrugBank.d75.s4|172-182|tolerated.|drug
DDI-DrugBank.d75.s5|23-31|bleeding|drug
DDI-DrugBank.d75.s6|3-13|clinically|drug
DDI-DrugBank.d75.s6|23-38|pharmacokinetic|drug
DDI-DrugBank.d75.s6|39-51|interactions|drug
DDI-DrugBank.d75.s6|60-70|anagrelide|drug
DDI-DrugBank.d75.s7|20-27|aspirin|brand
DDI-DrugBank.d75.s7|52-62|inhibition|drug
DDI-DrugBank.d75.s8|0-10|Anagrelide|drug
DDI-DrugBank.d75.s8|85-95|inhibition|drug
DDI-DrugBank.d75.s8|123-131|aspirin.|brand
DDI-DrugBank.d75.s9|0-10|Anagrelide|drug
DDI-DrugBank.d75.s9|46-53|CYP1A2.|brand
DDI-DrugBank.d75.s10|17-23|CYP1A2|brand
DDI-DrugBank.d75.s10|27-36|inhibited|drug
DDI-DrugBank.d75.s10|48-57|medicinal|drug
DDI-DrugBank.d75.s10|68-77|including|drug
DDI-DrugBank.d75.s10|78-90|fluvoxamine,|drug
DDI-DrugBank.d75.s10|100-109|medicinal|drug
DDI-DrugBank.d75.s10|149-158|influence|drug
DDI-DrugBank.d75.s11|0-10|Anagrelide|drug
DDI-DrugBank.d75.s11|37-47|inhibitory|drug
DDI-DrugBank.d75.s11|65-71|CYP1A2|brand
DDI-DrugBank.d75.s11|118-129|interaction|drug
DDI-DrugBank.d75.s11|141-155|coadministered|drug
DDI-DrugBank.d75.s11|156-165|medicinal|drug
DDI-DrugBank.d75.s11|175-182|sharing|drug
DDI-DrugBank.d75.s12|0-10|Anagrelide|drug
DDI-DrugBank.d75.s12|37-47|inhibitory|drug
DDI-DrugBank.d75.s12|65-71|CYP1A2|brand
DDI-DrugBank.d75.s12|118-129|interaction|drug
DDI-DrugBank.d75.s12|141-155|coadministered|drug
DDI-DrugBank.d75.s12|156-165|medicinal|drug
DDI-DrugBank.d75.s12|175-182|sharing|drug
DDI-DrugBank.d75.s12|213-226|theophylline.|drug
DDI-DrugBank.d75.s13|0-10|Anagrelide|drug
DDI-DrugBank.d75.s13|17-26|inhibitor|drug
DDI-DrugBank.d75.s14|15-24|medicinal|drug
DDI-DrugBank.d75.s14|66-75|inotropes|drug
DDI-DrugBank.d75.s14|76-86|milrinone,|drug
DDI-DrugBank.d75.s14|98-107|amrinone,|drug
DDI-DrugBank.d75.s14|108-117|olprinone|drug
DDI-DrugBank.d75.s15|11-17|single|drug
DDI-DrugBank.d75.s15|66-75|interfere|drug
DDI-DrugBank.d75.s15|81-91|anagrelide|drug
DDI-DrugBank.d75.s16|12-22|clinically|drug
DDI-DrugBank.d204.s0|5-17|administered|drug
DDI-DrugBank.d204.s0|36-45|following|drug
DDI-DrugBank.d204.s0|56-64|interact|drug
DDI-DrugBank.d204.s0|95-103|blocking|drug
DDI-DrugBank.d204.s0|166-173|induced|drug
DDI-DrugBank.d204.s1|36-45|insulin):|drug
DDI-DrugBank.d204.s2|17-29|antidiabetic|group
DDI-DrugBank.d204.s2|35-47|accordingly.|drug
DDI-DrugBank.d204.s3|0-23|Catecholamine-depleting|drug
DDI-DrugBank.d204.s3|37-48|reserpine):|drug
DDI-DrugBank.d204.s5|55-61|taking|drug
DDI-DrugBank.d204.s6|56-67|epinephrine|drug
DDI-MedLine.d124.s0|8-19|interaction|drug
DDI-MedLine.d124.s0|28-40|levofloxacin|drug
DDI-MedLine.d124.s0|56-72|pharmacokinetics|drug
DDI-MedLine.d124.s1|90-103|trovafloxacin|drug
DDI-MedLine.d124.s1|108-121|ciprofloxacin|drug
DDI-MedLine.d124.s1|127-139|administered|drug
DDI-MedLine.d124.s1|162-173|intravenous|drug
DDI-MedLine.d124.s1|189-198|morphine.|drug
DDI-MedLine.d124.s2|67-80|trovafloxacin|drug
DDI-MedLine.d124.s2|85-99|ciprofloxacin,|drug
DDI-MedLine.d124.s2|132-140|clinical|drug
DDI-MedLine.d124.s2|141-150|failures.|group
DDI-MedLine.d124.s3|12-24|investigated|drug
DDI-MedLine.d124.s3|54-65|interaction|drug
DDI-MedLine.d124.s3|88-101|levofloxacin.|drug
DDI-MedLine.d124.s5|9-22|levofloxacin,|drug
DDI-MedLine.d124.s6|13-21|starting|drug
DDI-MedLine.d124.s6|39-51|levofloxacin|drug
DDI-MedLine.d124.s8|104-119|determinations.|drug
DDI-MedLine.d124.s9|44-49|0.05)|drug_n
DDI-MedLine.d124.s9|86-92|9.93),|drug_n
DDI-MedLine.d124.s9|124-129|2.0),|drug_n
DDI-MedLine.d124.s9|173-185|levofloxacin|drug
DDI-MedLine.d124.s9|193-215|levofloxacin/oxycodone|drug
DDI-MedLine.d124.s10|41-53|levofloxacin|drug
DDI-MedLine.d124.s10|61-73|administered|drug
DDI-DrugBank.d296.s0|0-15|Diphenhydramine|drug
DDI-DrugBank.d296.s0|16-29|hydrochloride|drug
DDI-DrugBank.d296.s1|4-14|inhibitors|drug
DDI-DrugBank.d296.s1|27-36|intensify|drug
DDI-DrugBank.d296.s1|41-56|anticholinergic|group
DDI-DrugBank.d296.s1|57-65|(drying)|drug
DDI-DrugBank.d296.s1|77-92|antihistamines.|group
DDI-DrugBank.d526.s0|5-17|administered|drug
DDI-DrugBank.d526.s0|36-45|following|drug
DDI-DrugBank.d526.s0|56-64|interact|drug
DDI-DrugBank.d526.s0|78-94|corticosteroids.|group
DDI-DrugBank.d526.s1|0-12|Amphotericin|drug
DDI-DrugBank.d526.s1|18-37|potassium-depleting|drug
DDI-DrugBank.d526.s1|38-47|diuretics|group
DDI-DrugBank.d526.s1|48-66|(benzothiadiazines|drug
DDI-DrugBank.d526.s2|12-21|potassium|drug
DDI-DrugBank.d526.s2|41-51|intervals;|drug
DDI-DrugBank.d526.s3|4-13|potassium|drug
DDI-DrugBank.d526.s5|14-23|potassium|drug
DDI-DrugBank.d526.s6|4-13|potassium|drug
DDI-DrugBank.d526.s7|5-19|anticoagulants|group
DDI-DrugBank.d526.s7|30-41|prothrombin|drug
DDI-DrugBank.d526.s8|8-19|prothrombin|drug
DDI-DrugBank.d526.s8|38-51|anticoagulant|group
DDI-DrugBank.d526.s8|59-71|accordingly.|drug
DDI-DrugBank.d526.s9|36-44|insulin)|drug
DDI-DrugBank.d526.s9|45-55|diminished|drug
DDI-DrugBank.d526.s9|56-68|antidiabetic|group
DDI-DrugBank.d526.s11|17-29|antidiabetic|group
DDI-DrugBank.d526.s12|0-7|Aspirin|brand
DDI-DrugBank.d526.s12|8-17|increased|drug
DDI-DrugBank.d526.s13|34-42|aspirin.|brand
DDI-DrugBank.d526.s14|53-64|discontinue|group
DDI-DrugBank.d526.s14|65-73|steroids|group
DDI-DrugBank.d526.s14|101-108|aspirin|brand
DDI-DrugBank.d526.s15|62-69|aspirin|brand
DDI-DrugBank.d526.s16|25-36|accordingly|drug
DDI-DrugBank.d526.s17|14-24|phenytoin,|drug
DDI-DrugBank.d526.s17|28-36|rifampin|drug
DDI-DrugBank.d526.s17|37-46|increased|drug
DDI-DrugBank.d526.s17|109-118|induction|drug
DDI-DrugBank.d526.s18|33-43|diminished|drug
DDI-DrugBank.d526.s18|66-74|increase|drug
DDI-DrugBank.d526.s18|94-106|accordingly.|drug
DDI-DrugBank.d526.s19|9-17|steroids|group
DDI-DrugBank.d526.s20|17-23|giving|drug
DDI-DrugBank.d526.s21|0-8|Vaccines|drug
DDI-DrugBank.d526.s21|48-56|antibody|group
DDI-DrugBank.d526.s22|9-18|increased|drug
DDI-DrugBank.d526.s22|29-51|corticosteroid-binding|drug
DDI-DrugBank.d526.s22|52-61|globulin,|drug
DDI-DrugBank.d526.s22|70-80|increasing|drug
DDI-DrugBank.d526.s22|91-101|(inactive)|drug
DDI-DrugBank.d526.s23|60-76|corticosteroids.|group
DDI-DrugBank.d526.s24|25-35|initiated,|drug
DDI-DrugBank.d526.s24|94-103|increased|drug
DDI-DrugBank.d526.s24|145-156|terminated.|drug
DDI-DrugBank.d526.s25|34-49|Corticosteroids|group
DDI-DrugBank.d526.s25|65-85|nitrobluetetrazolium|drug
DDI-DrugBank.d526.s25|105-114|infection|drug
DDI-MedLine.d52.s0|15-25|vancomycin|drug
DDI-MedLine.d52.s0|69-83|antiresistance|group
DDI-MedLine.d52.s0|84-95|determinant|drug
DDI-MedLine.d52.s1|52-62|vancomycin|drug
DDI-MedLine.d52.s2|0-11|Recombinant|drug
DDI-MedLine.d52.s2|28-38|containing|group
DDI-MedLine.d52.s2|60-69|antisense|group
DDI-MedLine.d52.s2|99-109|vancomycin|drug
DDI-MedLine.d52.s2|135-143|combined|drug
DDI-MedLine.d52.s2|170-177|binding|drug
DDI-MedLine.d52.s2|178-184|domain|drug
DDI-MedLine.d52.s2|195-204|inducible|drug
DDI-MedLine.d52.s2|210-219|antisense|group
DDI-DrugBank.d93.s0|0-8|Clinical|drug
DDI-DrugBank.d93.s0|21-30|indicated|drug
DDI-DrugBank.d93.s0|136-145|including|drug
DDI-DrugBank.d93.s0|152-159|inhaled|drug
DDI-DrugBank.d93.s0|178-190|antibiotics,|group
DDI-DrugBank.d93.s0|228-237|vitamins,|drug
DDI-DrugBank.d93.s0|246-253|inhaled|drug
DDI-DrugBank.d93.s0|254-270|corticosteroids,|group
DDI-DrugBank.d93.s1|15-26|interaction|drug
DDI-DrugBank.d247.s0|0-11|Epinephrine|drug
DDI-DrugBank.d247.s1|55-61|taking|drug
DDI-DrugBank.d247.s1|62-71|monoamine|drug
DDI-DrugBank.d247.s1|80-85|(MAO)|brand
DDI-DrugBank.d247.s1|86-97|inhibitors.|drug
DDI-DrugBank.d247.s2|0-11|Epinephrine|drug
DDI-DrugBank.d247.s2|26-38|administered|drug
DDI-DrugBank.d247.s2|151-160|increased|drug
DDI-DrugBank.d247.s3|0-8|Combined|drug
DDI-DrugBank.d247.s3|21-27|induce|drug
DDI-DrugBank.d247.s4|12-24|administered|drug
DDI-DrugBank.d247.s4|46-55|preceding|drug
DDI-DrugBank.d247.s5|0-14|Administration|drug
DDI-DrugBank.d247.s5|18-29|epinephrine|drug
DDI-DrugBank.d247.s5|42-51|receiving|drug
DDI-DrugBank.d247.s5|52-64|cyclopropane|drug
DDI-DrugBank.d247.s5|80-91|hydrocarbon|drug
DDI-DrugBank.d247.s5|150-161|myocardium,|drug
DDI-DrugBank.d247.s5|166-172|induce|drug
DDI-DrugBank.d247.s6|50-64|administration|drug
DDI-DrugBank.d247.s6|86-94|blocking|drug
DDI-DrugBank.d247.s7|0-11|Epinephrine|drug
DDI-DrugBank.d247.s7|109-119|myocardium|drug
DDI-DrugBank.d247.s8|0-8|Diuretic|group
DDI-DrugBank.d247.s8|72-84|epinephrine.|drug
DDI-DrugBank.d247.s9|0-11|Epinephrine|drug
DDI-DrugBank.d247.s9|59-71|guanethidine|drug
DDI-DrugBank.d247.s9|72-81|resulting|drug
DDI-DrugBank.d247.s9|95-111|antihypertensive|group
DDI-DrugBank.d247.s9|123-132|requiring|drug
DDI-DrugBank.d247.s9|133-142|increased|drug
DDI-DrugBank.d206.s0|11-22|preliminary|drug
DDI-DrugBank.d206.s0|77-85|antacids|group
DDI-DrugBank.d206.s0|124-131|inhibit|drug
DDI-DrugBank.d206.s0|144-161|lactulose-induced|drug
DDI-DrugBank.d123.s0|5-16|quinolones,|drug
DDI-DrugBank.d123.s0|17-26|including|drug
DDI-DrugBank.d123.s0|27-41|ciprofloxacin,|drug
DDI-DrugBank.d123.s0|66-75|interfere|drug
DDI-DrugBank.d123.s0|99-108|caffeine.|drug
DDI-DrugBank.d123.s1|38-46|caffeine|drug
DDI-DrugBank.d123.s2|5-16|quinolones,|drug
DDI-DrugBank.d123.s2|17-26|including|drug
DDI-DrugBank.d123.s2|27-41|ciprofloxacin,|drug
DDI-DrugBank.d123.s2|98-108|creatinine|drug
DDI-DrugBank.d123.s2|121-130|receiving|drug
DDI-DrugBank.d123.s2|131-143|cyclosporine|drug
DDI-DrugBank.d123.s3|27-41|administration|drug
DDI-DrugBank.d123.s3|45-58|ciprofloxacin|drug
DDI-DrugBank.d123.s3|68-80|sulfonylurea|group
DDI-DrugBank.d123.s3|81-90|glyburide|drug
DDI-DrugBank.d123.s4|0-9|Histamine|drug
DDI-DrugBank.d123.s4|35-44|Histamine|drug
DDI-DrugBank.d123.s4|132-146|ciprofloxacin.|drug
DDI-DrugBank.d123.s5|60-69|inhibited|drug
DDI-DrugBank.d123.s5|85-99|administration|drug
DDI-DrugBank.d123.s5|103-117|ciprofloxacin,|drug
DDI-DrugBank.d123.s5|130-137|leading|drug
DDI-DrugBank.d123.s5|141-150|increased|drug
DDI-DrugBank.d123.s6|11-19|increase|drug
DDI-DrugBank.d123.s7|94-107|ciprofloxacin|drug
DDI-DrugBank.d123.s7|119-129|indicated.|drug
DDI-DrugBank.d123.s8|12-29|Cation-Containing|drug
DDI-DrugBank.d123.s8|51-65|administration|drug
DDI-DrugBank.d123.s8|71-81|quinolone,|drug
DDI-DrugBank.d123.s8|82-91|including|drug
DDI-DrugBank.d123.s8|92-106|ciprofloxacin,|drug
DDI-DrugBank.d123.s8|124-141|cation-containing|group
DDI-DrugBank.d123.s8|159-168|magnesium|drug
DDI-DrugBank.d123.s8|172-180|aluminum|drug
DDI-DrugBank.d123.s8|181-190|antacids,|group
DDI-DrugBank.d123.s8|203-208|VIDEX|brand
DDI-DrugBank.d123.s8|268-278|containing|group
DDI-DrugBank.d123.s8|279-287|calcium,|drug
DDI-DrugBank.d123.s8|347-361|ciprofloxacin,|drug
DDI-DrugBank.d123.s8|362-371|resulting|drug
DDI-DrugBank.d123.s8|385-390|urine|drug
DDI-DrugBank.d123.s9|0-7|Proquin|drug
DDI-DrugBank.d123.s9|21-33|administered|drug
DDI-DrugBank.d123.s10|10-16|window|drug
DDI-DrugBank.d123.s10|66-80|ciprofloxacin,|drug
DDI-DrugBank.d123.s10|99-111|administered|drug
DDI-DrugBank.d123.s10|144-153|antacids.|group
DDI-DrugBank.d123.s11|14-31|anti-inflammatory|group
DDI-DrugBank.d123.s11|47-56|aspirin):|brand
DDI-DrugBank.d123.s11|72-83|combination|drug
DDI-DrugBank.d123.s11|108-118|quinolones|drug
DDI-DrugBank.d123.s11|161-173|pre-clinical|drug
DDI-DrugBank.d123.s12|0-11|Omeprazole:|drug
DDI-DrugBank.d123.s12|49-62|ciprofloxacin|drug
DDI-DrugBank.d123.s12|86-93|Proquin|drug
DDI-DrugBank.d123.s12|121-128|Proquin|drug
DDI-DrugBank.d123.s12|156-166|omeprazole|drug
DDI-DrugBank.d123.s13|0-10|Omeprazole|drug
DDI-DrugBank.d123.s13|43-50|Proquin|drug
DDI-DrugBank.d123.s13|114-121|evening|drug
DDI-DrugBank.d123.s14|0-10|Phenytoin:|drug
DDI-DrugBank.d123.s14|35-44|phenytoin|drug
DDI-DrugBank.d123.s14|45-55|(increased|drug
DDI-DrugBank.d123.s14|102-111|receiving|drug
DDI-DrugBank.d123.s14|124-138|ciprofloxacin.|drug
DDI-DrugBank.d123.s15|23-33|interferes|drug
DDI-DrugBank.d123.s15|66-79|ciprofloxacin|drug
DDI-DrugBank.d123.s15|96-104|increase|drug
DDI-DrugBank.d123.s15|121-134|ciprofloxacin|drug
DDI-DrugBank.d123.s16|0-13|Theophylline:|drug
DDI-DrugBank.d123.s16|33-44|quinolones,|drug
DDI-DrugBank.d123.s16|56-70|administration|drug
DDI-DrugBank.d123.s16|74-87|ciprofloxacin|drug
DDI-DrugBank.d123.s16|93-105|theophylline|drug
DDI-DrugBank.d123.s16|151-163|theophylline|drug
DDI-DrugBank.d123.s16|188-199|elimination|drug
DDI-DrugBank.d123.s17|19-28|increased|drug
DDI-DrugBank.d123.s17|37-57|theophylline-related|drug
DDI-DrugBank.d123.s18|54-66|theophylline|drug
DDI-DrugBank.d123.s19|0-9|Warfarin:|drug
DDI-DrugBank.d123.s19|10-20|Quinolones|drug
DDI-DrugBank.d123.s19|75-88|anticoagulant|group
DDI-DrugBank.d123.s19|89-97|warfarin|drug
DDI-DrugBank.d123.s20|24-36|administered|drug
DDI-DrugBank.d123.s20|52-63|prothrombin|drug
DDI-DrugBank.d292.s0|26-39|administering|drug
DDI-DrugBank.d292.s0|115-133|anticholinesterase|group
DDI-DrugBank.d292.s1|0-5|Since|drug
DDI-DrugBank.d292.s1|18-36|anticholinesterase|group
DDI-DrugBank.d292.s1|46-58|(cholinergic|drug
DDI-DrugBank.d146.s0|0-10|Colchicine|drug
DDI-DrugBank.d146.s0|14-23|inhibited|drug
DDI-DrugBank.d146.s0|27-37|acidifying|drug
DDI-DrugBank.d146.s1|14-24|colchicine|drug
DDI-DrugBank.d146.s1|43-55|alkalinizing|drug
DDI-DrugBank.d146.s2|0-10|Colchicine|drug
DDI-DrugBank.d146.s2|15-23|increase|drug
DDI-DrugBank.d146.s3|54-65|colchicine.|drug
DDI-DrugBank.d267.s0|6-20|administration|drug
DDI-DrugBank.d267.s0|24-39|succinylcholine|drug
DDI-DrugBank.d267.s0|47-57|clinically|drug
DDI-DrugBank.d267.s0|96-104|blocking|drug
DDI-DrugBank.d267.s0|115-123|NUROMAX.|brand
DDI-DrugBank.d267.s1|11-18|NUROMAX|brand
DDI-DrugBank.d267.s1|26-41|succinylcholine|drug
DDI-DrugBank.d267.s1|83-98|succinylcholine|drug
DDI-DrugBank.d267.s2|13-21|clinical|drug
DDI-DrugBank.d267.s2|49-56|NUROMAX|brand
DDI-DrugBank.d267.s2|67-82|nondepolarizing|drug
DDI-DrugBank.d267.s2|97-105|blocking|drug
DDI-DrugBank.d267.s3|58-65|NUROMAX|brand
DDI-DrugBank.d267.s4|34-44|clinically|drug
DDI-DrugBank.d267.s5|48-56|blocking|drug
DDI-DrugBank.d267.s5|67-82|nondepolarizing|drug
DDI-DrugBank.d267.s5|98-105|NUROMAX|brand
DDI-DrugBank.d267.s5|106-113|include|drug
DDI-DrugBank.d267.s5|114-121|certain|drug
DDI-DrugBank.d267.s5|122-133|antibiotics|group
DDI-DrugBank.d267.s5|142-158|aminoglycosides,|drug
DDI-DrugBank.d267.s5|159-173|tetracyclines,|drug
DDI-DrugBank.d267.s5|174-185|bacitracin,|drug
DDI-DrugBank.d267.s5|186-197|polymyxins,|drug
DDI-DrugBank.d267.s5|198-209|lincomycin,|drug
DDI-DrugBank.d267.s5|210-222|clindamycin,|drug
DDI-DrugBank.d267.s5|223-232|colistin,|drug
DDI-DrugBank.d267.s5|237-243|sodium|drug
DDI-DrugBank.d267.s5|261-270|magnesium|drug
DDI-DrugBank.d267.s5|278-286|lithium,|drug
DDI-DrugBank.d267.s5|306-319|procainamide,|drug
DDI-DrugBank.d267.s5|324-334|quinidine.|drug
DDI-DrugBank.d267.s6|19-34|nondepolarizing|drug
DDI-DrugBank.d267.s6|49-57|blocking|drug
DDI-DrugBank.d267.s6|107-114|induced|drug
DDI-DrugBank.d267.s6|118-125|NUROMAX|brand
DDI-DrugBank.d267.s6|191-200|receiving|drug
DDI-DrugBank.d267.s6|201-210|phenytoin|drug
DDI-DrugBank.d267.s6|214-228|carbamazepine.|drug
DDI-DrugBank.d431.s0|0-12|Lansoprazole|drug
DDI-DrugBank.d431.s0|89-94|CYP3A|brand
DDI-DrugBank.d431.s0|99-106|CYP2C19|brand
DDI-DrugBank.d431.s1|24-36|lansoprazole|drug
DDI-DrugBank.d431.s1|51-61|clinically|drug
DDI-DrugBank.d431.s1|74-86|interactions|drug
DDI-DrugBank.d431.s1|155-164|warfarin,|drug
DDI-DrugBank.d431.s1|165-176|antipyrine,|group
DDI-DrugBank.d431.s1|177-190|indomethacin,|drug
DDI-DrugBank.d431.s1|202-212|phenytoin,|drug
DDI-DrugBank.d431.s1|213-225|propranolol,|drug
DDI-DrugBank.d431.s1|248-263|clarithromycin,|drug
DDI-DrugBank.d431.s1|267-278|terfenadine|drug
DDI-DrugBank.d431.s2|73-82|including|drug
DDI-DrugBank.d431.s2|83-90|CYP1A2,|brand
DDI-DrugBank.d431.s2|91-98|CYP2C9,|brand
DDI-DrugBank.d431.s2|99-107|CYP2C19,|brand
DDI-DrugBank.d431.s2|108-115|CYP2D6,|brand
DDI-DrugBank.d431.s2|120-126|CYP3A.|brand
DDI-DrugBank.d431.s3|5-17|lansoprazole|drug
DDI-DrugBank.d431.s3|22-34|administered|drug
DDI-DrugBank.d431.s3|54-66|theophylline|drug
DDI-DrugBank.d431.s3|67-75|(CYP1A2,|brand
DDI-DrugBank.d431.s3|76-83|CYP3A),|brand
DDI-DrugBank.d431.s3|86-91|minor|drug
DDI-DrugBank.d431.s3|92-100|increase|drug
DDI-DrugBank.d431.s3|127-139|theophylline|drug
DDI-DrugBank.d431.s4|63-75|theophylline|drug
DDI-DrugBank.d431.s4|92-103|interaction|drug
DDI-DrugBank.d431.s4|122-130|clinical|drug
DDI-DrugBank.d431.s5|13-23|individual|drug
DDI-DrugBank.d431.s5|75-87|theophylline|drug
DDI-DrugBank.d431.s5|100-112|lansoprazole|drug
DDI-DrugBank.d431.s5|138-144|ensure|group
DDI-DrugBank.d431.s5|145-155|clinically|drug
DDI-DrugBank.d431.s6|0-12|Lansoprazole|drug
DDI-DrugBank.d431.s6|44-54|clinically|drug
DDI-DrugBank.d431.s6|67-78|interaction|drug
DDI-DrugBank.d431.s6|84-96|amoxicillin.|drug
DDI-DrugBank.d431.s7|5-16|single-dose|drug
DDI-DrugBank.d431.s7|33-42|examining|drug
DDI-DrugBank.d431.s7|43-55|lansoprazole|drug
DDI-DrugBank.d431.s7|66-76|omeprazole|drug
DDI-DrugBank.d431.s7|88-100|administered|drug
DDI-DrugBank.d431.s7|179-189|inhibitors|drug
DDI-DrugBank.d431.s7|275-287|administered|drug
DDI-DrugBank.d431.s8|23-33|inhibitors|drug
DDI-DrugBank.d431.s8|62-69|minutes|drug
DDI-DrugBank.d431.s9|3-11|clinical|drug
DDI-DrugBank.d431.s9|20-28|antacids|group
DDI-DrugBank.d431.s9|34-46|administered|drug
DDI-DrugBank.d431.s9|66-78|lansoprazole|drug
DDI-DrugBank.d431.s10|13-22|interfere|drug
DDI-DrugBank.d431.s11|0-12|Lansoprazole|drug
DDI-DrugBank.d431.s11|40-47|lasting|drug
DDI-DrugBank.d431.s11|48-58|inhibition|drug
DDI-DrugBank.d431.s12|45-57|lansoprazole|drug
DDI-DrugBank.d431.s12|62-71|interfere|drug
DDI-DrugBank.d431.s12|134-145|determinant|drug
DDI-DrugBank.d431.s12|171-184|ketoconazole,|drug
DDI-DrugBank.d431.s12|185-195|ampicillin|drug
DDI-DrugBank.d431.s12|216-225|digoxin).|drug
DDI-DrugBank.d126.s0|5-16|interaction|drug
DDI-DrugBank.d126.s0|30-40|decitabine|drug
DDI-DrugBank.d126.s1|56-66|decitabine|drug
DDI-DrugBank.d126.s1|82-89|inhibit|drug
DDI-DrugBank.d126.s1|93-99|induce|drug
DDI-DrugBank.d126.s2|48-58|decitabine|drug
DDI-DrugBank.d126.s3|10-17|protein|drug
DDI-DrugBank.d126.s3|18-25|binding|drug
DDI-DrugBank.d126.s3|29-39|decitabine|drug
DDI-DrugBank.d126.s3|61-73|interactions|drug
DDI-DrugBank.d126.s3|109-116|protein|drug
DDI-DrugBank.d126.s3|141-149|proteins|drug
DDI-DrugBank.d326.s0|0-14|Phenothiazines|drug
DDI-DrugBank.d326.s0|17-23|Taking|drug
DDI-DrugBank.d326.s0|24-34|piperazine|drug
DDI-DrugBank.d326.s0|41-54|phenothiazine|drug
DDI-DrugBank.d326.s0|68-76|increase|drug
DDI-DrugBank.d326.s0|101-112|(seizures).|group
DDI-DrugBank.d326.s1|16-26|Antiminth)|drug
DDI-DrugBank.d326.s1|29-35|Taking|drug
DDI-DrugBank.d326.s1|36-46|piperazine|drug
DDI-DrugBank.d326.s1|97-108|piperazine.|drug
DDI-MedLine.d116.s0|0-8|Rifampin|drug
DDI-MedLine.d116.s0|13-22|warfarin:|drug
DDI-MedLine.d116.s0|30-42|interaction.|drug
DDI-MedLine.d116.s1|9-20|interaction|drug
DDI-MedLine.d116.s1|29-37|warfarin|drug
DDI-MedLine.d116.s1|42-50|rifampin|drug
DDI-MedLine.d116.s2|0-8|Rifampin|drug
DDI-MedLine.d116.s2|30-38|increase|drug
DDI-MedLine.d116.s2|43-51|warfarin|drug
DDI-MedLine.d116.s2|83-92|ingesting|drug
DDI-MedLine.d116.s3|16-30|administration|drug
DDI-MedLine.d116.s3|34-42|rifampin|drug
DDI-MedLine.d116.s3|47-55|warfarin|drug
DDI-MedLine.d116.s3|99-110|maintenance|drug
DDI-MedLine.d116.s3|119-127|warfarin|drug
DDI-MedLine.d116.s4|14-22|rifampin|drug
DDI-MedLine.d116.s4|37-45|warfarin|drug
DDI-MedLine.d116.s5|46-54|rifampin|drug
DDI-MedLine.d116.s5|58-64|induce|drug
DDI-MedLine.d116.s5|113-122|warfarin.|drug
DDI-MedLine.d116.s6|14-22|rifampin|drug
DDI-MedLine.d116.s6|30-38|warfarin|drug
DDI-MedLine.d116.s6|111-121|initiation|drug
DDI-MedLine.d116.s6|125-133|rifampin|drug
DDI-MedLine.d116.s6|178-186|rifampin|drug
DDI-MedLine.d116.s7|5-16|interaction|drug
DDI-MedLine.d116.s7|31-41|clinically|drug
DDI-DrugBank.d290.s0|8-20|interactions|drug
DDI-DrugBank.d290.s0|48-55|Prostin|drug
DDI-DrugBank.d290.s1|17-25|includes|drug
DDI-DrugBank.d290.s1|26-38|antibiotics,|group
DDI-DrugBank.d290.s1|47-57|penicillin|drug
DDI-DrugBank.d290.s1|62-73|gentamicin;|drug
DDI-DrugBank.d290.s2|22-30|dopamine|drug
DDI-DrugBank.d290.s4|4-14|diuretics,|group
DDI-DrugBank.d290.s5|29-44|pharmacokinetic|drug
DDI-DrugBank.d290.s5|55-67|interactions|drug
DDI-MedLine.d18.s0|42-52|budesonide|drug
DDI-MedLine.d18.s1|50-56|bovine|drug
DDI-MedLine.d18.s1|121-131|budesonide|drug
DDI-MedLine.d18.s1|136-147|determined.|drug
DDI-MedLine.d18.s2|21-31|budesonide|drug
DDI-MedLine.d18.s2|55-62|ethanol|drug
DDI-MedLine.d18.s2|152-160|impinger|drug
DDI-MedLine.d18.s3|39-47|scanning|drug
DDI-MedLine.d18.s3|96-104|scanning|drug
DDI-MedLine.d18.s3|177-185|starting|drug
DDI-MedLine.d18.s4|76-83|contain|group
DDI-MedLine.d18.s5|49-55|saline|drug
DDI-MedLine.d18.s6|9-18|increased|drug
DDI-MedLine.d18.s6|48-58|budesonide|drug
DDI-MedLine.d18.s6|128-139|equilibrium|drug
DDI-MedLine.d18.s7|14-23|increased|drug
DDI-MedLine.d18.s7|68-74|sodium|drug
DDI-MedLine.d18.s8|33-43|budesonide|drug
DDI-MedLine.d18.s8|44-53|following|drug
DDI-MedLine.d18.s8|74-83|indicated|drug
DDI-MedLine.d18.s8|121-131|budesonide|drug
DDI-MedLine.d18.s9|61-70|enhancing|drug
DDI-MedLine.d18.s9|115-127|administered|drug
DDI-DrugBank.d337.s0|0-9|Warfarin:|drug
DDI-DrugBank.d337.s0|22-36|administration|drug
DDI-DrugBank.d337.s0|40-50|daptomycin|drug
DDI-DrugBank.d337.s0|96-104|warfarin|drug
DDI-DrugBank.d337.s0|112-118|single|drug
DDI-DrugBank.d337.s0|163-179|pharmacokinetics|drug
DDI-DrugBank.d337.s2|48-66|placebo-controlled|group
DDI-DrugBank.d337.s2|120-131|simvastatin|drug
DDI-DrugBank.d337.s2|171-181|daptomycin|drug
DDI-DrugBank.d337.s3|16-33|co-administration|drug
DDI-DrugBank.d337.s3|55-65|inhibitors|drug
DDI-DrugBank.d337.s3|157-167|suspending|drug
DDI-DrugBank.d337.s3|193-203|inhibitors|drug
DDI-DrugBank.d337.s3|216-225|receiving|drug
DDI-DrugBank.d337.s4|78-91|interactions.|drug
DDI-DrugBank.d327.s0|45-57|experiencing|drug
DDI-DrugBank.d327.s0|58-67|increases|drug
DDI-DrugBank.d327.s0|77-88|prothrombin|drug
DDI-DrugBank.d327.s0|124-132|warfarin|drug
DDI-DrugBank.d327.s1|63-74|prothrombin|drug
DDI-DrugBank.d327.s1|89-99|clinically|drug
DDI-DrugBank.d327.s2|109-117|warfarin|drug
DDI-DrugBank.d327.s2|136-147|prothrombin|drug
DDI-DrugBank.d246.s0|18-29|butorphanol|drug
DDI-DrugBank.d246.s0|119-134|antihistamines)|group
DDI-DrugBank.d246.s0|149-158|increased|drug
DDI-DrugBank.d246.s1|52-63|butorphanol|drug
DDI-DrugBank.d246.s1|123-129|dosing|drug
DDI-DrugBank.d246.s1|163-175|administered|drug
DDI-DrugBank.d246.s1|231-239|opioids.|group
DDI-DrugBank.d246.s2|27-43|pharmacokinetics|drug
DDI-DrugBank.d246.s2|62-73|butorphanol|drug
DDI-DrugBank.d246.s2|74-86|administered|drug
DDI-DrugBank.d246.s2|90-96|STADOL|brand
DDI-DrugBank.d246.s2|125-141|coadministration|drug
DDI-DrugBank.d246.s2|147-153|single|drug
DDI-DrugBank.d246.s3|12-19|another|drug
DDI-DrugBank.d246.s3|53-69|pharmacokinetics|drug
DDI-DrugBank.d246.s3|73-84|butorphanol|drug
DDI-DrugBank.d246.s3|179-185|STADOL|brand
DDI-DrugBank.d246.s3|193-205|administered|drug
DDI-DrugBank.d246.s3|208-214|minute|drug
DDI-DrugBank.d246.s3|223-228|20-mg|drug_n
DDI-DrugBank.d246.s4|20-32|administered|drug
DDI-DrugBank.d246.s5|9-15|STADOL|brand
DDI-DrugBank.d246.s5|23-35|administered|drug
DDI-DrugBank.d246.s5|39-46|minutes|drug
DDI-DrugBank.d246.s5|93-104|butorphanol|drug
DDI-DrugBank.d246.s5|105-114|increased|drug
DDI-DrugBank.d246.s6|25-41|pharmacokinetics|drug
DDI-DrugBank.d246.s6|69-85|coadministration|drug
DDI-DrugBank.d246.s6|91-97|STADOL|brand
DDI-DrugBank.d246.s7|51-57|STADOL|brand
DDI-DrugBank.d246.s7|68-78|diminished|drug
DDI-DrugBank.d246.s7|90-102|administered|drug
DDI-DrugBank.d246.s7|152-159|minutes|drug
DDI-DrugBank.d246.s7|199-207|minimal.|drug
DDI-DrugBank.d246.s8|14-19|using|drug
DDI-DrugBank.d246.s8|20-26|STADOL|brand
DDI-DrugBank.d246.s8|34-41|IMITREX|brand
DDI-DrugBank.d246.s8|68-74|during|drug
DDI-DrugBank.d246.s8|95-103|migraine|drug
DDI-DrugBank.d246.s9|62-71|producing|drug
DDI-DrugBank.d246.s9|82-91|increases|drug
DDI-DrugBank.d246.s9|101-110|pressure.|group
DDI-DrugBank.d246.s10|4-20|pharmacokinetics|drug
DDI-DrugBank.d246.s10|39-50|butorphanol|drug
DDI-DrugBank.d246.s10|51-63|administered|drug
DDI-DrugBank.d246.s10|67-73|STADOL|brand
DDI-DrugBank.d246.s10|102-118|coadministration|drug
DDI-DrugBank.d246.s10|122-132|cimetidine|drug
DDI-DrugBank.d246.s10|141-146|QID).|brand
DDI-DrugBank.d246.s11|16-30|administration|drug
DDI-DrugBank.d246.s11|34-40|STADOL|brand
DDI-DrugBank.d246.s11|50-61|butorphanol|drug
DDI-DrugBank.d246.s11|85-101|pharmacokinetics|drug
DDI-DrugBank.d246.s11|107-113|300-mg|drug_n
DDI-DrugBank.d246.s11|122-133|cimetidine.|drug
DDI-DrugBank.d246.s12|34-45|butorphanol|drug
DDI-DrugBank.d246.s12|125-139|(erythromycin,|drug
DDI-DrugBank.d246.s12|212-219|initial|drug
DDI-DrugBank.d246.s12|236-245|intervals|drug
DDI-DrugBank.d246.s13|16-22|STADOL|brand
DDI-DrugBank.d246.s13|68-82|administration|drug
DDI-DrugBank.d246.s13|110-126|(oxymetazoline),|drug
DDI-DrugBank.d246.s14|33-44|anticipated|group
DDI-DrugBank.d246.s14|48-54|STADOL|brand
DDI-DrugBank.d246.s14|61-73|administered|drug
DDI-DrugBank.d246.s14|109-119|following,|drug
DDI-DrugBank.d246.s15|3-14|information|drug
DDI-DrugBank.d246.s15|45-56|butorphanol|drug
DDI-DrugBank.d246.s15|79-90|inhibitors.|drug
DDI-DrugBank.d150.s0|0-8|FLEXERIL|brand
DDI-DrugBank.d150.s0|18-34|life-threatening|drug
DDI-DrugBank.d150.s0|35-47|interactions|drug
DDI-DrugBank.d150.s0|57-68|inhibitors.|drug
DDI-DrugBank.d150.s1|0-8|FLEXERIL|brand
DDI-DrugBank.d150.s2|10-25|antidepressants|group
DDI-DrugBank.d150.s2|40-56|antihypertensive|group
DDI-DrugBank.d150.s2|67-79|guanethidine|drug
DDI-DrugBank.d150.s2|94-100|acting|drug
DDI-DrugBank.d150.s3|10-25|antidepressants|group
DDI-DrugBank.d150.s3|42-49|seizure|group
DDI-DrugBank.d150.s3|67-73|taking|drug
DDI-MedLine.d17.s0|9-20|interaction|drug
DDI-MedLine.d17.s0|24-37|prostaglandin|drug
DDI-MedLine.d17.s0|50-58|oxytocin|drug
DDI-MedLine.d17.s1|4-15|interaction|drug
DDI-MedLine.d17.s1|19-32|prostaglandin|drug
DDI-MedLine.d17.s1|55-63|oxytocin|drug
DDI-MedLine.d17.s2|15-23|measured|group
DDI-MedLine.d17.s2|43-49|margin|drug
DDI-MedLine.d17.s3|34-48|norepinephrine|drug
DDI-MedLine.d17.s3|53-61|oxytocin|drug
DDI-MedLine.d17.s4|33-42|increased|drug
DDI-MedLine.d17.s4|68-74|single|drug
DDI-MedLine.d17.s4|75-89|administration|drug
DDI-MedLine.d17.s4|93-102|oxytocin.|drug
DDI-MedLine.d17.s5|35-41|medium|drug
DDI-MedLine.d17.s5|42-51|contained|group
DDI-MedLine.d17.s5|52-61|oxytocin.|drug
DDI-MedLine.d17.s6|28-34|single|drug
DDI-MedLine.d17.s7|19-33|norepinephrine|drug
DDI-MedLine.d17.s7|34-42|remained|drug
DDI-MedLine.d17.s9|91-99|oxytocin|drug
DDI-DrugBank.d50.s0|20-31|interaction|drug
DDI-DrugBank.d50.s1|13-25|interactions|drug
DDI-DrugBank.d50.s1|53-60|ZOLADEX|brand
DDI-DrugBank.d332.s0|0-14|Administration|drug
DDI-DrugBank.d332.s0|47-56|receiving|drug
DDI-DrugBank.d332.s0|76-85|monoamine|drug
DDI-DrugBank.d332.s0|94-104|inhibiting|drug
DDI-DrugBank.d332.s2|49-58|utilizing|drug
DDI-DrugBank.d332.s2|99-109|myocardium|drug
DDI-DrugBank.d332.s2|113-128|catecholamines,|drug
DDI-DrugBank.d332.s2|129-143|administration|drug
DDI-DrugBank.d332.s2|267-276|including|drug
DDI-DrugBank.d110.s0|4-18|administration|drug
DDI-DrugBank.d110.s0|49-59|containing|group
DDI-DrugBank.d110.s0|60-71|epinephrine|drug
DDI-DrugBank.d110.s0|75-89|norepinephrine|drug
DDI-DrugBank.d110.s0|102-111|receiving|drug
DDI-DrugBank.d110.s0|112-121|monoamine|drug
DDI-DrugBank.d110.s0|130-141|inhibitors,|drug
DDI-DrugBank.d110.s0|152-167|antidepressants|group
DDI-DrugBank.d110.s0|171-185|phenothiazines|drug
DDI-DrugBank.d110.s2|68-78|monitoring|drug
DDI-DrugBank.d110.s3|11-25|administration|drug
DDI-DrugBank.d110.s4|4-21|para-aminobenzoic|drug
DDI-DrugBank.d110.s4|41-55|chloroprocaine|drug
DDI-DrugBank.d110.s4|56-64|inhibits|drug
DDI-DrugBank.d110.s5|11-25|chloroprocaine|drug
DDI-DrugBank.d110.s5|73-84|sulfonamide|drug
DDI-DrugBank.d110.s5|93-98|being|drug
DDI-DrugBank.d19.s0|49-56|certain|drug
DDI-DrugBank.d19.s0|97-105|increase|drug
DDI-DrugBank.d19.s0|146-154|clinical|drug
DDI-DrugBank.d19.s1|0-10|DISULFIRAM|brand
DDI-DrugBank.d19.s1|11-17|SHOULD|brand
DDI-DrugBank.d19.s1|31-38|CAUTION|brand
DDI-DrugBank.d19.s1|42-47|THOSE|brand
DDI-DrugBank.d19.s1|48-56|PATIENTS|brand
DDI-DrugBank.d19.s1|57-66|REVEIVING|brand
DDI-DrugBank.d19.s1|67-76|PHENYTOIN|brand
DDI-DrugBank.d19.s1|85-95|CONGENERS.|brand
DDI-DrugBank.d19.s2|0-5|SINCE|brand
DDI-DrugBank.d19.s2|10-21|CONCOMITANT|brand
DDI-DrugBank.d19.s2|22-36|ADMINISTRATION|brand
DDI-DrugBank.d19.s2|40-45|THESE|brand
DDI-DrugBank.d19.s2|50-55|DRUGS|brand
DDI-DrugBank.d19.s2|68-77|PHENYTOIN|brand
DDI-DrugBank.d19.s2|78-91|INTOXICATION,|brand
DDI-DrugBank.d19.s2|92-97|PRIOR|brand
DDI-DrugBank.d19.s2|101-114|ADMINISTERING|brand
DDI-DrugBank.d19.s2|115-125|DISULFIRAM|brand
DDI-DrugBank.d19.s2|131-138|PATIENT|brand
DDI-DrugBank.d19.s2|142-151|PHENYTOIN|brand
DDI-DrugBank.d19.s2|152-160|THERAPY,|brand
DDI-DrugBank.d19.s2|163-171|BASELINE|brand
DDI-DrugBank.d19.s2|172-181|PHENYTOIN|brand
DDI-DrugBank.d19.s2|182-187|SERUM|brand
DDI-DrugBank.d19.s2|188-193|LEVEL|brand
DDI-DrugBank.d19.s2|194-200|SHOULD|brand
DDI-DrugBank.d19.s2|204-213|OBTAINED.|brand
DDI-DrugBank.d19.s3|0-10|SUBSEQUENT|brand
DDI-DrugBank.d19.s3|14-24|INITIATION|brand
DDI-DrugBank.d19.s3|28-38|DISULFIRAM|brand
DDI-DrugBank.d19.s3|39-47|THERAPY.|brand
DDI-DrugBank.d19.s4|0-5|SERUM|brand
DDI-DrugBank.d19.s4|6-12|LEVELS|brand
DDI-DrugBank.d19.s4|16-25|PHENYTOIN|brand
DDI-DrugBank.d19.s4|26-32|SHOULD|brand
DDI-DrugBank.d19.s4|36-46|DETERMINED|brand
DDI-DrugBank.d19.s4|50-59|DIFFERENT|brand
DDI-DrugBank.d19.s4|69-77|EVIDENCE|brand
DDI-DrugBank.d19.s4|84-92|INCREASE|brand
DDI-DrugBank.d19.s4|102-112|CONTINUING|brand
DDI-DrugBank.d19.s4|121-128|LEVELS.|brand
DDI-DrugBank.d19.s5|0-9|INCREASED|brand
DDI-DrugBank.d19.s5|10-19|PHENYTOIN|brand
DDI-DrugBank.d19.s5|20-26|LEVELS|brand
DDI-DrugBank.d19.s5|27-33|SHOULD|brand
DDI-DrugBank.d19.s5|37-44|TREATED|brand
DDI-DrugBank.d19.s5|50-61|APPROPRIATE|brand
DDI-DrugBank.d19.s5|62-68|DOSAGE|brand
DDI-DrugBank.d19.s5|69-80|ADJUSTMENT.|brand
DDI-DrugBank.d19.s6|49-63|anticoagulants|group
DDI-DrugBank.d19.s6|69-78|beginning|drug
DDI-DrugBank.d19.s6|82-90|stopping|drug
DDI-DrugBank.d19.s6|103-108|since|drug
DDI-DrugBank.d19.s6|132-143|prothrombin|drug
DDI-DrugBank.d19.s7|9-15|taking|drug
DDI-DrugBank.d19.s8|25-37|discontinued|group
DDI-DrugBank.d19.s9|22-31|ingestion|drug
DDI-DrugBank.d19.s9|213-225|nitrosamine,|drug
DDI-DrugBank.d19.s11|22-29|finding|drug
DDI-DrugBank.d197.s0|109-121|interactions|drug
DDI-DrugBank.d197.s0|147-155|clinical|drug
DDI-DrugBank.d197.s1|0-40|Anesthetics/Sedatives/Hypnotics/Opioids:|group
DDI-DrugBank.d197.s1|41-58|Co-administration|drug
DDI-DrugBank.d197.s1|62-70|PRECEDEX|brand
DDI-DrugBank.d197.s1|115-122|opioids|group
DDI-DrugBank.d197.s3|3-18|pharmacokinetic|drug
DDI-DrugBank.d197.s3|19-31|interactions|drug
DDI-DrugBank.d197.s3|40-55|dexmedetomidine|drug
DDI-DrugBank.d197.s3|98-107|midazolam|drug
DDI-DrugBank.d197.s4|41-54|interactions,|drug
DDI-DrugBank.d197.s4|60-75|co-administered|drug
DDI-DrugBank.d197.s4|81-90|PRECEDEX,|brand
DDI-DrugBank.d197.s4|116-124|PRECEDEX|brand
DDI-DrugBank.d197.s5|63-77|administration|drug
DDI-DrugBank.d197.s5|81-89|PRECEDEX|brand
DDI-DrugBank.d197.s5|97-104|minutes|drug
DDI-DrugBank.d197.s5|163-173|clinically|drug
DDI-DrugBank.d197.s5|174-184|meaningful|drug
DDI-DrugBank.d197.s5|185-194|increases|drug
DDI-DrugBank.d197.s5|254-264|rocuronium|drug
DDI-DrugBank.d197.s5|265-280|administration.|drug
DDI-DrugBank.d306.s0|21-35|progestin-only|drug
DDI-DrugBank.d306.s0|64-79|enzyme-inducing|drug
DDI-DrugBank.d306.s0|98-113|anticonvulsants|group
DDI-DrugBank.d306.s0|114-124|phenytoin,|drug
DDI-DrugBank.d306.s0|125-139|carbamazepine,|drug
DDI-DrugBank.d306.s0|166-182|antituberculosis|group
DDI-DrugBank.d306.s0|188-197|rifampin.|drug
DDI-DrugBank.d306.s1|15-26|interaction|drug
DDI-DrugBank.d306.s1|62-74|antibiotics.|group
DDI-DrugBank.d304.s0|4-12|interact|drug
DDI-DrugBank.d304.s0|22-32|following:|drug
DDI-DrugBank.d304.s0|33-48|cholestyramine,|drug
DDI-DrugBank.d304.s0|49-59|colestipol|drug
DDI-DrugBank.d304.s0|70-78|thiazide|group
DDI-DrugBank.d304.s0|79-88|diuretics|group
DDI-DrugBank.d304.s0|105-113|diuretic|group
DDI-DrugBank.d304.s0|119-126|working|drug
DDI-DrugBank.d54.s0|48-56|increase|drug
DDI-DrugBank.d54.s0|71-78|vitamin|drug
DDI-DrugBank.d54.s0|91-99|clotting|drug
DDI-DrugBank.d54.s1|8-22|anticoagulants|group
DDI-DrugBank.d54.s1|32-37|being|drug
DDI-DrugBank.d54.s1|58-67|increases|drug
DDI-DrugBank.d54.s1|71-79|clotting|drug
DDI-DrugBank.d54.s2|28-42|anticoagulants|group
DDI-DrugBank.d54.s3|68-81|anticoagulant|group
DDI-DrugBank.d54.s4|56-69|anticoagulant|group
DDI-DrugBank.d54.s4|122-133|maintenance|drug
DDI-DrugBank.d54.s5|0-7|Insulin|drug
DDI-DrugBank.d54.s5|31-41|Initiating|drug
DDI-DrugBank.d54.s5|80-89|increases|drug
DDI-DrugBank.d54.s5|93-100|insulin|drug
DDI-DrugBank.d54.s6|126-135|endocrine|drug
DDI-DrugBank.d54.s7|9-18|receiving|drug
DDI-DrugBank.d54.s7|19-26|insulin|drug
DDI-DrugBank.d54.s7|75-81|during|drug
DDI-DrugBank.d54.s7|82-92|initiation|drug
DDI-DrugBank.d54.s8|0-15|Cholestyramine:|drug
DDI-DrugBank.d54.s8|16-30|Cholestyramine|drug
DDI-DrugBank.d54.s8|31-36|binds|drug
DDI-DrugBank.d54.s8|59-69|intestine,|drug
DDI-DrugBank.d54.s8|75-84|impairing|drug
DDI-DrugBank.d54.s9|17-25|indicate|drug
DDI-DrugBank.d54.s9|35-42|binding|drug
DDI-DrugBank.d54.s10|46-60|administration|drug
DDI-DrugBank.d54.s10|64-78|cholestyramine|drug
DDI-DrugBank.d54.s11|49-57|increase|drug
DDI-DrugBank.d54.s11|64-81|thyroxine-binding|drug
DDI-DrugBank.d54.s11|82-90|globulin|drug
DDI-DrugBank.d54.s12|20-34|nonfunctioning|drug
DDI-DrugBank.d54.s12|56-65|receiving|drug
DDI-DrugBank.d54.s12|100-113|levothyroxine|drug
DDI-DrugBank.d54.s12|163-173|increasing|drug
DDI-DrugBank.d54.s13|83-92|thyroxine|drug
DDI-DrugBank.d54.s13|123-131|increase|drug
DDI-DrugBank.d54.s13|135-144|thyroxine|drug
DDI-DrugBank.d54.s14|30-41|functioning|drug
DDI-DrugBank.d54.s14|107-115|increase|drug
DDI-DrugBank.d54.s14|151-170|estrogen-containing|group
DDI-DrugBank.d54.s14|176-190|contraceptives|group
DDI-DrugBank.d54.s15|56-66|imipramine|drug
DDI-DrugBank.d54.s15|87-102|antidepressants|group
DDI-DrugBank.d54.s15|107-115|increase|drug
DDI-DrugBank.d54.s15|149-163|antidepressant|group
DDI-DrugBank.d54.s18|29-38|increases|drug
DDI-DrugBank.d54.s18|73-81|increase|drug
DDI-DrugBank.d54.s19|0-9|Ketamine:|drug
DDI-DrugBank.d54.s19|15-27|administered|drug
DDI-DrugBank.d54.s21|14-23|Thyroxine|drug
DDI-DrugBank.d54.s21|24-33|increases|drug
DDI-DrugBank.d54.s21|59-73|catecholamines|drug
DDI-DrugBank.d54.s21|82-93|epinephrine|drug
DDI-DrugBank.d54.s21|98-113|norepinephrine.|drug
DDI-DrugBank.d54.s22|11-20|injection|drug
DDI-DrugBank.d54.s22|51-60|receiving|drug
DDI-DrugBank.d54.s22|82-91|increases|drug
DDI-DrugBank.d54.s22|104-117|precipitating|drug
DDI-DrugBank.d54.s22|127-140|insufficiency|drug
DDI-DrugBank.d54.s24|38-47|following|drug
DDI-DrugBank.d54.s24|79-88|interfere|drug
DDI-DrugBank.d54.s24|172-188|corticosteroids,|group
DDI-DrugBank.d54.s24|205-219|contraceptives|group
DDI-DrugBank.d54.s24|220-230|containing|group
DDI-DrugBank.d54.s24|242-259|iodine-containing|group
DDI-DrugBank.d54.s24|303-313|containing|group
DDI-DrugBank.d54.s25|73-87|interpretation|drug
DDI-DrugBank.d54.s26|52-61|measured.|group
DDI-DrugBank.d54.s27|24-43|estrogen-containing|group
DDI-DrugBank.d54.s27|49-63|contraceptives|group
DDI-DrugBank.d54.s27|64-72|increase|drug
DDI-DrugBank.d54.s28|16-25|increased|drug
DDI-DrugBank.d54.s28|26-32|during|drug
DDI-DrugBank.d54.s28|33-43|infectious|drug
DDI-DrugBank.d54.s30|19-55|hypo-thyroxine-binding-globulinemias|drug
DDI-DrugBank.d54.s31|4-13|incidence|drug
DDI-DrugBank.d54.s31|50-55|9000.|drug_n
DDI-DrugBank.d54.s32|4-11|binding|drug
DDI-DrugBank.d54.s32|15-24|thyroxine|drug
DDI-DrugBank.d54.s32|28-45|thyroxine-binding|drug
DDI-DrugBank.d54.s32|46-56|prealbumin|drug
DDI-DrugBank.d54.s32|57-63|(TBPA)|brand
DDI-DrugBank.d54.s32|67-76|inhibited|drug
DDI-DrugBank.d54.s34|2-11|Medicinal|drug
DDI-DrugBank.d54.s34|23-29|iodine|drug
DDI-DrugBank.d54.s34|30-40|interferes|drug
DDI-DrugBank.d54.s34|67-79|radio-iodine|drug
DDI-DrugBank.d54.s34|87-96|producing|drug
DDI-DrugBank.d54.s36|21-29|clinical|drug
DDI-DrugBank.d54.s36|112-121|indicates|drug
DDI-DrugBank.d54.s36|196-206|inactivity|drug
DDI-DrugBank.d535.s0|0-6|CYP450|brand
DDI-DrugBank.d535.s0|80-91|enfuvirtide|drug
DDI-DrugBank.d535.s0|129-141|interactions|drug
DDI-DrugBank.d535.s0|161-173|administered|drug
DDI-DrugBank.d535.s0|195-201|CYP450|brand
DDI-DrugBank.d535.s1|31-43|interactions|drug
DDI-DrugBank.d535.s1|55-69|antiretroviral|group
DDI-DrugBank.d535.s1|147-158|enfuvirtide|drug
DDI-DrugBank.d535.s1|189-203|antiretroviral|group
DDI-DrugBank.d258.s0|0-10|Loratadine|drug
DDI-DrugBank.d258.s0|39-53|coadministered|drug
DDI-DrugBank.d258.s0|80-93|erythromycin,|drug
DDI-DrugBank.d258.s0|94-105|cimetidine,|drug
DDI-DrugBank.d258.s0|110-122|ketoconazole|drug
DDI-DrugBank.d258.s0|126-136|controlled|group
DDI-DrugBank.d258.s0|137-145|clinical|drug
DDI-DrugBank.d258.s1|9-18|increased|drug
DDI-DrugBank.d258.s1|59-69|loratadine|drug
DDI-DrugBank.d258.s1|77-101|descarboethoxyloratadine|drug
DDI-DrugBank.d258.s1|116-125|following|drug
DDI-DrugBank.d258.s1|126-142|coadministration|drug
DDI-DrugBank.d258.s1|146-156|loratadine|drug
DDI-DrugBank.d258.s1|241-251|clinically|drug
DDI-DrugBank.d258.s1|294-305|loratadine,|drug
DDI-DrugBank.d258.s1|354-362|clinical|drug
DDI-DrugBank.d258.s2|41-51|intervals,|drug
DDI-DrugBank.d258.s3|39-49|cimetidine|drug
DDI-DrugBank.d258.s3|53-65|ketoconazole|drug
DDI-DrugBank.d258.s4|40-52|erythromycin|drug
DDI-DrugBank.d258.s4|72-88|coadministration|drug
DDI-DrugBank.d258.s4|92-102|loratadine|drug
DDI-DrugBank.d258.s4|134-146|erythromycin|drug
DDI-DrugBank.d258.s5|4-12|clinical|drug
DDI-DrugBank.d258.s6|12-20|findings|drug
DDI-DrugBank.d258.s6|39-44|TABLE|brand
DDI-DrugBank.d258.s7|0-5|TABLE|brand
DDI-DrugBank.d258.s7|59-69|Loratadine|drug
DDI-DrugBank.d258.s7|74-98|Descarboethoxyloratadine|drug
DDI-DrugBank.d258.s7|116-132|Coadministration|drug
DDI-DrugBank.d258.s7|133-144|(Loratadine|drug
DDI-DrugBank.d258.s8|0-10|Loratadine|drug
DDI-DrugBank.d258.s8|11-35|Descarboethoxyloratadine|drug
DDI-DrugBank.d258.s9|0-12|Erythromycin|drug
DDI-DrugBank.d258.s10|0-10|Cimetidine|drug
DDI-DrugBank.d258.s11|0-12|Ketoconazole|drug
DDI-DrugBank.d258.s12|31-39|increase|drug
DDI-DrugBank.d258.s12|88-102|contraceptives|group
DDI-DrugBank.d258.s12|107-118|loratadine.|drug
DDI-DrugBank.d263.s0|0-11|Zidovudine:|drug
DDI-DrugBank.d263.s0|36-51|pharmacokinetic|drug
DDI-DrugBank.d263.s0|52-63|interaction|drug
DDI-DrugBank.d263.s0|80-91|zalcitabine|drug
DDI-DrugBank.d263.s0|117-128|clinically.|drug
DDI-DrugBank.d263.s1|0-11|Zalcitabine|drug
DDI-DrugBank.d263.s1|50-63|intracellular|drug
DDI-DrugBank.d263.s1|165-170|lines|drug
DDI-DrugBank.d263.s1|171-176|(U937|brand
DDI-DrugBank.d263.s2|36-46|didanosine|drug
DDI-DrugBank.d263.s2|51-60|stavudine|drug
DDI-DrugBank.d263.s2|94-107|intracellular|drug
DDI-DrugBank.d263.s2|127-138|zalcitabine|drug
DDI-DrugBank.d263.s3|0-11|Lamivudine:|drug
DDI-DrugBank.d263.s3|104-114|lamivudine|drug
DDI-DrugBank.d263.s3|129-138|inhibited|drug
DDI-DrugBank.d263.s3|139-150|zalcitabine|drug
DDI-DrugBank.d263.s4|37-50|corresponding|drug
DDI-DrugBank.d263.s4|96-109|intracellular|drug
DDI-DrugBank.d263.s4|129-140|zalcitabine|drug
DDI-DrugBank.d263.s4|166-176|(including|drug
DDI-DrugBank.d263.s4|188-199|zalcitabine|drug
DDI-DrugBank.d263.s4|243-253|inhibited.|drug
DDI-DrugBank.d263.s5|0-11|Zalcitabine|drug
DDI-DrugBank.d263.s5|12-21|inhibited|drug
DDI-DrugBank.d263.s5|22-32|lamivudine|drug
DDI-DrugBank.d263.s5|86-91|100);|drug_n
DDI-DrugBank.d263.s6|78-88|lamivudine|drug
DDI-DrugBank.d263.s6|109-117|clinical|drug
DDI-DrugBank.d263.s6|135-145|lamivudine|drug
DDI-DrugBank.d263.s6|180-193|deoxycytidine|drug
DDI-DrugBank.d263.s6|194-200|kinase|drug
DDI-DrugBank.d263.s6|206-218|zalcitabine.|drug
DDI-DrugBank.d263.s7|48-62|administration|drug
DDI-DrugBank.d263.s7|66-77|zalcitabine|drug
DDI-DrugBank.d263.s7|82-92|lamivudine|drug
DDI-DrugBank.d263.s7|173-185|zalcitabine,|drug
DDI-DrugBank.d263.s7|216-230|antiretroviral|group
DDI-DrugBank.d263.s7|241-253|zalcitabine.|drug
DDI-DrugBank.d263.s8|76-84|clinical|drug
DDI-DrugBank.d263.s9|19-30|zalcitabine|drug
DDI-DrugBank.d263.s9|35-45|lamivudine|drug
DDI-DrugBank.d263.s10|0-11|Saquinavir:|drug
DDI-DrugBank.d263.s10|16-27|combination|drug
DDI-DrugBank.d263.s10|31-37|HIVID,|brand
DDI-DrugBank.d263.s10|38-49|saquinavir,|drug
DDI-DrugBank.d263.s10|86-98|combination)|drug
DDI-DrugBank.d263.s11|0-15|Pharmacokinetic|drug
DDI-DrugBank.d263.s11|62-73|elimination|drug
DDI-DrugBank.d263.s12|68-73|HIVID|brand
DDI-DrugBank.d263.s13|59-66|include|drug
DDI-DrugBank.d263.s13|67-81|antiretroviral|group
DDI-DrugBank.d263.s13|82-92|nucleoside|drug
DDI-DrugBank.d263.s13|121-131|cisplatin,|drug
DDI-DrugBank.d263.s13|186-198|hydralazine,|drug
DDI-DrugBank.d263.s13|199-210|iodoquinol,|drug
DDI-DrugBank.d263.s13|222-236|metronidazole,|drug
DDI-DrugBank.d263.s13|237-252|nitrofurantoin,|drug
DDI-DrugBank.d263.s13|253-263|phenytoin,|drug
DDI-DrugBank.d263.s13|264-274|ribavirin,|drug
DDI-DrugBank.d263.s13|279-291|vincristine.|drug
DDI-DrugBank.d263.s14|19-24|HIVID|brand
DDI-DrugBank.d263.s14|30-40|didanosine|drug
DDI-DrugBank.d263.s15|12-24|Pentamidine:|drug
DDI-DrugBank.d263.s15|40-45|HIVID|brand
DDI-DrugBank.d263.s15|56-67|interrupted|drug
DDI-DrugBank.d263.s16|13-22|fulminant|drug
DDI-DrugBank.d263.s16|56-67|intravenous|drug
DDI-DrugBank.d263.s16|68-79|pentamidine|drug
DDI-DrugBank.d263.s16|84-89|HIVID|brand
DDI-DrugBank.d263.s17|3-14|intravenous|drug
DDI-DrugBank.d263.s17|15-26|pentamidine|drug
DDI-DrugBank.d263.s17|61-68|carinii|drug
DDI-DrugBank.d263.s17|95-100|HIVID|brand
DDI-DrugBank.d263.s17|111-123|interrupted.|drug
DDI-DrugBank.d263.s18|0-13|Amphotericin,|drug
DDI-DrugBank.d263.s18|29-45|Aminoglycosides:|drug
DDI-DrugBank.d263.s18|60-73|amphotericin,|drug
DDI-DrugBank.d263.s18|89-104|aminoglycosides|drug
DDI-DrugBank.d263.s18|109-117|increase|drug
DDI-DrugBank.d263.s18|130-140|developing|drug
DDI-DrugBank.d263.s18|207-218|interfering|drug
DDI-DrugBank.d263.s18|247-258|zalcitabine|drug
DDI-DrugBank.d263.s18|268-275|raising|drug
DDI-DrugBank.d263.s18|285-295|exposure).|group
DDI-DrugBank.d263.s19|56-61|HIVID|brand
DDI-DrugBank.d263.s19|83-91|clinical|drug
DDI-DrugBank.d263.s19|107-117|monitoring|drug
DDI-DrugBank.d263.s20|14-25|Cimetidine:|drug
DDI-DrugBank.d263.s20|38-52|administration|drug
DDI-DrugBank.d263.s20|70-80|cimetidine|drug
DDI-DrugBank.d263.s20|95-106|elimination|drug
DDI-DrugBank.d263.s20|110-122|zalcitabine,|drug
DDI-DrugBank.d263.s20|138-148|inhibition|drug
DDI-DrugBank.d263.s20|179-191|zalcitabine.|drug
DDI-DrugBank.d263.s21|9-18|receiving|drug
DDI-DrugBank.d263.s21|34-45|combination|drug
DDI-DrugBank.d263.s21|51-62|zalcitabine|drug
DDI-DrugBank.d263.s21|121-132|zalcitabine|drug
DDI-DrugBank.d263.s22|0-29|Magnesium/Aluminum-containing|group
DDI-DrugBank.d263.s22|62-73|zalcitabine|drug
DDI-DrugBank.d263.s22|121-135|coadministered|drug
DDI-DrugBank.d263.s22|141-170|magnesium/aluminum-containing|group
DDI-DrugBank.d263.s23|4-12|clinical|drug
DDI-DrugBank.d263.s23|64-75|zalcitabine|drug
DDI-DrugBank.d263.s23|101-109|ingested|drug
DDI-DrugBank.d263.s23|130-159|magnesium/aluminum-containing|group
DDI-DrugBank.d263.s23|160-169|antacids.|group
DDI-DrugBank.d263.s24|75-86|zalcitabine|drug
DDI-DrugBank.d263.s24|91-105|metoclopramide|drug
DDI-DrugBank.d263.s24|110-125|coadministered.|drug
DDI-DrugBank.d263.s25|0-12|Doxorubicin:|drug
DDI-DrugBank.d263.s25|13-24|Doxorubicin|drug
DDI-DrugBank.d263.s25|46-57|zalcitabine|drug
DDI-DrugBank.d263.s25|80-90|inhibition|drug
DDI-DrugBank.d263.s26|32-43|zalcitabine|drug
DDI-DrugBank.d263.s26|106-114|clinical|drug
DDI-DrugBank.d516.s0|0-13|Theophylline:|drug
DDI-DrugBank.d516.s0|23-38|pharmacokinetic|drug
DDI-DrugBank.d516.s0|47-56|including|drug
DDI-DrugBank.d516.s0|86-98|theophylline|drug
DDI-DrugBank.d516.s0|177-190|lomefloxacin.|drug
DDI-DrugBank.d516.s1|3-11|clinical|drug
DDI-DrugBank.d516.s1|51-63|theophylline|drug
DDI-DrugBank.d516.s1|73-85|lomefloxacin|drug
DDI-DrugBank.d516.s1|139-151|theophylline|drug
DDI-DrugBank.d516.s1|192-204|theophylline|drug
DDI-DrugBank.d516.s2|7-17|individual|drug
DDI-DrugBank.d516.s2|18-30|theophylline|drug
DDI-DrugBank.d516.s2|64-74|clinically|drug
DDI-DrugBank.d516.s2|104-117|inter-action.|drug
DDI-DrugBank.d516.s3|0-8|Antacids|group
DDI-DrugBank.d516.s3|40-48|antacids|group
DDI-DrugBank.d516.s3|49-59|containing|group
DDI-DrugBank.d516.s3|60-69|magnesium|drug
DDI-DrugBank.d516.s3|73-82|aluminum,|drug
DDI-DrugBank.d516.s3|107-117|containing|group
DDI-DrugBank.d516.s3|164-177|(didanosine),|drug
DDI-DrugBank.d516.s3|280-292|lomefloxacin|drug
DDI-DrugBank.d516.s3|297-306|interfere|drug
DDI-DrugBank.d516.s4|11-23|administered|drug
DDI-DrugBank.d516.s4|39-51|lomefloxacin|drug
DDI-DrugBank.d516.s4|128-137|increased|drug
DDI-DrugBank.d516.s4|220-225|25%).|drug_n
DDI-DrugBank.d516.s5|0-10|Magnesium-|drug
DDI-DrugBank.d516.s5|15-34|aluminum-containing|group
DDI-DrugBank.d516.s5|35-44|antacids,|group
DDI-DrugBank.d516.s5|45-57|administered|drug
DDI-DrugBank.d516.s5|77-90|lomefloxacin,|drug
DDI-DrugBank.d516.s5|144-157|lomefloxacin.|drug
DDI-DrugBank.d516.s6|0-10|Separating|drug
DDI-DrugBank.d516.s6|36-48|lomefloxacin|drug
DDI-DrugBank.d516.s6|49-58|minimizes|drug
DDI-DrugBank.d516.s7|11-25|administration|drug
DDI-DrugBank.d516.s7|57-69|lomefloxacin|drug
DDI-DrugBank.d516.s7|70-76|dosing|drug
DDI-DrugBank.d516.s7|98-110|lomefloxacin|drug
DDI-DrugBank.d516.s7|111-117|dosing|drug
DDI-DrugBank.d516.s8|0-9|Caffeine:|drug
DDI-DrugBank.d516.s8|28-36|caffeine|drug
DDI-DrugBank.d516.s8|88-100|administered|drug
DDI-DrugBank.d516.s8|188-200|lomefloxacin|drug
DDI-DrugBank.d516.s8|207-212|being|drug
DDI-DrugBank.d516.s9|44-54|clinically|drug
DDI-DrugBank.d516.s9|79-94|pharmacokinetic|drug
DDI-DrugBank.d516.s9|116-124|caffeine|drug
DDI-DrugBank.d516.s9|150-163|paraxanthine.|drug
DDI-DrugBank.d516.s10|35-47|interactions|drug
DDI-DrugBank.d516.s10|51-62|individuals|drug
DDI-DrugBank.d516.s10|98-106|caffeine|drug
DDI-DrugBank.d516.s10|234-246|drug-induced|drug
DDI-DrugBank.d516.s11|6-16|quinolones|drug
DDI-DrugBank.d516.s11|54-66|interference|drug
DDI-DrugBank.d516.s11|90-99|caffeine,|drug
DDI-DrugBank.d516.s11|100-109|resulting|drug
DDI-DrugBank.d516.s11|177-185|increase|drug
DDI-DrugBank.d516.s11|228-237|caffeine.|drug
DDI-DrugBank.d516.s12|0-11|Cimetidine:|drug
DDI-DrugBank.d516.s12|12-22|Cimetidine|drug
DDI-DrugBank.d516.s12|48-57|interfere|drug
DDI-DrugBank.d516.s12|67-78|elimination|drug
DDI-DrugBank.d516.s12|88-99|quinolones.|drug
DDI-DrugBank.d516.s13|5-17|interference|drug
DDI-DrugBank.d516.s13|46-55|increases|drug
DDI-DrugBank.d516.s14|4-15|interaction|drug
DDI-DrugBank.d516.s14|24-36|lomefloxacin|drug
DDI-DrugBank.d516.s14|41-51|cimetidine|drug
DDI-DrugBank.d516.s15|0-13|Cyclosporine:|drug
DDI-DrugBank.d516.s15|39-51|cyclosporine|drug
DDI-DrugBank.d516.s15|95-107|cyclosporine|drug
DDI-DrugBank.d516.s15|134-143|quinolone|drug
DDI-DrugBank.d516.s16|20-32|lomefloxacin|drug
DDI-DrugBank.d516.s16|37-49|cyclosporine|drug
DDI-DrugBank.d516.s17|0-11|Omeprazole:|drug
DDI-DrugBank.d516.s17|15-25|clinically|drug
DDI-DrugBank.d516.s17|49-61|lomefloxacin|drug
DDI-DrugBank.d516.s17|62-78|pharmacokinetics|drug
DDI-DrugBank.d516.s17|79-84|(AUC,|brand
DDI-DrugBank.d516.s17|125-131|single|drug
DDI-DrugBank.d516.s17|140-152|lomefloxacin|drug
DDI-DrugBank.d516.s17|194-204|omeprazole|drug
DDI-DrugBank.d516.s18|11-21|omeprazole|drug
DDI-DrugBank.d516.s18|22-38|pharmacokinetics|drug
DDI-DrugBank.d516.s19|0-10|Phenytoin:|drug
DDI-DrugBank.d516.s19|60-69|phenytoin|drug
DDI-DrugBank.d516.s19|114-123|increased|drug
DDI-DrugBank.d516.s19|146-155|phenytoin|drug
DDI-DrugBank.d516.s19|156-162|sodium|drug
DDI-DrugBank.d516.s19|190-204|coadministered|drug
DDI-DrugBank.d516.s19|210-222|lomefloxacin|drug
DDI-DrugBank.d516.s20|0-12|Lomefloxacin|drug
DDI-DrugBank.d516.s20|57-66|phenytoin|drug
DDI-DrugBank.d516.s21|39-50|elimination|drug
DDI-DrugBank.d516.s21|54-68|lome-floxacin.|drug
DDI-DrugBank.d516.s22|3-11|increase|drug
DDI-DrugBank.d516.s22|39-48|increases|drug
DDI-DrugBank.d516.s22|138-150|individuals.|drug
DDI-DrugBank.d516.s23|0-12|Terfenadine:|drug
DDI-DrugBank.d516.s23|16-26|clinically|drug
DDI-DrugBank.d516.s23|86-96|intervals,|drug
DDI-DrugBank.d516.s23|103-114|terfenadine|drug
DDI-DrugBank.d516.s23|129-141|lomefloxacin|drug
DDI-DrugBank.d516.s23|142-159|pharmacokinetics,|drug
DDI-DrugBank.d516.s23|160-166|during|drug
DDI-DrugBank.d516.s23|178-192|administration|drug
DDI-DrugBank.d516.s23|196-208|lomefloxacin|drug
DDI-DrugBank.d516.s23|213-224|terfenadine|drug
DDI-DrugBank.d516.s24|0-9|Warfarin:|drug
DDI-DrugBank.d516.s24|10-20|Quinolones|drug
DDI-DrugBank.d516.s24|57-71|anticoagulant,|group
DDI-DrugBank.d516.s24|72-81|warfarin,|drug
DDI-DrugBank.d516.s25|24-36|administered|drug
DDI-DrugBank.d516.s25|52-63|prothrombin|drug
DDI-DrugBank.d516.s26|12-22|clinically|drug
DDI-DrugBank.d516.s26|67-78|prothrombin|drug
DDI-DrugBank.d516.s26|93-101|warfarin|drug
DDI-DrugBank.d516.s26|113-129|pharmacokinetics|drug
DDI-DrugBank.d516.s26|198-206|warfarin|drug
DDI-DrugBank.d516.s26|211-223|lomefloxacin|drug
DDI-DrugBank.d316.s0|0-6|CYP3A4|brand
DDI-DrugBank.d316.s0|18-28|Felodipine|drug
DDI-DrugBank.d316.s0|47-54|CYP3A4.|brand
DDI-DrugBank.d316.s1|0-17|Co-administration|drug
DDI-DrugBank.d316.s1|21-27|CYP3A4|brand
DDI-DrugBank.d316.s1|28-38|inhibitors|drug
DDI-DrugBank.d316.s1|44-57|ketoconazole,|drug
DDI-DrugBank.d316.s1|58-71|itraconazole,|drug
DDI-DrugBank.d316.s1|72-85|erythromycin,|drug
DDI-DrugBank.d316.s1|104-115|cimetidine)|drug
DDI-DrugBank.d316.s1|121-131|felodipine|drug
DDI-DrugBank.d316.s1|158-167|increases|drug
DDI-DrugBank.d316.s1|192-203|felodipine,|drug
DDI-DrugBank.d316.s1|221-229|increase|drug
DDI-DrugBank.d316.s2|6-15|increases|drug
DDI-DrugBank.d316.s2|45-54|increased|drug
DDI-DrugBank.d316.s2|77-85|pressure|group
DDI-DrugBank.d316.s2|90-99|increased|drug
DDI-DrugBank.d316.s3|38-55|co-administration|drug
DDI-DrugBank.d316.s3|59-71|itraconazole|drug
DDI-DrugBank.d316.s3|82-88|CYP3A4|brand
DDI-DrugBank.d316.s3|89-100|inhibitor).|drug
DDI-DrugBank.d316.s4|28-34|CYP3A4|brand
DDI-DrugBank.d316.s4|35-45|inhibitors|drug
DDI-DrugBank.d316.s4|50-65|co-administered|drug
DDI-DrugBank.d316.s4|71-82|felodipine.|drug
DDI-DrugBank.d316.s5|27-33|dosing|drug
DDI-DrugBank.d316.s5|34-44|felodipine|drug
DDI-DrugBank.d316.s6|4-13|following|drug
DDI-DrugBank.d316.s6|23-35|interactions|drug
DDI-DrugBank.d316.s6|56-68|Itraconazole|drug
DDI-DrugBank.d316.s6|69-86|Co-administration|drug
DDI-DrugBank.d316.s6|90-97|another|drug
DDI-DrugBank.d316.s6|130-140|felodipine|drug
DDI-DrugBank.d316.s6|146-158|itraconazole|drug
DDI-DrugBank.d316.s6|185-191|8-fold|drug_n
DDI-DrugBank.d316.s6|192-200|increase|drug
DDI-DrugBank.d316.s6|231-239|increase|drug
DDI-DrugBank.d316.s6|257-263|2-fold|drug_n
DDI-DrugBank.d316.s6|298-309|felodipine.|drug
DDI-DrugBank.d316.s7|0-12|Erythromycin|drug
DDI-DrugBank.d316.s7|13-30|Co-administration|drug
DDI-DrugBank.d316.s7|34-44|felodipine|drug
DDI-DrugBank.d316.s7|45-54|(PLENDIL)|brand
DDI-DrugBank.d316.s7|60-72|erythromycin|drug
DDI-DrugBank.d316.s7|109-117|increase|drug
DDI-DrugBank.d316.s7|191-202|felodipine.|drug
DDI-DrugBank.d316.s8|17-34|Co-administration|drug
DDI-DrugBank.d316.s8|38-48|felodipine|drug
DDI-DrugBank.d316.s8|93-99|2-fold|drug_n
DDI-DrugBank.d316.s8|100-108|increase|drug
DDI-DrugBank.d316.s8|171-182|felodipine.|drug
DDI-DrugBank.d316.s9|0-10|Cimetidine|drug
DDI-DrugBank.d316.s9|11-28|Co-administration|drug
DDI-DrugBank.d316.s9|32-42|felodipine|drug
DDI-DrugBank.d316.s9|48-58|cimetidine|drug
DDI-DrugBank.d316.s9|75-82|CYP-450|brand
DDI-DrugBank.d316.s9|83-93|inhibitor)|drug
DDI-DrugBank.d316.s9|109-117|increase|drug
DDI-DrugBank.d316.s9|167-178|felodipine.|drug
DDI-DrugBank.d316.s10|0-13|Beta-Blocking|drug
DDI-DrugBank.d316.s10|24-39|pharmacokinetic|drug
DDI-DrugBank.d316.s10|49-59|felodipine|drug
DDI-DrugBank.d316.s10|134-150|pharmacokinetics|drug
DDI-DrugBank.d316.s10|154-165|felodipine.|drug
DDI-DrugBank.d316.s11|46-55|increased|drug
DDI-DrugBank.d316.s12|3-13|controlled|group
DDI-DrugBank.d316.s12|14-22|clinical|drug
DDI-DrugBank.d316.s12|54-63|including|drug
DDI-DrugBank.d316.s12|93-105|administered|drug
DDI-DrugBank.d316.s12|111-121|felodipine|drug
DDI-DrugBank.d316.s12|136-146|tolerated.|drug
DDI-DrugBank.d316.s13|0-7|Digoxin|drug
DDI-DrugBank.d316.s13|39-46|PLENDIL|brand
DDI-DrugBank.d316.s13|51-67|pharmacokinetics|drug
DDI-DrugBank.d316.s13|71-78|digoxin|drug
DDI-DrugBank.d316.s13|102-109|failure|group
DDI-DrugBank.d316.s14|22-37|pharmacokinetic|drug
DDI-DrugBank.d316.s14|78-88|felodipine|drug
DDI-DrugBank.d316.s14|148-162|anticonvulsant|group
DDI-DrugBank.d316.s14|176-186|phenytoin,|drug
DDI-DrugBank.d316.s14|187-201|carbamazepine,|drug
DDI-DrugBank.d316.s15|42-52|felodipine|drug
DDI-DrugBank.d316.s16|0-5|Since|drug
DDI-DrugBank.d316.s16|8-18|clinically|drug
DDI-DrugBank.d316.s16|31-42|interaction|drug
DDI-DrugBank.d316.s16|50-62|anticipated,|group
DDI-DrugBank.d316.s16|75-91|antihypertensive|group
DDI-DrugBank.d316.s17|12-22|Felodipine|drug
DDI-DrugBank.d316.s17|27-35|increase|drug
DDI-DrugBank.d316.s18|30-41|felodipine,|drug
DDI-DrugBank.d316.s19|61-71|clinically|drug
DDI-DrugBank.d316.s19|84-96|interactions|drug
DDI-DrugBank.d316.s19|102-112|felodipine|drug
DDI-DrugBank.d316.s19|142-154|indomethacin|drug
DDI-DrugBank.d316.s20|27-35|CLINICAL|brand
DDI-DrugBank.d316.s20|36-49|PHARMACOLOGY,|brand
DDI-DrugBank.d316.s20|50-66|Pharmacokinetics|drug
DDI-DrugBank.d399.s0|0-11|Preliminary|drug
DDI-DrugBank.d399.s0|48-55|inhibit|drug
DDI-DrugBank.d399.s0|60-77|anti-inflammatory|group
DDI-DrugBank.d399.s1|22-34|inflammatory|drug
DDI-DrugBank.d399.s1|65-70|being|drug
DDI-DrugBank.d399.s1|96-108|clofazimine,|drug
DDI-DrugBank.d399.s1|134-142|continue|group
DDI-MedLine.d7.s0|9-21|theophylline|drug
DDI-MedLine.d7.s0|45-54|phenytoin|drug
DDI-MedLine.d7.s1|41-53|theophylline|drug
DDI-MedLine.d7.s1|102-111|phenytoin|drug
DDI-MedLine.d7.s1|112-127|administration.|drug
DDI-MedLine.d7.s2|19-31|theophylline|drug
DDI-MedLine.d7.s2|75-84|baseline.|drug
DDI-MedLine.d7.s3|13-24|interaction|drug
DDI-MedLine.d7.s3|31-37|within|drug
DDI-MedLine.d7.s3|51-60|beginning|drug
DDI-MedLine.d7.s4|5-13|combined|drug
DDI-MedLine.d7.s4|19-29|clinicians|drug
DDI-MedLine.d7.s4|52-61|phenytoin|drug
DDI-MedLine.d7.s4|157-169|theophylline|drug
DDI-DrugBank.d532.s0|12-23|interaction|drug
DDI-DrugBank.d532.s1|19-31|administered|drug
DDI-DrugBank.d532.s1|153-159|angina|drug
DDI-DrugBank.d532.s1|171-181|infarction|drug
DDI-DrugBank.d532.s2|23-31|included|drug
DDI-DrugBank.d532.s2|32-40|heparin,|drug
DDI-DrugBank.d532.s2|41-50|warfarin,|drug
DDI-DrugBank.d532.s2|86-93|calcium|drug
DDI-DrugBank.d532.s2|115-126|angiotensin|drug
DDI-DrugBank.d532.s2|127-137|converting|drug
DDI-DrugBank.d532.s2|145-156|inhibitors,|drug
DDI-DrugBank.d532.s2|157-168|intravenous|drug
DDI-DrugBank.d532.s2|188-200|ticlopidine,|drug
DDI-DrugBank.d532.s2|205-213|aspirin.|brand
DDI-DrugBank.d532.s3|0-8|Heparin,|drug
DDI-DrugBank.d532.s3|15-30|anticoagulants,|group
DDI-DrugBank.d532.s3|94-102|increase|drug
DDI-DrugBank.d532.s3|106-115|bleeding.|drug
DDI-DrugBank.d532.s4|135-146|antibodies.|group
DDI-DrugBank.d216.s0|17-24|Ethanol|drug
DDI-DrugBank.d216.s0|85-101|coadministration|drug
DDI-DrugBank.d216.s0|121-128|ethanol|drug
DDI-DrugBank.d216.s0|163-170|ethanol|drug
DDI-DrugBank.d216.s0|171-186|administration.|drug
DDI-DrugBank.d216.s1|0-11|Paroxetine:|drug
DDI-DrugBank.d216.s1|12-28|Coadministration|drug
DDI-DrugBank.d216.s1|32-38|single|drug
DDI-DrugBank.d216.s1|69-79|paroxetine|drug
DDI-DrugBank.d216.s1|115-130|pharmacokinetic|drug
DDI-DrugBank.d216.s1|150-162|interaction.|drug
DDI-DrugBank.d216.s2|11-27|Coadministration|drug
DDI-DrugBank.d216.s2|31-37|single|drug
DDI-DrugBank.d216.s2|96-106|clinically|drug
DDI-DrugBank.d216.s2|151-167|pharmacokinetics|drug
DDI-DrugBank.d216.s3|0-11|Olanzapine:|drug
DDI-DrugBank.d216.s3|12-28|Coadministration|drug
DDI-DrugBank.d216.s3|53-63|olanzapine|drug
DDI-DrugBank.d216.s4|4-15|interaction|drug
DDI-DrugBank.d216.s5|31-47|pharmacokinetics|drug
DDI-DrugBank.d216.s6|19-25|CYP3A4|brand
DDI-DrugBank.d216.s6|26-40|(Ketoconazole)|drug
DDI-DrugBank.d216.s6|41-47|CYP3A4|brand
DDI-DrugBank.d216.s6|81-92|elimination|drug
DDI-DrugBank.d216.s7|27-36|increased|drug
DDI-DrugBank.d216.s7|37-45|2.2-fold|drug_n
DDI-DrugBank.d216.s7|49-65|coadministration|drug
DDI-DrugBank.d216.s7|69-82|ketoconazole,|drug
DDI-DrugBank.d216.s7|92-101|inhibitor|drug
DDI-DrugBank.d216.s7|105-112|CYP3A4,|brand
DDI-DrugBank.d216.s8|19-28|increased|drug
DDI-DrugBank.d216.s8|29-37|1.4-fold|drug_n
DDI-DrugBank.d216.s8|42-51|1.3-fold,|drug_n
DDI-DrugBank.d216.s9|13-23|inhibitors|drug
DDI-DrugBank.d216.s9|27-33|CYP3A4|brand
DDI-DrugBank.d216.s9|41-54|itraconazole,|drug
DDI-DrugBank.d216.s9|55-70|clarithromycin,|drug
DDI-DrugBank.d216.s9|83-98|troleandomycin,|drug
DDI-DrugBank.d216.s9|110-121|nelfinavir)|drug
DDI-DrugBank.d216.s10|18-24|CYP3A4|brand
DDI-DrugBank.d216.s10|25-37|(Rifampicin)|drug
DDI-DrugBank.d216.s10|56-64|exposure|group
DDI-DrugBank.d216.s10|104-115|rifampicin,|drug
DDI-DrugBank.d216.s10|125-132|inducer|drug
DDI-DrugBank.d216.s10|136-143|CYP3A4.|brand
DDI-DrugBank.d216.s12|29-36|Protein|drug
DDI-DrugBank.d216.s12|79-87|proteins|drug
DDI-DrugBank.d216.s13|92-99|protein|drug
DDI-DrugBank.d216.s13|100-108|binding.|drug
DDI-DrugBank.d216.s14|0-14|Administration|drug
DDI-DrugBank.d216.s14|48-54|taking|drug
DDI-DrugBank.d216.s14|55-62|another|drug
DDI-DrugBank.d216.s14|83-96|protein-bound|drug
DDI-DrugBank.d216.s15|38-45|Digoxin|drug
DDI-DrugBank.d216.s15|48-54|single|drug
DDI-DrugBank.d216.s15|99-115|pharmacokinetics|drug
DDI-DrugBank.d216.s15|119-126|digoxin|drug
DDI-DrugBank.d216.s15|127-135|measured|group
DDI-DrugBank.d216.s15|152-161|following|drug
DDI-DrugBank.d216.s15|162-168|dosing|drug
DDI-DrugBank.d216.s16|0-9|Warfarin:|drug
DDI-DrugBank.d216.s16|27-39|administered|drug
DDI-DrugBank.d216.s16|76-92|pharmacokinetics|drug
DDI-DrugBank.d216.s16|104-117|(S)-warfarin,|drug
DDI-DrugBank.d216.s16|176-188|(prothrombin|drug
DDI-DrugBank.d216.s16|195-204|following|drug
DDI-DrugBank.d216.s16|207-213|single|drug
DDI-DrugBank.d216.s16|233-241|warfarin|drug
DDI-DrugBank.d81.s0|0-14|Nitroglycerin:|drug
DDI-DrugBank.d81.s0|25-37|(isradipine)|drug
DDI-DrugBank.d81.s0|54-68|coadministered|drug
DDI-DrugBank.d81.s0|74-88|nitroglycerin.|drug
DDI-DrugBank.d81.s1|0-20|Hydrochlorothiazide:|group
DDI-DrugBank.d81.s1|85-99|administration|drug
DDI-DrugBank.d81.s1|113-125|(isradipine)|drug
DDI-DrugBank.d81.s1|130-149|hydrochlorothiazide|group
DDI-DrugBank.d81.s2|49-59|isradipine|drug
DDI-DrugBank.d81.s2|63-71|existing|drug
DDI-DrugBank.d81.s2|72-91|hydrochlorothiazide|group
DDI-DrugBank.d81.s2|154-164|isradipine|drug
DDI-DrugBank.d81.s2|183-199|antihypertensive|group
DDI-DrugBank.d81.s3|0-12|Propranolol:|drug
DDI-DrugBank.d81.s3|18-24|single|drug
DDI-DrugBank.d81.s3|58-74|coadministration|drug
DDI-DrugBank.d81.s3|78-89|propranolol|drug
DDI-DrugBank.d81.s3|152-162|isradipine|drug
DDI-DrugBank.d81.s4|12-21|increases|drug
DDI-DrugBank.d81.s4|81-92|propranolol|drug
DDI-DrugBank.d81.s5|21-35|administration|drug
DDI-DrugBank.d81.s5|51-61|isradipine|drug
DDI-DrugBank.d81.s6|0-11|propranolol|drug
DDI-DrugBank.d81.s6|165-175|isradipine|drug
DDI-DrugBank.d81.s6|182-188|singly|drug
DDI-DrugBank.d81.s6|196-207|combination|drug
DDI-DrugBank.d81.s6|213-225|propranolol,|drug
DDI-DrugBank.d81.s6|238-249|propranolol|drug
DDI-DrugBank.d81.s6|256-262|singly|drug
DDI-DrugBank.d81.s6|270-281|combination|drug
DDI-DrugBank.d81.s6|287-298|isradipine.|drug
DDI-DrugBank.d81.s7|0-11|Cimetidine:|drug
DDI-DrugBank.d81.s7|67-77|cimetidine|drug
DDI-DrugBank.d81.s7|102-108|single|drug
DDI-DrugBank.d81.s7|122-132|isradipine|drug
DDI-DrugBank.d81.s7|160-168|increase|drug
DDI-DrugBank.d81.s7|172-182|isradipine|drug
DDI-DrugBank.d81.s7|237-245|increase|drug
DDI-DrugBank.d81.s8|3-13|isradipine|drug
DDI-DrugBank.d81.s8|25-34|initiated|drug
DDI-DrugBank.d81.s8|58-67|receiving|drug
DDI-DrugBank.d81.s8|68-78|cimetidine|drug
DDI-DrugBank.d81.s8|87-97|monitoring|drug
DDI-DrugBank.d81.s9|0-11|Rifampicin:|drug
DDI-DrugBank.d81.s9|66-76|rifampicin|drug
DDI-DrugBank.d81.s9|105-111|single|drug
DDI-DrugBank.d81.s9|125-135|isradipine|drug
DDI-DrugBank.d81.s9|163-173|isradipine|drug
DDI-DrugBank.d81.s10|3-13|rifampicin|drug
DDI-DrugBank.d81.s10|35-45|isradipine|drug
DDI-DrugBank.d81.s10|152-161|increased|drug
DDI-DrugBank.d81.s10|197-208|isradipine.|drug
DDI-DrugBank.d81.s11|0-9|Warfarin:|drug
DDI-DrugBank.d81.s11|47-57|clinically|drug
DDI-DrugBank.d81.s11|67-82|pharmacokinetic|drug
DDI-DrugBank.d81.s11|102-113|interaction|drug
DDI-DrugBank.d81.s11|122-132|isradipine|drug
DDI-DrugBank.d81.s11|145-153|warfarin|drug
DDI-DrugBank.d81.s11|172-178|single|drug
DDI-DrugBank.d81.s11|193-201|warfarin|drug
DDI-DrugBank.d81.s11|231-243|administered|drug
DDI-DrugBank.d81.s11|244-250|during|drug
DDI-DrugBank.d81.s11|302-313|isradipine.|drug
DDI-DrugBank.d81.s12|16-24|warfarin|drug
DDI-DrugBank.d81.s12|29-39|isradipine|drug
DDI-DrugBank.d81.s12|40-47|binding|drug
DDI-DrugBank.d81.s12|58-66|proteins|drug
DDI-DrugBank.d81.s13|0-8|Digoxin:|drug
DDI-DrugBank.d81.s13|25-39|administration|drug
DDI-DrugBank.d81.s13|53-65|(isradipine)|drug
DDI-DrugBank.d81.s13|70-77|digoxin|drug
DDI-DrugBank.d81.s13|83-94|single-dose|drug
DDI-DrugBank.d81.s13|95-110|pharmacokinetic|drug
DDI-DrugBank.d81.s13|176-184|digoxin.|drug
DDI-DrugBank.d81.s14|58-64|during|drug
DDI-DrugBank.d81.s14|130-137|calcium|drug
DDI-DrugBank.d81.s15|17-29|interactions|drug
DDI-DrugBank.d81.s15|52-60|clinical|drug
DDI-DrugBank.d81.s15|84-97|(isradipine),|drug
DDI-DrugBank.d81.s15|101-110|increased|drug
DDI-DrugBank.d81.s15|121-132|circulating|drug
DDI-DrugBank.d81.s15|133-139|fluids|group
DDI-DrugBank.d81.s15|169-180|interaction|drug
DDI-DrugBank.d433.s0|15-26|interaction|drug
DDI-DrugBank.d433.s1|66-76|monitoring|drug
DDI-DrugBank.d433.s1|123-134|combination|drug
DDI-DrugBank.d433.s2|32-38|injury|drug
DDI-DrugBank.d433.s2|83-94|combination|drug
DDI-DrugBank.d433.s2|139-146|injury,|drug
DDI-MedLine.d47.s0|12-19|buforin|drug
DDI-MedLine.d47.s0|36-47|combination|drug
DDI-MedLine.d47.s0|53-65|azithromycin|drug
DDI-MedLine.d47.s0|70-81|minocycline|drug
DDI-MedLine.d47.s0|82-89|against|drug_n
DDI-MedLine.d47.s0|90-105|Cryptosporidium|drug
DDI-MedLine.d47.s0|121-129|culture.|group
DDI-MedLine.d47.s1|13-33|anti-cryptosporidial|group
DDI-MedLine.d47.s1|46-53|buforin|drug
DDI-MedLine.d47.s1|70-81|combination|drug
DDI-MedLine.d47.s1|87-99|azithromycin|drug
DDI-MedLine.d47.s1|104-115|minocycline|drug
DDI-MedLine.d47.s1|120-133|investigated.|drug
DDI-MedLine.d47.s2|0-7|Buforin|drug
DDI-MedLine.d47.s2|43-52|increased|drug
DDI-MedLine.d47.s2|58-68|increasing|drug
DDI-MedLine.d47.s2|86-91|55.7%|drug_n
DDI-MedLine.d47.s3|48-56|combined|drug
DDI-MedLine.d47.s3|69-81|azithromycin|drug
DDI-MedLine.d47.s3|85-96|minocycline|drug
DDI-MedLine.d47.s4|0-7|Buforin|drug
DDI-MedLine.d47.s4|28-38|inhibiting|drug
DDI-MedLine.d47.s4|39-54|Cryptosporidium|drug
DDI-MedLine.d47.s4|83-94|combination|drug
DDI-MedLine.d47.s4|107-119|azithromycin|drug
DDI-MedLine.d47.s4|123-135|minocycline.|drug
DDI-DrugBank.d471.s0|0-7|Mineral|drug
DDI-DrugBank.d471.s0|12-22|interferes|drug
DDI-DrugBank.d471.s0|58-67|vitamins,|drug
DDI-DrugBank.d471.s0|68-77|including|drug
DDI-DrugBank.d471.s0|78-85|vitamin|drug
DDI-DrugBank.d471.s1|0-14|Administration|drug
DDI-DrugBank.d471.s1|18-26|thiazide|group
DDI-DrugBank.d471.s1|27-36|diuretics|group
DDI-DrugBank.d471.s1|86-91|being|drug
DDI-MedLine.d69.s0|27-35|tyrosine|drug
DDI-MedLine.d69.s0|70-86|contortrostatin,|group
DDI-MedLine.d69.s0|101-113|disintegrin,|drug
DDI-MedLine.d69.s0|128-140|disintegrins|drug
DDI-MedLine.d69.s0|141-151|echistatin|drug
DDI-MedLine.d69.s0|156-167|flavoridin.|drug
DDI-MedLine.d69.s1|16-27|disintegrin|drug
DDI-MedLine.d69.s1|28-43|contortrostatin|group
DDI-MedLine.d69.s1|83-95|disintegrins|drug
DDI-MedLine.d69.s1|96-106|echistatin|drug
DDI-MedLine.d69.s1|111-121|flavoridin|drug
DDI-MedLine.d69.s1|148-155|protein|drug
DDI-MedLine.d69.s1|156-164|tyrosine|drug
DDI-MedLine.d69.s2|21-36|contortrostatin|group
DDI-MedLine.d69.s2|66-74|tyrosine|drug
DDI-MedLine.d69.s2|109-117|proteins|drug
DDI-MedLine.d69.s2|153-162|including|drug
DDI-MedLine.d69.s2|170-179|induction|drug
DDI-MedLine.d69.s2|202-210|proteins|drug
DDI-MedLine.d69.s2|227-234|120-140|drug_n
DDI-MedLine.d69.s3|0-10|Echistatin|drug
DDI-MedLine.d69.s3|34-42|tyrosine|drug
DDI-MedLine.d69.s3|94-102|inhibits|drug
DDI-MedLine.d69.s3|118-133|contortrostatin|group
DDI-MedLine.d69.s4|10-18|proteins|drug
DDI-MedLine.d69.s4|32-40|tyrosine|drug
DDI-MedLine.d69.s4|72-87|contortrostatin|group
DDI-MedLine.d69.s4|124-131|protein|drug
DDI-MedLine.d69.s4|132-140|involved|drug
DDI-MedLine.d69.s4|144-152|integrin|drug
DDI-MedLine.d69.s4|153-163|signaling.|drug
DDI-MedLine.d69.s5|0-10|Flavoridin|drug
DDI-MedLine.d69.s5|78-101|contortrostatin-induced|group
DDI-MedLine.d69.s5|126-133|protein|drug
DDI-MedLine.d69.s5|137-147|MDA-MB-435|brand
DDI-MedLine.d69.s6|57-66|structure|group
DDI-MedLine.d69.s6|70-85|contortrostatin|group
DDI-MedLine.d69.s6|99-112|distinguishes|drug
DDI-MedLine.d69.s6|152-163|disintegrin|drug
DDI-DrugBank.d352.s0|38-46|insulin)|drug
DDI-DrugBank.d352.s3|31-40|interfere|drug
DDI-DrugBank.d352.s3|46-62|antihypertensive|group
DDI-DrugBank.d352.s3|76-89|guanethidine,|drug
DDI-DrugBank.d352.s4|18-32|phenothiazines|drug
DDI-DrugBank.d352.s4|52-61|anorectic|drug
DDI-DrugBank.d438.s0|35-46|investigate|drug
DDI-DrugBank.d438.s0|64-74|gabapentin|drug
DDI-DrugBank.d438.s0|78-85|inhibit|drug
DDI-DrugBank.d438.s0|120-128|(CYP1A2,|brand
DDI-DrugBank.d438.s0|129-136|CYP2A6,|brand
DDI-DrugBank.d438.s0|137-144|CYP2C9,|brand
DDI-DrugBank.d438.s0|145-153|CYP2C19,|brand
DDI-DrugBank.d438.s0|154-161|CYP2D6,|brand
DDI-DrugBank.d438.s0|162-169|CYP2E1,|brand
DDI-DrugBank.d438.s0|174-181|CYP3A4)|brand
DDI-DrugBank.d438.s0|226-231|using|drug
DDI-DrugBank.d438.s3|29-39|inhibition|drug
DDI-DrugBank.d438.s3|61-67|CYP2A6|brand
DDI-DrugBank.d438.s4|3-13|inhibition|drug
DDI-DrugBank.d438.s4|66-76|gabapentin|drug
DDI-DrugBank.d438.s5|0-10|Gabapentin|drug
DDI-DrugBank.d438.s5|54-63|interfere|drug
DDI-DrugBank.d438.s5|96-110|coadministered|drug
DDI-DrugBank.d438.s5|111-124|antiepileptic|group
DDI-DrugBank.d438.s6|9-20|interaction|drug
DDI-DrugBank.d438.s6|57-65|obtained|drug
DDI-DrugBank.d438.s6|79-88|involving|drug
DDI-DrugBank.d438.s7|0-10|Phenytoin:|drug
DDI-DrugBank.d438.s7|16-22|single|drug
DDI-DrugBank.d438.s7|72-81|Neurontin|drug
DDI-DrugBank.d438.s7|104-109|(N=8)|brand
DDI-DrugBank.d438.s7|110-120|maintained|drug
DDI-DrugBank.d438.s7|124-133|phenytoin|drug
DDI-DrugBank.d438.s7|169-179|gabapentin|drug
DDI-DrugBank.d438.s7|246-255|phenytoin|drug
DDI-DrugBank.d438.s7|260-269|phenytoin|drug
DDI-DrugBank.d438.s7|287-297|gabapentin|drug
DDI-DrugBank.d438.s7|298-315|pharmacokinetics.|drug
DDI-DrugBank.d438.s8|0-14|Carbamazepine:|drug
DDI-DrugBank.d438.s8|42-55|carbamazepine|drug
DDI-DrugBank.d438.s8|60-73|carbamazepine|drug
DDI-DrugBank.d438.s8|81-88|epoxide|drug
DDI-DrugBank.d438.s8|137-147|gabapentin|drug
DDI-DrugBank.d438.s9|0-5|N=12)|brand
DDI-DrugBank.d438.s9|6-21|administration.|drug
DDI-DrugBank.d438.s10|10-20|gabapentin|drug
DDI-DrugBank.d438.s10|21-37|pharmacokinetics|drug
DDI-DrugBank.d438.s10|56-69|carbamazepine|drug
DDI-DrugBank.d438.s10|70-85|administration.|drug
DDI-DrugBank.d438.s11|92-98|during|drug
DDI-DrugBank.d438.s11|111-121|gabapentin|drug
DDI-DrugBank.d438.s11|122-136|administration|drug
DDI-DrugBank.d438.s12|0-5|N=17)|brand
DDI-DrugBank.d438.s12|42-52|gabapentin|drug
DDI-DrugBank.d438.s12|53-68|pharmacokinetic|drug
DDI-DrugBank.d438.s13|41-56|pharmacokinetic|drug
DDI-DrugBank.d438.s13|89-99|gabapentin|drug
DDI-DrugBank.d438.s14|0-5|N=12)|brand
DDI-DrugBank.d438.s14|42-54|administered|drug
DDI-DrugBank.d438.s15|10-26|Coadministration|drug
DDI-DrugBank.d438.s15|27-33|(N=18)|brand
DDI-DrugBank.d438.s15|46-52|sodium|drug
DDI-DrugBank.d438.s15|76-85|Neurontin|drug
DDI-DrugBank.d438.s15|106-114|increase|drug
DDI-DrugBank.d438.s15|129-139|gabapentin|drug
DDI-DrugBank.d438.s16|0-10|Gabapentin|drug
DDI-DrugBank.d438.s16|37-52|pharmacokinetic|drug
DDI-DrugBank.d438.s18|17-28|interaction|drug
DDI-DrugBank.d438.s18|29-35|within|drug
DDI-DrugBank.d438.s19|13-29|Coadministration|drug
DDI-DrugBank.d438.s19|33-42|Neurontin|drug
DDI-DrugBank.d438.s20|0-5|N=48)|brand
DDI-DrugBank.d438.s20|16-27|hydrocodone|drug
DDI-DrugBank.d438.s21|0-5|N=50)|brand
DDI-DrugBank.d438.s21|65-79|administration|drug
DDI-DrugBank.d438.s21|83-94|hydrocodone|drug
DDI-DrugBank.d438.s22|60-74|administration|drug
DDI-DrugBank.d438.s22|85-94|Neurontin|drug
DDI-DrugBank.d438.s22|138-152|administration|drug
DDI-DrugBank.d438.s22|163-172|Neurontin|drug
DDI-DrugBank.d438.s23|23-34|interaction|drug
DDI-DrugBank.d438.s24|12-21|increases|drug
DDI-DrugBank.d438.s24|22-32|gabapentin|drug
DDI-DrugBank.d438.s25|17-28|interaction|drug
DDI-DrugBank.d438.s26|0-9|Morphine:|drug
DDI-DrugBank.d438.s26|12-22|literature|group
DDI-DrugBank.d438.s26|52-57|60-mg|drug_n
DDI-DrugBank.d438.s26|58-76|controlled-release|group
DDI-DrugBank.d438.s26|77-85|morphine|drug
DDI-DrugBank.d438.s26|98-110|administered|drug
DDI-DrugBank.d438.s26|130-136|600-mg|drug_n
DDI-DrugBank.d438.s26|137-146|Neurontin|drug
DDI-DrugBank.d438.s26|156-163|(N=12),|brand
DDI-DrugBank.d438.s26|169-179|gabapentin|drug
DDI-DrugBank.d438.s26|184-193|increased|drug
DDI-DrugBank.d438.s26|213-223|gabapentin|drug
DDI-DrugBank.d438.s26|224-236|administered|drug
DDI-DrugBank.d438.s26|245-254|morphine.|drug
DDI-DrugBank.d438.s27|0-8|Morphine|drug
DDI-DrugBank.d438.s27|9-24|pharmacokinetic|drug
DDI-DrugBank.d438.s27|63-77|administration|drug
DDI-DrugBank.d438.s27|81-90|Neurontin|drug
DDI-DrugBank.d438.s27|106-115|morphine.|drug
DDI-DrugBank.d438.s28|17-28|interaction|drug
DDI-DrugBank.d438.s29|0-11|Cimetidine:|drug
DDI-DrugBank.d438.s29|31-41|cimetidine|drug
DDI-DrugBank.d438.s29|56-62|(N=12)|brand
DDI-DrugBank.d438.s29|99-109|gabapentin|drug
DDI-DrugBank.d438.s29|126-136|creatinine|drug
DDI-DrugBank.d438.s30|5-15|cimetidine|drug
DDI-DrugBank.d438.s30|62-72|gabapentin|drug
DDI-DrugBank.d438.s30|77-88|creatinine,|drug
DDI-DrugBank.d438.s31|36-46|gabapentin|drug
DDI-DrugBank.d438.s31|50-60|cimetidine|drug
DDI-DrugBank.d438.s31|86-94|clinical|drug
DDI-DrugBank.d438.s32|14-24|gabapentin|drug
DDI-DrugBank.d438.s32|28-38|cimetidine|drug
DDI-DrugBank.d438.s33|62-77|pharmacokinetic|drug
DDI-DrugBank.d438.s33|90-103|norethindrone|drug
DDI-DrugBank.d438.s33|108-115|ethinyl|drug
DDI-DrugBank.d438.s33|126-135|following|drug
DDI-DrugBank.d438.s33|136-150|administration|drug
DDI-DrugBank.d438.s33|162-172|containing|group
DDI-DrugBank.d438.s33|183-196|norethindrone|drug
DDI-DrugBank.d438.s33|219-226|ethinyl|drug
DDI-DrugBank.d438.s33|267-283|coadministration|drug
DDI-DrugBank.d438.s33|287-297|gabapentin|drug
DDI-DrugBank.d438.s34|0-6|N=13).|brand
DDI-DrugBank.d438.s35|12-25|norethindrone|drug
DDI-DrugBank.d438.s35|53-67|coadministered|drug
DDI-DrugBank.d438.s35|73-84|gabapentin;|drug
DDI-DrugBank.d438.s36|5-16|interaction|drug
DDI-DrugBank.d438.s36|42-50|clinical|drug
DDI-DrugBank.d438.s37|57-67|gabapentin|drug
DDI-DrugBank.d438.s37|68-74|(N=16)|brand
DDI-DrugBank.d438.s38|51-61|gabapentin|drug
DDI-DrugBank.d438.s38|66-78|administered|drug
DDI-DrugBank.d438.s39|23-33|gabapentin|drug
DDI-DrugBank.d438.s39|60-69|following|drug
DDI-DrugBank.d438.s39|77-92|administration.|drug
DDI-DrugBank.d438.s41|0-10|Gabapentin|drug
DDI-DrugBank.d438.s41|11-26|pharmacokinetic|drug
DDI-DrugBank.d438.s42|5-14|indicates|drug
DDI-DrugBank.d438.s42|20-30|gabapentin|drug
DDI-DrugBank.d438.s43|58-66|readings|drug
DDI-DrugBank.d438.s43|128-135|urinary|drug
DDI-DrugBank.d438.s43|136-143|protein|drug
DDI-DrugBank.d438.s43|149-159|gabapentin|drug
DDI-DrugBank.d438.s43|179-192|antiepileptic|group
DDI-DrugBank.d438.s43|252-261|procedure|group
DDI-DrugBank.d438.s43|280-289|determine|drug
DDI-DrugBank.d438.s43|306-311|urine|drug
DDI-DrugBank.d438.s43|312-319|protein|drug
DDI-DrugBank.d325.s0|8-16|dopamine|drug
DDI-DrugBank.d325.s0|35-44|monoamine|drug
DDI-DrugBank.d325.s0|53-59|(MAO),|brand
DDI-DrugBank.d325.s0|60-70|inhibition|drug
DDI-DrugBank.d325.s0|125-134|dopamine.|drug
DDI-DrugBank.d325.s1|40-50|inhibitors|drug
DDI-DrugBank.d325.s1|51-57|within|drug
DDI-DrugBank.d325.s1|90-104|administration|drug
DDI-DrugBank.d325.s1|108-116|dopamine|drug
DDI-DrugBank.d325.s1|136-143|initial|drug
DDI-DrugBank.d325.s1|153-161|dopamine|drug
DDI-DrugBank.d325.s2|11-25|administration|drug
DDI-DrugBank.d325.s2|38-46|dopamine|drug
DDI-DrugBank.d325.s2|55-63|diuretic|group
DDI-DrugBank.d325.s2|98-110|potentiating|drug
DDI-DrugBank.d325.s2|121-126|urine|drug
DDI-DrugBank.d325.s3|10-25|antidepressants|group
DDI-DrugBank.d325.s4|19-27|dopamine|drug
DDI-DrugBank.d325.s4|63-71|blocking|drug
DDI-DrugBank.d325.s4|88-99|propranolol|drug
DDI-DrugBank.d325.s5|56-64|dopamine|drug
DDI-DrugBank.d325.s5|104-112|blocking|drug
DDI-DrugBank.d325.s6|0-16|Dopamine-induced|drug
DDI-DrugBank.d325.s6|106-114|blocking|drug
DDI-DrugBank.d325.s7|41-55|phenothiazines|drug
DDI-DrugBank.d325.s7|73-85|dopaminergic|drug
DDI-DrugBank.d325.s7|120-127|induced|drug
DDI-DrugBank.d325.s7|142-150|dopamine|drug
DDI-DrugBank.d325.s7|151-160|infusion.|drug
DDI-DrugBank.d325.s8|28-39|hydrocarbon|drug
DDI-DrugBank.d325.s8|52-60|increase|drug
DDI-DrugBank.d325.s8|114-124|myocardium|drug
DDI-DrugBank.d325.s8|142-149|certain|drug
DDI-DrugBank.d325.s8|150-163|intravenously|drug
DDI-DrugBank.d325.s8|164-176|administered|drug
DDI-DrugBank.d325.s8|177-192|catecholamines,|drug
DDI-DrugBank.d325.s8|201-210|dopamine.|drug
DDI-DrugBank.d325.s9|5-16|interaction|drug
DDI-DrugBank.d325.s9|87-98|stimulating|drug
DDI-DrugBank.d325.s9|119-133|catecholamines|drug
DDI-DrugBank.d325.s10|11-18|EXTREME|brand
DDI-DrugBank.d325.s10|19-26|CAUTION|brand
DDI-DrugBank.d325.s10|52-65|administering|drug
DDI-DrugBank.d325.s10|66-74|dopamine|drug
DDI-DrugBank.d325.s10|91-100|receiving|drug
DDI-DrugBank.d325.s10|101-113|cyclopropane|drug
DDI-DrugBank.d325.s10|129-140|hydrocarbon|drug
DDI-DrugBank.d325.s11|56-64|indicate|drug
DDI-DrugBank.d325.s11|70-86|dopamine-induced|drug
DDI-DrugBank.d325.s11|111-117|during|drug
DDI-DrugBank.d325.s11|148-160|propranolol.|drug
DDI-DrugBank.d325.s12|37-53|vasoconstricting|drug
DDI-DrugBank.d325.s12|70-81|ergonovine)|drug
DDI-DrugBank.d325.s13|0-14|Administration|drug
DDI-DrugBank.d325.s13|18-27|phenytoin|drug
DDI-DrugBank.d325.s13|40-49|receiving|drug
DDI-DrugBank.d325.s13|50-58|dopamine|drug
DDI-DrugBank.d325.s14|33-42|receiving|drug
DDI-DrugBank.d325.s14|43-51|dopamine|drug
DDI-DrugBank.d325.s14|73-82|phenytoin|drug
DDI-DrugBank.d325.s14|101-115|anticonvulsant|group
DDI-DrugBank.d419.s0|15-29|administration|drug
DDI-DrugBank.d419.s0|33-44|allopurinol|drug
DDI-DrugBank.d419.s0|49-59|ampicillin|drug
DDI-DrugBank.d419.s0|60-69|increases|drug
DDI-DrugBank.d419.s0|88-97|incidence|drug
DDI-DrugBank.d419.s0|120-129|receiving|drug
DDI-DrugBank.d419.s0|165-174|receiving|drug
DDI-DrugBank.d419.s0|175-185|ampicillin|drug
DDI-DrugBank.d419.s1|45-55|ampicillin|drug
DDI-DrugBank.d419.s1|73-84|allopurinol|drug
DDI-DrugBank.d419.s2|3-13|controlled|group
DDI-DrugBank.d419.s2|14-22|clinical|drug
DDI-DrugBank.d419.s2|33-42|AUGMENTIN|brand
DDI-DrugBank.d419.s2|80-91|allopurinol|drug
DDI-DrugBank.d419.s2|96-105|AUGMENTIN|brand
DDI-DrugBank.d419.s4|80-89|regarding|drug
DDI-DrugBank.d419.s4|126-135|AUGMENTIN|brand
DDI-DrugBank.d419.s4|143-154|allopurinol|drug
DDI-DrugBank.d419.s5|36-48|antibiotics,|group
DDI-DrugBank.d419.s5|49-58|AUGMENTIN|brand
DDI-DrugBank.d419.s5|94-108|contraceptives|group
DDI-DrugBank.d64.s0|74-83|receiving|drug
DDI-DrugBank.d64.s0|89-103|anticoagulants|group
DDI-DrugBank.d64.s0|139-153|anticoagulant.|group
DDI-DrugBank.d64.s1|9-22|determination|drug
DDI-DrugBank.d64.s1|26-37|prothrombin|drug
DDI-DrugBank.d64.s1|53-63|monitoring|drug
DDI-DrugBank.d64.s1|95-104|ascertain|drug
DDI-DrugBank.d64.s1|134-147|anticoagulant|group
DDI-DrugBank.d64.s2|30-40|individual|drug
DDI-DrugBank.d64.s2|68-79|interacting|drug
DDI-DrugBank.d64.s2|144-155|interaction|drug
DDI-DrugBank.d64.s2|212-226|administration|drug
DDI-DrugBank.d64.s2|238-249|interacting|drug
DDI-DrugBank.d64.s2|377-390|anticoagulant|group
DDI-DrugBank.d64.s3|13-18|since|drug
DDI-DrugBank.d64.s3|19-33|cholestyramine|drug
DDI-DrugBank.d64.s3|49-65|gastrointestinal|drug
DDI-DrugBank.d64.s3|94-108|anticoagulants|group
DDI-DrugBank.d64.s3|113-120|vitamin|drug
DDI-DrugBank.d64.s4|8-15|hydrate|drug
DDI-DrugBank.d64.s4|29-38|increased|drug
DDI-DrugBank.d64.s4|39-50|prothrombin|drug
DDI-DrugBank.d64.s4|63-73|displacing|drug
DDI-DrugBank.d64.s4|78-91|anticoagulant|group
DDI-DrugBank.d64.s4|97-104|protein|drug
DDI-DrugBank.d64.s4|105-112|binding|drug
DDI-DrugBank.d64.s4|124-134|diminished|drug
DDI-DrugBank.d64.s4|135-146|prothrombin|drug
DDI-DrugBank.d64.s4|164-173|increased|drug
DDI-DrugBank.d64.s4|223-233|induction,|drug
DDI-DrugBank.d64.s4|239-246|leading|drug
DDI-DrugBank.d64.s4|250-263|inter-patient|drug
DDI-DrugBank.d64.s4|286-297|prothrombin|drug
DDI-DrugBank.d64.s5|3-14|interacting|drug
DDI-DrugBank.d64.s5|49-60|prothrombin|drug
DDI-DrugBank.d64.s5|66-79|necessitating|drug
DDI-DrugBank.d64.s5|83-92|increased|drug
DDI-DrugBank.d64.s5|106-119|anticoagulant|group
DDI-DrugBank.d64.s5|123-131|maintain|drug
DDI-DrugBank.d64.s5|154-169|anticoagulation|group
DDI-DrugBank.d64.s5|187-200|discontinued,|group
DDI-DrugBank.d64.s5|201-209|increase|drug
DDI-DrugBank.d64.s5|233-242|bleeding.|drug
DDI-DrugBank.d64.s6|33-41|diminish|drug
DDI-DrugBank.d64.s6|47-60|anticoagulant|group
DDI-DrugBank.d64.s6|85-97|prothrom-bin|drug
DDI-DrugBank.d64.s6|134-142|include:|drug
DDI-DrugBank.d64.s6|158-167|steroids;|group
DDI-DrugBank.d64.s8|0-9|antacids;|group
DDI-DrugBank.d64.s9|0-15|antihistamines;|group
DDI-DrugBank.d64.s11|0-14|carbamazepine;|drug
DDI-DrugBank.d64.s12|8-17|hydrate*;|drug
DDI-DrugBank.d64.s14|0-15|cholestyramine;|drug
DDI-DrugBank.d64.s15|13-20|vitamin|drug
DDI-DrugBank.d64.s16|0-11|diuretics*;|group
DDI-DrugBank.d64.s19|0-13|griseofulvin;|drug
DDI-DrugBank.d64.s22|5-20|contraceptives;|group
DDI-DrugBank.d64.s25|0-12|ranitidine*;|drug
DDI-DrugBank.d64.s26|0-9|rifampin;|drug
DDI-DrugBank.d64.s27|11-22|prothrombin|drug
DDI-DrugBank.d64.s27|28-43|determinations;|drug
DDI-DrugBank.d64.s28|0-7|vitamin|drug
DDI-DrugBank.d64.s29|33-41|diminish|drug
DDI-DrugBank.d64.s29|47-60|anticoagulant|group
DDI-DrugBank.d64.s29|85-97|prothrom-bin|drug
DDI-DrugBank.d64.s29|134-142|include:|drug
DDI-DrugBank.d64.s29|158-234|steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral|group
DDI-DrugBank.d64.s29|235-280|hydrate*;chlordiazepoxide;cholestyramine;diet|drug
DDI-DrugBank.d64.s29|289-296|vitamin|drug
DDI-DrugBank.d64.s29|297-378|K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral|group
DDI-DrugBank.d64.s29|379-447|contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable|group
DDI-DrugBank.d64.s29|448-459|prothrombin|drug
DDI-DrugBank.d64.s29|465-487|determinations;vitamin|drug
DDI-DrugBank.d64.s29|488-498|C;warfarin|drug
DDI-DrugBank.d64.s29|499-505|sodium|drug
DDI-DrugBank.d64.s30|26-34|increase|drug
DDI-DrugBank.d64.s30|40-53|anticoagulant|group
DDI-DrugBank.d64.s30|68-77|increased|drug
DDI-DrugBank.d64.s30|78-89|prothrombin|drug
DDI-DrugBank.d64.s30|107-124|include:alcohol*;|drug
DDI-DrugBank.d64.s31|0-12|allopurinol;|drug
DDI-DrugBank.d64.s32|0-14|aminosalicylic|drug
DDI-DrugBank.d64.s34|9-18|steroids;|group
DDI-DrugBank.d64.s35|0-12|antibiotics;|group
DDI-DrugBank.d64.s36|0-11|bromelains;|drug
DDI-DrugBank.d64.s37|8-17|hydrate*;|drug
DDI-DrugBank.d64.s39|0-13|chymotrypsin;|drug
DDI-DrugBank.d64.s40|0-11|cimetidine;|drug
DDI-DrugBank.d64.s41|0-11|cinchophen;|drug
DDI-DrugBank.d64.s44|0-16|dextrothyroxine;|drug
DDI-DrugBank.d64.s48|0-11|diuretics*;|group
DDI-DrugBank.d64.s50|6-15|affecting|drug
DDI-DrugBank.d64.s56|0-13|indomethacin;|drug
DDI-DrugBank.d64.s57|0-9|influenza|drug
DDI-DrugBank.d64.s57|16-24|vaccine;|drug
DDI-DrugBank.d64.s58|0-10|inhalation|drug
DDI-DrugBank.d64.s62|0-14|metronidazole;|drug
DDI-DrugBank.d64.s63|0-11|miconazole;|drug
DDI-DrugBank.d64.s64|0-9|monoamine|drug
DDI-DrugBank.d64.s64|18-29|inhibitors;|drug
DDI-DrugBank.d64.s67|0-8|oxolinic|drug
DDI-DrugBank.d64.s69|0-15|pentoxifylline;|drug
DDI-DrugBank.d64.s72|0-10|phenytoin;|drug
DDI-DrugBank.d64.s76|0-10|quinidine;|drug
DDI-DrugBank.d64.s77|0-8|quinine;|drug
DDI-DrugBank.d64.s78|0-12|ranitidine*;|drug
DDI-DrugBank.d64.s79|0-27|salicylates;sulfinpyrazone;|drug
DDI-DrugBank.d64.s80|19-26|acting;|drug
DDI-DrugBank.d64.s81|0-9|sulindac;|drug
DDI-DrugBank.d64.s84|10-17|sodium;|drug
DDI-DrugBank.d64.s85|0-30|trimethoprim/sulfamethoxazole;|drug
DDI-DrugBank.d64.s86|11-22|prothrombin|drug
DDI-DrugBank.d64.s86|28-43|determinations;|drug
DDI-DrugBank.d64.s87|26-34|increase|drug
DDI-DrugBank.d64.s87|40-53|anticoagulant|group
DDI-DrugBank.d64.s87|68-77|increased|drug
DDI-DrugBank.d64.s87|78-89|prothrombin|drug
DDI-DrugBank.d64.s87|107-150|include:alcohol*;allopurinol;aminosalicylic|drug
DDI-DrugBank.d64.s87|176-215|steroids;antibiotics;bromelains;chloral|group
DDI-DrugBank.d64.s87|216-327|hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary|drug
DDI-DrugBank.d64.s87|369-378|affecting|drug
DDI-DrugBank.d64.s87|442-480|drugs;ibuprofen;indomethacin;influenza|drug
DDI-DrugBank.d64.s87|487-505|vaccine;inhalation|drug
DDI-DrugBank.d64.s87|528-594|acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine|drug
DDI-DrugBank.d64.s87|603-623|inhibitors;nalidixic|drug
DDI-DrugBank.d64.s87|624-646|acid;naproxen;oxolinic|drug
DDI-DrugBank.d64.s87|647-730|acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged|drug
DDI-DrugBank.d64.s87|753-845|narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides,|drug
DDI-DrugBank.d64.s87|851-874|acting;sulindac;thyroid|drug
DDI-DrugBank.d64.s87|903-950|sodium;trimethoprim/sulfamethoxazole;unreliable|drug
DDI-DrugBank.d64.s87|951-962|prothrombin|drug
DDI-DrugBank.d64.s87|968-991|determinations;warfarin|drug
DDI-DrugBank.d64.s87|992-998|sodium|drug
DDI-DrugBank.d64.s88|5-19|anticoagulants|group
DDI-DrugBank.d64.s88|87-98|tolbutamide|drug
DDI-DrugBank.d64.s88|122-132|inhibiting|drug
DDI-DrugBank.d64.s89|13-27|anticoagulants|group
DDI-DrugBank.d64.s89|32-41|interfere|drug
DDI-DrugBank.d64.s89|73-83|phenytoin,|drug
DDI-DrugBank.d64.s89|104-118|anticonvulsant|group
DDI-DrugBank.d64.s89|142-155|anticoagulant|group
DDI-DrugBank.d64.s89|160-169|phenytoin|drug
DDI-DrugBank.d64.s89|174-186|administered|drug
DDI-DrugBank.d64.s90|51-58|causing|drug
DDI-DrugBank.d64.s90|91-105|antineoplastic|group
DDI-DrugBank.d64.s90|129-136|inhibit|drug
DDI-DrugBank.d64.s90|160-167|aspirin|brand
DDI-DrugBank.d64.s90|192-209|anti-inflammatory|group
DDI-DrugBank.d64.s90|217-230|dipyridamole,|drug
DDI-DrugBank.d64.s90|231-248|hydrochloroquine,|drug
DDI-DrugBank.d64.s90|274-282|increase|drug
DDI-DrugBank.d64.s90|287-295|bleeding|drug
DDI-DrugBank.d64.s90|317-331|anticoagulants|group
DDI-DrugBank.d64.s90|340-348|altering|drug
DDI-DrugBank.d64.s90|349-360|prothrombin|drug
DDI-DrugBank.d64.s90|366-381|determinations.|drug
DDI-DrugBank.d64.s91|59-67|combined|drug
DDI-DrugBank.d64.s91|81-93|antiplatelet|group
DDI-DrugBank.d64.s91|98-111|anticoagulant|group
DDI-DrugBank.d64.s91|139-146|against|drug_n
DDI-DrugBank.d64.s91|150-159|increased|drug
DDI-DrugBank.d64.s91|168-176|inducing|drug
DDI-DrugBank.d64.s92|25-36|prothrombin|drug
DDI-DrugBank.d64.s93|50-61|indanedione|drug
DDI-DrugBank.d64.s93|62-77|anticoagulants,|group
DDI-DrugBank.d64.s93|78-87|including|drug
DDI-DrugBank.d64.s93|88-100|anisindione,|drug
DDI-DrugBank.d64.s93|132-140|alkaline|drug
DDI-DrugBank.d64.s93|141-146|urine|drug
DDI-DrugBank.d64.s93|169-178|interfere|drug
DDI-DrugBank.d64.s93|207-217|determined|drug
DDI-DrugBank.d64.s93|218-225|urinary|drug
DDI-DrugBank.d331.s0|112-124|administered|drug
DDI-DrugBank.d331.s0|125-135|bumetanide|drug
DDI-DrugBank.d331.s0|156-170|aminoglycoside|drug
DDI-DrugBank.d331.s0|171-182|antibiotics|group
DDI-DrugBank.d331.s0|192-197|being|drug
DDI-DrugBank.d331.s0|233-249|life-threatening|drug
DDI-DrugBank.d331.s1|90-100|bumetanide|drug
DDI-DrugBank.d331.s2|28-42|administration|drug
DDI-DrugBank.d331.s3|2-10|Lithium:|drug
DDI-DrugBank.d331.s3|11-18|Lithium|drug
DDI-DrugBank.d331.s3|54-63|diuretics|group
DDI-DrugBank.d331.s3|148-155|lithium|drug
DDI-DrugBank.d331.s4|60-71|natriuresis|group
DDI-DrugBank.d331.s4|76-90|hyperreninemia|drug
DDI-DrugBank.d331.s5|42-52|bumetanide|drug
DDI-DrugBank.d331.s5|53-64|natriuresis|group
DDI-DrugBank.d331.s5|98-104|sodium|drug
DDI-DrugBank.d331.s5|148-158|inhibitory|drug
DDI-DrugBank.d331.s6|31-43|administered|drug
DDI-DrugBank.d331.s7|2-15|Indomethacin:|drug
DDI-DrugBank.d331.s7|16-28|Indomethacin|drug
DDI-DrugBank.d331.s7|40-49|increases|drug
DDI-DrugBank.d331.s7|53-58|urine|drug
DDI-DrugBank.d331.s7|70-76|sodium|drug
DDI-DrugBank.d331.s7|92-98|during|drug
DDI-DrugBank.d331.s7|99-109|bumetanide|drug
DDI-DrugBank.d331.s7|124-132|inhibits|drug
DDI-DrugBank.d331.s7|137-155|bumetanide-induced|drug
DDI-DrugBank.d331.s7|156-164|increase|drug
DDI-DrugBank.d331.s7|175-180|renin|drug
DDI-DrugBank.d331.s8|24-34|bumetanide|drug
DDI-DrugBank.d331.s9|21-31|Bumetanide|drug
DDI-DrugBank.d331.s9|69-85|antihypertensive|group
DDI-DrugBank.d331.s9|93-106|necessitating|drug
DDI-DrugBank.d331.s10|2-10|Digoxin:|drug
DDI-DrugBank.d331.s10|65-72|digoxin|drug
DDI-DrugBank.d331.s11|59-69|bumetanide|drug
DDI-DrugBank.d331.s11|91-99|warfarin|drug
DDI-DrugBank.d331.s11|124-135|prothrombin|drug
DDI-DrugBank.d382.s0|38-48|inhibitor,|drug
DDI-DrugBank.d382.s0|56-63|inducer|drug
DDI-DrugBank.d382.s0|67-74|CYP3A4.|brand
DDI-DrugBank.d382.s1|22-29|inducer|drug
DDI-DrugBank.d382.s1|33-40|CYP2C9.|brand
DDI-DrugBank.d382.s2|28-44|pharmacokinetics|drug
DDI-DrugBank.d382.s3|14-23|inhibitor|drug
DDI-DrugBank.d382.s3|27-34|CYP3A4,|brand
DDI-DrugBank.d382.s3|50-58|increase|drug
DDI-DrugBank.d382.s3|84-98|coadministered|drug
DDI-DrugBank.d382.s3|99-108|medicinal|drug
DDI-DrugBank.d382.s3|147-154|CYP3A4.|brand
DDI-DrugBank.d382.s4|29-35|induce|drug
DDI-DrugBank.d382.s4|59-67|warfarin|drug
DDI-DrugBank.d382.s4|115-122|CYP2C9.|brand
DDI-DrugBank.d382.s5|0-16|Coadministration|drug
DDI-DrugBank.d382.s5|99-106|CYP2C9,|brand
DDI-DrugBank.d382.s5|115-125|phenytoin,|drug
DDI-DrugBank.d382.s6|26-34|interact|drug
DDI-DrugBank.d382.s6|74-88|P-glycoprotein|drug
DDI-DrugBank.d382.s6|133-144|interaction|drug
DDI-DrugBank.d382.s6|164-171|digoxin|drug
DDI-DrugBank.d382.s6|177-185|clinical|drug
DDI-DrugBank.d382.s6|191-202|interaction|drug
DDI-DrugBank.d382.s7|0-5|5-HT3|brand
DDI-DrugBank.d382.s7|22-30|clinical|drug
DDI-DrugBank.d382.s7|36-47|interaction|drug
DDI-DrugBank.d382.s7|81-91|clinically|drug
DDI-DrugBank.d382.s7|117-133|pharmacokinetics|drug
DDI-DrugBank.d382.s8|3-11|clinical|drug
DDI-DrugBank.d382.s8|20-31|interaction|drug
DDI-DrugBank.d382.s9|0-16|Corticosteroids:|group
DDI-DrugBank.d382.s9|71-76|125mg|drug_n
DDI-DrugBank.d382.s9|96-110|coadministered|drug
DDI-DrugBank.d382.s9|195-209|coadministered|drug
DDI-DrugBank.d382.s9|246-255|increased|drug
DDI-DrugBank.d382.s9|284-290|CYP3A4|brand
DDI-DrugBank.d382.s9|304-313|2.2-fold,|drug_n
DDI-DrugBank.d382.s10|73-87|coadministered|drug
DDI-DrugBank.d382.s10|116-125|exposures|group
DDI-DrugBank.d382.s10|160-168|obtained|drug
DDI-DrugBank.d382.s11|32-44|administered|drug
DDI-DrugBank.d382.s11|48-56|clinical|drug
DDI-DrugBank.d382.s13|86-95|increased|drug
DDI-DrugBank.d382.s13|129-135|CYP3A4|brand
DDI-DrugBank.d382.s13|150-159|1.34-fold|drug_n
DDI-DrugBank.d382.s13|176-184|2.5-fold|drug_n
DDI-DrugBank.d382.s13|223-237|coadministered|drug
DDI-DrugBank.d382.s13|238-251|intravenously|drug
DDI-DrugBank.d382.s14|152-166|coadministered|drug
DDI-DrugBank.d382.s14|194-203|exposures|group
DDI-DrugBank.d382.s14|243-251|obtained|drug
DDI-DrugBank.d382.s15|0-9|Warfarin:|drug
DDI-DrugBank.d382.s15|12-18|single|drug
DDI-DrugBank.d382.s15|19-25|125-mg|drug_n
DDI-DrugBank.d382.s15|49-61|administered|drug
DDI-DrugBank.d382.s15|152-160|warfarin|drug
DDI-DrugBank.d382.s16|77-85|warfarin|drug
DDI-DrugBank.d382.s16|86-96|determined|drug
DDI-DrugBank.d382.s16|135-147|S(-)warfarin|drug
DDI-DrugBank.d382.s16|151-157|CYP2C9|brand
DDI-DrugBank.d382.s16|227-238|prothrombin|drug
DDI-DrugBank.d382.s16|323-329|dosing|drug
DDI-DrugBank.d382.s17|23-31|warfarin|drug
DDI-DrugBank.d382.s17|45-56|prothrombin|drug
DDI-DrugBank.d382.s17|62-67|(INR)|brand
DDI-DrugBank.d382.s17|103-109|2-week|drug_n
DDI-DrugBank.d382.s17|148-157|following|drug
DDI-DrugBank.d382.s17|158-168|initiation|drug
DDI-DrugBank.d382.s17|176-181|3-day|drug_n
DDI-DrugBank.d382.s18|107-118|tolbutamide|drug
DDI-DrugBank.d382.s18|122-128|CYP2C9|brand
DDI-DrugBank.d382.s18|197-203|single|drug
DDI-DrugBank.d382.s18|212-223|tolbutamide|drug
DDI-DrugBank.d382.s18|235-248|admini,stered|drug
DDI-DrugBank.d382.s18|269-283|administration|drug
DDI-DrugBank.d382.s18|291-296|3-day|drug_n
DDI-DrugBank.d382.s19|5-20|contraceptives:|group
DDI-DrugBank.d382.s19|72-78|100-mg|drug_n
DDI-DrugBank.d382.s19|100-113|contraceptive|group
DDI-DrugBank.d382.s19|114-124|containing|group
DDI-DrugBank.d382.s19|135-142|ethinyl|drug
DDI-DrugBank.d382.s19|165-179|norethindrone,|drug
DDI-DrugBank.d382.s19|201-208|ethinyl|drug
DDI-DrugBank.d382.s19|252-265|norethindrone|drug
DDI-DrugBank.d382.s20|32-46|contraceptives|group
DDI-DrugBank.d382.s20|47-53|during|drug
DDI-DrugBank.d382.s20|54-68|administration|drug
DDI-DrugBank.d382.s21|11-16|3-day|drug_n
DDI-DrugBank.d382.s21|69-83|contraceptives|group
DDI-DrugBank.d382.s21|140-153|contraception|group
DDI-DrugBank.d382.s22|22-31|increased|drug
DDI-DrugBank.d382.s22|66-72|CYP3A4|brand
DDI-DrugBank.d382.s22|87-95|2.3-fold|drug_n
DDI-DrugBank.d382.s22|109-117|3.3-fold|drug_n
DDI-DrugBank.d382.s22|135-141|single|drug
DDI-DrugBank.d382.s22|155-164|midazolam|drug
DDI-DrugBank.d382.s22|174-188|coadministered|drug
DDI-DrugBank.d382.s23|25-34|increased|drug
DDI-DrugBank.d382.s23|60-69|midazolam|drug
DDI-DrugBank.d382.s23|79-94|benzodiazepines|drug
DDI-DrugBank.d382.s23|111-117|CYP3A4|brand
DDI-DrugBank.d382.s23|168-183|coadministering|drug
DDI-DrugBank.d382.s24|3-10|another|drug
DDI-DrugBank.d382.s24|22-33|intravenous|drug
DDI-DrugBank.d382.s24|34-48|administration|drug
DDI-DrugBank.d382.s24|138-147|midazolam|drug
DDI-DrugBank.d382.s24|179-193|administration|drug
DDI-DrugBank.d382.s24|201-206|3-day|drug_n
DDI-DrugBank.d382.s25|11-20|increased|drug
DDI-DrugBank.d382.s25|32-41|midazolam|drug
DDI-DrugBank.d382.s25|83-92|midazolam|drug
DDI-DrugBank.d382.s25|125-131|dosing|drug
DDI-DrugBank.d382.s26|34-44|clinically|drug
DDI-DrugBank.d382.s27|11-20|midazolam|drug
DDI-DrugBank.d382.s27|63-72|baseline.|drug
DDI-DrugBank.d382.s28|30-46|pharmacokinefics|drug
DDI-DrugBank.d382.s29|30-37|CYP3A4;|brand
DDI-DrugBank.d382.s30|11-27|coadministration|drug
DDI-DrugBank.d382.s30|58-65|inhibit|drug
DDI-DrugBank.d382.s30|66-72|CYP3A4|brand
DDI-DrugBank.d382.s30|96-105|increased|drug
DDI-DrugBank.d382.s31|26-40|administration|drug
DDI-DrugBank.d382.s31|67-73|CYP3A4|brand
DDI-DrugBank.d382.s31|74-84|inhibitors|drug
DDI-DrugBank.d382.s31|92-105|ketoconazole,|drug
DDI-DrugBank.d382.s31|106-119|itraconazole,|drug
DDI-DrugBank.d382.s31|132-147|troleandomycin,|drug
DDI-DrugBank.d382.s31|148-163|clarithromycin,|drug
DDI-DrugBank.d382.s31|175-186|nelfinavir)|drug
DDI-DrugBank.d382.s32|17-23|CYP3A4|brand
DDI-DrugBank.d382.s32|24-34|inhibitors|drug
DDI-DrugBank.d382.s32|63-69|2-fold|drug_n
DDI-DrugBank.d382.s32|70-78|increase|drug
DDI-DrugBank.d382.s32|131-145|administration|drug
DDI-DrugBank.d382.s33|30-37|CYP3A4;|brand
DDI-DrugBank.d382.s34|11-27|coadministration|drug
DDI-DrugBank.d382.s34|67-73|induce|drug
DDI-DrugBank.d382.s34|74-80|CYP3A4|brand
DDI-DrugBank.d382.s34|97-106|rifampin,|drug
DDI-DrugBank.d382.s34|107-121|carbamazepine,|drug
DDI-DrugBank.d382.s34|122-132|phenytoin)|drug
DDI-DrugBank.d382.s35|0-13|Ketoconazole:|drug
DDI-DrugBank.d382.s35|21-27|single|drug
DDI-DrugBank.d382.s35|28-34|125-mg|drug_n
DDI-DrugBank.d382.s35|58-70|administered|drug
DDI-DrugBank.d382.s36|0-13|Ketoconazole:|drug
DDI-DrugBank.d382.s36|21-27|single|drug
DDI-DrugBank.d382.s36|28-34|125-mg|drug_n
DDI-DrugBank.d382.s36|58-70|administered|drug
DDI-DrugBank.d382.s36|84-90|10-day|drug_n
DDI-DrugBank.d382.s36|116-129|ketoconazole,|drug
DDI-DrugBank.d382.s36|139-145|CYP3A4|brand
DDI-DrugBank.d382.s36|146-156|inhibitor,|drug
DDI-DrugBank.d382.s36|179-188|increased|drug
DDI-DrugBank.d382.s36|203-209|5-fold|drug_n
DDI-DrugBank.d382.s36|223-231|terminal|drug
DDI-DrugBank.d382.s36|256-265|increased|drug
DDI-DrugBank.d382.s36|280-287|3-fold.|drug_n
DDI-DrugBank.d382.s37|12-26|administration|drug
DDI-DrugBank.d382.s37|53-59|CYP3A4|brand
DDI-DrugBank.d382.s37|60-70|inhibitors|drug
DDI-DrugBank.d382.s38|0-9|Rifampin:|drug
DDI-DrugBank.d382.s38|17-23|single|drug
DDI-DrugBank.d382.s38|24-30|375-mg|drug_n
DDI-DrugBank.d382.s38|54-66|administered|drug
DDI-DrugBank.d382.s38|80-86|14-day|drug_n
DDI-DrugBank.d382.s38|112-121|rifampin,|drug
DDI-DrugBank.d382.s38|131-137|CYP3A4|brand
DDI-DrugBank.d382.s38|138-146|inducer,|drug
DDI-DrugBank.d382.s38|193-200|11-fold|drug_n
DDI-DrugBank.d382.s38|214-222|terminal|drug
DDI-DrugBank.d382.s38|257-264|3-fold.|drug_n
DDI-DrugBank.d382.s39|0-16|Coadministration|drug
DDI-DrugBank.d382.s39|47-53|induce|drug
DDI-DrugBank.d382.s39|54-60|CYP3A4|brand
DDI-DrugBank.d382.s40|11-23|interactions|drug
DDI-DrugBank.d382.s41|59-73|administration|drug
DDI-DrugBank.d382.s41|235-241|2-fold|drug_n
DDI-DrugBank.d382.s41|242-250|increase|drug
DDI-DrugBank.d382.s41|288-296|1.7-fold|drug_n
DDI-DrugBank.d382.s41|297-305|increase|drug
DDI-DrugBank.d382.s42|6-21|pharmacokinetic|drug
DDI-DrugBank.d382.s42|48-58|clinically|drug
DDI-DrugBank.d382.s42|59-69|meaningful|drug
DDI-DrugBank.d382.s42|106-114|pressure|group
DDI-DrugBank.d382.s42|136-143|induced|drug
DDI-DrugBank.d382.s43|0-11|Paroxetine:|drug
DDI-DrugBank.d382.s43|12-28|Coadministration|drug
DDI-DrugBank.d382.s43|151-161|paroxetine|drug
DDI-DrugBank.d382.s43|285-296|paroxetine.|drug
DDI-DrugBank.d143.s0|71-79|(CYP450)|brand
DDI-DrugBank.d143.s0|128-136|(CYP3A4)|brand
DDI-DrugBank.d143.s0|141-148|CYP2C8.|brand
DDI-DrugBank.d143.s1|4-10|CYP3A4|brand
DDI-DrugBank.d143.s1|54-65|intestines.|drug
DDI-DrugBank.d143.s2|34-43|inhibitor|drug
DDI-DrugBank.d143.s2|47-54|CYP3A4.|brand
DDI-DrugBank.d143.s3|44-56|interactions|drug
DDI-DrugBank.d143.s3|106-116|inhibitors|drug
DDI-DrugBank.d143.s3|120-128|inducers|drug
DDI-DrugBank.d143.s3|132-139|CYP3A4.|brand
DDI-DrugBank.d143.s4|49-61|interactions|drug
DDI-DrugBank.d143.s4|157-169|interactions|drug
DDI-DrugBank.d143.s4|180-192|anticipated.|group
DDI-DrugBank.d143.s5|87-103|antiarrhythmics.|group
DDI-DrugBank.d143.s6|103-112|measured.|group
DDI-DrugBank.d143.s7|77-89|interactions|drug
DDI-DrugBank.d143.s7|154-166|administered|drug
DDI-DrugBank.d143.s7|173-188|discontinuation|group
DDI-DrugBank.d143.s8|0-5|Since|drug
DDI-DrugBank.d143.s8|36-42|CYP3A4|brand
DDI-DrugBank.d143.s8|47-54|CYP2C8,|brand
DDI-DrugBank.d143.s8|77-84|inhibit|drug
DDI-DrugBank.d143.s8|134-142|increase|drug
DDI-DrugBank.d143.s9|18-25|include|drug
DDI-DrugBank.d143.s9|30-40|following:|drug
DDI-DrugBank.d143.s9|71-81|inhibitors|drug
DDI-DrugBank.d143.s9|95-102|inhibit|drug
DDI-DrugBank.d143.s9|103-109|CYP3A4|brand
DDI-DrugBank.d143.s9|113-120|varying|drug
DDI-DrugBank.d143.s10|29-35|taking|drug
DDI-DrugBank.d143.s10|58-67|indinavir|drug
DDI-DrugBank.d143.s10|105-114|increases|drug
DDI-DrugBank.d143.s13|0-10|Monitoring|drug
DDI-DrugBank.d143.s13|46-57|measurement|group
DDI-DrugBank.d143.s13|92-98|during|drug
DDI-DrugBank.d143.s13|120-129|inhibitor|drug
DDI-DrugBank.d143.s14|0-9|Histamine|drug
DDI-DrugBank.d143.s14|26-36|Cimetidine|drug
DDI-DrugBank.d143.s14|37-45|inhibits|drug
DDI-DrugBank.d143.s14|46-52|CYP3A4|brand
DDI-DrugBank.d143.s14|61-69|increase|drug
DDI-DrugBank.d143.s15|63-72|increased|drug
DDI-DrugBank.d143.s15|112-121|resulting|drug
DDI-DrugBank.d143.s15|125-134|increased|drug
DDI-DrugBank.d143.s16|37-43|during|drug
DDI-DrugBank.d143.s17|5-16|information|drug
DDI-DrugBank.d143.s17|43-51|changing|drug
DDI-DrugBank.d143.s17|57-68|intravenous|drug
DDI-DrugBank.d143.s18|24-31|certain|drug
DDI-DrugBank.d143.s18|32-38|CYP450|brand
DDI-DrugBank.d143.s18|48-57|including|drug
DDI-DrugBank.d143.s18|58-65|CYP1A2,|brand
DDI-DrugBank.d143.s18|66-73|CYP2C9,|brand
DDI-DrugBank.d143.s18|74-81|CYP2D6,|brand
DDI-DrugBank.d143.s18|86-93|CYP3A4.|brand
DDI-DrugBank.d143.s19|5-15|inhibition|drug
DDI-DrugBank.d143.s19|108-114|CYP450|brand
DDI-DrugBank.d143.s20|26-37|interaction|drug
DDI-DrugBank.d143.s20|38-45|include|drug
DDI-DrugBank.d143.s20|50-60|following:|drug
DDI-DrugBank.d143.s20|81-93|Cyclosporine|drug
DDI-DrugBank.d143.s20|94-101|(CYP3A4|brand
DDI-DrugBank.d143.s20|113-125|administered|drug
DDI-DrugBank.d143.s20|129-140|combination|drug
DDI-DrugBank.d143.s20|238-250|cyclosporine|drug
DDI-DrugBank.d143.s20|251-260|resulting|drug
DDI-DrugBank.d143.s20|273-284|creatinine,|drug
DDI-DrugBank.d143.s20|314-327|cyclosporine.|drug
DDI-DrugBank.d143.s21|30-41|Simvastatin|drug
DDI-DrugBank.d143.s21|42-49|(CYP3A4|brand
DDI-DrugBank.d143.s21|64-75|combination|drug
DDI-DrugBank.d143.s22|49-58|receiving|drug
DDI-DrugBank.d143.s22|59-66|digoxin|drug
DDI-DrugBank.d143.s22|76-90|administration|drug
DDI-DrugBank.d143.s22|134-142|increase|drug
DDI-DrugBank.d143.s22|152-159|digoxin|drug
DDI-DrugBank.d143.s22|217-225|clinical|drug
DDI-DrugBank.d143.s23|36-43|digoxin|drug
DDI-DrugBank.d143.s23|44-53|increases|drug
DDI-DrugBank.d143.s23|64-71|digoxin|drug
DDI-DrugBank.d143.s24|3-17|administration|drug
DDI-DrugBank.d143.s24|133-146|discontinued.|group
DDI-DrugBank.d143.s25|26-36|continued,|group
DDI-DrugBank.d143.s25|104-112|clinical|drug
DDI-DrugBank.d143.s26|43-52|digitoxin|drug
DDI-DrugBank.d143.s26|53-67|administration|drug
DDI-DrugBank.d143.s27|23-37|antiarrhythmic|group
DDI-DrugBank.d143.s27|53-63|quinidine,|drug
DDI-DrugBank.d143.s27|64-77|procainamide,|drug
DDI-DrugBank.d143.s27|96-106|phenytoin,|drug
DDI-DrugBank.d143.s28|32-41|increased|drug
DDI-DrugBank.d143.s28|65-75|quinidine,|drug
DDI-DrugBank.d143.s28|76-89|procainamide,|drug
DDI-DrugBank.d143.s28|94-103|phenytoin|drug
DDI-DrugBank.d143.s28|104-110|during|drug
DDI-DrugBank.d143.s29|0-9|Phenytoin|drug
DDI-DrugBank.d143.s30|36-45|quinidine|drug
DDI-DrugBank.d143.s30|46-55|increases|drug
DDI-DrugBank.d143.s30|56-65|quinidine|drug
DDI-DrugBank.d143.s31|36-48|procainamide|drug
DDI-DrugBank.d143.s31|74-83|increases|drug
DDI-DrugBank.d143.s31|109-121|procainamide|drug
DDI-DrugBank.d143.s31|135-147|procainamide|drug
DDI-DrugBank.d143.s32|0-9|Quinidine|drug
DDI-DrugBank.d143.s32|14-26|procainamide|drug
DDI-DrugBank.d143.s32|79-91|administered|drug
DDI-DrugBank.d143.s33|17-27|flecainide|drug
DDI-DrugBank.d143.s33|50-58|increase|drug
DDI-DrugBank.d143.s34|31-41|flecainide|drug
DDI-DrugBank.d143.s34|82-94|administered|drug
DDI-DrugBank.d143.s35|22-36|antiarrhythmic|group
DDI-DrugBank.d143.s35|52-61|initiated|drug
DDI-DrugBank.d143.s35|102-113|monitoring.|drug
DDI-DrugBank.d143.s36|0-11|Combination|drug
DDI-DrugBank.d143.s36|37-51|antiarrhythmic|group
DDI-DrugBank.d143.s36|97-113|life-threatening|drug
DDI-DrugBank.d143.s36|146-158|incompletely|drug
DDI-DrugBank.d143.s36|175-181|single|drug
DDI-DrugBank.d143.s36|191-203|incompletely|drug
DDI-DrugBank.d143.s37|0-6|During|drug
DDI-DrugBank.d143.s37|66-78|administered|drug
DDI-DrugBank.d143.s38|4-13|continued|group
DDI-DrugBank.d143.s38|33-47|antiarrhythmic|group
DDI-DrugBank.d143.s38|132-147|discontinuation|group
DDI-DrugBank.d143.s38|148-158|ordinarily|drug
DDI-DrugBank.d143.s39|20-30|continued,|group
DDI-DrugBank.d143.s39|200-210|continued.|group
DDI-DrugBank.d143.s40|54-68|antiarrhythmic|group
DDI-DrugBank.d143.s40|82-89|initial|drug
DDI-DrugBank.d143.s41|70-79|receiving|drug
DDI-DrugBank.d143.s41|91-99|blocking|drug
DDI-DrugBank.d143.s41|114-126|propranolol,|drug
DDI-DrugBank.d143.s41|129-135|CYP3A4|brand
DDI-DrugBank.d143.s41|136-146|inhibitor)|drug
DDI-DrugBank.d143.s41|150-157|calcium|drug
DDI-DrugBank.d143.s41|198-204|CYP3A4|brand
DDI-DrugBank.d143.s41|233-239|CYP3A4|brand
DDI-DrugBank.d143.s41|240-250|inhibitor)|drug
DDI-DrugBank.d143.s41|304-309|sinus|drug
DDI-DrugBank.d143.s42|29-37|continue|group
DDI-DrugBank.d143.s42|55-64|insertion|drug
DDI-DrugBank.d143.s42|119-124|sinus|drug
DDI-DrugBank.d143.s43|32-45|warfarin-type|drug
DDI-DrugBank.d143.s43|46-53|(CYP2C9|brand
DDI-DrugBank.d143.s43|58-64|CYP3A4|brand
DDI-DrugBank.d143.s43|76-89|anticoagulant|group
DDI-DrugBank.d143.s43|133-142|receiving|drug
DDI-DrugBank.d143.s43|189-198|bleeding.|drug
DDI-DrugBank.d143.s44|0-5|Since|drug
DDI-DrugBank.d143.s44|22-36|administration|drug
DDI-DrugBank.d143.s44|40-48|warfarin|drug
DDI-DrugBank.d143.s44|65-74|increases|drug
DDI-DrugBank.d143.s44|79-90|prothrombin|drug
DDI-DrugBank.d143.s44|139-152|anticoagulant|group
DDI-DrugBank.d143.s44|201-212|prothrombin|drug
DDI-DrugBank.d143.s45|78-89|stimulating|drug
DDI-DrugBank.d143.s45|107-113|CYP3A4|brand
DDI-DrugBank.d143.s45|122-133|induction).|drug
DDI-DrugBank.d143.s47|26-37|interaction|drug
DDI-DrugBank.d143.s47|38-45|include|drug
DDI-DrugBank.d143.s47|50-60|following:|drug
DDI-DrugBank.d143.s47|74-82|Rifampin|drug
DDI-DrugBank.d143.s47|95-102|inducer|drug
DDI-DrugBank.d143.s47|106-113|CYP3A4.|brand
DDI-DrugBank.d143.s48|0-14|Administration|drug
DDI-DrugBank.d143.s48|18-26|rifampin|drug
DDI-DrugBank.d143.s49|18-27|including|drug
DDI-DrugBank.d143.s49|88-95|induces|drug
DDI-DrugBank.d143.s49|96-103|CYP3A4.|brand
DDI-DrugBank.d143.s50|0-5|Since|drug
DDI-DrugBank.d143.s50|36-43|CYP3A4,|brand
DDI-DrugBank.d143.s50|111-120|receiving|drug
DDI-DrugBank.d143.s51|15-27|interactions|drug
DDI-DrugBank.d143.s51|54-61|(CYP3A4|brand
DDI-DrugBank.d143.s51|76-87|combination|drug
DDI-DrugBank.d143.s52|0-5|Sinus|drug
DDI-DrugBank.d143.s52|60-71|combination|drug
DDI-DrugBank.d143.s52|77-86|lidocaine|drug
DDI-DrugBank.d143.s52|87-94|(CYP3A4|brand
DDI-DrugBank.d143.s53|0-8|Seizure,|group
DDI-DrugBank.d143.s53|25-34|increased|drug
DDI-DrugBank.d143.s53|35-44|lidocaine|drug
DDI-DrugBank.d143.s53|96-110|administration|drug
DDI-DrugBank.d143.s53|114-125|intravenous|drug
DDI-DrugBank.d143.s54|41-47|CYP2D6|brand
DDI-DrugBank.d143.s54|52-59|CYP3A4.|brand
DDI-DrugBank.d143.s55|11-19|inhibits|drug
DDI-DrugBank.d143.s55|20-27|CYP2D6.|brand
DDI-DrugBank.d143.s56|0-14|Cholestyramine|drug
DDI-DrugBank.d143.s56|15-24|increases|drug
DDI-DrugBank.d143.s56|39-50|elimination|drug
DDI-DrugBank.d143.s57|0-12|Disopyramide|drug
DDI-DrugBank.d143.s57|13-22|increases|drug
DDI-DrugBank.d143.s58|0-17|Fluoroquinolones,|drug
DDI-DrugBank.d143.s58|18-27|macrolide|drug
DDI-DrugBank.d143.s58|28-40|antibiotics,|group
DDI-DrugBank.d143.s58|45-51|azoles|drug
DDI-DrugBank.d143.s59|78-84|taking|drug
DDI-DrugBank.d143.s59|101-118|fluoroquinolones,|drug
DDI-DrugBank.d143.s59|119-128|macrolide|drug
DDI-DrugBank.d143.s59|129-141|antibiotics,|group
DDI-DrugBank.d143.s59|145-151|azoles|drug
DDI-DrugBank.d143.s59|157-169|administered|drug
DDI-DrugBank.d143.s60|35-47|interactions|drug
DDI-DrugBank.d143.s60|90-104|administration|drug
DDI-DrugBank.d143.s60|110-122|propranolol,|drug
DDI-DrugBank.d143.s62|19-31|interactions|drug
DDI-DrugBank.d143.s62|80-94|administration|drug
DDI-DrugBank.d143.s62|117-127|phenytoin,|drug
DDI-DrugBank.d143.s63|130-135|being|drug
DDI-DrugBank.d143.s63|159-164|I.V.,|brand
DDI-DrugBank.d143.s63|234-242|increase|drug
DDI-DrugBank.d143.s64|83-95|experiencing|drug
DDI-DrugBank.d143.s64|140-149|receiving|drug
DDI-DrugBank.d143.s64|162-172|diuretics.|group
DDI-DrugBank.d407.s0|44-55|interaction|drug
DDI-DrugBank.d407.s1|34-43|interfere|drug
DDI-DrugBank.d407.s1|96-106|antibodies|group
DDI-DrugBank.d130.s0|0-10|Lincomycin|drug
DDI-DrugBank.d130.s0|48-56|blocking|drug
DDI-DrugBank.d130.s0|119-127|blocking|drug
DDI-DrugBank.d130.s1|52-61|receiving|drug
DDI-DrugBank.d130.s2|19-29|lincomycin|drug
DDI-DrugBank.d130.s2|34-46|erythromycin|drug
DDI-DrugBank.d130.s3|20-28|clinical|drug
DDI-DrugBank.d130.s3|71-83|administered|drug
DDI-MedLine.d106.s0|0-8|Clinical|drug
DDI-MedLine.d106.s0|25-33|warfarin|drug
DDI-MedLine.d106.s0|34-46|interactions|drug
DDI-MedLine.d106.s1|4-14|intensity,|drug
DDI-MedLine.d106.s1|45-58|anticoagulant|group
DDI-MedLine.d106.s1|59-71|interference|drug
DDI-MedLine.d106.s1|126-133|hydrate|drug
DDI-MedLine.d106.s1|171-183|investigated|drug
DDI-MedLine.d106.s1|199-208|receiving|drug
DDI-MedLine.d106.s1|209-217|coumarin|drug
DDI-MedLine.d106.s2|25-39|individualized|drug
DDI-MedLine.d106.s2|60-68|warfarin|drug
DDI-MedLine.d106.s2|123-131|control.|group
DDI-MedLine.d106.s3|0-11|Prothrombin|drug
DDI-MedLine.d106.s3|23-31|measured|group
DDI-MedLine.d106.s3|50-56|during|drug
DDI-MedLine.d106.s4|14-24|inhibition|drug
DDI-MedLine.d106.s4|38-44|during|drug
DDI-MedLine.d106.s4|49-63|administration|drug
DDI-MedLine.d106.s5|35-46|prothrombin|drug
DDI-MedLine.d106.s5|60-66|during|drug
DDI-MedLine.d106.s5|89-96|hydrate|drug
DDI-MedLine.d106.s6|17-29|glutethimide|drug
DDI-MedLine.d106.s6|44-56|administered|drug
DDI-MedLine.d106.s6|69-78|receiving|drug
DDI-MedLine.d106.s6|79-87|coumarin|drug
DDI-MedLine.d106.s7|49-59|decreasing|drug
DDI-MedLine.d106.s7|60-69|according|drug
DDI-MedLine.d106.s8|8-15|hydrate|drug
DDI-MedLine.d106.s8|33-41|interact|drug
DDI-MedLine.d106.s8|72-84|administered|drug
DDI-MedLine.d106.s8|85-98|anticoagulant|group
DDI-MedLine.d106.s8|129-139|clinically|drug
DDI-MedLine.d106.s9|29-36|hydrate|drug
DDI-MedLine.d106.s9|61-73|administered|drug
DDI-MedLine.d106.s9|111-122|prothrombin|drug
DDI-MedLine.d106.s9|128-138|monitoring|drug
DDI-MedLine.d106.s9|139-145|during|drug
DDI-MedLine.d106.s9|151-164|anticoagulant|group
DDI-DrugBank.d254.s0|62-69|opioids|group
DDI-DrugBank.d254.s0|112-124|potentiating|drug
DDI-DrugBank.d254.s0|138-147|INAPSINE.|brand
DDI-DrugBank.d254.s1|52-60|INAPSINE|brand
DDI-DrugBank.d254.s2|0-9|Following|drug
DDI-DrugBank.d254.s2|14-28|administration|drug
DDI-DrugBank.d254.s2|32-41|INAPSINE,|brand
DDI-MedLine.d23.s0|15-23|ketamine|drug
DDI-MedLine.d23.s0|63-72|tolerance|drug
DDI-MedLine.d23.s1|29-38|tolerance|drug
DDI-MedLine.d23.s1|65-74|ketamine,|drug
DDI-MedLine.d23.s1|120-127|ouabain|drug
DDI-MedLine.d23.s1|213-221|ouabain,|drug
DDI-MedLine.d23.s1|227-235|ketamine|drug
DDI-MedLine.d23.s2|24-31|induced|drug
DDI-MedLine.d23.s2|35-42|ouabain|drug
DDI-MedLine.d23.s2|70-75|sinus|drug
DDI-MedLine.d23.s2|83-92|following|drug
DDI-MedLine.d23.s2|93-107|administration|drug
DDI-MedLine.d23.s2|120-129|ketamine,|drug
DDI-MedLine.d23.s2|158-172|administration|drug
DDI-DrugBank.d534.s0|15-26|interaction|drug
DDI-MedLine.d71.s0|9-22|interactions:|drug
DDI-MedLine.d71.s1|0-14|Acetylcysteine|drug
DDI-MedLine.d71.s1|15-27|interference|drug
DDI-MedLine.d71.s1|33-38|urine|drug
DDI-MedLine.d71.s2|92-101|interfere|drug
DDI-MedLine.d71.s2|107-115|clinical|drug
DDI-MedLine.d71.s4|46-56|interferes|drug
DDI-MedLine.d71.s4|115-127|interpreted.|drug
DDI-MedLine.d71.s5|52-64|interference|drug
DDI-MedLine.d71.s5|68-82|acetylcysteine|drug
DDI-MedLine.d71.s5|92-97|urine|drug
DDI-MedLine.d71.s5|182-192|evaluating|drug
DDI-DrugBank.d260.s0|36-44|interact|drug
DDI-DrugBank.d260.s0|113-127|acetaminophen,|drug
DDI-DrugBank.d260.s0|128-138|acyclovir,|drug
DDI-DrugBank.d260.s0|139-161|angiotensin-converting|drug
DDI-DrugBank.d260.s0|169-180|inhibitors,|drug
DDI-DrugBank.d260.s0|181-195|aminosalicylic|drug
DDI-DrugBank.d260.s0|216-232|benzodiazepines,|drug
DDI-DrugBank.d260.s0|271-282|famotidine,|drug
DDI-DrugBank.d260.s0|308-325|anti-inflammatory|group
DDI-DrugBank.d260.s0|334-347|theophylline,|drug
DDI-DrugBank.d260.s0|352-364|zidovudine).|drug
DDI-DrugBank.d260.s2|0-10|Zidovudine|drug
DDI-DrugBank.d260.s2|40-52|discontinued|group
DDI-DrugBank.d260.s2|78-92|coadministered|drug
DDI-DrugBank.d260.s2|123-130|VISTIDE|brand
DDI-DrugBank.d260.s2|131-140|infusion.|drug
DDI-DrugBank.d260.s3|33-47|administration|drug
DDI-DrugBank.d260.s3|51-58|VISTIDE|brand
DDI-DrugBank.d260.s3|104-115|intravenous|drug
DDI-DrugBank.d260.s3|116-131|aminoglycosides|drug
DDI-DrugBank.d260.s3|139-150|tobramycin,|drug
DDI-DrugBank.d260.s3|151-162|gentamicin,|drug
DDI-DrugBank.d260.s3|167-177|amikacin),|drug
DDI-DrugBank.d260.s3|178-190|amphotericin|drug
DDI-DrugBank.d260.s3|205-216|intravenous|drug
DDI-DrugBank.d260.s3|217-229|pentamidine,|drug
DDI-DrugBank.d260.s3|230-241|vancomycin,|drug
DDI-DrugBank.d260.s3|260-277|anti-inflammatory|group
DDI-DrugBank.d260.s3|289-305|contraindicated.|group
DDI-DrugBank.d260.s4|20-32|discontinued|group
DDI-DrugBank.d260.s4|62-70|starting|drug
DDI-DrugBank.d260.s4|84-92|VISTIDE.|brand
DDI-DrugBank.d175.s0|26-34|Diuretic|group
DDI-DrugBank.d175.s0|56-65|diuretics|group
DDI-DrugBank.d175.s0|95-103|diuretic|group
DDI-DrugBank.d175.s0|125-136|instituted,|drug
DDI-DrugBank.d175.s0|263-271|pressure|group
DDI-DrugBank.d175.s0|280-286|within|drug
DDI-DrugBank.d175.s0|308-317|receiving|drug
DDI-DrugBank.d175.s0|322-329|initial|drug
DDI-DrugBank.d175.s1|61-70|minimized|drug
DDI-DrugBank.d175.s1|81-94|discontinuing|group
DDI-DrugBank.d175.s1|99-107|diuretic|group
DDI-DrugBank.d175.s1|111-121|increasing|drug
DDI-DrugBank.d175.s1|131-137|intake|drug
DDI-DrugBank.d175.s1|170-180|initiation|drug
DDI-DrugBank.d175.s1|237-247|initiating|drug
DDI-DrugBank.d175.s2|15-22|provide|drug
DDI-DrugBank.d175.s2|75-82|initial|drug
DDI-DrugBank.d175.s3|57-63|supine|drug
DDI-DrugBank.d175.s3|103-114|intravenous|drug
DDI-DrugBank.d175.s3|115-123|infusion|drug
DDI-DrugBank.d175.s3|134-141|saline.|drug
DDI-DrugBank.d175.s4|45-61|contraindication|group
DDI-DrugBank.d175.s4|132-140|pressure|group
DDI-DrugBank.d175.s4|145-154|increased|drug
DDI-DrugBank.d175.s5|7-13|Having|drug
DDI-DrugBank.d175.s5|108-117|receiving|drug
DDI-DrugBank.d175.s5|138-145|failure|group
DDI-DrugBank.d175.s6|11-24|nitroglycerin|drug
DDI-DrugBank.d175.s6|70-77|angina)|drug
DDI-DrugBank.d175.s6|93-99|having|drug
DDI-DrugBank.d175.s6|145-157|discontinued|group
DDI-DrugBank.d175.s6|165-173|starting|drug
DDI-DrugBank.d175.s7|11-17|during|drug
DDI-DrugBank.d175.s7|59-71|administered|drug
DDI-DrugBank.d175.s8|7-14|Causing|drug
DDI-DrugBank.d175.s8|15-20|Renin|drug
DDI-DrugBank.d175.s8|69-85|antihypertensive|group
DDI-DrugBank.d175.s8|104-109|renin|drug
DDI-DrugBank.d175.s9|13-22|diuretics|group
DDI-DrugBank.d175.s9|30-40|thiazides)|group
DDI-DrugBank.d175.s9|58-87|renin-angiotensin-aldosterone|drug
DDI-DrugBank.d175.s10|7-16|Affecting|drug
DDI-DrugBank.d175.s10|100-110|supporting|drug
DDI-DrugBank.d175.s10|117-125|pressure|group
DDI-DrugBank.d175.s10|138-147|receiving|drug
DDI-DrugBank.d175.s10|172-182|diuretics.|group
DDI-DrugBank.d175.s11|18-27|affecting|drug
DDI-DrugBank.d175.s11|67-75|blocking|drug
DDI-DrugBank.d175.s11|104-112|blocking|drug
DDI-DrugBank.d175.s12|16-24|blocking|drug
DDI-DrugBank.d175.s12|48-64|antihypertensive|group
DDI-DrugBank.d175.s13|7-17|Increasing|drug
DDI-DrugBank.d175.s13|24-33|Potassium|drug
DDI-DrugBank.d175.s13|34-39|Since|drug
DDI-DrugBank.d175.s13|103-112|potassium|drug
DDI-DrugBank.d175.s14|0-17|Potassium-sparing|drug
DDI-DrugBank.d175.s14|18-27|diuretics|group
DDI-DrugBank.d175.s14|82-91|potassium|drug
DDI-DrugBank.d175.s14|176-181|since|drug
DDI-DrugBank.d175.s14|213-221|increase|drug
DDI-DrugBank.d175.s14|231-241|potassium.|drug
DDI-DrugBank.d175.s15|17-27|containing|group
DDI-DrugBank.d175.s15|28-37|potassium|drug
DDI-DrugBank.d175.s16|25-38|Prostaglandin|drug
DDI-DrugBank.d175.s16|75-87|indomethacin|drug
DDI-DrugBank.d175.s16|103-119|antihypertensive|group
DDI-DrugBank.d175.s16|168-173|renin|drug
DDI-DrugBank.d175.s17|19-36|anti-inflammatory|group
DDI-DrugBank.d175.s17|51-59|aspirin)|brand
DDI-DrugBank.d175.s18|0-8|Lithium:|drug
DDI-DrugBank.d175.s18|25-32|lithium|drug
DDI-DrugBank.d175.s18|56-63|lithium|drug
DDI-DrugBank.d175.s18|104-113|receiving|drug
DDI-DrugBank.d175.s18|126-133|lithium|drug
DDI-DrugBank.d175.s18|142-151|inhibitor|drug
DDI-DrugBank.d175.s19|22-37|coad-ministered|drug
DDI-DrugBank.d175.s19|64-74|monitoring|drug
DDI-DrugBank.d175.s19|84-91|lithium|drug
DDI-DrugBank.d175.s20|5-13|diuretic|group
DDI-DrugBank.d175.s20|35-43|increase|drug
DDI-DrugBank.d175.s20|56-63|lithium|drug
DDI-DrugBank.d175.s21|86-101|pharmacokinetic|drug
DDI-DrugBank.d175.s21|102-119|captopril-digoxin|drug
DDI-DrugBank.d175.s21|120-131|interaction|drug
DDI-DrugBank.d175.s22|5-15|Diuretics:|group
DDI-DrugBank.d175.s22|16-26|Furosemide|drug
DDI-DrugBank.d175.s22|27-39|administered|drug
DDI-DrugBank.d175.s22|87-103|pharmacokinetics|drug
DDI-DrugBank.d175.s23|0-12|Allopurinol:|drug
DDI-DrugBank.d175.s23|66-81|pharmacokinetic|drug
DDI-DrugBank.d175.s23|82-93|interaction|drug
DDI-DrugBank.d175.s23|122-133|allopurinol|drug
DDI-DrugBank.d175.s23|139-151|administered|drug
DDI-DrugBank.d175.s24|70-75|urine|drug
DDI-DrugBank.d461.s0|74-85|antianxiety|group
DDI-MedLine.d138.s0|20-28|oxytocin|drug
DDI-MedLine.d138.s0|33-45|antidiuretic|group
DDI-MedLine.d138.s0|126-135|lactating|drug
DDI-MedLine.d138.s1|45-53|oxytocin|drug
DDI-MedLine.d138.s1|58-69|vasopressin|drug
DDI-MedLine.d138.s1|160-169|lactating|drug
DDI-MedLine.d138.s2|44-52|oxytocin|drug
DDI-MedLine.d138.s2|73-84|vasopressin|drug
DDI-MedLine.d138.s3|20-30|principles|drug
DDI-MedLine.d138.s3|82-94|investigated|drug
DDI-MedLine.d138.s3|166-172|drink.|drug
DDI-DrugBank.d422.s0|0-23|Catecholamine-depleting|drug
DDI-DrugBank.d422.s0|37-47|reserpine,|drug
DDI-DrugBank.d422.s0|97-105|blocking|drug
DDI-DrugBank.d422.s1|35-44|BREVIBLOC|brand
DDI-DrugBank.d422.s1|65-78|catecholamine|drug
DDI-DrugBank.d422.s2|11-22|interaction|drug
DDI-DrugBank.d422.s2|31-40|BREVIBLOC|brand
DDI-DrugBank.d422.s2|45-53|warfarin|drug
DDI-DrugBank.d422.s2|78-92|administration|drug
DDI-DrugBank.d422.s2|96-105|BREVIBLOC|brand
DDI-DrugBank.d422.s2|110-118|warfarin|drug
DDI-DrugBank.d422.s2|134-142|warfarin|drug
DDI-DrugBank.d422.s3|0-9|BREVIBLOC|brand
DDI-DrugBank.d422.s3|65-74|warfarin,|drug
DDI-DrugBank.d422.s3|104-114|clinically|drug
DDI-DrugBank.d422.s4|5-12|digoxin|drug
DDI-DrugBank.d422.s4|17-26|BREVIBLOC|brand
DDI-DrugBank.d422.s4|46-58|administered|drug
DDI-DrugBank.d422.s4|59-72|intravenously|drug
DDI-DrugBank.d422.s4|107-113|10-20%|drug_n
DDI-DrugBank.d422.s4|114-122|increase|drug
DDI-DrugBank.d422.s4|126-133|digoxin|drug
DDI-DrugBank.d422.s4|160-167|points.|drug
DDI-DrugBank.d422.s5|0-7|Digoxin|drug
DDI-DrugBank.d422.s5|23-32|BREVIBLOC|brand
DDI-DrugBank.d422.s5|33-50|pharmacokinetics.|drug
DDI-DrugBank.d422.s6|5-16|intravenous|drug
DDI-DrugBank.d422.s6|17-25|morphine|drug
DDI-DrugBank.d422.s6|30-39|BREVIBLOC|brand
DDI-DrugBank.d422.s6|59-71|administered|drug
DDI-DrugBank.d422.s6|105-113|morphine|drug
DDI-DrugBank.d422.s6|141-150|BREVIBLOC|brand
DDI-DrugBank.d422.s6|182-191|increased|drug
DDI-DrugBank.d422.s6|218-227|morphine.|drug
DDI-DrugBank.d422.s7|9-24|pharmacokinetic|drug
DDI-DrugBank.d422.s8|14-23|BREVIBLOC|brand
DDI-DrugBank.d422.s8|43-66|succinylcholine-induced|drug
DDI-DrugBank.d422.s8|114-124|undergoing|drug
DDI-DrugBank.d422.s9|39-54|succinylcholine|drug
DDI-DrugBank.d422.s9|73-83|BREVIBLOC,|brand
DDI-DrugBank.d422.s9|148-155|minutes|drug
DDI-DrugBank.d422.s9|161-169|minutes.|drug
DDI-DrugBank.d422.s10|13-25|interactions|drug
DDI-DrugBank.d422.s10|81-89|clinical|drug
DDI-DrugBank.d422.s10|102-111|BREVIBLOC|brand
DDI-DrugBank.d422.s10|156-161|being|drug
DDI-DrugBank.d422.s10|188-196|digoxin,|drug
DDI-DrugBank.d422.s10|197-206|morphine,|drug
DDI-DrugBank.d422.s10|207-222|succinylcholine|drug
DDI-DrugBank.d422.s10|226-235|warfarin.|drug
DDI-DrugBank.d422.s11|6-12|taking|drug
DDI-DrugBank.d422.s12|56-67|epinephrine|drug
DDI-DrugBank.d422.s13|33-44|considering|drug
DDI-DrugBank.d422.s13|56-65|BREVIBLOC|brand
DDI-DrugBank.d422.s14|48-57|receiving|drug
DDI-DrugBank.d422.s15|14-23|BREVIBLOC|brand
DDI-DrugBank.d422.s15|46-53|control|group
DDI-DrugBank.d422.s15|140-149|inotropic|drug
DDI-DrugBank.d422.s15|158-167|dopamine,|drug
DDI-DrugBank.d422.s15|168-180|epinephrine,|drug
DDI-DrugBank.d422.s15|185-199|norepinephrine|drug
DDI-DrugBank.d422.s15|225-233|blocking|drug
DDI-DrugBank.d422.s15|242-255|contractility|group
DDI-DrugBank.d359.s0|0-8|PEGANONE|brand
DDI-DrugBank.d359.s0|17-28|combination|drug
DDI-DrugBank.d359.s1|44-52|PEGANONE|brand
DDI-DrugBank.d359.s1|56-68|administered|drug
DDI-DrugBank.d359.s1|111-116|since|drug
DDI-DrugBank.d359.s1|117-125|paranoid|drug
DDI-DrugBank.d359.s1|154-160|during|drug
DDI-DrugBank.d359.s1|179-191|combination.|drug
DDI-DrugBank.d359.s2|10-21|interaction|drug
DDI-DrugBank.d359.s2|34-43|hydantoin|drug
DDI-DrugBank.d359.s2|44-58|antiepileptic,|group
DDI-DrugBank.d359.s2|59-69|phenytoin,|drug
DDI-DrugBank.d359.s2|78-86|coumarin|drug
DDI-DrugBank.d359.s2|87-101|anticoagulants|group
DDI-DrugBank.d359.s3|12-21|phenytoin|drug
DDI-DrugBank.d359.s3|46-54|coumarin|drug
DDI-DrugBank.d359.s3|127-135|coumarin|drug
DDI-DrugBank.d359.s3|136-150|anticoagulants|group
DDI-DrugBank.d359.s3|155-164|increased|drug
DDI-DrugBank.d359.s3|165-189|prothrombin-proconvertin|drug
DDI-DrugBank.d359.s4|16-24|coumarin|drug
DDI-DrugBank.d359.s4|25-39|anticoagulants|group
DDI-DrugBank.d359.s4|62-70|increase|drug
DDI-DrugBank.d359.s4|123-132|phenytoin|drug
DDI-DrugBank.d359.s4|136-146|inhibiting|drug
DDI-DrugBank.d359.s5|54-65|interaction|drug
DDI-DrugBank.d359.s5|74-82|ethotoin|drug
DDI-DrugBank.d359.s5|91-99|coumarin|drug
DDI-DrugBank.d359.s5|100-114|anticoagulants|group
DDI-DrugBank.d359.s6|34-47|administering|drug
DDI-DrugBank.d359.s6|48-56|PEGANONE|brand
DDI-DrugBank.d359.s6|69-78|receiving|drug
DDI-DrugBank.d359.s6|79-87|coumarin|drug
DDI-DrugBank.d359.s6|88-103|anticoagulants.|group
DDI-DrugBank.d525.s0|51-67|pharmacokinetics|drug
DDI-DrugBank.d525.s0|71-78|digoxin|drug
DDI-DrugBank.d525.s0|107-115|warfarin|drug
DDI-DrugBank.d525.s1|8-14|dosing|drug
DDI-DrugBank.d525.s1|41-47|during|drug
DDI-DrugBank.d525.s2|69-79|inhibitors|drug
DDI-DrugBank.d525.s2|83-89|CYP450|brand
DDI-DrugBank.d525.s2|149-161|ketoconazole|drug
DDI-DrugBank.d525.s2|166-178|fluconazole,|drug
DDI-DrugBank.d525.s2|186-196|inhibitors|drug
DDI-DrugBank.d525.s2|200-205|CYP3A|brand
DDI-DrugBank.d525.s2|277-294|pharmacokinetics.|drug
DDI-DrugBank.d525.s3|0-10|Ranitidine|drug
DDI-DrugBank.d525.s3|44-61|pharmacokinetics.|drug
DDI-DrugBank.d525.s4|97-105|thiazide|group
DDI-DrugBank.d525.s4|106-114|diuretic|group
DDI-DrugBank.d525.s4|115-137|(hydrochlorothiazide).|group
DDI-DrugBank.d525.s5|81-98|sustained-release|drug
DDI-DrugBank.d525.s5|99-106|calcium|drug
DDI-DrugBank.d525.s5|124-142|(sustained-release|drug
DDI-DrugBank.d525.s5|143-154|nifedipine)|drug
DDI-DrugBank.d525.s5|163-173|clinically|drug
DDI-DrugBank.d525.s5|194-207|interactions.|drug
DDI-DrugBank.d11.s0|35-44|STRATTERA|brand
DDI-DrugBank.d11.s0|55-67|administered|drug
DDI-DrugBank.d11.s0|93-98|being|drug
DDI-DrugBank.d11.s0|112-137|systemically-administered|drug
DDI-DrugBank.d11.s0|147-159|intravenous)|drug
DDI-DrugBank.d11.s0|276-285|resulting|drug
DDI-DrugBank.d11.s0|289-298|increases|drug
DDI-DrugBank.d11.s0|323-332|pressure.|group
DDI-DrugBank.d11.s1|0-6|CYP2D6|brand
DDI-DrugBank.d11.s1|7-17|inhibitors|drug
DDI-DrugBank.d11.s1|20-31|Atomoxetine|drug
DDI-DrugBank.d11.s1|64-70|CYP2D6|brand
DDI-DrugBank.d11.s1|82-103|4-hydroxyatomoxetine.|drug_n
DDI-DrugBank.d11.s2|18-28|inhibitors|drug
DDI-DrugBank.d11.s2|32-38|CYP2D6|brand
DDI-DrugBank.d11.s2|39-47|increase|drug
DDI-DrugBank.d11.s2|48-59|atomoxetine|drug
DDI-DrugBank.d11.s2|98-107|exposures|group
DDI-DrugBank.d11.s3|21-30|STRATTERA|brand
DDI-DrugBank.d11.s3|53-67|coadministered|drug
DDI-DrugBank.d11.s3|73-79|CYP2D6|brand
DDI-DrugBank.d11.s3|80-91|inhibitors,|drug
DDI-DrugBank.d11.s3|98-109|paroxetine,|drug
DDI-DrugBank.d11.s3|110-121|fluoxetine,|drug
DDI-DrugBank.d11.s3|126-136|quinidine.|drug
DDI-DrugBank.d11.s4|6-17|individuals|drug
DDI-DrugBank.d11.s4|31-41|paroxetine|drug
DDI-DrugBank.d11.s4|45-56|fluoxetine,|drug
DDI-DrugBank.d11.s4|68-79|atomoxetine|drug
DDI-DrugBank.d11.s4|103-109|8-fold|drug_n
DDI-DrugBank.d11.s4|137-143|4-fold|drug_n
DDI-DrugBank.d11.s4|157-168|atomoxetine|drug
DDI-DrugBank.d11.s5|30-46|coadministration|drug
DDI-DrugBank.d11.s5|66-76|inhibitors|drug
DDI-DrugBank.d11.s5|93-101|increase|drug
DDI-DrugBank.d11.s5|131-143|atomoxetine.|drug
DDI-DrugBank.d11.s6|54-63|pressure,|group
DDI-DrugBank.d11.s6|64-73|STRATTERA|brand
DDI-DrugBank.d430.s0|12-22|ranitidine|drug
DDI-DrugBank.d430.s1|4-12|clinical|drug
DDI-DrugBank.d430.s1|34-43|increased|drug
DDI-DrugBank.d430.s1|80-89|increases|drug
DDI-DrugBank.d430.s2|23-34|interaction|drug
DDI-DrugBank.d430.s3|9-19|containing|group
DDI-DrugBank.d430.s3|20-27|calcium|drug
DDI-DrugBank.d430.s3|70-79|interfere|drug
DDI-DrugBank.d47.s0|37-46|following|drug
DDI-DrugBank.d47.s0|57-69|administered|drug
DDI-DrugBank.d47.s0|89-96|LODOSYN|brand
DDI-DrugBank.d47.s0|151-162|combination|drug
DDI-DrugBank.d47.s1|13-22|receiving|drug
DDI-DrugBank.d47.s1|23-32|monoamine|drug
DDI-DrugBank.d47.s1|41-52|inhibitors,|drug
DDI-DrugBank.d47.s1|57-75|CONTRAINDICATIONS.|brand
DDI-DrugBank.d47.s2|0-8|Dopamine|drug
DDI-DrugBank.d47.s2|40-55|phenothiazines,|drug
DDI-DrugBank.d47.s3|51-61|Parkinsons|drug
DDI-DrugBank.d47.s3|107-116|phenytoin|drug
DDI-DrugBank.d47.s3|121-132|papaverine.|drug
DDI-DrugBank.d47.s4|9-15|taking|drug
DDI-DrugBank.d47.s4|33-40|LODOSYN|brand
DDI-DrugBank.d47.s4|76-87|combination|drug
DDI-DrugBank.d47.s6|4-12|clinical|drug
DDI-DrugBank.d47.s7|9-23|metoclopramide|drug
DDI-DrugBank.d47.s7|28-36|increase|drug
DDI-DrugBank.d47.s7|72-82|increasing|drug
DDI-DrugBank.d47.s7|91-100|emptying,|drug
DDI-DrugBank.d47.s7|101-115|metoclopramide|drug
DDI-DrugBank.d47.s7|150-157|control|group
DDI-DrugBank.d47.s7|165-173|dopamine|drug
DDI-DrugBank.d32.s0|0-13|Theophylline:|drug
DDI-DrugBank.d32.s0|50-62|administered|drug
DDI-DrugBank.d32.s0|67-73|200-mg|drug_n
DDI-DrugBank.d32.s1|9-16|morning|drug
DDI-DrugBank.d32.s1|72-78|single|drug
DDI-DrugBank.d32.s1|79-90|intravenous|drug
DDI-DrugBank.d32.s1|91-99|infusion|drug
DDI-DrugBank.d32.s1|103-115|theophylline|drug
DDI-DrugBank.d32.s2|4-20|pharmacokinetics|drug
DDI-DrugBank.d32.s2|24-36|theophylline|drug
DDI-DrugBank.d32.s3|32-48|pharmacokinetics|drug
DDI-DrugBank.d32.s3|52-64|theophylline|drug
DDI-DrugBank.d32.s3|65-77|administered|drug
DDI-DrugBank.d32.s3|98-111|investigated.|drug
DDI-DrugBank.d32.s4|0-8|Antacids|group
DDI-DrugBank.d32.s4|53-62|increased|drug
DDI-DrugBank.d32.s5|19-31|administered|drug
DDI-DrugBank.d32.s5|36-42|400-mg|drug_n
DDI-DrugBank.d32.s6|2-8|single|drug
DDI-DrugBank.d32.s7|19-29|ranitidine|drug
DDI-DrugBank.d32.s7|46-55|increased|drug
DDI-DrugBank.d32.s8|4-12|clinical|drug
DDI-DrugBank.d32.s8|32-41|increases|drug
DDI-DrugBank.d32.s9|82-94|interactions|drug
DDI-DrugBank.d32.s10|54-60|during|drug
DDI-DrugBank.d32.s10|82-97|cephalosporins.|drug
DDI-DrugBank.d32.s12|22-27|using|drug
DDI-DrugBank.d32.s12|63-72|determine|drug
DDI-DrugBank.d549.s0|62-73|interaction|drug
DDI-DrugBank.d549.s0|82-93|intravenous|drug
DDI-DrugBank.d549.s0|114-125|nifedipine,|drug
DDI-DrugBank.d549.s1|39-47|increase|drug
DDI-DrugBank.d549.s1|91-107|antihypertensive|group
DDI-DrugBank.d549.s2|0-5|Since|drug
DDI-DrugBank.d549.s2|15-23|inhibits|drug
DDI-DrugBank.d549.s2|68-77|increased|drug
DDI-DrugBank.d549.s2|86-95|bleeding,|drug
DDI-DrugBank.d549.s2|121-131|maintained|drug
DDI-DrugBank.d549.s2|135-150|anticoagulants.|group
DDI-DrugBank.d549.s3|0-6|During|drug
DDI-DrugBank.d549.s3|7-15|clinical|drug
DDI-DrugBank.d549.s3|60-75|anticoagulants,|group
DDI-DrugBank.d549.s3|76-86|diuretics,|group
DDI-DrugBank.d549.s3|107-114|calcium|drug
DDI-DrugBank.d549.s3|145-158|antipyretics,|group
DDI-DrugBank.d549.s3|172-191|antiinflammatories,|group
DDI-DrugBank.d549.s3|192-208|corticosteroids,|group
DDI-DrugBank.d549.s4|12-20|infusion|drug
DDI-DrugBank.d549.s4|54-70|pharmacokinetics|drug
DDI-DrugBank.d549.s4|74-82|digoxin.|drug
DDI-DrugBank.d549.s5|49-67|(pharmacokinetics)|drug
DDI-DrugBank.d549.s6|9-17|clinical|drug
DDI-DrugBank.d549.s6|80-88|indicate|drug
DDI-DrugBank.d549.s6|106-116|inhibition|drug
DDI-MedLine.d44.s1|17-30|intravascular|drug
DDI-MedLine.d44.s1|95-104|screening|drug
DDI-MedLine.d44.s2|83-96|determination|drug
DDI-MedLine.d44.s2|111-119|kinetics|drug
DDI-MedLine.d44.s2|207-214|59+/-11|drug_n
DDI-MedLine.d44.s2|229-241|cholesterol:|drug
DDI-MedLine.d44.s2|242-250|240+/-41|drug_n
DDI-MedLine.d44.s2|273-281|188+/-42|drug_n
DDI-MedLine.d44.s2|327-340|double-blind,|drug
DDI-MedLine.d44.s2|341-359|placebo-controlled|group
DDI-MedLine.d44.s2|371-385|administration|drug
DDI-MedLine.d44.s2|427-435|1-month.|drug_n
DDI-MedLine.d44.s3|2-9|1-month|drug_n
DDI-MedLine.d44.s3|29-37|inserted|drug
DDI-MedLine.d44.s4|14-27|intravenously|drug
DDI-MedLine.d44.s4|28-36|injected|drug
DDI-MedLine.d44.s4|85-100|14C-cholesteryl|drug_n
DDI-MedLine.d44.s4|101-107|oleate|drug
DDI-MedLine.d44.s4|112-123|3H-triolein|drug_n
DDI-MedLine.d44.s4|127-135|baseline|drug
DDI-MedLine.d44.s5|56-67|cholesterol|drug
DDI-MedLine.d44.s5|72-84|triglyceride|drug
DDI-MedLine.d44.s5|114-122|increase|drug
DDI-MedLine.d44.s5|136-147|lipoprotein|drug
DDI-MedLine.d44.s5|148-159|cholesterol|drug
DDI-MedLine.d44.s6|39-51|post-heparin|drug
DDI-MedLine.d44.s6|80-88|increase|drug
DDI-MedLine.d44.s6|92-107|3H-triglyceride|drug_n
DDI-MedLine.d44.s7|0-15|14C-cholesterol|drug_n
DDI-MedLine.d44.s8|105-115|indicating|drug
DDI-MedLine.d44.s8|173-179|future|group
DDI-DrugBank.d560.s0|11-21|inhibitors|drug
DDI-DrugBank.d560.s0|45-53|increase|drug
DDI-DrugBank.d560.s0|63-71|pressure|group
DDI-DrugBank.d560.s1|16-21|using|drug
DDI-DrugBank.d560.s1|32-40|inhaler,|drug
DDI-DrugBank.d560.s1|86-93|minutes|drug
DDI-DrugBank.d560.s1|101-106|using|drug
DDI-DrugBank.d560.s1|119-127|inhaler.|drug
DDI-DrugBank.d560.s2|45-55|increasing|drug
DDI-DrugBank.d58.s0|15-26|interaction|drug
DDI-DrugBank.d271.s0|22-31|resulting|drug
DDI-DrugBank.d271.s0|37-44|smoking|drug
DDI-DrugBank.d271.s0|72-80|nicotine|drug
DDI-DrugBank.d271.s0|108-124|pharmacokinetics|drug
DDI-DrugBank.d271.s0|128-135|certain|drug
DDI-DrugBank.d271.s0|179-194|antidepressants|group
DDI-DrugBank.d271.s0|199-212|theophylline.|drug
DDI-DrugBank.d271.s1|103-111|smoking.|drug
DDI-DrugBank.d154.s0|4-20|coadministration|drug
DDI-DrugBank.d154.s0|24-31|aspirin|brand
DDI-DrugBank.d154.s0|93-101|increase|drug
DDI-DrugBank.d154.s0|161-173|hydroxylated|drug
DDI-DrugBank.d154.s0|192-198|urine.|drug
DDI-DrugBank.d154.s1|26-37|interaction|drug
DDI-DrugBank.d154.s1|61-68|aspirin|brand
DDI-DrugBank.d154.s1|98-107|induction|drug
DDI-DrugBank.d154.s1|151-158|albumin|drug
DDI-DrugBank.d154.s1|159-166|binding|drug
DDI-DrugBank.d154.s2|79-87|obtained|drug
DDI-DrugBank.d154.s2|93-100|aspirin|brand
DDI-DrugBank.d154.s2|119-126|aspirin|brand
DDI-DrugBank.d154.s2|127-136|increases|drug
DDI-DrugBank.d154.s3|8-22|administration|drug
DDI-DrugBank.d154.s3|56-64|inducer,|drug
DDI-DrugBank.d154.s5|60-68|affinity|drug
DDI-DrugBank.d154.s5|73-81|albumin,|drug
DDI-DrugBank.d154.s5|106-113|binding|drug
DDI-DrugBank.d154.s5|146-153|albumin|drug
DDI-DrugBank.d154.s5|187-199|interaction.|drug
DDI-DrugBank.d154.s7|9-18|receiving|drug
DDI-DrugBank.d154.s7|19-30|hydantoins,|drug
DDI-DrugBank.d154.s7|48-61|sulfonylureas|group
DDI-DrugBank.d154.s7|85-94|increased|drug
DDI-DrugBank.d154.s8|12-21|receiving|drug
DDI-DrugBank.d154.s8|22-35|coumarin-type|drug
DDI-DrugBank.d154.s8|36-51|anticoagulants,|group
DDI-DrugBank.d154.s8|104-115|prothrombin|drug
DDI-DrugBank.d154.s9|9-18|receiving|drug
DDI-DrugBank.d154.s10|69-79|diuretics.|group
DDI-DrugBank.d154.s11|12-21|receiving|drug
DDI-DrugBank.d113.s0|0-9|Warfarin:|drug
DDI-DrugBank.d113.s0|24-30|sodium|drug
DDI-DrugBank.d113.s0|54-63|warfarin.|drug
DDI-DrugBank.d113.s1|30-36|sodium|drug
DDI-DrugBank.d113.s1|59-68|receiving|drug
DDI-DrugBank.d113.s1|69-78|warfarin,|drug
DDI-DrugBank.d113.s1|93-101|warfarin|drug
DDI-DrugBank.d113.s1|161-172|prothrombin|drug
DDI-DrugBank.d113.s2|0-8|Aspirin:|brand
DDI-DrugBank.d113.s2|20-34|administration|drug
DDI-DrugBank.d113.s2|38-45|aspirin|brand
DDI-DrugBank.d113.s2|70-76|sodium|drug
DDI-DrugBank.d113.s2|104-113|competing|drug
DDI-DrugBank.d113.s2|118-133|protein-binding|drug
DDI-DrugBank.d113.s3|4-11|urinary|drug
DDI-DrugBank.d113.s3|39-45|sodium|drug
DDI-DrugBank.d113.s3|63-71|aspirin,|brand
DDI-DrugBank.d113.s3|72-82|indicating|drug
DDI-DrugBank.d113.s3|110-116|sodium|drug
DDI-DrugBank.d113.s4|14-20|sodium|drug
DDI-DrugBank.d113.s5|50-64|administration|drug
DDI-DrugBank.d113.s6|29-43|administration|drug
DDI-DrugBank.d113.s6|60-73|hydrochloride|drug
DDI-DrugBank.d113.s6|127-134|sodium.|drug
DDI-DrugBank.d113.s7|0-9|Antacids:|group
DDI-DrugBank.d113.s7|22-36|administration|drug
DDI-DrugBank.d113.s7|40-48|aluminum|drug
DDI-DrugBank.d113.s7|53-62|magnesium|drug
DDI-DrugBank.d113.s7|63-73|hydroxides|drug
DDI-DrugBank.d113.s7|83-92|interfere|drug
DDI-DrugBank.d113.s7|126-133|sodium.|drug
DDI-DrugBank.d249.s0|0-8|Aspirin:|brand
DDI-DrugBank.d249.s0|21-35|administration|drug
DDI-DrugBank.d249.s0|54-61|aspirin|brand
DDI-DrugBank.d249.s0|122-129|binding|drug
DDI-DrugBank.d249.s0|136-142|during|drug
DDI-DrugBank.d249.s0|159-173|administration|drug
DDI-DrugBank.d249.s0|177-185|aspirin,|brand
DDI-DrugBank.d249.s0|186-195|resulting|drug
DDI-DrugBank.d249.s1|59-67|interact|drug
DDI-DrugBank.d249.s1|73-87|anticoagulants|group
DDI-DrugBank.d249.s1|95-103|warfarin|drug
DDI-DrugBank.d249.s1|152-157|since|drug
DDI-DrugBank.d249.s1|158-170|interactions|drug
DDI-DrugBank.d249.s2|8-22|prostaglandins|drug
DDI-DrugBank.d249.s2|142-151|including|drug
DDI-DrugBank.d249.s2|168-176|warfarin|drug
DDI-DrugBank.d249.s2|192-202|monitoring|drug
DDI-DrugBank.d249.s2|221-228|certain|drug
DDI-DrugBank.d249.s2|253-266|anticoagulant|group
DDI-DrugBank.d249.s3|0-8|Digoxin,|drug
DDI-DrugBank.d249.s3|23-36|Cyclosporine:|drug
DDI-DrugBank.d249.s3|85-99|prostaglandins|drug
DDI-DrugBank.d249.s3|104-112|increase|drug
DDI-DrugBank.d249.s3|129-136|certain|drug
DDI-DrugBank.d249.s4|28-36|increase|drug
DDI-DrugBank.d249.s4|61-68|digoxin|drug
DDI-DrugBank.d249.s4|90-98|increase|drug
DDI-DrugBank.d249.s4|99-111|cyclosporine|drug
DDI-DrugBank.d249.s5|13-18|begin|drug
DDI-DrugBank.d249.s5|19-25|taking|drug
DDI-DrugBank.d249.s5|44-52|increase|drug
DDI-DrugBank.d249.s5|88-93|NSAID|brand
DDI-DrugBank.d249.s5|100-106|taking|drug
DDI-DrugBank.d249.s5|107-115|digoxin,|drug
DDI-DrugBank.d249.s5|133-145|cyclosporine|drug
DDI-DrugBank.d249.s7|15-23|digoxin,|drug
DDI-DrugBank.d249.s8|0-8|Lithium:|drug
DDI-DrugBank.d249.s8|30-37|lithium|drug
DDI-DrugBank.d249.s8|58-67|increases|drug
DDI-DrugBank.d249.s8|68-75|lithium|drug
DDI-DrugBank.d249.s9|12-18|taking|drug
DDI-DrugBank.d249.s9|34-41|lithium|drug
DDI-DrugBank.d249.s9|57-64|lithium|drug
DDI-DrugBank.d249.s11|38-47|marketing|drug
DDI-DrugBank.d249.s11|86-93|insulin|drug
DDI-DrugBank.d249.s13|161-168|insulin|drug
DDI-DrugBank.d249.s14|0-10|Diuretics:|group
DDI-DrugBank.d249.s14|43-50|inhibit|drug
DDI-DrugBank.d249.s14|67-77|diuretics.|group
DDI-DrugBank.d249.s15|27-44|potassium-sparing|drug
DDI-DrugBank.d249.s15|45-54|diuretics|group
DDI-DrugBank.d249.s15|78-87|increased|drug
DDI-DrugBank.d249.s15|94-103|potassium|drug
DDI-DrugBank.d249.s16|41-58|(7-10/interaction|drug
DDI-DrugBank.d249.s16|83-97|administration|drug
DDI-DrugBank.d249.s16|101-114|azathioprine,|drug
DDI-DrugBank.d249.s16|121-133|chloroquine,|drug
DDI-DrugBank.d249.s16|134-150|D-penicillamine,|drug
DDI-DrugBank.d249.s16|165-177|doxycycline,|drug
DDI-DrugBank.d249.s16|181-190|digitoxin|drug
DDI-DrugBank.d249.s17|106-115|following|drug
DDI-DrugBank.d249.s17|120-130|initiation|drug
DDI-DrugBank.d249.s18|0-7|Protein|drug
DDI-DrugBank.d249.s18|8-15|Binding|drug
DDI-DrugBank.d249.s18|37-47|interferes|drug
DDI-DrugBank.d249.s18|48-57|minimally|drug
DDI-DrugBank.d249.s18|81-88|protein|drug
DDI-DrugBank.d249.s18|89-96|binding|drug
DDI-DrugBank.d249.s18|132-141|binding),|drug
DDI-DrugBank.d249.s18|185-194|binding),|drug
DDI-DrugBank.d249.s18|198-207|warfarin.|drug
DDI-DrugBank.d249.s19|0-17|Benzylpenicillin,|drug
DDI-DrugBank.d249.s19|18-29|ampicillin,|drug
DDI-DrugBank.d249.s19|30-40|oxacillin,|drug
DDI-DrugBank.d249.s19|41-59|chlortetracycline,|drug
DDI-DrugBank.d249.s19|60-72|doxycycline,|drug
DDI-DrugBank.d249.s19|73-85|cephalothin,|drug
DDI-DrugBank.d249.s19|86-99|erythromycin,|drug
DDI-DrugBank.d249.s19|104-120|sulfamethoxazole|drug
DDI-DrugBank.d249.s19|129-138|influence|drug
DDI-DrugBank.d249.s19|155-162|protein|drug
DDI-DrugBank.d249.s19|163-170|binding|drug
DDI-DrugBank.d249.s20|74-83|increases|drug
DDI-DrugBank.d249.s20|130-138|bleeding|drug
DDI-DrugBank.d249.s20|152-160|thrombin|drug
DDI-DrugBank.d249.s20|161-169|clotting|drug
DDI-DrugBank.d249.s20|183-194|fibrinogen,|drug
DDI-DrugBank.d249.s21|37-48|prothrombin|drug
DDI-DrugBank.d249.s21|61-75|thromboplastin|drug
DDI-DrugBank.d249.s22|64-74|instances,|drug
DDI-DrugBank.d249.s22|107-117|clinically|drug
DDI-DrugBank.d249.s23|16-29|prostaglandin|drug
DDI-DrugBank.d249.s23|41-51|inhibitor,|drug
DDI-DrugBank.d249.s23|80-87|inhibit|drug
DDI-DrugBank.d249.s23|88-101|prostaglandin|drug
DDI-DrugBank.d249.s23|112-121|interfere|drug
DDI-DrugBank.d437.s0|0-10|Amprenavir|drug
DDI-DrugBank.d437.s1|0-10|Amprenavir|drug
DDI-DrugBank.d437.s1|11-19|inhibits|drug
DDI-DrugBank.d437.s1|20-27|CYP3A4.|brand
DDI-DrugBank.d437.s2|28-43|coadministering|drug
DDI-DrugBank.d437.s2|77-88|inhibitors,|drug
DDI-DrugBank.d437.s2|92-100|inducers|drug
DDI-DrugBank.d437.s2|104-111|CYP3A4,|brand
DDI-DrugBank.d437.s2|169-176|CYP3A4.|brand
DDI-DrugBank.d437.s3|0-10|Amprenavir|drug
DDI-DrugBank.d437.s3|20-27|inhibit|drug
DDI-DrugBank.d437.s3|28-35|CYP2D6,|brand
DDI-DrugBank.d437.s3|36-43|CYP1A2,|brand
DDI-DrugBank.d437.s3|44-51|CYP2C9,|brand
DDI-DrugBank.d437.s3|52-60|CYP2C19,|brand
DDI-DrugBank.d437.s3|61-68|CYP2E1,|brand
DDI-DrugBank.d437.s3|72-79|uridine|drug
DDI-DrugBank.d437.s3|104-112|(UDPGT).|brand
DDI-DrugBank.d437.s4|39-49|amprenavir|drug
DDI-DrugBank.d437.s4|101-111|inhibitors|drug
DDI-DrugBank.d437.s4|124-133|receiving|drug
DDI-DrugBank.d437.s4|160-165|using|drug
DDI-DrugBank.d437.s5|0-9|Indinavir|drug
DDI-DrugBank.d437.s7|0-10|Saquinavir|drug
DDI-DrugBank.d437.s7|49-58|increased|drug
DDI-DrugBank.d437.s8|0-10|Nelfinavir|drug
DDI-DrugBank.d437.s8|49-58|increased|drug
DDI-DrugBank.d437.s9|11-27|Coadministration|drug
DDI-DrugBank.d437.s9|31-41|amprenavir|drug
DDI-DrugBank.d437.s10|0-16|Coadministration|drug
DDI-DrugBank.d437.s10|20-30|amprenavir|drug
DDI-DrugBank.d437.s10|74-91|historicalcontrol|group
DDI-DrugBank.d437.s10|148-158|amprenavir|drug
DDI-DrugBank.d437.s10|170-178|andCmin,|drug
DDI-DrugBank.d437.s11|0-10|Amprenavir|drug
DDI-DrugBank.d437.s11|17-26|inhibitor|drug
DDI-DrugBank.d437.s11|46-52|C.P.A.|brand
DDI-DrugBank.d437.s11|92-104|administered|drug
DDI-DrugBank.d437.s11|159-166|windows|drug
DDI-DrugBank.d437.s11|190-197|CYP3A4.|brand
DDI-DrugBank.d437.s12|57-73|life-threatening|drug
DDI-DrugBank.d437.s12|79-92|interactions.|drug
DDI-DrugBank.d437.s13|22-33|combination|drug
DDI-DrugBank.d437.s13|37-47|Amprenavir|drug
DDI-DrugBank.d437.s13|61-70|ritonavir|drug
DDI-DrugBank.d437.s13|110-121|cholesterol|drug
DDI-DrugBank.d437.s13|146-152|(AST),|brand
DDI-DrugBank.d437.s13|162-167|(ALT)|brand
DDI-DrugBank.d437.s14|23-30|testing|drug
DDI-DrugBank.d437.s14|61-71|initiating|drug
DDI-DrugBank.d437.s14|72-83|combination|drug
DDI-DrugBank.d437.s14|97-107|Amprenavir|drug
DDI-DrugBank.d437.s14|112-121|ritonavir|drug
DDI-DrugBank.d437.s14|138-147|intervals|drug
DDI-DrugBank.d437.s14|158-166|clinical|drug
DDI-DrugBank.d437.s14|242-248|during|drug
DDI-DrugBank.d437.s15|18-29|information|drug
DDI-DrugBank.d437.s15|30-40|concerning|drug
DDI-DrugBank.d437.s15|136-147|prescribing|drug
DDI-DrugBank.d437.s15|148-159|information|drug
DDI-DrugBank.d437.s15|164-170|NORVIR|brand
DDI-DrugBank.d269.s0|14-21|CYP2D6;|brand
DDI-DrugBank.d269.s1|21-33|debrisoquin:|drug
DDI-DrugBank.d269.s1|73-83|inhibitors|drug
DDI-DrugBank.d269.s1|87-93|CYP2D6|brand
DDI-DrugBank.d269.s1|103-113|quinidine,|drug
DDI-DrugBank.d269.s1|114-125|fluoxetine,|drug
DDI-DrugBank.d269.s1|126-137|paroxetine,|drug
DDI-DrugBank.d269.s1|215-223|increase|drug
DDI-DrugBank.d269.s2|42-50|clinical|drug
DDI-DrugBank.d269.s2|113-122|dizziness|drug
DDI-DrugBank.d269.s2|123-129|during|drug
DDI-DrugBank.d269.s2|155-164|resulting|drug
DDI-DrugBank.d269.s2|170-182|vasodilating|drug
DDI-DrugBank.d269.s2|227-237|a-blocking|drug
DDI-DrugBank.d269.s3|0-23|Catecholamine-depleting|drug
DDI-DrugBank.d269.s3|41-47|taking|drug
DDI-DrugBank.d269.s3|65-75|b-blocking|drug
DDI-DrugBank.d269.s3|115-129|catecholamines|drug
DDI-DrugBank.d269.s3|137-146|reserpine|drug
DDI-DrugBank.d269.s3|151-160|monoamine|drug
DDI-DrugBank.d269.s3|169-180|inhibitors)|drug
DDI-DrugBank.d269.s4|0-10|Clonidine:|drug
DDI-DrugBank.d269.s4|23-37|administration|drug
DDI-DrugBank.d269.s4|41-50|clonidine|drug
DDI-DrugBank.d269.s4|68-78|b-blocking|drug
DDI-DrugBank.d269.s4|105-120|blood-pressure-|group
DDI-DrugBank.d269.s4|125-144|heart-rate-lowering|drug
DDI-DrugBank.d269.s5|44-54|b-blocking|drug
DDI-DrugBank.d269.s5|70-79|clonidine|drug
DDI-DrugBank.d269.s5|89-100|terminated,|drug
DDI-DrugBank.d269.s5|105-115|b-blocking|drug
DDI-DrugBank.d269.s5|132-144|discontinued|group
DDI-DrugBank.d269.s6|0-9|Clonidine|drug
DDI-DrugBank.d269.s6|30-42|discontinued|group
DDI-DrugBank.d269.s6|75-85|decreasing|drug
DDI-DrugBank.d269.s7|0-13|Cyclosporine:|drug
DDI-DrugBank.d269.s7|21-30|increases|drug
DDI-DrugBank.d269.s7|46-58|cyclosporine|drug
DDI-DrugBank.d269.s7|88-97|following|drug
DDI-DrugBank.d269.s7|98-108|initiation|drug
DDI-DrugBank.d269.s7|165-174|suffering|drug
DDI-DrugBank.d269.s8|38-50|cyclosporine|drug
DDI-DrugBank.d269.s8|81-89|maintain|drug
DDI-DrugBank.d269.s8|90-102|cyclosporine|drug
DDI-DrugBank.d269.s8|118-124|within|drug
DDI-DrugBank.d269.s8|161-170|remainder|drug
DDI-DrugBank.d269.s9|42-54|cyclosporine|drug
DDI-DrugBank.d269.s10|12-27|interindividual|drug
DDI-DrugBank.d269.s10|96-108|cyclosporine|drug
DDI-DrugBank.d269.s10|151-161|initiation|drug
DDI-DrugBank.d269.s10|205-217|cyclosporine|drug
DDI-DrugBank.d269.s11|0-8|Digoxin:|drug
DDI-DrugBank.d269.s11|9-16|Digoxin|drug
DDI-DrugBank.d269.s11|36-45|increased|drug
DDI-DrugBank.d269.s11|64-71|digoxin|drug
DDI-DrugBank.d269.s11|91-103|administered|drug
DDI-DrugBank.d269.s12|5-12|digoxin|drug
DDI-DrugBank.d269.s12|17-22|COREG|brand
DDI-DrugBank.d269.s13|11-20|increased|drug
DDI-DrugBank.d269.s13|21-31|monitoring|drug
DDI-DrugBank.d269.s13|35-42|digoxin|drug
DDI-DrugBank.d269.s13|63-74|initiating,|drug
DDI-DrugBank.d269.s13|75-85|adjusting,|drug
DDI-DrugBank.d269.s13|89-102|discontinuing|group
DDI-DrugBank.d269.s13|103-109|COREG.|brand
DDI-DrugBank.d269.s14|47-55|Rifampin|drug
DDI-DrugBank.d269.s15|0-10|Cimetidine|drug
DDI-DrugBank.d269.s15|11-20|increased|drug
DDI-DrugBank.d269.s16|0-7|Calcium|drug
DDI-DrugBank.d269.s16|128-133|COREG|brand
DDI-DrugBank.d269.s16|137-152|co-administered|drug
DDI-DrugBank.d269.s17|26-36|b-blocking|drug
DDI-DrugBank.d269.s17|52-57|COREG|brand
DDI-DrugBank.d269.s17|67-79|administered|drug
DDI-DrugBank.d269.s17|92-99|calcium|drug
DDI-DrugBank.d269.s17|190-198|pressure|group
DDI-DrugBank.d269.s18|0-7|Insulin|drug
DDI-DrugBank.d269.s18|43-53|b-blocking|drug
DDI-DrugBank.d269.s18|81-101|blood-sugar-reducing|drug
DDI-DrugBank.d269.s18|112-119|insulin|drug
DDI-DrugBank.d269.s19|23-29|taking|drug
DDI-DrugBank.d269.s19|30-37|insulin|drug
DDI-DrugBank.d269.s19|69-79|monitoring|drug
DDI-MedLine.d59.s1|86-105|[(14)C]aminopyrine.|drug
DDI-MedLine.d59.s3|121-131|inhibitors|drug
DDI-MedLine.d59.s3|142-149|protein|drug
DDI-MedLine.d59.s3|150-156|kinase|drug
DDI-MedLine.d59.s3|162-172|calmodulin|drug
DDI-MedLine.d59.s3|173-179|kinase|drug
DDI-MedLine.d59.s4|0-12|Cytochalasin|drug
DDI-MedLine.d59.s4|142-152|histamine-|drug
DDI-MedLine.d59.s4|187-193|within|drug
DDI-MedLine.d59.s5|0-12|Cytochalasin|drug
DDI-MedLine.d59.s5|15-24|inhibited|drug
DDI-MedLine.d59.s5|50-63|intracellular|drug
DDI-MedLine.d59.s5|99-107|increase|drug
DDI-MedLine.d59.s6|29-41|cytochalasin|drug
DDI-MedLine.d59.s6|65-73|inositol|drug
DDI-MedLine.d59.s6|74-93|1,4,5-trisphosphate|drug_n
DDI-MedLine.d59.s6|162-172|containing|group
DDI-MedLine.d59.s6|225-235|suggesting|drug
DDI-MedLine.d59.s7|6-14|findings|drug
DDI-MedLine.d59.s7|28-41|intracellular|drug
DDI-MedLine.d59.s7|60-71|cholinergic|drug
DDI-MedLine.d59.s7|100-111|determining|drug
DDI-MedLine.d59.s7|180-188|coupling|drug
DDI-MedLine.d59.s7|234-244|maintained|drug
DDI-MedLine.d59.s7|248-253|actin|drug
DDI-MedLine.d139.s0|41-49|incisive|drug
DDI-MedLine.d139.s0|50-62|neuroleptics|drug
DDI-MedLine.d139.s0|78-90|monitoring];|drug
DDI-MedLine.d139.s0|116-122|during|drug
DDI-MedLine.d139.s0|173-185|neuroleptics|drug
DDI-MedLine.d139.s1|60-69|seemingly|drug
DDI-MedLine.d139.s2|48-60|neuroleptics|drug
DDI-MedLine.d139.s2|72-86|inappropriate,|drug
DDI-MedLine.d139.s2|87-92|being|drug
DDI-MedLine.d139.s3|8-17|improving|drug
DDI-MedLine.d139.s3|75-87|neuroleptics|drug
DDI-DrugBank.d88.s0|26-34|aluminum|drug
DDI-DrugBank.d88.s0|35-45|hydroxide-|drug
DDI-DrugBank.d88.s0|50-59|magnesium|drug
DDI-DrugBank.d88.s0|60-80|hydroxide-containing|group
DDI-DrugBank.d88.s0|106-122|pharmacokinetics|drug
DDI-DrugBank.d88.s0|126-138|capecitabine|drug
DDI-DrugBank.d88.s0|143-155|investigated|drug
DDI-DrugBank.d88.s1|18-26|increase|drug
DDI-DrugBank.d88.s1|55-67|capecitabine|drug
DDI-DrugBank.d88.s1|87-96|(5-DFCR);|brand
DDI-DrugBank.d88.s2|47-55|(5-DFUR,|brand
DDI-DrugBank.d88.s2|65-71|FBAL).|brand
DDI-DrugBank.d88.s3|0-8|Coumarin|drug
DDI-DrugBank.d88.s3|62-70|bleeding|drug
DDI-DrugBank.d88.s3|102-108|taking|drug
DDI-DrugBank.d88.s3|109-121|capecitabine|drug
DDI-DrugBank.d88.s3|141-160|coumarin-derivative|drug
DDI-DrugBank.d88.s3|161-175|anticoagulants|group
DDI-DrugBank.d88.s3|184-192|warfarin|drug
DDI-DrugBank.d88.s4|9-15|taking|drug
DDI-DrugBank.d88.s4|16-35|coumarin-derivative|drug
DDI-DrugBank.d88.s4|36-50|anticoagulants|group
DDI-DrugBank.d88.s4|70-82|capecitabine|drug
DDI-DrugBank.d88.s4|168-173|INR).|brand
DDI-DrugBank.d88.s5|0-11|Leucovorin:|drug
DDI-DrugBank.d88.s5|33-47|5-fluorouracil|drug_n
DDI-DrugBank.d88.s5|51-60|increased|drug
DDI-DrugBank.d88.s5|97-108|leucovorin.|drug
DDI-DrugBank.d88.s6|48-59|dehydration|drug
DDI-DrugBank.d88.s6|99-108|receiving|drug
DDI-DrugBank.d88.s6|116-126|leucovorin|drug
DDI-DrugBank.d568.s0|102-113|combination|drug
DDI-DrugBank.d568.s0|135-141|acting|drug
DDI-DrugBank.d568.s1|19-26|LEXAPRO|brand
DDI-DrugBank.d568.s1|94-102|clinical|drug
DDI-DrugBank.d568.s1|181-187|taking|drug
DDI-DrugBank.d568.s1|188-195|LEXAPRO|brand
DDI-DrugBank.d568.s2|0-9|Monoamine|drug
DDI-DrugBank.d568.s3|46-54|Aspirin,|brand
DDI-DrugBank.d568.s3|55-64|Warfarin,|drug
DDI-DrugBank.d568.s4|0-9|Serotonin|drug
DDI-DrugBank.d568.s5|31-43|case-control|group
DDI-DrugBank.d568.s5|139-148|interfere|drug
DDI-DrugBank.d568.s5|154-163|serotonin|drug
DDI-DrugBank.d568.s5|201-217|gastrointestinal|drug
DDI-DrugBank.d568.s5|218-226|bleeding|drug
DDI-DrugBank.d568.s5|269-274|NSAID|brand
DDI-DrugBank.d568.s5|278-285|aspirin|brand
DDI-DrugBank.d568.s5|310-319|bleeding.|drug
DDI-DrugBank.d568.s6|81-89|LEXAPRO.|brand
DDI-DrugBank.d568.s7|0-10|Cimetidine|drug
DDI-DrugBank.d568.s7|83-91|combined|drug
DDI-DrugBank.d568.s7|92-106|administration|drug
DDI-DrugBank.d568.s7|121-131|cimetidine|drug
DDI-DrugBank.d568.s7|158-166|increase|drug
DDI-DrugBank.d568.s8|4-12|clinical|drug
DDI-DrugBank.d568.s8|35-43|findings|drug
DDI-DrugBank.d568.s9|0-7|Digoxin|drug
DDI-DrugBank.d568.s9|80-88|combined|drug
DDI-DrugBank.d568.s9|89-103|administration|drug
DDI-DrugBank.d568.s9|122-129|digoxin|drug
DDI-DrugBank.d568.s9|130-137|(single|drug
DDI-DrugBank.d568.s9|185-201|pharmacokinetics|drug
DDI-DrugBank.d568.s9|226-234|digoxin.|drug
DDI-DrugBank.d568.s10|0-7|Lithium|drug
DDI-DrugBank.d568.s10|10-26|Coadministration|drug
DDI-DrugBank.d568.s10|77-84|lithium|drug
DDI-DrugBank.d568.s10|143-159|pharmacokinetics|drug
DDI-DrugBank.d568.s10|177-185|lithium.|drug
DDI-DrugBank.d568.s11|21-28|lithium|drug
DDI-DrugBank.d568.s11|91-98|lithium|drug
DDI-DrugBank.d568.s11|132-140|clinical|drug
DDI-DrugBank.d568.s12|8-15|lithium|drug
DDI-DrugBank.d568.s12|103-110|LEXAPRO|brand
DDI-DrugBank.d568.s12|115-122|lithium|drug
DDI-DrugBank.d568.s12|127-142|coadministered.|drug
DDI-DrugBank.d568.s13|0-8|Pimozide|drug
DDI-DrugBank.d568.s13|27-37|controlled|group
DDI-DrugBank.d568.s13|47-53|single|drug
DDI-DrugBank.d568.s13|62-70|pimozide|drug
DDI-DrugBank.d568.s13|76-91|co-administered|drug
DDI-DrugBank.d568.s13|178-186|increase|drug
DDI-DrugBank.d568.s13|238-246|pimozide|drug
DDI-DrugBank.d568.s15|38-49|interaction|drug
DDI-DrugBank.d568.s16|35-48|postmarketing|drug
DDI-DrugBank.d568.s16|57-67|describing|drug
DDI-DrugBank.d568.s16|111-125|incoordination|drug
DDI-DrugBank.d568.s16|126-135|following|drug
DDI-DrugBank.d568.s16|159-168|serotonin|drug
DDI-DrugBank.d568.s16|178-187|inhibitor|drug
DDI-DrugBank.d568.s16|188-194|(SSRI)|brand
DDI-DrugBank.d568.s17|61-72|fluoxetine,|drug
DDI-DrugBank.d568.s17|73-85|fluvoxamine,|drug
DDI-DrugBank.d568.s17|86-97|paroxetine,|drug
DDI-DrugBank.d568.s17|98-109|sertraline,|drug
DDI-DrugBank.d568.s17|139-149|clinically|drug
DDI-DrugBank.d568.s18|0-12|Theophylline|drug
DDI-DrugBank.d568.s18|15-23|Combined|drug
DDI-DrugBank.d568.s18|24-38|administration|drug
DDI-DrugBank.d568.s18|93-99|CYP1A2|brand
DDI-DrugBank.d568.s18|110-122|theophylline|drug
DDI-DrugBank.d568.s18|123-130|(single|drug
DDI-DrugBank.d568.s18|166-182|pharmacokinetics|drug
DDI-DrugBank.d568.s18|186-199|theophylline.|drug
DDI-DrugBank.d568.s19|14-26|theophylline|drug
DDI-DrugBank.d568.s19|34-50|pharmacokinetics|drug
DDI-DrugBank.d568.s20|0-8|Warfarin|drug
DDI-DrugBank.d568.s20|11-25|Administration|drug
DDI-DrugBank.d568.s20|89-105|pharmacokinetics|drug
DDI-DrugBank.d568.s20|109-118|warfarin,|drug
DDI-DrugBank.d568.s20|121-127|CYP3A4|brand
DDI-DrugBank.d568.s21|0-11|Prothrombin|drug
DDI-DrugBank.d568.s21|21-30|increased|drug
DDI-DrugBank.d568.s21|42-50|clinical|drug
DDI-DrugBank.d568.s22|0-13|Carbamazepine|drug
DDI-DrugBank.d568.s22|16-24|Combined|drug
DDI-DrugBank.d568.s22|25-39|administration|drug
DDI-DrugBank.d568.s22|90-103|carbamazepine|drug
DDI-DrugBank.d568.s22|174-190|pharmacokinetics|drug
DDI-DrugBank.d568.s22|194-208|carbamazepine,|drug
DDI-DrugBank.d568.s22|211-217|CYP3A4|brand
DDI-DrugBank.d568.s23|68-83|enzyme-inducing|drug
DDI-DrugBank.d568.s23|98-112|carbamazepine,|drug
DDI-DrugBank.d568.s23|134-147|carbamazepine|drug
DDI-DrugBank.d568.s23|154-162|increase|drug
DDI-DrugBank.d568.s23|235-250|coadministered.|drug
DDI-DrugBank.d568.s24|0-9|Triazolam|drug
DDI-DrugBank.d568.s24|12-20|Combined|drug
DDI-DrugBank.d568.s24|21-35|administration|drug
DDI-DrugBank.d568.s24|102-108|CYP3A4|brand
DDI-DrugBank.d568.s24|119-128|triazolam|drug
DDI-DrugBank.d568.s24|129-136|(single|drug
DDI-DrugBank.d568.s24|187-203|pharmacokinetics|drug
DDI-DrugBank.d568.s25|0-12|Ketoconazole|drug
DDI-DrugBank.d568.s25|15-23|Combined|drug
DDI-DrugBank.d568.s25|24-38|administration|drug
DDI-DrugBank.d568.s25|73-85|ketoconazole|drug
DDI-DrugBank.d568.s25|125-137|ketoconazole|drug
DDI-DrugBank.d568.s25|205-221|pharmacokinetics|drug
DDI-DrugBank.d568.s26|0-9|Ritonavir|drug
DDI-DrugBank.d568.s26|12-20|Combined|drug
DDI-DrugBank.d568.s26|21-35|administration|drug
DDI-DrugBank.d568.s26|41-47|single|drug
DDI-DrugBank.d568.s26|56-65|ritonavir|drug
DDI-DrugBank.d568.s26|83-89|CYP3A4|brand
DDI-DrugBank.d568.s26|113-122|inhibitor|drug
DDI-DrugBank.d568.s26|126-133|CYP3A4,|brand
DDI-DrugBank.d568.s26|178-194|pharmacokinetics|drug
DDI-DrugBank.d568.s26|205-214|ritonavir|drug
DDI-DrugBank.d568.s27|0-6|CYP3A4|brand
DDI-DrugBank.d568.s27|11-16|-2C19|brand
DDI-DrugBank.d568.s27|47-56|indicated|drug
DDI-DrugBank.d568.s27|62-68|CYP3A4|brand
DDI-DrugBank.d568.s27|73-78|-2C19|brand
DDI-DrugBank.d568.s27|103-111|involved|drug
DDI-DrugBank.d568.s28|9-25|coadministration|drug
DDI-DrugBank.d568.s28|54-63|ritonavir|drug
DDI-DrugBank.d568.s28|83-92|inhibitor|drug
DDI-DrugBank.d568.s28|96-103|CYP3A4,|brand
DDI-DrugBank.d568.s28|137-153|pharmacokinetics|drug
DDI-DrugBank.d568.s29|64-74|inhibition|drug
DDI-DrugBank.d568.s29|80-86|single|drug
DDI-DrugBank.d568.s30|32-39|P4502D6|brand
DDI-DrugBank.d568.s30|77-87|inhibitory|drug
DDI-DrugBank.d568.s30|114-121|CYP2D6.|brand
DDI-DrugBank.d568.s31|123-129|CYP2D6|brand
DDI-DrugBank.d568.s31|163-177|administration|drug
DDI-DrugBank.d568.s31|193-203|suggesting|drug
DDI-DrugBank.d568.s31|209-226|coadministration,|drug
DDI-DrugBank.d568.s31|261-269|inhibits|drug
DDI-DrugBank.d568.s31|270-277|CYP2D6,|brand
DDI-DrugBank.d568.s31|298-308|clinically|drug
DDI-DrugBank.d568.s32|40-50|suggesting|drug
DDI-DrugBank.d568.s32|60-66|CYP2D6|brand
DDI-DrugBank.d568.s32|67-77|inhibitory|drug
DDI-DrugBank.d568.s32|109-125|coadministration|drug
DDI-DrugBank.d568.s32|185-199|antidepressant|group
DDI-DrugBank.d568.s32|200-211|desipramine|drug
DDI-DrugBank.d568.s32|212-219|(single|drug
DDI-DrugBank.d568.s32|252-259|CYP2D6,|brand
DDI-DrugBank.d568.s32|278-286|increase|drug
DDI-DrugBank.d568.s32|306-314|increase|drug
DDI-DrugBank.d568.s32|325-337|desipramine.|drug
DDI-DrugBank.d568.s33|4-12|clinical|drug
DDI-DrugBank.d568.s33|34-41|finding|drug
DDI-DrugBank.d568.s34|25-34|indicated|drug
DDI-DrugBank.d568.s34|42-58|coadministration|drug
DDI-DrugBank.d568.s34|100-107|CYP2D6.|brand
DDI-DrugBank.d568.s35|13-27|Administration|drug
DDI-DrugBank.d568.s35|41-48|LEXAPRO|brand
DDI-DrugBank.d568.s35|101-109|increase|drug
DDI-DrugBank.d568.s35|126-134|increase|drug
DDI-DrugBank.d568.s35|196-202|single|drug
DDI-DrugBank.d568.s37|0-16|Coadministration|drug
DDI-DrugBank.d568.s37|20-27|LEXAPRO|brand
DDI-DrugBank.d568.s37|50-60|clinically|drug
DDI-DrugBank.d568.s37|90-98|pressure|group
DDI-DrugBank.d568.s38|26-31|(ECT)|brand
DDI-DrugBank.d568.s38|47-55|clinical|drug
DDI-DrugBank.d568.s38|71-79|combined|drug
DDI-DrugBank.d568.s39|12-26|Administration|drug
DDI-DrugBank.d568.s39|64-69|Since|drug
DDI-DrugBank.d568.s39|165-180|coadministered.|drug
DDI-DrugBank.d466.s0|22-34|Erythromycin|drug
DDI-DrugBank.d466.s0|39-51|Ketoconazole|drug
DDI-DrugBank.d466.s0|52-64|Fexofenadine|drug
DDI-DrugBank.d466.s0|91-98|minimal|drug
DDI-DrugBank.d466.s1|13-27|administration|drug
DDI-DrugBank.d466.s1|31-43|fexofenadine|drug
DDI-DrugBank.d466.s1|44-57|hydrochloride|drug
DDI-DrugBank.d466.s1|70-82|ketoconazole|drug
DDI-DrugBank.d466.s1|86-98|erythromycin|drug
DDI-DrugBank.d466.s1|106-115|increased|drug
DDI-DrugBank.d466.s1|141-154|fexofenadine.|drug
DDI-DrugBank.d466.s2|0-12|Fexofenadine|drug
DDI-DrugBank.d466.s2|34-50|pharmacokinetics|drug
DDI-DrugBank.d466.s2|61-73|erythromycin|drug
DDI-DrugBank.d466.s2|77-90|ketoconazole.|drug
DDI-DrugBank.d466.s3|23-35|fexofenadine|drug
DDI-DrugBank.d466.s3|36-49|hydrochloride|drug
DDI-DrugBank.d466.s3|99-114|co-administered|drug
DDI-DrugBank.d466.s3|127-139|erythromycin|drug
DDI-DrugBank.d466.s3|164-176|ketoconazole|drug
DDI-DrugBank.d466.s4|40-48|interval|drug
DDI-DrugBank.d466.s4|82-94|administered|drug
DDI-DrugBank.d466.s4|95-107|fexofenadine|drug
DDI-DrugBank.d466.s4|108-121|hydrochloride|drug
DDI-DrugBank.d466.s4|134-145|combination|drug
DDI-DrugBank.d466.s4|158-170|erythromycin|drug
DDI-DrugBank.d466.s4|174-187|ketoconazole.|drug
DDI-DrugBank.d466.s5|4-12|findings|drug
DDI-DrugBank.d466.s5|52-61|following|drug
DDI-DrugBank.d466.s5|93-105|fexofenadine|drug
DDI-DrugBank.d466.s5|106-122|pharmacokinetics|drug
DDI-DrugBank.d466.s5|139-156|co-administration|drug
DDI-DrugBank.d466.s5|162-174|fexofenadine|drug
DDI-DrugBank.d466.s5|175-188|hydrochloride|drug
DDI-DrugBank.d466.s8|33-42|exposure)|group
DDI-DrugBank.d466.s9|0-12|Erythromycin|drug
DDI-DrugBank.d466.s12|0-12|Ketoconazole|drug
DDI-DrugBank.d466.s15|34-40|within|drug
DDI-DrugBank.d466.s15|93-108|well-controlled|group
DDI-DrugBank.d466.s15|109-117|clinical|drug
DDI-DrugBank.d466.s16|23-35|interactions|drug
DDI-DrugBank.d466.s17|14-22|indicate|drug
DDI-DrugBank.d466.s17|28-40|ketoconazole|drug
DDI-DrugBank.d466.s17|44-56|erythromycin|drug
DDI-DrugBank.d466.s17|57-74|co-administration|drug
DDI-DrugBank.d466.s17|84-96|fexofenadine|drug
DDI-DrugBank.d466.s17|97-113|gastrointestinal|drug
DDI-DrugBank.d466.s18|14-22|increase|drug
DDI-DrugBank.d466.s18|49-61|fexofenadine|drug
DDI-DrugBank.d466.s18|111-126|p-glycoprotein.|drug
DDI-DrugBank.d466.s18|183-192|enhancing|drug
DDI-DrugBank.d466.s18|205-217|ketoconazole|drug
DDI-DrugBank.d466.s18|228-240|fexofenadine|drug
DDI-DrugBank.d466.s18|241-257|gastrointestinal|drug
DDI-DrugBank.d466.s18|275-287|erythromycin|drug
DDI-DrugBank.d466.s19|23-31|Antacids|group
DDI-DrugBank.d466.s19|32-46|Administration|drug
DDI-DrugBank.d466.s19|60-72|fexofenadine|drug
DDI-DrugBank.d466.s19|73-86|hydrochloride|drug
DDI-DrugBank.d466.s19|107-113|within|drug
DDI-DrugBank.d466.s19|117-124|minutes|drug
DDI-DrugBank.d466.s19|131-139|aluminum|drug
DDI-DrugBank.d466.s19|144-153|magnesium|drug
DDI-DrugBank.d466.s19|154-164|containing|group
DDI-DrugBank.d466.s19|193-205|fexofenadine|drug
DDI-DrugBank.d466.s20|0-7|ALLEGRA|brand
DDI-DrugBank.d466.s20|49-57|aluminum|drug
DDI-DrugBank.d466.s20|62-71|magnesium|drug
DDI-DrugBank.d466.s20|72-82|containing|group
DDI-DrugBank.d466.s20|83-92|antacids.|group
DDI-DrugBank.d466.s21|116-124|exposure|group
DDI-DrugBank.d466.s21|128-141|fexofenadine.|drug
DDI-DrugBank.d466.s22|36-44|clinical|drug
DDI-DrugBank.d466.s22|53-58|using|drug
DDI-DrugBank.d466.s22|59-68|histamine|drug
DDI-DrugBank.d466.s22|69-76|induced|drug
DDI-DrugBank.d466.s22|124-139|pharmacokinetic|drug
DDI-DrugBank.d466.s23|59-71|fexofenadine|drug
DDI-DrugBank.d466.s23|72-85|hydrochloride|drug
DDI-DrugBank.d466.s23|90-102|administered|drug
DDI-DrugBank.d466.s24|13-23|literature|group
DDI-DrugBank.d466.s25|4-12|clinical|drug
DDI-DrugBank.d466.s26|37-53|pharmacokinetics|drug
DDI-DrugBank.d466.s26|70-78|combined|drug
DDI-DrugBank.d466.s26|192-204|fexofenadine|drug
DDI-DrugBank.d466.s27|38-51|fexofenadine,|drug
DDI-DrugBank.d466.s27|75-82|ALLEGRA|brand
DDI-MedLine.d33.s0|0-12|Determinants|drug
DDI-MedLine.d33.s0|40-63|topoisomerase-targeting|drug
DDI-MedLine.d33.s0|64-73|antitumor|group
DDI-MedLine.d33.s1|66-77|determinant|drug
DDI-MedLine.d33.s2|126-133|control|group
DDI-MedLine.d33.s3|49-56|certain|drug
DDI-MedLine.d33.s3|147-160|proliferating|drug
DDI-MedLine.d33.s4|160-172|determinants|drug
DDI-MedLine.d33.s5|154-160|clinic|drug
DDI-MedLine.d33.s5|168-173|being|drug
DDI-MedLine.d33.s6|0-12|Determinants|drug
DDI-MedLine.d33.s6|144-156|DNA-damaging|drug
DDI-MedLine.d33.s7|12-21|enhancing|drug
DDI-MedLine.d33.s7|43-50|killing|drug
DDI-MedLine.d33.s7|94-102|limiting|drug
DDI-MedLine.d33.s7|129-139|overcoming|drug
DDI-MedLine.d33.s7|168-178|protecting|drug
DDI-MedLine.d33.s8|63-72|molecular|drug
DDI-MedLine.d33.s8|120-125|being|drug
DDI-MedLine.d33.s8|153-164|combination|drug
DDI-MedLine.d33.s8|220-225|being|drug
DDI-DrugBank.d22.s0|0-14|Aminosalicylic|drug
DDI-DrugBank.d22.s0|47-54|digoxin|drug
DDI-DrugBank.d22.s0|55-64|(Lanoxin,|drug
DDI-DrugBank.d22.s0|65-76|Lanoxicaps)|drug
DDI-DrugBank.d22.s1|25-31|taking|drug
DDI-DrugBank.d22.s1|32-39|digoxin|drug
DDI-DrugBank.d22.s1|46-52|taking|drug
DDI-DrugBank.d22.s1|53-67|aminosalicylic|drug
DDI-DrugBank.d22.s1|90-97|digoxin|drug
DDI-DrugBank.d22.s2|0-14|Aminosalicylic|drug
DDI-DrugBank.d22.s2|56-63|vitamin|drug
DDI-DrugBank.d22.s3|33-40|vitamin|drug
DDI-DrugBank.d22.s3|62-68|taking|drug
DDI-DrugBank.d22.s3|69-83|aminosalicylic|drug
DDI-MedLine.d95.s0|17-36|resveratrol-induced|drug
DDI-MedLine.d95.s1|30-36|induce|drug
DDI-MedLine.d95.s2|18-30|investigated|drug
DDI-MedLine.d95.s2|51-70|resveratrol-induced|drug
DDI-MedLine.d95.s2|139-154|dietary-induced|drug
DDI-MedLine.d95.s3|77-86|(P<0.001)|brand
DDI-MedLine.d95.s3|115-124|indicated|drug
DDI-MedLine.d95.s3|157-178|acetylcholine-induced|drug
DDI-MedLine.d95.s4|30-37|induced|drug
DDI-MedLine.d95.s4|116-129|noradrenaline|drug
DDI-MedLine.d95.s5|62-71|achieving|drug
DDI-MedLine.d95.s6|9-15|L-NAME|brand
DDI-MedLine.d95.s6|120-126|giving|drug
DDI-MedLine.d95.s7|0-12|Indomethacin|drug
DDI-MedLine.d95.s7|22-33|ineffective|drug
DDI-MedLine.d95.s7|37-45|altering|drug
DDI-MedLine.d95.s8|3-30|noradrenaline-precontracted|group
DDI-MedLine.d95.s8|137-147|indicating|drug
DDI-MedLine.d95.s8|158-169|independent|drug
DDI-MedLine.d95.s8|177-189|endothelium.|drug
DDI-MedLine.d95.s9|11-20|indicates|drug
DDI-DrugBank.d515.s0|43-51|combined|drug
DDI-DrugBank.d515.s0|92-101|involving|drug
DDI-DrugBank.d515.s0|102-112|ifosfamide|drug
DDI-DrugBank.d515.s0|125-135|ifosfamide|drug
DDI-DrugBank.d515.s0|194-203|including|drug
DDI-DrugBank.d23.s0|0-8|HEMABATE|brand
DDI-MedLine.d27.s0|27-32|brain|drug
DDI-MedLine.d27.s0|117-127|picrotoxin|drug
DDI-MedLine.d27.s0|150-163|antiedematous|group
DDI-MedLine.d27.s0|242-255|phentolamine.|drug
DDI-MedLine.d27.s1|17-27|picrotoxin|drug
DDI-MedLine.d27.s1|31-40|minimized|drug
DDI-MedLine.d27.s2|16-30|administration|drug
DDI-MedLine.d27.s2|34-44|picrotoxin|drug
DDI-MedLine.d27.s2|96-101|brain|drug
DDI-MedLine.d27.s3|46-54|included|drug
DDI-MedLine.d27.s3|83-91|measures|group
DDI-DrugBank.d276.s0|0-8|Antacids|group
DDI-DrugBank.d276.s0|9-19|containing|group
DDI-DrugBank.d276.s0|20-29|magnesium|drug
DDI-DrugBank.d276.s0|48-60|administered|drug
DDI-DrugBank.d276.s0|80-95|nitrofurantoin,|drug
DDI-DrugBank.d276.s1|23-34|interaction|drug
DDI-DrugBank.d276.s1|61-75|nitrofurantoin|drug
DDI-DrugBank.d276.s1|96-105|magnesium|drug
DDI-DrugBank.d276.s2|41-56|sulfinpyrazone,|drug
DDI-DrugBank.d276.s2|61-68|inhibit|drug
DDI-DrugBank.d276.s2|96-111|nitrofurantoin.|drug
DDI-DrugBank.d276.s3|4-13|resulting|drug
DDI-DrugBank.d276.s3|14-22|increase|drug
DDI-DrugBank.d276.s3|26-40|nitrofurantoin|drug
DDI-DrugBank.d276.s3|58-66|increase|drug
DDI-DrugBank.d276.s3|95-102|urinary|drug
DDI-DrugBank.d276.s3|141-148|urinary|drug
DDI-DrugBank.d276.s3|155-169|antibacterial.|group
DDI-DrugBank.d276.s4|65-80|nitrofurantoin,|drug
DDI-DrugBank.d276.s4|126-131|urine|drug
DDI-DrugBank.d276.s5|43-50|Fehling|drug
DDI-DrugBank.d341.s0|14-25|interaction|drug
DDI-DrugBank.d341.s0|63-69|ENBREL|brand
DDI-DrugBank.d341.s1|34-50|pharmacokinetics|drug
DDI-DrugBank.d341.s1|54-60|ENBREL|brand
DDI-DrugBank.d341.s2|92-98|ENBREL|brand
DDI-DrugBank.d341.s2|104-112|anakinra|drug
DDI-DrugBank.d341.s2|143-153|infections|drug
DDI-DrugBank.d341.s2|209-215|ENBREL|brand
DDI-DrugBank.d341.s3|50-56|ENBREL|brand
DDI-DrugBank.d341.s3|62-70|anakinra|drug
DDI-DrugBank.d341.s3|104-111|109/L).|brand
DDI-DrugBank.d341.s4|14-22|clinical|drug
DDI-DrugBank.d341.s4|66-80|sulfasalazine,|drug
DDI-DrugBank.d341.s4|90-96|ENBREL|brand
DDI-DrugBank.d341.s4|216-222|ENBREL|brand
DDI-DrugBank.d341.s4|229-242|sulfasalazine|drug
DDI-DrugBank.d341.s5|4-12|clinical|drug
DDI-DrugBank.d39.s0|8-14|taking|drug
DDI-DrugBank.d39.s0|20-32|antibiotics,|group
DDI-DrugBank.d39.s0|50-63|pyrimethamine|drug
DDI-DrugBank.d39.s0|64-74|invalidate|drug
DDI-DrugBank.d39.s0|90-97|vitamin|drug
DDI-DrugBank.d39.s1|0-10|Colchicine|drug
DDI-DrugBank.d39.s1|11-30|para-aminosalicylic|drug
DDI-DrugBank.d39.s1|54-60|intake|drug
DDI-DrugBank.d39.s1|114-121|vitamin|drug
DDI-DrugBank.d472.s0|34-39|(CNS)|brand
DDI-DrugBank.d472.s0|46-55|including|drug
DDI-DrugBank.d472.s0|65-81|antidepressants,|group
DDI-DrugBank.d472.s0|82-97|antihistamines,|group
DDI-DrugBank.d472.s0|98-113|antipsychotics,|group
DDI-DrugBank.d472.s0|120-128|pressure|group
DDI-DrugBank.d472.s0|141-152|(reserpine,|drug
DDI-DrugBank.d472.s0|250-258|sleeping|drug
DDI-DrugBank.d415.s0|0-13|Coumarin-Type|drug
DDI-DrugBank.d415.s0|49-59|controlled|group
DDI-DrugBank.d415.s0|122-133|prothrombin|drug
DDI-DrugBank.d415.s0|162-170|clotting|drug
DDI-DrugBank.d415.s0|184-196|administered|drug
DDI-DrugBank.d415.s0|200-211|individuals|drug
DDI-DrugBank.d415.s0|215-228|coumarin-type|drug
DDI-DrugBank.d415.s0|229-244|anticoagulants.|group
DDI-DrugBank.d415.s1|17-25|bleeding|drug
DDI-DrugBank.d415.s1|82-99|anti-inflammatory|group
DDI-DrugBank.d415.s1|117-129|administered|drug
DDI-DrugBank.d415.s1|145-158|coumarin-type|drug
DDI-DrugBank.d415.s1|159-174|anticoagulants,|group
DDI-DrugBank.d415.s1|213-226|administering|drug
DDI-DrugBank.d415.s1|252-267|anticoagulants.|group
DDI-DrugBank.d415.s2|0-8|Aspirin:|brand
DDI-DrugBank.d415.s2|35-42|aspirin|brand
DDI-DrugBank.d415.s2|67-84|anti-inflammatory|group
DDI-DrugBank.d415.s2|93-102|including|drug
DDI-DrugBank.d415.s2|139-156|anti-inflammatory|group
DDI-DrugBank.d415.s2|199-210|non-aspirin|brand
DDI-DrugBank.d415.s3|0-6|Single|drug
DDI-DrugBank.d415.s3|91-98|aspirin|brand
DDI-DrugBank.d415.s4|12-20|clinical|drug
DDI-DrugBank.d415.s5|55-72|anti-inflammatory|group
DDI-DrugBank.d415.s6|9-17|indicate|drug
DDI-DrugBank.d415.s7|39-51|administered|drug
DDI-DrugBank.d415.s8|51-68|co-administration|drug
DDI-DrugBank.d415.s8|72-82|cimetidine|drug
DDI-DrugBank.d415.s8|86-96|ranitidine|drug
DDI-DrugBank.d415.s9|12-20|Clinical|drug
DDI-DrugBank.d415.s9|103-114|natriuretic|group
DDI-DrugBank.d415.s9|125-135|furosemide|drug
DDI-DrugBank.d415.s9|140-149|thiazides|group
DDI-DrugBank.d415.s10|37-47|inhibition|drug
DDI-DrugBank.d415.s10|57-70|prostaglandin|drug
DDI-DrugBank.d415.s11|0-6|During|drug
DDI-DrugBank.d415.s11|101-109|failure,|group
DDI-DrugBank.d415.s11|124-130|assure|group
DDI-DrugBank.d415.s11|131-139|diuretic|group
DDI-DrugBank.d415.s12|0-8|Lithium:|drug
DDI-DrugBank.d415.s12|51-58|lithium|drug
DDI-DrugBank.d415.s12|91-98|lithium|drug
DDI-DrugBank.d415.s13|9-16|minimum|drug
DDI-DrugBank.d415.s13|17-24|lithium|drug
DDI-DrugBank.d415.s13|39-48|increased|drug
DDI-DrugBank.d415.s13|80-87|lithium|drug
DDI-DrugBank.d415.s13|109-115|during|drug
DDI-DrugBank.d415.s13|148-163|administration.|drug
DDI-DrugBank.d415.s14|35-45|inhibition|drug
DDI-DrugBank.d415.s14|55-68|prostaglandin|drug
DDI-DrugBank.d415.s15|25-32|lithium|drug
DDI-DrugBank.d415.s15|37-49|administered|drug
DDI-DrugBank.d415.s15|115-122|lithium|drug
DDI-DrugBank.d415.s16|20-27|lithium|drug
DDI-DrugBank.d149.s0|14-26|interactions|drug
DDI-DrugBank.d149.s0|30-38|HUMORSOL|brand
DDI-DrugBank.d149.s0|44-59|succinylcholine|drug
DDI-DrugBank.d149.s0|74-92|anticholinesterase|group
DDI-MedLine.d54.s0|0-11|Cholinergic|drug
DDI-MedLine.d54.s0|83-89|albino|drug
DDI-MedLine.d54.s1|87-93|albino|drug
DDI-MedLine.d54.s2|0-5|Since|drug
DDI-MedLine.d54.s2|100-106|during|drug
DDI-MedLine.d54.s3|75-84|following|drug
DDI-MedLine.d54.s3|88-98|injections|drug
DDI-MedLine.d54.s3|102-109|saline,|drug
DDI-MedLine.d54.s3|110-117|ethanol|drug
DDI-MedLine.d54.s3|130-143|physostigmine|drug
DDI-MedLine.d54.s3|159-167|atropine|drug
DDI-MedLine.d54.s4|0-7|Ethanol|drug
DDI-MedLine.d54.s4|86-92|saline|drug
DDI-MedLine.d54.s4|93-108|administration.|drug
DDI-MedLine.d54.s5|27-36|increased|drug
DDI-MedLine.d54.s6|0-13|Physostigmine|drug
DDI-MedLine.d54.s6|64-73|including|drug
DDI-MedLine.d54.s7|3-12|contrast,|group
DDI-MedLine.d54.s7|13-21|atropine|drug
DDI-MedLine.d54.s7|22-31|increased|drug
DDI-MedLine.d54.s7|78-88|decreasing|drug
DDI-MedLine.d54.s7|118-125|varying|drug
DDI-MedLine.d54.s8|0-13|Physostigmine|drug
DDI-MedLine.d54.s8|111-122|attenuating|drug
DDI-MedLine.d54.s8|133-142|influence|drug
DDI-MedLine.d54.s9|18-26|atropine|drug
DDI-MedLine.d54.s10|0-9|Atropine,|drug
DDI-MedLine.d54.s10|29-40|combination|drug
DDI-MedLine.d54.s11|17-23|saline|drug
DDI-MedLine.d54.s11|67-76|increases|drug
DDI-MedLine.d54.s11|134-141|showing|drug
DDI-MedLine.d54.s12|48-57|ethanol's|drug
DDI-MedLine.d54.s12|137-148|cholinergic|drug
DDI-DrugBank.d396.s0|9-18|receiving|drug
DDI-DrugBank.d396.s0|46-61|antipsychotics,|group
DDI-DrugBank.d396.s0|62-73|antianxiety|group
DDI-DrugBank.d396.s0|107-117|(including|drug
DDI-DrugBank.d396.s0|146-157|hydrocodone|drug
DDI-DrugBank.d396.s0|162-175|acetaminophen|drug
DDI-DrugBank.d396.s1|5-13|combined|drug
DDI-DrugBank.d396.s1|25-38|contemplated,|group
DDI-DrugBank.d396.s2|15-25|inhibitors|drug
DDI-DrugBank.d396.s2|39-54|antidepressants|group
DDI-DrugBank.d396.s2|60-71|hydrocodone|drug
DDI-DrugBank.d396.s2|89-97|increase|drug
DDI-DrugBank.d396.s2|123-137|antidepressant|group
DDI-DrugBank.d396.s2|141-153|hydrocodone.|drug
DDI-DrugBank.d396.s3|22-38|anticholinergics|group
DDI-DrugBank.d396.s3|44-55|hydrocodone|drug
DDI-DrugBank.d83.s0|12-25|warfarin-type|drug
DDI-DrugBank.d83.s0|26-39|anticoagulant|group
DDI-DrugBank.d83.s0|85-98|anticoagulant|group
DDI-DrugBank.d83.s0|99-105|during|drug
DDI-DrugBank.d83.s0|116-128|griseofulvin|drug
DDI-DrugBank.d83.s1|50-62|griseofulvin|drug
DDI-DrugBank.d83.s1|92-99|raising|drug
DDI-DrugBank.d83.s2|16-30|administration|drug
DDI-DrugBank.d83.s2|34-46|griseofulvin|drug
DDI-DrugBank.d83.s2|96-110|contraceptives|group
DDI-DrugBank.d83.s2|118-126|increase|drug
DDI-DrugBank.d83.s2|131-140|incidence|drug
DDI-DrugBank.d83.s2|157-166|bleeding.|drug
DDI-DrugBank.d248.s0|4-12|interact|drug
DDI-DrugBank.d248.s0|13-27|anticoagulants|group
DDI-DrugBank.d248.s0|37-57|hypo-prothrombinemic|drug
DDI-DrugBank.d248.s0|81-89|rifampin|drug
DDI-DrugBank.d248.s0|100-108|inducers|drug
DDI-DrugBank.d248.s0|197-212|corticosteroids|group
DDI-DrugBank.d248.s0|213-223|(increased|drug
DDI-DrugBank.d248.s0|234-251|corticosteroids).|group
DDI-DrugBank.d129.s0|14-22|increase|drug
DDI-DrugBank.d129.s0|43-58|anticoagulahts.|group
DDI-DrugBank.d129.s1|14-27|anticoagulant|group
DDI-DrugBank.d129.s1|62-70|maintain|drug
DDI-DrugBank.d129.s1|96-116|hypoprothrombinemia.|drug
DDI-DrugBank.d129.s2|11-25|administration|drug
DDI-DrugBank.d129.s3|99-106|insulin|drug
DDI-MedLine.d56.s0|15-22|ouabain|drug
DDI-MedLine.d56.s0|30-47|palytoxin-induced|drug
DDI-MedLine.d56.s0|48-59|contraction|group
DDI-MedLine.d56.s0|64-78|norepinephrine|drug
DDI-MedLine.d56.s0|94-104|guinea-pig|drug
DDI-MedLine.d56.s1|0-9|Palytoxin|drug
DDI-MedLine.d56.s1|10-16|(PTX),|brand
DDI-MedLine.d56.s1|17-31|C129H223N3O54,|brand
DDI-MedLine.d56.s1|46-52|marine|drug
DDI-MedLine.d56.s1|113-124|contraction|group
DDI-MedLine.d56.s1|153-164|contraction|group
DDI-MedLine.d56.s1|168-178|guinea-pig|drug
DDI-MedLine.d56.s2|19-26|ouabain|drug
DDI-MedLine.d56.s2|80-92|contraction;|group
DDI-MedLine.d56.s3|20-31|contraction|group
DDI-MedLine.d56.s4|19-31|phentolamine|drug
DDI-MedLine.d56.s4|55-66|contraction|group
DDI-MedLine.d56.s4|71-80|inhibited|drug
DDI-MedLine.d56.s5|5-12|ouabain|drug
DDI-MedLine.d56.s5|58-71|phentolamine,|drug
DDI-MedLine.d56.s5|94-105|contractile|group
DDI-MedLine.d56.s6|35-53|potassium-depleted|drug
DDI-MedLine.d56.s6|74-85|contractile|group
DDI-MedLine.d56.s7|26-40|norepinephrine|drug
DDI-MedLine.d56.s8|0-8|Exposure|group
DDI-MedLine.d56.s8|26-33|ouabain|drug
DDI-MedLine.d56.s8|54-63|increased|drug
DDI-MedLine.d56.s8|68-79|PTX-induced|drug
DDI-MedLine.d56.s9|6-15|indicated|drug
DDI-MedLine.d56.s9|42-53|contractile|group
DDI-MedLine.d56.s10|43-57|norepinephrine|drug
DDI-MedLine.d56.s10|93-100|ouabain|drug
DDI-MedLine.d56.s10|113-121|increase|drug
DDI-MedLine.d56.s10|129-143|norepinephrine|drug
DDI-MedLine.d56.s10|199-213|norepinephrine|drug
DDI-MedLine.d56.s10|286-295|inhibited|drug
DDI-MedLine.d56.s10|299-307|ouabain.|drug
DDI-DrugBank.d125.s0|25-33|clinical|drug
DDI-DrugBank.d125.s0|49-61|interactions|drug
DDI-DrugBank.d179.s1|0-13|Sulfapyridine|drug
DDI-DrugBank.d179.s1|18-26|interact|drug
DDI-DrugBank.d179.s1|43-53|following:|drug
DDI-DrugBank.d179.s1|56-69|Acetaminophen|drug
DDI-DrugBank.d179.s3|11-19|steroids|group
DDI-DrugBank.d179.s3|39-49|Anabolin],|drug
DDI-DrugBank.d179.s3|108-118|stanozolol|drug
DDI-DrugBank.d179.s3|126-136|Winstrol])|drug
DDI-DrugBank.d179.s5|21-30|(medicine|drug
DDI-DrugBank.d179.s6|2-15|Carbamazepine|drug
DDI-DrugBank.d179.s7|2-12|Carmustine|drug
DDI-DrugBank.d179.s8|2-13|Chloroquine|drug
DDI-DrugBank.d179.s9|2-12|Dantrolene|drug
DDI-DrugBank.d179.s9|20-29|Dantrium)|drug
DDI-DrugBank.d179.s10|2-14|Daunorubicin|drug
DDI-DrugBank.d179.s10|22-33|Cerubidine)|drug
DDI-DrugBank.d179.s14|2-12|Etretinate|drug
DDI-DrugBank.d179.s15|13-22|(medicine|drug
DDI-DrugBank.d179.s16|2-20|Hydroxychloroquine|drug
DDI-DrugBank.d179.s17|2-16|Mercaptopurine|drug
DDI-DrugBank.d179.s17|24-35|Purinethol)|drug
DDI-DrugBank.d179.s19|7-21|contraceptives|group
DDI-DrugBank.d179.s19|29-36|control|group
DDI-DrugBank.d179.s19|44-54|containing|group
DDI-DrugBank.d179.s20|8-23|anti-infectives|group
DDI-DrugBank.d179.s20|39-48|injection|drug
DDI-DrugBank.d179.s20|49-58|(medicine|drug
DDI-DrugBank.d179.s20|63-73|infection)|drug
DDI-DrugBank.d179.s21|2-16|Phenothiazines|drug
DDI-DrugBank.d179.s21|17-32|(acetophenazine|drug
DDI-DrugBank.d179.s21|40-48|Tindal],|drug
DDI-DrugBank.d179.s21|49-63|chlorpromazine|drug
DDI-DrugBank.d179.s21|71-82|Thorazine],|drug
DDI-DrugBank.d179.s21|83-95|fluphenazine|drug
DDI-DrugBank.d179.s21|103-113|Prolixin],|drug
DDI-DrugBank.d179.s21|114-126|mesoridazine|drug
DDI-DrugBank.d179.s21|145-157|perphenazine|drug
DDI-DrugBank.d179.s21|176-192|prochlorperazine|drug
DDI-DrugBank.d179.s21|200-211|Compazine],|drug
DDI-DrugBank.d179.s21|212-221|promazine|drug
DDI-DrugBank.d179.s21|229-238|Sparine],|drug
DDI-DrugBank.d179.s21|239-251|promethazine|drug
DDI-DrugBank.d179.s21|271-283|thioridazine|drug
DDI-DrugBank.d179.s21|302-317|trifluoperazine|drug
DDI-DrugBank.d179.s21|325-336|Stelazine],|drug
DDI-DrugBank.d179.s21|337-352|triflupromazine|drug
DDI-DrugBank.d179.s21|360-369|Vesprin],|drug
DDI-DrugBank.d179.s21|370-382|trimeprazine|drug
DDI-DrugBank.d179.s22|2-12|Plicamycin|drug
DDI-DrugBank.d179.s22|20-30|Mithracin)|drug
DDI-DrugBank.d179.s23|40-53|sulfapyridine|drug
DDI-DrugBank.d179.s23|65-74|medicines|drug
DDI-DrugBank.d179.s23|79-87|increase|drug
DDI-DrugBank.d179.s23|115-124|affecting|drug
DDI-DrugBank.d179.s24|2-17|Acetohydroxamic|drug
DDI-DrugBank.d179.s27|2-16|Nitrofurantoin|drug
DDI-DrugBank.d179.s27|24-35|Furadantin)|drug
DDI-DrugBank.d179.s28|2-12|Primaquine|drug
DDI-DrugBank.d179.s29|2-14|Procainamide|drug
DDI-DrugBank.d179.s30|2-11|Quinidine|drug
DDI-DrugBank.d179.s30|19-28|Quinidex)|drug
DDI-DrugBank.d179.s31|2-9|Quinine|drug
DDI-DrugBank.d179.s31|17-25|Quinamm)|drug
DDI-DrugBank.d179.s33|2-9|Vitamin|drug
DDI-DrugBank.d179.s33|52-65|sulfapyridine|drug
DDI-DrugBank.d179.s33|77-86|medicines|drug
DDI-DrugBank.d179.s33|91-99|increase|drug
DDI-DrugBank.d179.s33|127-136|affecting|drug
DDI-DrugBank.d179.s34|24-33|thinners)|drug
DDI-DrugBank.d179.s35|2-10|Ethotoin|drug
DDI-DrugBank.d179.s35|18-27|Peganone)|drug
DDI-DrugBank.d179.s36|2-13|Mephenytoin|drug
DDI-DrugBank.d179.s36|21-31|Mesantoin)|drug
DDI-DrugBank.d179.s36|39-52|sulfapyridine|drug
DDI-DrugBank.d179.s36|64-73|medicines|drug
DDI-DrugBank.d179.s36|78-86|increase|drug
DDI-DrugBank.d179.s36|123-132|medicines|drug
DDI-DrugBank.d179.s37|32-40|medicine|drug
DDI-DrugBank.d179.s37|72-85|antidiabetics|group
DDI-DrugBank.d179.s37|91-104|sulfapyridine|drug
DDI-DrugBank.d179.s37|109-117|increase|drug
DDI-DrugBank.d179.s37|145-154|affecting|drug
DDI-DrugBank.d179.s37|197-210|antidiabetics|group
DDI-DrugBank.d179.s38|55-68|sulfapyridine|drug
DDI-DrugBank.d179.s38|73-81|increase|drug
DDI-DrugBank.d179.s38|109-118|affecting|drug
DDI-DrugBank.d179.s39|52-65|sulfapyridine|drug
DDI-DrugBank.d179.s39|70-78|increase|drug
DDI-DrugBank.d179.s39|106-115|affecting|drug
DDI-DrugBank.d179.s40|2-11|Phenytoin|drug
DDI-DrugBank.d179.s40|19-28|Dilantin)|drug
DDI-DrugBank.d179.s40|36-45|phenytoin|drug
DDI-DrugBank.d179.s40|51-64|sulfapyridine|drug
DDI-DrugBank.d179.s40|69-77|increase|drug
DDI-DrugBank.d179.s40|105-114|affecting|drug
DDI-DrugBank.d179.s40|152-161|phenytoin|drug
DDI-DrugBank.d266.s0|28-35|CASODEX|brand
DDI-DrugBank.d266.s0|49-57|coumarin|drug
DDI-DrugBank.d266.s0|58-73|anticoagulants,|group
DDI-DrugBank.d266.s0|82-91|warfarin,|drug
DDI-DrugBank.d266.s0|103-118|protein-binding|drug
DDI-DrugBank.d266.s1|26-33|CASODEX|brand
DDI-DrugBank.d266.s1|65-74|receiving|drug
DDI-DrugBank.d266.s1|75-83|coumarin|drug
DDI-DrugBank.d266.s1|84-99|anticoagulants,|group
DDI-DrugBank.d266.s1|100-111|prothrombin|drug
DDI-DrugBank.d266.s1|168-181|anticoagulant|group
DDI-DrugBank.d229.s0|17-23|During|drug
DDI-DrugBank.d229.s0|44-50|sodium|drug
DDI-DrugBank.d229.s0|82-91|following|drug
DDI-DrugBank.d229.s0|105-115|injections|drug
DDI-DrugBank.d229.s1|9-15|sodium|drug
DDI-DrugBank.d229.s1|106-116|inhalation|drug
DDI-DrugBank.d229.s1|176-185|increases|drug
DDI-DrugBank.d229.s2|100-110|inhalation|drug
DDI-DrugBank.d229.s2|144-153|increased|drug
DDI-DrugBank.d229.s3|42-48|sodium|drug
DDI-DrugBank.d229.s3|104-114|inhalation|drug
DDI-DrugBank.d229.s3|235-245|inhalation|drug
DDI-DrugBank.d229.s3|295-304|increased|drug
DDI-DrugBank.d229.s3|309-318|incidence|drug
DDI-DrugBank.d281.s0|51-65|cephalosporins|drug
DDI-DrugBank.d281.s0|90-99|resulting|drug
DDI-DrugBank.d281.s0|103-112|increased|drug
DDI-DrugBank.d281.s0|132-145|cephalosporin|drug
DDI-DrugBank.d281.s1|79-84|urine|drug
DDI-DrugBank.d281.s1|120-128|Fehlings|drug
DDI-DrugBank.d281.s1|146-155|CLINITEST|brand
DDI-DrugBank.d281.s1|206-215|CLINISTIX|brand
DDI-DrugBank.d281.s2|20-28|indirect|drug
DDI-DrugBank.d281.s2|29-41|antiglobulin|group
DDI-DrugBank.d281.s3|56-70|cephalosporins|drug
DDI-DrugBank.d182.s0|3-11|clinical|drug
DDI-DrugBank.d182.s0|17-28|interaction|drug
DDI-DrugBank.d182.s1|14-20|single|drug
DDI-DrugBank.d182.s1|42-52|denileukin|drug
DDI-MedLine.d133.s0|28-45|bombesin-enhanced|drug
DDI-MedLine.d133.s0|71-81|intestinal|drug
DDI-MedLine.d133.s0|82-97|adenocarcinomas|drug
DDI-MedLine.d133.s0|98-105|induced|drug
DDI-MedLine.d133.s1|0-11|BACKGROUND:|brand
DDI-MedLine.d133.s1|27-35|combined|drug
DDI-MedLine.d133.s1|36-50|administration|drug
DDI-MedLine.d133.s1|54-62|bombesin|drug
DDI-MedLine.d133.s1|77-90|hydrochloride|drug
DDI-MedLine.d133.s1|106-113|calcium|drug
DDI-MedLine.d133.s1|138-147|incidence|drug
DDI-MedLine.d133.s1|176-186|intestinal|drug
DDI-MedLine.d133.s1|187-202|adenocarcinomas|drug
DDI-MedLine.d133.s1|203-210|induced|drug
DDI-MedLine.d133.s1|227-232|(AOM)|brand
DDI-MedLine.d133.s1|241-249|labeling|drug
DDI-MedLine.d133.s1|250-255|index|drug
DDI-MedLine.d133.s1|259-269|intestinal|drug
DDI-MedLine.d133.s1|283-295|investigated|drug
DDI-MedLine.d133.s2|0-8|METHODS:|brand
DDI-MedLine.d133.s2|18-27|beginning|drug
DDI-MedLine.d133.s2|86-96|injections|drug
DDI-MedLine.d133.s2|145-155|injections|drug
DDI-MedLine.d133.s2|159-167|bombesin|drug
DDI-MedLine.d133.s2|230-245|intraperitoneal|drug
DDI-MedLine.d133.s2|246-256|injections|drug
DDI-MedLine.d133.s3|0-8|RESULTS:|brand
DDI-MedLine.d133.s3|9-17|Bombesin|drug
DDI-MedLine.d133.s3|32-41|increased|drug
DDI-MedLine.d133.s3|46-55|incidence|drug
DDI-MedLine.d133.s3|59-69|intestinal|drug
DDI-MedLine.d133.s4|19-31|administered|drug
DDI-MedLine.d133.s4|93-103|intestinal|drug
DDI-MedLine.d133.s4|104-118|carcinogenesis|drug
DDI-MedLine.d133.s4|122-130|bombesin|drug
DDI-MedLine.d133.s4|177-189|involvement,|drug
DDI-MedLine.d133.s4|190-198|labeling|drug
DDI-MedLine.d133.s4|199-205|index,|drug
DDI-MedLine.d133.s4|216-221|index|drug
DDI-MedLine.d133.s4|246-256|intestinal|drug
DDI-MedLine.d133.s4|297-306|incidence|drug
DDI-MedLine.d133.s5|43-52|incidence|drug
DDI-MedLine.d133.s5|66-74|invasion|drug
DDI-MedLine.d133.s5|78-94|adenocarcinomas,|drug
DDI-MedLine.d133.s5|117-126|bombesin.|drug
DDI-MedLine.d133.s6|0-11|CONCLUSION:|brand
DDI-MedLine.d133.s6|18-26|findings|drug
DDI-MedLine.d133.s6|27-35|indicate|drug
DDI-MedLine.d133.s6|51-59|inhibits|drug
DDI-MedLine.d133.s6|127-137|intestinal|drug
DDI-DrugBank.d239.s0|23-32|examining|drug
DDI-DrugBank.d239.s0|48-60|interactions|drug
DDI-DrugBank.d239.s0|136-144|clinical|drug
DDI-DrugBank.d239.s1|8-20|interactions|drug
DDI-DrugBank.d239.s1|49-57|increase|drug
DDI-DrugBank.d239.s1|97-106|receiving|drug
DDI-DrugBank.d239.s1|116-127|inhibitors.|drug
DDI-DrugBank.d239.s2|4-21|co-administration|drug
DDI-DrugBank.d239.s2|63-77|nitroglycerin,|drug
DDI-DrugBank.d239.s2|93-103|milrinone,|drug
DDI-DrugBank.d239.s2|114-124|inhibitors|drug
DDI-DrugBank.d239.s2|170-185|co-administered|drug
DDI-DrugBank.d239.s2|203-211|clinical|drug
DDI-DrugBank.d77.s0|47-56|receiving|drug
DDI-DrugBank.d77.s0|57-72|anticholinergic|group
DDI-DrugBank.d77.s0|79-89|(including|drug
DDI-DrugBank.d77.s0|90-106|antiparkinsonism|group
DDI-DrugBank.d77.s0|132-145|atropine-like|drug
DDI-DrugBank.d77.s1|81-93|administered|drug
DDI-DrugBank.d77.s1|113-128|anticholinergic|group
DDI-DrugBank.d77.s2|80-87|contain|group
DDI-DrugBank.d77.s2|108-113|amine|drug
DDI-DrugBank.d77.s2|121-133|epinephrine,|drug
DDI-DrugBank.d77.s2|134-150|norepinephrine),|drug
DDI-DrugBank.d77.s2|151-156|since|drug
DDI-DrugBank.d77.s2|193-208|antidepressants|group
DDI-DrugBank.d77.s2|239-254|catecholamines.|drug
DDI-DrugBank.d77.s3|33-43|imipramine|drug
DDI-DrugBank.d77.s3|44-57|hydrochloride|drug
DDI-DrugBank.d77.s3|95-104|pressure.|group
DDI-DrugBank.d77.s4|0-10|Imipramine|drug
DDI-DrugBank.d77.s4|11-24|hydrochloride|drug
DDI-DrugBank.d77.s5|28-38|imipramine|drug
DDI-DrugBank.d77.s5|43-51|increase|drug
DDI-DrugBank.d77.s5|109-119|inhibitors|drug
DDI-DrugBank.d77.s5|127-138|cimetidine,|drug
DDI-DrugBank.d77.s5|139-150|fluoxetine)|drug
DDI-DrugBank.d77.s5|179-193|administration|drug
DDI-DrugBank.d77.s5|212-220|inducers|drug
DDI-DrugBank.d77.s5|242-253|phenytoin),|drug
DDI-DrugBank.d77.s5|286-296|imipramine|drug
DDI-DrugBank.d77.s6|67-79|metabolizing|drug
DDI-DrugBank.d77.s6|108-120|(debrisoquin|drug
DDI-DrugBank.d77.s6|121-133|hydroxylase)|drug
DDI-DrugBank.d77.s8|79-94|antidepressants|group
DDI-DrugBank.d77.s9|0-9|Depending|drug
DDI-DrugBank.d77.s9|63-71|increase|drug
DDI-DrugBank.d77.s9|133-141|increase|drug
DDI-DrugBank.d77.s9|163-168|TCA).|brand
DDI-DrugBank.d77.s10|13-20|certain|drug
DDI-DrugBank.d77.s10|27-34|inhibit|drug
DDI-DrugBank.d77.s12|3-13|individual|drug
DDI-DrugBank.d77.s12|101-111|inhibiting|drug
DDI-DrugBank.d77.s13|15-22|inhibit|drug
DDI-DrugBank.d77.s13|43-50|include|drug
DDI-DrugBank.d77.s13|95-106|(quinidine;|drug
DDI-DrugBank.d77.s14|0-11|cimetidine)|drug
DDI-DrugBank.d77.s14|66-82|antidepressants,|group
DDI-DrugBank.d77.s14|83-98|phenothiazines,|drug
DDI-DrugBank.d77.s14|115-130|antiarrhythmics|group
DDI-DrugBank.d77.s14|147-159|flecainide).|drug
DDI-DrugBank.d77.s15|24-33|serotonin|drug
DDI-DrugBank.d77.s15|43-53|inhibitors|drug
DDI-DrugBank.d77.s15|70-81|fluoxetine,|drug
DDI-DrugBank.d77.s15|82-93|sertraline,|drug
DDI-DrugBank.d77.s15|98-109|paroxetine,|drug
DDI-DrugBank.d77.s15|110-117|inhibit|drug
DDI-DrugBank.d77.s15|159-170|inhibition.|drug
DDI-DrugBank.d77.s16|20-28|SSRI-TCA|brand
DDI-DrugBank.d77.s16|29-41|interactions|drug
DDI-DrugBank.d77.s16|51-59|clinical|drug
DDI-DrugBank.d77.s16|98-109|inhibition,|drug
DDI-DrugBank.d77.s16|118-134|pharmacokinetics|drug
DDI-DrugBank.d77.s16|147-156|involved.|drug
DDI-DrugBank.d77.s17|25-34|indicated|drug
DDI-DrugBank.d77.s17|42-59|co-administration|drug
DDI-DrugBank.d77.s17|102-111|switching|drug
DDI-DrugBank.d77.s18|61-71|initiating|drug
DDI-DrugBank.d77.s18|99-104|being|drug
DDI-DrugBank.d77.s18|120-131|fluoxetine,|drug
DDI-DrugBank.d77.s19|29-44|antidepressants|group
DDI-DrugBank.d77.s19|65-72|inhibit|drug
DDI-DrugBank.d77.s19|166-180|antidepressant|group
DDI-DrugBank.d77.s20|79-88|increased|drug
DDI-DrugBank.d77.s20|107-121|antidepressant|group
DDI-DrugBank.d77.s21|63-68|going|drug
DDI-DrugBank.d77.s21|75-90|co-administered|drug
DDI-DrugBank.d77.s21|96-103|another|drug
DDI-DrugBank.d77.s21|124-133|inhibitor|drug
DDI-MedLine.d13.s0|9-20|amphetamine|drug
DDI-MedLine.d13.s1|18-28|literature|group
DDI-MedLine.d13.s1|29-37|contains|group
DDI-MedLine.d13.s1|75-87|amphetamines|drug
DDI-MedLine.d13.s1|93-100|35-year|drug_n
DDI-MedLine.d13.s2|6-14|included|drug
DDI-MedLine.d13.s2|110-120|poisonings|drug
DDI-MedLine.d13.s2|124-133|uncertain|drug
DDI-MedLine.d13.s2|188-199|intravenous|drug
DDI-MedLine.d13.s2|200-210|injection;|drug
DDI-MedLine.d13.s3|4-13|remainder|drug
DDI-MedLine.d13.s3|22-31|uncertain|drug
DDI-MedLine.d13.s4|3-12|contrast,|group
DDI-MedLine.d13.s4|72-83|amphetamine|drug
DDI-MedLine.d13.s4|124-131|suicide|drug
DDI-MedLine.d13.s5|7-16|remaining|drug
DDI-MedLine.d13.s6|60-69|resulting|drug
DDI-MedLine.d13.s6|75-86|intravenous|drug
DDI-MedLine.d13.s6|108-116|findings|drug
DDI-MedLine.d13.s7|57-68|intravenous|drug
DDI-MedLine.d13.s7|69-80|amphetamine|drug
DDI-MedLine.d13.s7|247-253|heroin|drug
DDI-MedLine.d13.s8|99-110|amphetamine|drug
DDI-MedLine.d13.s8|114-120|heroin|drug
DDI-DrugBank.d210.s0|4-15|inhibitors:|drug
DDI-DrugBank.d210.s0|48-56|diminish|drug
DDI-DrugBank.d210.s0|61-77|antihypertensive|group
DDI-DrugBank.d210.s0|88-99|Angiotensin|drug
DDI-DrugBank.d210.s0|100-110|Converting|drug
DDI-DrugBank.d210.s0|118-123|(ACE)|brand
DDI-DrugBank.d210.s0|124-135|inhibitors.|drug
DDI-DrugBank.d210.s1|48-62|administration|drug
DDI-DrugBank.d210.s1|81-86|VIOXX|brand
DDI-DrugBank.d210.s1|100-109|inhibitor|drug
DDI-DrugBank.d210.s1|178-186|increase|drug
DDI-DrugBank.d210.s1|204-212|pressure|group
DDI-DrugBank.d210.s1|246-255|inhibitor|drug
DDI-DrugBank.d210.s2|5-16|interaction|drug
DDI-DrugBank.d210.s2|59-65|taking|drug
DDI-DrugBank.d210.s2|66-71|VIOXX|brand
DDI-DrugBank.d210.s2|95-106|inhibitors.|drug
DDI-DrugBank.d210.s3|0-8|Aspirin:|brand
DDI-DrugBank.d210.s3|21-35|administration|drug
DDI-DrugBank.d210.s3|48-55|aspirin|brand
DDI-DrugBank.d210.s3|61-66|VIOXX|brand
DDI-DrugBank.d210.s3|84-93|increased|drug
DDI-DrugBank.d210.s3|159-164|VIOXX|brand
DDI-DrugBank.d210.s4|5-12|12-week|drug_n
DDI-DrugBank.d210.s4|96-105|incidence|drug
DDI-DrugBank.d210.s4|154-160|taking|drug
DDI-DrugBank.d210.s4|193-200|aspirin|brand
DDI-DrugBank.d210.s4|206-211|VIOXX|brand
DDI-DrugBank.d210.s4|246-252|taking|drug
DDI-DrugBank.d210.s5|9-15|taking|drug
DDI-DrugBank.d210.s5|25-32|aspirin|brand
DDI-DrugBank.d210.s6|17-22|VIOXX|brand
DDI-DrugBank.d210.s6|61-74|anti-platelet|group
DDI-DrugBank.d210.s6|115-123|aspirin,|brand
DDI-DrugBank.d210.s6|197-205|clotting|drug
DDI-DrugBank.d210.s7|41-46|VIOXX|brand
DDI-DrugBank.d210.s7|71-78|aspirin|brand
DDI-DrugBank.d210.s8|23-29|taking|drug
DDI-DrugBank.d210.s8|30-36|VIOXX,|brand
DDI-DrugBank.d210.s8|37-49|antiplatelet|group
DDI-DrugBank.d210.s8|74-86|discontinued|group
DDI-DrugBank.d210.s8|132-142|indication|drug
DDI-DrugBank.d210.s9|46-60|administration|drug
DDI-DrugBank.d210.s9|64-69|VIOXX|brand
DDI-DrugBank.d210.s9|74-81|aspirin|brand
DDI-DrugBank.d210.s10|0-11|Cimetidine:|drug
DDI-DrugBank.d210.s10|12-29|Co-administration|drug
DDI-DrugBank.d210.s10|49-59|cimetidine|drug
DDI-DrugBank.d210.s10|81-90|increased|drug
DDI-DrugBank.d210.s11|28-38|clinically|drug
DDI-DrugBank.d210.s12|0-8|Digoxin:|drug
DDI-DrugBank.d210.s12|105-116|elimination|drug
DDI-DrugBank.d210.s12|120-127|digoxin|drug
DDI-DrugBank.d210.s12|136-142|single|drug
DDI-DrugBank.d210.s13|12-20|Clinical|drug
DDI-DrugBank.d210.s13|41-55|post-marketing|drug
DDI-DrugBank.d210.s13|108-119|natriuretic|group
DDI-DrugBank.d210.s13|130-140|furosemide|drug
DDI-DrugBank.d210.s13|145-154|thiazides|group
DDI-DrugBank.d210.s14|37-47|inhibition|drug
DDI-DrugBank.d210.s14|57-70|prostaglandin|drug
DDI-DrugBank.d210.s15|0-13|Ketoconazole:|drug
DDI-DrugBank.d210.s15|14-26|Ketoconazole|drug
DDI-DrugBank.d210.s15|57-67|clinically|drug
DDI-DrugBank.d210.s15|92-108|pharmacokinetics|drug
DDI-DrugBank.d210.s16|0-8|Lithium:|drug
DDI-DrugBank.d210.s16|53-60|lithium|drug
DDI-DrugBank.d210.s16|93-100|lithium|drug
DDI-DrugBank.d210.s17|3-17|post-marketing|drug
DDI-DrugBank.d210.s17|56-65|increases|drug
DDI-DrugBank.d210.s17|76-83|lithium|drug
DDI-DrugBank.d210.s18|11-16|VIOXX|brand
DDI-DrugBank.d210.s18|21-28|lithium|drug
DDI-DrugBank.d210.s18|33-45|administered|drug
DDI-DrugBank.d210.s18|111-118|lithium|drug
DDI-DrugBank.d210.s19|13-18|VIOXX|brand
DDI-DrugBank.d210.s19|19-24|12.5,|drug_n
DDI-DrugBank.d210.s19|50-62|administered|drug
DDI-DrugBank.d210.s19|147-155|measured|group
DDI-DrugBank.d210.s19|181-190|receiving|drug
DDI-DrugBank.d210.s19|191-197|single|drug
DDI-DrugBank.d210.s20|34-39|VIOXX|brand
DDI-DrugBank.d210.s20|46-58|administered|drug
DDI-DrugBank.d210.s20|82-91|increased|drug
DDI-DrugBank.d210.s20|124-132|measured|group
DDI-DrugBank.d210.s20|158-167|receiving|drug
DDI-DrugBank.d210.s21|136-151|co-administered|drug
DDI-DrugBank.d210.s22|9-19|monitoring|drug
DDI-DrugBank.d210.s22|63-72|continued|group
DDI-DrugBank.d210.s22|76-81|VIOXX|brand
DDI-DrugBank.d210.s22|103-115|administered|drug
DDI-DrugBank.d210.s23|47-57|clinically|drug
DDI-DrugBank.d210.s23|82-98|pharmacokinetics|drug
DDI-DrugBank.d210.s23|102-109|ethinyl|drug
DDI-DrugBank.d210.s23|124-138|norethindrone.|drug
DDI-DrugBank.d210.s24|52-62|clinically|drug
DDI-DrugBank.d210.s24|87-103|pharmacokinetics|drug
DDI-DrugBank.d210.s25|0-9|Rifampin:|drug
DDI-DrugBank.d210.s25|10-27|Co-administration|drug
DDI-DrugBank.d210.s25|31-36|VIOXX|brand
DDI-DrugBank.d210.s25|42-50|rifampin|drug
DDI-DrugBank.d210.s25|74-81|inducer|drug
DDI-DrugBank.d210.s26|13-21|starting|drug
DDI-DrugBank.d210.s26|45-50|VIOXX|brand
DDI-DrugBank.d210.s26|113-118|VIOXX|brand
DDI-DrugBank.d210.s26|122-137|co-administered|drug
DDI-DrugBank.d210.s26|150-158|inducers|drug
DDI-DrugBank.d210.s27|0-12|Theophylline|drug
DDI-DrugBank.d210.s27|13-18|VIOXX|brand
DDI-DrugBank.d210.s27|19-24|12.5,|drug_n
DDI-DrugBank.d210.s27|39-51|administered|drug
DDI-DrugBank.d210.s27|74-83|increased|drug
DDI-DrugBank.d210.s27|91-103|theophylline|drug
DDI-DrugBank.d210.s27|119-126|(AUC(0-|brand
DDI-DrugBank.d210.s27|163-175|administered|drug
DDI-DrugBank.d210.s27|178-184|single|drug
DDI-DrugBank.d210.s27|185-191|300-mg|drug_n
DDI-DrugBank.d210.s27|200-213|theophylline.|drug
DDI-DrugBank.d210.s28|9-19|monitoring|drug
DDI-DrugBank.d210.s28|23-35|theophylline|drug
DDI-DrugBank.d210.s28|97-102|VIOXX|brand
DDI-DrugBank.d210.s28|106-115|initiated|drug
DDI-DrugBank.d210.s28|139-148|receiving|drug
DDI-DrugBank.d210.s28|149-162|theophylline.|drug
DDI-DrugBank.d210.s29|55-65|inhibition|drug
DDI-DrugBank.d210.s29|85-90|(CYP)|brand
DDI-DrugBank.d210.s30|39-50|interaction|drug
DDI-DrugBank.d210.s30|107-121|amitriptyline,|drug
DDI-DrugBank.d210.s30|122-130|tacrine,|drug
DDI-DrugBank.d210.s31|0-9|Warfarin:|drug
DDI-DrugBank.d210.s31|95-105|initiating|drug
DDI-DrugBank.d210.s31|109-117|changing|drug
DDI-DrugBank.d210.s31|118-123|VIOXX|brand
DDI-DrugBank.d210.s31|144-153|receiving|drug
DDI-DrugBank.d210.s31|154-162|warfarin|drug
DDI-DrugBank.d210.s31|182-187|since|drug
DDI-DrugBank.d210.s31|213-222|increased|drug
DDI-DrugBank.d210.s31|231-239|bleeding|drug
DDI-DrugBank.d210.s32|3-9|single|drug
DDI-DrugBank.d210.s32|56-65|receiving|drug
DDI-DrugBank.d210.s32|71-79|warfarin|drug
DDI-DrugBank.d210.s32|95-106|prothrombin|drug
DDI-DrugBank.d210.s32|112-121|(measured|group
DDI-DrugBank.d210.s32|134-143|increased|drug
DDI-DrugBank.d210.s33|3-17|post-marketing|drug
DDI-DrugBank.d210.s33|30-38|bleeding|drug
DDI-DrugBank.d210.s33|66-79|predominantly|drug
DDI-DrugBank.d210.s33|116-125|increases|drug
DDI-DrugBank.d210.s33|129-140|prothrombin|drug
DDI-DrugBank.d210.s33|158-167|receiving|drug
DDI-DrugBank.d210.s33|168-173|VIOXX|brand
DDI-DrugBank.d210.s33|192-201|warfarin.|drug
DDI-DrugBank.d160.s0|26-42|coadministration|drug
DDI-DrugBank.d160.s0|76-84|aluminum|drug
DDI-DrugBank.d160.s0|85-94|hydroxide|drug
DDI-DrugBank.d160.s0|95-105|containing|group
DDI-DrugBank.d160.s0|199-206|urinary|drug
DDI-DrugBank.d160.s0|275-285|suggesting|drug
DDI-DrugBank.d160.s1|38-52|administration|drug
DDI-DrugBank.d160.s1|72-80|aluminum|drug
DDI-DrugBank.d160.s1|81-90|hydroxide|drug
DDI-DrugBank.d160.s1|91-101|containing|group
DDI-DrugBank.d160.s1|102-110|antacids|group
DDI-DrugBank.d160.s1|132-141|following|drug
DDI-DrugBank.d160.s1|153-168|administration.|drug
DDI-DrugBank.d120.s0|15-24|producing|drug
DDI-DrugBank.d120.s1|0-16|anticholinergics|group
DDI-DrugBank.d120.s1|43-58|anticholinergic|group
DDI-DrugBank.d120.s1|70-85|anticholinergic|group
DDI-DrugBank.d120.s2|0-11|apomorphine|drug
DDI-DrugBank.d120.s2|20-29|ingestion|drug
DDI-DrugBank.d120.s2|80-91|apomorphine|drug
DDI-DrugBank.d120.s2|112-122|poisoning.|drug
DDI-MedLine.d93.s0|40-48|exposure|group
DDI-MedLine.d93.s1|48-57|integrity|drug
DDI-MedLine.d93.s2|0-12|Organometals|drug
DDI-MedLine.d93.s2|73-81|learning|drug
DDI-MedLine.d93.s3|0-5|Since|drug
DDI-MedLine.d93.s3|23-34|organoleads|drug
DDI-MedLine.d93.s3|78-87|influence|drug
DDI-MedLine.d93.s3|95-107|integration,|drug
DDI-MedLine.d93.s3|112-123|interaction|drug
DDI-MedLine.d93.s4|36-42|strain|drug
DDI-MedLine.d93.s4|95-105|injections|drug
DDI-MedLine.d93.s4|124-129|(TML)|brand
DDI-MedLine.d93.s4|163-169|saline|drug
DDI-MedLine.d93.s5|56-62|single|drug
DDI-MedLine.d93.s5|80-87|ethanol|drug
DDI-MedLine.d93.s6|83-91|ethanol.|drug
DDI-MedLine.d93.s7|27-35|righting|drug
DDI-MedLine.d93.s7|112-129|sound-attenuating|drug
DDI-MedLine.d93.s8|100-108|righting|drug
DDI-MedLine.d93.s8|156-165|controls.|group
DDI-MedLine.d93.s9|27-35|exposure|group
DDI-DrugBank.d293.s0|4-12|interact|drug
DDI-DrugBank.d293.s0|44-59|levothyroxine),|drug
DDI-DrugBank.d293.s0|60-77|iodine-containing|group
DDI-DrugBank.d293.s0|88-97|antacids,|group
DDI-DrugBank.d293.s0|120-131|famotidine,|drug
DDI-DrugBank.d293.s0|132-144|ranitidine),|drug
DDI-DrugBank.d293.s0|161-171|inhibitors|drug
DDI-DrugBank.d293.s0|179-192|lansoprazole,|drug
DDI-DrugBank.d293.s0|193-205|omeprazole).|drug
DDI-DrugBank.d293.s1|39-46|certain|drug
DDI-DrugBank.d132.s0|64-78|administration|drug
DDI-DrugBank.d132.s0|97-106|warfarin,|drug
DDI-DrugBank.d132.s0|167-178|prothrombin|drug
DDI-DrugBank.d132.s1|58-67|coumarins|drug
DDI-DrugBank.d132.s1|73-80|protein|drug
DDI-DrugBank.d132.s1|81-88|binding|drug
DDI-DrugBank.d132.s2|0-12|Accordingly,|drug
DDI-DrugBank.d132.s2|32-44|administered|drug
DDI-DrugBank.d132.s2|55-70|anticoagulants,|group
DDI-DrugBank.d132.s2|75-86|prothrombin|drug
DDI-DrugBank.d132.s2|120-126|during|drug
DDI-DrugBank.d132.s2|171-186|administration.|drug
DDI-DrugBank.d132.s3|29-43|anticoagulants|group
DDI-DrugBank.d132.s4|34-43|receiving|drug
DDI-DrugBank.d132.s4|108-119|tolbutamide|drug
DDI-DrugBank.d132.s4|137-144|fasting|drug
DDI-DrugBank.d132.s5|0-20|Hydrochlorothiazide:|group
DDI-DrugBank.d132.s5|55-69|administration|drug
DDI-DrugBank.d132.s5|88-107|hydrochlorothiazide|group
DDI-DrugBank.d132.s5|134-143|increased|drug
DDI-DrugBank.d132.s5|161-181|hydrochlorothiazide.|group
DDI-DrugBank.d132.s6|49-69|hydrochlorothiazide.|group
DDI-DrugBank.d132.s7|50-64|administration|drug
DDI-DrugBank.d132.s7|83-93|furosemide|drug
DDI-DrugBank.d132.s7|115-123|diuretic|group
DDI-DrugBank.d132.s9|0-9|Antacids:|group
DDI-DrugBank.d132.s9|22-36|administration|drug
DDI-DrugBank.d132.s9|40-48|antacids|group
DDI-DrugBank.d132.s10|46-55|antacids,|group
DDI-DrugBank.d132.s10|67-77|clinically|drug
DDI-DrugBank.d132.s10|95-103|antacids|group
DDI-DrugBank.d132.s10|118-128|continuous|group
DDI-DrugBank.d132.s11|0-14|Acetaminophen:|drug
DDI-DrugBank.d132.s11|49-63|administration|drug
DDI-DrugBank.d132.s11|82-95|acetaminophen|drug
DDI-DrugBank.d132.s11|127-135|increase|drug
DDI-DrugBank.d132.s11|156-170|acetaminophen.|drug
DDI-DrugBank.d132.s12|0-13|Acetaminophen|drug
DDI-DrugBank.d132.s13|0-5|Since|drug
DDI-DrugBank.d132.s13|6-19|acetaminophen|drug
DDI-DrugBank.d132.s13|87-101|administration|drug
DDI-DrugBank.d132.s13|120-133|acetaminophen|drug
DDI-DrugBank.d132.s13|174-184|monitoring|drug
DDI-DrugBank.d132.s14|12-26|administration|drug
DDI-DrugBank.d132.s14|45-58|acetaminophen|drug
DDI-DrugBank.d132.s14|188-213|diflunisal/acetaminophen)|drug
DDI-DrugBank.d132.s14|234-250|gastrointestinal|drug
DDI-DrugBank.d132.s14|286-298|administered|drug
DDI-DrugBank.d132.s15|4-12|clinical|drug
DDI-DrugBank.d132.s15|35-43|findings|drug
DDI-DrugBank.d132.s16|54-66|administered|drug
DDI-DrugBank.d132.s17|13-30|anti-inflammatory|group
DDI-DrugBank.d132.s18|0-13|Cyclosporine:|drug
DDI-DrugBank.d132.s18|14-28|Administration|drug
DDI-DrugBank.d132.s18|44-61|anti-inflammatory|group
DDI-DrugBank.d132.s18|87-99|cyclosporine|drug
DDI-DrugBank.d132.s18|128-136|increase|drug
DDI-DrugBank.d132.s18|140-160|cyclosporine-induced|drug
DDI-DrugBank.d132.s18|216-229|prostacyclin.|drug
DDI-DrugBank.d132.s19|47-53|taking|drug
DDI-DrugBank.d132.s19|54-67|cyclosporine,|drug
DDI-DrugBank.d132.s20|42-56|administration|drug
DDI-DrugBank.d132.s20|92-101|receiving|drug
DDI-DrugBank.d132.s20|102-114|indomethacin|drug
DDI-DrugBank.d132.s20|163-172|increased|drug
DDI-DrugBank.d132.s20|194-207|indomethacin.|drug
DDI-DrugBank.d132.s21|21-29|combined|drug
DDI-DrugBank.d132.s21|37-49|indomethacin|drug
DDI-DrugBank.d132.s21|96-112|gastrointestinal|drug
DDI-DrugBank.d132.s22|11-23|indomethacin|drug
DDI-DrugBank.d132.s23|89-98|increased|drug
DDI-DrugBank.d132.s23|114-130|gastrointestinal|drug
DDI-DrugBank.d132.s23|159-167|increase|drug
DDI-DrugBank.d132.s24|4-13|following|drug
DDI-DrugBank.d132.s24|14-25|information|drug
DDI-DrugBank.d132.s24|30-38|obtained|drug
DDI-DrugBank.d132.s25|0-8|Aspirin:|brand
DDI-DrugBank.d132.s25|120-127|aspirin|brand
DDI-DrugBank.d132.s25|133-145|administered|drug
DDI-DrugBank.d132.s26|0-9|Sulindac:|drug
DDI-DrugBank.d132.s26|26-40|administration|drug
DDI-DrugBank.d132.s26|59-67|sulindac|drug
DDI-DrugBank.d132.s26|101-109|lowering|drug
DDI-DrugBank.d132.s26|145-153|sulindac|drug
DDI-DrugBank.d132.s26|154-161|sulfide|drug
DDI-DrugBank.d132.s27|26-40|administration|drug
DDI-DrugBank.d132.s27|169-176|urinary|drug
DDI-DrugBank.d132.s27|207-218|glucuronide|drug
DDI-DrugBank.d132.s29|85-97|interpreting|drug
DDI-MedLine.d80.s0|0-14|Progestin-only|drug
DDI-MedLine.d80.s0|20-34|contraception:|group
DDI-MedLine.d80.s1|12-19|provide|drug
DDI-MedLine.d80.s1|20-31|information|drug
DDI-MedLine.d80.s1|60-66|insert|drug
DDI-MedLine.d80.s1|67-75|labeling|drug
DDI-MedLine.d80.s1|79-93|progestin-only|drug
DDI-MedLine.d80.s1|99-113|contraceptives|group
DDI-MedLine.d80.s1|114-119|(POC)|brand
DDI-MedLine.d80.s1|192-205|norethindrone|drug
DDI-MedLine.d80.s1|226-234|clinical|drug
DDI-MedLine.d80.s1|247-256|indicated|drug
DDI-MedLine.d80.s2|96-101|since|drug
DDI-MedLine.d80.s2|102-107|1975.|drug_n
DDI-MedLine.d80.s4|4-16|introductory|drug
DDI-MedLine.d80.s5|0-6|Future|group
DDI-MedLine.d80.s6|40-49|including|drug
DDI-MedLine.d80.s7|24-36|gonadotropin|drug
DDI-MedLine.d80.s8|31-43|endometrium,|drug
DDI-MedLine.d80.s9|4-12|clinical|drug
DDI-MedLine.d80.s10|30-48|(pharmacokinetics,|drug
DDI-MedLine.d80.s10|83-91|clinical|drug
DDI-MedLine.d80.s11|26-37|information|drug
DDI-MedLine.d80.s11|191-196|using|drug
DDI-MedLine.d80.s11|217-226|following|drug
DDI-MedLine.d80.s11|227-243|discontinuation.|group
DDI-MedLine.d80.s12|71-83|carbohydrate|drug
DDI-MedLine.d80.s12|140-149|pressure.|group
DDI-MedLine.d80.s13|81-89|findings|drug
DDI-MedLine.d80.s14|67-76|including|drug
DDI-MedLine.d80.s15|19-30|infections;|drug
DDI-MedLine.d80.s16|9-16|vaginal|drug
DDI-MedLine.d80.s16|17-26|bleeding;|drug
DDI-MedLine.d80.s17|0-7|uterine|drug
DDI-MedLine.d80.s17|8-17|fibroids;|group
DDI-MedLine.d80.s21|0-9|endocrine|drug
DDI-MedLine.d80.s28|26-38|interactions|drug
DDI-MedLine.d80.s28|100-108|feeding,|drug
DDI-MedLine.d80.s29|31-49|contraindications,|group
DDI-MedLine.d80.s29|50-62|indications,|drug
DDI-MedLine.d80.s29|67-80|instructions,|drug
DDI-MedLine.d80.s29|85-97|instructions|drug
DDI-MedLine.d80.s29|128-135|missing|drug
DDI-DrugBank.d152.s0|0-7|Certain|drug
DDI-DrugBank.d152.s0|8-17|endocrine|drug
DDI-DrugBank.d152.s0|62-81|estrogen-containing|group
DDI-DrugBank.d152.s0|87-102|contraceptives.|group
DDI-DrugBank.d152.s1|4-13|following|drug
DDI-DrugBank.d152.s1|87-106|sulfobromophthalein|drug
DDI-DrugBank.d152.s2|0-9|increased|drug
DDI-DrugBank.d152.s2|10-21|prothrombin|drug
DDI-DrugBank.d152.s2|39-44|VIII,|brand
DDI-DrugBank.d152.s3|10-22|antithrombin|group
DDI-DrugBank.d152.s4|0-9|increased|drug
DDI-DrugBank.d152.s4|10-32|norepinephrine-induced|drug
DDI-DrugBank.d152.s5|0-9|increased|drug
DDI-DrugBank.d152.s5|18-25|binding|drug
DDI-DrugBank.d152.s5|26-34|globulin|drug
DDI-DrugBank.d152.s5|35-40|(TBG)|brand
DDI-DrugBank.d152.s5|41-48|leading|drug
DDI-DrugBank.d152.s5|52-61|increased|drug
DDI-DrugBank.d152.s5|62-73|circulating|drug
DDI-DrugBank.d152.s5|100-108|measured|group
DDI-DrugBank.d152.s6|8-13|resin|drug
DDI-DrugBank.d152.s6|35-45|reflecting|drug
DDI-DrugBank.d152.s7|53-63|tolerance;|drug
DDI-DrugBank.d152.s11|0-9|increased|drug
DDI-DrugBank.d152.s11|16-28|triglyceride|drug
DDI-DrugBank.d531.s0|36-42|induce|drug
DDI-DrugBank.d531.s0|43-50|CYP3A4.|brand
DDI-DrugBank.d531.s1|39-45|CYP3A4|brand
DDI-DrugBank.d531.s1|92-106|coadministered|drug
DDI-DrugBank.d531.s1|112-119|SUSTIVA|brand
DDI-DrugBank.d531.s2|50-58|inhibits|drug
DDI-DrugBank.d531.s2|64-69|2C19,|brand
DDI-DrugBank.d531.s3|0-16|Coadministration|drug
DDI-DrugBank.d531.s3|132-146|coadministered|drug
DDI-DrugBank.d531.s5|12-18|induce|drug
DDI-DrugBank.d531.s5|19-25|CYP3A4|brand
DDI-DrugBank.d531.s5|55-64|rifampin,|drug
DDI-DrugBank.d531.s5|65-75|rifabutin)|drug
DDI-DrugBank.d531.s5|97-105|increase|drug
DDI-DrugBank.d531.s5|133-142|resulting|drug
DDI-DrugBank.d531.s6|5-17|interactions|drug
DDI-DrugBank.d531.s6|23-30|SUSTIVA|brand
DDI-DrugBank.d531.s7|35-49|Coadministered|drug
DDI-DrugBank.d531.s7|55-62|SUSTIVA|brand
DDI-DrugBank.d531.s9|6-12|Within|drug
DDI-DrugBank.d531.s9|29-43|Coadministered|drug
DDI-DrugBank.d531.s9|49-56|SUSTIVA|brand
DDI-DrugBank.d531.s10|0-15|Antihistamines:|drug
DDI-DrugBank.d531.s10|16-31|Benzodiazepines|drug
DDI-DrugBank.d531.s10|51-64|Anti-Migraine|drug
DDI-DrugBank.d531.s11|0-10|astemizole|drug
DDI-DrugBank.d531.s11|22-31|triazolam|drug
DDI-DrugBank.d531.s11|32-41|cisapride|drug
DDI-DrugBank.d531.s11|60-72|voriconazole|drug
DDI-DrugBank.d531.s16|0-8|Clinical|drug
DDI-DrugBank.d531.s17|0-10|Atazanavir|drug
DDI-DrugBank.d531.s18|0-10|atazanavir|drug
DDI-DrugBank.d531.s19|5-19|coadministered|drug
DDI-DrugBank.d531.s19|25-32|SUSTIVA|brand
DDI-DrugBank.d531.s19|86-96|atazanavir|drug
DDI-DrugBank.d531.s19|112-121|ritonavir|drug
DDI-DrugBank.d531.s19|133-140|SUSTIVA|brand
DDI-DrugBank.d531.s20|0-6|Dosing|drug
DDI-DrugBank.d531.s20|27-34|SUSTIVA|brand
DDI-DrugBank.d531.s20|39-49|atazanavir|drug
DDI-DrugBank.d531.s21|30-41|(continued)|group
DDI-DrugBank.d531.s24|0-8|Clinical|drug
DDI-DrugBank.d531.s25|0-14|Clarithromycin|drug
DDI-DrugBank.d531.s26|0-14|clarithromycin|drug
DDI-DrugBank.d531.s27|35-43|SUSTIVA;|brand
DDI-DrugBank.d531.s28|0-8|clinical|drug
DDI-DrugBank.d531.s29|3-13|uninfected|drug
DDI-DrugBank.d531.s29|51-60|receiving|drug
DDI-DrugBank.d531.s29|61-68|SUSTIVA|brand
DDI-DrugBank.d531.s29|73-88|clarithromycin.|drug
DDI-DrugBank.d531.s30|22-29|SUSTIVA|brand
DDI-DrugBank.d531.s30|61-76|clarithromycin.|drug
DDI-DrugBank.d531.s31|16-31|clarithromycin,|drug
DDI-DrugBank.d531.s31|40-53|azithromycin,|drug
DDI-DrugBank.d531.s32|6-15|macrolide|drug
DDI-DrugBank.d531.s32|16-28|antibiotics,|group
DDI-DrugBank.d531.s32|37-50|erythromycin,|drug
DDI-DrugBank.d531.s32|76-87|combination|drug
DDI-DrugBank.d531.s32|93-101|SUSTIVA.|brand
DDI-DrugBank.d531.s34|0-5|14-OH|brand
DDI-DrugBank.d531.s35|0-9|Indinavir|drug
DDI-DrugBank.d531.s36|0-9|indinavir|drug
DDI-DrugBank.d531.s37|20-30|indinavir,|drug
DDI-DrugBank.d531.s37|45-56|combination|drug
DDI-DrugBank.d531.s37|62-70|SUSTIVA,|brand
DDI-DrugBank.d531.s38|0-10|Increasing|drug
DDI-DrugBank.d531.s38|15-24|indinavir|drug
DDI-DrugBank.d531.s38|83-92|increased|drug
DDI-DrugBank.d531.s38|93-102|indinavir|drug
DDI-DrugBank.d531.s38|121-129|SUSTIVA.|brand
DDI-DrugBank.d531.s39|5-14|indinavir|drug
DDI-DrugBank.d531.s39|21-30|increased|drug
DDI-DrugBank.d531.s39|75-82|SUSTIVA|brand
DDI-DrugBank.d531.s39|108-117|indinavir|drug
DDI-DrugBank.d531.s39|160-166|33-46%|drug_n
DDI-DrugBank.d531.s39|171-178|39-57%,|drug_n
DDI-DrugBank.d531.s39|210-219|indinavir|drug
DDI-DrugBank.d531.s40|0-19|Lopinavir/ritonavir|drug
DDI-DrugBank.d531.s41|0-9|lopinavir|drug
DDI-DrugBank.d531.s42|7-15|increase|drug
DDI-DrugBank.d531.s42|19-38|lopinavir/ritonavir|drug
DDI-DrugBank.d531.s42|42-49|533/133|drug_n
DDI-DrugBank.d531.s42|132-143|combination|drug
DDI-DrugBank.d531.s42|149-157|SUSTIVA.|brand
DDI-DrugBank.d531.s45|0-16|Coadministration|drug
DDI-DrugBank.d531.s45|20-32|HIV-infected|drug
DDI-DrugBank.d531.s45|33-44|individuals|drug
DDI-DrugBank.d531.s45|63-72|injection|drug
DDI-DrugBank.d531.s46|19-28|increased|drug
DDI-DrugBank.d531.s47|78-87|increased|drug
DDI-DrugBank.d531.s48|0-7|Ethinyl|drug
DDI-DrugBank.d531.s49|0-7|ethinyl|drug
DDI-DrugBank.d531.s50|22-31|increased|drug
DDI-DrugBank.d531.s50|35-42|SUSTIVA|brand
DDI-DrugBank.d531.s51|0-8|clinical|drug
DDI-DrugBank.d531.s52|22-33|interaction|drug
DDI-DrugBank.d531.s52|57-71|contraceptives|group
DDI-DrugBank.d531.s52|135-148|contraception|group
DDI-DrugBank.d531.s52|184-199|contraceptives.|group
DDI-DrugBank.d531.s53|0-9|Rifabutin|drug
DDI-DrugBank.d531.s54|0-9|rifabutin|drug
DDI-DrugBank.d531.s55|23-32|rifabutin|drug
DDI-DrugBank.d531.s56|9-17|doubling|drug
DDI-DrugBank.d531.s56|22-31|rifabutin|drug
DDI-DrugBank.d531.s56|55-64|rifabutin|drug
DDI-DrugBank.d531.s57|0-8|Rifampin|drug
DDI-DrugBank.d531.s59|0-8|Clinical|drug
DDI-DrugBank.d531.s60|0-9|Ritonavir|drug
DDI-DrugBank.d531.s61|0-9|ritonavir|drug
DDI-DrugBank.d531.s62|0-11|Combination|drug
DDI-DrugBank.d531.s62|62-70|clinical|drug
DDI-DrugBank.d531.s62|88-98|dizziness,|drug
DDI-DrugBank.d531.s63|0-10|Monitoring|drug
DDI-DrugBank.d531.s63|48-55|SUSTIVA|brand
DDI-DrugBank.d531.s63|67-78|combination|drug
DDI-DrugBank.d531.s65|0-10|Saquinavir|drug
DDI-DrugBank.d531.s66|0-10|saquinavir|drug
DDI-DrugBank.d531.s67|36-45|inhibitor|drug
DDI-DrugBank.d531.s67|49-60|combination|drug
DDI-DrugBank.d531.s67|66-74|SUSTIVA.|brand
DDI-DrugBank.d531.s68|0-10|Sertraline|drug
DDI-DrugBank.d531.s69|0-10|sertraline|drug
DDI-DrugBank.d531.s70|13-23|sertraline|drug
DDI-DrugBank.d531.s70|49-57|clinical|drug
DDI-DrugBank.d531.s71|18-28|Clinically|drug
DDI-DrugBank.d531.s71|82-90|SUSTIVAb|brand
DDI-DrugBank.d531.s72|16-24|Warfarin|drug
DDI-DrugBank.d531.s73|46-55|increased|drug
DDI-DrugBank.d531.s73|72-80|SUSTIVA.|brand
DDI-DrugBank.d531.s74|17-26|Phenytoin|drug
DDI-DrugBank.d531.s74|41-54|Carbamazepine|drug
DDI-DrugBank.d531.s75|27-41|anticonvulsant|group
DDI-DrugBank.d531.s76|9-19|monitoring|drug
DDI-DrugBank.d531.s76|23-37|anticonvulsant|group
DDI-DrugBank.d531.s77|13-25|Itraconazole|drug
DDI-DrugBank.d531.s77|26-38|Ketoconazole|drug
DDI-DrugBank.d531.s78|5-16|interaction|drug
DDI-DrugBank.d531.s78|30-37|SUSTIVA|brand
DDI-DrugBank.d531.s78|48-57|imidazole|drug
DDI-DrugBank.d531.s78|62-70|triazole|drug
DDI-DrugBank.d531.s78|71-82|antifungals|group
DDI-DrugBank.d531.s79|0-7|SUSTIVA|brand
DDI-DrugBank.d531.s79|63-75|itraconazole|drug
DDI-DrugBank.d531.s79|80-93|ketoconazole.|drug
DDI-DrugBank.d531.s80|18-29|inhibitors:|drug
DDI-DrugBank.d531.s80|30-50|Saquinavir/ritonavir|drug
DDI-DrugBank.d531.s80|51-62|combination|drug
DDI-DrugBank.d531.s81|3-18|pharmacokinetic|drug
DDI-DrugBank.d531.s82|0-10|Amprenavir|drug
DDI-DrugBank.d531.s83|0-10|SUSTIVAhas|brand
DDI-DrugBank.d531.s84|0-14|Non-nucleoside|drug
DDI-DrugBank.d531.s84|37-47|inhibitors|drug
DDI-DrugBank.d531.s87|86-97|combination|drug
DDI-DrugBank.d531.s87|103-111|SUSTIVA.|brand
DDI-DrugBank.d531.s89|20-34|all-inclusive.|drug
DDI-DrugBank.d531.s90|42-53|interaction|drug
DDI-DrugBank.d531.s90|104-111|SUSTIVA|brand
DDI-DrugBank.d531.s90|142-152|following:|drug
DDI-DrugBank.d531.s90|153-171|aluminum/magnesium|drug
DDI-DrugBank.d531.s90|172-181|hydroxide|drug
DDI-DrugBank.d531.s90|182-191|antacids,|group
DDI-DrugBank.d531.s90|192-205|azithromycin,|drug
DDI-DrugBank.d531.s90|206-217|cetirizine,|drug
DDI-DrugBank.d531.s90|218-229|famotidine,|drug
DDI-DrugBank.d531.s90|230-242|fluconazole,|drug
DDI-DrugBank.d531.s90|243-254|lamivudine,|drug
DDI-DrugBank.d531.s90|266-277|nelfinavir,|drug
DDI-DrugBank.d531.s90|278-289|paroxetine,|drug
DDI-DrugBank.d531.s90|294-305|zidovudine.|drug
DDI-DrugBank.d531.s91|14-25|interaction|drug
DDI-DrugBank.d531.s91|63-70|SUSTIVA|brand
DDI-DrugBank.d531.s91|92-102|lamivudine|drug
DDI-DrugBank.d531.s91|107-118|zidovudine.|drug
DDI-DrugBank.d531.s92|0-10|Clinically|drug
DDI-DrugBank.d531.s92|23-35|interactions|drug
DDI-DrugBank.d531.s92|58-63|since|drug
DDI-DrugBank.d531.s92|195-206|elimination|drug
DDI-DrugBank.d133.s0|0-17|Co-administration|drug
DDI-DrugBank.d133.s0|21-26|BOTOX|brand
DDI-DrugBank.d133.s0|31-46|aminoglycosides|drug
DDI-DrugBank.d133.s0|63-74|interfering|drug
DDI-DrugBank.d133.s0|196-201|toxin|drug
DDI-DrugBank.d133.s1|14-27|administering|drug
DDI-DrugBank.d133.s1|38-47|botulinum|drug
DDI-DrugBank.d133.s1|48-58|neurotoxin|drug
DDI-DrugBank.d133.s1|89-95|within|drug
DDI-DrugBank.d133.s2|55-69|administration|drug
DDI-DrugBank.d133.s2|73-80|another|drug
DDI-DrugBank.d133.s2|81-90|botulinum|drug
DDI-DrugBank.d133.s2|91-96|toxin|drug
DDI-DrugBank.d133.s2|152-164|administered|drug
DDI-DrugBank.d133.s2|165-174|botulinum|drug
DDI-DrugBank.d133.s2|175-181|toxin.|drug
DDI-MedLine.d6.s0|0-15|Pharmacokinetic|drug
DDI-MedLine.d6.s1|4-20|pharmacokinetics|drug
DDI-MedLine.d6.s2|111-117|7-hour|drug_n
DDI-MedLine.d6.s4|19-26|protein|drug
DDI-MedLine.d6.s5|3-14|investigate|drug
DDI-MedLine.d6.s5|64-78|administration|drug
DDI-MedLine.d6.s5|127-142|pharmacokinetic|drug
DDI-MedLine.d6.s6|0-5|Since|drug
DDI-MedLine.d6.s6|21-33|well-defined|drug
DDI-MedLine.d6.s6|34-65|pharmacokinetic-pharmacodynamic|drug
DDI-MedLine.d6.s6|80-91|measurement|group
DDI-MedLine.d6.s6|95-110|pharmacokinetic|drug
DDI-MedLine.d6.s6|125-135|clinically|drug
DDI-MedLine.d6.s7|52-62|underlying|drug
DDI-MedLine.d6.s7|93-105|administered|drug
DDI-MedLine.d6.s7|113-126|protein-bound|drug
DDI-MedLine.d6.s7|172-189|pharmacokinetics.|drug
DDI-DrugBank.d328.s0|9-20|interaction|drug
DDI-DrugBank.d328.s0|95-105|hydrolyzed|drug
DDI-DrugBank.d328.s0|106-117|intravenous|drug
DDI-DrugBank.d328.s1|24-29|using|drug
DDI-DrugBank.d328.s1|34-45|intravenous|drug
DDI-DrugBank.d328.s1|132-145|interactions.|drug
DDI-DrugBank.d328.s2|45-58|predominantly|drug
DDI-DrugBank.d328.s2|109-114|being|drug
DDI-DrugBank.d328.s3|17-25|indicate|drug
DDI-DrugBank.d328.s3|56-65|inhibitor|drug
DDI-DrugBank.d328.s3|78-83|(IC50|brand
DDI-DrugBank.d328.s3|112-117|(IC50|brand
DDI-DrugBank.d328.s3|151-160|inhibitor|drug
DDI-DrugBank.d328.s3|172-177|(IC50|brand
DDI-DrugBank.d328.s3|208-213|(IC50|brand
DDI-DrugBank.d328.s4|0-8|Aspirin:|brand
DDI-DrugBank.d328.s4|21-35|administration|drug
DDI-DrugBank.d328.s4|39-46|aspirin|brand
DDI-DrugBank.d328.s4|80-89|increased|drug
DDI-DrugBank.d328.s5|23-36|anti-platelet|group
DDI-DrugBank.d328.s5|79-86|aspirin|brand
DDI-DrugBank.d328.s6|25-36|interaction|drug
DDI-DrugBank.d328.s6|43-52|comparing|drug
DDI-DrugBank.d328.s6|57-68|intravenous|drug
DDI-DrugBank.d328.s6|171-187|aspirin-mediated|brand
DDI-DrugBank.d328.s6|188-198|inhibition|drug
DDI-DrugBank.d328.s7|83-91|exposure|group
DDI-DrugBank.d328.s8|0-22|ACE-inhibitors:Reports|drug
DDI-DrugBank.d328.s8|47-55|diminish|drug
DDI-DrugBank.d328.s8|60-76|antihypertensive|group
DDI-DrugBank.d328.s8|87-102|ACE-inhibitors.|drug
DDI-DrugBank.d328.s9|5-16|interaction|drug
DDI-DrugBank.d328.s9|59-65|taking|drug
DDI-DrugBank.d328.s9|66-72|BEXTRA|brand
DDI-DrugBank.d328.s9|92-107|ACE-inhibitors.|drug
DDI-DrugBank.d328.s10|12-20|Clinical|drug
DDI-DrugBank.d328.s10|41-55|post-marketing|drug
DDI-DrugBank.d328.s10|108-119|natriuretic|group
DDI-DrugBank.d328.s10|130-140|furosemide|drug
DDI-DrugBank.d328.s10|145-154|thiazides|group
DDI-DrugBank.d328.s11|37-47|inhibition|drug
DDI-DrugBank.d328.s11|57-70|prostaglandin|drug
DDI-DrugBank.d328.s12|16-28|(Phenytoin):|drug
DDI-DrugBank.d328.s12|49-57|exposure|group
DDI-DrugBank.d328.s12|58-63|(AUC)|brand
DDI-DrugBank.d328.s12|128-143|co-administered|drug
DDI-DrugBank.d328.s12|191-200|phenytoin|drug
DDI-DrugBank.d328.s12|212-221|inducer).|drug
DDI-DrugBank.d328.s13|90-97|control|group
DDI-DrugBank.d328.s13|103-112|phenytoin|drug
DDI-DrugBank.d328.s13|113-130|coadministration.|drug
DDI-DrugBank.d328.s14|66-82|pharmacokinetics|drug
DDI-DrugBank.d328.s14|86-95|phenytoin|drug
DDI-DrugBank.d328.s15|5-16|interaction|drug
DDI-DrugBank.d328.s15|36-51|anticonvulsants|group
DDI-DrugBank.d328.s16|0-7|Routine|drug
DDI-DrugBank.d328.s16|8-18|monitoring|drug
DDI-DrugBank.d328.s16|57-63|BEXTRA|brand
DDI-DrugBank.d328.s16|74-83|initiated|drug
DDI-DrugBank.d328.s16|87-99|discontinued|group
DDI-DrugBank.d328.s16|115-129|anticonvulsant|group
DDI-DrugBank.d328.s18|0-16|Coadministration|drug
DDI-DrugBank.d328.s18|82-90|increase|drug
DDI-DrugBank.d328.s18|125-135|suggesting|drug
DDI-DrugBank.d328.s18|179-188|inhibitor|drug
DDI-DrugBank.d328.s19|103-109|5-fold|drug_n
DDI-DrugBank.d328.s19|161-171|suggesting|drug
DDI-DrugBank.d328.s20|0-8|Lithium:|drug
DDI-DrugBank.d328.s20|75-82|lithium|drug
DDI-DrugBank.d328.s20|155-163|exposure|group
DDI-DrugBank.d328.s20|176-183|lithium|drug
DDI-DrugBank.d328.s21|0-7|Lithium|drug
DDI-DrugBank.d328.s21|62-72|initiating|drug
DDI-DrugBank.d328.s21|76-84|changing|drug
DDI-DrugBank.d328.s21|98-104|BEXTRA|brand
DDI-DrugBank.d328.s21|117-126|receiving|drug
DDI-DrugBank.d328.s21|127-135|lithium.|drug
DDI-DrugBank.d328.s22|0-7|Lithium|drug
DDI-DrugBank.d328.s22|70-87|pharmacokinetics.|drug
DDI-DrugBank.d328.s23|0-9|Warfarin:|drug
DDI-DrugBank.d328.s23|42-55|anticoagulant|group
DDI-DrugBank.d328.s23|66-74|warfarin|drug
DDI-DrugBank.d328.s23|125-141|coadministration|drug
DDI-DrugBank.d328.s23|145-151|BEXTRA|brand
DDI-DrugBank.d328.s24|46-54|increase|drug
DDI-DrugBank.d328.s24|65-74|exposures|group
DDI-DrugBank.d328.s24|78-88|R-warfarin|drug
DDI-DrugBank.d328.s24|93-103|S-warfarin|drug
DDI-DrugBank.d328.s24|168-180|(prothrombin|drug
DDI-DrugBank.d328.s24|187-195|measured|group
DDI-DrugBank.d328.s24|207-216|warfarin.|drug
DDI-DrugBank.d328.s25|41-50|increased|drug
DDI-DrugBank.d328.s25|56-72|coadministration|drug
DDI-DrugBank.d328.s25|118-128|individual|drug
DDI-DrugBank.d328.s25|144-154|increased.|drug
DDI-DrugBank.d328.s26|56-62|during|drug
DDI-DrugBank.d328.s26|90-100|initiating|drug
DDI-DrugBank.d328.s26|114-120|BEXTRA|brand
DDI-DrugBank.d328.s26|133-142|receiving|drug
DDI-DrugBank.d328.s26|143-151|warfarin|drug
DDI-DrugBank.d328.s27|0-11|Fluconazole|drug
DDI-DrugBank.d328.s27|16-29|Ketoconazole:|drug
DDI-DrugBank.d328.s27|30-42|Ketoconazole|drug
DDI-DrugBank.d328.s27|47-58|fluconazole|drug
DDI-DrugBank.d328.s27|63-76|predominantly|drug
DDI-DrugBank.d328.s27|93-104|inhibitors,|drug
DDI-DrugBank.d328.s28|12-18|single|drug
DDI-DrugBank.d328.s28|24-38|administration|drug
DDI-DrugBank.d328.s28|82-94|ketoconazole|drug
DDI-DrugBank.d328.s28|99-110|fluconazole|drug
DDI-DrugBank.d328.s28|134-142|increase|drug
DDI-DrugBank.d328.s28|146-154|exposure|group
DDI-DrugBank.d328.s29|7-15|exposure|group
DDI-DrugBank.d328.s29|16-21|(AUC)|brand
DDI-DrugBank.d328.s29|40-49|increased|drug
DDI-DrugBank.d328.s29|59-73|coadministered|drug
DDI-DrugBank.d328.s29|79-90|fluconazole|drug
DDI-DrugBank.d328.s29|104-118|coadministered|drug
DDI-DrugBank.d328.s29|124-137|ketoconazole.|drug
DDI-DrugBank.d328.s30|11-20|Glyburide|drug
DDI-DrugBank.d328.s31|0-16|Coadministration|drug
DDI-DrugBank.d328.s31|59-68|glyburide|drug
DDI-DrugBank.d328.s31|111-127|pharmacokinetics|drug
DDI-DrugBank.d328.s31|128-138|(exposure)|group
DDI-DrugBank.d328.s32|0-16|Coadministration|drug
DDI-DrugBank.d328.s32|69-74|2-7))|drug_n
DDI-DrugBank.d328.s32|80-89|glyburide|drug
DDI-DrugBank.d328.s32|126-142|pharmacokinetics|drug
DDI-DrugBank.d328.s32|143-153|(exposure)|group
DDI-DrugBank.d328.s32|197-204|insulin|drug
DDI-DrugBank.d328.s33|0-16|Coadministration|drug
DDI-DrugBank.d328.s33|69-74|2-7))|drug_n
DDI-DrugBank.d328.s33|80-89|glyburide|drug
DDI-DrugBank.d328.s33|97-106|glyburide|drug
DDI-DrugBank.d328.s33|128-136|increase|drug
DDI-DrugBank.d328.s33|140-149|glyburide|drug
DDI-DrugBank.d328.s33|150-157|AUC0-12|brand
DDI-DrugBank.d328.s33|168-176|increase|drug
DDI-DrugBank.d328.s33|180-189|glyburide|drug
DDI-DrugBank.d328.s33|195-202|leading|drug
DDI-DrugBank.d328.s33|232-240|AUC0-24.|brand
DDI-DrugBank.d328.s34|0-7|Insulin|drug
DDI-DrugBank.d328.s35|58-74|coadministration|drug
DDI-DrugBank.d328.s35|80-86|within|drug
DDI-DrugBank.d328.s35|114-124|individual|drug
DDI-DrugBank.d328.s35|197-206|glyburide|drug
DDI-DrugBank.d328.s35|247-263|coadministration|drug
DDI-DrugBank.d328.s35|288-298|indicated.|drug
DDI-DrugBank.d328.s36|0-16|Coadministration|drug
DDI-DrugBank.d328.s36|20-29|glyburide|drug
DDI-DrugBank.d328.s37|0-11|Omeprazole:|drug
DDI-DrugBank.d328.s37|12-22|Omeprazole|drug
DDI-DrugBank.d328.s37|73-83|inhibitor.|drug
DDI-DrugBank.d328.s38|113-123|omeprazole|drug
DDI-DrugBank.d328.s39|0-16|Coadministration|drug
DDI-DrugBank.d328.s39|33-42|increased|drug
DDI-DrugBank.d328.s39|43-51|exposure|group
DDI-DrugBank.d328.s39|55-65|omeprazole|drug
DDI-DrugBank.d328.s39|66-71|(AUC)|brand
DDI-DrugBank.d328.s40|84-98|administration|drug
DDI-DrugBank.d328.s40|102-112|omeprazole|drug
DDI-DrugBank.d328.s41|51-61|omeprazole|drug
DDI-DrugBank.d328.s41|66-75|tolerated|drug
DDI-DrugBank.d328.s41|79-96|Zollinger-Ellison|drug
DDI-DrugBank.d328.s41|135-145|omeprazole|drug
DDI-DrugBank.d328.s42|0-16|Coadministration|drug
DDI-DrugBank.d328.s42|63-73|omeprazole|drug
DDI-DrugBank.d328.s43|52-58|induce|drug
DDI-DrugBank.d328.s43|81-92|combination|drug
DDI-DrugBank.d328.s43|98-111|contraceptive|group
DDI-DrugBank.d328.s43|112-133|norethindrone/ethinyl|drug
DDI-DrugBank.d328.s43|158-170|combination,|drug
DDI-DrugBank.d328.s44|0-16|Coadministration|drug
DDI-DrugBank.d328.s44|53-62|increased|drug
DDI-DrugBank.d328.s44|67-75|exposure|group
DDI-DrugBank.d328.s44|79-92|norethindrone|drug
DDI-DrugBank.d328.s44|97-104|ethinyl|drug
DDI-DrugBank.d328.s45|42-55|contraceptive|group
DDI-DrugBank.d328.s45|70-78|clinical|drug
DDI-DrugBank.d328.s45|101-110|increased|drug
DDI-DrugBank.d328.s45|111-120|exposures|group
DDI-DrugBank.d328.s46|6-15|increased|drug
DDI-DrugBank.d328.s46|16-25|exposures|group
DDI-DrugBank.d328.s46|29-42|norethindrone|drug
DDI-DrugBank.d328.s46|47-54|ethinyl|drug
DDI-DrugBank.d328.s46|105-114|selecting|drug
DDI-DrugBank.d328.s46|123-136|contraceptive|group
DDI-DrugBank.d328.s46|147-153|taking|drug
DDI-DrugBank.d328.s47|19-27|(Valium)|drug
DDI-DrugBank.d328.s48|7-15|exposure|group
DDI-DrugBank.d328.s48|44-53|increased|drug
DDI-DrugBank.d328.s48|61-70|following|drug
DDI-DrugBank.d328.s48|71-85|administration|drug
DDI-DrugBank.d328.s48|138-146|exposure|group
DDI-DrugBank.d328.s48|195-204|increased|drug
DDI-DrugBank.d328.s48|205-214|following|drug
DDI-DrugBank.d328.s48|215-229|administration|drug
DDI-DrugBank.d328.s49|53-61|exposure|group
DDI-DrugBank.d328.s49|67-81|coadministered|drug
DDI-DrugBank.d328.s49|214-223|increased|drug
DDI-DrugBank.d328.s49|224-232|exposure|group
DDI-DrugBank.d328.s50|29-36|against|drug_n
DDI-DrugBank.d328.s50|37-45|engaging|drug
DDI-DrugBank.d328.s50|70-79|requiring|drug
DDI-DrugBank.d328.s50|114-123|operating|drug
DDI-DrugBank.d328.s50|124-133|machinery|drug
DDI-DrugBank.d328.s50|137-144|driving|drug
DDI-MedLine.d21.s0|26-41|antidepressants|group
DDI-MedLine.d21.s2|15-29|antidepressant|group
DDI-MedLine.d21.s2|49-58|interfere|drug
DDI-MedLine.d21.s2|92-100|interact|drug
DDI-MedLine.d21.s3|155-169|antidepressant|group
DDI-MedLine.d21.s4|38-50|interference|drug
DDI-MedLine.d21.s4|54-69|antidepressants|group
DDI-MedLine.d21.s6|0-10|Imipramine|drug
DDI-MedLine.d21.s6|22-33|moclobemide|drug
DDI-MedLine.d21.s6|71-81|fluoxetine|drug
DDI-MedLine.d21.s6|93-103|sertraline|drug
DDI-MedLine.d21.s6|130-143|administered.|drug
DDI-MedLine.d21.s7|14-21|fasting|drug
DDI-MedLine.d21.s7|35-44|measured.|group
DDI-MedLine.d21.s8|99-109|determined|drug
DDI-MedLine.d21.s9|0-10|Imipramine|drug
DDI-MedLine.d21.s9|41-48|fasting|drug
DDI-MedLine.d21.s10|0-10|Fluoxetine|drug
DDI-MedLine.d21.s10|15-26|moclobemide|drug
DDI-MedLine.d21.s10|27-36|increased|drug
DDI-MedLine.d21.s11|0-10|Sertraline|drug
DDI-MedLine.d21.s11|27-35|increase|drug
DDI-MedLine.d21.s11|48-55|induced|drug
DDI-MedLine.d21.s12|43-65|streptozotocin-induced|drug
DDI-MedLine.d21.s12|106-116|procedures|group
DDI-MedLine.d21.s12|157-166|tolerance|drug
DDI-MedLine.d21.s13|0-6|Again,|drug_n
DDI-MedLine.d21.s13|7-17|sertraline|drug
DDI-MedLine.d21.s13|34-42|increase|drug
DDI-MedLine.d21.s14|41-51|sertraline|drug
DDI-MedLine.d21.s14|102-114|individuals,|drug
DDI-MedLine.d21.s14|130-147|antihyperglycemic|group
DDI-MedLine.d55.s0|28-41|acetaminophen|drug
DDI-MedLine.d55.s0|57-71|administration|drug
DDI-MedLine.d55.s0|75-83|caffeine|drug
DDI-MedLine.d55.s1|0-5|Since|drug
DDI-MedLine.d55.s1|6-14|caffeine|drug
DDI-MedLine.d55.s1|29-44|co-administered|drug
DDI-MedLine.d55.s1|50-64|acetaminophen,|drug
DDI-MedLine.d55.s1|74-82|clinical|drug
DDI-MedLine.d55.s1|83-91|interest|drug
DDI-MedLine.d55.s1|115-123|caffeine|drug
DDI-MedLine.d55.s1|149-163|acetaminophen.|drug
DDI-MedLine.d55.s2|57-71|administration|drug
DDI-MedLine.d55.s2|75-83|caffeine|drug
DDI-MedLine.d55.s3|13-22|increased|drug
DDI-MedLine.d55.s3|51-60|increased|drug
DDI-MedLine.d55.s3|61-70|incidence|drug
DDI-MedLine.d55.s4|58-71|acetaminophen|drug
DDI-MedLine.d55.s4|91-100|caffeine.|drug
DDI-DrugBank.d86.s0|45-60|anticholinergic|group
DDI-DrugBank.d86.s0|82-95|antipsychotic|group
DDI-DrugBank.d86.s0|106-122|chlorpromazine),|drug
DDI-DrugBank.d86.s0|126-142|antiparkinsonian|group
DDI-DrugBank.d86.s0|190-204|antidepressant|group
DDI-DrugBank.d86.s0|210-234|amitriptyline)--commonly|drug
DDI-DrugBank.d86.s0|256-271|anticholinergic|group
DDI-DrugBank.d86.s0|281-290|including|drug
DDI-DrugBank.d86.s0|387-398|temperature|group
DDI-DrugBank.d86.s1|37-47|following:|drug
DDI-DrugBank.d86.s1|48-77|anti-depressants/anti-anxiety|group
DDI-DrugBank.d86.s1|149-162|propranolol),|drug
DDI-DrugBank.d86.s1|163-176|sparfloxacin,|drug
DDI-DrugBank.d86.s1|177-191|grepafloxacin,|drug
DDI-DrugBank.d86.s1|192-205|guanethidine,|drug
DDI-DrugBank.d86.s1|230-242|cabergoline,|drug
DDI-DrugBank.d86.s1|243-251|lithium,|drug
DDI-DrugBank.d86.s1|284-293|codeine),|drug
DDI-DrugBank.d86.s1|319-337|drowsiness-causing|drug
DDI-DrugBank.d86.s1|338-352|antihistamines|group
DDI-DrugBank.d86.s1|360-377|diphenhydramine),|drug
